<SEC-DOCUMENT>0001144204-16-127502.txt : 20161011
<SEC-HEADER>0001144204-16-127502.hdr.sgml : 20161011
<ACCEPTANCE-DATETIME>20161011080734
ACCESSION NUMBER:		0001144204-16-127502
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		14
FILED AS OF DATE:		20161011
DATE AS OF CHANGE:		20161011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-213738
		FILM NUMBER:		161929448

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>v450214_s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>

     <HEAD>

          <TITLE></TITLE>

     </HEAD>

<BODY>

<DIV style="text-align: center; min-width: 708">


<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">



<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>As filed with the Securities and Exchange Commission on October 11, 2016 </B></P>

<H2 STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Registration No. 333-213738 </H2>

<DIV  STYLE="width: 100%; display: inline-block; *display:inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">UNITED STATES<BR> SECURITIES AND EXCHANGE COMMISSION<BR> Washington, D.C. 20549</Font> </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">AMENDMENT NO. 1 TO<BR>FORM S-1<BR> REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</Font> </H1>




<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 18pt; line-height: 20pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC. </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Exact name of registrant as specified in its charter) </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="708" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="237"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="229"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="237"></TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="line-height: 12pt; vertical-align: bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Delaware</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>2834</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>47-0883144</TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="padding-left: 0pt; text-indent: 0pt" ROWSPAN=1 COLSPAN=1>(State or other jurisdiction of<BR> incorporation or organization)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">(Primary Standard Industrial<BR> Classification Code Number)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">(I.R.S. Employer<BR> Identification Number)</TD>

</TR>

</TABLE></DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">373 Inverness Parkway<BR>Suite 206<BR>Englewood, Colorado 80112<BR>(720) 437-6580</Font> </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Address, including zip code and telephone number, including<BR> area code, of registrant&#146;s principal executive offices) </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Joshua R. Disbrow<BR> Chief Executive Officer<BR> 373 Inverness Parkway<BR>Suite 206<BR>Englewood, Colorado 80112<BR>Telephone: (720) 437-6580</Font> </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Name, address, including zip code and telephone number, including area code, of agent for service) </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Copies to:</I></B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="708" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="360"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="360"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1><B>Alexander M. Donaldson, Esq.<BR>Andrew J. Gibbons, Esq.<BR>Wyrick Robbins Yates &amp; Ponton LLP</B><BR>4101 Lake Boone Trail, Suite 300<BR>Raleigh, North Carolina 27607<BR>(919) 781-4000</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><B>Gregory Sichenzia, Esq.<BR>Marcelle Balcombe, Esq.<BR>Jeffrey Cahlon, Esq.<BR>Sichenzia Ross Friedman Ference LLP</B><BR>61 Broadway<BR>New York, New York 10006<BR>(212) 930-9700</TD>

</TR>

</TABLE></DIV>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), check the following box. <FONT STYLE="font-family: wingdings">x</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one): </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="682" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="258"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Large accelerated filer <FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Accelerated filer <FONT STYLE="font-family: wingdings">o</font></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>Non-accelerated filer <FONT STYLE="font-family: wingdings">o</font><BR><I>(Do not check if a smaller reporting company)</I></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Smaller reporting company <FONT STYLE="font-family: wingdings">x</font></TD>

</TR>

</TABLE></DIV>



<DIV STYLE="width: 100%; display: inline-block; *display:inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><FONT COLOR="RED">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</FONT> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="193"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT COLOR="RED"><B>PRELIMINARY PROSPECTUS</FONT></B></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><B><FONT COLOR="RED">SUBJECT TO COMPLETION</FONT></B></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><B><FONT COLOR="RED">DATED OCTOBER 11, 2016</FONT></B></TD>

</TR>

</TABLE></DIV>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Shares of Common Stock </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="361"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=3><B><FONT STYLE="font-size: 14pt">Warrants to Purchase </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<B> Shares of Common Stock</FONT></B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><IMG SRC="logo_aytu-bioscience.jpg" WIDTH="180" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 16pt; line-height: 18pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu BioScience, Inc. </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu BioScience, Inc. is offering &nbsp;&nbsp;&nbsp;&nbsp; shares of common stock and warrants to purchase up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. The shares of common stock and the warrants are immediately separable and will be issued separately in this offering. Each warrant will be exercisable for a period commencing on the date of issuance and expiring on May 2, 2021 and an exercise price equal to $6.00. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are also offering the shares of common stock that are issuable from time to time upon exercise of the warrants being offered by this prospectus. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock and warrants are listed on the OTCQX Market operated by OTC Markets Group, Inc. (or OTCQX) under the ticker symbols &#147;AYTU&#148; and &#147;AYTUW&#148;, respectively. On October 6, 2016, the last reported sale prices of our common stock and warrants on the OTCQX were $2.90 and $1.00, respectively. We intend to list our common stock and warrants on the NYSE MKT under the symbols &#147;AYTU&#148; and &#147;AYTUW&#148;, respectively, once we meet NYSE listing standards by raising $8,500,000 and achieving a $3.00 per share price, which we expect to do via a reverse split once approved by our stockholders in
November. See &#147;Market for our Common Stock&#148; on Page <a href="#t6MAR">47</a>. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page <a href="#t3RIS">8</a> of this prospectus, and under similar headings in any amendments or supplements to this prospectus.</B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="361"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Per Share</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Per Warrant</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Total</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Public offering price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discounts and commissions<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds to us, before expenses<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 11pt; font-size: 9pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Joseph Gunnar &amp; Co., LLC, the representative of the underwriters. See &#147;Underwriting&#148; for a description of compensation payable to the underwriters. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 11pt; font-size: 9pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Does not include proceeds from the exercise of the warrants, in cash, if any. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have granted a 45-day option to the representative of the underwriters to purchase up to &nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock and/or up to &nbsp;&nbsp;&nbsp;&nbsp; warrants solely to cover over-allotments, if any. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters expect to deliver the shares and warrants to purchasers in the offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="297"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="344"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=3>Joint Book-Running Managers<BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 18pt"><B>Joseph Gunnar &amp; Co.</B></FONT></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><FONT STYLE="font-size: 18pt"><B>Feltl and Company</FONT></B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=3>Lead Manager<BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 16pt"><B>Fordham Financial Management</FONT></B><BR></TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v449009_ifc.jpg" WIDTH="576" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="TOC"></a>TABLE OF CONTENTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="552"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="40"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t1PRO">Prospectus Summary</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t1PRO">1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t2THE">The Offering</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t2THE">6</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t3RIS">Risk Factors</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t3RIS">8</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t4SPE">Special Note Regarding Forward-Looking Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t4SPE">44</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t5USE">Use of Proceeds</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t5USE">46</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t6MAR">Market for Common Stock</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t6MAR">47</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t7DIV">Dividend Policy</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t7DIV">49</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t8DIL">Dilution</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t8DIL">50</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t9CAP">Capitalization</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t9CAP">52</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t10MAN">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t10MAN">54</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t11BUS">Business</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t11BUS">60</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t12MAN">Management</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t12MAN">97</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t13TRA">Transactions with Related Persons</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t13TRA">106</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t14SEC">Security Ownership of Certain Beneficial Owners and Management</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t14SEC">109</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t15DES">Description of Capital Stock</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t15DES">111</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t16UND">Underwriting</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t16UND">116</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t17LEG">Legal Matters</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t17LEG">123</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t18EXP">Experts</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t18EXP">123</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t19WHE">Where You Can Find More Information</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t19WHE">123</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#t20FIN">Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#t20FIN">F-1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should rely only on the information contained in this prospectus, as supplemented and amended. We have not authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus may only be accurate on the date of this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We urge you to read carefully this prospectus, as supplemented and amended, before deciding whether to invest in any of the common stock being offered. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless the context indicates otherwise, as used in this prospectus, the terms &#147;Aytu,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company&#148; and &#147;our business&#148; refer to Aytu BioScience, Inc. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including Natesto, ProstaScint, Primsol, MiOXSYS, RedoxSYS, and Luoxis. All other trade names, trademarks and service marks appearing in this prospectus are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this prospectus, appear with the trade name, trademark or service mark notice and then throughout the remainder of this prospectus without trade name, trademark or
service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">
i
<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t1PRO"></a>PROSPECTUS SUMMARY</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>This summary highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in shares of our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our securities, you should read the entire prospectus carefully, including &#147;Risk Factors&#148; beginning on page <a href="#t3RIS">8</a>, and the financial statements and related notes included
in this prospectus.</I> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Company Overview</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage specialty pharmaceutical company focused on acquiring, developing and commercializing novel products in the field of urology. We have multiple urology-focused products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs in the field of urology. We are initially concentrating on hypogonadism, prostate cancer, urinary tract infections, and male infertility and plan to expand into other urological indications for which there are significant medical needs. Our fiscal year end is June 30. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recently acquired exclusive U.S. rights to Natesto&reg; (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we launched Natesto in the United States with our direct sales force in July 2016. Natesto is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. Importantly, as Natesto is delivered via the nasal mucosa
and not the skin, there is no risk of testosterone transference to others, a known potential side effect and black box warning associated with all other topically applied TRTs, including the market leader AndroGel&reg;. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently market ProstaScint&reg; (capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. ProstaScint is approved by the FDA for use in both newly diagnosed, high-risk prostate cancer patients and patients with recurrent prostate cancer. We also market Primsol&reg; (trimethoprim hydrochloride)&nbsp;&#151;&nbsp;the only FDA-approved trimethoprim-only oral solution for urinary tract infections. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have a focused pipeline, including MiOXSYS<sup>TM</sup>, a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic Area (see &#147;Business&nbsp;&#151;&nbsp; Foreign Regulatory Approval&#148;)) and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our MiOXSYS system is a novel, point-of-care semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility. Male infertility is a prevalent and underserved condition and oxidative stress is widely implicated in its pathophysiology. MiOXSYS was developed from our core oxidation-reduction potential research platform known as RedoxSYS&reg;. We are advancing MiOXSYS toward FDA clearance and, as of the date of this prospectus, we will need to raise additional funding to complete the required clinical study. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the future we will look to acquire additional urology products, including existing products we believe can offer distinct commercial advantages. Our management team&#146;s prior experience has involved identifying clinical assets that can be re-launched to increase value, with a focused commercial infrastructure specializing in urology. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fiscal 2016 Corporate Highlights</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Executed on our commercial-focused business strategy, acquiring two additional FDA-approved, revenue-generating urology products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Secured exclusive U.S. rights to Natesto&reg;, the only FDA-approved nasally-administered testosterone product and only topically applied testosterone product without a black box safety warning;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Acquired global rights to Primsol&reg;, the only FDA-approved trimethoprim-only oral solution for treating urinary tract infections;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Built and expanded our commercial infrastructure, including proven commercial leadership and a nationwide specialty sales force;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Secured CE Marking and approval by Health Canada for MiOXSYS<sup>TM</sup>, our novel, proprietary device for the rapid assessment of male infertility; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Appointed three independent board directors and established the full spectrum of corporate governance policies and procedures in compliance with the listing requirements for both NYSE and NASDAQ. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fiscal 2016 Financial Highlights</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Grew annual revenues nearly ten-fold from $262,000 in fiscal 2015 to $2.6 million in fiscal 2016 (recently licensed Natesto is not included in either of these revenue numbers, as it was launched in July 2016);</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Demonstrated consistent quarterly revenue growth, with sales of $469,000, $669,000, and $937,000 in fiscal quarters two, three, and four, respectively;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Raised sufficient initial growth capital through convertible note and equity offerings to support our initial commercial infrastructure and three product launches; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Ended fiscal 2016 with $8.1 million in cash and cash equivalents. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto&reg; (testosterone) nasal gel.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into an agreement to acquire the exclusive U.S. rights to Natesto (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired on July 1, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable, Transportation Security Administration, or TSA-compliant, and easy to use. Importantly, Natesto is not
applied directly to the patient&#146;s skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a proprietary nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&#146;s female partner or children&nbsp;&#151;&nbsp;as other topically (primarily gels and solutions) administered TRTs do by virtue of their delivery directly onto the skin. We launched Natesto in the U.S. in July 2016 with our direct sales force, and we are positioning Natesto as the ideal treatment solution for men with active, busy lifestyles who suffer from hypogonadism. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint&reg; (capromab pendetide).</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We became a commercial stage company by virtue of our acquisition of ProstaScint in May 2015 and are generating sales of this FDA-approved prostate cancer imaging agent. As prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused product portfolio and pipeline. Prostate cancer is the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2,200,000 men were alive in 2006 with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on
healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion by 2017, a compound annual growth rate, or CAGR, of 7.5% since 2012. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol&reg; (trimethoprim solution).</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, we purchased Primsol from FSC Laboratories, Inc. Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections, or UTIs. This differentiated product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (&#147;sulfa&#148;). It is estimated that 150 million cases of urinary tract infections occur annually worldwide, and the annual estimated incidence is
0.5&nbsp;&#150;&nbsp;0.7/persons per year. Importantly, there are more than 1 million catheter-associated UTIs in the U.S. alone. As many of these patients are elderly and unable to swallow pills, an oral liquid formulation represents a convenient formulation for easier </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">administration. The acquisition of Primsol added a second established brand to our product portfolio. We expect to benefit from and continue to grow Primsol&#146;s established base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously marketed to these specialists. We can thus utilize the same sales channel as ProstaScint, leading to potential commercial synergies and product growth. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS<sup>TM</sup>.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">MiOXSYS is a rapid in vitro diagnostic semen analysis test used in the quantitative measurement of static oxidation reduction potential, or sORP, in human semen. MiOXSYS is a recently CE marked system and is an accurate, easy to use, and fast infertility assessment tool. It is estimated that 72.4 million couples worldwide experience infertility problems. In the United States, approximately 10% of couples are defined as infertile. Male infertility is responsible for between 40&nbsp;&#150;&nbsp;50% of all infertility cases and affects approximately 7% of all men. Male infertility is often unexplained (idiopathic), and this
idiopathic infertility is frequently associated with levels of oxidative stress in the semen. As such, having a rapid, easy-to-use diagnostic platform to measure oxidative stress should provide a practical way for male infertility specialists to improve semen analysis and infertility assessments without having to refer patients to outside clinical laboratories. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. The global male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess the
degree of oxidative stress, sperm motility and morphology, and potentially enable the monitoring of patients&#146; responses to antioxidant therapy as a treatment regimen for infertility. The MiOXSYS System received CE marking in Europe in January 2016 and obtained Health Canada Class II Medical Device approval in March 2016. We expect to advance MiOXSYS into clinical trials in the United States in order to enable 510(k) clearance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the MiOXSYS system, we are continuing to develop the global market for the RedoxSYS System across a range of applications. Specifically, we have begun initial commercializing of the RedoxSYS System for research use through distribution partners, primarily outside the U.S. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The technology underpinning the RedoxSYS and MiOXSYS systems was developed by Luoxis Diagnostics, Inc. in the two years immediately preceding the merger between Luoxis, Vyrix Pharmaceuticals, Inc., and us (under our former name of Rosewind Corporation) in April 2015. Upon the consummation of the merger, the RedoxSYS System and MiOXSYS System became our assets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Key elements of our business strategy include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of Natesto in the U.S. for the treatment of hypogonadism with our direct sales force. We launched Natesto in July 2016 and are targeting highprescribing TRT prescribers with a primary emphasis on urologists and male health practitioners.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of FDA-approved ProstaScint for the staging of both newly diagnosed high-risk and recurrent prostate cancer patients. We have begun commercializing ProstaScint in the U.S. and in key markets around the world.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of FDA-approved Primsol for the treatment of uncomplicated urinary tract infections. We are re-launching Primsol to urologists in the U.S. and in key markets around the world where appropriate.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Establish MiOXSYS as a leading in vitro diagnostic device in the assessment of male infertility.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Acquire additional marketed products and late-stage development assets within our core urology focus that can be efficiently marketed through our growing commercial organization.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Develop a pipeline of urology therapeutics, with a focus on identifying novel products with sufficient clinical proof of concept that require modest internal R&amp;D expense. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to augment our core in-development and commercial assets through efficient identification of complementary therapeutics, devices, and diagnostics related to urological disorders. We intend to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through asset purchases, licensing, co-development, or collaborative commercial arrangements (co-promotions, co-marketing, etc.). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management team has extensive experience across a wide range of business development activities and have in-licensed or acquired products from large, mid-sized, and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect that we will build a substantial portfolio of complementary urology products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We previously were developing Zertane for the treatment of premature ejaculation, or PE. However, we determined to direct our resources to our commercial stage products. As a result, at the end of fiscal 2016, we determined that the Zertane asset has no value as we do not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. We intend to sell or out-license Zertane although there can be no assurance that we will be successful in doing so or, if successful, the value, if any, we will receive for the asset. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Recent Developments</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our U.S.-based sales force was expanded in July 2016 and has now initiated promotion with a primary focus on Natesto. In the first six weeks since our sales force began promoting Natesto to urologists, endocrinologists, and other high-prescribing TRT targets, new prescriptions have grown every week. We believe new prescriptions have grown during this time due to our distinct focus on Natesto and the product&#146;s attractive profile. Additionally, redemptions for our Natesto co-pay coupons have increased significantly since field promotion began the week of July 25, 2016. As such, the number of weekly co-pay redemptions has
already exceeded the previous 2016 weekly high when Natesto was being promoted by the previous U.S. marketing partner, Endo Pharmaceuticals. Finally, we have implemented the Assure Rx program across all filled sales territories. This program has been developed to enable reduced co-pays and patient assistance with insurance reimbursement; prescriptions of Natesto have already been filled at Assure Rx partner pharmacies. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Corporate Information</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Vyrix Pharmaceuticals, Inc., or Vyrix, was incorporated under the laws of the State of Delaware on November 18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), or Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out of the sexual dysfunction therapeutics business, including the late-stage men&#146;s health product candidates, Zertane and Zertane-ED, from Ampio, which carve out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws of the State of Delaware on January 24, 2013 and was majority owned by
Ampio immediately prior to the completion of the Merger. Luoxis was focused on initially developing and advancing the RedoxSYS System. The MiOXSYS System was developed following the completed development of the RedoxSYS System. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On March 20, 2015, Rosewind formed Rosewind Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of the Merger, and on April 16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis, and Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into Rosewind with Rosewind as the surviving corporation (herein referred to as the Merger). Concurrent </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">with the closing of the Merger, Rosewind abandoned its pre-merger business plans, and we now solely pursue the specialty healthcare market, focusing on urological related conditions, including the business of Vyrix and Luoxis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 8, 2015, we (i) reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and (ii) effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares outstanding. On June 1, 2016, we amended our Certificate of Incorporation to reduce the number of authorized shares of common stock from 300.0 million to 100.0 million. On June 30, 2016, we amended our Certificate of Incorporation to effect a reverse stock split at a ratio of 1-for-12. The June 8, 2015 and June 30,
2016 reverse stock splits are herein referred to collectively as the Reverse Stock Splits. All financial data and share amounts in this prospectus give effect to the Reverse Stock Splits. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our principal executive office is located at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112. Our telephone number at our principal executive office is (720) 437-6580. Our corporate website is <I>http://aytubio.com.</I> The information on our corporate website is not part of, and is not incorporated by reference into, this prospectus. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t2THE"></a>THE OFFERING</Font> </H1>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Issuer </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">Aytu BioScience, Inc. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Securities offered by us </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock and warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Public offering price </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">$&nbsp;&nbsp;&nbsp;&nbsp; per share and $&nbsp;&nbsp;&nbsp;&nbsp; per warrant </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Option to purchase additional shares </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We have granted the underwriters an option for a period of 45 days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock and/or &nbsp;&nbsp;&nbsp;&nbsp; warrants, at the public offering price, less the underwriting discount. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Warrants </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">Each warrant will be exercisable for a period commencing on the date of issuance and expiring May 2, 2021 and have an exercise price of $6.00 per share. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Common stock to be outstanding immediately after this offering </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;&nbsp;&nbsp;&nbsp; shares, or &nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in full their option to purchase an additional&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock and/or &nbsp;&nbsp;&nbsp;&nbsp; warrants.<sup>(1)</sup> </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Use of proceeds </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We intend to use the net proceeds from this offering to (1) fund the final upfront payment of $4 million to Acerus under the license and supply agreement we entered into on April 22, 2016 to acquire Natesto; and (2) obtain additional capital to fund the further commercialization of Natesto, ProstaScint and Primsol, (3) to purchase complementary urology products and/or product candidates that will enhance our product portfolio and enable expansion of our commercial operations, (4) fund the remaining clinical development activities for MiOXSYS, to enable FDA clearance and (5) working capital for general corporate and administrative expenses. See &#147;Use of Proceeds&#148; on page <a href="#t5USE">46</a>. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Risk factors </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">This investment involves a high degree of risk. You should read the description of risks set forth under &#147;Risk Factors&#148; beginning on page <a href="#t3RIS">8</a> of this prospectus for a discussion of factors to consider before deciding to purchase our securities. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">OTCQX Trading Symbol of Common and Warrants </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&#147;AYTU&#148; and &#147;AYTUW&#148;, respectively. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Potential NYSE MKT Listing </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We intend to apply to list our common stock and warrants on the NYSE MKT under the symbols &#147;AYTU&#148; and &#147;AYTUW&#148;, respectively, once we meet NYSE listing standards. It is not clear when, or if, we will meet those standards. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Lock-up </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We and our directors and executive officers and certain stockholders have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after the date of this prospectus in the case of our directors and executive officers, and 90 days in the case of our company. See &#147;Underwriting&#148; beginning on page <a href="#t16UND">116</a>. </TD>

</TR>

</TABLE></DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Registered Securities </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">This prospectus also relates to the offering of the shares of common stock issuable upon the exercise of the warrants and the Underwriters&#146; warrants.</TD>

</TR>

</TABLE>

<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Based on 5,070,591 shares outstanding on August 31, 2016. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless otherwise indicated, all information in this prospectus assumes no exercise by the underwriters of their option to purchase up to shares of common stock and/or up to warrants to cover over-allotments, if any, and excludes as of August 31, 2016 (i) 762,217 shares of our common stock issuable upon exercise of outstanding stock options under our 2015 Stock Option and Incentive Plan at a weighted average exercise price of $3.52 per share, (ii) 2,284,465 shares of our common stock issuable upon exercise of outstanding warrants with an exercise price of $6.11 per share, (iii) shares of common stock issuable upon exercise of
the warrants offered hereby and (iv) shares of common stock underlying the warrants to be issued to the underwriters in connection with this offering.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t3RIS"></a>RISK FACTORS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Investing in our securities includes a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific factors discussed below, together with all of the other information contained in this prospectus. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our common stock to decline and could cause you to lose all or part of your investment.</I> </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Our Financial Condition and Capital Requirements</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern and may do so again in the future.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In their report accompanying our audited financial statements, our independent registered public accounting firm expressed substantial doubt as to our ability to continue as a going concern. A &#147;going concern&#148; opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. We believe our entry into the Purchase Agreement with Lincoln Park, pursuant to which, if we meet the conditions, we can require Lincoln Park to purchase up to $10.0 million of our common stock, can provide us with available capital, provided we can meet those conditions, of which
there can be no assurance. However, our ability to continue as a going concern will depend on our ability to obtain additional financing. Additional capital may not be available on reasonable terms, or at all. If adequate financing is not available, we would be required to terminate or significantly curtail our operations, or enter into arrangements with collaborative partners or others that may require us to relinquish rights to certain aspects of our products or product candidates, or potential markets that we would not otherwise relinquish. If we are unable to raise additional capital, our business would be jeopardized and we may not be able to continue operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have a limited operating history, have incurred losses, and can give no assurance of profitability.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage healthcare company with a limited operating history. Prior to implementing our commercial strategy in the fourth calendar quarter of 2015, we did not have a focus on profitability. As a result, we have not generated substantial revenue to date and are not profitable, and have incurred losses in each year since our inception. Our net loss for the years ended June 30, 2016 and 2015 was $28.2 million and $7.7 million, respectively. We have not demonstrated the ability to be a profit-generating enterprise to date, and without significant financing, there is substantial doubt about our ability to continue
as a going concern. We expect to incur substantial losses for the foreseeable future. Our ability to generate significant revenue is uncertain, and we may never achieve profitability. We have a very limited operating history on which investors can evaluate our potential for future success. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered by early-stage healthcare businesses, many of which will be beyond our control. These risks include the following:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">uncertain market acceptance of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">U.S. regulatory approval of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">foreign regulatory approval of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">lack of sufficient capital;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unanticipated problems, delays, and expense relating to product development and implementation;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">lack of sufficient intellectual property;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">competition; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">technological changes. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of our limited operating history, and the increasingly competitive nature of the markets in which we compete, our historical financial data, which, prior to April 16, 2015, consists of allocations of expenses from Ampio, is of limited value in anticipating future operating expenses. Our planned expense levels will be based in part on our expectations concerning future operations, which is difficult to forecast accurately based </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">on our limited operating history and the recentness of the acquisition of our products ProstaScint, Primsol and Natesto. We may be unable to adjust spending in a timely manner to compensate for any unexpected budgetary shortfall. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not received any substantial revenues from the commercialization of our current products to date and might not receive significant revenues from the commercialization of our current products or our product candidates in the near term. Even though ProstaScint and Primsol are each an approved drug that we are marketing, we only acquired ProstaScint in May 2015 and Primsol in October 2015 and have limited experience on which to base the revenue we could expect to receive from their sales. We acquired Natesto in April 2016 and launched it in July 2016 and consequently have no meaningful experience on which to base expected
revenue from Natesto. To obtain revenues from our products and product candidates, we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing products and completing clinical trials of our product candidates, obtaining positive results from those clinical trials, achieving marketing approval for those product candidates, manufacturing, marketing and selling our existing products and those products for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. We, and our collaborators, if any, may never succeed in these activities and, even if we do, or one of our collaborators does, we may never generate revenues that are sufficient enough for us to achieve profitability. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our product expansion and development efforts or other operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are expending resources to expand the market for Natesto, ProstaScint and Primsol, none of which might be as successful as we anticipate or at all and all of which might take longer and be more expensive to market than we anticipate. We also are currently advancing our product candidates through clinical development. Developing product candidates is expensive, lengthy and risky, and we expect to incur research and development expenses in connection with our ongoing clinical development activities with the MiOXSYS System. We also will need additional capital to uplist our common stock to the NYSE MKT. As of June 30, 2016, our
cash and cash equivalents were $8.1 million available to fund our operations offset by an aggregate $8.9 million in accounts payable and accrued liabilities and the Natesto payable. In May 2016, we conducted a public offering of our common stock and warrants from which we received net cash proceeds of approximately $6.6 million. Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to continue the expansion of marketing efforts for Natesto, ProstaScint and Primsol and to obtain regulatory approval for, and to commercialize, our current product candidate, the MiOXSYS System. Raising funds in the current
economic environment, as well our lack of operating history, may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. We intend to rely on the purchase agreement (the &#147;Purchase Agreement&#148;) we entered into with Lincoln Park Capital Fund, LLC in July 2016 for our capital needs, including further commercialization of our currently approved products. If we were unable to access a portion or the full amount of the Purchase Agreement, in the absence of any other financing sources, it would have a material adverse impact on our operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to expand any existing product or develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of
additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to obtain funding on a timely basis, we may be unable to expand the market for Natesto, ProstaScint or Primsol and/or be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of our current product candidate, the MiOXSYS system, or any future product candidate or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we do not obtain the capital necessary to fund our operations, we will be unable to successfully expand the commercialization of Natesto, ProstaScint and Primsol and to develop, obtain regulatory approval of, and commercialize, our current product candidate, the MiOXSYS System.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The expansion of marketing and commercialization activities for our existing products and the development of pharmaceutical products, medical diagnostics and medical devices is capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements will depend on, and could increase significantly as a result of, many factors including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs, progress and timing of our efforts to expand the marketing of Natesto, ProstaScint and Primsol;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">progress in, and the costs of, our pre-clinical studies and clinical trials and other research and development programs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of securing manufacturing arrangements for commercial production;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the scope, prioritization and number of our research and development programs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of establishing, expanding or contracting for sales and marketing capabilities for any existing products and if we obtain regulatory clearances to market our current product candidate, the MiOXSYS system;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual property rights. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts or our technologies, research or development programs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may not be able to access the full amounts available under the Lincoln Park Purchase Agreement, which could prevent us from accessing the capital we need to continue our operations, which could have an adverse effect on our business.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to rely on the purchase agreement (the &#147;Purchase Agreement&#148;) we entered into with Lincoln Park Capital Fund, LLC (&#147;Lincoln Park&#148;) in July 2016 for our near-term capital needs, including further commercialization of our currently approved products. After selling $500,000 of common stock on the day we executed the Purchase Agreement, pursuant to the terms of the Purchase Agreement, we may direct Lincoln Park to purchase up to $10,000,000 worth of shares of our common stock over a 36-month period, commencing upon the satisfaction of certain conditions, including that the registration statement is
declared effective by the SEC. Thereafter, on any trading day selected by us, we may sell shares of common stock to Lincoln Park in amounts up to 10,000 shares per regular sale (Regular Purchases), which may be increased to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">up to 20,000 shares depending on certain conditions as set forth in the Purchase Agreement, up to the aggregate commitment of $10,000,000. If the market price of our common stock is not below $7.00 per share on the purchase date, then the Regular Purchase amount may be increased to 15,000 shares. If the market price is not below $9.00 per share on the purchase date, then the Regular Purchase amount may be increased to 20,000 shares. Although there are no upper limits on the per share price Lincoln Park may pay to purchase our common stock, the Company may not sell more than $500,000 in shares of common stock to Lincoln Park per
any individual Regular Purchase. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to Regular Purchases, we may in our sole discretion direct Lincoln Park on each purchase date to make &#147;accelerated purchases&#148; on the following business day up to the lesser of (i) three times the number of shares purchased pursuant to such Regular Purchase or (ii) 30% of the trading volume on the accelerated purchase date at a purchase price equal to the lesser of (i) the closing sale price on the accelerated purchase date and (ii) 95% of the accelerated purchase date&#146;s volume weighted average price. We cannot submit an accelerated purchase notice if the stock price is below $3.00. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The purchase price of the shares related to the Purchase Agreement will be based on the prevailing market prices of the Company&#146;s shares of common stock, which shall be equal to the lesser of the lowest sale price of the common shares during the purchase date and the average of the three lowest closing sale prices of the common shares during the ten business days prior to the purchase date without any fixed discount. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depending on the prevailing market price of our common stock, we may not be able to sell shares to Lincoln Park for the maximum $10,000,000 over the term of the Purchase Agreement. Our inability to access a portion or the full amount of the Purchase Agreement, in the absence of any other financing sources, would have a material adverse impact on our operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our investment in Acerus Pharmaceuticals Corporation could decline in value.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 28, 2016, we purchased approximately $2.0 million worth of shares of common stock of Acerus Pharmaceutics Corporation as a condition to our licensing of Natesto. The per share purchase price was Cdn. $0.207. Acerus common stock is traded on the Toronto Stock Exchange under the symbol &#147;ASP.&#148; On August 31, 2016, the closing price per share was Cdn. $0.22. During the time that we own these shares, there can be no assurance that the value of that stock will not decline and we could lose our entire investment in that stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We will incur increased costs associated with, and our management will need to devote substantial time and effort to, compliance with public company reporting and other requirements.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a public company, we incur significant legal, accounting and other expenses that we did not incur as private companies during the majority of fiscal 2015. In addition, the rules and regulations of the SEC and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our corporate governance practices, with which we will need to comply. Further, we will continue to be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results. Based on currently available
information and assumptions, we estimate that we will incur approximately $0.5 million in expenses on an annual basis as a direct result of the requirements of being a publicly traded company. Our management and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those requirements could be expensive. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management conducted an assessment of the effectiveness of our internal control over financial reporting for the year ended June 30, 2016, and concluded that such control was effective. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">However, if in the future we were to conclude that our internal control over financial reporting were not effective, we cannot be certain as to the timing of completion of our evaluation, testing and remediation </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">11</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">actions or their effect on our operations because there is presently no precedent available by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section 404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn, could require us to restate our
operating results. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to conclude that we have effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us, when required, with an attestation report on the effectiveness of internal control over financial reporting as required by Section 404 of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to obtain listing on a securities
exchange such as the NYSE MKT. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Product Development, Regulatory Approval and Commercialization</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto, ProstaScint and Primsol may prove to be difficult to effectively commercialize as planned.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues from sales of Natesto, ProstaScint and Primsol. Specifically, we may encounter difficulty by virtue of:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to secure continuing prescribing of any of these products by current or previous users of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to effectively transfer and scale manufacturing as needed to maintain an adequate commercial supply of these products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of Natesto, ProstaScint or Primsol; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to effectively identify and align with commercial partners outside the United States, or the inability of those selected partners to gain the required regulatory, reimbursement, and other approvals needed to enable commercial success of ProstaScint or Primsol. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have limited experience selling our current products as they have been acquired from another company or are newly approved for sale. As a result, we may be unable to successfully commercialize our products and product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Despite our management&#146;s extensive experience in launching and managing commercial-stage healthcare companies, we have limited marketing, sales and distribution experience with our current products. Our ability to achieve profitability depends on attracting and retaining customers for our current products, and building brand loyalty for Natesto, ProstaScint and Primsol. To successfully perform sales, marketing, distribution and customer support functions, we will face a number of risks, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to attract and retain skilled support team, marketing staff and sales force necessary to increase the market for our approved products and to maintain market acceptance for our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the ability of our sales and marketing team to identify and penetrate the potential customer base; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the difficulty of establishing brand recognition and loyalty for our products. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, we may seek to enlist one or more third parties to assist with sales, distribution and customer support globally or in certain regions of the world. If we do seek to enter into these arrangements, we may not be successful in attracting desirable sales and distribution partners, or we may not be able to enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those of any third-party </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">12</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">sales and distribution partners, are not successful, our currently approved products may not achieve increased market acceptance and our product candidates may not gain market acceptance, which would materially impact our business and operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not be able to develop our current or any future product candidates. Our product candidates will require substantial additional clinical development, testing, and regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale
of any product candidate, we must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory approval process and is commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical programs, we cannot assure you that any of our product candidates will be successfully developed or commercialized. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are not permitted to market a product in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not be able to demonstrate that a product candidate is safe and effective to the satisfaction of the FDA;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may require that we conduct additional clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may not approve the formulation, labeling or specifications of any product candidate;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients or the public in general;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may disagree with our interpretation of data from our pre-clinical studies and clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may not accept data generated at our clinical trial sites;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">if an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA may change its approval policies or adopt new regulations. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These same risks apply to applicable foreign regulatory agencies from which we may seek approval for any of our product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate. Moreover, because a substantial portion of our business is or may be dependent upon our product candidates, any such setback in our pursuit of initial or additional regulatory approval would have a material adverse effect on our business and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we fail to successfully acquire new products, we may lose market position.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Acquiring new products is an important factor in our planned sales growth, including products that already have been developed and found market acceptance. If we fail to identify existing or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue source to help pay for our development activities as well as possible acquisitions. This failure would delay implementation of our business plan, which could have a negative adverse effect on our business and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we do not secure collaborations with strategic partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop products and generate meaningful revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may enter into collaborations with third parties to conduct clinical testing, as well as to commercialize and manufacture our products and product candidates. If we are able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and safety, obtaining regulatory approvals, and clinical trial results. Collaboration
revenues are not guaranteed, even when efficacy and safety are demonstrated. The current economic environment may result in potential collaborators electing to reduce their external spending, which may prevent us from developing our product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we succeed in securing collaborators, the collaborators may fail to develop or effectively commercialize our products or product candidates. Collaborations involving our product candidates pose a number of risks, including the following:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may not have sufficient resources or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may delay the development or commercialization of our product candidates in favor of developing or commercializing their own or another party&#146;s product candidate; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborators may decide to terminate or not to renew the collaboration for these or other reasons. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result, collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. For example, our former collaborator that licensed Zertane conducted clinical trials which we believe demonstrated efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic focus and thereafter terminated the collaboration agreement. The </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">14</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Merger also created a potential conflict with a principal customer of the acquired company, which sells a product to treat premature ejaculation in certain European markets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Collaboration agreements are generally terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&#146;s objectives and meet our expectations, we may be unable to advance our products or product candidates and may not generate meaningful revenues. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We or our strategic partners may choose not to continue an existing product or choose not to develop a product candidate at any time during development, which would reduce or eliminate our potential return on investment for that product.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At any time and for any reason, we or our strategic partners may decide to discontinue the development or commercialization of a product or product candidate. If we terminate a program in which we have invested significant resources, we will reduce the return, or not receive any return, on our investment and we will have missed the opportunity to have allocated those resources to potentially more productive uses. If one of our strategic partners terminates a program, we will not receive any future milestone payments or royalties relating to that program under our agreement with that party. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our pre-commercial product candidates are expected to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we or our collaborators may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pre-clinical testing and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical testing and clinical development necessary to commercialize a drug or biologic, and delays or failure can occur at any stage. Interim results of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful. A number
of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An unfavorable outcome in one or more trials would be a major set-back for that product candidate and for us. Due to our limited financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more product development programs, which could have a material adverse effect on our business, prospects and financial condition and on the value of our common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with clinical testing and trials, we face a number of risks, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a product candidate is ineffective, inferior to existing approved medicines, unacceptably toxic, or has unacceptable side effects;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">patients may die or suffer other adverse effects for reasons that may or may not be related to the product candidate being tested;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results may not confirm the positive results of earlier testing or trials; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results may not meet the level of statistical significance required by the FDA or other regulatory agencies to establish the safety and efficacy of the product candidate. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we do not successfully complete pre-clinical and clinical development, we will be unable to market and sell products derived from our product candidates and generate revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before an NDA may be submitted to the FDA. Although there are a large number of drugs and biologics in development in the United States and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved for commercialization, and only a small number achieve
</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">15</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">widespread physician and consumer acceptance following regulatory approval. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not receive regulatory approval of any of these product candidates and our business, prospects and financial condition will be materially harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Delays, suspensions and terminations in any clinical trial we undertake could result in increased costs to us and delay or prevent our ability to generate revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Human clinical trials are very expensive, time-consuming, and difficult to design, implement and complete. Should we undertake the development of a pharmaceutical product candidate, we would expect the necessary clinical trials to take up to 24 months to complete, but the completion of trials for any product candidates may be delayed for a variety of reasons, including delays in:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">validating test methods to support quality testing of the drug substance and drug product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining sufficient quantities of the drug substance or device ports;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">manufacturing sufficient quantities of a product candidate;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining approval of an IND from the FDA;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">determining dosing and clinical design and making related adjustments; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective treatments for the relevant disease and the eligibility criteria for the clinical trial. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The commencement and completion of clinical trials for our product candidates may be delayed, suspended or terminated due to a number of factors, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">lack of effectiveness of product candidates during clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse events, safety issues or side effects relating to the product candidates or their formulation or design;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">inability to raise additional capital in sufficient amounts to continue clinical trials or development programs, which are very expensive;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the need to sequence clinical trials as opposed to conducting them concomitantly in order to conserve resources;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to enter into collaborations relating to the development and commercialization of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure by us or our collaborators to conduct clinical trials in accordance with regulatory requirements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability or the inability of our collaborators to manufacture or obtain from third parties materials sufficient for use in pre-clinical studies and clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect to clinical trial results;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure of our collaborators to advance our product candidates through clinical development;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">16</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in patient enrollment, variability in the number and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">difficulty in patient monitoring and data collection due to failure of patients to maintain contact after treatment;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a regional disturbance where we or our collaborative partners are enrolling patients in our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">varying interpretations of our data, and regulatory commitments and requirements by the FDA and similar foreign regulatory agencies. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Many of these factors may also ultimately lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical trial, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, we may encounter delays or product candidate rejections based on new governmental regulations, future legislative or administrative actions, or changes in FDA policy or interpretation during the period of product development. If we obtain required regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">diminishment of any competitive advantages that such product candidates may have or attain. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Furthermore, if we fail to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">diminishment of any competitive advantages that such product candidates may have or attain;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays or termination in clinical trials or commercialization;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements to approved applications;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">product recalls or seizures;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">suspension of manufacturing;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawals of previously approved marketing applications; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">fines, civil penalties, and criminal prosecutions. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The medical device regulatory clearance or approval process is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances or approvals could prevent us from broadly commercializing the MiOXSYS System for clinical use.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System is subject to 510(k) clearance by the FDA prior to its marketing for commercial use in the United States, and to regulatory approvals beyond CE marking required by certain foreign governmental entities prior to its marketing outside the United States. In addition, any changes or modifications to a device that has received regulatory clearance or approval that could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, may require the submission of a new application for 510(k) clearance, pre-market approval, or foreign regulatory approvals. The 510(k)
clearance and pre-market approval processes, as well as the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve months from submission to obtain 510(k) clearance, and from one to three years from submission to obtain pre-market approval; however, it may take longer, and 510(k) clearance or pre-market approval may never be obtained. We have limited experience in filing FDA applications for 510(k) clearance and pre-market approval. In addition, we are required to continue to comply with applicable FDA and other regulatory requirements even after obtaining clearance or approval. There can be no assurance that we will obtain or maintain any required clearance or approval on a timely </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">17</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">basis, or at all. Any failure to obtain or any material delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The approval process for pharmaceutical and medical device products outside the United States varies among countries and may limit our ability to develop, manufacture and sell our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to market and sell our products in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional testing. We may conduct clinical trials for, and seek regulatory approval to market, our product candidates in countries other than the United States. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may decide to first seek regulatory approvals of a product candidate
in countries other than the United States, or we may simultaneously seek regulatory approvals in the United States and other countries. If we or our collaborators seek marketing approval for a product candidate outside the United States, we will be subject to the regulatory requirements of health authorities in each country in which we seek approval. With respect to marketing authorizations in Europe, we will be required to submit a European Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, which conducts a validation and scientific approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries and may involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining regulatory approvals from health authorities in countries outside the United States is likely to subject us to all of the risks associated with obtaining FDA approval described above. In addition, marketing approval by the FDA does not ensure approval by the health authorities of any other country, and approval by foreign health authorities does not ensure marketing approval by the FDA. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Even if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or they market our products, which could materially impair our ability to generate revenue.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we receive regulatory approval for a product candidate, this approval may carry conditions that limit the market for the product or put the product at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can market a product or the patient population that may utilize the product, or may be required to carry a warning in its labeling and on its packaging. Products with boxed warnings are subject to more restrictive advertising regulations than products without such warnings. These restrictions could make it more difficult to market any
product candidate effectively. Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators expect to continue to expend time, money and effort in all areas of regulatory compliance. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any of our products and product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of our approved products and product candidates for which we, or our collaborators, obtain marketing approval, as well as the manufacturing processes, post approval studies and measures, labeling, advertising and promotional activities for such products, among other things, are or will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of
records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">18</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">the indicated uses for which the product may be marketed or to the conditions of approval, including the FDA requirement to implement a REMS to ensure that the benefits of a drug or biological product outweigh its risks. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding off-label use and if we, or our collaborators, do not market any of our product
candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed, and our business will be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the initiation or completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product.
The achievement of many of these milestones may be outside of our control. All of such milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our available capital resources or capital constraints we experience;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll patients who meet clinical trial eligibility criteria;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our receipt of approvals from the FDA and other regulatory agencies and the timing thereof;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other actions, decisions or rules issued by regulators;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to access sufficient, reliable and affordable supplies of compounds used in the manufacture of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the efforts of our collaborators with respect to the commercialization of our products; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business, prospects and results of operations may be harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely, and will rely in the future, on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical trials conducted in reliance on third parties may be delayed, suspended, or terminated if:</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">19</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the third parties do not successfully carry out their contractual duties or fail to meet regulatory obligations or expected deadlines;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we replace a third party; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the quality or accuracy of the data obtained by third parties is compromised due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Even if collaborators with which we contract in the future successfully complete clinical trials of our product candidates, those product candidates may not be commercialized successfully for other reasons.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we contract with collaborators that successfully complete clinical trials for one or more of our product candidates, those candidates may not be commercialized for other reasons, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to receive regulatory clearances required to market them as drugs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">being subject to proprietary rights held by others;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">being difficult or expensive to manufacture on a commercial scale;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">having adverse side effects that make their use less desirable; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failing to compete effectively with products or treatments commercialized by competitors. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization as a result of these regulations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The manufacturing processes and facilities of third-party manufacturers we have engaged for our current approved products are, and any future third-party manufacturer will be, required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product
commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">administrative or judicially imposed sanctions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctions or the imposition of civil penalties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">recall or seizure of the product in question;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">total or partial suspension of production or distribution;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA&#146;s refusal to grant pending future clearance or pre-market approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawal or suspension of marketing clearances or approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical holds;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">warning letters;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal to permit the export of the product in question; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">criminal prosecution. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">20</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We face substantial competition from companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We compete with companies that design, manufacture and market already-existing and new urology products. We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and/or our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest
in new technologies, more substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">expand the market for our approved products, especially Natesto, ProstaScint and Primsol;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">successfully commercialize our product candidates alone or with commercial partners;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">discover and develop product candidates that are superior to other products in the market;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtain required regulatory approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">attract and retain qualified personnel; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtain patent and/or other proprietary protection for our product candidates. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Established pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could make our products and product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us. Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are developing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto competes in a large, growing market. The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the MiOXSYS System and ProstaScint, we compete with companies that design, manufacture and market already existing and new in-vitro diagnostics and diagnostic imaging systems and radio-imaging agents for cancer detection. Additionally, with respect to Primsol, we compete with numerous companies who produce antimicrobial treatments for various pathogens inclusive of products containing trimethoprim as contained in Primsol. There are any number of antibiotics available on the market that could compete with Primsol. Even though Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well
established in current guidelines for treating UTIs, we may not be able to effectively compete with these existing antibiotics. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience in new product development, greater regulatory expertise,
more </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">21</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any new product we develop or commercialize that competes with a currently-approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect one or more of the following:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our or our collaborators&#146; ability to set a price we believe is fair for our approved products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to generate revenue from our approved products and achieve profitability; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the availability of capital. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2010 enactments of the Patient Protection and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation Act, are expected to significantly impact the provision of, and payment for, health care in the United States. Various provisions of these laws have only recently taken effect or have yet to take effect, and are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide
additional support for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and medical devices and reduce demand and prices for our products and product candidates, if approved. This could harm our or our collaborators&#146; ability to market any approved products and generate revenues. As we expect to receive significant revenues from reimbursement of our Natesto, ProstaScint and Primsol products by commercial third-party payors and government payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any of our products and product candidates approved in the future, and could cause an increase in our compliance,
manufacturing, or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us to sell any approved product at a price acceptable to us or any of our future collaborators. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in some foreign countries, the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the medicinal product on the market. A member state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched in the European Union do not follow price structures of the United States and generally tend to have significantly lower prices. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">22</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our financial results will depend on the acceptance among hospitals, third-party payors and the medical community of our products and product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our future success depends on the acceptance by our target customers, third-party payors and the medical community that our products and product candidates are reliable, safe and cost-effective. Many factors may affect the market acceptance and commercial success of our products and product candidates, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to convince our potential customers of the advantages and economic value our products and product candidates over existing technologies and products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the relative convenience and ease of our products and product candidates over existing technologies and products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the introduction of new technologies and competing products that may make our products and product candidates less attractive for our target customers;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our success in training medical personnel on the proper use of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the willingness of third-party payors to reimburse our target customers that adopt our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the acceptance in the medical community of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the extent and success of our marketing and sales efforts; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">general economic conditions. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If third-party payors do not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While Natesto, ProstaScint and Primsol are already FDA-approved and generating revenues in the U.S., they may not receive, or continue to receive, physician or hospital acceptance, or they may not maintain adequate reimbursement from third party payors. Additionally, even if one of our product candidates is approved and reaches the market, the product may not achieve physician or hospital acceptance, or it may not obtain adequate reimbursement from third party payors. We expect to sell our Primsol products and possibly other product candidates to target customers substantially all of whom receive reimbursement for the health
care services they provide to their patients from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&#146;s determination that use of a product is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a covered benefit under its health plan;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">appropriate and medically necessary for the specific indication;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">cost effective; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">neither experimental nor investigational. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining coverage and reimbursement approval for a product from each government or third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that allows our potential customers to make a profit or even cover their
costs. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">23</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our products, which would result in a significant shortfall in achieving
revenue expectations and negatively impact our business, prospects and financial condition. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing risks and inefficiencies may adversely affect our ability to produce our products.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of the acquisition of ProstaScint from Jazz Pharmaceuticals, we terminated the relationship with the third-party manufacturer of ProstaScint. We have initiated the process of transferring the manufacturing to Biovest International, which we believe is a qualified manufacturer and with whom we have entered into a Master Services Agreement. In the event that this manufacturing transfer does not occur by the time our current inventory expires, we may not be able to supply sufficient quantities and on a timely basis, while maintaining product quality, acceptable manufacturing costs and complying with regulatory
requirements, such as quality system regulations. In addition, we expect to engage third parties to manufacture components of the MiOXSYS and RedoxSYS systems. We have an agreement for supplies of Natesto with Acerus, from whom we license Natesto, and have entered into a supply agreement for Primsol with the same manufacturer used by FSC Laboratories, from whom we purchased Primsol. For any future product, we expect to use third-party manufacturers because we do not have our own manufacturing capabilities. In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing our current products, there could be significant differences between our estimates and the actual amounts of product we require. If we do not effectively maintain our supply agreements for
Natesto and Primsol, we will face difficulty finding replacement suppliers, which could harm sales of those products. If we do not effectively transition sites with our manufacturing and development partners to enable to production scale of ProstaScint, or if we do not secure collaborations with manufacturing and development partners to enable production to scale of the MiOXSYS system, we may not be successful in selling ProstaScint or in commercializing the MiOXSYS system in the event we receive regulatory approval of the MiOXSYS System. If we fail in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of our products and product candidates. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured these components ourselves, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reliance on third parties for regulatory compliance and quality assurance;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">possible breaches of manufacturing agreements by the third parties because of factors beyond our control;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">possible regulatory violations or manufacturing problems experienced by our suppliers; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, if we are unable to secure the needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition our third party manufacturing. We may not be able to meet the demand for our products if one or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers for any of our products or product candidates in a timely manner and on terms acceptable to us. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">24</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Any third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays in, our product commercialization as a result of these regulations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The manufacturing processes and facilities of third-party manufacturers we engage are required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of
previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">administrative or judicially imposed sanctions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctions or the imposition of civil penalties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">recall or seizure of the product in question;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">total or partial suspension of production or distribution;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA&#146;s refusal to grant pending future clearance or pre-market approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawal or suspension of marketing clearances or approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical holds;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">warning letters;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal to permit the export of the product in question; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">criminal prosecution. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our future profitability will depend, in part, on our ability to commercialize our products and product candidates in foreign markets for which we intend to primarily rely on collaboration with third parties. If we commercialize our products or product candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our inability to directly control commercial activities because we are relying on third parties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">import or export licensing requirements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">longer accounts receivable collection times;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">longer lead times for shipping;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">25</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">language barriers for technical training;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to our products;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">foreign currency exchange rate fluctuations;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our customers&#146; ability to obtain reimbursement for our products in foreign markets; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Foreign sales of our products or product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We are subject to various regulations pertaining to the marketing of our approved products.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are subject to various federal and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other remuneration for the purchase of our products, including inducements to potential patients to request our products and services. Additionally, any product promotion educational activities, support of continuing medical education programs, and other interactions with health-care professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly
and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third party payer, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely impact the marketing of our existing products or delay introduction of our product candidates, which may have a material adverse effect on our business,
operating results and financial condition. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our products and product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, if a product candidate receives marketing approval and we or others identify undesirable side effects caused by the product after the approval, or if drug abuse is determined to be a significant problem with an approved product, a number of potentially significant negative consequences could result, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory authorities may withdraw or limit their approval of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory authorities may require the addition of labeling statements, such as a &#147;Black Box warning&#148; or a contraindication;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may decide to remove the product from the marketplace;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we could be sued and held liable for injury caused to individuals exposed to or taking the product; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our reputation may suffer. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">26</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing an affected product or product candidates and significantly impact our ability to successfully commercialize or maintain sales of our product or product candidates and generate revenues. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto contains, and future our other product candidates may contain, controlled substances, the manufacture, use, sale, importation, exportation, prescribing and distribution of which are subject to regulation by the DEA.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto, which is approved by the FDA, is regulated by the DEA as a Schedule III controlled substance. Before any commercialization of any product candidate that contains a controlled substance, the DEA will need to determine the controlled substance schedule, taking into account the recommendation of the FDA. This may be a lengthy process that could delay our marketing of a product candidate and could potentially diminish any regulatory exclusivity periods for which we may be eligible. Natesto is, and our other product candidates may, if approved, be regulated as &#147;controlled substances&#148; as defined in the Controlled
Substances Act of 1970, or CSA, and the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to our third-party manufacturers and to distributors, prescribers and dispensers of our product candidates. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled substances. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is regulated by the DEA as a Schedule III controlled substance. Consequently, the manufacturing, shipping, storing, selling and using of the products will be subject to a high degree of regulation. Also, distribution, prescribing and dispensing of these drugs are highly regulated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because of their restrictive nature, these laws and regulations could limit commercialization of our product candidates containing controlled substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If testosterone replacement therapies are found, or are perceived, to create health risks, our ability to sell Natesto could be materially adversely affected and our business could be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent publications have suggested potential health risks associated with testosterone replacement therapy, such as increased cardiovascular disease risk, including increased risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood cells, development of clinical prostate disease, including prostate cancer, and the suppression of sperm production. Prompted by these events, the FDA held a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further. The FDA has also asked health care professionals and patients to report side effects involving
prescription testosterone products to the agency. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At the T-class Advisory Committee meeting held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population for whom testosterone replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated with testosterone replacement therapy. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">27</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At the meeting, the Advisory Committee voted that the FDA should require sponsors of testosterone products to conduct a post marketing study (e.g. observational study or controlled clinical trial) to further assess the potential cardiovascular risk. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It is possible that the FDA&#146;s evaluation of this topic and further studies on the effects of testosterone replacement therapies could demonstrate the risk of major adverse cardiovascular events or other health risks or could impose requirements that impact the marketing and sale of Natesto, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">mandate that certain warnings or precautions be included in our product labeling;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">require that our product carry a &#147;black box warning&#148;; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limit use of Natesto to certain populations, such as men without specified conditions. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Demonstrated testosterone replacement therapy safety risks, as well as negative publicity about the risks of hormone replacement therapy, including testosterone replacement, could hurt sales of and impair our ability to successfully relaunch Natesto, which could have a materially adverse impact on our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">FDA action regarding testosterone replacement therapies could add to the cost of producing and marketing Natesto.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA is requiring post-marketing safety studies for all testosterone replacement therapies approved in the U.S. to assess long-term cardiovascular events related to testosterone use. Depending on the total cost and structure of the FDA&#146;s proposed safety studies there may be a substantial cost associated with conducting these studies. Pursuant to our license agreement with Acerus Pharmaceuticals is, Acerus is obligated to reimburse us for the entire cost of any studies required for Natesto by the FDA. However, in the event that Acerus is not able to reimburse us for the cost of any required safety studies, we may be
forced to incur this cost, which could have a material adverse impact on our business and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our approved products may not be accepted by physicians, patients, or the medical community in general.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if the medical community accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the product if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to any existing medicines or treatments. We cannot predict the degree of market acceptance of any of our approved products, which will depend on a number of factors, including, but not limited to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the efficacy and safety of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the approved labeling for the product and any required warnings;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the advantages and disadvantages of the product compared to alternative treatments;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our and any collaborator&#146;s ability to educate the medical community about the safety and effectiveness of the product;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the reimbursement policies of government and third-party payors pertaining to the product; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the market price of our product relative to competing treatments. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development processes may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the
discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">28</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Intellectual Property Risks Related to Our Business</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to compete may decline if we do not adequately protect our proprietary rights or if we are barred by the patent rights of others.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our commercial success depends on obtaining and maintaining proprietary rights to our products and product candidates as well as successfully defending these rights against third-party challenges. We will only be able to protect our products and product candidates from unauthorized use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent protection for our products and product candidates is uncertain due to a number of factors, including that:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not have been the first to make the inventions covered by pending patent applications or issued patents;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not have been the first to file patent applications for our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may independently develop identical, similar or alternative products, compositions or devices and uses thereof;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any or all of our pending patent applications may not result in issued patents;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our compositions, devices and methods may not be patentable;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may design around our patent claims to produce competitive products which fall outside of the scope of our patents; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may identify prior art or other bases which could invalidate our patents. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we have or obtain patents covering our products and product candidates, we may still be barred from making, using and selling them because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products that are similar or identical to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices, and some of these relate to our products and product candidates. These could materially affect our ability to sell our products and develop our product candidates. Because patent applications can take many
years to issue, there may be currently pending applications unknown to us that may later result in issued patents that our products and product candidates may infringe. These patent applications may have priority over patent applications filed by us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in
the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">29</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which
could harm our business, prospects, financial condition and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Pharmaceutical and medical device patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent positions of pharmaceutical and medical device companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with
certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to re-examination proceedings, post-grant review and/or inter partes review in the USPTO. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, re-examination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, changes in or different interpretations of patent laws in the United States and foreign countries may permit others to use our discoveries or to develop and commercialize our technology and products and product candidates without providing any compensation to us, or may limit the number of patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to obtain and maintain patent protection and trade secret protection of our products and product candidates, we could lose our competitive advantage and competition we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Developments in patent law could have a negative impact on our business.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From time to time, the United States Supreme Court, other federal courts, the United States Congress or the USPTO may change the standards of patentability and any such changes could have a negative impact on our business. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a &#147;first-to-invent&#148; system to a &#147;first-to-file&#148; system, changes the way issued patents are challenged, and changes the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed regulations and procedures to govern the
full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions, became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend any patents that may issue from our patent applications, all of which could have a material adverse effect on our business. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">30</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to patent protection, because we operate in the highly technical field of discovery and development of therapies and medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all
confidential information developed by the party or made known to the party by us during the course of the party&#146;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We may not be able to enforce our intellectual property rights throughout the world.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of our patents, if obtained, or the misappropriation of our other
intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Third parties may assert ownership or commercial rights to inventions we develop.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have or expect to have written agreements with collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with collaborators with respect to joint inventions or inventions made by our collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from
a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&#146;s materials where required, or if disputes otherwise arise with </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">31</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">respect to the intellectual property developed with the use of a collaborator&#146;s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such
inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We might employ individuals who were previously employed at universities or other biopharmaceutical or medical device companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend
against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is significant litigation in the pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products or product candidates infringe the intellectual property rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us
from using the patented drugs, compositions or devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could
lead to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&#146;s patent rights;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we or our collaborators having to enter into license arrangements that may not be available on commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business, prospects and financial condition. As a result, we could be prevented from commercializing our products and product candidates. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">32</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Our Organization, Structure and Operation</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We intend to acquire, through asset purchases or in-licensing, businesses or products, or form strategic alliances, in the future, and we may not realize the intended benefits of such acquisitions or alliances.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to acquire, through asset purchases or in-licensing, additional businesses or products, form strategic alliances and/or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses or assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses or assets if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or
acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition or alliance, we will achieve the expected synergies to justify the transaction. These risks apply to our acquisition of ProstaScint in May 2015, Primsol in October 2015 and Natesto in April 2016. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In fiscal 2016 and 2015, the great majority of our net revenue and gross accounts receivable were due to one significant customer, the loss of which could materially and adversely affect our results of operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During fiscal 2016 and fiscal 2015, one customer accounted for 86% and 83%, respectively, of our net revenue. At June 30, 2016 and 2015, this same customer accounted for 69% and 99%, respectively, of our gross accounts receivable. Although we have been growing our revenue, particularly in fiscal 2016, and launched Natesto after the close of fiscal 2016, and therefore expect to increase revenue and not be as reliant on this one customer, at least for fiscal 2017, and perhaps beyond, the loss of this customer could have a material adverse effect on our results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to operate our business effectively may suffer if we or Ampio terminate our services agreement, or if we are unable to establish on a cost-effective basis our own administrative and other support functions in order to operate as a stand-alone company after the expiration or termination of our services agreement with Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the Merger, we relied on administrative and other resources of Ampio to operate our business. We have entered into a services agreement to retain the ability for specified periods to use certain Ampio resources. We may elect to continue this agreement for an indefinite period of time. Any decision by us to terminate this agreement would be approved by disinterested members of our management and board of directors under our procedures regarding related party transactions. After the termination of this agreement, we will need to create our own administrative and other support systems or contract with third parties to
replace Ampio&#146;s services. These services may not be provided at the same level, and we may not be able to obtain the same benefits that we received prior to the separation. These services may not be sufficient to meet our needs, and if our agreement with Ampio is terminated, we may not be able to replace these services at all or obtain these services at prices and on terms as favorable as we currently have with Ampio. Any failure or significant downtime in our own administrative systems or in Ampio&#146;s administrative systems during the transitional period could result in unexpected costs, impact our results or prevent us from paying our suppliers or employees and performing other administrative services on a timely basis. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of August 31, 2016, we had 58 full-time employees, and in connection with being a public company, we expect to continue to increase our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities. Due to
our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">33</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">financial resources from other projects, such as the planned expanded commercialization of our approved products and the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to expand the market for our approved products and develop our product candidates, if approved, and compete effectively will depend, in part, on our ability to
effectively manage the future development and expansion of our company. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</Font> </H3>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our success depends to a significant degree upon the technical and management skills of our officers and key personnel. Although our executive officers Joshua and Jarrett Disbrow and Jonathan McGrael have employment agreements, the existence of an employment agreement does not guarantee the retention of the executive officer for any period of time, and each agreement obligates us to pay the officer lump sum severance (two years' for Messrs. Disbrow and six months' for Mr. McGrael) if we terminate him without cause, as defined in the agreement, which could hurt our liquidity. The loss of the services of any of these individuals
would likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers or key personnel. The loss of any of our key executives, or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on our business. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We compete for such personnel against numerous companies, including larger, more established companies with significantly greater financial resources than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical and medical device products. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration of a patient&#146;s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. These lawsuits may divert our management from pursuing our
business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business, financial condition and operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we maintain general liability, clinical trial liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition, inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products and product candidates that receive regulatory approval, which could adversely affect our business. Product liability claims could also harm our reputation, which may adversely affect our
collaborators&#146; ability to commercialize our products successfully. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In order to satisfy our obligations as a public company, we may need to hire additional qualified accounting and financial personnel with appropriate public company experience in the event that we no longer utilize the finance and administrative functions of Ampio.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a public company, we must establish and maintain effective disclosure and financial controls. We may need to hire additional accounting and financial personnel with appropriate public company experience and technical accounting knowledge, and it may be difficult to recruit and maintain such personnel. Even if we are </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">34</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">able to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment and the indirect consequences related to the diversion of management resources from product development efforts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Despite the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our product candidates which could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We are upgrading our enterprise resource planning system and may experience difficulties with the upgrade or after its full implementation.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of the growth of our business, we needed to upgrade our enterprise resource planning, or ERP, system, which upgrade we began in July 2016. Our ERP system is critical to our ability to accurately maintain books and records, keep track of product inventory, marketing and sales, and prepare our financial statements. The implementation of the new ERP system will require additional investment of significant financial and human resources. In addition, we may not be able to successfully complete the full implementation of the ERP system without experiencing difficulties. Any disruptions, delays or deficiencies in the
design and implementation of the new ERP system could adversely affect our ability to monitor our business and prepare our financial statements on an accurate and timely basis. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2016, we had federal net operating loss carryforwards of approximately $24.8 million. The available net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2032 and will completely expire in 2035. Under the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and the regulations promulgated thereunder, including, without limitation, the consolidated income tax return regulations, various corporate changes could limit our ability to use our net operating loss carryforwards and other tax attributes (such as research tax credits) to offset our income.
Because Ampio&#146;s equity ownership interest in our company fell to below 80% in January 2016, we will be deconsolidated from Ampio&#146;s consolidated federal income tax group. As a result, certain of our net operating loss carryforwards may not be available to us and we may not be able to use them to offset our U.S. federal taxable income. As a consequence of the deconsolidation, it is possible that certain other tax attributes and benefits resulting from U.S. federal income tax consolidation may no longer be available to us. Our company and Ampio do not have a tax sharing agreement that could mitigate the loss of net operating losses and other tax attributes resulting from the deconsolidation or our incurrence of liability for the taxes of other members of the consolidated group by reason of the joint and several liability of group members. In addition to the deconsolidation risk, an &#147;ownership change&#148; (generally a 50% change (by value) in equity ownership over a three
year period) under Section 382 of the Code could limit our ability to offset, post-change, our U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. Either the deconsolidation or the ownership change scenario could result in increased future tax liability to us. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our historical financial information as a business conducted by Ampio may not be representative of our results as an independent public company.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The historical financial information included herein does not necessarily reflect what our financial position, operating results or cash flows would have been had we been an independent entity during the year ended </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">35</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">June 30, 2015. The historical costs and expenses reflected in our financial statements include amounts for certain corporate functions historically provided by Ampio, including costs of finance and other administrative services, and income taxes. These expense allocations were developed on the basis of what we and Ampio considered to be reasonable prices for the utilization of services provided or the benefits received by us. The historical financial information in our audited financial statements may not be indicative of what our results of operations, financial position, changes in equity and cash flows would have been had we
been a separate stand-alone entity during the periods presented or will be in the future. We have not made adjustments to reflect many significant changes that will occur in our cost structure, funding and operations as a result of our separation from Ampio, including changes in our employee base, changes in our tax structure, potential increased costs associated with reduced economies of scale and increased costs associated with being a publicly traded, stand-alone company, such as compliance costs, nor have we made offsetting adjustments to reflect the benefits of this offering, as these factors are presently difficult to quantify. These same risks will apply to the financial information of any business we acquire when it is included in our financial statements. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to Securities Markets and Investment in our Securities</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">There is not now, and there may never be, an active and orderly trading market for our common stock.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An active trading market for our shares may never develop or be sustained. As a result, investors in our common stock must bear the economic risk of holding those shares for an indefinite period of time. Although our common stock is quoted on the OTCQX, an over-the-counter quotation system, trading of our common stock is extremely limited and sporadic and at very low volumes. We do not now, and may not in the future, meet the initial listing standards of any national securities exchange, and we presently anticipate that our common stock will continue to be quoted on the OTCQX or another over-the-counter quotation system for the
foreseeable future. In those venues, our stockholders may find it difficult to obtain accurate quotations as to the market value of their shares of our common stock, and may find few buyers to purchase their stock and few market makers to support its price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the price for which you purchased them, or at all. Further, an inactive market may also impair our ability to raise capital by selling additional equity in the future, and may impair our ability to enter into strategic partnerships or acquire companies or products by using shares of our common stock as consideration. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our ability to uplist our common stock to the NYSE MKT is subject to us meeting applicable listing criteria.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to apply for our common stock to be listed on the NYSE MKT, a national securities exchange. The NYSE MKT requires companies desiring to list their common stock to meet certain listing criteria including total number of stockholders; minimum stock price, total value of public float, and in some cases total shareholders&#146; equity and market capitalization. Our failure to meet such applicable listing criteria could prevent us from listing our common stock on NYSE MKT. In the event we are unable to uplist our common stock, our common stock will continue to trade on the OTCQX market, which is generally considered less
liquid and more volatile than the NYSE MKT. Our failure to uplist our common stock could make it more difficult for you to trade our common stock shares, could prevent our common stock trading on a frequent and liquid basis and could result in the value of our common stock being less than it would be if we were able to uplist. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we apply and our common stock is accepted for uplisting on the NYSE MKT, our failure to meet the continued listing requirements of the NYSE MKT could result in a delisting of our common stock.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our common stock were to be uplisted on the NYSE MKT, and thereafter we fail to satisfy the continued listing requirements of the NYSE MKT, such as the corporate governance requirements or the minimum closing bid price requirement, NYSE MKT may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we anticipate that we would take actions to restore our compliance with the NYSE MKT requirements, such exchange, stabilize our market price,
improve the liquidity of our common stock, prevent our common stock from dropping below such exchange&#146;s minimum bid price requirement, or prevent future non-compliance with such exchange&#146;s listing requirements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">36</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If we fail to comply with the continued trading standards of the OTCQX U.S. Premier tier, it may result in our common stock moving tiers in the OTC Markets.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is currently quoted for trading on the OTCQX U.S. Premier tier, and the continued quotation of our common stock on the OTCQX U.S. Premier tier is subject to our compliance with a number of standards. These standards include the requirement of our common stock to have a minimum bid price of $1.00 per share as of the close of business for at least one of every thirty consecutive calendar days. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At August 31, 2016, our executive officers, directors and entities affiliated with certain of our directors beneficially owned approximately 38% of our outstanding shares of common stock. Therefore, these stockholders have the ability to influence us through their ownership position. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited
acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The sale of shares of our common stock to Lincoln Park under the Purchase Agreement may cause substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Purchase Agreement with Lincoln Park, we may sell to Lincoln Park, from time to time and under certain circumstances, up to $10,500,000 of our common stock over approximately 36 months subsequent to the effective date of the registration statement that covers the resale by Lincoln Park of up to 1,155,136 shares of our common stock issuable under the Purchase Agreement. As required under the Purchase Agreement and related registration rights agreement, we filed and had declared effective a registration statement for the resale by Lincoln Park of additional shares of our common stock that we may sell and issue to
Lincoln Park. We may be required to file and have declared effective additional registration statements in connection with our Purchase Agreement with Lincoln Park. Generally, with respect to the Purchase Agreement, we have the right, but no obligation, to direct Lincoln Park to periodically purchase up to $10,500,000 of our common stock in specific amounts under certain conditions, which periodic purchase amounts can be increased under specified circumstances. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depending upon market liquidity at the time, sales of shares of our common stock to Lincoln Park may cause the trading price of our common stock to decline. Lincoln Park may ultimately purchase all, some or none of the $10,500,000 of common stock under the Purchase Agreement, and after it has acquired shares, Lincoln Park may sell all, some or none of those shares. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. The sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more
difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. However, we have the right to control the timing and amount of any sales of our shares to Lincoln Park, and the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We sold $500,000 of common stock to Lincoln Park in July 2016 when we executed the Purchase Agreement. As a result, as of the date of this prospectus we may sell an aggregate of $10,000,000 pursuant to the Purchase Agreement, assuming we meet the conditions required for sale. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Future sales and issuances of our equity securities or rights to purchase our equity securities, including pursuant to equity incentive plans, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To the extent we raise additional capital by issuing equity securities, including pursuant to the Purchase Agreement with Lincoln Park, our stockholders may experience substantial dilution. We may, as we have in the past, sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">37</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">other equity securities in more than one transaction, investors may be further diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to existing stockholders. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to our 2015 Stock Plan, our Board of Directors is authorized to award up to a total of 833,334 shares of common stock or options to purchase shares of common stock to our officers, directors, employees and non-employee consultants (which we intend to seek stockholder approval to increase to 2,000,000 shares at our 2016 annual meeting planned to be held on November 15, 2016). As of June 30, 2016, options to purchase 322,302 shares of common stock issued under our 2015 Stock Plan at a weighted average exercise price of $18.01 per share were outstanding. In addition, at June 30, 2016, there were outstanding warrants to
purchase an aggregate of 2,201,627 shares of our common stock at a weighted average exercise price of $6.19. Stockholders will experience dilution in the event that additional shares of common stock are issued under our 2015 Stock Plan, or options issued under our 2015 Stock Plan are exercised, or any warrants are exercised for shares of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The trading price of our common stock is likely to be highly volatile, and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the products or product candidates we acquire for commercialization;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">actual or anticipated adverse results or delays in our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our failure to expand the market for our currently approved products or commercialize our product candidates, if approved;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unanticipated serious safety concerns related to the use of any of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conditions or trends in the healthcare, biotechnology and pharmaceutical industries;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">introduction of new products offered by us or our competitors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to maintain an adequate rate of growth and manage such growth;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">issuances of debt or equity securities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">sales of our common stock by us or our stockholders in the future, or the perception that such sales could occur;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">trading volume of our common stock;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">general political and economic conditions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">effects of natural or man-made catastrophic events; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other events or factors, many of which are beyond our control.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">38</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse regulatory decisions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">additions or departures of key scientific or management personnel;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">changes in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our dependence on third parties, including CROs and scientific and medical advisors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to uplist our common stock to a national securities exchange;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">actual or anticipated variations in quarterly operating results;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to meet or exceed the estimates and projections of the investment community; </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#147;Risk Factors,&#148; could have a dramatic and material adverse impact on
the market price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">FINRA sales practice requirements may limit a stockholder&#146;s ability to buy and sell our stock.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#146;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or
low-priced securities will not be suitable for at least some customers. Because these FINRA requirements are applicable to our common stock, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any trading market for our common stock that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no securities or industry analysts commence coverage of our company, the trading price for our stock could be negatively affected. If securities or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one
or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading volume to decline. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have a substantial number of shares of authorized but unissued capital stock, and if we issue additional shares of our capital stock in the future, our existing stockholders will be diluted.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Certificate of Incorporation authorize the issuance of up to 100,000,000 shares of our common stock and up to 50,000,000 shares of preferred stock with the rights, preferences and privileges that our Board of Directors may determine from time to time. As of August 31, 2016, we had 5,070,591 shares of our common stock issued and outstanding, which represents approximately 5.1% of our total authorized shares of common stock. In addition to capital raising activities, which we expect to continue to pursue in order to raise the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">39</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">funding we will need in order to continue our operations, other possible business and financial uses for our authorized capital stock include, without limitation, future stock splits, acquiring other companies, businesses or products in exchange for shares of our capital stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances, attracting and retaining employees by the issuance of additional securities under our equity compensation plans, or other transactions and corporate purposes that our Board of Directors deems are in the best interest of our company.
Additionally, shares of our capital stock could be used for anti-takeover purposes or to delay or prevent changes in control or our management. Any future issuances of shares of our capital stock may not be made on favorable terms or at all, they may not enhance stockholder value, they may have rights, preferences and privileges that are superior to those of our common stock, and they may have an adverse effect on our business or the trading price of our common stock. The issuance of any additional shares of our common stock will reduce the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock. Additionally, any such issuance will reduce the proportionate ownership and voting power of all of our current stockholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan or otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect that we will need significant additional capital in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior
to those of holders of our common stock. Further, any future sales of our common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Some provisions of our charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Provisions in our Certificate of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the authorization of 50,000,000 shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limiting the removal of directors by the stockholders;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">allowing for the creation of a staggered board of directors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions
are </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">40</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">approved by the board of directors. This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired by or beneficial to our stockholders. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any provision of our Certificate of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay for our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers and employees may result in substantial expenses.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Certificate of Incorporation and our Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate of Incorporation and our Bylaws and individual indemnification agreements we intend to enter with each of our directors and executive officers provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by the Delaware law and, subject to certain conditions, advance the expenses incurred by any director or
officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We do not intend to pay cash dividends on our capital stock in the foreseeable future.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">There is not now and may not be an active liquid trading market for our publicly traded warrants.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is no established active public trading market for our publicly traded warrants issued in May 2016 and that trade on the OTCQX. Although we plan to apply to have the warrants listed on the NYSE MKT, there is no assurance our application will be approved, or even if it is approved, that an active trading market will develop or if one develops that it will be maintained. Without an active market, the liquidity of the warrants will remain limited. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In the event we are unable to maintain an effective registration statement with respect to all of the shares issuable pursuant to the Purchase Agreement, we may not be able to access the full amount available under the Purchase Agreement.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The registration statement we have filed with the SEC for the resale of shares issuable pursuant to the Purchase Agreement with Lincoln Park, does not register all of the shares issuable pursuant to the Purchase Agreement with Lincoln Park. In order to access the Purchase Agreement beyond the shares offered thereunder, we must have an effective registration statement on file for any amount of shares in excess of the 1,155,136 shares registered and offered thereby. For us to issue additional shares pursuant to the Purchase Agreement, we will have to file one or more registration statements for those additional shares. However,
we cannot assure you that we will be able to do so, or that the SEC will declare effective any registration statement that we may file. If we do not file and maintain an effective registration statement for the resale of additional shares issuable pursuant to the Purchase Agreement, we will be unable to access any additional funds that may be available under the Purchase Agreement. If we were unable to access a portion or the full remaining amount available to us under the Purchase Agreement, in the absence of any other financing sources, it would have a material adverse impact on our operations. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">41</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Risks Related to this Offering</Font> </H1>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Investors in this offering will experience immediate and substantial dilution in net tangible book value.</Font> </H3>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The public offering price will be substantially higher than the net tangible book value per share of our outstanding shares of common stock. As a result, based upon the assumptions set forth in &#147;Dilution&#148;, investors purchasing shares in this offering will incur immediate dilution of $1.96 per share, based on an assumed public offering price of $2.90 per share (the closing price of our common stock as quoted on OTCQX on October 6, 2016). See &#147;Dilution&#148; for a more complete description of how the value of your investment in our common stock will be diluted upon the completion of this offering. </P>



<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">We have not determined a specific use for a portion of the net proceeds from this offering, and we may use these proceeds in ways with which you may not agree.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While we currently intend to use the net proceeds received from this offering to (1) fund the final upfront payment of $4 million to Acerus under the license and supply agreement we entered into on April 22, 2016 to acquire Natesto; and (2) fund the further commercialization of Natesto, ProstaScint and Primsol, the acquisition of complementary urology products and/or product candidates, completion of clinical development activities for the MiOXSYS system, and for working capital and for other general corporate purposes, our management will have considerable discretion in the application of the proceeds received in connection
with this offering. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may be used for corporate purposes that do not improve our profitability or increase our share price. The net proceeds from this offering may also be placed in investments that do not produce income or lose value. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sales of a substantial number of shares of our common stock following this offering may adversely affect the market price of our common stock and the issuance of additional shares will dilute all other stockholders.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sales of a substantial number of shares of our common stock in the public market or otherwise following this offering, or the perception that such sales could occur, could adversely affect the market price of our common stock. After completion of this offering, our existing security holders will own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our common stock assuming there is no exercise of the underwriters&#146; over-allotment option. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After completion of this offering, there will be approximately &nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding. In addition, our Certificate of Incorporation permits the issuance of up to approximately &nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock after the completion of this offering, as well as up to 50,000,000 shares of preferred stock. Thus, we have the ability to issue substantial amounts of common stock in the future, which would dilute the percentage ownership held by the investors who purchase shares of our common stock in this offering. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We and our officers, directors and certain stockholders have agreed, subject to customary exceptions, not to, without the prior written consent of the Representative during the period ending 180 days from the date of this offering in the case of our directors and officers and 90 days from the date of this offering in the case of us and certain stockholders, directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of our common stock, enter into any swap or other derivatives transaction that transfers to another any of the economic benefits or risks of ownership of shares of our
common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for our common stock or any other securities of ours or publicly disclose the intention to do any of the foregoing. After the lock-up agreements with our directors and officers pertaining to this offering expire 180 days from the date of this offering unless waived earlier by the managing underwriter, all of our outstanding shares will be eligible for sale in the public market. Sales of a significant number of these shares of common stock in the public market could reduce the market price of the common stock. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">42</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The warrants are speculative in nature.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrants to be issued to investors in this offering do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to purchase shares of common stock at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the warrants may exercise their right to acquire shares of common stock at an exercise price of $6.00 per share, prior to 5:00 p.m., New York time, on May 2, 2021, after which date any unexercised warrants will expire and have no further value. There can be no assurance
that the market price of the common stock will ever equal or exceed the exercise price of the warrants, and consequently, whether it will ever be profitable for holders of the warrants to exercise the warrants. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In the event we are unable to maintain an effective registration statement with respect to the shares issuable upon exercise of the warrants, holders of the warrants may be unable to exercise the warrants.</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No warrants will be exercisable unless at the time of exercise a prospectus relating to common stock issuable upon exercise of the warrants is current and the common stock has been registered or qualified or deemed to be exempt under the federal securities laws and the securities laws of the state of residence of the holder of the warrants. Under the terms of the warrant agent agreement, we have agreed to meet these conditions and use our reasonable and best efforts to maintain a current prospectus relating to common stock issuable upon exercise of the warrants until the exercise or expiration of the warrants. However, we
cannot assure you that we will be able to do so, and if we do not maintain a current prospectus related to the common stock issuable upon exercise of the warrants, holders may be unable to exercise their warrants. If the prospectus relating to the common stock issuable upon the exercise of the warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the warrant will only be exercisable on a cashless basis, as described in the warrant agent agreement.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">43</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t4SPE"></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus, including the sections entitled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; contains forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the commercial success and market acceptance of any of our products and product candidates that are approved for marketing in the United States or other countries;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to manufacture sufficient amounts of our product candidates for clinical trials and our products for commercialization activities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our need for, and ability to raise, additional capital;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the number, designs, results and timing of our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the regulatory review process and any regulatory approvals that may be issued or denied by the U.S. Food and Drug Administration or other regulatory agencies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our need to secure collaborators to license, manufacture, market and sell any products for which we receive regulatory approval in the future;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the medical benefits, effectiveness and safety of our products and product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the safety and efficacy of medicines or treatments introduced by competitors that are targeted to indications which our products and product candidates have been developed to treat;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our current or prospective collaborators&#146; compliance or non-compliance with their obligations under our agreements with them; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other factors discussed elsewhere in this prospectus. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and
which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus. Actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus, and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">44</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">45</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t5USE"></a>USE OF PROCEEDS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate that the maximum net proceeds from the sale of the shares of common stock we are offering will be approximately $12.5 million (or approximately $14.4 million if the underwriters exercise in full their option to purchase additional shares of common stock and/or warrants), after deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate that we will use the proceeds from this offering as follows:</P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="354"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1>Use of Proceeds</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Minimum Offering Amount</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Maximum Offering Amount</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><P STYLE="padding-left: 20pt; text-indent: -20pt; margin-bottom: -12pt">1.</P><P STYLE="margin-top: 0pt; padding-left: 20pt">Contractual payment to Acerus<sup>&#040;1&#041;</sup></P></TD>          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><P STYLE="padding-left: 20pt; text-indent: -20pt; margin-bottom: -12pt">2.</P><P STYLE="margin-top: 0pt; padding-left: 20pt">Further commercialization of Natesto, ProstaScint and Primsol</P></TD>          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><P STYLE="padding-left: 20pt; text-indent: -20pt; margin-bottom: -12pt">3.</P><P STYLE="margin-top: 0pt; padding-left: 20pt">Potential acquisition(s) of complementary urology products<sup>&#040;2&#041;</sup></P></TD>          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><P STYLE="padding-left: 20pt; text-indent: -20pt; margin-bottom: -12pt">4.</P><P STYLE="margin-top: 0pt; padding-left: 20pt">Remaining clinical development of Mioxsys</P></TD>          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><P STYLE="padding-left: 20pt; text-indent: -20pt; margin-bottom: -12pt">5.</P><P STYLE="margin-top: 0pt; padding-left: 20pt">Working capital for general corporate and administrative expenses</P></TD>          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>900,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1><B><I>Total</I></B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>8,500,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>14,400,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>




<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">The final upfront payment to Acerus under the license and supply agreement we entered into on April 22, 2016 to acquire Natesto.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">The Company intends to pursue strategic acquisitions of complementary urology products that enhance our product portfolio and enable expansion of our commercial operations. We seek to identify unique products with urologic indications that may be non-strategic, undervalued or under-resourced by the company that currently markets the product. While we are actively pursuing the acquisitions of additional products and product candidates, we currently have no agreements for the acquisition of any products or product candidates. We are actively identifying unique product assets to acquire based on specific attributes including but not limited to: therapeutic area/indication; growth potential; intellectual property position (patents, regulatory, manufacturing or development technicalities, etc.), valuation, strategic fit, commercial orientation and other factors. Indications of interest include products to treat conditions such as urinary
incontinence, sexual dysfunction, hypogonadism, prostate and other urological cancers, urinary tract infections, and other urological conditions.</TD>

</TR>

</TABLE>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development efforts, the timing and progress of any collaborative or strategic partnering efforts, and the competitive environment for our planned products. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend
to temporarily invest the proceeds in short-term, interest-bearing instruments. </P>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">46</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t6MAR"></a>MARKET FOR COMMON STOCK</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is quoted on the OTCQX under the symbol &#147;AYTU.&#148; Prior to December 14, 2015, our common stock was quoted on the OTCQB Market. The following table sets forth the range of bid and asked closing quotations for our common stock on the OTCQX or OTCQB, for the periods shown. The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent actual transactions. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30, 2015</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29.40</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>36.48</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>23.40</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>141.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29.16</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ending June 30, 2016</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>57.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>55.56</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>57.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>37.68</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>42.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7.32</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.60</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30, 2017</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter (through October 6, 2016) </TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.18</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.90</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 6, 2016, the closing price as reported on the OTCQX of our common stock was $2.90. As of October 6, 2016, there were 473 holders of record of our common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to apply to list our common stock on the NYSE MKT under the symbol &#147;AYTU&#148; once we meet NYSE listing standards. We believe that we will qualify, and intend to list our common stock and warrants on the NYSE MKT, upon securing at least $8,500,000 in gross proceeds from this offering and achieving a per share closing price of $3.00 or greater for our stock. In case our stock price does not reach this level otherwise, we plan to seek stockholder approval in November 2016 for a reverse stock split to help us meet the stock price listing standard. However, it is not clear when, or if, we will meet the NYSE listing
standards. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Equity Compensation Plan Information</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, our shareholders approved the adoption of a stock and option award plan (the &#147;2015 Plan&#148;), under which 833,334 shares were reserved for future issuance under restricted stock awards, options, and other equity awards. The 2015 Plan permits grants of equity awards to employees, directors and consultants. The following table displays equity compensation plan information as of June 30, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Plan Category</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Securities to be<BR> Issued upon<BR> Exercise of<BR> Outstanding<BR> Options,<BR> Warrants and Rights<BR> (a)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted-Average<BR> Exercise Price of<BR> Outstanding<BR> Options,<BR> Warrants and Rights<BR> (b)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Securities<BR> Remaining Available<BR> for Issuance under<BR> Equity Compensation<BR> Plans (Excluding<BR> Securities Reflected in<BR> Column (a))<BR>(c)</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Equity compensation plans approved by security holders</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>322,302</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>511,032</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Equity compensation plans not approved by security holders</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>162,746</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4.49</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>485,048</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>13.47</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>511,032</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The above table excludes all grants of equity awards to employees, directors and consultants after June 30, 2016. In connection with our private placement of approximately $4.7 million of common stock in 2013, we were obligated to issue to the placement agent warrants to purchase 8,553 shares of our common stock. The placement agent warrants have a term of five years from the date of issuance and an exercise price of $54.36. </P>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">47</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our private placement of approximately $5.2 million of convertible notes in July and August 2015, we were obligated to issue to the placement agents&#146; warrants for an amount of shares equal to 8% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest. The placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to 100% of the price per share at which equity securities were sold in our next equity financing, and provide for cashless exercise. Those warrants were
not approved by our stockholders. In connection with the conversions of the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering of common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of 22,254 shares of our common stock at an exercise price of $7.80 per share, and an aggregate of 22,564 shares of our common stock at an exercise price of $4.80 per share. In connection with our May 2016 public offering, we issued warrants to purchase an aggregate of 109,375 shares of common stock at an exercise price of $6.00 to the underwriters of the public offering. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">48</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t7DIV"></a>DIVIDEND POLICY</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not paid any cash dividends on our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in our operations. The declaration and payment of dividends in the future, of which there can be no assurance, will be determined by the Board of Directors in light of conditions then existing, including earnings, financial condition, capital requirements and other factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the distribution of the dividend:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we would not be able to pay our debts as they become due in the usual course of business; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as set forth above, there are no restrictions that currently materially limit our ability to pay dividends or which we reasonably believe are likely to limit materially the future payment of dividends on common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board of Directors has the right to authorize the issuance of preferred stock, without further stockholder approval, the holders of which may have preferences over the holders of our common stock as to payment of dividends. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">49</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t8DIL"></a>DILUTION</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If you purchase shares in this offering, your interest will be diluted to the extent of the difference between the public offering price per share and the net tangible book value per share of our common stock after this offering. Our net tangible book value as of June 30, 2016 was $(3,689,738) million, or $(0.99) per share of common stock. &#147;Net tangible book value&#148; is total assets minus the sum of liabilities and intangible assets. &#147;Net tangible book value per share&#148; is net tangible book value divided by the total number of shares of common stock outstanding. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After giving effect to the sale by us in this offering of an assumed 4,310,345 shares and warrants to purchase 2,155,172 shares of common stock at an assumed offering price of $2.90 per share (the closing price of our common stock as quoted on OTCQX on October 6, 2016) and after deducting the estimated underwriting discounts and commissions and estimated offering expenses that we will pay, our net tangible book value as of June 30, 2016 would have been approximately $7,585,262, or $0.94 per share of common stock. This amount represents an immediate increase in net tangible book value of $1.93 per share to existing stockholders
and an immediate dilution of $1.96 per share to purchasers in this offering. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table illustrates the dilution: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Assumed offering price per share</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.90</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net tangible book value per share as of June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.99</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in net tangible book value per share attributable to this offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.93</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Pro forma net tangible book value per share after this offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.94</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dilution per share to new investors</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.96</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This table:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of options to purchase an aggregate of 322,302 shares of common stock issued under our 2015 Stock Plan and outstanding and exercisable on June 30, 2016;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 8,553 shares of common stock with an exercise price of $54.36 per share issued by Luoxis and assumed by us in April 2015, and outstanding on June 30, 2016;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 22,254 shares of our common stock that were issued in February 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $7.80, and provide for cashless exercise;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 22,564 shares of our common stock that were issued in May 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $4.80, and provide for cashless exercise;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 1,733,322 shares of our common stock that were issued in the public offering of common stock and warrants we completed on May 6, 2016. These warrants are exercisable for five years from issuance and have an exercise price equal to $6.00;</TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 305,559 shares of our common stock that were issued upon the closing of our public offering on May 5, 2016. These warrants are exercisable for five years from issuance and have an exercise price equal to $6.00; </TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 109,375 shares of common stock issued to the underwriters of our public offering. These warrants are exercisable beginning May 2, 2017 until May 2, 2021 and have an exercise price equal to $6.00; and</TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes exclusion of all activity after June 30, 2016.</TD>

</TR>

</TABLE>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">50</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based on the table above, if the underwriters exercise in full their option to purchase 646,552 additional shares and/or additional warrants, our net tangible book value per share after giving effect to this offering would be $1.07 per share, which amount represents an immediate increase in net tangible book value of $2.06. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we issue any additional shares in connection with outstanding options or warrants, there will be additional dilution. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">51</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t9CAP"></a>CAPITALIZATION</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2016 on:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an actual basis; and</TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on a pro forma as adjusted basis to give effect to an aggregate of 1,000,000 restricted shares issued in July 2016 to directors and executive officers, an aggregate of 186,190 shares issued to Lincoln Park Capital Fund, LLC in July 2016, aggregate of 142,457 shares issued as bonus compensation in August 2016 to executive officers; and an aggregate of 40,000 shares issued to Lincoln Park Capital Fund LLC in September 2016. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on a pro forma adjusted basis to give effect to the sale by us in this offering of 4,310,345 shares of common stock and warrants to purchase 2,155,172 shares of common stock at an assumed offering price of $2.90 per share (the closing price of our common stock as quoted on OTCQX on October 6, 2016) after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD>

</TR>

</TABLE>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should read this table in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited financial statements for the years ended June 30, 2016 and 2015, and the related notes thereto, included in this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="205"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=19>At June 30, 2016</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Actual</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Adjustments<BR> for shares<BR> issued in the<BR> quarter ended<BR>September 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As Adjusted<BR> for shares<BR> issued in the<BR> quarter ended<BR>September 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Adjustments<BR> for Offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro Forma<BR> Adjusted for<BR> the Offering</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,054,190</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>631,480</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,685,670</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,225,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,910,670</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term debt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common stock, $0.001 par value: 100,000,000 shares authorized, actual, as adjusted and pro forma; 3,741,944 shares issued and outstanding, actual, 5,110,591 shares issued and outstanding, as adjusted, and 9,420,936 shares issued and outstanding, pro forma as adjusted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>137</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>511</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>432</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>943</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>56,646,304</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,371,353</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>61,017,657</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,224,568</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>73,242,225</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(46,561,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(46,561,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(46,561,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total stockholder&#146;s equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,085,253</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,371,490</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,456,743</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,225,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26,681,743</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total capitalization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>10,085,253</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>4,371,490</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>14,456,743</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>12,225,000</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>26,681,743</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of shares to be outstanding immediately after giving effect to this offering as shown above is based on 3,741,944 shares outstanding as of June 30, 2016 and:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of options to purchase an aggregate of 322,302 shares of common stock issued under our 2015 Stock Plan and outstanding and exercisable on June 30, 2016;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 8,553 shares of common stock with an exercise price of $54.36 per share issued by Luoxis and assumed by us in April 2015, and outstanding on June 30, 2016;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 22,254 shares of our common stock that were issued in February 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $7.80, and provide for cashless exercise;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">52</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 22,564 shares of our common stock that were issued in May 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $4.80, and provide for cashless exercise;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 1,733,322 shares of our common stock that were issued in the public offering of common stock and warrants we completed on May 6, 2016. These warrants are exercisable for five years from issuance and have an exercise price equal to $6.00;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 305,559 shares of our common stock that were issued upon the closing of our public offering on May 5, 2016. These warrants are exercisable for five years from issuance and have an exercise price equal to $6.00;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes no exercise of warrants to purchase 109,375 shares of common stock issued to the underwriters of our public offering. These warrants are exercisable beginning May 2, 2017 until May 2, 2021 and have an exercise price equal to $6.00; and</TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">assumes exclusion of all activity after June 30, 2016. </TD>

</TR>

</TABLE>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">53</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t10MAN"></a>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF<BR> FINANCIAL CONDITION AND RESULTS OF OPERATIONS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Overview</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage specialty pharmaceutical company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. We are currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, urinary tract infections and male infertility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) and Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and
effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, we effected another reverse stock split in which each common stock holder received one share of common stock for each 12 shares. All share and per share amounts in this prospectus have been adjusted to reflect the effect of these two reverse stock splits (herein referred to collectively as the Reverse Stock Splits). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2015, we entered into an asset purchase agreement with Jazz Pharmaceuticals, Inc., pursuant to which we purchased assets related to Jazz Pharmaceuticals&#146; product known as ProstaScint (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#147;ProstaScint Business&#148;), and assumed certain of Jazz Pharmaceuticals&#146; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of the upfront payment of $1.0 million. We also paid an additional $500,000
within five days after transfer for the ProstaScint-related product inventory and $227,000 on September 30, 2015 (which represents a portion of certain FDA fees). We also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, we entered into an asset purchase agreement with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we purchased assets related to FSC&#146;s product known as Primsol (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of FSC&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. We paid $500,000 at closing for the Primsol Business and we paid an additional
$142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also paid $500,000 on April 1, 2016 and $500,000 on July 1, 2016, and must pay $250,000, which we anticipate paying in October 2016 (together, the &#147;Installment Payments&#148;), for a total purchase price of $1,892,000. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, we and Biovest International, Inc., or Biovest, (whose contract manufacturing business is now known as Cell Culture Company, or C3) entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us for our product ProstaScint. The agreement provides that we may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders for ProstaScint. We expect to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing,
release or storage of ProstaScint. The agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, we may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">54</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2016, we entered into a license and supply agreement to acquire the exclusive U.S. rights to Natesto nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we received on July 1, 2016. We paid Acerus an upfront fee of $2.0 million upon execution of the agreement. On or around October 3, 2016 we will pay an additional $2.0 million. On January 1, 2017, we will pay an additional $4.0 million. We also purchased on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2,534,800 (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or
approximately US $0.16 per share. We could not dispose of these shares until after August 29, 2016 and have not yet sold any of these shares. We also agreed to make various payments up to an aggregate of $37.5 million based on net sales of Natesto. During the term of the agreement, we will purchase all of our Natesto product needs from Acerus at a designated price. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2016, we sold in an underwritten public offering 1,562,500 shares of our common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate 1,562,500 shares of common stock at a combined public offering price of $4.80 per share and related warrant. Each warrant is exercisable for five years from issuance and has an exercise price equal to $6.00. In addition, we granted the underwriters a 45-day option to purchase up to an additional 234,375 shares of common stock and/or 234,375 additional warrants. The underwriters elected a partial exercise of their over-allotment option to purchase 170,822 warrants.
The net cash proceeds from the sale of the shares and warrants were approximately $6.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2016, we entered into a purchase agreement (the &#147;Purchase Agreement&#148;), together with a registration rights agreement (the &#147;Registration Rights Agreement&#148;), with Lincoln Park Capital Fund, LLC (&#147;Lincoln Park&#148;),. Upon signing the Purchase Agreement, Lincoln Park agreed to purchase 133,690 shares of our common stock for $500,000 as an initial purchase under the agreement. We also issued as a commitment fee to Lincoln Park of 52,500 shares of common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the terms and subject to the conditions of the Purchase Agreement, we have the right to sell to and Lincoln Park is obligated to purchase up to an additional $10.0 million in amounts of shares of our common stock, subject to certain limitations, from time to time, over the 36-month period commencing on the date that a registration statement, which we agreed to file with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed. We have filed the required registration statement and it has been declared effective by the SEC. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of the date of this prospectus, we have financed operations through a combination of private and public debt and equity financings including net proceeds from the private placements of stock and convertible notes. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, as of the date of this prospectus, we believe we will have sufficient cash to meet our projected operating requirements for only the next several months. See &#147;Liquidity and Capital Resources.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have only begun to generate revenues from the commercialization of our product candidates in the last fiscal year. We have recognized approximately $2.1 million in revenue from ProstaScint, Primsol and RedoxSYS sales during fiscal 2016. We have incurred accumulated net losses since our inception, and at June 30, 2016, we had an accumulated deficit of $46.6 million. Our net loss was $28.2 million for fiscal 2016 and we used $10.7 million in cash from operations during that year. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Significant Accounting Policies and Estimates</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Information regarding our Significant Accounting Policies and Estimates is contained in Note 2 to the Financial Statements. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Newly Issued Accounting Pronouncements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Information regarding the recently issued accounting standards (adopted and not adopted as of June 30, 2016) is contained in Note 2 to the Financial Statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">55</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Results of Operations&nbsp;&#151;&nbsp;June 30, 2016 Compared to June 30, 2015</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Results of operations for the year ended June 30, 2016 (&#147;fiscal 2016&#148;) and the year ended June 30, 2015 (&#147;fiscal 2015&#148;) reflected losses of approximately $28.2 million and $7.7 million, respectively. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Revenue</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product and service revenue</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The total product and service revenue recognized during 2016 was $2.1 million, related to the sale of our products ProstaScint and Primsol, as well as the RedoxSYS and MiOXSYS Systems. The product and service revenue in fiscal 2015 was $176,000 which was from the ProstaScint product and the RedoxSYS System. The increase in product revenue of over 1000% from fiscal 2015 to 2016 is due to our acquisitions of those products, which occurred late in fiscal 2015 and early fiscal 2016, respectively, and expanded marketing of those products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include discounts, chargebacks, distributor fees, processing fees, as well as allowances for returns and Medicaid rebates. Provision balances relating to estimated amounts payable to direct customers are netted against accounts receivable and balances relating to indirect customers are included in accounts payable and accrued liabilities. The provisions recorded to
reduce gross product sales and net product sales are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gross product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,657,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>178,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Provisions to reduce gross product sales to net product and service sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(606,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,051,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>176,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Percentage of provisions to gross sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22.8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">License revenue</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During fiscal 2016 and fiscal 2015, we recognized $512,000 and $86,000, respectively, in license revenue. In 2012, we received a payment of $500,000 for our license agreement of Zertane with a Korean pharmaceutical company. This payment was deferred and was being recognized over 10 years. In 2014, we received a payment of $250,000 for our license agreement of Zertane with a Canadian-based supplier. This payment was deferred and was being recognized over seven years. At June 30, 2016, Aytu determined that the Zertane asset has no value as Aytu does not have the resources to complete the necessary clinical trials and bring it to
market before the patents expire. Therefore, the remaining unamortized deferred revenue of $426,000 which was outstanding as of the date it was determined not to proceed with the clinical trials was recognized as of June 30, 2016. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Expenses</Font> </H3>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Cost of Sales</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The cost of sales of $957,000 and $88,000 recognized for fiscal 2016 and fiscal 2015, respectively, are related to the ProstaScint and Primsol products and the RedoxSYS and MiOXSYS Systems. We expect to see cost of sales to continue to increase in the year ending June 30, 2017 (&#147;fiscal 2017&#148;) as we expect our sales to continue to grow. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">56</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs consist of clinical trials and sponsored research, manufacture transfer expense, labor, stock-based compensation, sponsored research&nbsp;&#151;&nbsp;related party and consultants and other. These costs relate solely to research and development without an allocation of general and administrative expenses and are summarized as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="381"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing tech transfer</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,304,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Clinical trials and sponsored research</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,278,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,244,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Labor</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>427,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>411,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>89,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>517,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sponsored research&nbsp;&#150;&nbsp;related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>192,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>204,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Consultants and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>47,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>6,320,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3,423,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Comparison of Years Ended June 30, 2016 and 2015</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses increased $2.9 million, or 84.6%, in fiscal 2016 over fiscal 2015. This was due primarily to switching our manufacturing process for our ProstaScint product to a new manufacturer, which is still in progress as of June 30, 2016 offset by a $428,000 reduction in stock-based compensation. We expect that the research and development expenses will decrease in fiscal 2017 as compared to fiscal 2016 since the transfer of the ProstaScint manufacturing is almost complete and since we should have no more clinical cost related to Zertane. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">General and Administrative</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses consist of personnel costs for employees in executive, business development and operational functions and director fees; stock-based compensation; patents and intellectual property; professional fees including legal, auditing, accounting, investor relations, shareholder expense and printing and filing of SEC reports; occupancy, travel and other including rent, governmental and regulatory compliance, insurance, and professional subscriptions. These costs are summarized as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="381"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Labor</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,684,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>979,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>814,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patent costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>303,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>488,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Professional fees</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,630,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,440,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Occupancy, travel and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,086,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>619,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Management fee&nbsp;&#150;&nbsp;related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>308,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>311,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>8,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>4,337,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Comparison of Years Ended June 30, 2016 and 2015</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative costs increased $4.5 million, or 103.5%, in fiscal 2016 over fiscal 2015. The increase in labor costs, stock-based compensation, and occupancy, travel and other primarily relates to increased costs related to the increase in professional staffing during fiscal 2016 as compared to fiscal 2015, bonuses earned, increased travel expense and stock options granted as well as the continuing vesting of stock option awards granted in previous years. We expect general and administrative expenses to increase in fiscal 2017 due to the expected overall growth of our company. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Impairment of Intangible Assets</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Impairment of intangible assets was $7.5 million for fiscal 2016 related to the impairment of the Zertane in process research and development (IPRD) (see Note 2 to the financial statements). We did not recognize any impairment expense in fiscal 2015. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">57</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Amortization of Intangible Assets</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Amortization of intangible assets was $665,000 and $45,000 for fiscal 2016 and fiscal 2015, respectively. This expense increased due to the acquisition of the ProstaScint and Primsol businesses in late fiscal 2015 and early fiscal 2016, respectively, and the corresponding amortization of their finite-lived intangible assets. As we continue to license and purchase additional assets as part of our business strategy we would expect this non-cash expense to continue to grow. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash Used in Operating Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During fiscal 2016, our operating activities used $10.7 million in cash. The use of cash was approximately $17.5 million lower than the net loss due primarily to non-cash charges for asset impairment, amortization of the beneficial conversion feature, stock-based compensation, depreciation, amortization and accretion, unrecognized loss on investment, noncash interest expense, amortization of prepaid research and development related party, an increase in accounts payable and accrued liabilities and an increase accrued compensation offset by an increase to inventory and a decrease to deferred revenue. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During fiscal 2015, our operating activities used $6.6 million in cash. The use of cash was approximately $1.1 million lower than the net loss due primarily to non-cash charges for stock-based compensation, depreciation and amortization, amortization of prepaid research and development-related party, an increase in accounts payable and an increase in contingent consideration related to the ProstaScint asset purchase. Cash used in operating activities also included a $24,000 deferred tax benefit and a $607,000 decrease in payable to Ampio. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash Used in Investing Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During fiscal 2016, cash was used to acquire Natesto, Primsol, our investment in Acerus, the purchase of fixed assets as well as the refund of a deposit for office space. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During fiscal 2015, cash was used to acquire ProstaScint as well as deposits for office space. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Net Cash from Financing Activities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash of $16.7 million provided by financing activities during fiscal 2016 was primarily related to our registered public offering of $7.5 million of common stock and warrants offset by issuance costs of $905,000, the issuance of convertible promissory notes which reflects gross proceeds of $5.2 million offset by the cash portion of the debt issuance costs of $298,000, as well as the $5.0 million stock subscription payment from Ampio and $200,000 for a sale of stock subscriptions in January 2016 as well as the issuance costs of $30,000 related to the debt conversion. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash provided by financing activities in fiscal 2015 was $12.4 million which reflects a $7.4 million loan from Ampio which was later converted to stock, a $5.0 million stock subscription payment from Ampio, $27,000 paid out to Luoxis option holders pursuant to the Merger and $20,000 paid out for liabilities pursuant to the Merger. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Contractual Obligations and Commitments</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Information regarding our Contractual Obligations and Commitments is contained in Note 7 to the Financial Statements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Liquidity and Capital Resources</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a relatively young company and we have not yet generated substantial revenue as our primary activities are focused on commercializing our approved products, acquiring products and developing our product candidates, and raising capital. As of June 30, 2016, we had cash and cash equivalents totaling $8.1 million available to fund our operations offset by an aggregate of $8.9 million in accounts payable and accrued liabilities and the Natesto payables. In April 2016, we spent $2.0 million for the Natesto licensing agreement and approximately $2.0 million to purchase 12,245,411 shares of Acerus common stock. We have a
remaining commitment of $6.0 million during fiscal year 2017. In May 2016, we completed a registered public offering of common stock and warrants for $6.3 million in proceeds, net of expenses. Based upon our resources at June 30, 2016, and assuming we can access the $10.0 million purchase agreement with </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">58</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Lincoln Park Capital entered into in July 2016, we believe we have adequate capital to continue operations into the second quarter of fiscal 2017. We intend to raise up to an additional $12.5 million in fiscal 2017, which, if successful, we believe would provide adequate capital to continue operations through fiscal 2017 and into 2018. We also intend to seek additional capital within the next 12 months to help acquire new products as well as to support general operations. We will evaluate the capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or other
financing instruments, depending on market conditions relative to our need for funds at such time. We will seek to raise additional capital at such time as we conclude that such capital is available on terms that we consider to be in the best interests of our Company and our stockholders. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have prepared a budget for fiscal 2017 which reflects cash requirements from operations of approximately $3.0 million per quarter. Depending on the availability of capital, we may expend additional funds for the purchase of assets and commercialization of products. Accordingly, it may be necessary to raise additional capital and/or enter into licensing or collaboration agreements. At this time, we expect to satisfy our future cash needs through private or public sales of our securities or debt financings. We cannot be certain that financing will be available to us on acceptable terms, or at all. Over the last three years,
including recently, volatility in the financial markets has adversely affected the market capitalizations of many bioscience companies and generally made equity and debt financing more difficult to obtain. This volatility, coupled with other factors, may limit our access to additional financing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we cannot raise adequate additional capital in the future when we require it, we could be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts or our research or development programs. We also may be required to relinquish greater or all rights to product candidates at less favorable terms than we would otherwise choose. This may lead to impairment or other charges, which could materially affect our balance sheet and operating results. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Going Concern</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The continuation of our business is dependent upon obtaining further financing and achieving a break even or profitable level of operations in our business. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current or future stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. There are no assurances that we will be able to obtain additional financing through private placements and/or bank financing or other means necessary to support our working capital requirements. To
the extent that funds generated from operations and any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to us. These conditions raise substantial doubt about our ability to continue as a going concern. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Off Balance Sheet Arrangements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not have off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &#147;variable interest entities.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Impact of Inflation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In general, we believe that our operating expenses can be negatively impacted by increases in the cost of clinical trials due to inflation and rising health care costs.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">59</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t11BUS"></a>BUSINESS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Overview</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a commercial-stage specialty pharmaceutical company focused on acquiring, developing and commercializing novel products in the field of urology. We have multiple urology-focused products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs in the field of urology. We are initially concentrating on hypogonadism, prostate cancer, urinary tract infections, and male infertility and plan to expand into other urological indications for which there are significant medical needs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recently acquired exclusive U.S. rights to Natesto&reg; (testosterone), a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we launched Natesto in the United States with our direct sales force in July 2016. Natesto is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. Importantly, as Natesto is delivered via the nasal mucosa and not the
skin, there is no risk of testosterone transference to others, a known potential side effect and black box warning associated with all other topically applied TRTs, including the market leader AndroGel&reg;. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently market ProstaScint&reg; (capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. ProstaScint is approved by the FDA for use in both newly diagnosed, high-risk prostate cancer patients and patients with recurrent prostate cancer. We also market Primsol&reg; (trimethoprim hydrochloride)&nbsp;&#151;&nbsp;the only FDA-approved trimethoprim-only oral solution for urinary tract infections. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have a focused pipeline, including primarily MiOXSYS, a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic Area (see &#147;Business&nbsp;&#151;&nbsp;Foreign Regulatory Approval&#148;)) and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our MiOXSYS system is a novel, point-of-care semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility. Male infertility is a prevalent and underserved condition and oxidative stress is widely implicated in its pathophysiology. MiOXSYS was developed from our core oxidation-reduction potential research platform known as RedoxSYS&reg;. We are advancing MiOXSYS toward FDA clearance and, as of the date of this prospectus, we will need to raise additional funding to complete the required clinical study. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the future we will look to acquire additional urology products, including existing products we believe can offer distinct commercial advantages. Our management team&#146;s prior experience has involved identifying clinical assets that can be re-launched to increase value, with a focused commercial infrastructure specializing in urology. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto&reg; (testosterone).</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into an agreement to acquire the exclusive U.S. rights to Natesto<sup>TM</sup> (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired on July 1, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable, Transportation Security Administration, or TSA-compliant, and easy to use. Importantly,
Natesto is not applied directly to the patient&#146;s skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a proprietary nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&#146;s female partner or children&nbsp;&#151;&nbsp;as other topically (primarily gels and solutions) administered TRTs do by virtue of their delivery directly onto the skin. We launched Natesto in the U.S. in July 2016 with our direct sales force, and we are positioning Natesto as the ideal treatment solution for men with active, busy lifestyles who suffer from hypogonadism. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">60</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint&reg; (capromab pendetide).</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We became a commercial stage company by virtue of our acquisition of ProstaScint in May 2015 and are generating sales of this FDA-approved prostate cancer imaging agent. As prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused product portfolio and pipeline. Prostate cancer is the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2,200,000 men were alive in 2006 with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on
healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion by 2017, a compound annual growth rate, or CAGR, of 7.5% since 2012. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol&reg; (trimethoprim solution).</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 5, 2015, we purchased Primsol from FSC Laboratories, Inc. Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating uncomplicated urinary tract infections, or UTIs. This differentiated product is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfamethoxazole (&#147;sulfa&#148;). It is estimated that 150 million cases of urinary tract infections occur annually worldwide, and the annual estimated incidence is
0.5&nbsp;&#150;&nbsp;0.7/persons per year. Importantly, there are more than 1 million catheter-associated UTIs in the U.S. alone. As many of these patients are elderly and unable to swallow pills, an oral liquid formulation represents a convenient formulation for easier administration. The acquisition of Primsol added a second established brand to our product portfolio. We expect to benefit from and continue to grow Primsol&#146;s established base of prescribers, which already includes a significant proportion of urologists despite the fact that it has not been previously marketed to these specialists. We can thus utilize the same sales channel as ProstaScint, leading to potential commercial synergies and product growth. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS<B><sup>TM</sup></B></Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">MiOXSYS is a rapid in vitro diagnostic semen analysis test used in the quantitative measurement of static oxidation-reduction potential, or sORP, in human semen. MiOXSYS is a recently CE marked system and is an accurate, easy to use, and fast infertility assessment tool. It is estimated that 72.4 million couples worldwide experience infertility problems. In the United States, approximately 10% of couples are defined as infertile. Male infertility is responsible for between 40&nbsp;&#150;&nbsp;50% of all infertility cases and affects approximately 7% of all men. Male infertility is often unexplained (idiopathic), and this
idiopathic infertility is frequently associated with levels of oxidative stress in the semen. As such, having a rapid, easy-to-use diagnostic platform to measure oxidative stress should provide a practical way for male infertility specialists to improve semen analysis and infertility assessments without having to refer patients to outside clinical laboratories. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. The global male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess the
degree of oxidative stress, sperm motility and morphology, and potentially enable the monitoring of patients&#146; responses to antioxidant therapy as a treatment regimen for infertility. The MiOXSYS System received CE marking in Europe in January 2016 and obtained Health Canada Class II Medical Device approval in March 2016. We expect to advance MiOXSYS into clinical trials in the United States in order to enable 510(k) clearance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the MiOXSYS System, we are continuing to develop the global market for the RedoxSYS System across a range of applications. Specifically, we have begun initial commercializing of the RedoxSYS System for research use through distribution partners, primarily outside the U.S. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">61</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The technology underpinning the RedoxSYS and MiOXSYS systems was developed by Luoxis Diagnostics, Inc. in the two years immediately preceding the merger between Luoxis, Vyrix Pharmaceuticals, Inc., and us (under our former name of Rosewind Corporation) in April 2015. Upon the consummation of the merger, the RedoxSYS System and MiOXSYS System became our assets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Key elements of our business strategy include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of Natesto in the U.S. for the treatment of hypogonadism with our direct sales force. We launched Natesto in July 2016 and are targeting high-prescribing TRT prescribers with a primary emphasis on urologists and male health practitioners.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of FDA-approved ProstaScint for the staging of both newly diagnosed high-risk and recurrent prostate cancer patients. We have begun commercializing ProstaScint in the U.S. and in key markets around the world.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expand the commercialization of FDA-approved Primsol for the treatment of uncomplicated urinary tract infections. We are re-launching Primsol to urologists in the U.S. and in key markets around the world where appropriate.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Establish MiOXSYS as a leading in vitro diagnostic device in the assessment of male infertility.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Acquire additional marketed products and late-stage development assets within our core urology focus that can be efficiently marketed through our growing commercial organization.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Develop a pipeline of urology therapeutics, with a focus on identifying novel products with sufficient clinical proof of concept that require modest internal R&amp;D expense. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to augment our core in-development and commercial assets through efficient identification of complementary therapeutics, devices, and diagnostics related to urological disorders. We intend to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through asset purchases, licensing, co-development, or collaborative commercial arrangements (co-promotions, co-marketing, etc.). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management team has extensive experience across a wide range of business development activities and have in-licensed or acquired products from large, mid-sized, and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect that we will build a substantial portfolio of complementary urology products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We previously were developing Zertane for the treatment of premature ejaculation, or PE. However, we determined to direct our resources to our commercial-stage products. As a result, at the end of fiscal 2016, we determined that the Zertane asset has no value as we do not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. We intend to sell or out-license Zertane although there can be no assurance that we will be successful in doing so or, if successful, the value, if any, we might receive for the asset. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our Strategy</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to create value by implementing a focused, three-pronged strategy. Our primary focus is on expanding the commercialization of the recently acquired Natesto in the U.S, growing our current, revenue-generating products, and building a complementary portfolio of aligned urology assets. In just over one year since our merger we have acquired or in-licensed three FDA-approved, marketed assets, launched a specialty urology sales force, initiated ex-U.S. partnering discussions for our commercial products ProstaScint and Primsol, advanced our lead diagnostic asset MiOXSYS to CE marking, engaged in asset purchase and licensing
discussions for products aligned to our strategy, and launched Natesto in the U.S. through our own sales force. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe the strategy of focusing on commercializing assets prescribed by urologists makes sense for several reasons. First, urology is a large yet concentrated specialty practice area that can be efficiently targeted. There are approximately 10,000 active urologists in the U.S., and we believe that this audience can be efficiently reached with a relatively small, focused sales force. Additionally, 90% of urologists practice in metropolitan areas where concentrated sales targeting can be achieved and &#147;windshield&#148; or sales </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">62</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">representative driving time between targets can be minimized. Importantly, 81% of urologists practice in group practices, and over 60% are in practices of four or more physicians. Further, and important in building a balanced yet focused product portfolio, sub-specialization within large urology clinics is common whereby there is frequently individual clinical focus on specific areas within urology including prostate cancer and conditions, infertility, sexual dysfunction, urinary incontinence, hypogonadism, etc. This enables a company to offer multiple products to the various sub-specialties within these focused, concentrated
customer targets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, urologists treat a wide range of conditions and are thus appropriate targets across a broad range of clinical assets (Natesto&nbsp;&#151;&nbsp;hypogonadism; ProstaScint&nbsp;&#151;&nbsp;prostate cancer; Primsol&nbsp;&#151;&nbsp;urinary tract infections; MiOXSYS&nbsp;&#151;&nbsp;male infertility). Importantly, in urology, direct physician office purchasing of drugs, devices, and diagnostics is common. Along with this, a significant proportion of urology groups are privately-owned and often own and operate their own outpatient surgery centers and in-office laboratories. Further, large urology group practices have
substantial payer influence and can have the ability to negotiate as large groups to achieve better reimbursement and coverage for favored treatments and procedures. Perhaps as important as these other factors, urologists are exposed to relatively limited promotional focus by &#147;Big Pharma&#148; and we believe can therefore be accessed and impacted more readily by an emerging company, such as Aytu, over time. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aytu BioScience&#146;s Strategic Value Drivers</Font> </H2>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v449009_chrt-org.jpg" WIDTH="329" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The primary elements of our strategy are:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Expanding the commercialization of ProstaScint and Primsol, our revenue-generating, FDA-approved products in the United States via a direct commercial infrastructure. Launching ProstaScint, Primsol, and MiOXSYS outside the United States via a developing distribution network. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is a novel, recently FDA-approved testosterone replacement therapy, or TRT, indicated for the treatment of hypogonadism in men. Natesto is the only nasal formulation of testosterone and is delivered via a proprietary nasal gel to enable simple, discreet use of testosterone into the nostrils. By virtue of applying Natesto to the nasal mucosa, and not to the man&#146;s skin, there is no risk of transference to others. As such Natesto is the only TRT that does not have a black box warning associated with this potential for transference. Additionally, Natesto is a convenient form of testosterone that does not require
application to large areas of the man&#146;s body (arms, shoulders, upper torso, under arms) as required with market-leading products AndroGel and Axiron. A convenient form of TRT, applied two-to-three times in the nostrils, may be an appropriate option for men over 45 with hypogonadism who have active lifestyles, travel frequently, and value having a discreet way to treat their hypogonadism. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">63</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Low testosterone is a condition affecting approximately 13 million U.S. men, with U.S. revenues estimated at $2.4 billion in 2013. The market is expected to grow to $5.0 billion by 2017, and we believe multiple factors are in place to position Natesto favorably in gaining market share in this large, growing market. By gaining less than a 5% share of the current U.S. market (assuming similar pricing and reimbursement), a novel TRT product could achieve annual revenues in excess of $100.0 million. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint has several unique selling features that we believe will enable significant sales growth and regular use by healthcare providers diagnosing and treating prostate cancer. ProstaScint is the only imaging agent that specifically targets prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy. In multiple clinical studies researchers have shown that when SPECT/CT scans were used in patients pre-treated with ProstaScint, ProstaScint imaging was highly sensitive in detecting prostate cancer and significantly predictive of 10-year biochemical disease free survival in prostate cancer patients
(86.6% vs. 65.5%; p=0.0014). Additionally, the American Cancer Society specifically recognizes ProstaScint by name in current prostate cancer diagnosis guidelines. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prostate cancer is the second most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2.2 million men were alive in 2006 with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5% since 2012. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol is an antimicrobial agent that is indicated to treat uncomplicated urinary tract infections (UTIs). Primsol is the only oral solution containing trimethoprim and offers a novel solution for UTI patients who are either allergic to sulfamethoxazole (which is commonly combined with trimethoprim) or have difficulty swallowing pills. Because many prostate cancer patients have temporary urinary catheters placed, they are frequently diagnosed with recurrent urinary tract infections. Primsol offers a solution to those patients and enables us to sell multiple products to a similar base of U.S. prescribing clinicians. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>United States</I>.&nbsp;&nbsp;We have launched a commercial infrastructure in the U.S. in order to support increased sales and distribution of Natesto, ProstaScint and Primsol in the U.S. We have a highly experienced sales force that is distinctly focused on impacting the prescribing of urologists, and through this efficient sales channel we are able to increase prescribing of our unique urology assets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Ex-U.S</I>.&nbsp;&nbsp;As neither ProstaScint nor Primsol have been previously approved and marketed outside the U.S., we believe we can realize commercial opportunities through efficient corporate partnerships in key markets around the world. Also, with MiOXSYS now CE Marked we can develop a distribution network to launch this first-in-class in vitro diagnostic device.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Developing a pipeline of novel urological therapeutics through assertive acquisition, licensing, or co-promotion, inclusive of both marketed and late-stage development assets. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to diversify our product portfolio and create more value, we intend to seek to acquire complementary products or product candidates to develop and/or commercialize, including marketed assets. Initially, the focus will be on acquiring products or product candidates for urological conditions but we will opportunistically consider other products or product candidates based on their ability to create value and complement our focus. We plan to pursue product acquisitions, inclusive of therapeutics, diagnostics, and devices, which we will evaluate for their strategic fit and potential for near-term and/or accretive value to
us. In a little over a year from the Company&#146;s merger in April 2015 we began generating revenue from the acquisition of both ProstaScint and Primsol, and we later launched Natesto in July 2016. We expect to continue to identify and acquire additional, complementary urology assets in the future.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Completing U.S. studies in male infertility with the MiOXSYS System to enable 510k de novo clearance by FDA. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With MiOXSYS now CE marked and available for sale in many markets outside the U.S., we are positioned to initiate our clinical studies in the U.S. to enable 510k de novo clearance. We expect to receive guidance from FDA on clinical study design and patient criteria and implement the required clinical program as soon as </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">64</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">possible, subject to additional funding. If approved, MiOXSYS would be the first and only semen analysis diagnostic test for the detection of oxidative stress in infertility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. As such, we have bolstered our research focus in this area with the MiOXSYS System to complement our focus on urologic conditions. The global male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the pathophysiology of idiopathic male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile men.
With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative stress and monitor patients&#146; responses to antioxidant therapy and improve diagnosis of male infertility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through our extensive network of researchers developed at one of our predecessor companies Luoxis, the RedoxSYS System has demonstrated the potential to have broad clinical applications inclusive of male infertility in semen analysis studies. Studies have been completed at a major U.S. university and major hospital outside the U.S. in the evaluation of male infertility. As such, we developed the MiOXSYS System as a line extension to RedoxSYS to specifically assess oxidative stress in semen as a tool to assess male infertility. In January 2016, the MiOXSYS System received CE Marking and is now available for sale in multiple
ex-U.S. markets including Europe, the Middle East, and parts of Asia. In March 2016, the MiOXSYS System obtained Health Canada Class II Medical Device approval. With Health Canada approval in place, the Company expects to begin initial marketing of the product in Canada. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our FDA&nbsp;&#151;&nbsp;Approved Urology Products</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Three of our products have received FDA approval for marketing in the U.S.: Natesto, ProstaScint and Primsol. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto for Testosterone Replacement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&reg; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective on July 1, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable, TSA-compliant, and easy to use. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, Natesto is not applied directly to the patient&#146;s skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a patented nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&#146;s female partner or children&nbsp;&#151;&nbsp;as other topically (primarily gels) administered TRTs do by virtue of their delivery directly onto the skin. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v449009_img-testnasal.jpg" WIDTH="225" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Image of Natesto (testosterone) nasal gel</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The unique delivery of Natesto also enables simple, discreet use by a single three times daily application into the nose and may improve compliance over topical forms that are applied to large sections of the arms, shoulders, and other large areas of the man&#146;s upper torso. It also offers a more discreet method of TRT administration compared to films/patches (Androderm &amp; Testoderm, which is applied to the scrotum) </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">65</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and doesn&#146;t involve the pain, potential for site injection infections, and the administration inconvenience of the injectable TRTs such as Testopel and Aveed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A concern associated with the use of the currently marketed testosterone gels is the unintentional transfer of testosterone to women (or children) by skin contact with the man&#146;s application site. In the event of a female partner receiving inadvertent testosterone exposure due to intimate contact with her male partner, she may develop hyperandrogenism, a condition characterized by excess levels of androgens. This condition may result in women developing acne, scalp hair loss, excessive facial or body hair, breast atrophy, and other symptoms. Natesto, as it is nasally administered, does not present this potential
complication of &#145;transference&#146; and thus does not have a black box warning as is associated with the topically applied testosterone supplements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe Natesto offers additional distinct clinical advantages over market-leading AndroGel, which advantages may translate into clinical adoption of Natesto over AndroGel and other topically-applied TRT products. First, Natesto achieves C<sub>max</sub>, or maximum concentration of testosterone, of 1,044 ng/dL, while AndroGel achieves a lower C<sub>max</sub> of 845 ng/dL. Additionally, Natesto achieves C<sub>max</sub> within 40 minutes, which is a rapid onset of action for a topically applied TRT. Natesto also enables effective restoration of serum testosterone levels with a low dose of only 5.5 mg per nasal actuation (5.5
mg per pump per nostril), while AndroGel delivers substantially more testosterone of 20.25 mg per pump (1-3 pumps may be applied per the AndroGel prescribing information). Importantly, Natesto&#146;s prescribing information also indicates a relatively low incidence of rising Prostate-Specific Antigen (PSA), which is a well characterized effect of testosterone supplementation. Natesto yields a 5.1% incidence of rising PSA in the product information, while AndroGel yields 11.1%. While head-to-head comparative studies have not been conducted between these two products, we believe clinicians will recognize the potential benefits offered by Natesto over other topically-applied TRTs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter&#146;s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) above the normal range.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The U.S. Testosterone Replacement Therapy Market</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe we have an opportunity to increase revenue with Natesto in the U.S. Natesto competes in a large, growing market. The U.S. TRT market is large, with annual revenues in the U.S. in 2013 of $2.4 billion. Revenues are expected to increase to $5 billion by 2017. If the TRT market grows as expected, with as little as 5% market penetration, a novel, patent-protected TRT product could achieve sales of $250 million. Even at the current market size of over $2.4 billion, a product with 5% market penetration could achieve sales in excess of $100 million annually, assuming comparatively similar product pricing and reimbursement
levels as seen with other TRTs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are also FDA-approved. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">66</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The actively marketed, FDA-approved TRTs include: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="93"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="144"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="128"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="85"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="93"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Brand Name</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Form of Delivery</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Company</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Year Approved</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Black Box Warning</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Androderm&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Film/Patch</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Allergan</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1995</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>AndroGel&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">AbbVie</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2000</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Aveed&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Injection</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2014</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Axiron&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Solution</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Eli Lilly &amp; Company</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2010</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Fortesta&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2010</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Striant&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Extended Release Tablet</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2003</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Testim&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2002</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Testoderm&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Film/Patch</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Johnson &amp; Johnson</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1993</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Testopel&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Injection</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Endo Pharmaceuticals</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1972</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">No</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Vogelxo&reg;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Gel</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Upsher-Smith</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2014</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">Yes</TD>

</TR>

</TABLE></DIV>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AndroGel&reg;, marketed by AbbVie, is the leading TRT and had 2012 revenues of $1.15 billion. AndroGel had over half of the total TRT market across its 1.0% and 1.62% formulations of the product. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, however, AndroGel is beginning to face generic threats with the expiration of key patents for its 1.0% formulation, and Teva Pharmaceuticals has a competitive generic product in waiting. AbbVie has attempted to block Teva&#146;s launch through the filing of a citizen&#146;s petition. Products with significant shares of the TRT market and promotional spending include Axiron, Testim, Fortesta, Androderm, and Testopel. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe there are multiple factors in the U.S. TRT market that are favorable to Natesto and our company as we seek to expand commercialization of Natesto. First, the TRT market has demonstrated 5.5% growth on a quarter-over-quarter basis (quarter ended June 30, 2016 versus quarter ended June 30, 2015). With this expanding market we expect to capture a significant number of prescriptions from both newly diagnosed patients and currently treated patients who may be dissatisfied with current treatment. Additionally, the promotion of TRT products by major competitors including both AbbVie (AndroGel) and Eli Lilly &amp; Company
(Axiron) has been reduced. We believe this enables us to more effectively compete in this large, growing market. For example, direct-to-consumer advertising by these larger companies has been reduced, which should provide a more &#145;even playing field&#146; among newer, smaller competitive entrants like Aytu. Finally, with the advent and increasing popularity of &#145;high deductible plans&#146; provided by health insurers, many patients are paying more money out of pocket for their prescriptions, and TRT out-of-pocket prices have risen. With limited true low cost generic options in the TRT market, we expect that Natesto will be afforded a more equal footing in this competitive, growing market. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">About Hypogonadism</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male hypogonadism is a condition in which the body does not produce enough testosterone&nbsp;&#151;&nbsp;the hormone that plays a key role in masculine growth and development during puberty&nbsp;&#151;&nbsp;or has an impaired ability to produce sperm or both. Men can be born with male hypogonadism, or it can develop later in life from injury or infection. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Hypogonadism is formally defined as deficient or absent male gonadal function that results in insufficient testosterone secretion. Hypogonadism may be caused primarily by testicular failure, or secondarily by hypothalamic-pituitary axis dysfunction, resulting in the production or release of insufficient testosterone to maintain testosterone-dependent functions and systems. It can also result from a combination of testicular failure and hypothalamic-pituitary axis dysfunction. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Hypogonadism affects an estimated 13 million men in the United States, and although it may occur in men at any age, low testosterone levels are especially common in older males. More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to 35. Studies suggest that hypogonadism in adult men is often underdiagnosed and under treated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Low testosterone, as male hypogonadism is also known, is associated with a number of signs and symptoms, most notably loss of libido and erectile dysfunction (ED). Other signs of low testosterone include depressive symptoms, a decrease in cognitive abilities, irritability and lethargy or loss of energy. Deficient endogenous testosterone also has negative effects on bone mass and is a significant risk factor for osteoporosis in men. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">67</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Progressive decrease in muscle mass and muscle strength and testicular dysfunction, often resulting in impaired sperm production, are also associated with low testosterone levels. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A younger patient may have pure hypogonadism as a primary event, whereas an older man may have an age-related decline in testosterone production that is a part of his ED profile. However, because both ED and loss of libido are hallmarks of hypogonadism, for a patient who presents with ED it is recommended that he have a basic hormone profile to determine if he has low testosterone. Treatments to normalize testosterone can not only improve libido, energy level and the potential to have normal erections, but can also improve the response to sildenafil, if that is deemed appropriate treatment. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto Clinical Studies Demonstrating Safety and Efficacy</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto has been shown to be safe and effective in men with hypogonadism. It was approved by the FDA in May 2014. In its pivotal clinical trial, Natesto was evaluated for efficacy in a 90-day, open-label, multicenter study of 306 hypogonadal men. Eligible patients were 18 years of age and older (mean age 54 years) and had morning serum total testosterone concentrations less than 300 ng/dL. Patients were Caucasian (89%), African-American (6%), Asian (5%), or of other ethnicities (less than 1%). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patients were instructed to self-administer Natesto (11 mg of testosterone) intranasally either two or three times daily. The primary endpoint was the percentage of patients with an average serum total testosterone concentration (C<sub>avg</sub>) within the normal range (300 to 1050 ng/dL) on Day 90. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The secondary endpoint was the percentage of patients with a maximum total testosterone concentration (C<sub>max</sub>) above three predetermined limits: greater than 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL. A total of 78 hypogonadal men received Natesto (11 mg of testosterone) three times daily (33 mg of testosterone daily). Of these, a total of 73 hypogonadal men were included in the statistical evaluation of efficacy (total testosterone pharmacokinetics) on Day 90 based on the intent-to-treat (ITT) population with last observation carried forward (LOCF). Ninety percent of these 73 patients had a
C<sub>avg</sub> within the normal range (300 to 1050 ng/dL) on Day 90. The percentages of patients with C<sub>avg</sub> below the normal range (less than 300 ng/dL) and above the normal range (greater than 1050 ng/dL) on Day 90 were 10% and 0%, respectively. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The table below (Table 3 from the Natesto Prescribing Information) summarizes the mean (SD) serum total testosterone concentrations on Day 90 in 69 patients who had a full pharmacokinetic sampling profile and were treated with Natesto (11 mg of testosterone) three times daily for 90 days. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Table 3: Mean (SD) Serum Total Testosterone Concentrations on Day 90 Following<BR> Administration of Natesto (11 mg of testosterone) Three Times Daily</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="221"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="229"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=3 STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Natesto</B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=3 STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(11 mg of testosterone) Three Times Daily (N=69)</B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">C<sub>avg </sub>(ng/dL)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">421 (116)</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">C<sub>max </sub>(ng/dL)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1044 (378)</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">C<sub>min </sub>(ng/dL)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">215 (74)</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">68</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the same clinical trial studying the safety and efficacy of Natesto, which was conducted at 39 U.S. outpatient sites, it was shown that 70% of the per protocol patients in the twice-daily &#145;titration arm&#146; (n=141) achieved normal testosterone levels. Ninety-one percent of the per protocol patients in the thrice-daily group (n=77) achieved normal testosterone levels, demonstrating that the majority of men in both treatment groups achieved normalization of testosterone levels while taking Natesto. The efficacy of both B.I.D. (twice daily) and T.I.D. (three times daily) dosing of Natesto is demonstrated in the graphs
below: </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v449009_chrt-line.jpg" WIDTH="361" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto Product Features and Patient Benefits</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe Natesto has a unique opportunity to gain market share in the more than $2.4 billion U.S. market given the product&#146;s novel features and patient benefits including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Ease of administration; Appropriate for men with busy, active lives;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Established efficacy in pivotal FDA trials with a unique, low dose of testosterone; Effective in improving serum testosterone levels while using a proven, lower dose of testosterone;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Discreet product presentation and ease of transport (TSA compliant); Important for men who travel frequently and desire a simple, portable solution that travels easily with them;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">69</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">No risk of secondary exposure to testosterone due to dermal transference, an important consideration when thinking about a hypogonadal man&#146;s partner&#146;s or child&#146;s safety; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Safety, with a lower incidence of rising PSA levels than the market leading product AndroGel; Natesto demonstrates a 5.5% rate of rising PSA levels in clinical trials, while AndroGel demonstrated a rising PSA rate of over 11% in clinical trials. This is an important consideration as physicians concerned with understanding and tracking prostate cancer risk frequently monitor PSA levels in men over 50 years of age. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto has proven efficacy and a product profile well suited for men suffering from hypogonadism who have active, busy lifestyles who want a simple, discreet TRT option. We believe Natesto can play an important role in the treatment of hypogonadism, a condition affecting approximately 13 million U.S. men. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto Market Opportunity</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Two recent developments have presented a unique opportunity for Natesto that we believe will enable us to effectively compete and be well positioned in the more than $2.4 billion TRT market. As previously indicated, AndroGel&#146;s patent expired in 2015 and, unless a citizen&#146;s petition filed by AbbVie to delay a Teva Pharmaceuticals generic is successful long-term, we expect a generic entrant to begin eroding AbbVie&#146;s market share. As a result, we expect there to be diminished promotional support in the form of fewer physician details and lower overall promotional spending by AbbVie. In conjunction with the market
leader&#146;s diminished intellectual property position and potential diminished promotional spending, the TRT market has received increased scrutiny from the FDA. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 31, 2014 and subsequently on March 3, 2015, the FDA issued Safety Announcements relating to the possible increased risk of non-fatal heart attacks and strokes in patients taking testosterone. While the FDA has not concluded that the FDA-approved testosterone treatment increases the risk of stroke, heart attack, or death, this recent safety consideration has caused patient advocates and consumer groups to ask for increased scrutiny on the direct to consumer advertising associated with the leading testosterone replacement products, most notably AndroGel and Axiron. As a result, we expect decreased advertising spending
in the TRT category to enable newer, less established products like Natesto to more effectively infiltrate the market through on-label, physician-directed promotion with a direct selling effort. While the potential safety concerns may cause a decrease in physician prescribing, we expect that physicians will continue to prescribe TRTs for patients for whom TRT treatment is appropriate. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Leading urology groups including the American Urological Association, or AUA, have strongly commented in favor of continued prescribing of TRTs for appropriate patients, and the safety data precipitating the FDA&#146;s comments have been called into question. Importantly, the FDA has not called for discontinuation of TRTs. Rather, patients were encouraged to speak with their health care professional and not stop taking TRTs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the FDA&#146;s initial statement about the potential cardiovascular risks associated with TRT treatment, the agency commented: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Patients should not stop taking their prescribed testosterone products without first discussing their questions or concerns with their health care professionals. ... The prescribing information in the drug labels of FDA-approved testosterone products should be followed.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, following the FDA&#146;s statement, the AUA issued a strong response reiterating the clinical importance of low testosterone and maintaining their support for the appropriate use of testosterone replacement therapy: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Men with hypogonadism may also experience reduced muscle mass and strength and increased body fat. Hypogonadism may also contribute to reduced bone mineral density and anemia. Testosterone therapy is appropriate treatment for patients with clinically significant hypogonadism, including those with idiopathic clinical hypogonadism that may or may not be age-related, after full discussion of potential adverse effects.&#148; </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">70</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additional publications publicly refuted the validity of the data that precipitated the FDA&#146;s safety concern in a subsequent statement following the 2014 annual meeting of the AUA: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;During the last several months there has been a firestorm of negative media attention regarding testosterone deficiency and its treatment, precipitated by a study reporting an increased rate of nonfatal myocardial infarction (MI) associated with testosterone prescriptions. This public judgment of T therapy demands a response. As researchers and clinicians with extensive experience with T deficiency and its treatment, we disagree that the recent study published in PLOS (Public Library of Science) One presents any credible evidence that T prescriptions increase health risks, and we find baseless the general assertion that
testosterone is prescribed to men &#147;who are simply reluctant to accept the fact that they are getting older.&#148; We object to comments questioning whether T deficiency is real, regardless of whether it is called hypogonadism or &#147;low T&#148; as used in advertisements.&#148; (Note: The PLOS is an open access online publication venue, and while peer reviewed it is not a published medical journal.) </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AbbVie&#146;s sales of AndroGel dropped 5% in the first half of 2014, following the FDA&#146;s initial Safety Announcement and the subsequent reaction of the AUA and others. In the face of significant new competitive entrants (Aveed, Vogelxo) at that time and the FDA&#146;s expressed safety concerns, this represents a relatively insignificant sales decline. We believe this decline speaks to a real, present need in hypogonadism and a substantial opportunity for newly marketed products like Natesto. Natesto has proven safety, a recent FDA approval that speaks to the product&#146;s efficacy, and unique product features and patient
benefits we believe will set Natesto apart from the topically administered competitive products in the more than $2.4 billion U.S. TRT market. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint for the Detection of Prostate Cancer</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On May 20, 2015, we acquired ProstaScint&reg; from Jazz Pharmaceuticals. ProstaScint Kit, or capromab pendetide, is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific antigen. ProstaScint targets prostate specific membrane antigen, or PSMA, a protein uniquely expressed by prostate tissue. A radioactive substance called Indium (In 111) is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody is infused into the patient and is taken up by prostate cancer cells which can be detected and visualized with a special nuclear medicine scan (single-photon emission tomography,
or SPECT). ProstaScint has been shown to be clinically effective in determining the course of treatment for a patient who has had a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated efficacy in patients classified as high risk or with recurrent prostate cancer. ProstaScint has been approved by the FDA and Health Canada, and significant clinical data exist demonstrating the significant predictive value in prostate cancer staging. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Prostate Cancer Market</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">According to the American Cancer Society prostate cancer is the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2.2 million men were alive in 2006 with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5% since 2012.
Importantly, ProstaScint is the only FDA-approved radiopharmaceutical (for use in radioimmunoscintigraphy) specifically indicated for prostate cancer screening and is specifically highlighted in the American Cancer Society practice guidelines for prostate cancer screening and staging. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prostate cancer is classified into four stages based on severity: Stages 1 through 4. Stage 3 is considered &#147;high risk&#148; and Stage 4 is when cancer has become metastatic. Radioimmunoscintigraphy has been established as a diagnostic to stage cancer malignancy and one of the most widespread clinical uses has been for the detection of prostate cancer. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">71</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Clinical Data</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Multiple clinical studies have been conducted in the United States and published in peer-reviewed publications that consistently demonstrate substantial clinical efficacy of ProstaScint in staging prostate cancer patients and specifically identify whether the cancer is confined to the prostate or has metastasized to other parts of the body. Through more accurate clinical staging and identification of metastatic prostate cancer, clinicians are able to better direct therapeutic interventions and improve outcomes. A brief summary of key clinical findings for ProstaScint from select studies are summarized below. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE BORDER="1" BORDERCOLOR="black" CELLPADDING="2" CELLSPACING="0" STYLE="vertical-align: text-top; text-indent: 0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; *margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt" WIDTH="608">

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Principal Investigator(s)/<BR> Primary Authors</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Publication</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Patient Population</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Conclusion/Results</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Ellis RJ et al.</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Int. J. Radiation Oncology Biol. Phy. (2010)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Patients presenting for primary radiotherapy having a clinical diagnosis of localized primary prostate cancer; Patients evaluated for tumor stage using conventional staging and<BR> SPECT/CT (N=239)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">SPECT/CT imaging with ProstaScint pre-treatment was significantly predictive of 10-year biochemical disease-free survival (86.6% vs. 65.5%; p=0.0014)</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Haseman MK et al.</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Urology (2007)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Men with prostate cancer who underwent imaging with ProstaScint pretreatment; Patients were divided according to the presence or absence of central abdominal uptake (CAU) (N=341)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">SPECT/CT imaging with ProstaScint pretreatment effectively predicted death rates among patients with central abdominal uptake (CAU), and demonstrated that prostate cancer-specific death rates were 10 times higher in patients identified with ProstaScint as having central abdominal uptake (p=0.005).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Ellis RJ et al.</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Brachytherapy (2005)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Men with prostate cancer of all risk categories who underwent imaging with ProstaScint pretreatment; patients were divided into low, intermediate, and high risk and underwent brachytherapy (N=239)</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">SPECT/CT imaging with ProstaScint pretreatment effectively predicted biochemical disease recurrence regardless of the patient&#146;s risk category;<BR> 7-year outcomes data from brachytherapy patients with treatment based on the ProstaScint scan showed a significant difference in biochemical disease-free survival.</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Radiation oncology experts have published numerous papers expressing the potential for expanded use of ProstaScint in prostate cancer imaging due to advances in imaging technologies since the product&#146;s initial approval. Since the early 2000s, significantly greater image resolution has been enabled due to the advent of dual head cameras (and improved imaging in general) along with the use of co-registered images where radiologists now combine the images of SPECT and computerized tomography, or CT, or magnetic resonance imaging, or MRI. Because of these factors, we believe there is significant commercial opportunity for
ProstaScint. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Product Information</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is provided as a two-vial kit which contains all of the non-radioactive ingredients necessary to produce a single unit dose for administration by intravenous injection. The ProstaScint vial contains 0.5 mg of capromab pendetide in 1 mL of sodium phosphate buffered saline solution adjusted to pH 6; a sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. The vial of sodium acetate buffer contains 82 mg of sodium acetate in 2 mL of water for injection adjusted to pH 5&nbsp;&#150;&nbsp;7 with glacial acetic acid; it is a sterile, pyrogen-free, clear, and colorless solution.
Neither solution contains a preservative. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">72</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each kit also includes one sterile 0.22 &#956;m Millex&reg; GV filter, prescribing information, and two identification labels. The hospital is responsible for addition of Indium (In 111). ProstaScint may also be helpful in conjunction with other scans (CT or MRI) for higher risk patients, by detecting lymph nodes in the abdomen that are involved with prostate cancer cells, but may still appear falsely normal on CT or MRI scans. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The procedure to administer ProstaScint is as follows: the patient is given an intravenous, or IV, infusion of the monoclonal antibody, and 30 minutes later, a scan is performed. A second scan is done between 96 and 120 hours (4&nbsp;&#150;&nbsp;5 days) after the infusion. The first scan (on the day of the infusion) takes approximately 1 hour, while the second scan takes approximately 2.5 hours. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint Uses</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (e.g. chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated in patients who are not at high risk. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium (In 111) ProstaScint following radiation therapy has not been studied. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information provided by Indium (In 111) ProstaScint imaging should be considered in conjunction with other diagnostic information. Scans that are positive for metastatic disease should be confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy unless medically contraindicated. Scans that are negative for metastatic disease should not be used in lieu of histological confirmation. ProstaScint is not indicated as a screening tool for carcinoma of the prostate nor for re-administration for the purpose of assessment of response to treatment. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint was initially marketed by Cytogen Corporation, which was acquired by EUSA Pharma. Jazz Pharmaceuticals acquired EUSA in June 2012 but significantly reduced promotion of ProstaScint due to a lack of strategic focus. Despite limited commercialization efforts, peak annual unit sales of ProstaScint of 8,216 kits were achieved. At current pricing, this unit sales volume would equate to approximately $14.6 million in annual revenue. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol for the Treatment of Urinary Tract Infections</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015 we acquired Primsol (trimethoprim hydrochloride oral solution) from FSC Laboratories, Inc. Primsol is the only FDA-approved trimethoprim-only oral solution for urinary tract infections and is standard therapy for such infections. Primsol is a sulfa-free, pleasant tasting, dye-free liquid that is appropriate for patients that are sulfa allergic and individuals that have difficulty swallowing pills. Primsol has demonstrated efficacy in eradicating key pathogens implicated in urinary tract infections including <I>E. coli</I> and has demonstrated similar efficacy to trimethoprim-sulfamethoxazole combination agents.
Primsol addresses a significant issue as many patients experience an allergic reaction to sulfamethoxazole. As the only oral solution containing only trimethoprim, Primsol offers distinct advantages over sulfa-containing antibacterial agents. Primsol was approved by the FDA in 2000 and was originally marketed by Ascent Pediatrics. FSC Laboratories acquired Primsol from Taro Pharmaceutical. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 4, 2016, we entered into a co-promotion agreement for Primsol oral solution with Allegis Pharmaceuticals. Under the agreement, the third party will exclusively promote Primsol to pediatricians across the U.S. We retain all other rights in the U.S. and around the world and will continue to market the product in urologic indications. This co-promotion enables us to focus exclusively on the urology channel while monetizing Primsol by virtue of a relationship with a company focused on selling to a non-core non-urology audience than can drive prescription growth of Primsol. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">About Primsol</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol is a solution of the synthetic antibacterial trimethoprim in water prepared with the aid of hydrochloric acid. Each 5 mL for oral administration contains trimethoprim hydrochloride equivalent to 50 mg trimethoprim and the inactive ingredients bubble gum flavor, fructose, glycerin, methylparaben, </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">73</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">monoammonium glycyrrhizinate, povidone, propylparaben, propylene glycol, saccharin sodium, sodium benzoate, sorbitol, water and hydrochloric acid and/or sodium hydroxide to adjust pH to a range of 3.0&nbsp;&#150;&nbsp;5.0. Primsol is indicated for the treatment of initial episodes of uncomplicated urinary tract infections in adults due to susceptible strains of the following organisms: <I>Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter</I> species and coagulase-negative Staphylococcus species, including <I>S. saprophyticus</I>. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the treatment of uncomplicated urinary tract infections the usual oral adult dosage of Primsol is 100 mg (10 mL) every 12 hours or 200 mg (20 mL) every 24 hours, each for 10 days. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Urinary tract infections, or UTIs are among the most common diagnoses in the U.S., where the prevalence is estimated at 8.1 million physician office visits. Additionally, one fourth of women will have recurrent UTIs requiring the repeated use of oral antibiotics. Current UTI treatment recommendations include the use of trimethoprim-containing products given the compound&#146;s longstanding, established efficacy profile in effectively eradicating the key pathogens implicated in UTIs. Primsol has demonstrated efficacy in the eradication of the key pathogens implicated in urinary tract infections as demonstrated by a series of
quantitative methods and clinical studies. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations, or MICs, to eradicate pathogens implicated in urinary tract infections. These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of trimethoprim powder. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MIC values should be interpreted according to the following criteria: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For testing aerobic microorganisms isolated from urinary tract infections: </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MIC (mcg/mL) Interpretation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&le; 8</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Susceptible (S)</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&ge; 16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Resistant (R)</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A report of &#147;Susceptible&#148; indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of &#147;Intermediate&#148; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small
uncontrolled technical factors from causing major discrepancies in interpretation. A report of &#147;Resistant&#148; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; and other therapy should be selected. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard trimethoprim powder as contained in Primsol provides the following MIC values against E. coli demonstrating significant susceptibility of this primary causal organism in urinary tract infections: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="120"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="418"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><B>Microorganism MIC</B></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left"><B>(mcg/mL)</B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><I>Escherichia coli</I></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">0.5&nbsp;&#150;&nbsp;2</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trimethoprim has been shown to be active against the following microbial strains as indicated below and demonstrated through in vitro and clinical studies. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aerobic gram-positive microorganisms</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Staphylococcus species (coagulase-negative strains, including S. saprophyticus)</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Streptococcus pneumoniae (penicillin-susceptible strains) </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">74</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aerobic gram-negative microorganisms</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Enterobacter species</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Escherichia coli</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Haemophilus influenza (excluding beta-lactamase negative, ampicillin resistant strains)</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Klebsiella pneumonia</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Proteus mirabilis </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol has demonstrated efficacy in the treatment of uncomplicated urinary tract infections without the potential side effects and allergic reactions sometimes attributed to sulfa-containing trimethoprim formulations. Importantly, and despite the fact that FSC Laboratories did not historically promote Primsol to urologists, 26% of Primsol prescriptions over the six-year period of September 2009 through August 2015 were written by urologists. This, we believe, underscores the unmet market opportunity for Primsol in presenting this treatment option more assertively to urologists. As our sales team will already be accessing
urologists through their promotion of ProstaScint, Primsol can be positioned as a first-line treatment option for urologists treating uncomplicated UTIs. With two FDA-approved products directed at urologists, we are able to efficiently drive awareness and increase through a focused field effort. ProstaScint and Primsol are commercially complementary and enable us to utilize our field sales force&#146;s synergies to affect prescription growth on both products while directing promotional efforts to our urology customers. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol was previously marketed by FSC Laboratories. Due to FSC&#146;s strategic refocusing and new product acquisitions to which sales efforts were diverted, Primsol had only limited commercial emphasis in the three to four years preceding our acquisition of the product. Despite FSC&#146;s limited commercial focus, annual unit sales of 7,842 units were achieved. At current pricing, this would result in annual revenues of approximately $5.3 million. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS In Vitro Diagnostic System for Male Infertility</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Male infertility is a significant medical condition that urologists and infertility specialists treat frequently in the office setting or specialized fertility centers around the world. Of all sexually active couples, 8% to 12% are infertile and male infertility is the sole cause or contributing factor up to 50% of the time. The global male infertility market is large and growing. The market for male infertility diagnosis and treatments is expected to grow to more than $300 million globally by 2020, with a CAGR of nearly 5% from 2014 to 2020. Despite the prevalence of male infertility, difficulties remain in effectively
diagnosing root causes. Oxidative stress assessment is considered a standard practice in complex andrology laboratories around the world, but due to various factors oxidative stress testing is not routinely employed in clinicians&#146; offices or standard laboratory settings. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Seminal oxidative stress has been well established throughout the peer-reviewed literature to play a substantial role in unexplained male infertility, and researchers and clinicians actively consider oxidative stress when conducting laboratory infertility assessment. While oxidative stress is well established as a leading contributing factor to male infertility, a significant proportion of male infertility remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess oxidative stress in semen and plasma. This lack of standardization has resulted in poor implementation of
semen and plasma analysis around the world. Further, current testing platforms are cost-prohibitive for small office settings or local medical laboratories and require extensive training and on-site expertise. Additionally, antioxidant supplementation is frequently recommended to patients by clinicians without an effective method of measuring treatment success. As such, we believe introducing the MiOXSYS System to assess oxidative stress levels in semen and seminal fluid represents a significant commercial opportunity and novel way for clinicians to assess male factor infertility and assess therapeutic responses of patients in a simple, reliable, and cost-effective way. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System was CE marked in January 2016, and we expect to initiate early commercialization efforts outside the U.S. by the middle of fiscal 2017. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">75</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An attractive aspect of the reproductive health market relates to reimbursement as infertility treatments and the associated diagnostic tests are generally paid directly by patients. The current infertility treatments could cost in excess of $10,000 per treatment cycle, so the addition of a moderately priced oxidative stress test would consume nominal relative costs while providing specific, actionable information needed to improve the oxidative status of infertile patients. The current infertility treatments include antioxidant supplements and lifestyle modifications that lower oxidative stress (e.g., smoking cessation,
exercise, dietary changes, etc.), so the measurements reported by the MiOXSYS System could effectively guide treatment in the infertile patients. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The global male infertility market is expected to grow to more than $300 million by 2020. With a substantial base of conditions for which the MiOXSYS System may present utility, we believe there is significant revenue potential from this first-in-class system. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of our strategy to develop future clinical applications of the RedoxSYS System (the MiOXSYS System&#146;s predecessor product for plasma and whole blood detection), we have conducted initial studies in male reproductive health. Male infertility is a significant medical condition in which oxidative stress is well known to play a substantial role. As such, we believe developing a clinical application to assess oxidative stress levels with the uniquely designed and programmed MiOXSYS System for semen analysis represents a significant commercial opportunity. Oxidative stress is well established as a leading contributing
factor to male infertility. Further, a significant proportion of male infertility remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess oxidative stress in semen and seminal plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis around the world. Further, currently available tests are cumbersome, time consuming to perform, and costly. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted initial proof-of-concept clinical studies in male infertility with a leading research center in the United States, which demonstrated that oxidation-reduction potential effectively measures oxidative stress levels in semen and seminal plasma&nbsp;&#151;&nbsp;and that these levels strongly correlate with established markers of infertility. Semen analysis studies are routinely conducted to assess causes of infertility, so we expect clinicians and oxidative stress researchers to readily integrate the MiOXSYS System into routine use upon the completion of more extensive studies and regulatory clearance for this use.
Additional studies are now in the late planning stages that will evaluate the MiOXSYS System&#146;s performance in the detection of oxidative stress levels and correlations with key semen parameters in both healthy and infertile males. The MiOXSYS System must receive 510(k) de novo clearance from the FDA before we can market it for clinical use in the United States. We expect to begin envolling patients in a single clinical study prior to year-end with 501(k) de novo clearance expected in late 2017. Of the $300 million male infertility market projected for 2020, the North American, Middle Eastern, and Asia Pacific markets dominate due to prevalence, awareness of treatment, and availability of treatment resources. Thus, it is important that we have already established distribution relationships and direct access to major oxidative stress researchers in many of these important markets. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following our initial proof of concept studies with a leading center in the United States with the MiOXSYS system, we conducted our CE mark-enabling study with over 300 infertile patients. The two key studies conducted with these leading centers are presented below. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United States-Based Proof-of-Concept Clinical Study</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fifty-one (51) male patients were seen in a national clinic for suspected infertility. In addition to standard semen analyses (WHO 5<sup>th</sup> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values were normed to sperm concentration (mv/10<sup>6</sup> sperm/mL) and compared across six semen parameters that are associated with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology. Higher sORP values are associated with a higher state of oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patients with abnormally low ejaculate volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total number, have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen samples that had fewer normal sperm had slightly, but not significantly, higher sORP values. Thus, most abnormal semen parameters appear to be associated with higher measures of oxidative stress. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">76</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">When samples that achieve all six parameters associated with fertile semen are compared to samples that fail one or more of the parameters, the samples that meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<sup>6</sup> sperm/mL separated those that met fertility standards from those that did not. In the current study, 85.7% of samples that met standards fell below this cutoff value, whereas 71.8% of those that failed one or more parameters had sORP values above this cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff
is abnormal in at least one of the semen parameters, is 96.5%. Lastly, the more parameters that a semen sample falls within the abnormal range, the higher the sORP values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on one or two. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Data derived from patients of the national clinic confirms the results obtained in an international fertility clinic. Overall, semen that falls into the abnormal range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by higher sORP values. These values are uniquely obtained using the MiOXSYS System for semen analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2016, we observed encouraging data from two prospective studies of the MiOXSYS System that demonstrated its clinical utility as a tool for measuring ORP to assess the degree of oxidative stress levels in human semen. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The first study measured sORP in the semen samples of infertile men that correlated well with the sperm concentration, motility, and morphology. The second study further suggests that sORP is an easy to determine one-step indicator of increased oxidative stress in semen samples of infertile men especially with leukocytospermia. The results are currently being validated in a larger cohort of infertile men. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">International Pivotal Clinical Study</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Three-hundred sixty-six (366) male partners from couples seeking fertility advisement in an international clinic were recruited. In addition to standard semen analyses (WHO 5<sup>th</sup> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values were normed to sperm concentration (mv/10<sup>6</sup> sperm/mL) and compared across six semen parameters that are associated with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology. Higher sORP values are associated with a higher state of oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patients with abnormally low ejaculate volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total number, have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen samples that had fewer normal sperm had significantly higher sORP values than those that fell into the range of normal morphology. Thus, most abnormal semen parameters appear to be associated with higher measures of
oxidative stress. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">When samples that achieve all six parameters associated with fertile semen are compared to samples that fail one or more of the parameters, the samples that meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<sup>6</sup> sperm/mL separated those that met fertility standards from those that did not. In the current study, 91.43% of samples that met fertility standards fell below this cutoff value whereas 59.5% of those that failed one or more had sORP values above this cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff
is abnormal in at least one of the semen parameters, is 98.6%. Lastly, the more parameters that a semen samples falls within the abnormal range, the higher the sORP values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on one or two. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Data derived from patients at this international clinic confirms the results obtained in United States fertility clinic. Overall, semen that falls into the abnormal range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by higher sORP values. These values are obtained uniquely using the MiOXSYS System for semen analysis. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">77</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Proof of concept clinical studies have been conducted at the Cleveland Clinic&#146;s Department of Urology, and two posters were presented at the 2015 American Society for Reproductive Medicine in November 2015. These abstracts are presented below. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Establishing the Oxidation-Reduction Potential in Semen and Seminal Plasma</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A. Agarwal,<sup>1</sup> S. S. Du Plessis,<sup>1,2</sup> R. Sharma,1 L. Samanta,<sup>1,3</sup> A. Harlev,<sup>1,4</sup> G. Ahmad,<sup>1,5</sup> S. Gupta,<sup>1</sup> E. S. Sabanegh<sup>6</sup>; 1. Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology, Stellenbosch University, Tygerberg, South Africa, 3. Redox Biology Laboratory, School of Life Sciences, Ravenshaw University, Orissa, India, 4. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 5. Physiology and Cell Biology, University of Health Sciences, Lahore, Pakistan, 6. Department of Urology, Cleveland Clinic, Cleveland, OH
</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Abstract:</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Objective:</B>&nbsp;&nbsp;Oxidation-reduction potential (ORP) is a novel measure of oxidative stress or redox imbalance in biological samples. Static ORP (sORP) provides an integrated measure of the balance between total oxidants and reductants in a biological system, whereas capacity ORP (cORP) equates to the amount of antioxidant reserves. sORP has been shown to correlate well with illness and injury severity that accompanies the state of oxidative stress; cORP correlates with the ability to respond to illness or injury. Our objectives were to evaluate whether 1) ORP can be measured in semen and seminal plasma samples and
2) ORP levels correlate with sperm motility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Design:</B>&nbsp;&nbsp;Prospective study measuring ORP in both semen and seminal plasma. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Materials and Methods:</B>&nbsp;&nbsp;Semen samples (n=18) from normal control subjects were divided into two fractions and the seminal plasma was isolated from one fraction (300 x g, 7min). Sperm count and motility were assessed manually. sORP (mV/106 sperm) and cORP (&#956;C/106 sperm) were measured in both fractions (RedoxSYS&reg;, Aytu BioScience). Values are reported as Mean &plusmn; SEM. Spearman correlation and Receiver Operating Characteristic curves (ROC) were used for statistical analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Results:</B>&nbsp;&nbsp;sORP and cORP levels in semen correlated significantly with the levels in seminal plasma. A significant negative correlation existed between sperm motility and sORP in both semen (r=-0.609; p=0.004) and seminal plasma (r=-0.690; p=0.002). Furthermore, a sORP cutoff of 4.73mV/106 sperm in semen (sensitivity = 100%, specificity = 89.5%, AUC=0.947) and 4.65mV/106 sperm in seminal plasma (sensitivity = 100%, specificity = 93.8%, AUC = 0.969) was highly predictive of abnormal sperm motility. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Conclusions:</B>&nbsp;&nbsp;RedoxSYS&reg; accurately measured sORP and cORP in both semen and seminal plasma samples. Based on high sensitivity as assessed by ROC analysis, sORP levels can be used to screen infertile men with oxidative stress. These results are being validated in a larger cohort of infertile men. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Effect of Time on Oxidation-Reduction Potential in Semen and Seminal Plasma</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">R. Sharma,<sup>1</sup> S. S. Du Plessis,<sup>1,2</sup> A. Agarwal,<sup>1</sup> A. Harlev,<sup>1,3</sup> L. Samanta,<sup>1,4</sup> G. Ahmad,<sup>1,5</sup> S. Gupta,<sup>1</sup> E. S. Sabanegh<sup>6</sup>; 1. Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology, Stellenbosch University, Tygerberg, South Africa, 3. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 4. Redox Biology Laboratory, School of Life Science, Ravenshaw University, Orissa, India, 5. Physiology and Cell Biology, University of Health Sciences, Lahore, Pakistan, 6. Department of Urology, Cleveland Clinic,
Cleveland, OH </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Abstract:</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Objective:</B>&nbsp;&nbsp;Oxidation-reduction potential (ORP) is a novel measure of oxidative stress or redox imbalance in biological fluids. Reactive oxygen species (ROS) are highly reactive and have a very short half-life. ROS levels in the seminal ejaculate should be measured within an hour after collection to prevent a reduction in ROS levels over time. The traditional methods of measuring seminal ROS are time sensitive and time consuming, making it difficult to use them for diagnostic purposes. It would be highly advantageous to employ a method that is independent of semen age and provides results in real time. The
objective was to assess the effect of time on static ORP (sORP), which provides a snapshot of current redox balance, and capacity ORP (cORP) which is indicative of the amount of antioxidant reserves available. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">78</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Design:</B>&nbsp;&nbsp;Prospective study measuring ORP in semen and seminal plasma samples at time 0 and 120 minutes. Materials and Methods: The sORP and cORP of both semen (n=18) and seminal plasma (n=15) samples from normal control subjects were measured after liquefaction (time 0) and after 120 minutes of incubation at room temperature (RedoxSYS&reg;, Aytu BioScience). Values are mean &plusmn; SEM. Spearman correlation was used for statistical analysis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Results:</B>&nbsp;&nbsp;A significant correlation was seen between sORP at time 0 and 120 minutes in semen and seminal plasma. Similar correlations were found for cORP values at both time intervals. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Conclusions:</B>&nbsp;&nbsp;ORP values are not affected by the age of semen or seminal plasma for up to 120 minutes, making it easier to employ this new technology for diagnostic use. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">RedoxSYS System for Research Use</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We completed the development of the RedoxSYS System (MiOXSYS&#146; predecessor product) during the two years preceding the Merger. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. This enabled the launch of the RedoxSYS System into the research market around the world. We also received a CE marking in Europe in January 2016 and Health Canada clearance in March 2016 to begin the market development of the RedoxSYS System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized. We launched
sales efforts into the research market in late 2014 and since that time have placed the RedoxSYS System at a number of prominent research centers in the United States, Europe, and Israel. We expect to leverage these research relationships and build numerous applications in areas where researchers are studying oxidative stress. Currently, there are no available research platforms that measure oxidation-reduction potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal fluid, tissue, and cells). While oxidative stress is commonly studied in research settings around the world (both academia and industry), the current assessment methods are incomplete, time consuming, and often impractical for assessing oxidative stress completely. To position the RedoxSYS System effectively in the research market, we have placed key personnel in the United States, Europe, and Asia to develop direct research business relationships as well as distribution networks.
Through these proof of concept studies and clinical exploratory studies, we identified the application of oxidation-reduction potential in male infertility assessment. As such, MiOXSYS was developed specifically for assessing semen and seminal plasma ORP levels. While we expect additional clinical applications to be developed through these applications, our near-term focus is on completing the development of MiOXSYS for use in semen analysis for male infertility assessment. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Background on the MiOXSYS System</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">MiOXSYS is a novel, portable device that measures oxidation-reduction potential, or ORP, a global measure of oxidative stress. MiOXSYS is the first and only system that measures ORP in biologic specimens to provide a complete measure of redox balance, which is broadly implicated across a wide range of both acute and chronic conditions. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Potential Role of ORP in Diagnosing Male Infertility</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Oxidation-reduction potential is defined in the published literature as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;ORP in a biological system is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents contribute to the ORP. Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric oxide, peroxynitrite, transition metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include thiols, vitamin C, tocopherol, &#946;-carotene, lycopene, uric acid, bilirubin, and flavonoids. Enzymes such as superoxide dismutase, or SOD, catalase, and glutathione peroxidase, are involved in the conversion of ROS into less
reactive species. ORP monitoring of plasma represents a single measurement that integrates the overall quantitative balance among the oxidants and reductants of the system.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Given that ORP represents a single, global measure of oxidative stress in a biological system, we believe the potential for ORP to serve as a standardized marker in semen analysis and other aspects of infertility assessment is significant. A major limitation of oxidative stress assays relates to the fact that there is poor standardization in testing. As many factors contribute to oxidative stress (e.g., free radical proliferation, </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">79</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">antioxidant depletion, DNA damage, etc.), it is important to have an integrated measure that combines all known and unknown oxidants and reductants in the respective system into one measurement. We believe ORP is an integrated measure of oxidative stress that can be easily and quickly measured with the MiOXSYS System. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the context of infertility, having an integrated value representing all relevant biologic constituents contributing to oxidative stress will enable simple, robust analysis in a two to three minute test. There are various techniques in use to assess semen in cases of male infertility. The most commonly implemented techniques involve DNA fragmentation, oxidative stress analysis, microscopic examination, sperm penetration assays, sperm agglutination, computer assisted semen analysis, and others. The currently available oxidative stress analysis tools are widely considered expensive and cumbersome to use in routine clinical
practice. In both developed countries as well as in the developing world, expensive analysis tools and recurring reagent expenses make routine testing nearly impossible to implement with regularity. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The MiOXSYS System Overview</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System is comprised of two distinct, patented components that enable a system capable of measuring the ORP and antioxidant capacity of a biological fluid: an analyzer and sensor strips. In mechanical terms, ORP is defined as the potential between a working electrode, and a reference electrode at equilibrium. The RedoxSYS System has been specifically studied in human whole blood, serum, semen, seminal plasma, blood plasma, and other biological fluids. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS System measures two distinct elements to determine a patient&#146;s oxidation reduction potential:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Static ORP&nbsp;&#151;&nbsp;the standard potential between a working electrode and a reference electrode with no driving current (or extremely small current). This is proportional to the balance of redox agents and is what is classically defined as ORP. Low ORP values mean that the biological sample is in the normal range of oxidative stress. Higher than normal ORP values means that the biological sample is in a higher oxidation state.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Capacity&nbsp;&#151;&nbsp;the measure of antioxidant reserve available in the body&#146;s system. High capacity values mean that the biological sample has levels of antioxidant reserves. Lower than normal capacity values means that the biological sample has below normal antioxidant reserves. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The MiOXSYS Analyzer</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS analyzer is a portable, lightweight desktop platform that may be used in a clinical or research laboratory or near a patient care area. The analyzer is a small device that accepts an inserted sensor that has collected a small specimen as obtained by traditional specimen collection procedures. The analyzer is battery powered and equipped with a custom 5 lead strip connector. The reader consists of a Galvanostat analog circuit with greater than 1012 MHz input impedance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The analyzer contains a 10 MHz external crystal (internal 4X PLL for 40 MHz operation), and a programming/serial header is externally accessible. The device has internal power/heart-beat indicator LED, primary storage of 128Mbit (16Mbyte) SPI Flash (3.3V) (Bulk data storage), and secondary storage of 2Mbit (256Kbyte) SPI FRAM (3.3V) (Hi-Speed Storage). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS analyzer contains a user-friendly interface that is flexibly designed to accommodate multiple endpoints depending upon the specific clinical condition being considered. The interface is LCD, 16x2, with a white backlight, variable delay auto-off time-out. Two status LED indicators are visible through front panel mounted lenses. Further, the reader contains three DPDT push-button switches (Left, Center, Right), power on button(s) for battery mode operation, switch usage switch, audible alerts, strip detection, and test completion signals. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, the MiOXSYS analyzer enables data transfer, has USB serial communication, and is configured for data download to a connected PC. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">80</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS analyzer&#146;s power management consists of an external 5VDC power jack with input capacitance and filtering, a boost converter supplied by external 5VDC power or internal Li-Ion battery, and provides main 5VDC digital board supply. The reader functions with or without the battery connected. The battery lasts in excess of 24 hours with continuous operation to enable prolonged use outside of a laboratory setting. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Image of the MiOXSYS Analyzer</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v449009_img1.jpg" WIDTH="178" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The MiOXSYS Sensor Strips</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The MiOXSYS sensor strips, via standard biological specimen collection techniques, receive 20&nbsp;&#150;&nbsp;40 microliters of a specimen from which the ORP clinical analysis is performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated with the sensors. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Image of the MiOXSYS Sensor Strips</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v449009_img2.jpg" WIDTH="232" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Regulatory Pathway</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We achieved ISO 13485: 2003 in late 2013 following the successful development of a compliant medical device quality system. Following the issuance of our ISO certification, we obtained CE marking for the RedoxSYS System, which has enabled initial market development in Europe and markets that accept a CE marking. In December 2015, we achieved CE marking for MiOXSYS following technical validation and clinical study completion in male infertility. In March 2016, we obtained Health Canada Class II Medical approvals for MiOXSYS. In the United States, we intend to pursue 510k de novo clearance with the FDA for the MiOXSYS System. We
have recent, ongoing correspondence with the FDA and have confirmed that MiOXSYS is appropriate for the 510k de novo pathway, and we are pursuing regulatory clearance through this pathway. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United States Commercial Strategy</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the clinical studies to measure oxidative stress in male infertility are successful, we expect to pursue that intended use for the MiOXSYS System via the FDA 510k de novo pathway. If cleared for the infertility intended use, we intend to seek to commercialize the MiOXSYS System as a new tool for the assessment of oxidative stress in infertility in men. We envision pursuing a direct sales effort to high priority urology/andrology laboratories, infertility clinics and reference centers across the United States. We have identified the primary, influential centers in the United States and believe our commercial deployment will
be efficient through a focused sales and marketing effort. We intend to seek to sell the MiOXSYS System into individual centers and laboratories but will focus our revenue model on the repeat ordering of the disposable, </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">81</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">single use MiOXSYS sensor strips. We expect to realize a favorable gross margin on the basis of estimated low cost of goods sold on both components of the system. We envision an average selling price for the disposable sensors of approximately $25&nbsp;&#150;&nbsp;$40. We envision selling the MiOXSYS analyzers for $2,500&nbsp;&#150;&nbsp;$5,500 but will also pursue an instrument rental agreement model with minimum disposable sensor purchase requirements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also intend to leverage our urology commercialization efforts with other products with a focus on urology centers, infertility clinics, and reproductive health laboratories around the United States. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe a focused sales force at the onset of commercialization will enable effective representation of our products and penetration of the reproductive health market. Our sales efforts into the research markets will be enabled initially through a full-time business development professional who will focus on collaborative research and research sales to major oxidative stress centers in the United States. We expect to pursue identical pricing in the research market and the clinical diagnostics markets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ROW Commercial Strategy</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to undertake a similar strategy outside the United States for the RedoxSYS and MiOXSYS systems while complementing our efforts in infertility and research with adjunct applications in critical care conditions. To efficiently execute across our strategy, we intend to utilize a network of established distributors in the target markets in Europe and Asia. We have already engaged with distributors in multiple countries, while many other potential distributors are in advanced stages of discussions with us. We anticipate slightly reduced pricing outside the U.S. for the disposable sensors given the anticipated lower pricing
observed ex-US for diagnostic and research products. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Our Business Development Strategy&nbsp;&#151;&nbsp;Identifying &amp; Acquiring Complementary Urology Assets</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A key growth and value driver for our Company is the ongoing identification and acquisition of novel urology products for commercialization. We seek to identify unique products with urologic indications that may be non-strategic, undervalued or under-resourced by the company that currently markets the product. We believe that we can continue to acquire strategically aligned products at an appropriate valuation and grow those products via our focused sales and marketing efforts. We will also consider acquiring novel, late-stage development products that represent unique commercial opportunities and can be efficiently developed.
</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are actively identifying unique product assets to acquire based on specific attributes including but not limited to: therapeutic area/indication; growth potential; intellectual property position (patents, regulatory, manufacturing or development technicalities, etc.), valuation, strategic fit, commercial orientation and other factors. Indications of interest include products to treat conditions such as urinary incontinence, sexual dysfunction, hypogonadism, prostate and other urological cancers, urinary tract infections, and other urological conditions. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Past Product Candidate&nbsp;&#151;&nbsp;Zertane for the Treatment of Premature Ejaculation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for the on-demand treatment of premature ejaculation, or PE. We had been developing Zertane utilizing a regulatory pathway pursuant to Section 505(b)(2) of the FDCA, as the active ingredient is already well characterized for the treatment of pain, and we were relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. The FDA accepted the IND for Zertane in late 2015. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While we had partnerships in place to market Zertane in South Korea and Brazil in the event of regulatory approval in those countries, and had entered into an agreement with Endo Ventures Limited, which recently acquired Paladin Labs Inc., or Paladin, a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America, we decided to cease the development of Zertane as of June 30, 2016 because we are directing our resources towards our commercial-stage products and do
not plan to complete the necessary clinical trials and bring Zertane to market ourselves prior to the expiration of the patent covering the product. We intend to attempt to sell or out-license Zertane to one or more third parties to develop independently. We can provide no assurance as to the value, if any, we might receive for Zertane in the event we were to out-license or sell it. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">82</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Government Regulation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While we do not have any pharmaceutical product candidates that we are actively developing as of the date of this prospectus, we may in the future acquire such products. Currently, we are developing two medical device candidates, the RedoxSYS and MiOXSYS Systems, for which regulatory approval must be received before we can market them. Regulatory approval processes for our current and any future product candidates are discussed below. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Approval Process for Pharmaceutical Products</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">FDA Approval Process for Pharmaceutical Products</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending
NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pharmaceutical product development in the United States typically involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory and animal studies under the FDA&#146;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated current good manufacturing requirements, or cGMP, including a quality system regulating manufacturing, the submission and acceptance of an IND application, which must become effective before human clinical trials may begin in the United States, obtaining the approval of Institutional Review
Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pre-clinical tests generally include laboratory evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must become effective before human clinical trials can
begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations, as well as international scientific standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity of clinical trial data. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin. In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by an independent IRB or Ethics Committee, or EC. The
IRB considers, among other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA&#146;s GCP requirements. The FDA and/or IRB may order the temporary, or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted at any time, or impose other sanctions for failure to comply with requirements under the appropriate entity jurisdiction. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1 clinical trials, a product candidate is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to be used. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">83</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The main purpose of the trial is to assess a product candidate&#146;s safety and the ability of the human body to tolerate the product candidate. Phase 1 clinical trials generally include less than 50 subjects or patients. During Phase 2 trials, a product candidate is studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it is intended to be used in order to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential efficacy of the product candidate for specific target diseases or medical conditions, and
(iii) assess dosage tolerance and determine the optimal dose for Phase 3 trials. Phase 3 trials are generally undertaken to demonstrate clinical efficacy and to further test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase 3 trials are generally designed to reach a specific goal or endpoint, the achievement of which is intended to demonstrate the candidate product&#146;s clinical efficacy and adequate information for labeling of the approved drug. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are three main types of NDAs, which are covered by Section 505 of the FDC Act: (1) an application that contains full reports of investigations of safety and efficacy (Section 505(b)(1)); (2) an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the application has not obtained a right of reference (Section 505(b)(2)); and (3) an application that contains information to show that the proposed product is identical in active ingredient, dosage form,
strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product (Section 505(j)). Section 505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by the applicant. In the pre-IND briefing meeting with Ampio and in June 2012, the FDA agreed that our NDA may be submitted under Section 505(b)(2). As such, we intend to rely on studies published in the scientific literature and reference FDA-approved NDAs for tramadol-containing products (NDAs 21-693, 20-281 and 21-692) to support the safety and efficacy demonstrated in our clinical program. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2.3 million and the manufacturer and/or sponsor under an approved
NDA are also subject to annual product and establishment user fees, currently approximately $0.1 million per product and $0.6 million per establishment. These fees are typically increased annually. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the FDA&#146;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug products are reviewed within ten months; most applications for priority review drugs are reviewed in six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, or
provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy, to an advisory committee&nbsp;&#151;&nbsp;typically a panel that includes clinicians and other experts&nbsp;&#151;&nbsp;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not
approve the product unless compliance with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA, the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">84</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if
compliance with regulatory standards is not maintained or problems are identified following initial marketing. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">The Hatch-Waxman Act</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#146;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths
and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#147;generic equivalents&#148; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#146;s Orange Book that: 1) the required patent information has not been filed; 2) the listed patent has expired; 3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or 4) the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the applicant
does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the
infringement case that is favorable to the ANDA applicant. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ANDA application also will not be approved until any non-patent exclusivity listed in the Orange Book for the referenced product has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients during which ANDAs for generic versions of those drugs cannot be submitted, unless the submission contains a Paragraph IV challenge to a listed patent&nbsp;&#151;&nbsp;in which case the submission may be made four years following the original product approval. Federal law provides for a period of three years of exclusivity during which FDA cannot grant
effective approval of an ANDA based on the approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use; the approval of which was required to be supported by new clinical trials conducted by, or for, the applicant. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Post-Approval Regulation</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if a product candidate receives regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product from </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">85</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers. We cannot be certain that we or our present or future contract manufacturers or suppliers will
be able to comply with cGMP regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the FDA approves one or more of our product candidates, we and the contract manufacturers we use for manufacture of clinical supplies and commercial supplies must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval. The labeling, advertising, promotion, marketing and distribution of a drug or biologic product or medical devices, also must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which
include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing us to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Approval Process for Medical Devices</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, the FDCA, FDA regulations and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. The FDA regulates the design, manufacturing, servicing, sale and distribution of medical devices, including molecular diagnostic test kits and instrumentation systems. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless an exemption applies, each medical device we wish to distribute commercially in the United States will require marketing authorization from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval, also called PMA approval. The type of marketing authorization is generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the level of
regulatory control deemed necessary to ensure the device&#146;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling, premarket notification and adherence to the FDA&#146;s current Good Manufacturing Practices, or cGMP, known as the Quality System Regulations, or QSR. Class II devices are intermediate risk devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls and include life sustaining, life-supporting or implantable devices,
devices of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Most Class I devices and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior authorization from the FDA. Some Class I devices that have not been so exempted and Class II devices are eligible for marketing through the 510(k) clearance pathway. By contrast, devices placed in Class III require PMA approval prior to commercial marketing. The PMA </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">86</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">approval process is more stringent, time-consuming and expensive than the 510(k) clearance process, however, the 510(k) clearance process has also become increasingly stringent and expensive. The FDA has provided initial guidance to us that the RedoxSYS and MiOXSYS Systems are appropriate for the 510(k) clearance process, likely through the de novo pathway. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">510(k) Clearance.&nbsp;&nbsp;To obtain 510(k) clearance for a medical device, an applicant must submit a premarket notification to the FDA demonstrating that the device is &#147;substantially equivalent&#148; to a device legally marketed in the United States that is not subject to PMA approval, commonly known as the &#147;predicate device.&#148; A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics or (ii) different technological characteristics and the information submitted demonstrates that the device is as safe and
effective as a legally marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process can exceed 90 days and may extend to a year or more. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a modification could significantly affect the device&#146;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product at
any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Before we can submit a medical device for 510(k) clearance, we may have to perform a series of generally short studies over a period of months, including method comparison, reproducibility, interference and stability studies to ensure that users can perform the test successfully. Some of these studies may take place in clinical environments, but are not usually considered clinical trials. For PMA submissions, we would generally be required to conduct a longer clinical trial over a period of years that supports the clinical utility of the device and how the device will be used. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although clinical investigations of most devices are subject to the investigational device exemption, or IDE, requirements, clinical investigations of diagnostic tests, including our products and products under development, are generally exempt from the IDE requirements. Thus, clinical investigations by intended users for intended uses of our products generally do not require the FDA&#146;s prior approval but may require approval of an Institutional Review Board, or IRB, and written informed consent by the patient, provided the clinical evaluation testing is non-invasive, does not require an invasive sampling procedure that
presents a significant risk, does not intentionally introduce energy into the subject and is not used as a diagnostic procedure without confirmation by another medically established test or procedure. In addition, our products must be labeled per FDA regulations &#147;for research use only-RUO&#148; or &#147;for investigational use only-IUO,&#148; and distribution controls must be established to assure that our products distributed for research, method comparisons or clinical evaluation studies are used only for those purposes. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Regulation after FDA Clearance or Approval</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any devices we manufacture or distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. We are required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which include, among other things, testing, control and documentation requirements. Noncompliance with these standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production, refusal of the government to grant 510(k) clearance or PMA approval of
devices, withdrawal of marketing approvals and criminal prosecutions, fines and imprisonment. Our contract manufacturers&#146; facilities operate under the FDA&#146;s cGMP requirements. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Foreign Regulatory Approval</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Outside of the United States, our ability to market our product candidates will be contingent also upon our receiving marketing authorizations from the appropriate foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">87</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">generally encompasses risks similar to those we will encounter in the FDA approval process. The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite approvals, may vary widely from country to country and differ from those required for FDA approval. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the European Union, we are required under the European Medical Device Directive (Council Directive 93/42/EEC) to affix the CE mark to certain of our products in order to sell the products in member countries of the European Union. The CE mark is an international symbol that represents adherence to certain essential principles of safety and effectiveness mandated in the European Medical Device Directive, which are referred to as the &#147;essential requirements&#148;. Once affixed, the CE mark enables a product to be sold within the European Economic Area, or EEA, which is composed of the 28 member states of the EU plus
Norway, Iceland and Liechtenstein as well as other countries that accept the CE mark. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To demonstrate compliance with the essential requirements, we must undergo a conformity assessment procedure which varies according to the type of medical device and its classification. Except for low risk medical devices (Class I with no measuring function and which are not sterile) where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a
notified body. Depending on the relevant conformity assessment procedure, the notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. The notified body issues a CE certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we modify our devices, we may need to apply for permission to affix the CE mark to the modified product. Additionally, we may need to apply for a CE mark for any new products that we may develop in the future. Certain products regulated as medical devices according to EC-Directives are subject to vigilance requirements for reporting of adverse events. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will be subject to additional regulations in other countries in which we market, sell and import our products, including Canada. We or our distributors must receive all necessary approvals or clearance prior to marketing and/or importing our products in those markets. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The International Standards Organization, or ISO, promulgates internationally recognized standards, including those for the requirements of quality systems. To support ISO certifications, surveillance audits are conducted by a notified body yearly and recertification audits every three years that assess continued compliance with the relevant ISO standards. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Other Regulatory Matters</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp;Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also
comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">88</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead
the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United States Patent Term Restoration and Marketing Exclusivity</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depending upon the timing, duration and other specific aspects of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval
date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, if any of our NDA&#146;s are approved, we intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond the current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, or NCE. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. Recently, the FDA stated that it may change its interpretation of 5-year NCE exclusivity determinations to apply to each
drug substance in a fixed-combination drug product, not for the drug product as a whole. If this change is implemented, for example, a fixed-combination drug product that contains a drug substance with a single, new active moiety would be eligible for 5 year NCE exclusivity, even if the fixed-combination also contains a drug substance with a previously approved active moiety. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a Section 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA
by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">89</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric
exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Reimbursement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto is covered by many commercial insurance providers and pharmacy benefit management companies and is largely dependent upon reimbursement for continued use in the U.S. market. However, Natesto is covered under a Rebate Agreement between us and Centers for Medicare and Medicaid Services. This, in turn, enables states to offer public payer coverage of Natesto through their separate Medicare and public assistance programs. Additionally, privately managed Medicare Part D plans may choose to cover Natesto prescriptions through their plans&#146; pharmacy benefits. ProstaScint is dependent upon reimbursement for continued use in
the U.S. market, and ProstaScint does have a reimbursement code as assigned by the American Medical Association. ProstaScint is currently reimbursed by Medicare, Medicaid, and various private health plans. However, reimbursement is not universally available throughout the United States for ProstaScint. Primsol is also dependent upon reimbursement for continued use in the U.S. market, and Primsol is covered under a Rebate Agreement between us and Centers for Medicare and Medicaid Services. This, in turn, enables states to offer public payer coverage of Primsol through their separate Medicaid and public assistance programs. Primsol is also covered by many private payers who offer coverage benefits to patients for branded, prescription antibiotic treatments. We do not anticipate that the sales of our product candidate, the MiOXSYS System, if approved for sale in the U.S., will be heavily dependent upon reimbursement by third-party payors. Traditionally, sales of pharmaceutical products
that are not &#147;life style&#148; indications depend, in part, on the extent to which products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Lack of third-party reimbursement for our product candidate or a decision by a third-party payor to not cover our product candidates could reduce physician usage of the product candidate and have a material adverse effect on our sales, results of operations and financial condition. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">DEA Regulation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto, already approved by the FDA, is a &#147;controlled substance&#148; as defined in the Controlled Substances Act of 1970, or CSA, because it contains testosterone. As a result, the U.S. Drug Enforcement Agencies, or DEA, regulate Natesto and have listed it as a Schedule III substance. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">90</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. Similarly, separate registrations are also required for separate facilities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The DEA typically inspects a facility to review its security measures prior to issuing a registration and on a periodic basis. Reports must also be made for thefts or losses of any controlled substance, and to obtain authorization to destroy any controlled substance. In addition, special permits and notification requirements apply to imports and exports of narcotic drugs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The DEA establishes annually an aggregate quota for how much of a controlled substance may be produced in total in the United States based on the DEA&#146;s estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. Our or our manufacturers&#146; quotas of an active ingredient may not be sufficient to meet commercial demand or complete clinical trials. Any delay, limitation or refusal by
the DEA in establishing our or our manufacturers&#146; quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in administrative, civil or criminal enforcement action that could have a material adverse effect on our business, results of operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those registrations. In some circumstances, violations could result in criminal proceedings.
</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Individual states also independently regulate controlled substances. We and our manufacturers will be subject to state regulation on distribution of these products, including, for example, state requirements for licensures or registration. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Intellectual Property</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has an exclusive license from Acerus Pharmaceuticals Corporation for the United States to intellectual property related to a nasal gel drug product containing testosterone to treat hypogonadism in males, including the FDA approved product Natesto&reg;, as well as an authorized generic version and OTC versions thereof. The license includes sublicense rights to intellectual property owned by Mattern Pharmaceuticals and exclusively licensed to Acerus by Mattern Pharmaceuticals. The sublicensed intellectual property includes four Orange Book listed patents directed at nasal gel formulations containing testosterone or methods
of testosterone replacement therapy by nasal administration of the same. It further includes a pending application, and two patents that are not listed in the Orange Book directed at a method of making a testosterone formulation and a method for reducing physical or chemical interactions between a nasal testosterone formulation and a plastic container. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Acerus license also grants rights to intellectual property owned by Acerus which includes twelve nonprovisional patent applications, some of which may be abandoned. These patent applications include at least three pending applications directed to testosterone titration methods, intranasal testosterone bio-adhesive gel formulations, and controlled release testosterone formulations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have an extensive range of intellectual property for Primsol, MiOXSYS, and RedoxSYS. We have patent protection in the United States and several other large markets worldwide. Specifically, we have numerous patents issued and pending for the RedoxSYS/MiOXSYS systems and their use in the U.S., Europe, Canada, Israel, Japan, and China. Further, we have patent protection in the United States and several other large markets worldwide for the use of tramadol hydrochloride to treat PE. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have restructured our patent portfolio related to RedoxSYS/MiOXSYS to focus on the United States and core foreign jurisdictions which include Europe, Canada, Israel, Japan and China. In other foreign jurisdictions, patents and pending applications will be allowed to lapse through non-payment of annuities </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">91</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">for issued patents and non-response to outstanding actions for pending applications. The portfolio to be supported in the United States and core foreign jurisdictions consists of 17 issued patents and 20 pending applications. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The portfolio primarily consists of four families filed in the United States and in core foreign jurisdictions. The first family includes six issued patents and five pending applications with claims directed to the measurement of the ORP of a patient sample to evaluate various conditions. The standard 20-year expiration for patents in this family is in 2028. The second family includes two pending United States applications, two issued United States patents and four pending applications in core foreign jurisdictions with claims directed to the measurement of the ORP capacity of a patient sample to evaluate various conditions.
The standard 20-year expiration for patents in this family is in 2033. The third family includes seven issued patents and four pending applications with claims directed to devices and methods for the measurement of ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2032. The fourth family includes one pending United States application, one issued United States patent, and five pending applications in core foreign jurisdictions with claims directed to multiple layer gel test strip measurement devices and methods of making for use in measuring ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2033. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Primsol is protected by a formulation patent and its regulatory designation. By virtue of the fact that Primsol was approved as an NDA and the extremely large backlog of Abbreviated New Drug Applications at the FDA (two to three year review time currently), we do not expect generic competition for Primsol in the next three to four years. There are currently no generic competitors filed with the FDA under Paragraph IV, which is required of potential generic competitors seeking to genericize an on-patent NDA. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ProstaScint is protected by significant trade secrets and manufacturing know-how related to the production of the product and linkage of the base monoclonal antibody and imaging component. The antibody in the ProstaScint product is produced by a proprietary cell line. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also maintain trade secrets and proprietary know-how that we seek to protect through confidentiality and nondisclosure agreements. These agreements may not provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information. If we do not adequately protect our trade secrets and proprietary know-how, our competitive position and business prospects could be materially harmed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to seek United States and foreign patent protection for drug and diagnostic products we discover, as well as therapeutic and diagnostic products and processes. We expect also to seek patent protection or rely upon trade secret rights to protect certain other technologies which may be used to discover and characterize drugs and diagnostic products and processes, and which may be used to develop novel therapeutic and diagnostic products and processes. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent positions of companies such as ours involve complex legal and factual questions and, therefore, their enforceability cannot be predicted with any certainty. Our issued and licensed patents, and those that may be issued to us in the future, may be challenged, invalidated or circumvented, and the rights granted under the patents or licenses may not provide us with meaningful protection or competitive advantages. Our competitors may independently develop similar technologies or duplicate any technology developed by us, which could offset any advantages we might otherwise realize from our intellectual property.
Furthermore, even if our product candidates receive regulatory approval, the time required for development, testing, and regulatory review could mean that protection afforded us by our patents may only remain in effect for a short period after commercialization. The expiration of patents or license rights we hold could adversely affect our ability to successfully commercialize our pharmaceutical drugs or diagnostics, thus harming our operating results and financial position. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will be able to protect our proprietary intellectual property rights from unauthorized use by third parties primarily to the extent that such rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. If we must litigate to protect our intellectual property from infringement, we may incur substantial costs and our officers may be forced to devote significant time to litigation-related matters. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">92</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">laws of the United States. Our pending patent applications, or those we may file or license from third parties in the future, may not result in patents being issued. Until a patent is issued, the claims covered by an application for patent may be narrowed or removed entirely, thus depriving us of adequate protection. As a result, we may face unanticipated competition, or conclude that without patent rights the risk of bringing product candidates to market exceeds the returns we are likely to obtain. We are generally aware of the scientific research being conducted in the areas in which we focus our research and development
efforts, but patent applications filed by others are maintained in secrecy for at least 18 months and, in some cases in the United States, until the patent is issued. The publication of discoveries in scientific literature often occurs substantially later than the date on which the underlying discoveries were made. As a result, it is possible that patent applications for products similar to our drug or diagnostic products and product candidates may have already been filed by others without our knowledge. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights, and it is possible that our development of products and product candidates could be challenged by other pharmaceutical or biotechnology companies. If we become involved in litigation concerning the enforceability, scope and validity of the proprietary rights of others, we may incur significant litigation or licensing expenses, be prevented from further developing or commercializing a product or product candidate, be required to seek licenses that may not be available from third
parties on commercially acceptable terms, if at all, or subject us to compensatory or punitive damage awards. Any of these consequences could materially harm our business. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Competition</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The healthcare industry is highly competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Significant competitive factors in our industry include product efficacy and safety; quality and breadth of an organization&#146;s technology; skill of an organization&#146;s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals; government reimbursement rates for, and the average selling price of, products; the availability of raw materials and qualified manufacturing capacity; manufacturing
costs; intellectual property and patent rights and their protection; and sales and marketing capabilities. Market acceptance of our current products and product candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative therapies or tests, (ii) the actual or perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing, and distribution capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a very small biopharmaceutical company compared to other companies that we are competing against. Our current and potential competitors include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies. Many of our current and potential competitors have substantially greater financial, technical and human resources than we do and significantly more experience in the marketing, commercialization, discovery, development and regulatory approvals of products, which could place us at a significant competitive disadvantage or deny us marketing exclusivity rights. Specifically,
our competitors will most likely have larger sales teams and have more capital resources to support their products then we do. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accordingly, our competitors may be more successful than we may be in achieving widespread market acceptance and obtaining FDA approval for product candidates. We anticipate that we will face intense and increasing competition as new products enter the market, as advanced technologies become available and as generic forms of currently branded products become available. Finally, the development of new treatment methods for the diseases we are targeting could render our products non-competitive or obsolete. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We cannot assure you that any of our products that we acquire or successfully develop will be clinically superior or scientifically preferable to products developed or introduced by our competitors. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current approved products compete in highly competitive fields whereby there are numerous options available to clinicians including generics. These generic treatment options are frequently less expensive and more widely available. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">93</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Natesto competes in a large, growing market. The U.S. TRT market is large, with annual revenues in the U.S. in 2013 of $2.4 billion. If the TRT market grows as expected, with as little as 5% market penetration, a novel, patent-protected TRT product could achieve sales of $250 million. Even at the current market size of approximately $2.4 billion, a product with 5% market penetration could achieve sales of approximately $120 million annually, assuming comparatively similar product pricing and reimbursement levels as seen with other TRTs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Currently, there are several FDA approved imaging techniques for cancer in general, however there is only one SPECT-specific agent targeting prostate cancer&nbsp;&#151;&nbsp;ProstaScint. The other imaging methods are F18-fluorodeoxyglucose (F18-FDG), C11-Acetate, and C11-Choline. The primary advantage of these methods is that they all use PET imaging, a technique with better resolution than SPECT. The use of PET is also a disadvantage, however, since it uses radiolabels with short half-lives necessitating the need for a local or on-site cyclotron to generate the labels. The half-life of fluorine-18 (F18) and of carbon-11 (C11)
are approximately 110 and 20 minutes, respectively. The radiolabel used by ProstaScint is Indium-11, with a half-life of about 2&nbsp;&#150;&nbsp;3 days. This longer time period allows the radiolabel to be made remotely and shipped to the imaging facility; however, it does use SPECT as the imaging modality. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As indicated, ProstaScint is the only radio-imaging marker that is specific for prostate specific membrane antigen (PMSA). ProstaScint is based on radiolabeling the antibody against PSMA, a protein express by prostate cells. This specificity for prostate cells is what allows ProstaScint to detect the metastases of prostate cancer regardless of location. The mechanism of labeling for F18-FDG, C11-Acetate, and C11-Choline is the intracellular accumulation of these markers in cancer cells, due to the fact that cancer cells typically have a higher cellular metabolism than non-cancerous cells. Thus, these markers can accumulate in
any type of cancer cell with a high metabolism. Unfortunately for these technologies, prostate cancer cells tend to have a lower cellular metabolism resulting in higher false positives attributed to hyperplasia and prostatitis. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In a meta-analysis of 21 studies evaluating accuracy, sensitivity, specificity, positive/negative predictive values, ProstaScint using combined SPECT/CT imaging was comparable to PET/CT imaging based on F18-FDG and C11-Choline. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are any number of antibiotics available on the market that could compete with Primsol. However, Primsol is the only FDA-approved liquid formulation of trimethoprim, an antibiotic that is well established in current guidelines for treating UTIs. Further, Primsol is the only trimethoprim oral solution on the U.S. market that does not contain sulfamethoxazole, or sulfa. Therefore, Primsol is appropriate for UTI patients that have difficulty swallowing tablets, such as the elderly, and particularly for patients that experience adverse reactions to sulfa. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS/RedoxSYS</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to MiOXSYS competitive offerings, there are other oxidative stress diagnostic tests available throughout the world, although none are approved in the United States for clinical use. Diagnostic systems that are marketed for clinical use outside the United States include the FRAS 4 system (H&amp;D srl), FREE Carpe Diem (Diacron International), and the FORM and FORMPlus systems (Callegari srl). These systems are used in both research and clinical settings but do not generate significant sales in the clinical setting. If approved in the United States for clinical use, these systems could present competition to the
MiOXSYS System. However, their testing parameters differ significantly from MiOXSYS and would need to demonstrate clinical superiority to MiOXSYS in order to substantially detract from MiOXSYS prescribing and sales. Additionally, to our knowledge these systems have not demonstrated clinical feasibility in human semen or seminal plasma. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">94</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our strategy is to minimize our research and development activities. When we do conduct research and development, we intend to utilize consultants with domain experience for research, development and regulatory guidance. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our MiOXSYS System has been developed in conjunction with numerous medical device and diagnostic development consultants. Further, we have relationships with regulatory consultants who are actively assisting in the development of our regulatory strategy with the FDA. To complement our internal clinical research efforts with the MiOXSYS System, we have engaged with numerous universities around the world to identify and develop research and clinical applications for the MiOXSYS System. Through these engagements we have access to data and analyses that enable us to develop new uses for the MiOXSYS and RedoxSYS systems.
Additionally, we have formal research agreements in place with two prominent U.S.-based universities and one prominent European university for which we are paying a research fee. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our business strategy is to use cGMP compliant contract manufacturers for the manufacture of clinical supplies as well as for commercial supplies if required by our commercialization plans, and to transfer manufacturing responsibility to our collaboration partners when possible. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 22, 2016, we entered into a license and supply agreement with Acerus pursuant to which we will pay Acerus a supply price per unit of the greater of (i) a fixed percentage of Acerus&#146; cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) a low double digit percentage of the net selling price for the first year of the agreement, that increases in each of the second and third years and remains constant after that. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">ProstaScint</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have acquired a two-year supply of ProstaScint through our asset purchase agreement with Jazz Pharmaceuticals, which we project to last through calendar 2017. Further, we have begun the process of transferring the manufacturing of ProstaScint to a new contract manufacturer as discussed below. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 8, 2015, we and Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us for ProstaScint. The agreement provides that we may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders for ProstaScint. We expect to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of ProstaScint. The agreement provides customary terms and conditions,
including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, we may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason. In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $5.3 million, of which we paid $1.0 million upon submission of the work order and $500,000 in each of January and April 2016. In June 2016, we paid $300,000 and in July of 2016, we paid another $500,000 towards this project. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into a supply agreement for Primsol with the same manufacturer used by FSC Laboratories, from whom we purchased Primsol. Pursuant to the agreement, we can order supply as needed at a fixed price for the first two years of the agreement through September 30, 2017; thereafter we will negotiate the price but do not expect the supply price to increase by more than 25%. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">95</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">MiOXSYS/RedoxSYS</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have completed the technical development of the RedoxSYS System by engaging contract development and manufacturing companies in the United States. We secured supply and quality agreements with manufacturers for both the RedoxSYS and MiOXSYS instruments as well as the RedoxSYS and MiOXSYS sensor strips. Both manufacturers hold long-standing ISO 13485:2003 certifications and are established medical device manufacturers. Both manufacturers have high volume manufacturing capacity such that production volumes can be easily scaled. Both manufacturers have been audited by our quality engineers and are fully compliant. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Employees</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of August 31, 2016, we had 58 full-time employees and utilized the services of a number of consultants on a temporary basis. Overall, we have not experienced any work stoppage and do not anticipate any work stoppage in the foreseeable future. None of our employees is subject to a collective bargaining agreement. Management believes that relations with our employees are good. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Properties</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In August 2015, Aytu entered into a 37 month non-cancellable operating lease for new office space effective September 1, 2015. The new lease has initial base rent of $8,500 per month beginning in October 2015, with the total base rent over the term of the lease of approximately $318,000 which includes rent abatements. We have also opened a 1,333 square foot office in Raleigh, North Carolina for which the lease runs until July 31, 2018. We believe our current office space is sufficient to meet our current needs. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognize rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Legal Proceedings</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are currently not party to any material legal or administrative proceedings and are not aware of any material pending or threatened legal or administrative proceedings in which we will become involved. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Available Information</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our principal executive offices are located at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112 USA, and our phone number is (720) 437-6580. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We maintain a website on the internet at <I>http://aytubio.com</I>. We make available free of charge through our website, by way of a hyperlink to a third-party site that includes filings we make with the SEC website (<I>www.sec.gov)</I>, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports electronically filed or furnished pursuant to Section 15(d) of the Exchange Act. The information on our website is not, and shall not be deemed to be, a part of this prospectus or incorporated into any other filings we make with the SEC. In addition, the public may read
and copy any materials we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington D.C., 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Code of Ethics</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have adopted a written code of ethics that applies to our officers, directors and employees, including our principal executive officer and principal accounting officer. We intend to disclose any amendments to, or waivers from, our code of ethics that are required to be publicly disclosed pursuant to rules of the SEC by filing such amendment or waiver with the SEC. This code of ethics and business conduct can be found in the corporate governance section of our website, <I>http://aytubio.com</I>.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">96</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t12MAN"></a>MANAGEMENT</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth the names and ages of all of our directors and executive officers. Our Board of Directors is currently comprised of five members, who are elected annually to serve for one year or until their successor is duly elected and qualified, or until their earlier resignation or removal. Executive officers serve at the discretion of the Board of Directors and are appointed by the Board of Directors. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="144"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="37"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="394"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Age</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Position</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Joshua R. Disbrow</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">41</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chairman &amp; Chief Executive Officer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Jarrett T. Disbrow</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">41</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Operating Officer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Gregory A. Gould</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">50</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Financial Officer, Secretary, and Treasurer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Jonathan H. McGrael</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">46</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Vice President of Commercial Operations</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Michael Macaluso</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">64</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Carl C. Dockery</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">53</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>John A. Donofrio, Jr.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">49</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Gary V. Cantrell</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">61</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a biographical summary of the experience of our executive officers and directors during the past five years, and an indication of directorships held by the director in other companies subject to the reporting requirements under the federal securities law. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Joshua R. Disbrow&nbsp;&#151;&nbsp;Chairman and Chief Executive Officer</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Joshua R. Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow was also the Chief Operating Officer of Ampio since December 2012. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company&#146;s second full-time employee. Mr. Disbrow led the company&#146;s commercial efforts from inception to the company&#146;s acquisition in 2010 and growth to over $127
million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012, he had led the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience, an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University. Mr. Disbrow&#146;s experience in executive management and marketing within the
pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a director of our Company in light of our business and structure. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Jarrett T. Disbrow&nbsp;&#151;&nbsp;Chief Operating Officer</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jarrett Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix from November 2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals&#146; acquisition in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Prior to founding
Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing. Mr. Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. Mr. Disbrow served on our Board of Directors from April 2015 to July 2016. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">97</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Gregory A. Gould&nbsp;&#151;&nbsp;Chief Financial Officer, Secretary, and Treasurer</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Gregory A. Gould has been our Chief Financial Officer since April 16, 2015. Mr. Gould is also the Chief Financial Officer of Ampio where he has been employed since June 2014. Prior to joining Ampio, he provided financial and operational consulting services to the biotech industry through his consulting company, Gould LLC from April 2012 until June 2014. Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare from November 2006 until the company was sold to Linden Capital Partners in April 2012. During the period from July 2011 until April 2012 Mr. Gould also served as the Interim President and Chief Executive
Officer of SeraCare Life Sciences. Mr. Gould has held several other executive positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould&#146;s tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855 million. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the Eligard&reg; products. Mr. Gould was the Chief Financial Officer at Colorado MedTech, Inc., a publicly traded medical device design and manufacturing company where he negotiated the transaction to sell the company to KRG Capital Partners. Mr. Gould began his career as an auditor with Arthur Andersen, LLP. He currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company pursuing
anti-viral agents for the treatment of HIV. Mr. Gould graduated from the University of Colorado with a BS in Business Administration and is a Certified Public Accountant. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Jonathan H. McGrael&nbsp;&#151;&nbsp;Vice President of Commercial Operations</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jonathan McGrael joined us on September 30, 2015 as Vice President of Sales and in May 2016 became our Vice President of Commercial Operations. Mr. McGrael has spent 17 years in the pharmaceutical industry and has held positions of increasing responsibility in sales, sales training, marketing, sales management, and leadership development. Until September 15, 2015, he was Director of Sales at Arbor Pharmaceuticals, which he joined in 2010 as that company&#146;s 14<sup>th</sup> employee. Under his leadership the sales organization grew from 10 sales representatives to over 400 and achieved significant, consistent revenue growth
throughout his leadership tenure. Mr. McGrael also designed comprehensive leadership development and training programs for sales leaders, as well as a marketing structure that ensured &#147;plug-and-play&#148; incorporation of new products. Mr. McGrael began his career at TAP Pharmaceuticals (now Takeda) where he held positions within the sales and marketing divisions. He received an MS in Public Health from Missouri State University and a BS in Human Bio-Dynamics also from Missouri State University. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Michael Macaluso&nbsp;&#151;&nbsp;Director</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Michael Macaluso has been a member of our Board of Directors since April 2015. Mr. Macaluso is also the Chairman and Chief Executive Officer of Ampio. Mr. Macaluso has been a member of Ampio Pharmaceuticals&#146; Board of Directors since March 2010 and Ampio&#146;s Chief Executive Officer since January 2012. Mr. Macaluso served in the roles of president and Chief Executive Officer of Isolagen, Inc. (AMEX: ILE) from June 2001 until September 2004. Mr. Macaluso also served on the board of directors of Isolagen from June 2001 until April 2005. From October 1998 until June 2001, Mr. Macaluso was the owner of Page International
Communications, a manufacturing business. Mr. Macaluso was a founder and principal of International Printing and Publishing, a position Mr. Macaluso held from 1989 until 1997, when he sold that business to a private equity firm. Mr. Macaluso&#146;s experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Carl C. Dockery&nbsp;&#151;&nbsp;Director</Font> </H4>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Carl Dockery joined our Board as an independant director in April 2016. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery&#146;s career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London
reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd&#146;s and the London Underwriting Centre brokering various types of reinsurance placements. Mr. Dockery serves as a director of CytoDyn Inc. (OTCQB: &#147;CYDY&#148;), a biotechnology company. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in </P>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">98</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Humanities. Mr. Dockery&#146;s financial expertise and experience, as well as his experience as a director of a publicly traded biopharmaceutical company, led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">John A. Donofrio, Jr.&nbsp;&#151;&nbsp;Director</Font> </H4>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">John Donofrio joined our Board as an independant director in July 2016. He is a Senior Finance Executive with 24 years of experience in the pharmaceutical industry across a broad range of areas, including consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. He has served as the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, since
August 2013. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. At Merz, Mr. Donofrio is accountable for financial performance, cost management, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. He was also the Senior Finance Partner accountable for the U.S. Specialty Business Units of GlaxoSmithKline plc. Mr. Donofrio served as a director of Vyrix Pharmaceuticals from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North
Carolina State University. Mr. Donofrio&#146;s financial expertise and experience in the pharmaceutical industry, led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>



<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Gary V. Cantrell&nbsp;&#151;&nbsp;Director</Font> </H4>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Gary Cantrell joined our Board as an independant director in July 2016. He has 30 years of experience in the life sciences industry ranging from clinical experience as a respiratory therapist to his current exclusive consulting role with Mayne Pharma (ASX: MYX) as Business Development Executive focused on acquiring branded prescription assets for Mayne&#146;s U.S. Specialty Brands Division. Mr. Cantrell served as CEO of Yasoo Health Inc., a global specialty nutritional company from 2007 through June 2015, highlighted by the sale of its majority asset AquADEKs to Actavis in March 2016. Previously, he was President of The Catevo
Group, a U.S.-based healthcare consulting firm. Prior to that, he was Executive Vice President, Sales and Marketing for TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company, where he led all commercial activities for a public specialty pharmaceutical business. His previous 22 years were at GlaxoSmithKline plc where he held progressively senior management positions in sales, marketing and business development. Mr. Cantrell is a graduate of Wichita State University and serves as an advisor to several emerging life science companies. He served as a director for Yasoo Health Inc., Yasoo Health Limited and Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, which was sold to Cordis, while a Division of Johnson &amp; Johnson in March 2013. Mr. Cantrell served as a director of Vyrix Pharmaceuticals from February 2014 to April 2015. Mr. Cantrell&#146;s experience in consulting and executive management
within the pharmaceutical industry led to the conclusion that he should serve as a director of our company in light of our business and structure. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Family Relationships</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jarrett T. Disbrow, our Chief Operating Officer, is the brother of Joshua R. Disbrow, our Chairman and Chief Executive Officer. There are no other family relationships among or between any of our current or former executive officers and directors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Involvement in Certain Legal Proceedings</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of our directors or executive officers has been involved in any legal proceeding in the past 10 years that would require disclosure under Item 401(f) of Regulation S-K promulgated under the Securities Act. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Board Committees</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board has established an Audit Committee, Compensation Committee and Nominating and Governance Committee. Our Audit Committee consists of Mr. Donofrio (Chair), Mr. Cantrell and Mr. Dockery. Our </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">99</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compensation Committee consists of Mr. Cantrell (Chair), Mr. Dockery and Mr. Donofrio. Our Nominating and Governance Committee consists of Mr. Dockery (Chair), Mr. Cantrell and Mr. Donofrio. The independence of our directors is discussed below under the caption &#147;Director Independence.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each of the above-referenced committees operates pursuant to a formal written charter. The charters for these committees, which have been adopted by our Board, contain a detailed description of the respective committee&#146;s duties and responsibilities and are available on our website at <I>http://aytubio.com</I> under the &#147;Investor Relations&nbsp;&#151;&nbsp;Corporate Governance&#148; tab. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board has determined Mr. Donofrio qualifies as an audit committee financial expert, as defined in Item 407(d)(5) of Regulation S-K promulgated by the SEC. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Stockholder Proposals</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our bylaws establish procedures for stockholder nominations for elections of directors and bringing business before any annual meeting or special meeting of stockholders. A stockholder entitled to vote in the election of directors may nominate one or more persons for election as directors at a meeting only if written notice of such stockholder&#146;s intent to make such nomination or nominations has been delivered to our Corporate Secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the prior year&#146;s annual meeting. In the event that the date of the
annual meeting is more than 30 days before or more than 60 days after the anniversary date of the prior year&#146;s annual meeting, the stockholder notice must be given not more than 120 days nor less than the later of 90 days prior to the date of the annual meeting or, if it is later, the 10<sup>th</sup> day following the date on which the date of the annual meeting is first publicly announced or disclosed by us. These notice deadlines are the same as those required by the SEC&#146;s Rule 14a-8. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the bylaws, a stockholder&#146;s notice must set forth among other things: (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder; and (b) as to any other business that the stockholder proposes to bring before the meeting, a brief
description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There have been no changes to these nominating procedures since the adoption of the bylaws. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Executive Compensation</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with Item 402 of Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the makeup of and compensation for our company&#146;s directors and named executive officers. On April 16, 2015, we acquired Luoxis and Vyrix in the Merger. Because for certain periods some of our named executive officers were, prior to the Merger on April 16, 2015, employed by Luoxis and Vyrix, we are providing past compensation information concerning such executive officers with respect to Luoxis and Vyrix. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In establishing executive compensation, our Board is guided by the following goals:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the executive officers and directors for work required for a company of our size and scope;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">compensation should align the executive officers&#146; and directors&#146; interests with the long-term interests of stockholders; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">compensation should assist with attracting and retaining qualified executive officers and directors. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Compensation of Directors</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current compensation package for non-employee directors, effective July 1, 2017, consists of: an annual cash retainer of $25,000 for each director, $10,000 for each committee chair and $5,000 for each other </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">100</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">committee member; a one-time grant of 65,000 restricted shares of stock upon appointment to the board; and an annual stock option grant of 15,000 shares thereafter. In April 2016, we prorated for the last quarter of fiscal 2016 the annual cash retainer (amounting to $6,250) and also made the annual grant of 100,000 stock options to our then two non-employee directors. Prior to April 1, 2016, we paid no cash compensation and made no annual stock option grants. We also reimburse directors for expenses incurred in connection with their service as director. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table provides information regarding all compensation paid to non-employee directors of Aytu during the fiscal year ended June 30, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="272"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Fees Earned<BR> or Paid in<BR> Cash</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Stock Option<BR> Awards<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All Other<BR> Compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael Macaluso<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,250</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,169</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>40,419</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Carl C. Dockery<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,250</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,169</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>40,419</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gary V. Cantrell<sup>&#040;2&#041;</sup><sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>John A. Donofrio Jr<sup>&#040;2&#041;</sup><sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">This column reflects the aggregate grant date fair value computed in accordance with Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASC, Topic 718. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">As of June 30, 2016, the number of shares underlying options held by each non-employee director was as follows: 18,750 shares for Mr. Macaluso; 8,334 shares for Mr. Dockery; none for Mr. Cantrell; and none for Mr. Donofrio. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Gary V. Cantrell and John A. Donofrio Jr. were each appointed a director in July 2016 and therefore received no compensation or equity awards from Aytu in the fiscal year ended June 30, 2016. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Executive Officer Compensation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth all cash compensation earned, as well as certain other compensation paid or accrued for the years ended June 30, 2016 and 2015 to each of the following named executive officers. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="122"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="29"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="34"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 7pt">Name and Principal Position<BR>(a)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Year<BR>(b)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Salary<BR> ($)<BR>(c)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Bonus<BR> ($)<BR>(d)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Stock Award<BR> ($)<BR>(e)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Option Award<BR> ($)<sup>&#040;1&#041;</sup><BR>(f)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Non-Equity<BR> Incentive<BR> Plan <BR>Compensation ($)<BR>(g)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Change in<BR> Pension<BR> Value and<BR> Nonqualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)<BR>(h)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">All Other<BR> Compensation<BR> ($)<BR>(i)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Total<BR> ($)<BR>(j)</FONT></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top; font-style: italic" ROWSPAN=1 COLSPAN=1>Named Executive Officers<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1>Joshua R. Disbrow<sup>&#040;2&#041;</sup><BR> <I>Chief Executive Officer<BR> since December 2012</I></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>312,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>559,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,121,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>246,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>202,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>198,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,045</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;3&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>653,545</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1>Jarrett T. Disbrow<sup>&#040;4&#041;</sup><BR> <I>Chief Operating Officer</I><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>287,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>559,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,096,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>218,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>223,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1>Gregory A. Gould<sup>&#040;5&#041;</sup><BR> <I>Chief Financial Officer<BR> since June 2014</I><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-top" ROWSPAN=3 COLSPAN=1>Jonathan H. McGrael<sup>&#040;6&#041;</sup><BR> <I>VP of Commercial Operations</I><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140,417</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>237,737</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>186,337</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,233</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;7&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>577,724</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Option awards are reported at fair value at the date of grant. See &#147;Notes to the Financial Statements&nbsp;&#151;&nbsp; Note 10&nbsp;&#151;&nbsp;Equity Instruments.&#148; Pre-Merger option awards made in August 2014 to Joshua R. Disbrow and Gregory A. Gould were cancelled in April 2015 and the expenses were reversed. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Joshua R. Disbrow received a salary increase to $250,000 effective April 16, 2015 when he was appointed Chief Executive Officer of Aytu. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">This was a cash payout of in-the-money options issued to Mr. Disbrow by Luoxis, which options were cashed out in the Merger. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">101</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Jarrett T. Disbrow received a salary increase to $250,000 effective April 16, 2015 when he was appointed Chief Operating Officer of Aytu. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Mr. Gould was appointed to Chief Financial Officer, Secretary and Treasurer effective April 16, 2015. His compensation expense is part of the shared service agreement with Ampio, except for his bonus, which was paid directly by us to Mr. Gould. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">Mr. McGrael was hired on September 16, 2015 and his annual salary was increased on May 15, 2016 from $175,000 to $190,000. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(7)</TD>

          <TD STYLE="text-align: left">Represents reimbursed relocation expenses. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our executive officers are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf. Executives are reimbursed for business expenses directly related to Aytu business activities, such as travel, primarily for business development as we grow and expand our product lines. On average, each executive incurs between $1,000 to $3,000 of out-of-pocket business expenses each month. The executive management team meets weekly and determines which activities they will work on based upon what we determine will be the most beneficial to our company and our shareholders. No interest is
paid on amounts reimbursed to the executives. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Grants of Plan-Based Awards</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information regarding grants of plan-based awards to the Named Executive Officers during the year ended June 30, 2016: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="232"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Grant Date</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All Other<BR> Option Awards:<BR> Number of<BR> Securities<BR> Underlying Options<BR> (&#35;)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Exercise Price of<BR> Option Awards<BR> ($/Share)<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Grant Date<BR> Fair Value of<BR> Option Awards<BR> ($)<sup>&#040;1&#041;</sup></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-style: italic" ROWSPAN=1 COLSPAN=1>Named Executive Officers<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joshua R Disbrow</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>559,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jarrett T Disborw</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>559,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gregory A Gould</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,834</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;2&#041;</sup><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jonathan H McGrael</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2015</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,667</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>186,337</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">The amounts reported in this column represent the aggregate grant date fair value computed in accordance with FASB ASC 718, excluding the effect of any estimated forfeitures and may not correspond to the actual value that will be realized by the named executive officer. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">The fair value of this award was recognized by Ampio Pharmaceuticals as at the date of grant, Ampio was the parent company and in accordance with GAAP, since Mr. Gould is still an Ampio employee, it was appropriate for Ampio to recognize the expense. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">On July 7, 2016, the Board reset the option exercise price on these options from $18.12 to $3.23. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">102</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Outstanding Equity Awards at Fiscal Year-End 2016</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table contains certain information concerning unexercised options for the Named Executive Officers as of June 30, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="186"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=19>Option Awards</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=1>Name<BR> (a)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Exercisable<BR> (&#35;)<BR> (b)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Unexercisable<BR> (&#35;)<BR> (c)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Equity<BR> Incentive<BR> Plan Awards:<BR> Number of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Unearned<BR> Options<BR> (&#35;)<BR> (d)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Option<BR> Exercise<BR> Price<BR> ($)<BR> (e)<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Option<BR> Expiration<BR> Date<BR> (f)</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-style: italic" ROWSPAN=1 COLSPAN=1>Named Executive Officers<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joshua R. Disbrow</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2025</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jarrett T. Disbrow</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2025</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gregory A. Gould</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,834</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2025</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jonathan H. McGrael</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,667</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>11/11/2025</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">On July 7, 2016, the Board reset the option exercise price on these options from $18.12 to $3.23. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Employment Agreements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We entered into an employment agreement with Joshua Disbrow in connection with his employment as our Chief Executive Officer. The agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result of officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary. Mr. Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and
conditions of such plans. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We entered into an employment agreement with Jarrett Disbrow, our Chief Operating Officer, in connection with his employment with us. The agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result of the officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary. Mr. Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the
terms and conditions of such plans. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2015, we entered into an employment agreement with Jonathan McGrael, our Vice President of Sales, in connection with his employment with us. The agreement is at will, subject to termination by us with or without Cause or as a result of the officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr. McGrael is entitled to receive $175,000 in annual salary, plus a discretionary performance bonus with a target of 43% of his base salary. Mr. McGrael will also receive up to $20,000 for relocation reimbursement. Mr. McGrael is also eligible to participate in the benefit plans
maintained by us from time to time, subject to the terms and conditions of such plans. On May 15, 2016, we amended Mr. McGrael&#146;s contract to increase his salary to $190,000 and to name him our Vice President of Commercial Operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Payments Provided Upon Termination for Good Reason or Without Cause</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the employment agreements, in the event Joshua Disbrow&#146;s or Jarrett Disbrow&#146;s employment is terminated without Cause by us or either officer terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal to two times his base salary in effect at the date of termination, as well as continued participation in the health and welfare plans for up to two years. All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long as a Change in Control is not in effect, then all
options which are </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">103</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to &nbsp;1/24<sup>th</sup> the number of option shares multiplied by the number of full months of such officer&#146;s employment shall be deemed vested and immediately exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be exercisable by such officer. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Good Reason&#148; with respect to the agreements with Joshua Disbrow and Jarrett Disbrow, means, without the officer&#146;s written consent, there is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction in the officer&#146;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in the officer&#146;s responsibilities or authority);</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction of the level of the officer&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below certain specified amounts); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material change in the principal geographic location at which the officer must perform his services. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Cause&#148; with respect to the agreements with Joshua Disbrow and Jarrett Disbrow, means:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than a traffic violation which is a misdemeanor;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful malfeasance or willful misconduct by the officer in connection with his employment;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">gross negligence in performing any of his duties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful and deliberate violation of any of our policies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unintended but material breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable satisfaction of the board;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#146;s relationship with us;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful and deliberate breach of his obligations under the employment agreement; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the case of Mr. McGrael&#146;s termination without Cause or with Good Reason, we will be obligated to pay him any accrued compensation and continue his salary for six months. In addition, all unvested options will receive accelerated vesting in full. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Good Reason&#148; with respect to the agreement with Mr. McGrael, means, without the officer&#146;s written consent, there is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction in the officer&#146;s overall responsibilities or authority, or scope of duties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a material reduction of the level of the officer&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below certain specified amounts); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the Company&#146;s material breach of the employment agreement. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Cause&#148; with respect to the agreement with Mr. McGrael means:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, a felony or misdemeanor involving moral turpitude;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful malfeasance or willful misconduct by the officer in connection with his employment;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">gross negligence in performing any of his duties;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">104</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">material failure to comply with our workplace rules, policies or procedures which is not cured within fifteen days of written notice;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">material breach of our Proprietary Information and Inventions Agreement;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">material breach of the employment agreement which is not cured within fifteen days of written notice;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#146;s relationship with us; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">willful failure or refusal to perform his material duties under the employment agreement or failure to follow any specific lawful instructions of the Chief Executive Officer or his designee which is not cured within fifteen days of written notice. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The severance benefits described above are contingent on each officer executing a general release of claims. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Payments Provided Upon a Change in Control</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the employment agreements for Joshua Disbrow and Jarrett Disbrow, in the event of a Change in Control of us, all stock options, restricted stock and other stock-based grants granted or may be granted in the future by us to the officers will immediately vest and become exercisable. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&#147;Change in Control&#148; means: the occurrence of any of the following events:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the acquisition by any individual, entity, or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (the &#147;Acquiring Person&#148;), other than us, or any of our Subsidiaries, of beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding voting securities of us entitled to vote generally in the election of directors (excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the acquisition of us by another entity by means of any transaction or series of related transactions to which we are party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes) other than a transaction or series of related transactions in which the holders of the voting securities of us outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of shares in us held by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such other surviving or resulting entity is a
wholly-owned subsidiary immediately following such acquisition, its parent); or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the sale or other disposition of all or substantially all of the assets of us in one transaction or series of related transactions. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our only obligation to Joshua Disbrow and Jarrett Disbrow had a Change in Control occurred as of June 30, 2016, would be the acceleration of the vesting of all options held by them at that date. On June 30, 2016, the closing price of our common stock was below the exercise price for all of the options held by Joshua Disbrow and Jarrett Disbrow and therefore there would have been no economic benefit to them upon the acceleration of vesting of those options. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">105</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t13TRA"></a>TRANSACTIONS WITH RELATED PERSONS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Related Party Transactions</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We describe below all transactions and series of similar transactions, other than compensation arrangements, during the last three fiscal years, to which we were a party or will be a party, in which:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the amounts involved exceeded or will exceed $120,000; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Merger</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, pursuant to the Merger Agreement entered into among Rosewind, Luoxis, Vyrix and two subsidiaries of Rosewind created solely for the purposes of the Merger, and which did not survive the Merger, the Merger occurred in two stages. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the first stage, each of Vyrix and Luoxis merged with one of Rosewind&#146;s merger subsidiaries. Vyrix and Luoxis survived these mergers. The outstanding shares of stock of Vyrix and the outstanding shares of stock of Luoxis were converted into the right to receive shares of our common stock. The Vyrix stock and the Luoxis stock were each converted at an exchange factor. The exchange factor for each of them was determined upon the basis of a relative value opinion obtained by Ampio, the parent company of Vyrix and Luoxis. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Vyrix were converted into
shares of Vyrix as the surviving corporation. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as the surviving corporation. After completion of the first stage, Vyrix and Luoxis became subsidiaries of Rosewind. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the second stage, which occurred on the same day as the first stage, each of Vyrix and Luoxis merged with Rosewind with Rosewind surviving. The first and second stage mergers are referred to collectively as the &#147;Merger.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Concurrently with the Merger:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Ampio purchased 396,816 shares of our common stock for (i) issuance to Rosewind of a promissory note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger; (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Rosewind</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On March 3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of which Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such trusts. None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Luoxis and Vyrix</Font> </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ampio Loan Agreements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any
outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. On April 16, 2015, in connection with the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">106</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio has an option of
converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. On April 16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, Ampio received 396,816 shares of common stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Services Agreements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2013, Luoxis entered into a services agreement with Ampio whereby Ampio provides corporate overhead services and a shared facility with Luoxis in exchange for $15,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. In January 2014, Vyrix entered into a services agreement with Ampio whereby Ampio provides corporate overhead services to Vyrix in exchange for $7,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. Both agreements
were assigned to us upon the closing of the Merger. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, the prior service agreements were canceled and Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties. This agreement was amended in April 2016, which reduced the monthly amount to $18,000. This agreement was amended again in July 2016, which reduced the monthly amount to approximately $17,000 per month. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and development of Luoxis&#146; RedoxSYS System. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire
March 2019 and cannot be terminated prior to March 2017. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Review, Approval or Ratification of Transactions with Related Persons</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Effective upon its adoption in July 2016, pursuant to the Audit Committee Charter, the Audit Committee is responsible for reviewing and approving all related party transactions as defined under Item 404 of Regulation S-K, after reviewing each such transaction for potential conflicts of interests and other improprieties. Our policies and procedures for review and approval of transactions with related persons are in writing in our Code of Conduct and Ethics available on our website at <I>http://aytubio.com</I> under the &#147;Investor Relations&nbsp;&#151;&nbsp;Corporate Governance&#148; tab. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the adoption of the Audit Committee Charter, and due to the small size of our company, we did not have a formal written policy regarding the review of related party transactions, and relied on our Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest. Our </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">107</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board of Directors reviewed any such transaction in light of the particular affiliation and interest of any involved director, officer or other employee or stockholder and, if applicable, any such person&#146;s affiliates or immediate family members. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Director Independence</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is not listed on any exchange. Consequently, no exchange rules regarding director independence are applicable to us. Audit Committee members must satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, for listed companies. In order to be considered to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory
fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Three of our five directors, namely Messrs. Dockery, Donofrio and Cantrell, are independent under the definition of the NYSE. The other two directors are not independent under either definition due to (i) being an executive officer of our Company, in the case of Josh Disbrow, and (ii) the payments we make to Ampio under the services agreement with Aytu, in the case of Mr. Macaluso. </P>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">108</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t14SEC"></a>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth information with respect to the beneficial ownership of our common stock as of August 31, 2016 for:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each beneficial owner of more than 5% of our outstanding common stock;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each of our director and named executive officers; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">all of our directors and executive officers as a group. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include common stock that can be acquired within 60 days of August 31, 2016. The percentage ownership information shown in the table is based upon 5,070,591 shares of common stock outstanding as of August 31, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of August 31, 2016. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the table below is based on information known to us or ascertained by us from public filings made by the
stockholders. Except as otherwise indicated in the table below, addresses of the director, executive officers and named beneficial owners are in care of Aytu BioScience, Inc., 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="434"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name of Beneficial Owner</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Shares Beneficially Owned</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage of Shares Beneficially Owned</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>5% Stockholders:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Alpha Venture Capital Partners, L.P.<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>837,300</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Directors and Named Executive Officers:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joshua R. Disbrow<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>296,863</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jarrett T. Disbrow<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>267,673</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gregory A. Gould<sup>&#040;4&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>227,733</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jonathan H. McGrael<sup>&#040;5&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael Macaluso<sup>&#040;6&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>119,156</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Carl C. Dockery<sup>&#040;7&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>912,301</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16.6</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>John Donofrio<sup>&#040;8&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>68,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gary Cantrell<sup>&#040;9&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>72,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>All directors and executive officers as a group (eight persons)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,104,976</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>37.6</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">Represents beneficial ownership of less than 1%. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Carl C. Dockery is the President of the general partner of Alpha Venture Capital Partners, L.P. and therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P. The address of Alpha Venture Capital Partners, L.P. is 2026 Crystal Wood Drive, Lakeland, Florida 33801. For securities beneficially owned by Alpha Venture Capital Partners, L.P., see footnote 7 below. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">109</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Consists of (i) 86,029 shares, (ii) 190,000 restricted shares and (iii) 20,834 shares issuable upon the exercise of warrants. Does not include 46,548 shares held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&#146;s immediate family) and Mr. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Consists of (i) 81,839 shares, (ii) 165,000 restricted shares and (iii) 20,834 shares issuable upon the exercise warrants. Does not include 46,548 shares held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&#146;s immediate family) and Mr. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Consists of (i) 41,899 shares, (ii) 165,000 restricted shares, and (iii) 20,834 shares issuable upon exercise of vested options. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Consists of 140,000 restricted shares. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">Consists of (i) 29,780 shares, (ii) 65,000 restricted shares, and (iii) 24,376 shares issuable upon exercise of vested options. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(7)</TD>

          <TD STYLE="text-align: left">Consists of (i) 65,000 restricted shares, (ii) 10,001 shares issuable upon exercise of vested options, (iii) 420,633 shares held by Alpha Venture Capital Partners, L.P and (iv) 416,667 shares issuable upon the exercise warrants held by Alpha Venture Capital Partners, L.P. Mr. Dockery is the President of the general partner of Alpha Venture Capital Partners, L.P. and therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(8)</TD>

          <TD STYLE="text-align: left">Consists of (i) 65,000 restricted shares, and (ii) 3,750 shares issuable upon exercise of vested options. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(9)</TD>

          <TD STYLE="text-align: left">Consists of (i) 65,000 restricted shares, (ii) 3,750 shares issuable upon the exercise of warrants, and (iii) 3,750 shares issuable upon exercise of vested options. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">110</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t15DES"></a>DESCRIPTION OF CAPITAL STOCK</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">General</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are authorized to issue up to 100.0 million shares of common stock, $0.0001 par value per share, and 50.0 million shares of preferred stock, $0.0001 par value per share. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of August 31, 2016, a total of 5,070,591 shares of our common stock were issued and outstanding and no shares of our preferred stock were issued and outstanding. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to hold our annual meeting of shareholders on November 15, 2016, at which meeting we intend to ask our shareholders to approve an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number between 1-for-2 and 1-for-4, as determined by our board of directors, at any time before November 15, 2017, if and as determined by our board of directors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Common Stock</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The holders of common stock are entitled to one vote per share. Our Certificate of Incorporation does not expressly prohibit cumulative voting. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of the Board of Directors and issued in the future. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Preferred Stock</Font> </H2>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Certificate of Incorporation provides our Board of Directors with the authority, without any vote of the holders of common stock, to divide the preferred stock into series and to fix and determine the rights and preferences of the shares of any series of preferred stock established to the full extent permitted by the laws of the State of Delaware and the Certificate of Incorporation. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants Outstanding Prior to this Offering</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of August 31, 2016, we had outstanding warrants to purchase an aggregate of 2,284,465 shares of our common stock, consisting of:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 8,553 shares that were originally issued by Luoxis in 2013 and, in connection with the Merger, were converted into warrants to purchase shares of our common stock at a purchase price of $54.36 per share. These warrants expire on May 30, 2018;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 22,254 shares of our common stock that were issued in February 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $7.80, and provide for cashless exercise;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 22,564 shares of our common stock that were issued in May 2016 to the placement agents in our private placement of convertible notes that we conducted in July and August 2015. These placement agents&#146; warrants have a term of five years from the date of issuance of the related notes in July and August 2015, have an exercise price of $4.80, and provide for cashless exercise;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 1,733,322 shares of our common stock that were issued in the public offering of common stock and warrants we completed on May 6, 2016. These warrants are exercisable for five years from issuance and have an exercise price equal to $6.00;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 305,559 shares of our common stock that were issued upon the closing or our public offering on May 5, 2016. These warrants are exercisable for five years from issuance and have an exercise price equal to $6.00;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">111</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 109,375 shares of common stock issued to the underwriters of our public offering. These warrants are exercisable beginning May 2, 2017 until May 2, 2021 and have an exercise price equal to $6.00; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Warrants to purchase 82,838 shares of common stock issued in a settlement to the Luoxis shareholders. These warrants expire on July 7, 2021 and have an exercise price equal to $4.00. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants Issued in this Offering</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>The following summary of certain terms and provisions of the warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of the warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part of. Prospective investors should carefully review the terms and provisions set forth in the form of warrant.</I> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Exercisability.</I>&nbsp;&nbsp;The warrants are exercisable immediately upon issuance and at any time up to May 6, 2021. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). Unless otherwise specified in the warrant, the holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of
the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Cashless Exercise.</I>&nbsp;&nbsp;In the event that a registration statement covering shares of common stock underlying the warrants, or an exemption from registration, is not available for the resale of such shares of common stock underlying the warrants, the holder may, in its sole discretion, exercise the warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, elect instead to receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant. In
no event shall we be required to make any cash payments or net cash settlement to the registered holder in lieu of issuance of common stock underlying the warrants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Exercise Price.</I>&nbsp;&nbsp;The initial exercise price per share of common stock purchasable upon exercise of the warrants is $6.00. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Certain Adjustments.</I>&nbsp;&nbsp;The exercise price and the number of shares of common stock purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of our common stock. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Transferability.</I>&nbsp;&nbsp;Subject to applicable laws, the warrants may be transferred at the option of the holders upon surrender of the warrants to us together with the appropriate instruments of transfer. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Warrant Agent and Exchange Listing.</I>&nbsp;&nbsp;The warrants will be issued in registered form under a warrant agency agreement between VSTock Transfer, LLC, as warrant agent, and us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Fundamental Transaction.</I>&nbsp;&nbsp;If, at any time while the warrants are outstanding, (1) we consolidate or merge with or into another corporation and we are not the surviving corporation, (2) we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets, (3) any purchase offer, tender offer or exchange offer (whether by us or another individual or entity) is completed pursuant to which holders of our shares of common stock are permitted to sell, tender or exchange their shares of common stock for other securities, cash or property and has been accepted by the holders
of 50% or more of our outstanding shares of common stock, (4) we effect any reclassification or recapitalization of our shares of common stock or any compulsory share exchange pursuant to which our shares of common stock are converted into or exchanged for other securities, cash or property, or (5) we consummate a stock or share purchase agreement or other business combination with another person or entity whereby such other person or entity acquires more than 50% of our outstanding shares of common stock, each, a &#147;Fundamental Transaction,&#148; then upon </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">112</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">any subsequent exercise of the warrants, the holders thereof will have the right to receive the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration payable as part of the Fundamental Transaction. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Rights as a Stockholder.</I>&nbsp;&nbsp;Except as otherwise provided in the warrants or by virtue of such holder&#146;s ownership of shares of our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Listing of Warrants.</I>&nbsp;&nbsp;The warrants are quoted on the OTCQX under the symbol &#147;AYTUW&#148;. We intend to apply to list the warrants on the NYSE MKT once we meet NYSE listing standards. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Options</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the closing of the Merger, each of Vyrix and Luoxis had an option plan and had made equity grants thereunder. On April 16, 2015, upon the closing of the Merger, an aggregate of $27,476 was paid to holders of in-the-money options and all equity compensation plans of Vyrix and Luoxis were terminated and all the awards granted thereunder were cancelled. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 1, 2015, our stockholders approved the 2015 Stock Option and Incentive Plan, which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 833,334 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to hold our annual meeting of shareholders on November 15, 2016, at which meeting we intend to ask our shareholders to approve amendments to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 833,334 shares to 2,000,000 shares, (ii) increase the number of shares that may be issued as incentive stock options from 833,334 shares to 2,000,000 shares, and (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar
year period, and (B) granted to any one individual that is intended to qualify as &#147;performance-based compensation&#148; under Section 162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle, in each case from 166,667 shares to 1,000,000 shares. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of August 31, 2016, we had outstanding options to purchase an aggregate of 762,217 shares of our common stock at a weighted average exercise price of $3.52 per share. Of these, an aggregate of 140,840 are exercisable. The remainder have vesting requirements with an aggregate of 129,167 vesting one third on each of November 11, 2016, 2017 and 2018, an aggregate of 47,086 vesting one quarter on each of November 11, 2016, 2017, 2018 and 2019, an aggregate of 3,125 vesting one quarter on each of August 7, 2016, 2017, 2018 and 2019, and an aggregate of 442,499 vesting one quarter on each of July 7, 2017, 2018 and 2019. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2015 Plan is administered by our Board or a committee designated by the Board (as applicable, the Administrator). The Administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2015 Plan. The Administrator may delegate to our Chief Executive Officer the authority to grant stock options and other awards to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange
Act and not subject to Section 162(m) of the Code, subject to certain limitations and guidelines. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Persons eligible to participate in the 2015 Plan are full or part-time officers, employees, non-employee directors, directors and other key persons (including consultants and prospective officers) of our company and its subsidiaries as selected from time to time by the Administrator in its discretion. Approximately 30 individuals are currently eligible to participate in the 2015 Plan, which includes officers, employees who are not officers, non-employee director, former employees and other individuals who are primarily consultants. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">113</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2015 Plan provides that upon the effectiveness of a &#147;sale event&#148; as defined in the 2015 Plan, except as otherwise provided by the Administrator in the award agreement, all stock options, stock appreciation rights and other awards will be assumed or continued by the successor entity and adjusted accordingly to take into account the impact of the transaction. To the extent, however, that the parties to such sale event do not agree that all stock options, stock appreciation rights or any other awards shall be assumed or continued, then such stock options and stock appreciation rights shall become fully exercisable
and the restrictions and conditions on all such other awards with time-based conditions will automatically be deemed waived. Awards with conditions and restrictions relating to the attainment of performance goals may become vested and non-forfeitable in connection with a sale event in the Administrator&#146;s discretion. In addition, in the case of a sale event in which our stockholders will receive cash consideration, we may make or provide for a cash payment to participants holding options and stock appreciation rights equal to the difference between the per share cash consideration and the exercise price of the options or stock appreciation rights in exchange for the cancellation thereto. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Quotation on the OTCQX U.S. Premier Market</Font> </H2>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our common stock is quoted on the OTCQX U.S. Premier Market under the symbol &#147;AYTU&#148;. We intend to apply to list our common stock on the NYSE MKT under the symbol &#147;AYTU&#148; once we meet NYSE listing standards. We believe that we will qualify, and intend to list our common stock and warrants on the NYSE MKT, upon securing at least $8,500,000 in gross proceeds from this offering and achieving a per share closing price of $3.00 or greater for our stock. In case our stock price does not reach this level otherwise, we plan to seek stockholder approval in November 2016 for a reverse stock split to help us meet the
stock price listing standard. However, it is not clear when, or if, we will meet the NYSE listing standards. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Transfer Agent</Font> </H2>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The transfer agent of our common stock is VStock Transfer. Their address is 18 Lafayette Place, Woodmere, NY 11598.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Director Duties</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under Delaware law, every member of the Company's Board of Director owes fiduciary duties, including the duty of care and the duty of loyalty, to a corporation and its stockholders. The duty of care requires directors to act in good faith and make rational decisions based on adequate information, just as any other prudent person would, given similar circumstances. As with most, if not all, companies, and as permitted by Delaware law, our certificate of incorporation eliminates a director's personal liability for breaches of the duty of care to the fullest extent permitted by law. The duty of loyalty concerns the relationship
between a director's interests and those of the corporation and its stockholders. The law imposes the duty of loyalty to ensure that directors, acting in good faith, serve the interests of the corporation and all its stockholders before the directors' own interests or those of a specific stockholder or class of stockholders. A corporation may not eliminate a director's personal liability for a breach of the duty of loyalty, though it may provide indemnification against such claims, which we do under our bylaws and indemnification agreements. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Delaware Anti-Takeover Law and Provisions of Our Certificate of Incorporation and Bylaws</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Delaware Anti-Takeover Law.</I>&nbsp;&nbsp;We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding specified shares; or</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">114</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">at or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66&nbsp;2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Section 203 defines a &#147;business combination&#148; to include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any merger or consolidation involving the corporation and the interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation to or with the interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In general, Section 203 defines an &#147;interested stockholder&#148; as any person that is:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the owner of 15% or more of the outstanding voting stock of the corporation;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an affiliate or associate of the corporation who was the owner of 15% or more of the outstanding voting stock of the corporation at any time within three years immediately prior to the relevant date; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the affiliates and associates of the above. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under specific circumstances, Section 203 makes it more difficult for an &#147;interested stockholder&#148; to effect various business combinations with a corporation for a three-year period, although the stockholders may, by adopting an amendment to the corporation&#146;s certificate of incorporation or bylaws, elect not to be governed by this section, effective 12 months after adoption. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our certificate of incorporation and bylaws do not exclude us from the restrictions of Section 203. We anticipate that the provisions of Section 203 might encourage companies interested in acquiring us to negotiate in advance with our board of directors since the stockholder approval requirement would be avoided if a majority of the directors then in office approve either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Certificate of Incorporation and Bylaw.</I>&nbsp;&nbsp;Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change of control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, these provisions include:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the authorization of 50,000,000 shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limiting the removal of directors by the stockholders;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">allowing for the creation of a staggered board of directors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">115</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t16UND"></a>UNDERWRITING</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Joseph Gunnar &amp; Co., LLC is acting as representative of the underwriters (the &#147;Representative&#148;). We have entered into an underwriting agreement dated &#149;, 2016 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of common stock and warrants listed next to its name in the following table: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Warrants</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Joseph Gunnar &amp; Co., LLC</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Feltl and Company, Inc.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Fordham Financial Management, Inc.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total:</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters are committed to purchase all the shares of common stock and warrants offered by us other than those covered by the option to purchase additional shares and/or warrants described below, if they purchase any shares or warrants. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&#146; obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&#146;
certificates and legal opinions. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters are offering the shares and warrants, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the underwriters to purchase a maximum of &#149; additional shares (15% of the shares sold in this offering) and/or &#149; additional warrants (15% of the warrants sold in this offering) from us to cover over-allotments, if any. If the underwriters exercise all or part of this option, they will purchase shares and warrants covered by the option at the public offering price that appears on the cover page of this prospectus, less the underwriting discount. If this option is
exercised in full, the total price to the public will be $&#149; and the total net proceeds, before expenses, to us will be $&#149;. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Discounts</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Per<BR> Share</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Per<BR> Warrant</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total Without<BR> Over-Allotment<BR> Option</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total With Full<BR> Over-Allotment<BR> Option</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Public offering price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discount (7%)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Non-accountable expense allowance (1%)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds, before expenses, to us</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#149;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters propose to offer the shares and warrants offered by us to the public at the public offering price set forth on the cover of this prospectus. In addition, the underwriters may offer some of the shares to other securities dealers at such price less a concession of $&#149; per share. If all of the shares and warrants offered by us are not sold at the public offering price, the Representative may change the offering price and other selling terms by means of a supplement to this prospectus. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">116</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to pay the Representative a non-accountable expense allowance of 1% of the public offering price at the closing, excluding the over-allotment option. We have paid an expense deposit of $10,000 to the Representative, which will be applied against such non-accountable expense allowance. The advance will be returned to the Company to the extent not actually incurred in accordance with FINRA Rule 5110(f)(2)(c). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have also agreed to pay the following expenses of the Representative relating to the offering: (a) all fees, expenses and disbursements relating to background checks of our officers and directors in an amount not to exceed $5,000 per individual and $15,000 in the aggregate; (b) all filing fees and communication expenses associated with the review of this offering by FINRA; (c) all fees, expenses and disbursements relating to the registration, qualification or exemption of securities offered under the securities laws of such states and foreign jurisdictions designated by the Representative; (d) the fees and expenses of the
Representative&#146;s legal counsel, not to exceed $37,500; (e) $29,500 for the underwriters&#146; use of Ipreo&#146;s book-building, prospectus tracking and compliance software for this offering; and (f) $20,000 of the Representative&#146;s actual accountable road show expenses for the offering. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate that the total expenses of the offering payable by us, excluding the total underwriting discount, will be approximately $225,000. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Discretionary Accounts</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Lock-Up Agreements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to &#147;lock-up&#148; agreements, we and our executive officers and directors and certain stockholders, have agreed, subject to limited exceptions, without the prior written consent of the Representative not to directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic
benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities of the Company or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days from the date of this prospectus, in the case of our directors and officers, and 90 days from the date of this prospectus, in the case of our company. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Underwriters&#146; Warrants</Font> </H2>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to issue to certain of the Underwriters warrants to purchase up to a total of &#149; shares of common stock (7% of the shares of common stock sold in this offering, excluding the over-allotment option). The warrants will be exercisable at any time, and from time to time, in whole or in part, during the four-year period commencing one year from the effective date of the offering, which period shall not extend further than five years from the effective date of the offering in compliance with FINRA Rule 5110(f)(2)(G). The warrants are exercisable at a per share price equal to 125% of the public offering price per
share in the offering. The underwriters (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation. However, the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant exercise price. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">117</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Right of First Refusal</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Until August 6, 2017 certain of the Underwriters will have a right of first refusal to each act as an investment broker, book-runner and/or placement agents for any future public or private equity and debt offering that we conduct during such period. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Electronic Offer, Sale and Distribution of Shares</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members. The Representative may agree to allocate a number of shares and warrants to underwriters and selling group members for sale to its online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the
registration statement of which this prospectus forms a part, has not been approved or endorsed by us, and should not be relied upon by investors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Stabilization</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering transactions, penalty bids and purchases to cover positions created by short sales.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Stabilizing transactions permit bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the shares while the offering is in progress.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Over-allotment transactions involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing shares in the open market.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Syndicate covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Penalty bids permit the Representative to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our shares of common stock or preventing or retarding a decline in the market price of our shares of common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected in the over-the-counter
market or otherwise and, if commenced, may be discontinued at any time. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">118</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Passive market making</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common stock on the OTCQX in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, then that bid must then be lowered when specified purchase limits are
exceeded. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Other Relationships</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain of the underwriters and their affiliates have provided and may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates for which they have received and may in the future receive customary fees.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Without limiting the generality of the foregoing, (i) Joseph Gunnar &amp; Co., LLC and Fordham Financial Management, Inc. are party to an advisory agreement with us, dated July 27, 2016, pursuant to which they have received aggregate cash advisory fees of $200,000, and (ii) Joseph Gunnar &amp; Co., LLC and Fordham Financial Management, Inc. acted as underwriters under our public offering that closed May 6, 2016, pursuant to which they received customary fees and commissions. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Offer restrictions outside the United States</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons
into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Australia</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made
available in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer to the offeree under this prospectus. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">China</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&#146;s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to &#147;qualified domestic institutional investors.&#148; </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">119</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">European Economic Area&nbsp;&#151;&nbsp;Belgium, Germany, Luxembourg and Netherlands</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&#147;Prospectus Directive&#148;), as implemented in Member States of the European Economic Area (each, a &#147;Relevant Member State&#148;), from the requirement to produce a prospectus for offers of securities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(a)</TD>

          <TD STYLE="text-align: left">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(b)</TD>

          <TD STYLE="text-align: left">to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than &#8364;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than &#8364;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(c)</TD>

          <TD STYLE="text-align: left">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(d)</TD>

          <TD STYLE="text-align: left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">France</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code mon&eacute;taire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorit&eacute; des march&eacute;s financiers (&#147;AMF&#148;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&#176; and D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d&#146;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&#176; and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial
Code and any implementing regulation. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ireland</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &#147;Prospectus Regulations&#148;). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of
the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">120</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Israel</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel,
directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Italy</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&nbsp;&#151;&nbsp;$$&nbsp;&#151;&nbsp;Aga e la Borsa, &#147;CONSOB&#148; pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&#147;Decree No. 58&#148;), other than:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">to Italian qualified investors, as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 (&#147;Regulation no. 1197l&#148;) as amended (&#147;Qualified Investors&#148;); and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971 as amended. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Japan</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &#147;FIEL&#148;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional
Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Portugal</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The securities have not been offered or sold and will not be offered or sold, </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">121</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comissao do Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &#147;qualified
investors&#148; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sweden</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#147;qualified investors&#148; (as defined in the Financial Instruments Trading Act). Only such investors may receive
this document and they may not distribute it or the information contained in it to any other person. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Switzerland</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the
securities may be publicly distributed or otherwise made publicly available in Switzerland. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This document is personal to the recipient only and not for general circulation in Switzerland. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United Arab Emirates</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the
allotment or redemption of such shares, may be rendered within the United Arab Emirates by the Company. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">United Kingdom</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&#147;FSMA&#148;)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#147;qualified investors&#148; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document,
any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">122</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (&#147;FPO&#148;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &#147;relevant persons&#148;). The investments to which this document relates are
available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Canada</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories
of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t17LEG"></a>LEGAL MATTERS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The validity of the securities being offered by this prospectus will be passed upon for us by Wyrick Robbins Yates &amp; Ponton, LLP, Raleigh, North Carolina. Certain legal matters in connection with this offering have been passed upon for the underwriters by Sichenzia Ross Friedman Ference LLP, New York, New York. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t18EXP"></a>EXPERTS</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The financial statements of Aytu BioScience, Inc. at June 30, 2016 and 2015, and for each of the two years in the period ended June 30, 2016, included in this prospectus have been audited by EKS&amp;H LLLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t19WHE"></a>WHERE YOU CAN FIND MORE INFORMATION</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus, which constitutes a part of the registration statement on Form S-1 that we have filed with the SEC under the Securities Act, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, you should refer to the registration statement and the exhibits filed as part of that document. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other
document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#146;s website at <I>http://www.sec.gov</I>. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">123</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also maintain a website at <I>http://aytubio.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning us at: 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, (720) 437-6580.<B></B></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">124</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="t20FIN"></a>INDEX TO THE FINANCIAL STATEMENTS<BR> AYTU BIOSCIENCE, INC.</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="536"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfRIR">Report of Independent Registered Public Accounting Firm</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfRIR">F-2</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfBS">Balance Sheets</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfBS">F-3</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfSO">Statements of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfSO">F-4</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfSSE">Statements of Stockholders&#146; Equity (Deficit)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfSSE">F-5</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfSCF">Statements of Cash Flows</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfSCF">F-6</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tfNFS">Notes to the Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tfNFS">F-8</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfRIR"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To the Board of Directors and Stockholders<BR> Aytu Bioscience, Inc.<BR> Englewood, Colorado </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have audited the accompanying balance sheets of Aytu BioScience, Inc. (the &#147;Company&#148;) as of June 30, 2016 and 2015, and the related statements of operations, stockholders&#146; equity, and cash flows for each of the periods then ended. The Company&#146;s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Aytu BioScience, Inc. as of June 30, 2016 and 2015, and the results of its operations and its cash flows for each of the periods then ended, in conformity with accounting principles generally accepted in the United States of America. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>

<P STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">/s/ EKS&amp;H LLLP </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">September 1, 2016<BR> Denver, Colorado </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tfBS"></a>AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Balance Sheets</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="426"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Assets</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,054,190</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>162,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>157,058</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Inventory, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>524,707</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,442</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>215,558</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>370,888</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Investment in Acerus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,041,362</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,120,227</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,042,432</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fixed assets, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>231,430</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29,706</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Developed technology, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,159,736</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>780,125</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Customer contracts, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,353,375</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>711,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Trade names, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>194,472</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>79,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Natesto asset</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,549,797</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>221,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>74,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>In-process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>296,611</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>628,776</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term portion of prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>213,471</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>335,454</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deposits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,888</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>14,222,780</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,142,947</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>24,343,007</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,185,379</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Liabilities and Stockholders&#146; Equity</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Current liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,519,711</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,195,368</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Natesto payable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,379,675</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,200,930</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>196,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deferred rent</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,104,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,477,585</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,869,122</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>425,893</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred rent</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,215</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,449</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Warrant derivative liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>275,992</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>14,257,754</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,568,927</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Commitments and contingencies (Note 7)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 3,741,944 in 2016 and 1,188,307 in 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>119</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>56,646,304</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,997,674</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(46,561,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(18,381,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total stockholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,085,253</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>15,616,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total liabilities and stockholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>24,343,007</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,185,379</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> <a name="tfSO"></a>Statements of Operations</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="426"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Product and service revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,050,838</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>176,068</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>License revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>511,607</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,562,445</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>261,782</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cost of sales</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>957,076</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>88,109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,127,772</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,219,361</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>191,991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>203,992</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sales, general and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,517,592</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,980,974</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sales, general and administrative&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>307,704</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>311,004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Impairment of intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Amortization of intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>664,707</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>90,662</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total operating expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>24,266,842</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,894,102</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss from operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(21,704,397</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(7,632,320</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Other (expense)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest (expense)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,491,486</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(114,994</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Unrealized loss on investment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(971,629</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Derivative (expense)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(12,572</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total other (expense)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(6,475,687</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(114,994</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss, before income tax</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(28,180,084</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(7,747,314</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deferred income tax benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(28,180,084</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Weighted average number of Aytu common shares outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,741,137</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>767,326</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Basic and diluted Aytu net loss per common share</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(16.18</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(10.07</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> <a name="tfSSE"></a>Statements of Stockholders&#146; Equity</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="189"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=2 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Additional<BR> paid-in<BR> capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Ampio<BR> Stock<BR> Subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated<BR> Deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total Stockholders&#146; Equity</TD>

</TR>

<TR>

          <TD STYLE="width: 6px; vertical-align: bottom; font-weight: normal; font-size: 10pt; text-align: center" ROWSPAN=1><!-- NEW-GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>658,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,027,278</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10,657,937</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,369,407</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>180,371</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,999,982</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock to Ampio in exchange for Aytu debt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>216,445</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,999,978</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Liabilities paid pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20,013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20,013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis options paid-out pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(27,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(27,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Reverse merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>133,039</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(13</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,017,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,017,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,188,307</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>119</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,997,674</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(18,381,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,616,452</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,641</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>199,997</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>962,150</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>96</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,090,753</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,090,849</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of warrants related to the convertible promissory notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>136,828</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>136,828</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock, net of $1,202,231 in issuance costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,562,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>156</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,237,718</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,237,874</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued in connection with equity financing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,059,895</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,059,895</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued in connection with equity financing to the placement agents for the over-allotment<BR> option</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,493</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,493</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustment for rounding of shares due to stock split</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,346</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>902,946</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>902,946</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(28,180,084</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(28,180,084</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balance&nbsp;&#150;&nbsp;June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3,741,944</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>56,646,304</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(46,561,425</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>10,085,253</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> <a name="tfSCF"></a>Statements of Cash Flows</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="429"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows from operating activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(28,180,084</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(7,723,404</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>902,946</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,017,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation, amortization and accretion</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>874,789</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>118,202</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Asset impairment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of debt issuance costs</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>182,759</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of beneficial conversion feature</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,943,073</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Noncash interest expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>221,024</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Derivative expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,572</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,983</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>121,984</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Unrecognized loss on investment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>971,629</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred taxes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments to reconcile net loss to net cash used in operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) in accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5,369</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(157,058</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) in inventory</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(485,265</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(39,442</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Decrease in prepaid expenses and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>155,330</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>150,434</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Increase) in prepaid research and development&nbsp;&#150;&nbsp;related party (Note 11)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in accounts payable and accrued liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,623,469</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>547,314</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in accrued compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,004,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>196,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>(Decrease) in payable to Ampio</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(607,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in deferred rent</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,875</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>(Decrease) in deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(511,607</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(85,714</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(10,657,449</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(6,634,214</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows used in investing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deposits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,998</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(4,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchases of fixed assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(252,932</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchase of ProstaScint Business</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchase of Primsol asset</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,040,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchase of Natesto license</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Investment in Acerus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2,012,991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,303,925</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,004,886</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash flows from financing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from convertible note from Ampio converted to stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from convertible promissory notes, net (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,175,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Debt issuance costs (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(298,322</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Costs related to the conversion of the convertible promissory notes to equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(29,754</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription payment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Luoxis option payout pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(27,476</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Liabilities paid out pursuant to the merger</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20,013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sale of stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from issuance of equity financing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,520,493</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Issuance costs related to equity financing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(904,914</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>16,662,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>12,352,511</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net change in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>701,129</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,713,411</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at beginning of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,639,650</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at end of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>8,054,190</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7,353,061</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">AYTU BIOSCIENCE, INC.<BR>&nbsp;<BR> Statements of Cash Flows&nbsp;&#150;&nbsp;(continued)</Font> </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="429"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Non-cash transactions:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio stock subscription</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ampio unpaid debt converted to stock, received prior to 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration related to the ProstaScint purchase</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>102,931</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Primsol asset purchase included in primsol payable, $1,250,000 less future accretion of $173,000</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,077,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Conversion of convertible promissory notes and interest of $221,000 to common stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,396,024</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,379,675</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant derivative liability related to the issuance of the registered offering placement agent warrants (Note 8)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>297,317</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Reclassification of liability based warrants to equity presentation related to the convertible promissory notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>136,828</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Beneficial conversion feature related to convertible promissory notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,943,073</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Debt issuance costs related to notes that converted to equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(218,494</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Basis of Presentation and Business Combinations </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tfNFS"></a>Aytu BioScience, Inc. (&#147;Aytu&#148;, the &#147;Company&#148; or &#147;we&#148;) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a commercial-stage specialty healthcare company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing significant medical needs in the areas of urological cancers, hypogonadism, urinary tract infections, male infertility, and sexual dysfunction. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Basis of Presentation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) and Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and
effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the &#147;Reverse Stock Splits&#148;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combination&nbsp;&#151;&nbsp;ProstaScint</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&#147;Jazz Pharmaceuticals&#148;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&#146; product known as ProstaScint&reg; (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#147;ProstaScint Business&#148;), and assumed certain of Jazz Pharmaceuticals&#146; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of
the upfront payment of $1.0 million. We also agreed to pay an additional $500,000 which was paid after transfer for the ProstaScint-related product inventory and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2016 at $699,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s allocation on consideration transferred for ProstaScint as of the purchase date May 20, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Estimated<BR> Fair Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>727,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,590,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>74,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total assets acquired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,391,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Basis of Presentation and Business Combinations &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. Amortization expense of $159,000 was recognized in fiscal 2016. Future amortization from the year ended June 30, 2016 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2021</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>159,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Thereafter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>616,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,411,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combination&nbsp;&#151;&nbsp;Primsol</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&#147;FSC&#148;). Pursuant to the agreement, Aytu purchased assets related to FSC&#146;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of FSC&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu paid $500,000 at closing for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 payable no later than September 30, 2016 (together, the &#147;Installment Payments&#148;). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Fair Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>182,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,470,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>147,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets acquired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,799,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Included in tangible assets is $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets is developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which will be amortized over a six-year period. Amortization expense of $174,000 was recognized in fiscal 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2016, the accrued payable adjusted for the present value was $701,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Future amortization from the year ended June 30, 2016 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2021</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>245,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Thereafter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>72,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,297,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-9</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 1&nbsp;&#151;&nbsp;Business, Basis of Presentation and Business Combinations &nbsp;&#150;&nbsp;(continued)</H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">License and Supply Agreement&nbsp;&#151;&nbsp;Natesto</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April, 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&reg; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we will acquire effective upon the expiration of the current licensee&#146;s rights, which occurred on June 30, 2016. The licensee&#146;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. On September 5, 2016 we will pay an additional $2,000,000 (the &#147;Second Upfront&#148;). On January 1, 2017, we will pay an additional $4,000,000 (the &#147;Third Upfront&#148;). We also purchased on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2,534,800 (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. Aytu could not dispose of these shares until after August 29, 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37,500,000): </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$2,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $25,000,000 (the &#147;First Milestone&#148;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$5,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $50,000,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$7,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $75,000,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$10,000,000 if net sales during any four consecutive calendar quarter period equal or exceed $100,000,000; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">$12,500,000 if net sales during any four consecutive calendar quarter period equal or exceed $125,000,000. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The contingent consideration was valued at $3.2 million using a Monte Carlo simulation. The fair values of the net identifiable asset acquired totaled $10.5 million which will be amortized over eight years. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2016, the accrued payable adjusted for the present value was $5.4 million and the contingent consideration held a value of $3.2 million. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Cash and Cash Equivalents</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. Aytu&#146;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-10</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Revenue Recognition</Font> </H3>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">License Agreements and Royalties</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Product &amp; Service Sales</Font> </H4>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu recognizes revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Estimated Sales Returns and Allowances</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company&#146;s reported revenue could result. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Accounts Receivable</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2016 we had an allowance for doubtful accounts of $41,000, and as of June 30, 2015, no allowance for doubtful accounts had been recorded. The Company had one customer whose revenue individually represented 10% or more of the Company&#146;s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company&#146;s total accounts receivable, as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the year ended June 30, 2016, one customer accounted for 86% of net revenue. For the year ended June 30, 2015, one customer accounted for 83% of gross revenue. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At June 30, 2016, one customer accounted for 69% of gross accounts receivable. At June 30, 2015, one customer accounted for 99% of gross accounts receivable. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Inventories</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Trading Securities</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trading securities are carried at fair value with unrealized gains and losses recorded in earnings. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-11</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fixed Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="274"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="106"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=2 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Estimated<BR> Useful Lives in years</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>June 30,</TD>

</TR>

<TR>

          <TD STYLE="width: 6px; vertical-align: bottom; font-weight: normal; font-size: 10pt; text-align: center" ROWSPAN=1><!-- NEW-GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Office equipment and furniture</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;&#150;&nbsp;5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>201,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Lab equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;&#150;&nbsp;5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Leasehold improvements</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>45,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less accumulated depreciation and amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(112,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Fixed assets, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>231,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2016, Aytu had $24,000 included in Office equipment and furniture for a new phone system and the new enterprise resource system, neither of which had been placed in service nor were being depreciated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu recorded the following depreciation expense in the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>51,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">In-Process Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In-process research and development (&#147;IPRD&#148;) relates to the Company&#146;s Zertane product and clinical trial data acquired in connection with the 2011 acquisition of DMI BioSciences, Inc. (&#147;DMI BioSciences&#148;) by Ampio, the former parent company of Aytu. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD was considered an indefinite-lived intangible asset and its fair value was assessed annually and written down if impaired. At the time the Zertane product obtained regulatory approval and commercial production began, IPRD would have been
reclassified to an intangible that will be amortized over its estimated useful life. However, as of June 30, 2016, because we are directing our resources towards our commercial-stage products, the Company determined that this asset has no value as the Company does not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. The IPRD was expensed and is included in impairment of intangible assets in the accompanying statements of operations. The Company will try to market the Zertane asset to other pharmaceutical companies during fiscal year 2017 but there is no guarantee that the Company will be able to monetize this asset. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Patents</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences and were being amortized over the remaining U.S. patent lives of approximately 11 years, which expires in March 2022. For the fiscal year ended June 30, 2016, because we are directing our resources towards our commercial-stage products, the Company determined that this asset had no value as the Company does not have the
resources to complete the necessary clinical trials and bring it to market before the patents expire. The remaining fair value of the Zertane patents have been expensed as of June 30, 2016. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-12</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The cost of the Luoxis patents were $380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent lives of approximately 15 years, which expires in March 2028. Patents consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>880,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>880,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less accumulated amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(583,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(251,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Patents, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>297,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>629,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu recorded the following amortization expense in the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>332,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>71,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Future amortization from the year ended June 30, 2016 is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2021</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Thereafter</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>172,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>297,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Business Combinations</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&#146;s (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 805, &#147;Business Combinations&#148;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business
combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Goodwill</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The ProstaScint and Primsol purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-13</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May 20, 2015 and Primsol that occurred on October 5, 2015. There
was no impairment of goodwill for the year ended June 30, 2016. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Use of Estimates</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent
consideration, sales returns and allowances, useful lives of fixed assets and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Income Taxes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&#146;s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu&#146;s taxes are computed and reported on a &#147;separate return&#148; basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit
carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&#146;s policy is to record a liability for the difference
between the benefits that are both recognized and measured pursuant to FASB ASC 740-10, &#147;Accounting for Uncertainty in Income Taxes&nbsp;&#151;&nbsp;an interpretation of FASB Statement No. 109&#148; (&#147;ASC 740-10&#148;) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Stock-Based Compensation</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-14</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Research and Development</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs are expensed as incurred with expenses recorded in the respective period. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Income (Loss) Per Common Share</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2016 and 2015. Although there were common stock equivalents of 2,523,929, and 8,553 shares outstanding at June 30, 2016 and 2015, respectively, consisting of stock options and warrants; they were not included in the calculation of the diluted net loss per share because they
would have been anti-dilutive. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Fair Value of Financial Instruments</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash flows. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Derivative Liability</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu accounts for financial instruments (convertible debt with embedded derivative features&nbsp;&#151;&nbsp;conversion options and conversion provisions) and related warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants was calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods will be recorded as
unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Impairment of Long-Lived Assets</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Indefinite-lived intangible assets, including acquired IPR&amp;D, are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of the fair value of the asset to its carrying value, without consideration of any recoverability test. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based on the Company&#146;s evaluation as of June 30, 2016, an impairment existed for IPRD as we do not anticipate any future cash flows from this asset (see In-Process Research and Development). As of June 30, 2015, there had been no impairment for long-lived assets. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-15</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Adoption of Newly Issued Accounting Pronouncements</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2015, the FASB issued Accounting Standards Update (&#147;ASU&#148;) 2015-16, &#147;Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,&#148; which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period&#146;s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated
amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of March 31, 2016, the Company has early adopted this standard, there was no material impact on our financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2015, the FASB issued ASU 2015-03, &#147;Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&#148; to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, &#147;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit
Arrangements&nbsp;&#151;&nbsp; Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting&#148; which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter ended September 30, 2015, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was no impact on the Company&#146;s financial statements related to this adoption as the Company did not have any debt issuance costs prior to adoption. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 &#147;Income Taxes: Balance Sheet Classification of Deferred Taxes.&#148; The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and require that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2016</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2016, the FASB issued ASU 2016-09, &#147;Compensation&nbsp;&#151;&nbsp;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting&#148;. The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to significantly impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those
fiscal years, beginning after December 15, 2016. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this standard on its financial statements however, the Company believes that the impact will not be material. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-16</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2016, the FASB issued ASU 2016-02, &#147;Leases (Topic 842)&#148;. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital
and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2016, the FASB issued ASU 2016-01, &#147;Financial Instruments&nbsp;&#151;&nbsp;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&#148; which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting
from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, the FASB issued ASU 2015-11, &#147;Simplifying the Measurement of Inventory.&#148; ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company&#146;s financial position or
results of operations. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In August 2014, the FASB issued ASU 2014-15, &#147;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is currently evaluating
the impact the adoption of ASU 2014-15 will have on its financial statements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2014, the FASB issuing ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the &#147;New Revenue Standard&#148;). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures
about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-17</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its financial statements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 3&nbsp;&#151;&nbsp;Going Concern </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As reflected in the accompanying financial statements, the Company has a net loss of $28.2 million and net cash used in operations of $10.7 million for the year ended June 30, 2016, and stockholders&#146; equity of $10.1 million and an accumulated deficit of $46.6 million at June 30, 2016. In addition, the Company is in the early stage of commercialization and has not yet generated any profits. These factors raise substantial doubt about the Company&#146;s ability to continue as a going concern. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on management&#146;s plans, which include continuing to raise equity-based financing. There is no assurance that the Company will be successful in accomplishing this objective. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 4&nbsp;&#151;&nbsp;License Agreement/Revenue Recognition </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2011, Ampio entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&#147;PE&#148;) and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $500,000 upfront payment, the net proceeds of which were $418,000 after withholding of Korean tax. The upfront payment was deferred and was being
recognized as license revenue over a ten-year period. Milestone payments of $3.2 million could have been earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which could have taken several years. In addition, Aytu could have earned a royalty based on 25% of net sales, as defined, if the royalty exceeded the transfer price of the Zertane product. No royalties have been earned to date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2014, Vyrix entered into a Distribution and License Agreement (the &#147;Paladin Agreement&#148;) with Endo Ventures Limited, which acquired Paladin Labs Inc. (&#147;Paladin&#148;), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement expires on a country by country basis upon the later of 15 years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $250,000 to Vyrix upon signing
the Paladin Agreement and is obligated to make milestone payments aggregating up to $3,025,000 based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment was deferred and was being recognized as license revenue over a seven-year period. In addition, the Paladin Agreement provides that Paladin pay royalties based on sales volume. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-18</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 4&nbsp;&#151;&nbsp;License Agreement/Revenue Recognition &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At the end of fiscal 2016, Aytu determined that the Zertane asset has no value as Aytu does not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. The remaining deferred revenue of $426,000 was recognized as of June 30, 2016. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 5&nbsp;&#151;&nbsp;Fair Value Considerations </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu&#146;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the convertible notes was approximately the face value of the notes (see Note 8 for more information). The valuation policies are determined by the Chief Financial Officer and approved by the Company&#146;s Board of Directors. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu.
Unobservable inputs are inputs that reflect Aytu&#146;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="white-space: nowrap; padding-right: 2px; width: 40px; text-align: left">Level&nbsp;1:</TD>

          <TD STYLE="text-align: left">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="white-space: nowrap; padding-right: 2px; width: 40px; text-align: left">Level&nbsp;2:</TD>

          <TD STYLE="text-align: left">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="white-space: nowrap; padding-right: 2px; width: 40px; text-align: left">Level&nbsp;3:</TD>

          <TD STYLE="text-align: left">Unobservable inputs that are supported by little or no market activity. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu&#146;s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu&#146;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-19</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 5&nbsp;&#151;&nbsp;Fair Value Considerations &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table presents Aytu&#146;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2016, by level within the fair value hierarchy: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=15>Fair Value Measurements Using</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Level 1</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Level 2</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Level 3</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><U>June 30, 2016</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>ASSETS<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Investment in Acerus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,041,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,041,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>LIABILITIES<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant derivative liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>276,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>276,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,869,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,869,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><U>June 30, 2015</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>ASSETS<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Investment in Acerus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>LIABILITIES<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant derivative liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contingent consideration</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The estimated fair value of the Company&#146;s investment, which is classified as Level 1 (quoted price is available), was $1,041,000 as of June 30, 2016. The estimated fair value of the Company&#146;s marketable securities is determined using the quoted price in the active market based on the closing price as of the balance sheet date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="161"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="102"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=1>As of June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Maturity in Years</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Initial Cost</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Unrealized</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Fair Value</TD>

</TR>

<TR>

          <TD STYLE="width: 6px; vertical-align: bottom; font-weight: normal; font-size: 10pt; text-align: center" ROWSPAN=1><!-- NEW-GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=3>Gains</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Losses</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Investment in Acerus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>Less than 1 year</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,013,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(972,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,041,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrant derivative liability for the warrants was valued using the Black-Scholes valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions in valuing the warrant derivative liability were based on estimates of the value of Aytu common stock, the exercise price of $6.00, the term of 5 years, volatility of 75% and a risk free interest rate of 1.32% at issuance. At June 30, 2016, these warrants were re-valued with an adjusted term of 4.84 years, volatility of 75% and a risk free interest rate of 0.986%. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Derivative<BR> Instruments</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance as of June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant issuances</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Reclassification of warrant liability to equity upon note conversion</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(137,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Change in fair value included in earnings</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balance as of June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>276,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-20</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 6&nbsp;&#151;&nbsp;Income Taxes </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As previously discussed in Note 2&nbsp;&#151;&nbsp;Summary of Significant Accounting Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ended on or before December 31, 2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company&#146;s taxes have been computed and reported on a &#147;separate return&#148; basis. Ampio and Aytu do not have a tax sharing agreement. Accordingly, certain tax attributes, e.g., net operating loss carryforwards, reflected in these financial statements, may or may not be available to
Aytu. In January 2016, Ampio&#146;s ownership fell below 80% so that Aytu will no longer be included in the Ampio consolidated income tax return. The deconsolidation resulted in approximately $4.5 million of the net operating loss carryforwards originating prior to the incorporation of Vyrix and Luoxis to no longer be available to Aytu. Upon deconsolidation, the deferred income tax asset and related valuation allowance for these pre-incorporation net operating losses have been removed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Income tax benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and State of Colorado) differs from the income tax provision (benefit) in the Aytu&#146;s financial statements. The following table reflects the reconciliation for the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=15>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Benefit at statutory rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(9,581,229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(34.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,634,087</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(34.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>State income taxes, net of federal benefit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(853,203</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(216,183</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2.79</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,156</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>426,725</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.51</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest on convertible debt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75,148</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.27</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Change in valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,672,155</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30.77</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,397,527</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30.95</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Reduction of net operating losses upon deconsolidation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,674,110</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.94</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5,863</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.02</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,108</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net income tax provision (benefit)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>0.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(23,910</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.30</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="370"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred tax assets (liabilities):<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>190,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred rent</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>445,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>73,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net operating loss carry forward</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,202,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,337,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Intangibles</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>606,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>453,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Share-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>327,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Acquired in-process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,779,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Unrealized loss on investment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrant liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>153,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Inventory</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>192,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Allowance for doubtful accounts</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total deferred income tax assets (liabilities)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,305,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,274,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less: Valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(11,305,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,274,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total deferred income tax assets (liabilities)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-21</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 6&nbsp;&#151;&nbsp;Income Taxes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has recorded income tax benefits in its statements of operations since inception, stemming from its operating losses, and is expected to incur operating losses for the foreseeable future. During the year ended June 30, 2015, the net deferred tax liability was reduced to zero based upon the operating losses, thus Aytu established a valuation allowance offsetting any future net deferred tax asset. As such, Aytu would no longer record income tax benefits in its results of operations after the year ended June 30, 2015 because management is currently unable to conclude that it is more likely than not that a benefit will be
realized. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these
deductible differences, net of the valuation allowance provided. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has federal net operating loss carryforwards of approximately $24.8 million and $17.1 million as of June 30, 2016 and June 30, 2015, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2032 through 2035. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL
utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. Under the provisions of the Internal Revenue Code, substantial changes in the Company&#146;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2016 and 2015, the Company has no liability for gross unrecognized tax benefits or related interest and penalties. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has made its best estimates of certain income tax amounts included in the financial statements. Application of the Company&#146;s accounting policies and estimates, however, involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically included in the Ampio consolidated tax
return. Under the general statute of limitations, the Company would not be subject to federal or Colorado income tax examinations for years prior to 2012 and 2011, respectively. However, given the net operating losses generated since inception, all tax years since inception are subject to examination. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-22</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Commitments and Contingencies </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Commitments and contingencies are described below and summarized by the following table as of June 30, 2016: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="138"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="36"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2017</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2018</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2019</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2020</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2021</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Thereafter</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prescription Database</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,902,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>731,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>598,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>573,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Natesto</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Manufacturing agreement</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Service agreement</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>204,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>204,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Primsol</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>750,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>750,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Office Lease</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>317,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>142,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>145,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Sponsored research agreement with related party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>70,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>14,743,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9,897,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,243,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,103,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,500,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Prescription Database</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information, whereby Aytu agreed to pay approximately $1,902,000 over three years for access to the database of prescriptions written for Natesto. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Natesto</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $8,000,000 for the exclusive U.S. rights to Natesto of which $6,000,000 is payable in fiscal year 2017. Additionally, Aytu is required to make the first milestone payment even if the milestone is not reached. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Manufacturing Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 8, 2015, Aytu and Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us for ProstaScint. In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $5.0 million, of which we paid $1.0 million upon submission of the work order and $500,000 in each of January and April 2016. We will pay an additional $2,000,000 in fiscal 2017, and $500,000 in both fiscal 2018 and 2019. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Service Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties. This agreement was amended in April 2016, which reduced the monthly amount to $18,000. This agreement was amended again in July 2016, which reduced the monthly amount to approximately $17,000 per month. For the years ended June 30, 2016 and 2015, the Company paid approximately $310,000 for this service
agreement. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Primsol</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2015, Aytu entered into an asset purchase agreement with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we purchased assets related to FSC&#146;s product known as Primsol (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#147;Primsol Business&#148;), and assumed certain of FSC&#146;s liabilities, including those related to the sale and marketing of Primsol arising after the closing. We </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-23</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 7&nbsp;&#151;&nbsp;Commitments and Contingencies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">paid $500,000 at closing for the Primsol Business and we paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also paid $500,000 on April 1, 2016 and $500,000 on July 1, 2016 and must pay $250,000 no later than September 30, 2016 (together, the &#147;Installment Payments&#148;), for a total purchase price of $1,892,000. This amount is included in accounts payable and accrued liabilities on the balance sheet. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Office Lease</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2015, Aytu entered into a 37 month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term of the lease of approximately $112,000. In August 2015, the Company entered into a 37 month operating lease in Englewood, Colorado effective September 1, 2015. This lease has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000 which includes rent abatements. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences
between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Rent expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>120,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>51,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement with Related Party</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (&#147;TRLLC&#148;), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146; notice. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 8&nbsp;&#151;&nbsp;Convertible Promissory Notes </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Convertible Promissory Notes</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (&#147;Notes&#148;) with an aggregate principal amount of $5.2 million. The sale of the Notes was pursuant to a private placement. Debt issuance costs totaled $401,000, which include the $103,000 fair value of the placement agent warrants. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Notes were an unsecured obligation. Aytu did not have the right to prepay the Notes prior to the maturity date. Interest accrued on the Notes in the following amounts: (i) 8% simple interest per annum for the first six months and (ii) 12% simple interest per annum thereafter if not converted during the first nine months. Interest accrued, was payable with the principal upon maturity, conversion or acceleration of the Notes and could have been paid in kind or in cash, in Aytu&#146;s sole discretion. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Placement agents for the offerings sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu has an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8% of the gross proceeds of Notes sold by the placement agents and is obligated to issue warrants for an amount of shares to be equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents in the private placement, in addition to a
previously paid non-refundable retainer fee of $20,000. The placement agent warrants had a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to the conversion price per share at which the Notes are converted into common stock. Change in fair value is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the debt. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-24</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 8&nbsp;&#151;&nbsp;Convertible Promissory Notes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrants were recorded at fair value as long-term liabilities on the Balance Sheet (see Note 5). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon Aytu&#146;s adoption of ASU 2015-3, the issuance costs associated with the Notes were recorded as a long-term liability and were presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the terms of the convertible promissory note agreements, if Aytu sold equity securities at any time while the notes were outstanding in a financing transaction that was not a Qualified Financing (a public offering of Aytu stock resulting in gross proceeds of at least $5.0 million (excluding indebtedness converted in such financing) prior to the maturity date of the Notes), the holders of the convertible promissory notes had the option, but not the obligation, to convert the outstanding principal and accrued interest as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal
to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. As a result of Aytu&#146;s sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, for a period of ten business days (which was extended to 15 business days by the Company, or February 10, 2016) following receipt of the notice, noteholders had the option to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal to 120% of the number of shares calculated by dividing such note balance by $7.80, which was the per share purchase price paid in the equity financing described above. On February 10, 2015, the date of the conversion, an aggregate of $4,125,000 of principal and
$143,000 of accrued interest on the notes converted into an aggregate of 656,591 shares of Aytu&#146;s common stock under the original terms of the agreement. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2016, Aytu completed a registered public offering which was considered a Qualified Financing and all outstanding notes were forced to convert into the same arrangement that was given in the offering. At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion increasing it to 130% of shares calculated by dividing such note balance by $4.80, which was the per share purchase price in the registered offering. On May 6, 2016, the date of conversion, an aggregate of $1,050,000 of principal and $78,000 of accrued interest on
the notes converted into an aggregate of 305,559 shares of Aytu&#146;s common stock and 305,559 warrants according to the terms of the agreement. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the conversion of the Aytu notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8% of the number of shares of Aytu&#146;s common stock for the notes sold by the placement agents issued upon conversion of the notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of 22,254 shares of our common stock at an exercise price of $7.80 per share. As a result of the second note conversion, on May 6, 2016, Aytu issued warrants to the placement agents
to purchase an aggregate of 22,564 shares of our common stock at an exercise price of $4.80 per share. These warrants are exercisable for five years from the date of issuance of the related notes in July and August 2015. The warrants have a cashless exercise feature. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Also in connection with the conversion of the notes, Aytu recorded a beneficial conversion feature of $4.9 million which was recorded as a debt discount; this amount represents that carrying amount of the notes at the date of conversion. The beneficial conversion feature was expensed upon conversion of the notes to interest expense. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-25</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 9&nbsp;&#151;&nbsp;Common Stock </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Capital Stock</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At June 30, 2016 and 2015, Aytu had 100 million and 300 million shares, respectively, of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. In May 2016, the Aytu shareholders voted to reduce the authorized common stock outstanding from 300 million to 100 million shares. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In May 2016, we raised gross proceeds of approximately $7.5 million through a public offering of 1,562,500 Units, offering costs totaled $1.2 million resulting in net proceeds of $6.3 million. Each Unit consists of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock. The common stock issued had a relative fair value of $4.2 million. The warrants have an exercise price of $6.00 per share and will expire five years from the date of issuance. These warrants have a relative fair value of $2.1 million. We also granted the underwriters a 45-day option (the Over-Allotment Option) to purchase up an
additional 234,375 shares of common stock and/or warrants. The underwriters exercised 170,822 of this over-allotment option for the warrants and paid $0.12 per over-allotment warrant. These warrants have the same terms as the warrants offered in the registered offering. These warrants have a relative fair value of $20,000, which was the purchase price per the underwriting agreement. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 30, 2016, Aytu effected a reverse stock split in which each common stock holder received one share of common stock for each 12 shares. All share and per share amounts for all periods presented in this report have been adjusted to reflect the effect of this reverse stock split. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Options</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 143,236 shares of common stock, both of which were terminated on April 16, 2015 upon the closing of the Merger. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Luoxis options that were in the money and all outstanding Vyrix options issued under the 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option, if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $27,000. The Company
recognized compensation of $422,000 and $189,000 related to the Luoxis and Vyrix options that had accelerated vesting as of the Merger date. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $433,000 of previously recognized compensation was reversed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 1, 2015, Aytu&#146;s stockholders approved the 2015 Stock Option and Incentive Plan (the &#147;2015 Plan&#148;), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 833,334 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the 2015 Stock Plan, 833,334 shares of its common stock, were reserved for issuance. The fair value of the options was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-26</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The assumptions are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="322"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="96"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>75&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>1.16&#37;&nbsp;&#150;&nbsp;1.90&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term (years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3.75&nbsp;&#150;&nbsp;6.25</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Forfeiture rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock option activity is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="301"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Life in Years</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>326,469</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited/Cancelled</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,167</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>322,302</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>18.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>9.33</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Exercisable at June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>139,798</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>16.76</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>9.42</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Available for grant at June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>511,032</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table details the options outstanding at June 30, 2016 by range of exercise prices: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="84"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="84"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="84"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="84"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="84"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="92"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Range of<BR> Exercise Prices</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Options<BR> Outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Life of Options<BR> Outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Options<BR> Exercisable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,668</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.79</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,668</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.72</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>301,467</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.37</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>123,130</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>55.56</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,167</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>55.56</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>4.11</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>322,302</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>18.01</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>9.33</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>139,798</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>16.76</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-27</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and sales, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the years ended June 30 2016 and 2015: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>89,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>519,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Selling, general and administrative expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Stock options</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>814,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>499,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>903,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,018,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Unrecognized expense at June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,267,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average remaining years to vest</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.66</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Warrants</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A summary of all warrants is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="286"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR> Average<BR> Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted Average<BR> Remaining<BR> Contractual<BR> Life in Years</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,553</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>54.36</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.92</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted in fiscal 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Expired in fiscal 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2015</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,553</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>54.36</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.92</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued to placement agents for convertible promissory notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7.80</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued to investors in connection with the registered offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,733,322</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued to placement agents for convertible promissory notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,564</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.80</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued to placement agents for the registered offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>109,375</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Warrants issued to convertible note holders who converted May 5, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>305,559</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>6.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Outstanding June 30, 2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2,201,627</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>6.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>4.71</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-28</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 10&nbsp;&#151;&nbsp;Equity Instruments &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our private placement of approximately $5.2 million of convertible notes in July and August 2015, the Company was obligated to issue to the placement agents&#146; warrants for an amount of shares equal to 8% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest. The placement agents warrants have a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to 100% of the price per share at which equity securities were sold in our next equity financing, and provide for cashless exercise. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the conversions of the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering of common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of 22,254 shares of our common stock at an exercise price of $7.80 per share, and an aggregate of 22,564 shares of our common stock at an exercise price of $4.80 per share. These warrants have a fair value of $87,000 and $50,000, respectively. As discussed in Note 5, these amount were reclassified from liability accounting to equity upon the
second conversion of the convertible notes in May 2016. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Also in connection with the conversion of the notes in May 2016, the noteholders that converted also received 305,559 warrants (see Note 8). These warrants have a term of five years with an exercise price of $6.00 per share. These warrants are accounted for under equity treatment and have a fair value of $480,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our May 2016 public offering, we issued warrants to purchase an aggregate of 109,375 shares of common stock at an exercise price of $6.00 and a term of five years to the underwriters of the public offering. These warrants are accounted for under liability accounting and are fair valued at each reporting period (see Note 5). At June 30, 2016, these warrants had a fair value of $276,000. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Also in connection with our May 2016 public offering, we issued to investors warrants to purchase an aggregate of 1,733,322 shares of common stock, which includes the over-allotment warrants, at an exercise price of $6.00 with a term of five years. These warrants are accounted for under equity treatment (see Note 9). </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The warrants issued in connection with our registered offering are all registered and tradable on the OTCQX under the ticker symbol &#147;AYTUW&#148;. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant
for treasury securities of similar maturity. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The assumptions are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="322"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="96"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended June 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2016</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2015</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>75&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>1.07&nbsp;&#150;&nbsp;1.76&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Contractual term (years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>4.2&nbsp;&#150;&nbsp;5.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-29</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 11&nbsp;&#151;&nbsp;Related Party Transactions </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Ampio Loan Agreements</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any
outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $1,600,000 with interest rates from 3.11%&nbsp;&#150;&nbsp;3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio has an option of
converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $3,000,000 with interest rates from 3.11%&nbsp;&#150;&nbsp;3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 16, 2015, Ampio received 396,816 shares of common stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Services Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has service agreements with Ampio which are described in Note 7. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Sponsored Research Agreement</Font> </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; as of September 2014, this amount had been paid
in full. This agreement is set to expire in March 2019 but can be terminated earlier but not until after March 2017. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-30</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AYTU BIOSCIENCE, INC<BR>&nbsp;<BR> Notes to the Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 12&nbsp;&#151;&nbsp;Employee Benefit Plan </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aytu has a 401(k) plan that allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. As of June 30, 2016, Aytu does not match employee contributions. Starting in fiscal 2017, the Company will match 50% of the first 6% contributed to the plan by employees. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Note 13&nbsp;&#151;&nbsp;Subsequent Events </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2016, Aytu cancelled and re-issued certain outstanding stock option agreements as well as issued an additional 441,999 stock options to executives, employees, directors and consultants. Aytu also issued 1.0 million shares of restricted stock to executive officers and directors. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On July 27, 2016, we entered into a purchase agreement (the &#147;Purchase Agreement&#148;), together with a registration rights agreement (the &#147;Registration Rights Agreement&#148;), with Lincoln Park Capital Fund, LLC (&#147;Lincoln Park&#148;), an Illinois limited liability company. Upon signing the Purchase Agreement, Lincoln Park agreed to purchase 133,690 shares of our common stock for $500,000 as an initial purchase under the agreement. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the terms and subject to the conditions of the Purchase Agreement, we have the right to sell to and Lincoln Park is obligated to purchase up to an additional $10.0 million in amounts of shares of our common stock (&#147;Common Stock&#148;), subject to certain limitations, from time to time, over the 36-month period commencing on the date that a registration statement, which we agreed to file with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the Purchase Agreement, we issued as a commitment fee to Lincoln Park 52,500 shares of Common Stock. Joseph Gunnar &amp; Co., LLC (&#147;Joseph Gunnar&#148;) and Fordham Financial Management, Inc. (&#147;Fordham&#148;) acted as Financial Advisor on our behalf. Upon the execution of the Purchase Agreement, we paid $50,000 to Joseph Gunnar and $50,000 to Fordham. Upon the earlier of six months from the execution of the Purchase Agreement or upon the effectiveness of the resale registration statement to be filed pursuant to the Registration Rights Agreement, we will pay an additional $50,000 to Joseph Gunnar and
$50,000 to Fordham.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-31</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</P>

<H2 STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR></H2>

<DIV  STYLE="width: 100%; display: inline-block; *display:inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Shares of Common Stock</Font> </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><FONT STYLE="font-size: 14pt">Warrants to Purchase &nbsp;&nbsp;&nbsp;&nbsp; Shares of Common Stock &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR> </Font></H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="logo_aytu-bioscience.jpg" WIDTH="180" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR> &nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> &nbsp;<BR> &nbsp;<BR> </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">PROSPECTUS</Font> </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> &nbsp;<BR> &nbsp;<BR> &nbsp;<BR>&nbsp;<BR> &nbsp;<BR> &nbsp;<BR></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="672" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="312"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="344"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=3>Joint Book-Running Managers<BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><FONT STYLE="font-size: 18pt"><B>Joseph Gunnar &amp; Co.</B></FONT></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><FONT STYLE="font-size: 18pt"><B>Feltl and Company</FONT></B></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=3>Lead Manager<BR></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 16pt"><B>Fordham Financial Management</FONT></B><BR></TD>

</TR>

</TABLE></DIV>

<DIV STYLE="width: 100%; display: inline-block; *display:inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">PART II<BR>INFORMATION NOT REQUIRED IN PROSPECTUS</Font> </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Item 13. Other Expenses of Issuance and Distribution.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth all costs and expenses paid or payable by us in connection with the sale of the securities being registered, other than underwriting discounts and commissions. All amounts shown are estimates except for the Securities Exchange Commission, or SEC, registration fee. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="517"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount Paid or to be Paid</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>SEC registration fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,862</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>NYSE MKT listing fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>55,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Printing expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>40,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Legal fees and expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>97,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounting fees and expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Miscellaneous expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>19,638</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>225,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->*&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">Estimated as permitted under Item 511 of Regulation S-K. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Item 14. Indemnification of Directors and Officers.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation, or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or
enterprise. The indemnity may include expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#146;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his conduct was illegal. A Delaware corporation may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees)
actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#146;s best interests except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred. Our certificate of incorporation and bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General Corporation Law. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">transaction from which the director derives an improper personal benefit;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unlawful payment of dividends or redemption of shares; or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">breach of a director&#146;s duty of loyalty to the corporation or its stockholders. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As permitted by the Delaware General Corporation Law, we have entered into indemnity agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director and officer to the fullest extent permitted by law and advance expenses to each indemnitee in connection with any proceeding in which indemnification is available. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, or otherwise. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Item 15. Recent Sales of Unregistered Securities.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following transactions give effect to the 1-for-12.174 reverse stock split effected on June 8, 2015 and the 1-for-12 reverse stock split effected on June 30, 2016. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Rosewind</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On March 17, 2014, Rosewind issued Ruth Harrison Revocable Trust 124 shares of its common stock in consideration for $2,700.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On March 19, 2014, Rosewind issued James B. Wiegand 4,108 shares of its common stock in consideration of cancelation of notes totaling $90,000.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On March 20, 2014, Rosewind issued Michael Wiegand 685 shares of its common stock in consideration of services valued at $15,000.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On May 8, 2014, Rosewind issued Larry Willis 685 shares of its common stock in consideration for $15,000.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On September 25, 2014, Rosewind issued Craig K. Olson 685 shares of its common stock in consideration of $15,000.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On March 3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of which Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such trusts. None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On April 16, 2015, Rosewind issued an aggregate of 1,055,268 shares of common stock to the stockholders of Vyrix and Luoxis in the merger of Vyrix and Luoxis with subsidiaries owned by Rosewind. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales and issuances of the securities described in this section were exempt from registration either (a) under Section 4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of Section 4(2), (b) Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c) under Regulation S promulgated under
the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their relationships with Rosewind to information about Rosewind. The sales of these securities were made without any general solicitation or advertising. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Vyrix</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">In November 2013, Vyrix issued 136,904 shares of its common stock to Ampio at a purchase price of $0.015 per share, and in consideration of the transfer of certain intellectual property assets of Ampio. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The foregoing transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales and issuances of the securities described in this section were exempt from registration either (a) under Section 4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of Section 4(a)(2), (b) Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c) under Regulation S promulgated under
the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their relationships with Vyrix, to information about Vyrix. The sales of these securities were made without any general solicitation or advertising. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Luoxis</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">In 2013, Luoxis issued 31,848 shares of its common stock were issued at $146.09 per share resulting in $4,653,000 of gross proceeds. Net proceeds were $3,980,000 after placement agents and legal fees. The placement agents also received 8,553 warrants to purchase Luoxis common stock at $54.36 per share valued at $313,000 in connection with the closing. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Except as noted below, the offers, sales and issuances of the securities described in this section were exempt from registration either (a) under Section 4(a)(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of Section 4(a)(2), (b) Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c) under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their relationships with Luoxis, to information about Luoxis. The sales of these securities were made without any general solicitation or advertising. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Aytu BioScience, Inc.</Font></H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">In July and August 2015, we issued $5,175,000 of convertible notes in a private placement under Section 506 of Regulation D. In connection with the private placement, pursuant to the exemption from registration provided by Section 4(a)(2), we issued to the placement agents a warrant to purchase an amount of shares of our common stock equal to 8% of the gross number of shares of our common stock issuable upon conversion of the convertible notes and all accrued interest thereon. The placement agents&#146; warrant has a term of five years from the date of issuance of the related notes in July and August 2015, will have an exercise price equal to 100% of the price per share at which equity securities are sold in our next equity financing, and provides for cashless exercise.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On February 10, 2016, we completed the conversion of $4,125,000 in convertible notes and $143,000 of accrued interest. The notes were issued in financings that closed in July and August 2015. Upon the conversion, we issued an aggregate of 656,592 shares common stock. After this conversion, an aggregate of $1,050,000 of principal of convertible notes remained outstanding.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On May 5, 2016, we issued 305,559 shares of common stock and warrants to purchase 305,559 shares of common stock to holders of convertible notes that automatically converted into shares of common stock and warrants to purchase common stock, which conversion was triggered by the closing of our public offering of common stock and warrants on May 6, 2016.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On July 7, 2016, we issued 1,000,000 shares of restricted stock as compensation to certain executive officers and directors, which vest on July 7, 2026.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On July 7, 2016, we issued warrants to purchase up to an aggregate of 82,838 shares of our common stock to Luoxis stockholders in a settlement, which warrants expire on July 7, 2021 and have an exercise price of $4.00.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On July 27, 2016, we issued 52,500 shares of common stock to Lincoln Park Capital Fund, LLC as a commitment fee and sold 133,690 shares of common stock to Lincoln Park Capital Fund, LLC, for an aggregate purchase price of $500,000, both pursuant to the Purchase Agreement dated July 27, 2016 between us and Lincoln Park Capital Fund, LLC.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On August 2, 2016, we issued an aggregate of 142,457 shares of common stock as bonuses for performance in 2016 to three executive officers.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The offers, sales and issuances of the securities described in this section were exempt from registration under Section 4(a)(2) of the Securities Act, and where noted above, pursuant to Rule 506 of Regulation D, in that the transactions were between an issuer and sophisticated investors and did not involve any public offering within the meaning of Section 4(a)(2). The sales of these securities were made without any general solicitation or advertising. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Item 16. Exhibits and Financial Statement Schedules.</Font> </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">(a) Exhibits.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="288"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit No.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Description</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Registrant&#146;s<BR> Form</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Date<BR> Filed</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit<BR> Number</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Filed<BR> Herewith</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>1.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Underwriting Agreement by and between Aytu BioScience, Inc. and Joseph Gunnar Co., LLC as representative of the several underwriters named therein.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">X</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>2.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Agreement and Plan of Merger among Rosewind, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind, dated as of April 16, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>2.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Certificate of Merger</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">2.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>3.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Certificate of Incorporation</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/09/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>3.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Certificate of Amendment of Certificate of Incorporation effective June 1, 2016</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/02/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>3.3</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Certificate of Amendment of Certificate of Incorporation of Aytu Bioscience, Inc., effective June 30, 2016</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/01/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>3.4</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Bylaws</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/09/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">3.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>4.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Convertible Note issued in 2015 Convertible Note Financing</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/24/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>4.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Placement Agent Warrant issued in 2015 Convertible Note Financing</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/24/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>4.3</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Warrant Agent Agreement, dated May 6, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">5/6/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>4.4</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Underwriters Warrant, dated May 6, 2016</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">5/6/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>4.5</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Amendment to Warrant Agent Agreement between Aytu BioScience, Inc. and VStock Transfer LLC</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4.5</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>4.6</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Underwriter&#146;s Warrant for 2016 Public Offering</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">X</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="288"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit No.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Description</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Registrant&#146;s<BR> Form</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Date<BR> Filed</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit<BR> Number</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Filed<BR> Herewith</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>5.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Opinion of Wyrick Robbins Yates &amp; Ponton LLP</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">X</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.1&#134;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Indemnification Agreement, to be entered into between the Registrant and its directors and officers</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.2&#134;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Employment Agreement between the Registrant and Joshua R. Disbrow, dated as of April 16, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.3&#134;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Employment Agreement between the Registrant and Jarrett Disbrow, dated as of April 16, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.3</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.4&#35;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Asset Purchase Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Valeant International (Barbados) SRL, effective as of December 2, 2011</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K/A</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/08/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.4</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.5&#35;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Manufacturing and Supply Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Ethypharm S.A., dated September 10, 2012</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K/A</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/08/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.5</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.6&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">License, Development and Commercialization Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011 (incorporated by reference to Exhibit 10.1 of Ampio Pharmaceutical&#146;s Form 8-K/A filed October 5, 2011; File No. 001-25182)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.7&#35;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Distribution Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and FBM Industria Farmaceutica, Ltda., dated as of March 1, 2012</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K/A</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/08/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.7</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.8&#35;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Distribution and License Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9, 2014</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K/A</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/08/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.8</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.9&#35;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated September 1, 2009</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K/A</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">6/08/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.9</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;10.10&#35;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Addendum No. 4 to Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated March 17, 2014</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">5/27/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.14</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.11</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Promissory Note issued by Ampio to the Registrant on April 16, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.11</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.12</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Subscription Agreement between the Registrant and Ampio, dated April 16, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.12</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.13</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Voting Agreement between the Registrant and Ampio, dated April 21, 2015 (incorporated by reference to Exhibit 10.1 to Ampio&#146;s Form 8-K filed April 22, 2015; File No. 001-35182)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.14</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Asset Purchase Agreement between Jazz Pharmaceuticals, Inc. and Rosewind Corporation, dated May 20, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">5/27/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.14</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="288"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit No.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Description</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Registrant&#146;s<BR> Form</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Date<BR> Filed</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit<BR> Number</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Filed<BR> Herewith</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Aytu BioScience 2015 Stock Option and Incentive Plan</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/01/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Note Purchase Agreement for 2015 Convertible Note Financing</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/24/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.17</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.17</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Asset Purchase Agreement, dated October 5, 2015, between Aytu BioScience, Inc. and FSC Laboratories, Inc.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10/07/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.18</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.18</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Master Services Agreement between Biovest International, Inc. and Aytu BioScience, Inc., entered into on October 8, 2015, and effective October 5, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10/13/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.19</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.19</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Subscription Agreement for January 2016 common stock purchases</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">1/20/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.20</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">License and Supply Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/25/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.21</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Subscription Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/25/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.22</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">First Amendment, dated May 15, 2016, to Employment Agreement dated September 16, 2015 between Aytu BioSciences, Inc. and Jonathan McGrael</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">5/16/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.23</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Purchase Agreement, dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/28/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>10.24</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Registration Rights Agreement dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">7/28/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">10.2</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>16.1&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Letter from HJ &amp; Associates, LLC, dated April 22, 2015</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">8-K</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">4/22/15</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">16.1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>23.1&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Consent of EKS&amp;H LLLP, Independent Registered Public Accounting Firm.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">X</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>23.2&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Consent of Wyrick Robbins Yates &amp; Ponton LLP (included as part of Exhibit 5.1)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">X</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>24.1&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Power of Attorney (included on page S-<a href="#tSIG">1</a>)</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">X</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;101.INS</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">XBRL Instance Document</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">101.INS</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;101.SCH</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">XBRL Taxonomy Extension Schema Document</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">101.SCH</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;101.CAL</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">XBRL Taxonomy Extension Calculation Linkbase Document</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">101.CAL</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;101.DEF</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">XBRL Taxonomy Extension Definition Linkbase Document</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">101.DEF</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;101.LAB</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">XBRL Taxonomy Extension Label Linkbase Document</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">101.LAB</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="288"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="50"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit No.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Description</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Registrant&#146;s<BR> Form</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Date<BR> Filed</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit<BR> Number</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Filed<BR> Herewith</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;101.PRE</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">XBRL Taxonomy Extension Presentation Linkbase Document</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">S-1</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">9/21/16</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">101.PRE</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"></TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#35;</TD>

          <TD STYLE="text-align: left">The company has received confidential treatment of certain portions of this agreement. These portions have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">&#134;</TD>

          <TD STYLE="text-align: left">Indicates a management contract or any compensatory plan, contract or arrangement. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">(b) Financial statement schedule.</Font> </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">Item 17. Undertakings.</Font> </H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(a)</TD>

          <TD STYLE="text-align: left">The undersigned registrant hereby undertakes: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(i)</TD>

          <TD STYLE="text-align: left">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933 (the &#147;Act&#148;); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(ii)</TD>

          <TD STYLE="text-align: left">To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(iii)</TD>

          <TD STYLE="text-align: left">To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">That, for the purpose of determining any liability under the Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(b)</TD>

          <TD STYLE="text-align: left">Insofar as indemnification for liabilities arising under the Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission, or SEC, such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(c)</TD>

          <TD STYLE="text-align: left">The undersigned registrant hereby undertakes that: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">For purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif"><a name="tSIG"></a>SIGNATURES</Font> </H1>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Englewood, State of Colorado, on the 11<sup>th</sup> day of October, 2016. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 244px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">AYTU BIOSCIENCE, INC.</Font> </H2>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 241px"></TD>

          <TD STYLE="width: 20px; text-align: left">By:</TD>

          <TD STYLE="text-align: left">/s/ Joshua R. Disbrow<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Joshua R. Disbrow<BR> Chairman and Chief Executive Officer </TD>

</TR>

</TABLE>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><font Style="FONT-FAMILY: Times New Roman, Times, Serif">POWER OF ATTORNEY</Font> </H1>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joshua R. Disbrow and Gregory A. Gould as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act
and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="173"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="266"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="136"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Signature</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Title</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Date</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Joshua R. Disbrow<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Joshua R. Disbrow</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chairman and Chief Executive Officer<BR><I>(Principal Executive Officer)</I></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">October 11, 2016</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Gregory A. Gould<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Gregory A. Gould</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Financial Officer<BR> <I>(Principal Financial and Accounting Officer)</I></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">October 11, 2016</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Michael Macaluso<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Michael Macaluso</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">October 11, 2016</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Gary V. Cantrell<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Gary V. Cantrell</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">October 11, 2016</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Carl C. Dockery<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Carl C. Dockery</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">October 11, 2016</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ John A. Donofrio, Jr.<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>John A. Donofrio, Jr.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">October 11, 2016</TD>

</TR>

</TABLE></DIV>



</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">S-1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">



</DIV>

</B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B>

</I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>v450214_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDERWRITING AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JOSEPH GUNNAR &amp; CO., LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>as Representative of the Several Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">New York, New York<BR>
[&bull;], 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Joseph Gunnar &amp; Co., LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As Representative of the several Underwriters named on Schedule
1 attached hereto<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">30 Broad Street, 11th Fl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned, Aytu BioScience,
Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including,
without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries
or affiliates of Aytu BioScience, Inc., the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;)
with Joseph Gunnar &amp; Co., LLC. (hereinafter referred to as &ldquo;you&rdquo; (including its correlatives) or the &ldquo;<B>Representative</B>&rdquo;)
and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative is acting as representative (the
Representative and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an
&ldquo;<B>Underwriter</B>&rdquo;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Purchase and Sale of Securities</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">1.1</FONT></TD><TD STYLE="text-align: justify"><U>Firm Securities</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal">1.1.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Nature and Purchase
of Firm Securities</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the
Company agrees to issue and sell to the several Underwriters, an aggregate of [&bull;] shares (&ldquo;Firm Shares&rdquo;) of the
Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), together with Common Stock purchase
warrants to purchase up to an aggregate of [&bull;] shares of Common Stock (each a &ldquo;Firm Warrant&rdquo; and collectively
the &ldquo;Firm Warrants&rdquo; and together with the Firm Shares, the &ldquo;Firm Securities&rdquo;). Each Firm Warrant shall
be exercisable for a period of [&bull;] years at an exercise price of $[&bull;] (the &ldquo;Firm Warrant Exercise Price&rdquo;),
subject to adjustment as provided in the agreement evidencing the Firm Warrant.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares and Firm Warrants set forth
opposite their respective names on <U>Schedule 1</U> attached hereto and made a part hereof at a purchase price of $[&bull;] per
Firm Security ([93]% of the per Firm Security offering price). The Firm Securities are to be offered initially to the public at
the offering price set forth on the cover page of the Prospectus (as defined in Section 2.1.1 hereof).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal">1.1.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Securities Payment
and Delivery</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Delivery
and payment for the Firm Securities shall be made at 10:00 a.m., Eastern time, on the third (3<SUP>rd</SUP>) Business Day following
the effective date (the &ldquo;Effective Date&rdquo;) of the Registration Statement (as defined in Section 2.1.1 below) (or the
fourth (4<SUP>th</SUP>) Business Day following the Effective Date if the Registration Statement is declared effective after 4:01
p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices of Sichenzia
Ross Friedman Ference LLP, 61 Broadway, 32<SUP>nd</SUP> Floor, New York, NY 10006</FONT></FONT><FONT STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(&ldquo;Representative
Counsel&rdquo;), or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by
the Representative and the Company. The hour and date of delivery and payment for the Firm Securities is called the &ldquo;Closing
Date.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
for the Firm Securities shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of
the Company upon delivery of the certificates (in form and substance reasonably satisfactory to the Underwriters) representing
the Firm Shares and Firm Warrants (or through the facilities of the Depository Trust Company (&ldquo;DTC&rdquo;)) for the account
of the Underwriters. The Firm Securities shall be registered in such name or names and in such authorized denominations as the
Representative may request in writing at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated
to sell or deliver the Firm Securities except upon tender of payment by the Representative for all of the Firm Securities. The
term &ldquo;Business Day&rdquo; means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions
are authorized or obligated by law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">1.2</FONT></TD><TD STYLE="text-align: justify"><U>Over-allotment Option</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Securities</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Securities,
the Company hereby grants to the Underwriters an option (the &ldquo;Over-allotment Option&rdquo;) to purchase up to (a) [&bull;]
additional shares of Common Stock (the &ldquo;Option Shares&rdquo;) at a purchase price of $[&bull;] per one Option Share and/or
(b) up to [&bull;] additional warrants (the &ldquo;Option Warrants&rdquo; and collectively with the Option Shares, the &ldquo;Option
Securities&rdquo;) at a purchase price of $[&bull;] per Option Warrant , (the &ldquo;Warrant Purchase Price&rdquo;), which may
be purchased in any combination of Option Shares and/or Option Warrants. The Firm Securities and the Option Securities are hereinafter
referred to together as the &ldquo;Public&nbsp;Securities.&rdquo; The offering and sale of the Public Securities is hereinafter
referred to as the &ldquo;Offering.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to
all (at any time) or any part (from time to time) of the Option Securities within 45 days after the Effective Date. The Underwriters
shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed
in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares and/or Option
Warrants to be purchased and the date and time for delivery of and payment for the Option Securities (the &ldquo;Option Closing
Date&rdquo;), which shall not be later than three (3) full Business Days after the date of the notice or such other time as shall
be agreed upon by the Company and the Representative, at the offices of Representative Counsel or at such other place (including
remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If such
delivery and payment for the Option Securities does not occur on the Closing Date, the Option Closing Date will be as set forth
in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Securities, subject
to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of
Option Shares and/or Option Warrants specified in such notice and (ii) each of the Underwriters, acting severally and not jointly,
shall purchase that portion of the total number of Option Shares and/or Option Warrants then being purchased as set forth in <U>Schedule
1</U> opposite the name of such Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Securities shall be made on the Option Closing Date by wire transfer in Federal (same
day) funds, payable to the order of the Company upon delivery to you of certificates (in form and substance reasonably satisfactory
to the Underwriters) representing the Option Securities (or through the facilities of DTC) for the account of the Underwriters.
The Option Securities shall be registered in such name or names and in such authorized denominations as the Representative may
request in writing at least two (2) full Business Days prior to the Option Closing Date. The Company shall not be obligated to
sell or deliver the Option Shares and/or Option Warrants except upon tender of payment by the Representative for the applicable
Option Shares and/or Option Warrants.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">1.3</FONT></TD><TD STYLE="text-align: justify"><U>Underwriter&rsquo;s Warrants</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
Warrants</U>. The Company hereby agrees to issue and sell to the Underwriters on the Closing Date an option (&ldquo;Underwriter&rsquo;s
Warrant&rdquo;) for the purchase of an aggregate of [&bull;] shares of Common Stock, representing 7% of the Firm Shares (excluding
the Option Shares), for an aggregate purchase price of $100.00. The Underwriter&rsquo;s Warrant agreement, in the form attached
hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;Underwriter&rsquo;s Warrant Agreement&rdquo;), shall be exercisable, in whole or in
part, commencing on a date which is one (1) year after the Effective Date and expiring on the five-year anniversary of the Effective
Date at an initial exercise price per share of Common Stock of $[&bull;], which is equal to 125% of the initial public offering
price of the Firm Shares. The Underwriter&rsquo;s Warrant Agreement and the shares of Common Stock issuable upon exercise thereof
are hereinafter referred to together as the &ldquo;Underwriter&rsquo;s Securities.&rdquo; The Representative understands and agrees
that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Underwriter&rsquo;s Warrant Agreement
and the underlying shares of Common Stock and by its acceptance
thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Underwriter&rsquo;s Warrant Agreement, or
any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the
effective economic disposition of such securities to
anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner
of the Representative or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up
restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery</U>.
Delivery of the Underwriter&rsquo;s Warrant Agreement shall be made on the Closing Date and shall be issued in the name or names
and in such authorized denominations as the Underwriters may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriters as of the Applicable Time (as defined
below), as of the Closing Date and as of the Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.1</FONT></TD><TD STYLE="text-align: justify"><U>Filing of Registration Statement</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pursuant
to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;), including any related prospectus
or prospectuses, for the registration of the Public Securities and the Underwriter&rsquo;s Securities under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), which registration statement and amendment or amendments have been prepared
by the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations
of the Commission under the Securities Act (the &ldquo;Securities Act Regulations&rdquo;) and will contain all material statements
that are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations. Except as the
context may otherwise require, such registration statement, as amended, on file with the Commission at the time the registration
statement became effective (including the Preliminary Prospectus included in the registration statement, financial statements,
schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to be a
part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act Regulations (the &ldquo;Rule
430A Information&rdquo;)), is referred to herein as the &ldquo;Registration Statement.&rdquo; If the Company files any registration
statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term &ldquo;Registration Statement&rdquo;
shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement has been declared effective
by the Commission on the date hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Each
prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information
that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &ldquo;Preliminary
Prospectus.&rdquo; The Preliminary Prospectus, subject to completion, dated [&bull;], 2016, that was included in the Registration
Statement immediately prior to the Applicable Time is hereinafter called the &ldquo;Pricing Prospectus.&rdquo; The final prospectus
in the form first furnished to the Underwriters for use in the Offering is hereinafter called the &ldquo;Prospectus.&rdquo; Any
reference to the &ldquo;most recent Preliminary Prospectus&rdquo; shall be deemed to refer to the latest Preliminary Prospectus
included in the Registration Statement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;Applicable
Time&rdquo; means [TIME] [a.m./p.m.], Eastern time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;Issuer
Free Writing Prospectus&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities
Act Regulations (&ldquo;Rule 433&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in
Rule 405 of the Securities Act Regulations) relating to the Public Securities that is (i)&nbsp;required to be filed with the Commission
by the Company, (ii)&nbsp;a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether
or not required to be filed with the Commission, or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i)
because it contains a description of the Public Securities or of the Offering that does not reflect the final terms, in each case
in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s
records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;Issuer
General Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433 (the &ldquo;Bona
Fide Electronic Road Show&rdquo;)), as evidenced by its being specified in <U>Schedule 2-B</U> hereto. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;Issuer
Limited Use Free Writing Prospectus&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Pricing Disclosure
Package&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing Prospectus
and the information included on <U>Schedule 2-A</U> hereto, all considered together.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pursuant
to the Exchange Act</U>. The Company has filed with the Commission a Form 8-A (File Number 000-53121) providing for the registration
pursuant to Section 12(g) under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), of the shares
of Common Stock. The registration of the shares of Common Stock under the Exchange Act has been declared effective by the Commission
on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Listing</U>. The shares of Common Stock have been approved for quotation on the OTCQX Market operated by OTC Markets Group, Inc.</FONT>
<FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">(the &ldquo;Exchange&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, removing the shares of Common Stock from quotation
on the Exchange, nor has the Company received any notification that the Exchange is contemplating terminating such quotation except
as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Stop Orders, etc</U>. Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued any
order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted
or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied
with each request (if any) regarding the Registration Statement, any Preliminary Prospectus or the Prospectus from the Commission
for additional information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Disclosures
in Registration Statement</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal">2.4.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Compliance with Securities
Act and 10b-5 Representation</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including
the prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto,
and the Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of
the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection
with this Offering</FONT></FONT><FONT STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">and
the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or
at any Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits
or will omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of
the circumstances under which they were made, not misleading. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Pricing Disclosure Package, as of the Applicable Time, as of the date of this Agreement, at the Closing Date or at any Option Closing
Date (if any), did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; [and each
Issuer Limited Use Free Writing Prospectus hereto] does not conflict in any material respect with the information contained in
the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, and each such Issuer Limited
Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus as of the Applicable Time, did not
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty
shall not apply to statements made or statements omitted in reliance upon and in conformity with written information furnished
to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing
Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information
provided by or on behalf of any Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: [the second paragraph, second sentence under the heading &ldquo;Discounts&rdquo;; the first paragraph
under the heading &ldquo;Stabilization&rdquo; and each paragraph under the heading &ldquo;Offer restrictions outside of the United
States&rdquo;] (the &ldquo;Underwriters&rsquo; Information&rdquo;); and</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of
any filing with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date, included, includes
or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however,
that this representation and warranty shall not apply to the&nbsp;Underwriters&rsquo; Information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other
documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that
have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company
is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred to in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, or (ii)&nbsp;is material to the Company&rsquo;s business, has been duly authorized and validly
executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the
Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability may
be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y)&nbsp;as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z)&nbsp;that
the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses
and to the discretion of the court before which any proceeding therefor may be brought. None of such agreements or instruments
has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in default
thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or
both, would constitute a default thereunder, except for any default or event which would not reasonably be expected to result in
a Material Adverse Change. To the Company&rsquo;s knowledge, performance by the Company of the material provisions of such agreements
or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any
governmental agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each,
a &ldquo;Governmental Entity&rdquo;), including, without limitation, those relating to environmental laws and regulations, except
for any default or event which would not reasonably be expected to result in a Material Adverse Change, except as may be disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior
Securities Transactions</U>. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit
of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Preliminary Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulations</U>.
The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the material effects
of federal, state, local and all foreign regulation material to the Company&rsquo;s business as currently contemplated are correct
in all material respects and no other such regulations are required to be disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus which are not so disclosed; provided, however, the Company makes no representation with respect
to the disclosure in the Registration Statement set forth under the heading &ldquo;Offer restrictions outside the United States&rdquo;.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Changes
After Dates in Registration Statement</U>.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no material adverse
change in the financial position or results of operations of the Company, nor any change or development that, singularly or in
the aggregate, would involve a material adverse change, in or affecting the condition (financial or otherwise), results of operations,
business, assets or prospects of the Company (a &ldquo;Material Adverse Change&rdquo;); (ii)&nbsp;there have been no material transactions
entered into by the Company, other than as contemplated pursuant to this Agreement; and (iii)&nbsp;no officer or director of the
Company has resigned from any position with the Company, which would reasonably be expected to cause a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued any securities
or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or
made any other distribution on or in respect to its capital stock.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Accountants</U>. To the knowledge of the Company, EKS&amp;H LLLP (the &ldquo;Auditor&rdquo;), whose report is filed with the Commission
as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent registered public accounting
firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. The
Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange
Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules included in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, fairly present the financial position and the results of operations
of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity
with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;), consistently applied throughout the periods involved (provided
that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the
aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included in the Registration Statement
present fairly the information required to be stated therein. Except as included therein, no historical or pro forma financial
statements are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the
Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information and the related
notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly compiled
and prepared in all material respects in accordance with the applicable requirements of the Securities Act and the Securities Act
Regulations and present fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable
and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. All
disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding &ldquo;non-GAAP
financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation
G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations
(including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may
have a material current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of
operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, during the periods to which they apply (a) neither
the Company nor any of its direct and indirect subsidiaries, including each entity disclosed or described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus as being a subsidiary of the Company (each, a &ldquo;Subsidiary&rdquo; and, collectively,
the &ldquo;Subsidiaries&rdquo;), has incurred any material liabilities or obligations, direct or contingent, or entered into any
material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or
made any distribution of any kind with respect to its capital stock, (c) there has not been any change in the capital stock of
the Company or any of its Subsidiaries, or, other than in the course of business, any grants under any stock compensation plan,
and (d) there has not been any material adverse change in the Company&rsquo;s long-term or short-term debt.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date
the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the
Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any
Option Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized,
but unissued shares of Common Stock of the Company or any security convertible or exercisable into shares of Common Stock of the
Company, or any contracts or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or convertible
securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Valid
Issuance of Securities, etc</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Outstanding
Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement
have been duly authorized and validly issued and are fully paid and non-assessable; to the Company&rsquo;s knowledge, the holders
thereof have no rights of rescission with respect thereto, and are not subject to personal liability solely by reason of being
such holders; and none of such securities were issued in violation of the preemptive rights of any holders of any security of the
Company or similar contractual rights granted by the Company. The authorized shares of Common Stock conform in all material respects
to all statements relating thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
The offers and sales of the outstanding shares of Common Stock were at all relevant times either registered under the Securities
Act and the applicable state securities or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties
of the purchasers of such Shares, exempt from such registration requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Sold Pursuant to this Agreement</U>. The Public Securities and Underwriter&rsquo;s Securities have been duly authorized for issuance
and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and
will not be subject to personal liability solely by reason of being such holders; the Public Securities and Underwriter&rsquo;s
Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual
rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public
Securities and Underwriter&rsquo;s Securities have been duly and validly taken. The Public Securities and Underwriter&rsquo;s Securities
conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Underwriter&rsquo;s
Warrant Agreement has been duly and validly taken; the shares of Common Stock issuable upon exercise of the Underwriter&rsquo;s
Warrant have been duly authorized and reserved for issuance by all necessary corporate action on the part of the Company and when
paid for and issued in accordance with the Underwriter&rsquo;s Warrant and the Underwriter&rsquo;s Warrant Agreement, such shares
of Common Stock will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal
liability by reason of being such holders; and such shares of Common Stock are not and will not be subject to the preemptive rights
of any holders of any security of the Company or similar contractual rights granted by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the
Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include
any such securities in a registration statement to be filed by the Company. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Validity
and Binding Effect of Agreements</U>. This Agreement and the Underwriter&rsquo;s Warrant Agreement have been duly and validly authorized
by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable
against the Company in accordance with their respective terms, except: (i)&nbsp;as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii)&nbsp;as enforceability of any indemnification
or contribution provision may be limited under the federal and state securities laws; and (iii)&nbsp;that the remedy of specific
performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of
the court before which any proceeding therefor may be brought.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Underwriter&rsquo;s Warrant Agreement
and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance
by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time
or both: (i)&nbsp;result in a material breach of, or conflict with any of the terms and provisions of, or constitute a material
default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property
or assets of the Company pursuant to the terms of any material agreement or instrument to which the Company is a party; (ii)&nbsp;result
in any violation of the provisions of the Company&rsquo;s Certificate of Incorporation (as the same may be amended or restated
from time to time, the &ldquo;Charter&rdquo;) or the by-laws of the Company; or (iii)&nbsp;violate any existing applicable law,
rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Defaults; Violations</U>. No material default exists in the due performance and observance of any term, covenant or condition of
any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument
evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by
which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not in violation
of any term or provision of its Charter or by-laws, or in violation of any franchise, license, permit, applicable law, rule, regulation,
judgment or decree of any Governmental Entity material to the Company&rsquo;s business.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.14</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Corporate
Power; Licenses; Consents</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.14.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conduct
of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
has all requisite corporate power and authority, and has all materially necessary authorizations, approvals, orders, licenses,
certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct
its business purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.14.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions
and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained.
No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid
issuance, sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this
Agreement and the Underwriter&rsquo;s Warrant Agreement and as contemplated by the Registration Statement, the Pricing Disclosure
Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations of
the Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>D&amp;O
Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;Questionnaires&rdquo;)
completed by each of the Company&rsquo;s directors and officers immediately prior to the Offering (the &ldquo;Insiders&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal shareholders as described in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined
in Section 2.24 below), provided to the Underwriters, is true and correct in all material respects and the Company has not become
aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and
incorrect.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation;
Governmental Proceedings</U>. There is no material action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus or in connection with the Company&rsquo;s listing application for the listing of the Public Securities
on the Exchange. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Good
Standing</U>. The Company has been duly organized and is validly existing as a corporation and is in good standing under the laws
of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to
qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks
which the Company believes are adequate, including, but not limited to, directors and officers insurance coverage at least equal
to $5,000,000 and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able
(i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar
institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in
a Material Adverse Change. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.19</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Transactions
Affecting Disclosure to FINRA</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Finder&rsquo;s
Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims,
payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee
by the Company or any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements
or understandings of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo;
compensation, as determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments
Within Twelve (12) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&rsquo;s
fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company
persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp; any person or entity that has any
direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the Effective Date,
other than the payment to the Underwriters as provided hereunder in connection with the Offering. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Affiliation</U>. There is no (i) officer or director of the Company, (ii)&nbsp;to the Company&rsquo;s knowledge, beneficial owner
of 5% or more of any class of the Company's securities or (iii) to the Company&rsquo;s knowledge, beneficial owner of the Company's
unregistered equity securities which were acquired during the 180-day period immediately preceding the filing of the Registration
Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance
with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information</U>.
All information provided by the Company in its FINRA questionnaire to Representative Counsel specifically for use by Representative
Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete
in all material respects.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices Act</U>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to
customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official
or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company
(or assist it in connection with any actual or proposed transaction) that (i)&nbsp;would subject the Company to any damage or penalty
in any civil, criminal or governmental litigation or proceeding, (ii)&nbsp;if not given in the past, would reasonably be expected
to have had a Material Adverse Change or (iii)&nbsp;if not continued in the future, would reasonably be expected to adversely affect
the assets, business, operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting
controls and procedures are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices
Act of 1977, as amended.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with OFAC</U>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries, is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;OFAC&rdquo;),
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;Money Laundering
Laws&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the
Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Representative
Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-Up
Agreements.</U> <U>Schedule 3</U> hereto contains a complete and accurate list of the Company&rsquo;s officers, directors and,
to the Company&rsquo;s knowledge, each owner of at least 10% of the Company&rsquo;s outstanding shares of Common Stock (or securities
convertible or exercisable into shares of Common Stock) (collectively, the &ldquo;Lock-Up Parties&rdquo;). The Company has caused
each of the Lock-Up Parties to deliver to the Representative an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit
B</U> (the &ldquo;Lock-Up Agreement&rdquo;), prior to the execution of this Agreement. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization
or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the
conduct of business requires such qualification, except where the failure to qualify would not have a material adverse effect on
the assets, business or operations of the Company taken as a whole. The Company&rsquo;s ownership and control of each Subsidiary
is as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Related
Party Transactions</U>. There are no business relationships or related party transactions involving the Company or any other person
required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not been described
as required.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing
Prospectus and the Prospectus captioned &ldquo;Management.&rdquo; The qualifications of the persons serving as board members and
the overall composition of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002
and the rules promulgated thereunder (the &ldquo;Sarbanes-Oxley Act&rdquo;) applicable to the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.28</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Sarbanes-Oxley
Compliance</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure
Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that will comply with Rule 13a-15
or 15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure that all material information
concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s
Exchange Act filings and other public disclosure documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley
Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company&rsquo;s
future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions
of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accounting
Controls</U>. The Company and its Subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo; (as
defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) to comply with the requirements of the Exchange Act
and have been designed by, or under the supervision of, their respective principal executive and principal financial officers,
or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements
in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal controls.
The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known
to the Company&rsquo;s management and that have adversely affected or are reasonably likely to adversely affect the Company&rsquo;
ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company&rsquo;s management,
whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
controls over financial reporting. </FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to
register as an &ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Labor Disputes</U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of
the Company, is imminent. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property Rights</U>. The Company and each of its Subsidiaries owns or possesses or has valid rights to use all patents, patent
applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses,
inventions, trade secrets and similar rights (&ldquo;Intellectual Property Rights&rdquo;) necessary for the conduct of the business
of the Company and its Subsidiaries as currently carried on and as described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary
for the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will
involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. Neither
the Company nor any of its Subsidiaries has received any notice alleging any such infringement, fee or conflict with asserted Intellectual
Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material
Adverse Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of
any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened
action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights,
and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in
the aggregate, together with any other claims in this Section 2.34, reasonably be expected to result in a Material Adverse Change;
(C) the Intellectual Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights
licensed to the Company have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part,
and there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging
the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable
basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 2.34, reasonably
be expected to result in a Material Adverse Change; (D) there is no pending or, to the Company&rsquo;s knowledge, threatened action,
suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property
Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company is
unaware of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate,
together with any other claims in this Section 2.34, reasonably be expected to result in a Material Adverse Change; and (E) to
the Company&rsquo;s knowledge, no employee of the Company is in or has ever been in violation in any material respect of any term
of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation
agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates
to such employee&rsquo;s employment with the Company, or actions undertaken by the employee while employed with the Company and
could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s
knowledge, all material technical information developed by and belonging to the Company which is material to the Company&rsquo;s
business and has not been patented has been kept confidential. The Company is not a party to or bound by any options, licenses
or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth
in the Registration Statement, the Pricing Disclosure Package and the Prospectus and are not described therein. The Registration
Statement, the Pricing Disclosure Package and the Prospectus contain in all material respects the same description of the matters
set forth in the preceding sentence. To the Company&rsquo;s knowledge, none of the technology employed by the Company that is material
to the Company&rsquo;s business has been obtained or is being used by the Company in violation of any contractual obligation binding
on the Company or, to the Company&rsquo;s knowledge, any of its officers, directors or employees, or otherwise in violation of
the rights of any persons.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities
prior to the date hereof or has duly obtained extensions of time for the filing thereof unless the failure to file such returns
will not have a material adverse effect on the Company. Each of the Company and its Subsidiaries has paid all taxes (as hereinafter
defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the Company or such
respective Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the
Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including
the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no tax liabilities
have been asserted in writing (and are currently pending) by any taxing authority in connection with any of the returns or taxes
asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns
or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term &ldquo;taxes&rdquo; means
all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium,
property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any
interest and any penalties, additions to tax or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all
returns, declarations, reports, statements and other documents required to be filed in respect to taxes.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>ERISA
Compliance</U>. The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security
Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;ERISA&rdquo;)) established
or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects
with ERISA. &ldquo;ERISA Affiliate&rdquo; means, with respect to the Company, any member of any group of organizations described
in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations
thereunder (the &ldquo;Code&rdquo;) of which the Company is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA)
has occurred or is reasonably expected to occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained
by the Company or any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established or maintained by the Company
or any of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would reasonably be expected to have
any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates
has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of,
or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee
benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under
Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure
to act, which would cause the loss of such qualification.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Laws</U>. The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable
to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (&ldquo;Applicable
Laws&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change;
(B) has not received any warning letter, untitled letter or other correspondence or notice from any other governmental authority
alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;Authorizations&rdquo;); (C) possesses
all material Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of
any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any governmental authority or third party alleging that any product operation or
activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental authority or
third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received
notice that any governmental authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations
and has no knowledge that any such governmental authority is considering such action; (F) has filed, obtained, maintained or submitted
all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented
by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to
be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, &ldquo;dear doctor&rdquo;
letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect
or violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to initiate any such notice
or action.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ineligible
Issuer</U>.&nbsp; At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness
of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant
made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at
the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405, without taking account
of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible
issuer.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Real
Property</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company
and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items
of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case
free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially
affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company
or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its subsidiaries, considered
as one enterprise, and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has
received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or
any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such
Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease, which would reasonably
be expected to have a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contracts
Affecting Capital</U>. There are no transactions, arrangements or other relationships between and/or among the Company, any of
its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that would reasonably be expected to materially
affect the Company&rsquo;s or its Subsidiaries&rsquo; liquidity or the availability of or requirements for their capital resources
required to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus
which have not been described or incorporated by reference as required.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loans
to Directors or Officers</U>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers
or directors of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Smaller
Reporting Company</U>.&nbsp; As of the time of filing of the Registration Statement, the Company was a &ldquo;smaller reporting
company,&rdquo; as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Industry
Data</U>.&nbsp; The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure
Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable
and accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.42</FONT></TD><TD STYLE="text-align: justify">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal"><U>Intentionally
Omitted</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">2.43</FONT></TD><TD STYLE="text-align: justify">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal"><U>Intentionally
Omitted</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Testing-the-Waters
Communications</U>. The Company has not (i) alone engaged in any Testing-the-Waters Communications, other than Testing-the-Waters
Communications with the written consent of the Representative and with entities that are qualified institutional buyers within
the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501
under the Securities Act and (ii) [authorized anyone other than the Representative to engage in Testing-the-Waters Communications].
The Company confirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications.
The Company has not distributed any Written Testing-the-Waters Communications other than those listed on <U>Schedule 2-C</U> hereto.
&ldquo;Written Testing-the-Waters Communication&rdquo; means any Testing-the-Waters Communication that is a written communication
within the meaning of Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Electronic
Road Show</U>. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule&nbsp;433(d)(8)(ii) of the
Securities Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule&nbsp;433(h) of the Securities
Act Regulations) is required in connection with the Offering.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">2.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Margin
Securities</U>. The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the &ldquo;Federal Reserve Board&rdquo;), and none of the proceeds of Offering will be used, directly
or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness
which was originally incurred to purchase or carry any margin security or for any other purpose which would reasonably be expected
to cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings of Regulation T,
U or X of the Federal Reserve Board. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Covenants of the Company</U>. The Company covenants and agrees
as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
to Registration Statement</U>. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to
the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement
to which the Representative shall reasonably object in writing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Federal
Securities Laws</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will
notify the Representative promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration
Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii)&nbsp;of the receipt
of any comments from the Commission; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement
or any amendment or supplement to the Prospectus or for additional information; (iv)&nbsp;of the issuance by the Commission of
any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing
or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Public
Securities and Underwriter&rsquo;s Securities for offering or sale in any jurisdiction, or of the initiation or threatening of
any proceedings for any of such purposes or of any examination pursuant to Section&nbsp;8(d) or 8(e) of the Securities Act concerning
the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of the Securities
Act in connection with the Offering of the Public Securities and Underwriter&rsquo;s Securities. The Company shall effect all filings
required under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b)
(without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of
prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not,
it will promptly file such prospectus. The Company shall use its best efforts to prevent the issuance of any stop order, prevention
or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange
Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and
in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to
the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;Rule 172&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur
or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company,
to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading;
(ii)&nbsp;amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or
the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to
a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the Pricing Disclosure Package or the Prospectus,
as the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company
will promptly (A)&nbsp;give the Representative notice of such event; (B)&nbsp;prepare any amendment or supplement as may be necessary
to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure Package or the Prospectus comply
with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies
of any such amendment or supplement and (C)&nbsp;file with the Commission any such amendment or supplement; provided that the Company
shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall reasonably
object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters
may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the
Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of its
intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration
of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s)
a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which
the Representative or counsel for the Underwriters shall reasonably object. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts
to maintain the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister the shares
of Common Stock under the Exchange Act without the prior written consent of the Representative other than in connection with a
merger or sale of the Company or similar business combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Free
Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall
not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission
or retained by the Company under Rule 433; provided that the Representative shall be deemed to have consented to each Issuer General
Use Free Writing Prospectus hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i)
that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such
free writing prospectus consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto,
including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of
an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing
Prospectus conflicted or would conflict with the information contained in the Registration Statement or included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the
Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct
such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Testing-the-Waters
Communications</U>. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or
occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an
untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify
the Representative and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to
eliminate or correct such untrue statement or omission.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
to the Underwriters of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available
to the Representative and counsel for the Representative, without charge, signed copies of the Registration Statement as originally
filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts,
and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed and
each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment
thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
to the Underwriters of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to each
Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company
hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by
Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented)
as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
and Events Requiring Notice to the Representative</U>. The Company shall use its best efforts to cause the Registration Statement
to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative
immediately and confirm the notice in writing: (i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto;
(ii)&nbsp;of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that
purpose; (iii)&nbsp;of the issuance by any state securities commission of any proceedings for the suspension of the qualification
of the Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for
that purpose; (iv)&nbsp;of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration
Statement or Prospectus; (v)&nbsp;of the receipt of any comments or request for any additional information from the Commission;
and (vi)&nbsp;of the happening of any event during the period described in this Section 3.5 that, in the judgment of the Company,
makes any statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue
or that requires the making of any changes in (a) the Registration Statement in order to make the statements therein not misleading,
or (b) in the Pricing Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend
such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such order.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Review
of Financial Statements</U>. For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall
cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial
statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quotation</U>.
The Company shall use its best efforts to maintain the quotation of the shares of Common Stock (including the Public Securities)
on the Exchange for at least three years from the date of this Agreement. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Public Relations Firm</U>. As of the Effective Date, the Company shall have retained a financial public relations firm reasonably
acceptable to the Representative and the Company, which shall initially be Tiberend Strategic Advisors, which firm shall be experienced
in assisting issuers in initial public offerings of securities and in their relations with their security holders, and shall retain
such firm or another firm reasonably acceptable to the Representative for a period of not less than one (1) years after the Effective
Date. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">3.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Reports
to the Representative</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Periodic
Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available
to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time
furnishes generally to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each
periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations;
(ii) a copy of every press release and every news item and article with respect to the Company or its affairs which was released
by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement
filed by the Company under the Securities Act; and (v) such additional documents and information with respect to the Company and
the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably request; provided
the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably
acceptable to the Representative and Representative Counsel in connection with the Representative&rsquo;s receipt of such information.
Documents filed with the Commission pursuant to its EDGAR system or made available through the Company&rsquo;s website shall be
deemed to have been delivered to the Representative pursuant to this Section 3.9.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer
agent and registrar reasonably acceptable to the Representative (the&nbsp;&ldquo;Transfer Agent&rdquo;) and shall furnish to the
Representative at the Company&rsquo;s sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative
may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Vstock Transfer
LLC is acceptable to the Representative to act as Transfer Agent for the shares of Common Stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trading
Reports</U>. During such time as the Public Securities are listed on the Exchange, the Company shall provide to the Representative,
at the Company&rsquo;s expense, such reports published by Exchange relating to price trading of the Public Securities, as the Representative
shall reasonably request<I>.</I></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">3.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Payment
of Expenses</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.10.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Expenses Related to the Offering</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date,
if any, to the extent not paid at the Closing Date, all reasonable, necessary and accountable expenses incident to the performance
of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and expenses relating
to the registration of the shares of Common Stock to be sold in the Offering (including the Over-allotment Shares) with the Commission;
(b) all Public Filing System filing fees associated with the review of the Offering by FINRA; (c) all fees, expenses and disbursements
relating to background checks of the Company&rsquo;s officers and directors in an amount not to exceed $5,000 per individual and
$15,000 in the aggregate; (d) all fees, expenses and disbursements relating to the registration or qualification of the Public
Securities under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions as the Representative may reasonably
designate (including, without limitation, all filing and registration fees; (e) all fees, expenses and disbursements relating to
the registration, qualification or exemption of the Public Securities under the securities laws of such foreign jurisdictions as
the Representative may reasonably designate; (f) the costs of all mailing and printing of the underwriting documents (including,
without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected
Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all
amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably
deem necessary; (g) the costs and expenses of a public relations firm; (h) the costs of preparing, printing and delivering certificates
representing the Public Securities; (i) fees and expenses of the transfer agent for the shares of Common Stock; (j) stock transfer
and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters; (k) the fees and expenses
of the Company&rsquo;s accountants; (l) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives;
(m) fees and expenses of the Representative&rsquo;s legal counsel not to exceed $75,000; (n) the $29,500 cost associated with the
Underwriter&rsquo;s use of Ipreo&rsquo;s book-building, prospectus tracking and compliance software for the Offering; and (o) up
to $20,000 of the Underwriters&rsquo; actual accountable &ldquo;road show&rdquo; expenses for the Offering. The Representative
may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing Date, if any,
the expenses set forth herein to be paid by the Company to the Underwriters. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-accountable
Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10.1, on the Closing Date
it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable expense
allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of the Firm Shares (excluding the
Option Shares), less the Advance (as such term is defined in Section 8.3 hereof), provided, however, that in the event that the
Offering is terminated, the Company agrees to reimburse the Underwriters pursuant to Section 8.3 hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the
application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders as soon as practicable,
but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement, an
earnings statement (which need not be certified by independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities
Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stabilization</U>.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken or shall take, directly or indirectly, any action designed to or that has constituted or that would reasonably be expected
to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Public Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Internal
Controls</U>. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that:
(i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii)&nbsp;transactions
are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability
for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization;
and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
As of the date of this Agreement, the Company shall retain an independent registered public accounting firm reasonably acceptable
to the Representative, and the Company shall continue to retain a nationally or regionally recognized independent registered public
accounting firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that
the Auditor is acceptable to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA</U>.
For 180 days following the date of this Agreement, the Company shall advise the Representative (who shall make an appropriate filing
with FINRA) if it is or becomes aware that (i) any officer or director of the Company, (ii) any beneficial owner of 5% or more
of any class of the Company's securities or (iii) any beneficial owner of the Company's unregistered equity securities which were
acquired during the 180 days immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated
person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in
a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering
and the other transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">3.18</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Company
Lock-Up Agreements</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.18.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restriction
on Sales of Capital Stock</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written
consent of the Representative, it will not, for a period of 90 days after the date of this Agreement (the &ldquo;Lock-Up Period&rdquo;),
(i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital
stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company;
(ii) file or caused to be filed any registration statement with the Commission relating to the offering by the Company of any shares
of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of
the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional
bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is
to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">The
restrictions contained in this Section 3.18.1 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the
issuance by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security
outstanding on the date hereof, of which the Representative has been advised in writing or (iii) the issuance by the Company of
stock options or shares of capital stock of the Company under any equity compensation plan of the Company, provided that in each
of (ii) and (iii) above, the underlying shares shall be restricted from sale during the entire Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">Notwithstanding
the foregoing, if (i) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material news or
a material event relating to the Company occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that
it will release earnings results or becomes aware that material news or a material event will occur during the 16-day period beginning
on the last day of the Lock-Up Period, the restrictions imposed by this Section 3.18.1 shall continue to apply until the expiration
of the 18-day period beginning on the issuance of the earnings release or the occurrence of such material news or material event,
as applicable, unless the Representative waives, in writing, such extension; provided, however, that this extension of the Lock-Up
Period shall not apply to the extent that FINRA has amended or repealed NASD Rule 2711(f)(4), or has otherwise provided written
interpretive guidance regarding such rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member of
a national securities association from publishing or distributing any research report, with respect to the securities of an Emerging
Growth Company prior to or after the expiration of any agreement between the broker, dealer, or member of a national securities
association and the Emerging Growth Company or its shareholders that restricts or prohibits the sale of securities held by the
Emerging Growth Company or its shareholders after the initial public offering date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.18.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restriction
on Continuous Offerings</U>. Notwithstanding the restrictions contained in Section 3.18.1, the Company, on behalf of itself and
any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of 12 months
after the date of this Agreement, directly or indirectly in any &ldquo;at-the-market&rdquo; or continuous equity transaction, offer
to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company or any
securities convertible into or exercisable or exchangeable for shares of capital stock of the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
of D&amp;O Lock-up Period</U>. If the Representative, in its sole discretion, agrees to release or waive the restrictions set forth
in the Lock-Up Agreements described in Section 2.24 hereof for an officer or director of the Company and provide the Company with
notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver,
the Company agrees to announce the impending release or waiver by a press release substantially in the form of <U>Exhibit C</U>
hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Blue
Sky Qualifications</U>. The Company shall use its reasonable best efforts, in cooperation with the Underwriters, if necessary,
to qualify the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions
(domestic or foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to
complete the distribution of the Public Securities; provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which
it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reporting
Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception
afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities as may be required under
Rule 463 under the Securities Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Emerging
Growth Company Status</U>. The Company shall promptly notify the Representative if the Company ceases to be an Emerging Growth
Company at any time prior to the later of (i) completion of the distribution of the Public Securities within the meaning of the
Securities Act and (ii) fifteen (15) days following the completion of the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligations of the Underwriters to purchase and pay for the Public Securities, as provided
herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof
and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the
Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the
following conditions:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Regulatory
Matters</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not later than 5:00 p.m.,
Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at each
of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary
Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or,
to the Company&rsquo;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the
Commission for additional information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission
in the manner and within the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment
providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements
of Rule 430A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount
of compensation allowable or payable to the Underwriters as described in the Registration Statement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Company
Counsel Matters</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion of Wyrick Robbins
Yates &amp; Ponton, LLP, counsel to the Company, dated the Closing Date and addressed to the Representative, substantially in the
form of <U>Exhibit D</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Special Intellectual Property Counsel for the Company</U>. On the Closing Date, the Representative shall have received the opinion
of Sheridan Ross P.C., special intellectual property counsel for the Company, dated the Closing Date, addressed to the Representative
substantially in the form of Exhibit E attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Option
Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable
opinions of each counsel listed in Sections 4.2.1 and 4.2.2, dated the Option Closing Date, addressed to the Representative and
in form and substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made
by such counsels in their respective opinions delivered on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance</U>.
In rendering such opinions, such counsel may rely: (i)&nbsp;as to matters involving the application of laws other than the laws
of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of
other counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii)&nbsp;as to matters of fact,
to the extent they deem proper, on certificates or other written statements of officers of the Company and officers of departments
of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company, provided
that copies of any such statements or certificates shall be delivered to Representative Counsel if requested. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Comfort
Letters</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cold
Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements
and information of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements
and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed
to the Representative and in form and substance reasonably satisfactory to you and to the Auditor, dated as of the date of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down
Comfort Letter</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from
the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms
the statements made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date
not more than three (3) business days prior to the Closing Date or the Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Officers&rsquo;
Certificates</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing
Date (if such date is other than the Closing Date), of its Chief Executive Officer, its President and its Chief Financial Officer
stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free
Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable
Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue
statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option
Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing
Date (or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement
thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact
and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
in which they were made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which
is required to be set forth in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus,
(iii) to their knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other
than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct and the Company
has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to
the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and (iv) there has not been, subsequent
to the date of the most recent audited financial statements included or incorporated by reference in the Pricing Disclosure Package,
any material adverse change in the financial position or results of operations of the Company, or any change or development that,
singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting
the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except as set forth
in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary&rsquo;s
Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate
of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively,
certifying: (i)&nbsp;that each of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect;
(ii)&nbsp;that the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full force and effect
and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel
and the Commission; and (iv)&nbsp;as to the incumbency of the officers of the Company. The documents referred to in such certificate
shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Changes</U>. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i)&nbsp;there shall have
been no material adverse change or development involving a prospective material adverse change in the condition or prospects or
the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in
the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;no action, suit or proceeding, at law
or in equity, shall have been pending or threatened against the Company or any Insider before or by any court or federal or state
commission, board or other administrative agency wherein an unfavorable decision, ruling or finding would reasonably be expected
to cause a materially adversely affect the business, operations, prospects or financial condition or income of the Company, except
as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iii)&nbsp;no stop order shall have
been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; and
(iv)&nbsp;the Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendments or supplements thereto
shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations,
and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto
shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">4.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Delivery
of Agreements</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-Up
Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies
of the Lock-Up Agreements from each of the persons and entities listed in <U>Schedule 3</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter&rsquo;s
Warrant Agreement</U>. On the Closing Date, the Company shall have delivered to the Representative executed copies of the Underwriter&rsquo;s
Warrant Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Documents</U>. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall have been furnished with
such documents and opinions as they may require for the purpose of enabling Representative Counsel to deliver an opinion to the
Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the
conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities
and the Underwriter&rsquo;s Securities as herein contemplated shall be satisfactory in form and substance to the Representative
and Representative Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Indemnification</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Indemnification
of the Underwriters</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and
each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates,
counsel, and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act (collectively the &ldquo;Underwriter Indemnified Parties,&rdquo; and each an &ldquo;Underwriter
Indemnified Party&rdquo;), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited
to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced
or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and
the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them
may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws
of foreign countries (a &ldquo;Claim&rdquo;), (i) arising out of or based upon any untrue statement or alleged untrue statement
of a material fact contained in (A) the Registration Statement, the Pricing Disclosure Package, any Preliminary Prospectus, the
Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters Communication (as from time to time each
may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the Company
in connection with the marketing of the Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors
by the Company (whether in person or electronically); or (C) any application or other document or written communication (in this
Section 5, collectively called &ldquo;application&rdquo;) executed by the Company or based upon written information furnished by
the Company in any jurisdiction in order to qualify the Public Securities and Underwriter&rsquo;s Securities under the securities
laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities
exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission
was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information or (ii)&nbsp;otherwise arising in connection
with or allegedly in connection with the Offering. The Company also agrees that it will reimburse each Underwriter Indemnified
Party for all fees and expenses (including but not limited to any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action
between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any
third party, or otherwise) (collectively, the &ldquo;Expenses&rdquo;), and further agrees wherever and whenever possible to advance
payment of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending
any Claim. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>.</FONT>
<FONT STYLE="font-weight: normal">If any action is brought against an Underwriter Indemnified Party in respect of which indemnity
may be sought against the Company pursuant to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company
in writing of the institution of such action and the Company shall assume the defense of such action, including the employment
and reasonable fees of counsel (subject to the reasonable approval of such Underwriter Indemnified Party) and payment of actual
and reasonable expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter Indemnified Party
shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at
the expense of the Company, and shall be advanced by the Company. The Company shall not be liable for any settlement of any action
effected without its consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior
written consent of the Underwriters, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate
any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought
hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement, compromise, consent or
termination (i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified
Party, from all liabilities, expenses and claims arising out of such action for which indemnification or contribution may be sought
and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any Underwriter
Indemnified Party.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of the Company</U>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement, its employees, representatives and agents and each person who controls the
Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability,
claim, damage and expense described in the foregoing indemnity from the Company to the several Underwriters, as incurred, but only
with respect to untrue or alleged untrue statements or omissions or alleged omissions made in the Registration Statement, any Preliminary
Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application, in reliance
upon, and in strict conformity with, the Underwriters&rsquo; Information. In case any action shall be brought against the Company
or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package
or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against
any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other person
so indemnified shall have the rights and duties given to the Underwriter Indemnified Parties by the provisions of Section 5.1.2.
The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against the Company
or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Public Securities or in connection with
the Registration Statement, the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus or any Written
Testing-the-Waters Communication.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Contribution</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold
harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect
thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to
the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect
thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand,
and the Underwriters, on the other, from the Offering of the Public Securities, or (ii) if the allocation provided by clause (i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred
to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect
to the statements or omissions that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as
any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds from the Offering
of the Public Securities purchased under this Agreement (before deducting expenses) received by the Company, as set forth in the
table on the cover page of the Prospectus, on the one hand, and the total underwriting discounts and commissions received by the
Underwriters with respect to the shares of the Common Stock purchased under this Agreement, as set forth in the table on the cover
page of the Prospectus or as otherwise disclosed in the Prospectus, on the other hand. The relative fault shall be determined by
reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material
fact relates to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge,
access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree
that it would not be just and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation
(even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take
into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of
the loss, claim, damage or liability, or action in respect thereof, referred to above in this Section 5.3.1 shall be deemed to
include, for purposes of this Section 5.3.1, any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 5.3.1 in no event shall
an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions
received by such Underwriter with respect to the Offering of the Public Securities exceeds the amount of any damages that such
Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another
party (&ldquo;contributing party&rdquo;), notify the contributing party of the commencement thereof, but the failure to so notify
the contributing party will not relieve it from any liability which it may have to any other party other than for contribution
hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party
or its representative of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate
therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be
liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party
seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution
without the written consent of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended
to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise
available. Each Underwriter&rsquo;s obligations to contribute pursuant to this Section 5.3 are several and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Default by an Underwriter</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
Not Exceeding 10% of Firm Shares or Option Shares</U>. If any Underwriter or Underwriters shall default in its or their obligations
to purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised hereunder, and if the number of the
Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm
Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which
the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Default
Exceeding 10% of Firm Shares or Option Shares</U>. In the event that the default addressed in Section 6.1 relates to more than
10% of the Firm Shares or Option Shares, you may in your discretion arrange for yourself or for another party or parties to purchase
such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one (1) Business Day
after such default relating to more than 10% of the Firm Shares or Option Shares, you do not arrange for the purchase of such Firm
Shares or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure
another party or parties satisfactory to you to purchase said Firm Shares or Option Shares on such terms. In the event that neither
you nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this
Section 6, this Agreement will automatically be terminated by you or the Company without liability on the part of the Company (except
as provided in Sections 3.9 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however,
that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided,
further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to
the Company for damages occasioned by its default hereunder.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Postponement
of Closing Date</U>. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the
non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the
right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business
Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package
or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration
Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made
necessary. The term &ldquo;Underwriter&rdquo; as used in this Agreement shall include any party substituted under this Section
6 with like effect as if it had originally been a party to this Agreement with respect to such shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Additional Covenants</U>.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
Composition and Board Designations</U>. The Company shall use reasonable best efforts to ensure that: (i)&nbsp;the qualifications
of the persons serving as members of the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley
Act, with the Exchange Act and with the listing rules of the Exchange or any other national securities exchange, as the case may
be, in the event the Company seeks to have its Public Securities listed on another exchange or quoted on an automated quotation
system, and (ii)&nbsp;if applicable, at least one member of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit
committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of the Exchange.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prohibition
on Press Releases and Public Announcements</U>. The Company shall not issue press releases or engage in any other publicity, without
the Representative&rsquo;s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1<SUP>st</SUP>)
Business Day following the forty-fifth (45<SUP>th</SUP>) day after the Closing Date, other than normal and customary releases issued
in the ordinary course of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
of First Refusal</U>. Until August 6, 2017, the Representative shall have
an irrevocable right of first refusal (the &ldquo;Right of First Refusal&rdquo;) to act as sole and exclusive investment banker, sole and exclusive book-runner, sole and exclusive financial advisor,
sole and exclusive underwriter and/or sole and exclusive placement agent, at the Representative&rsquo;s sole and exclusive discretion,
for each and every future public and private equity and debt offering, including all equity linked financings (each, a &ldquo;Subject
Transaction&rdquo;), during such period, of the Company, or any successor to or subsidiary of the Company, on
terms and conditions customary to the Representative for such Subject Transactions. For the avoidance of any doubt, subject to
the terms hereto, during such period, the Company shall not retain, engage or solicit any additional investment
banker, book-runner, financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written
consent of the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For a period of twelve
(12) months after the Closing Date, the Company shall notify the Representative of its intention to pursue a Subject Transaction,
including the material terms thereof, by providing written notice thereof by registered mail or overnight courier service addressed
to the Representative.&nbsp; If the Representative fails to exercise its Right of First Refusal with respect to any Subject Transaction
within ten (10) Business Days after the mailing of such written notice, then the Representative shall have no further claim or
right with respect to the Subject Transaction. The Representative may elect, in its sole and absolute discretion, not to exercise
its Right of First Refusal with respect to any Subject Transaction; provided that any such election by the Representative shall
not adversely affect the Representative&rsquo;s Right of First Refusal with respect to any other Subject Transaction during the
twelve (12) month period agreed to above. If the Representative exercises its Right of First Refusal under this Section, it shall
diligently pursue the consummation of the Subject Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Effective Date of this Agreement and Termination Thereof</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date</U>. This Agreement shall become effective when both the Company and the Representative have executed the same and delivered
counterparts of such signatures to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i)&nbsp;if any domestic
or international event or act or occurrence has materially disrupted, or in your reasonable opinion will in the immediate future
materially disrupt, general securities markets in the United States; or (ii)&nbsp;if trading on the New York Stock Exchange or
the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have
been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any
other government authority having jurisdiction; or (iii)&nbsp;if the United States shall have become involved in a new war or an
increase in major hostilities which, in the Representative&rsquo;s reasonable judgment, makes it impractical to proceed with the
Offering; or (iv)&nbsp;if a banking moratorium has been declared by a New York State or federal authority; or (v)&nbsp;if a moratorium
on foreign exchange trading has been declared which materially adversely impacts the United States securities markets; or (vi)&nbsp;if
the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity
or malicious act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed
with the delivery of the Firm Shares or Option Shares; or (vii)&nbsp;if the Company is in material breach of any of its representations,
warranties or covenants hereunder that has a material adverse effect on the Company&rsquo;s business; or (viii)&nbsp;if the Representative
shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the Company,
or such adverse material change in general market conditions as in the Representative&rsquo;s judgment would make it impracticable
to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriters for
the sale of the Public Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section
6.2 above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein
or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual
and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable (including the fees
and disbursements of Representative Counsel) up to $100,000 inclusive of the $50,000 advance for non-accountable expenses previously
paid by the Company to the Representative (the &ldquo;Advance&rdquo;) and upon demand the Company shall pay the full amount thereof
to the Representative on behalf of the Underwriters; provided, however, that such expense cap in no way limits or impairs the indemnification
and contribution provisions of this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be
reimbursed to the Company to the extent not actually incurred in compliance with FINRA Rule 5110(f)(2)(C).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement,
and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and
shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part
hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations,
Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates
of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i)&nbsp;any
investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii)&nbsp;delivery of and payment for the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered
or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be
deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Joseph Gunnar &amp; Co., LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">30 Broad Street, 11th Fl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, NY 10004<BR>
Attn: Mr. Eric Lord, Head of Investment Banking/Underwritings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No.: (646) 461-2729</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Sichenzia Ross Friedman Ference LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">61 Broadway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, New York 10006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attn: Gregory Sichenzia, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Fax No.: (212) 930-9725</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Aytu Bioscience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">373 Inverness Parkway, Suite 206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Englewood, Colorado 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Joshua R. Disbrow, Chief Executive
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Wyrick Robbins Yates &amp; Ponton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4101 Lake Boone Trail, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Raleigh, North Carolina 27607</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Alexander M. Donaldson, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (919) 781-4865</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with
this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms
and conditions of that certain engagement letter between the Company and Joseph Gunnar &amp; Co., LLC., dated December 23, 2015,
and the addendum thereto, dated as of September 6, 2016 shall remain in full force and effect.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding
Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters,
the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors,
legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors
and assigns&rdquo; shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance with
the laws of the State of New York, without giving effect to conflict of laws principles thereof. Each of the Company and the Underwriters
hereby agree that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be
brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern
District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the Company
and the Underwriters hereby waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.
Any such process or summons to be served upon the Company or the Underwriters may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The
parties hereto agree that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all
of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders
and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any
and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution
in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same
agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission
shall constitute valid and sufficient delivery thereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver,
etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed
or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof
or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach,
non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance
or non-fulfillment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space
provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">AYTU BIOSCIENCE, INC. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Joshua R. Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Confirmed as of the date first written above mentioned, on behalf
of itself and as Representative of the several Underwriters named on <U>Schedule 1</U> hereto:</P>
</TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">JOSEPH GUNNAR &amp; CO., LLC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Eric Lord</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Head of Investment Banking/Underwritings</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">[ISSUER] &ndash; <FONT STYLE="font-variant: small-caps">Underwriting
Agreement</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; font-style: normal"><FONT STYLE="font-size: 10pt">Underwriter</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Total</B><BR>
                           <B>Number of</B><BR>
                           </FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Firm Shares</B></FONT></P></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">Total <BR>
    Number of <BR>
    Firm <BR>
    Warrants</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">Total <BR>
    Number of <BR>
    Option <BR>
    Shares</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">Total <BR>
    Number of <BR>
    Option <BR>
    Warrants</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; font-style: normal"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: normal; font-style: normal; text-align: left"><FONT STYLE="font-size: 10pt">Joseph Gunnar
    &amp; Co., LLC.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"><FONT STYLE="font-size: 10pt">Fordham Financial Management
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">Feltl and Company</TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 12pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt"><B>TOTAL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 0.5pt; text-align: left; border-bottom: Black 2.5pt double"></TD><TD STYLE="font-size: 0.5pt; text-align: right; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 0.5pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 0.5pt; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 0.5pt; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 0.5pt; text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 0.5pt; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-1</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2-A</U></B><U STYLE="text-decoration: none"><BR>
<BR>
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Firm Shares: [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Firm Warrants [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Option Shares: [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Option Warrants [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Purchase Price per Option Warrant [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Purchase Price per Option Share [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Public Offering Price per Firm Security [&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Discount per Firm Security: $[&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Non-accountable expense allowance per Firm Security:
$[&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Proceeds to Company per Firm Security (before expenses): $[&bull;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">[None.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2-C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Written Testing-the-Waters Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">[None.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-1</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-indent: -8.8pt"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; padding-top: 0.7pt; padding-bottom: 0.7pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-top: 0.7pt; padding-bottom: 0.7pt">&nbsp;</TD>
    <TD STYLE="width: 66%; border-bottom: black 1pt solid; padding-top: 0.7pt; padding-bottom: 0.7pt"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt"><FONT STYLE="font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt"><FONT STYLE="font-size: 10pt">Jarrett T. Disbrow</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Operating Officer and Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt"><FONT STYLE="font-size: 10pt">Gregory A. Gould</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer, Secretary, and Treasurer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt"><FONT STYLE="font-size: 10pt">Jonathan H. McGrael</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Vice President of Sales</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt"><FONT STYLE="font-size: 10pt">Michael Macaluso</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt">Carl
    C. Dockery</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt">John
    A. Donofrio, Jr.</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt">Gary
    V. Cantrell</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-bottom: 0.7pt; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt">Alpha
    Venture Capital Partners, L.P.</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-bottom: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">5%+ Beneficial owner</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-1</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Underwriter&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2pt">THE REGISTERED HOLDER OF
THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS
HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE
THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN
(I)&nbsp; AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF ANY SUCH
UNDERWRITER OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2pt">THIS PURCHASE WARRANT IS
NOT EXERCISABLE PRIOR TO [________________] [<B>DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE OFFERING</B>]. VOID AFTER
5:00 P.M., EASTERN TIME, [___________________] [<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Purchase of [_____] Shares of Common
Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AYTU BIOSCIENCE, INC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase Warrant</U>. THIS CERTIFIES
THAT, in consideration of funds duly paid by or on behalf of _________ (&ldquo;<B>Holder</B>&rdquo;), as registered owner of this
Purchase Warrant, to Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), Holder is entitled, at any
time or from time to time from [________________] [<B>DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE OFFERING</B>] (the &ldquo;<B>Commencement
Date</B>&rdquo;), and at or before 5:00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p.m., Eastern time, [____________] [<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE
OF THE OFFERING</B>] (the&nbsp;&rdquo;<B>Expiration&nbsp;Date</B>&rdquo;), but not thereafter, to subscribe for, purchase and receive,
in whole or in part, up to [____] shares of common stock of the Company, par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;),
subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized
by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with
the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate
this Purchase Warrant. This Purchase Warrant is initially exercisable at $[___] per Share [<B>125% of the price of the Shares sold
in the Offering</B>]; <U>provided</U>, <U>however</U>, that upon the occurrence of any of the events specified in Section 6 hereof,
the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon
such exercise, shall be adjusted as therein specified. The term &ldquo;<B>Exercise Price</B>&rdquo; shall mean the initial exercise
price or the adjusted exercise price, depending on the context.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise Form</U>.
In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and delivered
to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased payable in
cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official
bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration
Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease
and expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless Exercise</U>.&nbsp;
If at any time after the Commencement Date there is no effective registration statement registering, or no current prospectus available
for, the resale of the Shares by the Holder, then in lieu of exercising this Purchase Warrant by payment of cash or check payable
to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares equal to the value
of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together
with the exercise form attached hereto, in which event the issue to Holder, Shares in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: left"><FONT STYLE="font-size: 10pt"><U>Y(A-B)</U></FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="5" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;A</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Where,</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The number of Shares to be issued to Holder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Y</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The number of Shares for which the Purchase Warrant is being exercised;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The fair market value of one Share; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The Exercise Price.</FONT></TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 76%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this Section
2.2, the fair market value of a Share is defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.1pt; text-align: justify; text-indent: -23.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">if the Company&rsquo;s common stock is traded on a securities exchange, the value shall be deemed
to be the closing price on such exchange prior to the exercise form being submitted in connection with the exercise of the Purchase
Warrant; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.15pt; text-align: justify; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">if the Company&rsquo;s common stock is actively traded over-the-counter, the value shall be deemed
to be the closing bid prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; if there
is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Company&rsquo;s
Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legend</U>.
Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;The securities represented
by this certificate have not been registered under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), or applicable
state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant
to an effective registration statement under the Securities Act, or pursuant to an exemption from registration under the Securities
Act and applicable state law which, in the opinion of counsel to the Company, is available.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">3.</TD><TD STYLE="text-align: justify"><U>Transfer</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General Restrictions</U>.
The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell,
transfer, assign, pledge or hypothecate this Purchase Warrant following the Effective
Date to anyone other than: (i) an underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or
partner of any such underwriter or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b)&nbsp;cause
this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call
transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except
as provided for in FINRA Rule 5110(g)(2). After the Effective Date, transfers to others may be made subject
to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver
to the Company the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment
of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business Days transfer this Purchase
Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to
the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or
such portion of such number as shall be contemplated by any such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions
Imposed by the Securities Act</U>. The securities evidenced by this Purchase Warrant shall not be transferred unless and until:
(i) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption
from registration under the Securities Act and applicable state securities laws, the availability of which is established to the
reasonable satisfaction of the Company (the Company hereby agreeing that the opinion of Sichenzia Ross Friedman Ference LLP shall
be deemed satisfactory evidence of the availability of an exemption), or (ii) a registration statement or a post-effective amendment
to the Registration Statement relating to the offer and sale of such securities has been filed by the Company and declared effective
by the U.S. Securities and Exchange Commission (the&nbsp;&rdquo;<B>Commission</B>&rdquo;) and compliance with applicable state
securities law has been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">4.</TD><TD STYLE="text-align: justify"><U>Registration Rights</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Demand Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Right</U>. The Company, upon written demand (a &ldquo;<B>Demand Notice</B>&rdquo;) of the Holder(s) of at least 51% of the
Purchase Warrants and/or the underlying Shares (&ldquo;Majority Holders&rdquo;), agrees to register, on one occasion, all or any
portion of the Shares underlying the Purchase Warrants (collectively, the &ldquo;<B>Registrable Securities</B>&rdquo;). On such
occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within sixty
(60) days after receipt of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective
promptly thereafter, subject to compliance with review by the Commission; <U>provided</U>, <U>however</U>, that the Company shall
not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder
is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to participate
in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary
offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty
(30) days after such offering is consummated. The demand for registration may be made at any time during a period of four (4)
years beginning on the Commencement Date. The Company covenants and agrees to give written notice of its receipt of any Demand
Notice by any Holder(s) to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten
(10) days after the date of the receipt of any such Demand Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms</U>. The
Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts
to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such
States as are reasonably requested by the Holder(s); <U>provided</U>, <U>however</U>, that in no event shall the Company be required
to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register
or license to do business in such State or submit to general service of process in such State, or (ii) the principal shareholders
of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration
statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective for a period of at least twelve (12)
consecutive months after the date that the Holders of the Registrable Securities covered by such registration statement are first
given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell
the shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if
the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding
the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section 4.1.2 on only one
(1) occasion and such demand registration right shall terminate on the fifth anniversary of the effectiveness of the registration
statement in accordance with FINRA Rule 5110(f)(2)(G)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left">4.2</TD><TD STYLE="text-align: justify"><U>&ldquo;Piggy-Back&rdquo; Registration</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant of Right</U>.
In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right, for a period
of no more than two (2) years from the date of effectiveness of the registration statement in accordance with FINRA Rule 5110(f)(2)(G)(v),
to include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection
with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form);
<U>provided</U>, <U>however</U>, that if, solely in connection with any primary underwritten public offering for the account of
the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares
of Common Stock which may be included in the Registration Statement because, in such underwriter(s)&rsquo; judgment, marketing
or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to
include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder
requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made
pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought
to be included by such Holders; <U>provided</U>, <U>however</U>, that the Company shall not exclude any Registrable Securities
unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities
in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms</U>. The
Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to
the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company during the two (2) year period following the Commencement Date until such time as all of the Registrable
Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the &ldquo;piggy-back&rdquo;
rights provided for herein by giving written notice within ten (10) days of the receipt of the Company&rsquo;s notice of its intention
to file a registration statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number
of times the Holder may request registration under this Section 4.2.2; <U>provided</U>, <U>however</U>, that such registration
rights shall terminate on the [sixth] anniversary of the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt; text-align: left">4.3</TD><TD STYLE="text-align: justify"><U>General Terms</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of
the Securities Exchange Act of 1934, as amended (&ldquo;<B>Exchange Act</B>&rdquo;), against all loss, claim, damage, expense or
liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating, preparing or
defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise,
arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which
the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement between the Underwriters
and the Company, dated as of [___________], 2016. The Holder(s) of the Registrable Securities to be sold pursuant to such registration
statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim,
damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act
or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for
specific inclusion in such registration statement to the same extent and with the same effect as the provisions contained in Section
5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise of
Purchase Warrants</U>. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise their
Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents Delivered
to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter
of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the
Company, dated the effective date of such registration statement (and, if such registration includes an underwritten public offering,
an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold comfort&rdquo;
letter dated the effective date of such registration statement (and, if such registration includes an underwritten public offering,
a letter dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting
firm which has issued a report on the Company&rsquo;s financial statements included in such registration statement, in each case
covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and,
in the case of such accountants&rsquo; letter, with respect to events subsequent to the date of such financial statements, as are
customarily covered in opinions of issuer&rsquo;s counsel and in accountants&rsquo; letters delivered to underwriters in underwritten
public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering requesting
the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between
the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or its staff
with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance
notice, with respect to information contained in or omitted from the registration statement as it deems reasonably necessary to
comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties
and opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent
and at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting
Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any
Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder
and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other
terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties to
any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that
any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also be
made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or
agreements with the Company or the underwriters except as they may relate to such Holders, their Shares and their intended methods
of distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents to
be Delivered by Holder(s)</U>. Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Damages</U>.
Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to
the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened
breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the
necessity of posting bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New Purchase Warrants to be Issued</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial Exercise
or Transfer</U>. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or
in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax
if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase
Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number
of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost Certificate</U>.
Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant
and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant
of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction
shall constitute a substitute contractual obligation on the part of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">6.</TD><TD STYLE="text-align: justify"><U>Adjustments</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments to
Exercise Price and Number of Securities</U>. The Exercise Price and the number of Shares underlying the Purchase Warrant shall
be subject to adjustment from time to time as hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Share Dividends;
Split Ups</U>. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares
is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective day
thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares, and
the Exercise Price shall be proportionately decreased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Aggregation
of Shares</U>. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares
is decreased by a reverse stock split, consolidation, combination or reclassification of Shares or other similar event, then, on
the effective date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding
Shares, and the Exercise Price shall be proportionately increased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities upon Reorganization, etc</U>. In case of any reclassification or reorganization of the outstanding Shares other than
a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such Shares, or in the case of any share
reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or
share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in any reclassification
or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the
property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder
of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant)
to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the
kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization,
share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder
of the number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if
any reclassification also results in a change in Shares covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant
to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications,
reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in Form
of Purchase Warrant</U>. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1,
and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in
the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase
Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the
Commencement Date or the computation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Substitute Purchase
Warrant</U>. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into,
another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification
or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall
execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding
or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise
of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation
or share reconstruction or amalgamation, by a holder of the number of Shares of the Company for which such Purchase Warrant might
have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental
Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The
above provision of this Section shall similarly apply to successive consolidations or share reconstructions or amalgamations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Elimination of Fractional Interests</U>.
The Company shall not be required to issue certificates representing fractions of Shares upon the exercise of the Purchase Warrant,
nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that
all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number
of Shares or other securities, properties or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation and Listing</U>. The
Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise
of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise
thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise Price therefor,
in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued,
fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company further covenants and agrees
that upon exercise of the Purchase Warrants and payment of the exercise price therefor, all Shares and other securities issuable
upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any
shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use its commercially reasonable efforts to
cause all Shares issuable upon exercise of the Purchase Warrants to be listed (subject to official notice of issuance) on all national
securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market) on which the Shares issued
to the public in the Offering may then be listed and/or quoted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">8.</TD><TD STYLE="text-align: justify"><U>Certain Notice Requirements</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Right to Receive Notice</U>. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to
receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events
described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event
at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books for the determination
of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of
the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder
a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is
given to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events Requiring
Notice</U>. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events:
(i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or
distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer
to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable
for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution, liquidation
or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale
of all or substantially all of its property, assets and business shall be proposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Change
in Exercise Price</U>. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section
6 hereof, send notice to the Holders of such event and change (&ldquo;<B>Price Notice</B>&rdquo;). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company&rsquo;s
Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transmittal
of Notices</U>. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall
be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company,
to following address or to such other address as the Company may designate by notice to the Holders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">If to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><BR>
Sichenzia Ross Friedman Ference LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">61 Broadway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, New York 10006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attn: Gregory Sichenzia, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Fax No.: (212) 930-9725</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Aytu Bioscience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">373 Inverness Parkway, Suite 206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Englewood, Colorado 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Joshua R. Disbrow, Chief Executive
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Wyrick Robbins Yates &amp; Ponton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4101 Lake Boone Trail, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Raleigh, North Carolina 27607</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Alexander M. Donaldson, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (919) 7841-4865</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">9.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>.
The Company and Joseph Gunnar, as Representative of the Underwriters (the &ldquo;Representative&rdquo;), may from time to time
supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity, to correct
or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make
any other provisions in regard to matters or questions arising hereunder that the Company and the Representative may deem necessary
or desirable and that the Company and the Representative deem shall not adversely affect the interest of the Holders. All other
modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification
or amendment is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>.
This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this
Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding Effect</U>.
This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted
assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any
legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein
contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law;
Submission to Jurisdiction; Trial by Jury</U>. This Purchase Warrant shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. Each of the Company and the
Holder hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant
shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the
Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the
Company and the holder hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company or the Holder may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company and the Holder in any action, proceeding
or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from
the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred
in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf
of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver, etc</U>.
The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision
hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver
of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and
no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent
breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution in
Counterparts</U>. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same
agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Agreement</U>.
As a condition of the Holder&rsquo;s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to
the complete exercise of this Purchase Warrant by Holder, if the Company and the Representative enter into an agreement (&ldquo;<B>Exchange
Agreement</B>&rdquo;) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash
or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[<I>Signature Page Follows</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Purchase Warrant to be signed by its duly authorized officer as of the ____ day of _______, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">AYTU BIOSCIENCE, INC. </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Form to be used to exercise Purchase
Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: __________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of common stock, par value $0.0001 per share (the
&ldquo;<B>Shares</B>&rdquo;), of Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and hereby makes
payment of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as
to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase
Warrant representing the number of Shares for which this Purchase Warrant has not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______ Shares,
as determined in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; margin-left: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Y(A-B)</FONT></TD>
    <TD STYLE="width: 69%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Where,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The number of Shares to be issued to Holder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Y</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The number of Shares for which the Purchase Warrant is being exercised;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The fair market value of one Share which is equal to $_____; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-decoration: none; text-align: right"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">The Exercise Price which is equal to $______ per share</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with
respect to the calculation shall be resolved by the Company in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please issue
the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" NOWRAP STYLE="text-align: justify">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature Guaranteed</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 46%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INSTRUCTIONS FOR REGISTRATION OF SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 41%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 51%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Print in Block Letters)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOTICE: The signature
to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or
any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Form to be used to assign Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(To be executed by the registered Holder
to effect a transfer of the within Purchase Warrant):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, __________________
does hereby sell, assign and transfer unto the right to purchase shares of common stock, par value $0.0001 per share, of Aytu BioScience,
Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), evidenced by the Purchase Warrant and does hereby authorize the
Company to transfer such right on the books of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: __________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" NOWRAP STYLE="text-align: justify">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature Guaranteed</FONT></TD>
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 2%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 46%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;NOTICE: The signature to this
form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or
any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having
membership on a registered national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">September [&bull;],
2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joseph Gunnar &amp; Co., LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representatives of the several underwriters, named on Schedule
1 to the Underwriting Agreement referenced below<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Joseph Gunnar &amp; Co., LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">810 Seventh Avenue, 18<SUP>th</SUP> Floor<BR>
New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that Joseph Gunnar &amp; Co., LLC (the &ldquo;<B>Representative</B>&rdquo;) proposes to enter into an Underwriting Agreement (the
&ldquo;<B>Underwriting Agreement</B>&rdquo;) with Aytu BioScience, Inc, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
providing for the public offering (the &ldquo;<B>Public Offering</B>&rdquo;) of shares of common stock, par value $0.0001 per share
(the &ldquo;Common Stock&rdquo;) and warrants to purchase share of common stock of the Company (the &ldquo;<B>Securities</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To induce the
Representative to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without
the prior written consent of the Representative, the undersigned will not, during the period commencing on the date hereof
and ending [__] days after the date of the final prospectus (the &ldquo;<B>Prospectus</B>&rdquo;) relating to the Public
Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise
transfer or dispose of, directly or indirectly, any Common Stock or any securities convertible into or exercisable or
exchangeable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the
undersigned has or hereafter acquires the power of disposition (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;);
(2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by
delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to the
registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or
disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up
Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up
Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up
Securities acquired in open market transactions after the completion of the Public Offering;<I> </I><U>provided</U> that no
filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;),
shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in such
open market transactions; (b) transfers of Lock-Up Securities as a <I>bona fide</I> gift, by will or intestacy or to a family
member or trust for the benefit of a family member (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means
any relationship by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a
charity or educational institution; or (d) if the undersigned, directly or indirectly, controls a corporation, partnership,
limited liability company or other business entity, any transfers of Lock-Up Securities to any shareholder, partner or member
of, or owner of similar equity interests in, the undersigned, as the case may be; <U>provided</U> that in the case of any
transfer pursuant to the foregoing clauses&nbsp;(b), (c) or (d), (i) any such transfer shall not involve a disposition for
value, (ii) each transferee shall sign and deliver to the Representative a lock-up agreement substantially in the form of
this lock-up agreement and (iii) no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be
voluntarily made. The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&rsquo;s transfer agent and registrar against the transfer of the undersigned&rsquo;s Lock-Up Securities except in
compliance with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If (i) during the last
17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company
occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results or becomes
aware that material news or a material event will occur during the 16-day period beginning on the last day of the Lock-Up Period,
the restrictions imposed by this lock-up agreement shall continue to apply until the expiration of the 18-day period beginning
on the issuance of the earnings release or the occurrence of such material news or material event, as applicable, unless the Representative
waives, in writing, such extension; provided, however, that this extension of the Lock-Up Period shall not apply to the extent
that FINRA has amended or repealed NASD Rule 2711(f)(4), or has otherwise provided written interpretive guidance regarding such
rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member of a national securities association from
publishing or distributing any research report, with respect to the securities of an Emerging Growth Company prior to or after
the expiration of any agreement between the broker, dealer, or member of a national securities association and the Emerging Growth
Company or its shareholders that restricts or prohibits the sale of securities held by the Emerging Growth Company or its shareholders
after the initial public offering date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned agrees
that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement during
the period from the date hereof to [and including the 34<SUP>th</SUP> day] following the expiration of the initial Lock-Up Period,
the undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such action unless
it has received written confirmation from the Company that the Lock-Up Period (as may have been extended pursuant to the previous
paragraph) has expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the undersigned
is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable
to any issuer-directed or &ldquo;friends and family&rdquo; Securities that the undersigned may purchase in the Public Offering,
(ii) the Representative agrees that, at least three (3) business days before the effective date of any release or waiver of the
foregoing restrictions in connection with a transfer of Lock-Up Securities, the Representative will notify the Company of the impending
release or waiver, and (iii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by
press release through a major news service at least two (2) business days before the effective date of the release or waiver. Any
release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2) business
days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver
is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing
to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms remain in
effect at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No provision in this
agreement shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable
or exchangeable for or convertible into Common Stock, as applicable; <U>provided</U> that the undersigned does not transfer the
Common Stock acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant to
the terms of this lock-up agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into or
modification of a so-called &ldquo;10b5-1&rdquo; plan at any time (other than the entry into or modification of such a plan in
such a manner as to cause the sale of any Lock-Up Securities within the Lock-Up Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public
Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned&rsquo;s
heirs, legal representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
understands that, if the Underwriting Agreement is not executed by [November 30, 2016], or if the Underwriting Agreement
(other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and
delivery of the Securities to be sold thereunder, then this lock-up agreement shall be void and of no further force or
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not the
Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made
pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Name - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Signature)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Name of Signatory, in the case of entities - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Title of Signatory, in the case of entities - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 9%; text-decoration: none; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="width: 45%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[COMPANY]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[COMPANY] (the &ldquo;Company&rdquo;) announced
today that Joseph Gunnar &amp; Co., LLC, acting as representative for the underwriters in the Company&rsquo;s recent public offering
of _______ shares of the Company&rsquo;s common stock, is [waiving] [releasing] a lock-up restriction with respect to _________
shares of the Company&rsquo;s common stock held by [certain officers or directors] [an officer or director] of the Company. The
[waiver] [release] will take effect on _________, 20___, and the shares may be sold on or after such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release is not an offer or sale
of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities
may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act
of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 57; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">Ex. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>EXHIBIT D</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 58; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">Ex. D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>3
<FILENAME>v450214_ex4-6.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 4.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Underwriter&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2pt">THE REGISTERED HOLDER OF
THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS
HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE
THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN
(I)&nbsp; AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF ANY SUCH
UNDERWRITER OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2pt">THIS PURCHASE WARRANT IS
NOT EXERCISABLE PRIOR TO [________________] [<B>DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE OFFERING</B>]. VOID AFTER
5:00 P.M., EASTERN TIME, [___________________] [<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the Purchase of [_____] Shares of Common
Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">AYTU BIOSCIENCE, INC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
Warrant</U>. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of _________ (&ldquo;<B>Holder</B>&rdquo;),
as registered owner of this Purchase Warrant, to Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
Holder is entitled, at any time or from time to time from [________________] [<B>DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE
OF THE OFFERING</B>] (the &ldquo;<B>Commencement Date</B>&rdquo;), and at or before 5:00&#9;p.m., Eastern time, [____________]
[<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>] (the&nbsp;&rdquo;<B>Expiration&nbsp;Date</B>&rdquo;),
but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [____] shares of common stock of the Company,
par value $0.0001 per share (the &ldquo;<B>Shares</B>&rdquo;), subject to adjustment as provided in Section 6 hereof. If the Expiration
Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the
next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date,
the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable
at $[___] per Share [<B>125% of the price of the Shares sold in the Offering</B>]; <U>provided</U>, <U>however</U>, that upon the
occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise
price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term &ldquo;<B>Exercise
Price</B>&rdquo; shall mean the initial exercise price or the adjusted exercise price, depending on the context.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify"><U>Exercise</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Form</U>. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and
delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased
payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or
official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time,
on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented
hereby shall cease and expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>.&nbsp; If at any time after the Commencement Date there is no effective registration statement registering, or no
current prospectus available for, the resale of the Shares by the Holder, then in lieu of exercising this Purchase Warrant by payment
of cash or check payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares
equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to
the Company, together with the exercise form attached hereto, in which event the issue to Holder, Shares in accordance with the
following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="vertical-align: top; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><U>Y(A-B)</U></FONT></TD>
    <TD STYLE="width: 77%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Where,</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The number of Shares to be issued to Holder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Y</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The number of Shares for which the Purchase Warrant is being exercised;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The fair market value of one Share; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The Exercise Price.</FONT></TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this Section
2.2, the fair market value of a Share is defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.1pt; text-align: justify; text-indent: -23.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">if the Company&rsquo;s common stock is traded on a securities
exchange, the value shall be deemed to be the closing price on such exchange prior to the exercise form being submitted in connection
with the exercise of the Purchase Warrant; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.15pt; text-align: justify; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">if the Company&rsquo;s common stock is actively traded
over-the-counter, the value shall be deemed to be the closing bid prior to the exercise form being submitted in connection with
the exercise of the Purchase Warrant; if there is no active public market, the value shall be the fair market value thereof, as
determined in good faith by the Company&rsquo;s Board of Directors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legend</U>.
Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;The securities represented
by this certificate have not been registered under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), or applicable
state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant
to an effective registration statement under the Securities Act, or pursuant to an exemption from registration under the Securities
Act and applicable state law which, in the opinion of counsel to the Company, is available.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify"><U>Transfer</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Restrictions</U>. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder
will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant following the Effective Date to anyone other than: (i) an underwriter or a selected dealer participating in the Offering, or (ii)
a bona fide officer or partner of any such underwriter or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1),
or (b)&nbsp;cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder,
except as provided for in FINRA Rule 5110(g)(2). After the Effective Date, transfers to others may be made
subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder
must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Purchase Warrant
and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business Days transfer
this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of
like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable
hereunder or such portion of such number as shall be contemplated by any such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions
Imposed by the Securities Act</U>. The securities evidenced by this Purchase Warrant shall not be transferred unless and until:
(i) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption
from registration under the Securities Act and applicable state securities laws, the availability of which is established to the
reasonable satisfaction of the Company (the Company hereby agreeing that the opinion of Sichenzia Ross Friedman Ference LLP shall
be deemed satisfactory evidence of the availability of an exemption), or (ii) a registration statement or a post-effective amendment
to the Registration Statement relating to the offer and sale of such securities has been filed by the Company and declared effective
by the U.S. Securities and Exchange Commission (the&nbsp;&rdquo;<B>Commission</B>&rdquo;) and compliance with applicable state
securities law has been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify"><U>Registration Rights</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1</TD><TD STYLE="text-align: justify"><U>Demand Registration</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Right</U>. The Company, upon written demand (a &ldquo;<B>Demand Notice</B>&rdquo;) of the Holder(s) of at least 51% of the
Purchase Warrants and/or the underlying Shares (&ldquo;Majority Holders&rdquo;), agrees to register, on one occasion, all or any
portion of the Shares underlying the Purchase Warrants (collectively, the &ldquo;<B>Registrable Securities</B>&rdquo;). On such
occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within sixty
(60) days after receipt of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective
promptly thereafter, subject to compliance with review by the Commission; <U>provided</U>, <U>however</U>, that the Company shall
not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder
is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to participate
in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary
offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty
(30) days after such offering is consummated. The demand for registration may be made at any time during a period of four (4)
years beginning on the Commencement Date. The Company covenants and agrees to give written notice of its receipt of any Demand
Notice by any Holder(s) to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten
(10) days after the date of the receipt of any such Demand Notice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms</U>. The
Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts
to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such
States as are reasonably requested by the Holder(s); <U>provided</U>, <U>however</U>, that in no event shall the Company be required
to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register
or license to do business in such State or submit to general service of process in such State, or (ii) the principal shareholders
of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration
statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective for a period of at least twelve (12)
consecutive months after the date that the Holders of the Registrable Securities covered by such registration statement are first
given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell
the shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if
the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding
the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section 4.1.2 on only one
(1) occasion and such demand registration right shall terminate on the fifth anniversary of the effectiveness of the registration
statement in accordance with FINRA Rule 5110(f)(2)(G)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.2</TD><TD STYLE="text-align: justify"><U>&ldquo;Piggy-Back&rdquo; Registration</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Right</U>. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right,
for a period of no more than two (2) years from the date of effectiveness of the registration statement in accordance with FINRA
Rule 5110(f)(2)(G)(v), to include the Registrable Securities as part of any other registration of securities filed by the Company
(other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form
S-8 or any equivalent form); <U>provided</U>, <U>however</U>, that if, solely in connection with any primary underwritten public
offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation
on the number of shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)&rsquo;
judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall
be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to
which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities
shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities
sought to be included by such Holders; <U>provided</U>, <U>however</U>, that the Company shall not exclude any Registrable Securities
unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities
in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms</U>. The
Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to
the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company during the two (2) year period following the Commencement Date until such time as all of the Registrable
Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the &ldquo;piggy-back&rdquo;
rights provided for herein by giving written notice within ten (10) days of the receipt of the Company&rsquo;s notice of its intention
to file a registration statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number
of times the Holder may request registration under this Section 4.2.2; <U>provided</U>, <U>however</U>, that such registration
rights shall terminate on the [sixth] anniversary of the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">4.3</TD><TD STYLE="text-align: justify"><U>General Terms</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of
the Securities Exchange Act of 1934, as amended (&ldquo;<B>Exchange Act</B>&rdquo;), against all loss, claim, damage, expense or
liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating, preparing or
defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise,
arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which
the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement between the Underwriters
and the Company, dated as of [___________], 2016. The Holder(s) of the Registrable Securities to be sold pursuant to such registration
statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim,
damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses reasonably incurred in investigating,
preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act
or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for
specific inclusion in such registration statement to the same extent and with the same effect as the provisions contained in Section
5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise of
Purchase Warrants</U>. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise their
Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents
Delivered to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each
underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of
counsel to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold
comfort&rdquo; letter dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered
public accounting firm which has issued a report on the Company&rsquo;s financial statements included in such registration statement,
in each case covering substantially the same matters with respect to such registration statement (and the prospectus included
therein) and, in the case of such accountants&rsquo; letter, with respect to events subsequent to the date of such financial statements,
as are customarily covered in opinions of issuer&rsquo;s counsel and in accountants&rsquo; letters delivered to underwriters in
underwritten public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering
requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence
between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission
or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon
reasonable advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably
necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records
and properties and opportunities to discuss the business of the Company with its officers and independent auditors, all to such
reasonable extent and at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting
Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any
Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder
and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other
terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties to
any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that
any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also be
made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or
agreements with the Company or the underwriters except as they may relate to such Holders, their Shares and their intended methods
of distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents to
be Delivered by Holder(s)</U>. Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Damages</U>.
Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to
the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened
breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the
necessity of posting bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify"><U>New Purchase Warrants to be Issued</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial
Exercise or Transfer</U>. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in
whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax
if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase
Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number
of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost Certificate</U>.
Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant
and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant
of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction
shall constitute a substitute contractual obligation on the part of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify"><U>Adjustments</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments
to Exercise Price and Number of Securities</U>. The Exercise Price and the number of Shares underlying the Purchase Warrant shall
be subject to adjustment from time to time as hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Share
Dividends; Split Ups</U>. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective
day thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares,
and the Exercise Price shall be proportionately decreased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Aggregation
of Shares</U>. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares
is decreased by a reverse stock split, consolidation, combination or reclassification of Shares or other similar event, then, on
the effective date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding
Shares, and the Exercise Price shall be proportionately increased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities upon Reorganization, etc</U>. In case of any reclassification or reorganization of the outstanding Shares other than
a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such Shares, or in the case of any share
reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or
share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in any reclassification
or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the
property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder
of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant)
to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the
kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization,
share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder
of the number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if
any reclassification also results in a change in Shares covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant
to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications,
reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in Form
of Purchase Warrant</U>. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1,
and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in
the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase
Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the
Commencement Date or the computation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Substitute Purchase
Warrant</U>. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into,
another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification
or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall
execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding
or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise
of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation
or share reconstruction or amalgamation, by a holder of the number of Shares of the Company for which such Purchase Warrant might
have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental
Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The
above provision of this Section shall similarly apply to successive consolidations or share reconstructions or amalgamations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Elimination of Fractional Interests</U>.
The Company shall not be required to issue certificates representing fractions of Shares upon the exercise of the Purchase Warrant,
nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that
all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number
of Shares or other securities, properties or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation and Listing</U>. The
Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise
of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise
thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise Price therefor,
in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued,
fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company further covenants and agrees
that upon exercise of the Purchase Warrants and payment of the exercise price therefor, all Shares and other securities issuable
upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any
shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use its commercially reasonable efforts to
cause all Shares issuable upon exercise of the Purchase Warrants to be listed (subject to official notice of issuance) on all national
securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market) on which the Shares issued
to the public in the Offering may then be listed and/or quoted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify"><U>Certain Notice Requirements</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Right to Receive Notice</U>. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to
receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events
described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event
at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books for the determination
of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of
the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder
a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is
given to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events Requiring
Notice</U>. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events:
(i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or
distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings,
as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer
to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable
for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution, liquidation
or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale
of all or substantially all of its property, assets and business shall be proposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Change
in Exercise Price</U>. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section
6 hereof, send notice to the Holders of such event and change (&ldquo;<B>Price Notice</B>&rdquo;). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company&rsquo;s
Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transmittal
of Notices</U>. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall
be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company,
to following address or to such other address as the Company may designate by notice to the Holders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">If to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><BR>
Sichenzia Ross Friedman Ference LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">61 Broadway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, New York 10006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attn: Gregory Sichenzia, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Fax No.: (212) 930-9725</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Aytu Bioscience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">373 Inverness Parkway, Suite 206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Englewood, Colorado 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Joshua R. Disbrow, Chief Executive
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Wyrick Robbins Yates &amp; Ponton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4101 Lake Boone Trail, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Raleigh, North Carolina 27607</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attention: Alexander M. Donaldson, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (919) 7841-4865</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>.
The Company and Joseph Gunnar, as Representative of the Underwriters (the &ldquo;Representative&rdquo;), may from time to time
supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity, to correct
or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make
any other provisions in regard to matters or questions arising hereunder that the Company and the Representative may deem necessary
or desirable and that the Company and the Representative deem shall not adversely affect the interest of the Holders. All other
modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification
or amendment is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Purchase Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof,
and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding Effect</U>.
This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted
assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any
legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein
contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law;
Submission to Jurisdiction; Trial by Jury</U>. This Purchase Warrant shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. Each of the Company and the
Holder hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant
shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the
Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the
Company and the holder hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any process or summons to be served upon the Company or the Holder may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such
mailing shall be deemed personal service and shall be legal and binding upon the Company and the Holder in any action, proceeding
or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from
the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred
in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf
of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver, etc</U>.
The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision
hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver
of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and
no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent
breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution in
Counterparts</U>. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same
agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange
Agreement</U>. As a condition of the Holder&rsquo;s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any
time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and the Representative enter into an agreement
(&ldquo;<B>Exchange Agreement</B>&rdquo;) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged
for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[<I>Signature Page Follows</I>]</B></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Purchase Warrant to be signed by its duly authorized officer as of the ____ day of _______, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">AYTU BIOSCIENCE, INC. </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 55%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Form to be used to exercise Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Date: __________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The undersigned
hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of common stock, par value $0.0001 per share (the
&ldquo;<B>Shares</B>&rdquo;), of Aytu BioScience, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and hereby makes
payment of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as
to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase
Warrant representing the number of Shares for which this Purchase Warrant has not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The undersigned
hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______ Shares,
as determined in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Y(A-B)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Where,</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="4" STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The number of Shares to be issued to Holder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Y</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The number of Shares for which the Purchase Warrant is being exercised;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">A</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The fair market value of one Share which is equal to $_____; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-decoration: underline"><FONT STYLE="font-size: 10pt">B</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD COLSPAN="4" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">The Exercise Price which is equal to $______ per share</FONT></TD></TR>
<TR>
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 63%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">The undersigned
agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with
respect to the calculation shall be resolved by the Company in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Please issue
the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: justify"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="width: 12%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 28%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 47%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature Guaranteed</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INSTRUCTIONS FOR REGISTRATION OF SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 45%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Print in Block Letters) </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOTICE: The signature to
this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any
change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>Form to be used to assign Purchase Warrant</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(To be executed by the registered Holder to
effect a transfer of the within Purchase Warrant):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FOR VALUE RECEIVED, __________________ does
hereby sell, assign and transfer unto the right to purchase shares of common stock, par value $0.0001 per share, of Aytu BioScience,
Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), evidenced by the Purchase Warrant and does hereby authorize the
Company to transfer such right on the books of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dated: __________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: justify"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="width: 13%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 29%; text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Signature Guaranteed</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTICE: The signature to this form must correspond
with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered
national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>v450214_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">October 11, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">373 Inverness Parkway, Suite 206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Englewood, Colorado 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We have acted as counsel to Aytu BioScience,
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the proposed issuance of up to $28,421,429 of shares
(the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, $0.0001 par value per share (the &ldquo;Common Stock&rdquo;), together
with warrants to purchase shares of Common Stock up to an amount equal in number to half of the number of Shares to be offered
and sold to investors as well as warrants to purchase shares of Common Stock to be issued to the Representatives (defined below)
(collectively, the &ldquo;Warrants&rdquo;), all to be offered and sold pursuant to the registration statement on Form S-1 as filed
by the Company with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant to the Securities Act of 1933,
as amended (the &ldquo;Act&rdquo;), together with the exhibits thereto and the documents incorporated by reference therein (the
&ldquo;Registration Statement&rdquo;), and the related prospectus which forms a part of and is included in the Registration Statement
(the &ldquo;Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The shares are to be sold pursuant to an
Underwriting Agreement to be entered into by and among the Company and Joseph Gunnar &amp; Co., LLC and Fordham Financial Management,
Inc. as representatives of the several underwriters named therein (the &ldquo;Representatives&rdquo;), the form of which has been
filed as Exhibit 1.1 to the Registration Statement (the &ldquo;Underwriting Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In connection with this opinion, we have
examined and relied upon the Registration Statement, the Prospectus, the Company&rsquo;s Certificate of Incorporation, as currently
in effect, the Company&rsquo;s Bylaws, as currently in effect, the Underwriting Agreement, and such instruments, documents, certificates
and records that we have deemed relevant and necessary for the basis of our opinion hereinafter expressed. In such examination,
we have assumed: (i)&nbsp;the authenticity of original documents and the genuineness of all signatures; (ii)&nbsp;the conformity
to the originals of all documents submitted to us as copies; (iii)&nbsp;the truth, accuracy and completeness of the information,
representations and warranties contained in the records, documents, instruments and certificates we have reviewed; and (iv)&nbsp;the
due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">On the basis of the foregoing, and in reliance
thereon, we are of the opinion that (i) the Shares, when sold in accordance with the Registration Statement, the Prospectus and
the Underwriting Agreement, will be validly issued, fully paid and nonassessable, (ii) provided that the Warrants have been duly
executed and delivered by the Company, then the Warrants, when issued and sold in accordance with the Registration Statement, the
Prospectus and the Underwriting Agreement, will be valid and legally binding obligations of the Company, enforceable against the
Company in accordance with their terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium or other similar laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles
(regardless of whether such enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith
and fair dealings, and (iii) the Warrant Shares, when issued and sold against payment therefor in accordance with the terms of
the Warrants and in accordance with the Registration Statement and the Prospectus, will be duly authorized, validly issued, fully
paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This opinion is limited to the Delaware
General Corporation Law, including the statutory provisions of the Delaware General Corporate Law and all applicable provisions
of the Delaware Constitution and reported judicial decisions interpreting these laws, and, with regard to our opinion in (ii)&nbsp;above regarding the enforceability of the Warrants, the New York Business Corporation Law, including the statutory provisions of the New York Business Corporation Law and all applicable provisions of the New York Constitution and reported judicial decisions interpreting these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We hereby consent to the use of our name
wherever it appears in the Registration Statement and the Prospectus, and in any amendment or supplement thereto, the filing of
this opinion as an exhibit to the Registration Statement and the incorporation by reference of this opinion in the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In giving this consent, we do not admit
that we are within the category of persons whose consent is required by Section&nbsp;7 of the Securities Act or the rules and regulations
promulgated thereunder by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245.5pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245.5pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245.5pt; text-indent: 1.75in">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245.5pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245.5pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 245.5pt; text-indent: 1.75in">/s/ Wyrick Robbins Yates&nbsp;&amp;
Ponton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>v450214_ex23x1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public
Accounting Firm</B></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We hereby consent
to the inclusion in this Registration Statement (No. 333-213738) on Form S-1 and related prospectus of Aytu BioScience, Inc. (the &ldquo;Company&rdquo;)
of our report dated September 1, 2016, with respect to the balance sheets of the Company as of June 30, 2016 and 2015 and the related
statements of operations, stockholders&rsquo; deficit, and cash flows for the years then ended. We also consent to the reference
to our firm under the heading &ldquo;Experts&rdquo; in the Registration Statement and prospectus.</P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5in; text-align: right">/s/ EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Denver, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 11, 2016&#9;</P>



<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>line.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 line.gif
K1TE&.#EA 0 ! (       /___R'Y!       +      !  $   ("1 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_aytu-bioscience.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_aytu-bioscience.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( '4!2 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M7E^:4,5@JDG4H-LHHHKZX\X**** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>5Y7+$2]I3R/(\IA[+"NMB,+1]&\(?\@V?_ *_I?_2>VKJJY7PA_P @V?\
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M/NK#4)O#'C;POJ.M>$/$]OI^H:??W/A_7-2@LM0L;J2*[A_U^/V6?VE?A?\
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M27L[K4[.WN[FR3RM2DE6:*VG99(D!C92PK[#K\G/^"Z/_*)3]N+_ +));_\
MJ:>%:'L_1_D"W7JOS/YEO^(Q+XT_]&1?"_\ \/!XK_\ F-K^U/\ 96^,5[^T
M1^S!^SA^T!J6AVOAG4?CI\!?@_\ &*_\-V-Y+J-EX>O?B;\/?#OC6ZT.SU"X
MAMI[ZUTF?6Y+"WO)K>"6YBMTGDAB=V1?\8"O]AG_ ()E?\HW/^"?/_9D'[*'
M_JAO -1!MMW?3]2YI)*RZ_H?;]%%%604]0T^PU>POM*U6QL]3TO4[.YT_4M-
MU"VAO;#4+"]A>VO+&^L[E);>[L[NWEDM[FVN(Y(9X9'BE1T=E/\ FW_\%._V
M-/'?_!-G]K3Q9X.\.:?JZ_ 7X@WNK^-_@'K&I6FI2^&=7\&:C+;SWW@HWUQK
M6LR:AXI^$M]>VO@[7;F]UF+Q5J6G6OAGQMJNFZ1I/CW1[.X_TG*_(C_@M?\
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M_C\?\%"?VU?B!_P4#_:U^+/[3WCXWVGQ^,]:-AX \&76J3:I:?#;X7:$7L/
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MF6+S3&8FTJ=3#UL34<J=#+ZO-.O@\)@J$,+@L%AH594J6#P6&HSI5;595?\
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M(_VC)])OM#3P]!?V2ZA/ _P2\,:SKWA36K>WU;3YX?'_ (P^('A3Q7X?75/
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M_8V_[N&_]:K^.590W?I^J-9[+U_1G[?4445J9'X@_P#!QY_RAC_;)_[MY_\
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M$\&>#--U36]*@\0>.?%^I:'X.\,0WL5]XBUS2[#?<K_L8_L__"+2?V?O@/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>spacer.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 spacer.gif
K1TE&.#EA 0 ! (           "'Y! $     +      !  $   ("1 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>v449009_chrt-line.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v449009_chrt-line.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$(! L"W ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MAUDL[J"ZC'S.O+P.Z_>1UZ_>1QU4X +E%)D>HZXZCKZ?7VZT9&<9&?3//Y4
M+15,:CIYO3I@O[,ZD(9+DZ>+J WHMXC;K+<&TW^>(8VO+19)3'Y:&ZMPS SQ
M;KF1Z]>E !12%E&<L!C&<D#&>F?3/;/6E) ZD#)P,]SZ?6@ HI,@ DD #J<\
M#ZT9'J/S].M "T452M=2TZ^DN8;*_LKR6RF>WO(K6Z@N)+2>.26%X+E(9':"
M9)H)XGCE".LD,J%0T;@ %VBBD!!S@@X.#@YP1U!]"/2@!:**0D#J0,],GK0
MM%%)D>HYZ<]: %HI,CU'7'4=?3Z^W6EH **,CU%)D>HZXZ]QU'U]J %HI,@$
M D G.!GDXZX'?'?%+0 44?Y_+K02!U(&3@9[GT^M !11TZT4 %%)D8SD8]<\
M<=>:7(XY'/3W^GK0 44T,IY#*1P,@@\DX Z]SP/4\4[('4XH **,CKGCUI"0
M,Y(&!DY(& .I/H/>@!:* 00"""",@CD$'H0>X-% !129''(YX'/4GH!ZYI:
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M7&N>*_AS8^)/&BWOBWP?)<>(([J+75NWF:T2XGO%$BJTWH'PO_;Z^#'Q+O\
M5-'OM)\<_"/Q#H6FW^K:MX1^-=AX4\ ^+[6PT_1=:\17%P= F\97]]!'#H.B
M2ZY-+<Q0PQZ/?:9J;RI9W+3Q?CC\0OVDO@CKNH?L*?&J;5[3XC? OX"_ Q_
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M725KBV@356N-,NULJY(NRL];.]]-7\/KT]=2>9VO=/?1+71;^G6WR/O3P?\
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M'B75_#-AX'UN&3PW>Z_<SZ1?2Z5/J!TN4VT]_/!'+9VL@LG%LDD/A?[-=O\
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M3YCNGU6W=/U.X\/^'-$\)V4MAH-A]CLYKI[^6W6ZO+N0W<L4-O(X^V37$O\
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MH6_C74_AYX8NKWP-XIC7Q'XHA\8Z=X2T6&ROK+^UUM;/6)[_ ,RVN];L-!2
M1O-J0TL!(93ED[Z/35I_UOI^ 7BK;=DU_P #8_1O2?"?A_1;34[#2K#[##K&
MK76L7\+W5[-]KU.Y^SFZND>ZN9I41Q;0XCMS% H3*P1[GW'A?PGX=\'Z>NC>
M&M-.FZ7;AO+B-W?7B%9IKBZFQ<7]S=3'$UU<,<RM@R; 51$5=JZN[.UM#?7$
MY2UC2)FN"DKR(LS)'&R*D;2 R,ZJ^$S@_,  2/E/PC^W;^RGXW^(-E\*/#'Q
M1.I>/;^]M-.M/#__  @_Q%LA/>:C9-J5I!_:>H>$;71$\ZR4S>9-J4<,?^KE
MD24[*2N[VN^]KO;N/1-;+M\_^#V/H[2?!OAC0]1U+5=)TP6=_J]]>:A?7+7V
MH3?:K^_GCN;F9(;FZF@03S0QR+' D42[2D42(6!>O@WPW_PDB>+1IJCQ$-V=
M02^OY%7_ $#^S!FV-RMES8_N.;0<YD&9AYE?G'-_P58_9KTO]ICQ+^SYXI\0
MZCX?D\-7>L^$GU6X\"^*;R&;XB:/X_/@EO#UM>:,=8E,4C1W%S#J$NAVNE%(
M6E?6(6:*SE_4!-C^4\;GG?M"Y5'QD'S%*@G;@[<XP>1D4.ZWOJOP[?\  $N5
M[6WVT[[G-3>#O#+>))?%S:6S>(FM8;9M1%W?_-#:O!+!"MH+L6)D5[:!EQ;*
M[[,.[*SAKUEX<T>SU>;7[:Q\G5;RTDM[FZ:YNVDDBN;E;V:)K229[6/=<JLI
M>-%=&!B4B,D'\G?!/[0/_!2OXV:]X\U?X-Z!^Q3_ ,*Y\#>*;3PLVG>.K;XV
M6'Q'U;5X/!7@GQCJ<=BVD^)+GPB\-S#XPBL='GU#4-*1;N,1ZE]GM86OY_<?
M@+^VGKOB/XQ7?[-_Q_\ !Z?#WXVVGAW6O%$5KH.GVU[X0UK1=!U&VT&[U/1]
M7TKQQXXGAM;W6[+Q*=-M-;32=4.G:=!)?V5E// E[3C+7RT:3U27==D%XZ=.
MJNK*_J?<7B/P9X;\7BQ'B'3#?C3?M7V5#=W]H4^V>09\&QNK8ON-M 3YF_;L
M^3:&?==U;P[H^MSZ;=:C:F>XTR^L]1LB)KF-H9K)Y)+9VC@N(581O*Y(E66-
MB=KHX  ^5]#_ &^_V2O%'C*;P#H?Q9-YXM@\O?I:^!/B7:X\W2IM:7=?W?@V
M#36SIEO-<C;>'&WR3B=EB/NWP_\ C)\-OBA>:_:>!/$AUZX\,ZOJNAZZATC7
MM,:PU719;*+4[/S-9TO3H[F.U?4+,>;9/<V\QFW6\TRQRE%:5MG9>3LAWB]+
MJ[\U=V.PNO#>C3:QIOB.6P,NJZ+]L&FW"7-X7B_M&U6PO ;=9EMG+VRB,^=%
M/L +Q^7)ERS6_"/A[Q#=Z#?:U8B\O/#.H+JNB3F[O;;[#J"36\\<_E6MS!%<
MD2VL#B&\2>%O*VF,J[ALSP?\1_!GCZ\\2V?A/63JMQX/US4_#GB*(:?JM@-/
MUK2=9UGP_J5FS:E8V:7GV?6- U>T%Q8M<VLIM/M$$\MK<6T\WQO^V7^TA\4O
MAQJ?PC^$'P#L/ U]\7_C;K.NZ)I-_P#$BT\2#P3HEA92>%O#W]J7VH>&=<TC
M7[*YMO$7Q#\)3"33[+6IAI<.M30637EM9Q7*2;=EO^EKO\+L&UOOY>=[?G9>
M1][D$L%D8NRN)(W91&G!PL0*D[FSDC@D@YP<8KD_$_@3PKXQAMK/Q#I U.&T
M\[R(S?ZG9"/SWMY9?,>PNK>1=[VL#)N,F?+PNQ7?=^67PV_;E^+_ ,&_BIK?
MP'_;6TKP(?&.C_#C4OB98ZU\"]/\4ZUH%YX:T_Q'8>#;:XDO_'/BTZN;^XU3
M2_%=V]J^C6CFR_LB9G@N9;NTKRE/VTOV\F^%J_MC_P#"#? <?LSC.[0U_P"$
MT'Q4Y\1'X6#SM _X65_PB#_\5_\ Z9'LUU]OAS_36VZI_H=4H2T>BO9)WWO>
MUO6Q+DNS?=6U2ZWN?M[K.C:9X@TZ?3-8@_M'3[N.6VGA66>W#I<0S6\NZ:SF
MAFC0P3RQLZ2!DW;UPZJP@MO#.@V>A)X>MK )HT4-K;)9)=WDH6*Q6W2V0W,D
MYNR8EMH!EIB[[,R,Y=]W._"OXC^'/B]X%T3XB>$HM3A\/^(1JBV4.K6T%E?+
M_96L7^B79GM;>YNX8V:\TVX,16YD#P-&[;&9HT\9USXG^+M+_:O\*?"S^U/!
MUOX-U?X?6GB&?29K;Q>_B^[OIF^*H:XLY[5'\'I9J/"^CEUU!H[\BWU/:7+:
M6%E)W:U35V_*VY3MH[7O9??^A]$1>%]#BT3_ (1J.R5-&B5T%H+N\<[)[IKV
M96G:?[4OF3L[!OM#%0V%VHH2C4/#FBW^A2>';NQ\[1_L;V;Z>ES=B26P^QO8
MM"DT<\=WN>U=H%=9Q)N(<2B7#CY&M/\ @HK^QMJ&KZ#H=I\8?,U;Q1?IIFB6
MJ_#[XIQG4+YYH;:.#SY?!"6UMF:>*/S+Z:WA&\L9 BLR_8NF:K8ZSIFGZQIT
MPN-/U:SM+S3KL130M/8W]O'=6C^7<1Q7$,DL$J2[)HHS&6VR*CAE U);IKKK
M=:]]05GM;;IV&Z%I6EZ#I-AHVCVAL-+TVW2"RM9)KB4P0G+^49;J6XN)&1F8
M.9II'5LJ6.!C*T?P9X>T+2=2T71M.-CI6KRW,M_:275_*99KNRM].N)A-<W-
MQ<J7M+6"(1130QC8739*SNWY_P#[4O\ P4X^ 7[+OQ>\-_![Q?J^HKK]R-7_
M .$MDB\&^(-8L_#)A\,>'O%&A&ZO+*>T-V=;L_$%L(CHEIX@\F<M'J7]E>6\
MK>;:3_P4?^&UG^UGX_TWQ+\0;.S_ &>;?X,+XL\+:\/#'Q*NM0F\16FI>%;#
M45DT2"RO9+:"$P>+<./"EG<2-:1M'>RK=QB^KEDU?6SUZZZV7SOL)RC>WR[6
MTU_R9^I\7A301H]QH'V!AI,TD;7%H]Q>)YTT#6Q2X6X^TM<JA-K!M5)E0[#D
M'<X:/5/"'AO6O#,WA'5M/CN?#ESY?VNQ:_O[8GR=0CU.#%U;W$5Z,7\4<QVW
M<6=OEG?$S1'@OAK^T#\(?C!X2N/'/P\\7GQ#X5MY8[>755T'Q/I&R26#2;N)
M#9:[HNF:DS-!KFER%DLV0?:MA8/#<+#PGPR_;,_9J^,OCNY^&GPZ^(L?B7QC
M!Y/FZ+_PAOCW2"GF:/?Z^GF:AK_A;2](?=I>EWUVGEWS[?(\A]MU+##(K2UT
MEIJ]'H^[[!IW5[66VJ_R/?;'PGH&GZJFLV-@8-4&D+HXNS=7LFW3A<I="W,$
MMS+;EEN$23>8O/XV&;82I?/H&CW]_<ZG<Z>[W\EO;:9)+-/=VYGM].GO;F#R
MHHI_*,2RZG>2+*D2R/YA61F2.()IWQN1IMQ-820+=Q64T]G)=>?]E>Z2W=[?
M[:(%^T-:-+L:Y6$"=H]WECS,"OSM^%O[9^C^&;GX^S_M$>/?!.DZ7X,^-OC#
MP=X2E\*^'/BMJ]W:V.B:G!IM[::TMSI&L*/(DOM%BLET5(K+S9M0D$0MUC=4
MDW=K=6]=P;2LFE9]=+;'WA'X'\,CP\O@]].+^'H%N!#8M=W\:J+TW;W6R\6\
M-]()&O[G<6N?W1E CVA8]DUMX.\.6=_I5_;:8+>YT31+'P]IURU[?OY&CZ;,
MLUG8"*6Y:&98I%607<XEO)-NV61T)KPKX??ME?LV?%77_%/AGP#\2#KVM^#-
M ;Q/XFLO^$0\>Z6-+T)1:EKU;G6?"VG6EYD7=N3:Z?/=W9+C_1\H^WY:\(?\
M%5OV:O$O[0?B'X(:CXFU+0GTC7=6\$Z5?WW@;Q6\.N>-[#QM;>$;'3+6YTD:
MT\=KJ9GDF@O=5TC1[1$A>2^O-/)CM97:6NCTU:?G_F%X]UT[?U8_1U_!WAV7
MQ);>*FTH-K^G^=]EU%K[4$$?VNP&FS[;5;@V4FZR'D'S+=]G^L3;,?,J6;P_
MH^IZE::]>6$CZM:PQ6UM<2374$D,=O=O=P"2UBN%ML)<.TH9XI&=64.60A!\
MZ>+OVWOV8/ _C>#X<>*?B>=*\97GF_9='_X0SXAWOF?9](MM=GQJ.F^$[S2X
M]FE7=O='S+U-WF>0FZX22%=;XH_M=_L\_!?Q-J_A?XF?$0^&?$&B: GB34M-
M'A3QSK"VN@O ;D:@]SX?\,ZK8SR&..1A;VMU-=B,*AMA)\M%I=I;=GM_D%X^
M6_EOW/?Y-"TN?6;7Q!):&35[2T;38+KSKE1';'[0[*84F%LRDW$X#O;M)F0#
M<-J;=5N49=P*,-H=<, #PV[H .<9W'N>",5\=ZK^W=^SA#\#_%G[0/A_QO>^
M)/AWX,NM'M-8U2P\(>+[:Z2[UK5O"VD6L,>D:[H^A:E<CS?&6ARN\<0CC2Y9
MS(SVMS%'QW['?_!0GX%?M;Z)HUCX8\12Q?$BZ_M'^U?!DGA#Q3HPL/(N_$\U
MB!?74&I^'W-WH/AJXU7]QXFO0I(AF^S7LJZ?&FI=4]._3K]P[J]KK7_AOO/K
MZ/X=^#XQJMN-*'DZSJ=]XAU*%=0U-C=ZMJ("7FH;S?"2 W"C;]DMC'9Q=88T
M:M/2O"?AW1M0GU+3+'[-J%Q;Z;:SS&ZO9FDMM*L/[-TR(0SW4T(^R:?BW+I&
MLDV/.G:68F2OD?\ ;'_;G^$W['NE^&IO&EW?2:[XEU[1M'M],L/#6IZS);:;
MK-MXH>+5;B:&YTNR2TAO/#%U;RQPZE=:@K%'CTN:*43Q^A^"_P!K7X)>*/@G
MX)^.S^+#;>"O&&CK>V^J/X8\4I+%?6>IIX<UNRDTM-)N]4B;3?$HGT@L(KBW
MG\DW5G>7NG-'?R.TK)ZV>WG\OE^'D).-WMIU_P"#_6Y[M9^$?#VGR:T]CIXM
MW\0PV]MK#F[OI!?V]O;S6L4(\ZYD%L5@GECWV@AD;<79BZJPOZ/HFF>'[6:T
MTFV%E!+=/>2HT]Q.K3RI%"[^9=2S2+N2&(!5(3Y,A068GQGX)?M/_ S]HVUN
MKOX,>-_^$SMK&V%]<2?\(UXO\/>3;_;[G3!*R>*_#^A2./MUI<0;(D>7$?F;
M/*=)&3]IG]H7P7^R_P#"#Q%\8_B!)>1^'?#]WH.GRQZ=I<^L7MS>Z]KECHUM
M%#903VH>-3>/<.\UW;)&D#MN>7RK>96;?+K=VT_(>F^FE]5^)Z=X4\">%? D
M-Q%X5TT:1:W7E?:XC?:C?>?Y#W+09DU*\NWA\J2\N&'E,/,\W:^0D87K-O/S
M.I<K\V["-Y)^\I49 &<_/P0>,C%?GO\ !'_@I3^S'\5OA;J'Q!U#QX^D3>&O
MLG_"=:9+X%\>QCPW_;/B+5M$\,_N;;1];AOO[833DN/^)-J6L_9?-#ZC_9S%
MK>'WWP?^UG^S[X_\(:]X^\(>/EUCPMX:&J1ZWJS>%/&UB;0:-I=KK6I(;+4_
M#=EJ5R;?3KVVN?\ 1;2=)O-\F RW"21(W&6MU+31NS_,2<>C2^?Z=#VG0O"V
M@>';S6K[1M.:TN?$&I3:IJDS7-[,EW?RR32RW/\ I-S<QP+(UQ*42VCAARV%
MB4!=L%UX*\.WM]J>HWFGK+=ZI)ILM[(+R_0&32EC6QDVQW,<8$/E1LP2.%7"
M$2B4%B?+_@]^T]\#?CO;^++CX4^-V\5P>"-7BT'Q03X:\7:'_96L2B<K8JGB
M30-'-XH%O+B?3A=VHV?Z_P"9,^:Z%^WW^R3XF\:M\/=%^+)O/&#[0VC'P)\2
M[<8&E3:V M_=>#8=+YTJ":Y;-\<[?(_X^&6$B4M;*5UO:^BZ7#W?+OT_KN?4
M:>%]";5K37?L!&IZ=IL&A6ES)<7B :?:7(O((XXA<M;RH+C]XLTD+SORKRL@
MV5?O-'T[4WM3=V9E%EY_DEYKF$Q_:0OF;!%(HEW&-0WF'Y,#9U(K\TO"'_!5
MC]FSQ!^T!XA^!VJ>(]0T&32O$.K>!M'U*]\"^*I(M;\<6/C6V\(:?I5I=:2-
M;DAMM2::2>WOM4T?1[*-87DOKW3V,=K+^GS2(=Q+L$3&2FX$;N!N&,G)X7:#
MCG.*&I)J]UV?_!^>H*S3M;ST7Y%2^LK34+*[L[^'[3!?6=S8W<)DD@DGLKF.
M2*>)?)=)%:2.1HU:)XY 3E)48 C!T+P;X9\,:7=Z-HFF?V?INHWSZQ>VTE[J
M$PEO)TMHGD:>\NKFXA<BTM088I$A!B^5 7D+_,_B']OS]DGPO?6NGZ]\5ULK
MZ\UO3?#EM%_P@?Q+NO,U?5K=+O3[3S;3P;<1IY\$B2?:'D6UBSMFFC<%1[1=
M_'7X3V?PYN?BQ=>*0O@"VDTV.XU]M"\1R"-]7.F_V<G]E)H[ZVZSMJVG$;--
M<0FX!G,7DSF)-26C36O9[A>/==>WS.\\.>%M"\&Z8FE>'; :=IT&[R[=KJ\N
M1^]N)[EOWU]<74_^ONIWYD;E]@PBHJKJWA_1=;NK"\U6PDN9M+OK6ZLF\ZZ@
M%O=V,DDMM>8M[B%9(8FED.)D>)]W[R-@% \.^#W[6O[/?Q]O/[,^$OQ!/BZ]
M7_E@_A7QOH>[=%J=Q\\GB7PUHT+8BT;4G7$G'V8*?GF@67S[5O\ @H5^Q[HM
MS#9:I\7VMKFX\11^$HH3X!^*$_F>()9)(H]-9[?P3-$ \D4BFZ=UL1MRUR%*
MDNTK[.^^SOK_ )@W&VZM\K'T[J^F:GX=\/ZM/\._#OA_5_$5Q=O?VND^*/%N
ML^%M U"YU+63>ZK-?^);#PSX[U#2\1W^I:A:I9^%]2BN+T6^F;;"SF^W67RE
M^S=^SC\4? OQB^+O[0'QO\7>%O$WQ$^*FB^$M ATCPA%>3:3X2T[PY:0:9?I
M#KLFB>#(_$0U^UT'PG?2/<>"-'FT>ZLKG3[:>[ADN-0U/VO7OVE_@CX8TKP!
MK&O^-18Z5\4;'5=1\!S_ /"-^+;H:[9Z'#97&JRF"ST&YGTP6<6HV3+%K$6G
MRS"4+;),T4H2S\7OC'X6^'^EZUH]QK267CB_\"^.=?\ "&G/IVMSQW\OABQT
MF.XEEOM/MOLUHEKJ?B7PU"RSZC87$JZ@9+1F2TO)K07,KJUN;1NVMD]?DFM?
M0'R[W6FJ2>G]/H>T.<,C 2;V=8FVH&/E$DG<NX!8\]90"R]!6%<>%=!O-=T[
MQ1/9*^KZ5]L^Q7BW=YB/[=9KIUS^X2XCM'WVRK%^]@EVX+ILERY_/?\ 8U_:
MJU/QA\+OC?X]^-6M6>FZ=X'^/7Q*\'6NI6EMXIU3[+X<\,^'?"^LP1B"2\\2
MZEYD$%UJMP(K..&T_=JEO9QSR%9_=_ O[<?[+/Q%T#4_$W@WXG_VSH>D_8O[
M1NAX)^(>G);?;[V\T^TV6FK>$K"[D\Z\L;J-O)@DV&+S9-D;QNYRR3:2;MI=
M)^7^8736K2O9V=CZ9T#0-'\,:9#HV@VILM,MY96MK83W-T(WN)&GE<3WEQ<7
M$BM-)(QWRL%8E% 50! GA3P_!K<GB=-.8ZV8EMWO%N;UF:-7OVP+4W1M!\VJ
M7S$B -B8\XBA$?YC_#+_ (*8?##]I'X/_%K4/@UXDL-+^*/@OP!\1/&</AOQ
MMX0\=:3%9^&_"NA6ZKX@N+_0?[5T]]OB35],@6UTWQ)_;+6C2RQ:="T7V@>\
M_"[]K+PWH?P#\,?$G]H+QQX1TI]0M=+C_M?P3X=^)>H:=)C0?!DMRMW;W^C:
MIK[ZH-4\30"XG$4EI+;WMJT<TLL&HO"W&2OWO9KJ^OS0<T7;;:ZVT_R/K:\\
M$^&+_4-5U*[TT27VMVILM6F^VZ@HNK9].?21%LCNXXH#]@D> -;Q0R$MYF_S
M@)1)<^$/#]QH/_".3:<7T6*T^PI8_:KY6^S1V;6*JEPMRMV[?9&,*YN-S$[S
M)YN'KQKX>_M9_L_?%7P?XF^('@+Q\->\(^$]&OO$.OZM_P (IXUTO^S](TBW
MUNZO[PV&M>&].U.[^S0^'-9D%O8V5S=2_8ML$$LEQ:+/Y>__  46_8VBU?3=
M#?XR,-5UFYL[;3K1OA_\5&%Q-J-R;.T2.=? YMH#+<@Q(UQ-$D7WYF2/YZ5I
M/I)V\GIV] O'NM?37_/4^S-,L+;2]/LM,LHVCTVQLK.PL+7+N;2UL+>.VBA>
M:622>1D2)$+32R2[D.]V;<QTDSCDACG[PZ'\N!CI@>F>]9>B:QIWB#1]'U[1
M;@7>CZWIECK&G79AN+=KK3M4M8KZQNA!<Q07$)N+>>.9HKF&*XCW[9HHY0R#
M57&.!M]N!C\LC\C4E(6BBB@ IKJ&4J1N!QQG&<$'J/SIU(V[!V;=W;=G'7G.
M.>F?QH B9E\Q4+;7;/E<$]%R_MT_O'Z<U^%7[4O@#PMX[_X*D?!73/%FC?VG
M8+\(OAQJ,,']HZC9?O5_:(\0V\=QYFFWMG-_J;RY3R7D*_O-S)O2-E_=564C
M"CRT'7(" YY^3!QUSN^OJ:\LU?X*_#?6_B3IGQ=U#PGH=UX\TG0[+P_9:[<Z
M%H,^IVNEV.O2^)[:.WU.?2I=9AEAUF5[R)(=3CMX[AFN(X4NB;@U%\K;\FOO
M)DF]--U]Q^7_ .S)^RC\$=7_ &G?VQGUKPG_ &E::3XA\*-I4?\ ;OBVS_LX
M7_COX_07-OOM/$<4EW^ZM;)/.N1(?W>Z/8SREORA^&,'B6S_ &2=6\/>%++_
M (I35?&/PDL/%$'VFP^2*Z_: LTTL>9J3-J3>9>W=VV=.GC9,XN'6+RBO]7N
M@> /"7ACQ)XI\6Z'H5GIVN>,TTV/Q%?6FF:99W6IMI%_XAU*TFO;JSL[>\O9
M%N_%.L2B2^N;HA[N=XA%+/=27'G_ (?_ &:O@?X;\,>,/!-C\,? @\'>/[*S
MTWQ;X0;P7X0'A/6;*Q>]DM;74M AT&#2]1A6;4;JY6'4[2]B%W,\T<:/)(7M
M5%=MIOX;+M:U[?-7^;)<'I9VLW=][WLOQ/Q"?]E#]HS7+_PG\:_$L?\ 8GA7
MP7\%="T7P[-O\"ZE_:'P_P##DQ\6:18^78>(X=1M?M6G33O]IOM*NM:@\K;=
M2SSR);"3X"_L\?">Y_X)-WNN1^%,ZUXD^S?VM=?VYXD_TK^Q_P!I/6+.P_<-
MK:VD'D6BF/\ T:&#S?OS>;+\U?L;X*_8X_9F^'^H:GJ'AOX/_#JWOM0BO;.!
MS\/_  !$^B:5=3VL\>DZ(UAX7LIM-T+39K* Z;8([VUF5RJLP0IZ3X9^"7PQ
M\*_#&W^$&B>#/#UM\/[3S?+\,2>'?#\.BMY_B"X\4/YFBVFDV^B'&MW$NH)M
MTQ<7;"[.Z[+7#-U;VWTDGIIIJVM^]O*^H*&_FFN]GT9_.1X?O[B\\%_\$P[N
M^N/M5Q-\<OAXC2^4D'F3+^U%\=$B'EPHL:;8D1.%"G;N8[B2?Z@K#Y[2R+KM
M8V=NI&[.4$2L&R, 988QU_"O$YOV8_@5??"G3?@IJ?PU\$:U\.]#DU2ZT'P]
MK'@[P?J-AH&J:M-KL\^M:)I-QH#Z'I6L03>)=:EM=1L]*AN(Y-1O'=I&O+MI
M^Y^&?PK\ ?!WPQ#X/^'?AC0O"GA])H[J6PT/1=%T*VN[]-.L-,;4KNUT/3M+
MLKC4I[/2["&XO&M1-+';11EA%##''$I*6UU9OMLVW?2WW%137SM\FE:WGZGX
MK^(?A%\.OB]_P5P^)FE?$7P[_P )!8:=_P (9Y$7]KZ[I6/M?[,\%S+\^A:G
MIDQS-IEBWSR/_J<+M2299/C+X1_#GX[_ !"_:$_;$\'?##2<ZEJ?B/\ :#^&
MVK)]O\'#RO %[XWTW2[[2=WB&^LK=]EQ>Z>/M]M=1ZTW6&_1//D3^F2W^"WP
MXM/B;J7Q?@\*Z##X_P!5^Q_;O$\6AZ%'K=S]A\/MX8MOM&M)I2ZU-Y.BL=/B
M\[4Y/+M";2/9:$V]<'\4OV3_ -G;XOZA'KGC7X/_  ZU+Q+!<I<W/BUOA_X&
MO/%%_;13ZA>3:/>Z]JWAS4]0NM+NM0U.[U.YT^281SZC)]L=A,TC25&HE;>W
M*ELK77==5]SVUT)<+W]6_5?<_P!3\&_^%<W/@?XV_L9?L[_M)7/VOP=X4A_:
M!MK_ $7R8X/(-_X,3Q?;6G]I> [Z[U27['JLVA#SX=;N?M'V?,C);2WEL/=O
MVO\ P?\ !WPY^VEILW@J/RO']]\,_'D7Q#M=WBE_L@B7]G+_ (1 ^?JUU/HL
M_G:4\TN-#">7_J]3)N=N/M#]JW1O"7PZ\%?"[X;Z-^Q_'\<OA)HECX@LM4\*
M>#_V?],^)FI^&H5G\*ZAI#^%-"M8K'PSH]QKNOSMJOBAKFQB35/[*OKZU3[;
M8ES\U_LK? W3?C#\>;_XCG]EO7_V</A#X0\#ZC8>']%\?_!&W^#_ ,3O'&JZ
M_P"(O 5U=VWC_3CI&I^&/$VGZ3<>!/$8T>&ROK:YL/#WB/31*DSZO?M9TI?:
MNTDF[)K77>U[J[UMZN]B;=%K=K773R_JW^7P-JVG6VL?L>^+M.U&/S],O?\
M@J)K^C7\.^2+[19W/PND@NK7S('BN(O-MY77SH726/.Z.57 (^J/VV?V5_@_
MHO[8/[,^K6'AC[,GB;_A<O\ :]A_;7BB;/\ 8WPO\*6UA_I4WB&4C!E>;_18
M[?.[RYO- ##]@U_95^!7_"-7GA0_#CPG+H>H?$FX^+;:=)X0\'O91^.KNP_L
MTZXUI_PCOV-=16S_ '!U,VSZPL1,1U)HCY==YXP^#OP\\>^*/"'C/Q3X7TG5
M?$'@;_A(/^$=U&]T30[[4++_ (2;3[72M7V7>HZ7>7MM]ILK.W@;[#=6GG0Q
MI%<_:(42-9]HKZ72O)Z>?*U^**Y'Y;*WXGY#ZMX9L?AU^U#_ ,%#M"^'>G_V
M4+/]CKQ[K&EVWVJ:^W:X_P *O@^UO^^URXOL>9/%;?\ 'Q,UFFWYX@ADS^=W
MP4_9E^/?[1_P3\?V7A#2_)T^7XJZ]/XAU;[=X,D^R>-+RV\":OK[_8-3U_0Y
MY_MD>GZ7#ML7&DV^_P RR566XB?^I&#X4^ ;?XD:Y\5(?#NCIXY\1^%AX3U_
M5X](T5;K6="6736%MJ-^FG+K&HH4TC3+0PWNHSV?V:QM;?[-BUM_*\LUO]C;
M]F#Q)XS_ .$ZUCX&_"B^U><WDFKV=U\,_A[<Z;XDOKZ74;FYU/Q);W7A>>YU
MC4_M>J7%\+RZO&F^VK'<R%Y5=I!5+;+6RU=]U&SV:W[@X7ZVU>W9N_9K3M8_
M(_2?A18^.?\ @J%\2=+^,=K_ ,)?JUAI>FVLFH>?-H'F0ZU^S)?K.GV7PMJ-
MI;)NT^'3[7<LCN/L_G(T4\LY/K7_  3.T6W\)?M%_M<>%-%'V3PSI'Q?^/=K
MI>G9>?[)'8>.O 6FV,7VR[EN=0G\C3[:*#?<W,K2[?-F9YRTC?J[;?!+X8VW
MQ)U#XNP^$-!3X@ZJ+5;_ ,2MX?\ #ZZS<I:: WA:%9=9325UN8)H+OIJB;4I
M MHWV-0MF3;E?!GP8^&_P]\3^*?%WA+PEH>A^(O&FJZYJWB#5=)T'0=,N]3O
MO$>H6NIZM<7U]INEV5]>RWM]96US=37MS=37$L,<US)/-''(B<TU;^XH[=;[
M_=I<%%IWT^)O?I;_ #/B_P#X*5_&O1/A?\*-+\-ZCX'_ .$YU;Q]]N_L.S_X
M26[\,^3_ ,(MXD\"7^I#[1!I6H6TF^VU!)/]+GL]OV/9;_:)+@HGP1\)=-^+
M.B_M@?MPZ?\ &[QC_P )I\0F_8Q\=ZEK4W_"/>&O#G]FC_A&O@_;Z/IWE^$9
M)=$O-NC0V5_]KM'&?[3^RW4?VJRE8_N;\5/@S\,OC9X<G\)_%+P3X7\;:/((
M1#;^*/#?A_Q)':;+[3M2D^PQ>(M+U:U@-Q=:3I\EUMMCYK6EN[8D@@DC\S\-
M_L@?LY>"]3NM7\)?";P%X6N]1\*W_@O4V\.^ _ NB/JGA_4]2&IWUMJ[:9X9
MM9;Z*YGC@AGAN)7LIK6SL8YK61[=) 1E%1LT_P ^J>E]E96:Z[C<6W?^MFOU
MW/PC^&GP0^&&K_\ !/S]LCQQ?^&?-\42?M/:C;_VG_;7B%-D%YXH^!UW<#[%
M#JT6G-YD][=<_9 Z>=\C*D<:IR_@F_TCQU\0_P!A_P &?'&Y_M/X9R?\-+;;
M+R;FRW;=#N]5/^D>$$L]?7;K]GI,O-T,^7Y?-D]S&W]&ND_L]_"#1/!'B7X<
M6'@3PK'X(\9:^_BGQ#X='ACPPFDZOKLDVD7)O;[2(=%BTC4+@2:!I4XN;ZQN
MKP2V%M+]H+6MLT.?J?[,_P "-=^'FC_"O7_A?X!\1^#_  [_ &A_8FD>(/!/
M@[6+31/[7UR/Q'J7]G6%[H,VEZ;_ &EJD,-U=_9-.@^V2P0S3^;<1).*]HM=
M'K)M6Z)JWG]WKW%R/3;1?>]?TZGX9'PO\'_#G_!7W3X_A5#^^N- M'\;P>9X
MH_T;QU-^T]M\2OYGB.XG2;R7@TY-ND%='D^]8 #S\_TC$HJ[CSY7RYY'/"GC
M\O4<\5\X>$/V2/V=/ /BO2?&W@OX1_#WPQXDT?0K#18=6\.^ ? NBW=TFGZE
M;:O'J5Y?:3X;L[^?6)[^SM;FXO%NXA++;P3+$DT4<J?2&Y5Y56.[DA5'!]6
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M$K673ISJ$<9EGMMEP45?(EAG"S!1DHI]W_DTO1J[UZ[!*+;3TT_S3_&Q\"?
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M?!/A[X8_#W0?!=PMOY_A#1O!?AO2_"\S6?V 6HFT"QTV#2I'M%TK3!;A[1C
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MCO\ 9Q\#R6=YX8^$GP_TK5K72=8T2ZUVP\!>!+'6]:TS6M1T_4[BTUG4]/\
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M6K>)O$FDC0]2\00:>WA_^SCJIT[-K%JMW97>H&-I()[J>!O)JIX/_9-_9U\
M>,/#/C_P-\(_AYX-\4^%?[9_LS5O#/@'P-X>U'_B>:7=:+>^??Z/X;LM1_Y!
MU[=VT7V>]M_W%U<0R^=!/+$XYI\VCUYOQ22Z^6O?J'*_=VTM^#U_X'8_*G]D
MMG3_ ()/?M(P@^7(NB?M'QRI@/L#_"=W^]RK91T;Y2<9QD$$#Y>_9AT+PAXP
M^/G[$_A3XBVOVOPI)\,O$MWI>G^?JD'V[5Y?@UJ4VO3?:]"FM=2MMD>C^%9O
M+N+D6K>5Y=DH9]1$O[YG]D?]G0:SXSUR#X3?#ZSN_'WAF^\(:]'9>!/ UO!<
M:-J5AIVFW<81/#7FRO);Z7;(RWDUY:OL"R6TB+''':U/]E+]GK6? ^D_#S6_
MA#\.-9\+Z%&D.C6FJ> /!&HII*I!H=M*^GP7?AV73[":^@\.Z-!?-:V4(N8M
M/M(F 2TM%@/:)<UK^\]?+W;?-IZWT;#E>FWN_CK?Y'X?_M9Z#I?@O]M3XN6_
MP_3[$GBSX'_'-?&]MNN+CS;;1/V+M;;2!YVMS71CV6]WJ3_\2AK:1M^VZ\UU
M@V]9\$/@/\+=9_X)H_'CQ-J'AS?KVGZ'\4/&=I>?VOXB7'B*T^ 6DZA;WOV>
M#6(K(XO97E^S2V[V/.Q[5HL(/V9\&?LN_ ;X?>%=?\'^$_A5\/=(M/%VBZIX
M?\7:C8>!O!MAJWB32]3M-8L#9^(KO3?#]E'K%O%INOZII=K;ZG:W-NFFW=Q8
MF&2"XN$FZGP]\%?ACX:^'>N_"W1/!_AVS\#>(+/4]+UKP[;^'_#]OH]]#JNA
MP>'=12[TFTTJ#2+F*YTB"*QN%N]/F6:U5;:>.2U58%'--):IKE5^Z3U?E?M]
MX*+OK;5/3LVM+'R_^PEXU\,^'_V1/V5O#?B'5OL^L^*_A[<PZ!:?8-0E^V0^
M&9KNYNXOM%C:36MO]@TY[7Y[V>V>ZQ^Z-Q.9%'WZ"2,D8/IG./Q%?.B?LK?L
M_;_ )E^$WP[NF^&=KK5GX1CO/ G@J>WLK;Q!9Q6.I00(WAW-M"MK!##%%IGV
M",)##'.LT<:H/HI#E0<,,YR&&&ZXY_+CVQ42:;NKZMMWMWT_X):36]MDM/)#
MJ***D84A&01DCW!P?SI:0].N/>@"NQ;^%59D_P"6'"YW>LA.S@?./E]NO-?G
M#^U?^W1\3/V?_CAX)^ WPI_9H_X:!\8^.?"WAOQ/80M\9M!^%7E/XF\7>(_!
MMKIZ2>)/"6LZ4435-&TY5N)]8ML_VUNEAAMM.GNI?T@BR%C#(8B=^(QF0+@G
MK*H*C<,,-Q')VC)%?C)^U&P_X>@?LY=<#X8_"$@J"X,8_:$\0X<E00J$<EB<
M*.2>:J"3=GV;^Y-]/0F3LKI]4OO?:WF>X^!_^"A]S9_$G0OA#^U#\%S^S-\0
M?$UG>:AHN@CXC1_&4WECI>FZW=:K<?VK\//!+Z);?8M2T&\TKR;O4H)KG;]M
MMDD@,2S?I8X8*QR&)'"XQE^D8!+$*=^WD@X//&,U^%W_  6@U+2]6L/@CX4\
M.R6NN?%2>#XCW/A/POIE\EWXDFMAJ/PXDUFXM]"A::2X@_LK2]6E::ZM'C2/
M3-0DMV$EG<-%Y'_P4"U[P?JVN?$<^'XA\>OC)\+?"6L>*-2:SEU/P!IOPBU.
MW\!:+XK\+>)[_6S"W@/Q,6TK18_%-GH=S=7$&I7/A%O"TEM<:EKCV4E\BERM
M:73NK-I6?=]_-]DKLGF:NGKJM=%O_7;U/V]^.'QU\%? +PYHGB7QQ,+2'Q#X
MHTWP?IJB'5)WN=7U:QU:_L[<S:1H^LR1I,FC78+7,$-JA7=-=1L8DE]P8@$*
MS%2V<%006QR>F<8]R<\XK^77XS>'M+^.'[ ?[+_Q"^*^FC7O&+?&[X*>!);W
M[;<:8D/A8_!?5-;?1UC\-SZ3H]P(]4U;495U**T.H2B;:EX;6."*/['_ &G_
M (9?LU>%M=^%G[,'@'X;W_Q6/A+_ (3C[/\ LO:)K/Q.L+^\_MZS\/\ Q"F^
MT?%1)]7U#2_L_P!HO/B'%]LUB3[=#ITOARWV0.;6)<BLE>SO);;\OSTW2UTU
M;;5M7S/73MU[W\M=KNU_*Y^X? P641EF"C&"6R.!E1WQWX&![4K 9Q]\XSL;
MZXSD\#'Y]?6OR<_X(XZYXIUK]E;Q'!XLTB'0KW0?C1XMT.W\/VVL:1XAAT?3
MIO"O@+7EB37]$3['JGVJZUN\U-G\VXGM6U!M.>55LD@A^V/VJ_$_P_\ !GP'
M\9ZY\2/&5O\ #[PC!<^&H;WQ1/I.I>(/L-S<^*=%AL8H]%TF.;4[^6]N3%:&
M*VBD:VCFDOIE6WM9G27&TN7?6VB].GS*OI?ROO\ J?139!!^9F/2/< IQP>H
MP,#YN>_3FCY6 VX"ELL0,!R>JD<9W \DY'8YK^2W1]?\4_!7]HS]G[4OA=\&
MY/@=H/Q$_P"%K?;O$^I>/;+QAJ?C;_A$O LL%K]I\#^-;>[\0^#?^$;O-5U#
M3X?,L=-_X2&WU:/5U^V6-K:3+ZIX$^"NM?$K]H[]L[XO/XX>RN/@9\3?VBOB
M#H/AJ/PI!?RW^H?#+QW9^)]+TR/4H=3LFC>Z>_-@ES<:5K,:,@GEL-1+BV2_
M9J]N9V[VZWMW\U]Y'/Y?B?T^?+D[4 ).T;<*9-GRX)QQLQ@;L\<+3B&(4#!!
M/)4;1C/0J6)8'/(SSCWK^4=O#OQH^)GACQ#\;/AU\'?'7BCXY7OB3Q$+7XAZ
M1HNJ75G;6UKXWU/PC;Z?)HLFBKX##Z7X&T^Y\)--<V$4]W<:=-J4H/B%GEK^
MG'X3:MXTU?P!H-_\1-*GT/Q?<'4UU73KJ2Q>:,IK6IPV"%M-M[6R)FTR&RG7
MR(5(651)NE$CM,X<MM4_N_*[?WV*C*_2WY?H>D8.?E';:<':JGNVWN1QT/3C
M/>OAW5_VN=8TW]M/PG^RM#X,TRXTKQ)_;WVGQ:VJW<>I6?\ 8_PHB^(T/E:;
M]D-I+]HN9#ICYNAL@47 S(?+K\\OV^_ GQ'N?VBM+\>?%KX=ZU\7OV9-$\)6
M0FU?0)18K\)]:TWQSXRUF3Q7K5E\.$O_ !]J6D>!/A^VI76HSZS:6WAR\&IP
MQ:C>PZTEC$_G/QN^%'AO]H+_ (*0?"/P=X:\:VEIX'U'_A/O-U#3=-?Q'9:U
M]D^!&DZHGEW,>L:?=6G]G:OHL\#^3J(\^5I(Y,QP&!ZC!6;>JY7JM>6UM=]]
M=O7L2Y.Z25M5ZM:_U<_HR\M0H8-C9R7 PQ0$L4)')7.3CITX)YI R[Q@AGVA
MU4*4RLFX LQR"2%8_P )R.1R*_G@N/%OC']B#Q1^U?\ L^_#*:XUCP/X6^%G
MBKQ?X=M[;3[-1X3U?7_AAX!U6YU^[GU:R\8ZM>66G:C+=WL_]M:VVD8OU@D6
MUMX((Z\W^(?@#6/A=^S#X5_;<\,_&'1KSXJ^(=&T'Q;XCM$T7PVD^L-\08?A
M]&OA6*.\UK4M#@N/ ]W\2O%^JWE_I?@^.XU*+78X+ZQTNVLM'>R/9KK*R=N7
M3>ZOKV\_PN/G\M=;^7^9_346# $'=D@# *D!B%9LG/*C+#ITQU(I@=6#%&9]
MCM%)DD>65^\PW ;F7CE<YSP:_FK\6?%#XB_ _P",7Q#U)_#7B#P-X=_:D\%>
M)_"7@31-2T6:Z2]\8^&/@[JO@?PU9:3JVI^';R[UJ\O/B'XOT1(K0KI4'V_4
M[32KIKNSDWQ\O\,?VG?BS\$?A#\6?V;OBS8:AI'Q+^/UOX[U3X=6NO6&F>']
M5OD^*GAC3_ ?A%],T6/PO+;:JESK^DZE'9-<:E8K?7,4UI*EK'")R>R?==/S
MUMKK;?07/Y?UT/Z?PV. "X4 EB>1N&1U&><XXZ#K3>2QW;791L;"[5+'Y@H5
MBQ!*L/FW,O)X[#^6SX4_LY7OQ7_:J\+_  3^)'B5X] M?AQ\*M1\9:-<:"ML
M]WK?B']FO2?']S:RWFE:UI6H6$ND>*K<^:-/U00W$D1A,-M9$V!_3[]@?1/$
M7P1^+7QQ_9:CUMM9\"?#O4F\0Z).VE6>F;;_ ,1>!_@AXAN(/*DEU76=PN/%
MVJL&N_$-[&PE!CMX8EMH;92A;K?2^VZO:_\ P!J=W:W6V]]=S]+?&GBW1O ?
MA[4/%GB"Y^RZ5I*6?VI_)NYTA6^U"VTRW80V5M>7#2-=7L,.Z&WDPCDNJ1!Y
M$^+/V.OVI/CG^T_96GCW7/@+H?P\^$^N^?\ V%XFMO'VE>)M0U+^S)?$^C:G
MYEBK:7JUO]C\2^'X=/3[7H%OYL%ZTT'FVUN;V3OOV[_ 'A/XD?LO?$/PUXST
MC^W=&DO?!NHMI_V_4M,)NK7QOX>\B3[5I5[8W8,7F.=@G$;Y^>-L#'X)_#O1
M/!G[,W_!.OP;\=/A/X(FT[XM>//^$B_MKXBQ:WKFIV&C_P#"+_'.^\'Z=]NT
MC7V\0^"H?[0\-:_J6A6WF6&F>9,YND^VZM'#- 1BG&_5NW3M>^ZZ7_!),)-I
M^25_76W9^G^1_53R>%!"KSA6"YD'_+(\?<(ZG&WWI!NWIM!&2^_YAM1MHRI7
M +@'A<$!22<D<5_/?\7OA(/V%_&/[//Q%^"_C"RU1OB1\1/A+X;\:>#K&SL;
MB_\ B#JOC#5-3UWQ'\0;.ZUS6?&U_H]EXL/A'2M+M]'\.:3;Z3I\TB2:1?13
M--;7>G\*/V<M1_:Z_:9^-WC[Q)XTE\'#P5:>%;J#PK-X575Y8[[QWXH^.$FI
MPSZI;ZSX6F@EL/L%E;.EU83B9[1C%'9/+.C'LU:_.N6V]M;WM:U[^=^P<[O;
MEU[7/W\W$HA7+ [@03P$S\[N#CS I P@VD@D GK7SE\//VF_ OQ.^(OQ%^&7
MA.9+S7_AC>^+M.\0(T.M0 :CX+UVR\/ZM81G4-#TVR4B]U"V"W5IJ&IVRAO]
M'-[$'GC]ZUK1;+Q'I.J^'=9A%WI.LZ?>:5JT'G20&^TW4[6:SO;,O:3075KY
M]K<2PBXMIXKB/_60R))M=?YZ/V,_V5O@)K_[;W[3NH:OX -U??#+XR?&GQ1X
M(F_X2GQG"VBZMX+^+GA:?PUJ @M?$,,>J#3III7%MJL>H6MZ6V7T%VH50HI-
M2;Z1O^*2&VTU;J_OT/U3_8A_:RU?]K3P!J'B_6_!VF>#M0L/LN[2],U2[U:W
M;[5K7BS2QF>[M+4C;!X;BN.-V7NI$.WRUW?;*?(@#EE.3DLV]BW. Q4#=\N.
M>,* N<BOY4OV*_V(=&_:!^ _C[QC>^)=GB:Q_P"$5_X0ZX71KJ4:']I\9>*M
M+\0_N[?Q9HVG:G_:>GZ*B?\ $TMG^Q9W66V<-)+S<7[5OQH^*7P?_9?^$&O#
M5/$7ASQ3J8E\9:;I^@Z2_P#PL1=8^,'Q9\)W_A.VO-!\)07_ (?U'7/#-[:Z
M#"^@ZFFIVWV:/5;*U74+O[2+=--OE:T=FK6:T_K];$J=EJKZ:.^^I_6D0S,I
MR.1\K$$IT)P4W!B=N>=PQQQQ@^=?%[QM<?#+X3_$_P"(]M81:M-\//AYXU\;
MVMA<W#V\>IS^%?#>I:]%I\UU''++;0WDM@MI+/'#(\<4K.L;E0#^1G[ '@_X
MX?#/]I'6_"\?P?\ &GP__9WUSX<>)M4MK3Q#IUS;6>C>,9O$7AW^RKF/6O$N
MF)XLU=F\-:+8Z'#:B_33;@/)JKQ-?6]T7_3K]JA@W[+G[2?_ "S9O@'\80<
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MOA>>_FL(9-.TZ_N+^T$UUX9\.>(' DN+:VG*A]=> !D(,=NC,Y=V"_3!/E@
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MM<S0P23Q6S7QA$[PQO,(Q(\43,4'RC\0OV]_!7@K]L;PU^QSIOAI?$?CC5M
M\$:YKVJ_VOJVCR>'+/QKXLL_#L*BVG\'76E:N+*UU;1M6 L_%$<EP=0^PO!:
MR6EU/%R'AKXP>,O@Q_P3P_9T\0_#KX>>._B;XU?]G[X(_P!@>&? ?@_Q9XLO
MYBNA_#^QU82MX:\%^-HK/RM+U6^OXSJ5@@N8-/O/L6\V\\UI^)/P@U?6? G[
M8OP%U7Q_X(^,</Q0\1V7@.]\91^)O@1\8/!&IZC<+\;O[(T?44T._P# EM9P
MV">%_#WAO3$O-&L(M+GGLIVFF;6%U8O48I\S=K>\DNM]=;7O9=WIW$Y6M\FW
MZV]?/]#]M?VW/^"A#_LB75KI%I\,[3QCJ%S8Z5JEQ=7WBRZT>UT[2]1U;Q!I
M OIK*T\,:F^H,U]H<%DD$&HV]RLFJK=R1&UT^7[3]*_M"_&+X@_!_P"%]U\0
M_ /PMMOB=>:5Y/\ :>B7OC'3?"SP?;O$.BZ'9XU?4+:59/-BU.\NSY-G-L%@
MEM)Y9N$E'P__ ,%D+]M3_89M]1:WN=/%]\2?AS>""ZM[F&\MDNK/6)UCN;&Z
MM[:]M[A#)Y,]I=6MO=6\@=;B"&2-T7]6](C9],MX%!,$GF[9&&QDVW$KM^Z?
M;*VYQMY(P/F&5(J791@[:WE?71V:7]?J&K<M7LK:;7^7Z'.?#3X@Z#\4O OA
M7QYX;N?-T?Q/H6AZY:N(KZ-D.M:/8:S!"_V^ST^ZE"VNH0%I)+*V9R?GCAD#
MQ)U.NZYIGAS2;O6M9NUL=-L1;?:;TV]S=>6US<Q6D8^S6<<UT^^>>&/,:/M\
MW<Y"([#\RO\ @DWJU]-\$?BKH4H:?2O"G[0GCGPOX;N51!!'H&A>$?AQ9Z/9
M12QPYNT6V)DCOKFZO+F=#NFNKCB2D_X*]>-]8\.?LB^,?#VCB2"Y\6?\(\7U
M40PS6VE_V'\3?AI>J+G[393V0^V)--:PFYN[',AS#]IE"Q <5SN.MKV\[;_D
M._NW\OQV/9?V6?VP;_\ :0T;XA_$:Y\ VO@OX,>'=,TS5O!'C>W\22ZY<^*(
M;7_A([3QG'>Z =&TKQ!IJ:%JWAN^MX?M.B6K:C'&7LX[R-X+B;G_ -F+_@H!
MX*_:>^//Q@^"'AOPP--N/A3J'Q M?^$B&LZM>'7[+P+XRT#PC]K;2=0\&Z"N
MF)JK^((+XVG]KZA)9>7]FW789[J'RC]IGQ=H_P"RM^PSI/PM\ W UW4OB6WC
MWX0^!=,T%+G7-=U_4OB!IOQ%O&7P[X?@MO&6K^(;RW\0:A8::FG61DEN=2U&
MPT^.\M)KVULY?R3T"_G_ &>?C-^RA\7W^%?QI\ Z5J5G\"O!'QC\0^.O@G\;
MO!V@'Q=>>*H?$_Q"U ZWX]\!1:,DAMM$-\=.\,+'8+96=W=Z+<I:VMX!:C&7
M,]KW45KTZ][O9*VOR)<FK;O9O;KT\DEZ;'[Q_##]L'5M>_:#U+]G'XL_#2U^
M%WCR3['_ ,(C!;>*QXP7Q7L\$ZAX[U_S'T/1)M'T;^P]&ATUT_M+7D_M Z@P
ML]UU:S60^Y5*L5PP=L;L;"$ #$;E5B=K C&=Q/4@8-?BI_P5RM8/#6H? ?XD
MZ%LB\;Z'_P +0_LFW63SKS5?[3@^&N@W_P!EL;I[BU/V'2)YGGQI5WB(^<?(
MD"W*_M&NI:?+>2Z;'>6DE_$BR3V2W4/VN*%Q%B9[;?YPB(FA EV;"TBJ&W'%
M1)*T9)64D]%?2SL_E?S]2DW=IN]GH_7[BW\DFY?E(!(9=I^\",]>.N.Q^M-;
M+$DON !*HH*AN/F5R2P8'''"A03G=6-XBU[0O#.D7FM>(]4LM$T2P%N+W5-0
MN%AM+87%U!9VRS2L0(_.N[BW@C)/S2RI'U85_+IK&H:3I7C[X&_'#X+_  PN
MO$MK'\5O BS?M2ZEXEU3P5;>)H)_B)X*\'3CPY\'O']M#%KO]CQS:S\.=7_X
M1?3=4?2Y((_%.K?89KJQN"1AS7UM;^NK7EM=Z[!*7+;2_P"A_5&I"_*<Y(\W
M&?\ 5J<#"\8PG;&/8495R5!PW'S+PX&,J=Y'.]1VQ@$@\U_-SIOPJU/]K7]N
MS7/"'C/QG_9OA:X^".I^*=<T<^';>Z.MS3?&*/3-3LQ?Z7J/AK4M.&I:=XDN
MK47-E<A+3R_.M[<3M')!H67QQ^)/[*_P<_;U^&/@34Y(]-_9S\>?#KPY\+M0
M;2]&^S^&-#\3?&KQ)#=V]PVM:-XA%Z+W2+Z.P@G\5ZIJ]T[1B>SN([R0[7[/
MHI)NRNK6W=M'?7\_(7/UMIK;7LNUM#]A/VQ/VD=3_9C\!^!?&>D^%K#Q=-XO
M^*WAOX;26.H:C<:7!9P>(-'\2ZH^J+);VUT\]Q;/X>2&.W=8HW2ZE9I5*J&^
MAOA_XCG\:>!/ WC*XMH["?Q7X0\-^))K""1I8+&77=%L]5DM897"O(ML]TT"
M3,JM)$F2BECC^7S]J']FCP_\+_@E^RC\:?#/CK3X_&?Q*_:5\,^'/B#*;*)G
M\?Z7H^I>,K325L[?4/$^H:;H_P#86FZ*FB2GPOI%O<WDNK175_.U[#$+C^ES
MX%G9\$?@T!P!\*OAXQ Y9O\ BD=)7:%Y88.&W '[I'0DT2C%15G?WFKVM>RV
MM=[!%MM]-$[;]=_FCB/BW^TK\/\ X-^-_AU\/O$,ZGQ#\1_^$O\ ['M8X-:B
M0_\ "(:1INMZAE['0=5LC_H.J02?Z7?6/.5@^TS%X8_)? '[7>M>,OVO?&G[
M-,_@K3K'2_"O@3Q'XKM_%$6LW4U]>RZ'\3K+P#%%+IKV26T4-Q;W3:A)MN3,
MDR"!28R9!^9W_!37]GKX.^,OVROV:]1\2^#QJ%[\2O\ A<?_  G$[>(O$]DN
MK?\ "'?"OP#!X:W"QUNTM]-^PQ6L"+_92Z?]L*9OOM;NY;AK;]ESP_\ %[_@
MH9XW^#L.LGPW\-?"WP<\2V2^&%TV^UO[=H&A_&]?"PT-M:/B#3=?LQ<Z!J8T
M\ZH^J3WEOY'VMGEO9?M$;48VU_EO?>VWFOPZ"YG>W1.UMNY_2@58GEAG QP=
MAZYRF[)(Z@[AU'H<M4J3MV@R)C?NPS+N^Z=^ &^7G SP-IP:_FYTOX@_$/\
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MUNM0TKXB^(!#-H>LZ?J $<C0I+<);76GQ%<SMMOKVLF_T+;LK[_\%V_4]?\
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M#[PQHG@8:-H.COK^K:C--9W$EX[6LJR">2]>>:3](_#ND_V'I5GH[7^KZT+
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MWP)XE^-GQC^+7B6?4-6C^-'PMN_A?X@\/W<NC7^CV.G7^C>%?#]SJ&EZ5?\
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MS;&ZO-!N?&OA;Q]\8-?C?51)9SM%?>(/$DZ6L>HPZJT%K&EE;SQB,W4W3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3&8J.%RQ.%7(&[OUZ#Y03SZ8ZD4^HMQR5^8?,3N*@ +T
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M5+^O+] HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<<#)_A/S#')J2I;NVWNQK8****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *BE+@,R EEQM7!(;<0#D#DX&2,8P>M2TSG<Q&XXQQGCIV&./7W- # '0X+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.BW_ (8.JVOB&Y\#6MD^JZ/X>N;:QT*^NO#TMWIZV%E;&>XL;6.W;F/V-_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M26TL?[1"122,%2I(PV 2HX\P#.3&3T?I2J<S?O)+2VG^:5KH<+6T=]?0DHI
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M>. HYQD=<$_A3ZC1APN-I))()./F);*L1A\YR=I.W.#CI4E9%A1110 4444
M%?@'\>/^4_'P9_[1[_#O_P!;1UBOW\K\ _CQ_P I^/@S_P!H]_AW_P"MHZQ5
M1W?H_P A/9_+\T?OY132Q )QTX&3MSS@]>GL>A[<$5\>G_@H?^P"&V?\-R?L
M>^9L\PQ_\-,?!<2>6#M,@3_A-=Q3=\NX @ME<[ABI&?8E%8GAWQ+X>\7^']#
M\6^$]=T;Q/X6\3Z1IGB#PUXE\/:I8ZSX?\1:!K5E!J>C:WH>LZ=/<Z=JNDZM
MIMS;ZAINHV-S<6=]93PW5K-+!+'(VSO7*C(RV<9."<#)P#RV.^.G>@!U%%%
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MDDFN;FYG>29YEOTOVB[KUO=^EAQOYV\[?=T]3:4Y=05? R58+\F&!(!/L,*
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MV7COP1:7UU,/A?\ \(YI.LWNO:$^H_VQ#J=C:7LOAZ.QMJ_4;_@K4!_PWO\
M\$CSW7_AO;')QS\&?AOG(Z'VR#CMBCX[@#_@OW\&N!S_ ,$]/AV/P_X;2UCM
MT'X52U2]&]E]E:=/U$^OHN_5Z]3]T/!?@W0?AWX+\)> O"6G6>E>%O!'AC0/
M!_A?2+.SLK&RT[0?#6E6FC:-8VUAIMK8Z=9PV>F6,%M#;:?9VEE;Q1)#:VL%
MNB1)U2O&[8 &5^X^%PV1\WE-DYQC#XZ'@T\HIZY]L,PQ],$8/;(P<$CH2* B
MC&%48SMP -N>NT=L]\8SWK,H=1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV]A#I&LM:Z8+C4H;"8F5;IOHC]I/_@GS^VMXPUCX8_M!_!OX@_",?M1^#O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%%  2!R:\8_:'L? >I? [XLQ_$RU^W> ;7X>^+=3\76OGZS;>
M=X=TC1KK5M6C\_P^\>M1[K2Q?YM,+7PQ_HT<LA$;^SUY5\<?">F^/?@O\7/
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M\)%-X&\;WVA2ZQGXR^&?#.M:1_:>C>*O!TO]GI>:DEG_ &=L6>[N[S5)K?\
MHY^('C?X2:7%<?#_ .(GQ"\#>';KQCHT^E)X?\5>+/#.D:QJVG^(OMVC(UGI
M6N7<<E_%?2)>V-J1974%S/!/;".=HIHA_*U^T!\(/V@_V9?C3\3?%7[&W[8?
M[-.G>%/B'X]\:ZKJ7A&Z_:#\;6?B#P[=>*/%>M:O=6MSH'PLTS0--TB32['P
MYX5TB[AN+B]DLIQ-I\DEQ"--E@F"O?1WMIHVK=]/T8Y-Z:I+KJONZ_D?K%_P
M2O\ V\_B9^TI8>*?A=^T/8?8/C%X)_L/[9/]J\/W7]L_\))-\0_$5O\ NO _
M@_0?"VG?V=X6T'1$_=:A=_:]^Y_(U%;N";]FJ_$C_@DU^S-H'PCA\7^-O&GQ
MR^%'QM^-GBK^P/[9U#P!\3++XDSZ5_8;?$?2-.\^[U;0--\6V/V[PEJ5K!%]
MKN[C[4FDWL<'DZ98QQ2?MO4SMS:?U^0XW:U_S_S_ .& Y[#/MTJJWRQJ(_E3
M) 3KYI)/[O<W*;SD;S]W.?2K5%241* R+QLV@*Z_>P /FCSWQTW#KC(H)^X[
MIM*[LG=G9GCM][=QVXJ6B@"%58*$D;=@XWX"[\\XVJ?EQDKU_ASWIQP.C;0
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M\.ZCI_B#6#JNL0W.DZ8=-TFXN[T:AJEO/IUF8/M-[#+;12HWH%>"?M4"]?\
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MC7[6VU:W64SZ/--I-VL.I0K!/:7$DMC,R7<<=O=6LS.@$4\,F)5_A_A\#?\
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MZ+\ST3X#LW_#_CXR/\HC/_!/;XAC:<B4.?VT='.W'W>%ZC.00>PK]^P[L(R
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MLI%V@\ $X9L  ;CG<0![CN2<8Y.*333L]T-:I,?1112&%%%% !1110 4444
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M.LSIK]G>K)HPELX7NJ_H<_X(Z?#7]F'X=_!GQ0W[-/BJVUJTU[^Q/^$D\/\
MV'QQINI>'/[+\5?$\:/_ &A!X^U2^UA?[7EOM>O;3?:V&ZWBWK]JM7LY$_G6
M^):?M;?LP^/O#'@[7OV0OB/XI3X,?'+1?B!X>^('A;X _$O7/#?B[2_AUK5_
MI>DV^H^*[T: -?\ "^OC0)M:O(K&UTJWU2PN+?4K:]L1,\</]$?_  1O_9Y^
M*7P?^#OC#Q?\6]"C\(>(?B?_ ,(_M\*QZ9XBT"XT#_A"O%'Q0TP^9H?B;1-,
MOM+_ +4L=3TW45Q<ZA]N2Y-X?LD,UO')M-KE=FK]6K:Z]=+WZZ.WH91O=;^C
M;TT[?AKM\S]>]?N=&M="UJZU^>*VT*#2=1N-<GN7EMX;?1H;.9]3GN)$*300
M16:322S(4>-%+HP8 U_*'\;-8_82\4_M*>(]*\,_\$[M3^*OA;7/BS\1]#\>
M?M"0?M,?'?PEH-Q\1]//C[Q'K6F6OA6XL(["[N-9.E:9KT/_  C>J_V5!9>(
M0=.,]AI4_F_U:>*-!M_%'AOQ'X<OF9+;Q#H.K^'[MHRBE;35]/N+&>2-IH;B
M,,L=RV'E@GB##YX95!1OXO/VK?@#^US\"OCY\1O"'P!\=_ _XG^%G^)'CGX[
M0>%+3Q/\3?&OB;P0/%'B;Q7\/$_X3C0O!>C:1IWAH:+IESH_A_4]EL?[.\4:
MSINDC5[BWU&ULFBG;WM[K6ROJNNS7X]-M2I]-NNK/VH_X)8>(/V1;_Q'\1M+
M^%G[-LW[+GQ2T[_A$/[8\%ZW\6?BG\0M7US[78?$.XT_[*OQ M=-MD_LSPZF
MHZM/_95M<[K7Q#$;[R9+*RDD_;ZOP._X(T?L\^)K*T\=?M%?%#XF?#;XE>-_
M&G_",?V5-\+_ !GJ'C+0=(_X1R7XH^!K[[5)XAT1-7T_^T-(?3TA^S:Y=?:K
MRPU!9O(M;6"T/[XTIVYO=O:RW[_C_P /Y#CMTWZ!1@9SW (_ XS_ "%%%04-
M9%8@D9*D$<D8(Z'@_P Z%15 "C 7..2<9Y/4_P Z=10 @ '0=L?AG- 4 Y [
MD]3U/4TM% $3Y8[2<+R"./WFX=NA&SJ<=>^!7\]W[2=_/I'_  7?^&FK6UC-
MJDND_P#!-SP;?0:1!O2?49K#]L;7;F*UAECAN)5DNVB6VC\NWN&#R!EBE8!&
M_H29<DG)R1A<'D;AM)'IC.21TQFOP$^/"B3_ (+Z?!R%@KJ?^">?P]5RX#+(
M#^V?K"M#(3D.'!R\9&&!.?2JCO\ )^703V?]=4?R?_\ !3?]L7X[_$?]OGXT
M>*-7UR[\-7WP<^,'Q1\(_#O1KOPYX9N+SPIHT)MOA[-98;PEI<^N&X\/>&-,
MC,^NV.J7D$>VX%S]J::_N?@6*S^+7CCXL^#R_AWQ/JWQ3\=>(O"D/@[2[7PO
M+_;7B;Q#+JUIX5\*V^@Z)9Z9#!JUQ>:MIUOHME!9V,L5[J<$EDZ37@G4_P!,
M_P#P4Z_9(_9\\:_\%=_AGX*MM&U317^-VI_%'6OBO9>'=.\$Z;I9U?P_^SSX
M+\9Z5J>C6\?AN[)O]>UB2_UKQ3>^)+35KK5-9U"_U&VEANKN:Z.+_P %A/@W
MX.^#G_!3?X(:[\%/!F@_#71OV??V0/ /[3#6'PV\.Z7X-T@:C\-?VD/BOKMU
MJTMKX2TO2[47S?9K%+B_,VBSF.RM%DUZP^S0S+:W2N_>V6MEHGU[=&A7WT6B
M=WU>K7XO?U/K#_@DMI7Q.T#_ (*<>$M ^+>DZEHWC30_^"0.@:/JFBZQ8V6E
M:QHUSIG[07PWL[[1]8TNSA@DTO5--U6'4K6_T_48(-2LKJ&6VNX8F1$'U]_P
M<6[A^P7XL(W3%O["VQ(A+-CXR_!#.W8&9L#YC@' !SQDU\_?\$WOB&?BS_P5
M9\._$B6_COKSQY_P2%T?QEJ=U%=?:KU]4\4?M(^!->O?ML[7NI2M>-+J)DNO
MM%]>7!D??+=7#-YTGOO_  <7F0?L#^+R"T;1_P!@9:$LDIW_ !G^"&/LAZG
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M$+N*@A1\PC48( ZJ%' 9SRH'WNIJ1,D9(QN.X C! (! 8=F'0CL:D8^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OCW_@H;_R8#^W)_V9
M[^TS_P"J6\;5]A5\>_\ !0W_ ),!_;D_[,]_:9_]4MXVIK=>J_- ?F'\!_\
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M3FL?[7N]4OK"WO?UA_X.,23^P5XKVC(7^PMYSC;N^,OP/V\=3NZ<=.]?Q/\
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M@Z_JUZMIXQ\.ZGH>M?:/'7AFYT&_GTOQ%I7V*/5YKW3)733X;QK<# ^!BO\
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MT['EL/T1K^;O_@BY\1?&'P_^(OQ4_9=U+6/^$N\)^'_^$'_X1?4?[/TO0/\
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M3>H^)=7V_P!M>+;R&V^WZO86MN?[)T*'SH+2U^W>8\$5XG[R:!\ ?AC\9_\
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MQ>DG6>YGDCBMRL:-+(Q.V*)&D+;0V/[3B#N)& #C<3QDC[N#WYX.?H*_A_\
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M3X&^&?[4/P0;ROB]^Q]XFU_XR!,:(_\ ;_@;PWH-OX\\1>&=WB[6;?PQI?\
M;&O_  P\!1?VS_PC_B;6-/\ LV^QTN>RFUFSU#AKK]L3PU^V7_P2%_;%\=VU
MW]H\:^$/V0OVA/ /QDTC[/J$/_"/_%OP_P#LQMK/Q#TC[?)X8\+Z3JO]E:MX
MH6V_M#PM9W/AF^W>=H=Y-; Q6_[4,#D+&%QN4MO'R!!]XQ;> _.>>,YS7\(7
M_!?/Q9-\$?VP_$/_  H/4/$OPF3XO? W5O!_QIM?!]V_@/2/B7'X_P#BC\8_
M^%C-XF@\&7.DCQD_C(:3HT>M'Q7_ &FOB&UTVU37;6]%G:^6UJK;6UOZO_/;
M^F+9^O\ 7]?TC^T3]F3S5^"/@F.5MTT?_"2>;'M49W^+M?9/G7Y1A<-\I.<8
M.#7OX)(R1@^F<X_$5_*W_P $*?\ @J[%\0/!6L? #]IGXE?#?PY<> ?[/_X0
M+QCXQ\9+H^O^+/\ A*M6^+WC3Q3_ &SXA\?_ !&O9-=_L*.RT'2]/_L;1K/^
MR[*>ULM1^T"6RND_J+TG6M(U^QM]9T#6=,UO1+SS6L]3T;4+74K&\DMIY+2=
M+2\LI9K2XCBN+>>WF6*5F2[BFB?:Z.JDD[M]&W9ZV_(:VMU5D_N_+S-JBH0Y
M#='*E=_3)#$XV=<#:.2O48SFE#,#S@J2 H&3(<G#$CIA2<DCH@)/2I&2T5&&
M;>5(R.2&4$@<X 8Y^]W(].:DH 1B "QZ*"WY#/:OSK_X*=_LM?#?]K/]F27P
M?\3[#[=HW@OQWX1^(FCI]JUZVVZ];#5?!<4F[P]XA\-W38T?QSK*[+JZNK(^
M9N:Q:Z6UNK3]$V_A_P!X?UKP;]IL ? _QN0 #GPV<@8Y/B[0 3QW(X)ZFG'X
MEZK\Q/9^C/Y[_P#@@1_P3J^ /_"@/V4/^"@XTS?\<#_PO7?K?VWQHOGX\:_&
M3X)+_P 2W_A-_P#A$8O*\(_Z)QX+^?'V@_\ $S_XFU?T_MN8-\OF*D9_=;@F
MZY7^'?U&1\N[F,9SVK\B/^"!Y)_X),_LHDDDG_A>F2>2<?M*?&,#)/)P.*_8
M/ SG SC&>^/3/I1)ZOR;_,9'$'$:[QM8@'9D'R\@?N]PX?8<C?\ Q=:DHHI
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MV[3(TLIH5'H@<L5VKE3NW-G&S'W>",MN/''3J:?@$$$ @]1C@_6EJ1A1110
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MCG^TKQ=+,D.81$3U2$Y((;Y<@,<X91@ DGJQZDC@BD,DHHHH **** "BBB@
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MQME_<?9_)N+9O*AM[:&/[[J9N\KVM\K#CHK7O\[V_!!1378JI( )&."P4')
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MO&V8$+XN!Y1_HM#G=@XD1<GS%()$GW3%Y:98D*2Q/8'D<9K\W_CW_P $C?\
M@GK^TY\6?%'QO^.'[/H\<_%'QO\ V)_PDOB@_%?XW>&#J/\ PC7AK1_".C8T
M3PC\2M \/6OV3P[H&DZ<?[.TFU\[[)]KN_/OKBYN9IYKO75:Z*RW\[;?TK!;
MMW6^NSZ?Y^OR^]O!GCCPMX_TV;5_"6I#5].MKR32YKDV.H6++=0V]K=21&/4
M[2RG8""]MI"RPM$QEVK(7214_&O_ (([O(WQ-_X*Y!D4L/\ @J-^T?''&, /
M%'XBN"KDDLH8AF+9QG:H"@]?TN_9=_9'_9[_ &+_  !JWPL_9I^'7_"N/ &M
M^*[_ ,?ZIHY\7>-_%_VOQ?J6B^'_  [>ZE_:/C_Q+XIUJW%QHOA;0;7[';ZC
M%I<7V'SXK..[N;V>X_-;_@CDZR?$W_@K>5"@C_@J-^T@KE9!(-X\03ED)7*J
MZYRR?> 89 !&4NOI^J'V]?\ ,_;Q2'Y5@5QQA2"#TP<D9!.<@ =.O>OPI_X+
M3?\ !-CX,?M(_ ;XQ_M,:IK.M^#_ (E? 3X#_$+QYI0T#2?"LNC^*U^%O@WX
MJ>/['1=:%QHJ:]#/KFOZ[)_:.L0^(&CCM;6$1Z8;PM>C]VJ^/O\ @H9_R8'^
MW'_V9]^TQ_ZI;QK0F[Z==/R&?DI^R)_P0F_9%TKX">%;J^\3_%.Z\9ZK_;GV
MKQQI!^&6B>(XOL/C/Q+'!_9FIS?#?5]4L=^E2)I%[YNJ7GVJP66WC^SV\HMX
MOI+P9_P39_:7_9OM;RY_9V_X*!_&KQCI.APW>L>'/AO^T];^,/C/87VJQBWU
M>30DU#PU\<O@9H>FZ?KNM:?'$DC:''#I\&MZ^;V2_DU%[NW_ $@_9C_Y(=X(
M_P"YE_\ 4OU^O>JIR=WKI=Z=+?III??S)232?5I7?<_"[QY^V_\ \%/_ -F&
M&77OC]^Q#\,OB%\)=-DCT>[^*G@#XR^%?A7(+^ZGFL-#NY/!NJ?$'X[^)Y1J
MUQ912S11PNULGB&UBNKR$Z)?7&H^K_LX?\%IOV)?V@M=TSP4?B"WA'XFZGJ%
MEI5CX'7PK\6]=2:^U.;4_L</_"1?\*JT;0(_.TZPM]1\R:]CAC:\^RRR)/;N
M'_7JODK]H_\ 8E_9M_:OTG5]*^-WP\/BT:II]W8BX_X2OQ[H!A-Q;:7")A!X
M2\5^'&E\EM$TA_*$D?F?8]I=1<W)F$XO>-O..GX._P ]V%FMG]_]?=L?4.G7
MUMJ]C8ZGI\[W-AJ$-MJ-G<JLMOYUI=0I<6Y>*X1)@LD,J2-')'%(-P5T1U91
MJ5_/)??\$6_B9\ =3OO&7[!O[4Q^ %UIL]SKNB>"O^%'Z!\53J5[9W#ZKINA
M?\)%\9/BGK*69O)-&\'Z3_:5W:O%;_V-]NN(6&HZI'+V'@O]JG_@KO\ L[W+
M>%/C[^PGXU_:GT$$V%K\<O!?Q,^#F@WU^ND)=M)KTWP>^"7@#QQK>F?\)-=:
MGHMA'I5V4.EQ:==ZE"\]K#JSVJY5T:>J5GH]?7HNK=D"?=-?\#^ME<_>EOX?
M]X?UKP?]IS_DAWC?_N6O_4OT"OD_PO\ \%2?V9+6ULK3X^ZIXK_9;\7WDPMG
MT#X^?"_XW?"K34NI;N5;.&+QC\4_A-\//#%T[:3)IFN70AO,:;INHBZU#R+2
MUGNZM?M,?MO_ +'LW[-GC/Q?8?M0_ 76=!,OA*WCO/#OQ4\%^)9;B\NO$_AJ
M>.TMK#0=7U'4;F\6SN8[Z>TM[.6XM; 27US%#:0S3QB336G7Y;[WVMY[>8-I
MIV[/39[=GK\MSQO_ (('?\HF/V4/^ZZ_^M*_&.OV$K\#?^#?C]H_X":[_P $
M^OV?OV?]%^+7@2\^-G@C_A:W_"3?"[_A(;*#QC9_\)+\;/C/XUT;[-H]W)#<
M:M]H\)0R^(9O[&74/L&EK]JU'[)&RD_O8=IPA/S* PB_B&.![[<_+O\ NY[T
MGN_-O\RB:BHU(!Y!3UR"0?\ @1&!@]#GG/%(#N&6&&&,#^%3GC#X"MG /4X/
MRGFD!+15<,WF,CC<IC+;P0&&6QY8C4;V4#)$H^4D[1S3N06);8TF-JXW$;!S
MR.&R.>V,]Z )J*CP0JA!@!N1UPN3GKS^7/I2!0K$J#AF+$889D/5LGD KD?W
M,\#DB@#\"/V<_P#E.K_P4?\ ^[/_ /UCS7*_?ISP.0,L!\RE@<YXP",'W/ K
M\ OV<&#_ /!=7_@I#M  /_#'WFC<-QQ^Q[KNS<IPR=..!N'/(K]^@[$XQU')
M!!V-T*X'7;_>Z'I52^S_ (4);OU_1'\CW_!T9XEO?!GB3_@GQXAL%F6\LS^U
MCY=U;WDEC=6PN+']GZQ;[/=0*UQ")X;IXY!']Z(F%R49J_3R+_@G#;?M%_L2
M? GX%6G[37Q^^!/@KPG9_&S2/%.F_ CQ%'X%T3XK^'?B7XTUXZQX8^(_AN)K
MK2O$?A^&UEU&SBTK48[NPG@UG6TN[>6/4YHJ_+#_ (.B;"R\=^+_ -@SP/I^
MHV3ZG"?VI/[2@MKJVO=0THR:;^S]J]J;_2X[J"YM?M\%G(]I]I> 3P;KF#S8
MEPW]>D6[;AV+O_$^S8&Y., ?+P, [2>G/)HNU%>M]>_H_)K[@T;OY6_'_@,_
MDW^-G_!-;_@H!^RW:>//@)^QJO[4W[7_ .S_ /%O]ECQ1\(-2_X69^V+\,?
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M_A#/A]X._P"$!\=3:UX@T+7]%_MOXT^*+75?%7_".>']=\*:-_:-B9='U?\
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MOD_V!\KCG'W>?3/7H<U-14C(P& .0A^8] >4]_5SW[&D8'!"9#$#;NSL7DY
MQR#C@@?[(J6B@#QGXJ?L_P#P1^.FFS:7\7OA#\-OB9:M%=K:+\0_ 'A'QF=*
MGO+ Z9->Z4/$^C:O'8WS6>V$W,4>\QQQ1OOB01U^6GQ*_P""*?PD?4KOQ?\
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M_,(S@#:QPN4!3*@'G=R0*E7.20<#)&/4Y^]GKTXQTJ1CJ*** "BBB@ HHHH
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M-;L;G4/%^@^$+72?%L7CKX&V5GIWCNSN+V;_ (2G0X)+"RL$2%[&V2<20/\
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M&0I/S8&!NSR,=MI7/\6:EHH 9M(Z,3D_,6QR.A(PH&X  #^'CD$\TWRR6!.
M5&%9<[@.1R""A)'7Y>YQCBI:* (5CP>  PZD$D 'NN<\[<_>!&>V*_CX_P""
MOD8'_!?W_@EY*55IO^,)X][%@!#_ ,-I_$QN I4>8&Y!*E><'C K^PL?>;_@
M/\J_CY_X*^_\I^_^"7G_ '9/_P"MI?$RJCN_1_D!_8,0PR5QD_WLXX^GM2(K
M*"K,6P?E8XW$$ _-M55R&+ ;5 VA<Y.33Z*D H/(ZD>XQG]01^E%% #0",\_
MRY]SQU]<87T%1+"$+%<+NDDD)!);+XR1NRN3C# C:!]T \U/10!&(PJA5
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MI?66FV?VFZB^TW]Y:V<.^XN(8W_(#]F;]I;]G5OV_?VX;]?CU\&'T_QY\3/
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M_@JY^TI^SKJ?[>__  3;&G_'SX+WH^"^L?MT^'OC&;/XH>"+K_A4VOZC\,O
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MTXRW/4YYZ"OT]K\P[O\ Y2W:I_V9[^SG_P"IU_P4 JH]?\+_ "$]OFOS1^G
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M[$W_ *VE\3*J.[]'^0']A5%%%2 4444 %%%% !2%0>O/XGCW'/!]".1ZTM%
M#2JGJ.1T.3D9ZX.<C/?!&1P:4  8   Z # _(4M% !1110 4444 &,__ *R/
MY4W8N<X/X$CGUX/WCT+?>()!.#BG44 (  <@ ?3C/UQU]L]*-H P!@>G;_\
M5[=*6B@! ,=/YD_EGH/8<"EHHH **** "@@$8(!'H>1110 FT<9&<9QDDGGK
MR<TFQ><@'(P<\Y7^[SGY?]G[OM3J* $"@  # '3V'H/0=@!P!P..*145!A%"
MKV51A1U/"C@9)). ,GD\TZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH :44D$J,KG:<<KG@[3U7(X.,9[YI=HSNQSTSWQZ9].^.F><9I:* &[%].^>
M"1@G@D8/!()&1S@D=":4*H)( !;&XXY;' W'J<#@9)P.!2T4 %%%% !1110
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M?^U+F]M-9GM+7[1X9T'6Y++[:-&U6'S[A4CM_(\R0IYML)?Y&?B3\)/^"?\
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MI3L8OL=N%+U_8K^U)^SEX!_:W^!/CC]G_P"*5E]N\#^/1X:&NV/VG6K;SO\
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M_P"1;^)?A;3VW:?X6T[[FFIC;\VZ<SSW!RK^;1;Z/Y?>%_)_A_F?VJ45_/\
M_P#$.=^P7_T*?_E>^,O_ ,_"G#_@W/\ V"N_A'/O_;_QF'_O;Z+1_F_!A=]G
M^'^9^_U1NS!6*;<C !;.T'.#G;\W3I@'GKQFOP%_XAS_ -@G_H4/_*_\9O\
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M:.?8^V(D+E&QXE^U!\)OB!\:/A3JO@/X>?%_4O@KJVHO?/?^--(TG6=6U?\
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M7AFVAM;SP8^H6,^MR>%H9[C2]4U2VF_M"62..[M;6:[L_P!N_P!CK4]4U?\
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MM?H$7=?A_5Q]%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY+'PMXP_9B\,6%G_ &OIGAR:]MELO&6G1V]['::=;)9PW5UJMO\ LZ5 X 3
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M%'_!0SXYOMS)_P 6RZEL_P#)$-3'R*, _+][(..HQUK?E35N5+W;WMKJK_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7YR?M6_L?> ?%FM:C^T#+^T-XY_9W\6:)HECX=;QI'KOP
M9TKP-8:=J/BN]N9DUF7XM?";XB:9;2ZM>>)Y=,M)B8FDN_['M+3R;B6X>\_1
MNO@?_@IM?7=C^Q'\:;K3](MM?N(IOARHTV^EACMI=_Q8\#(_F&XQ&1 K>=&"
M?]8BE22,546[I)VNTGZ,4K6;M>R;7W'Y%^+OVOOVL? FCSS_  I_X*W_ /!)
M?X@PVGE_9;'XL_'7X2RW4WVBZMDG_=_"KX<>$Y)?+:\U&;]W*NR.RTUGRHU%
M;G]3?V!OVZ?#O[47P_NF\<?%K]FS5/BO8^)Y]#?PW\'O'6FW5OJ.FVVB>#2V
MM:9HFI^+-=\0W5A>>)/$%W866H!8K:9)-,M! E\T@F_F-^"W[+/_  1D\2_L
MQ67C+QO\>?B'HWC_ %+[3_:T5I\,Y[VPT/['\0=5TJQ^QLO[/%_=3?VGHL%H
MUQY&MR>7-*PDVQI]D3GOV5M-\%_#?X\?L8:_\%]7\1>$O$WC;X@?LZVWB7PY
MI%Z-&\+>(?!'B3QEX=O=9U>\T_0]"\,"=M6U"QTJPN-+U75]0GETZVB@OK*[
M$4-S;Z.-[Z);[1MM?:VC3UN];]-B.:UK7]&[_P##/LC^[ '[N""O.<]3CIMQ
MP??VIU9NEO/-96<TX DELK.1RIRC2R6R-+Y2%W:)1(3P[R%ACYS@L=*L30*:
M44EB1]_&[D\[>G?C'MCWIU% #5557:HPHSQDGJ23R3GO2A0#D#]32T4 &!D'
MTZ?C7S)^VJ3_ ,,<?M:C_JV3X\G\?^%6^*Z^FZ^8_P!M;_DSC]K7_LV/X\_^
MJM\5TUNO5?FA/9^C_)GB7_!*?G_@GU^S3_V*GB'_ -3[Q;7Z#M_#_O#^M?GQ
M_P $I_\ E'U^S1_V*GB'_P!3[Q;7Z#M_#_O#^M.7Q2]6"V7HOR'4445(PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **0D#&2!D@#) R3T ]2>PI: "O%/VA?B[X,^!?PD\4_%#X
M@SK;>$O#+Z$-4>0:F(V_MKQ'I/AZP7?I&G:K?JQU+5;1@+>QG;Y<3"*W,L\?
MM60<X(..O/3C//IP0?I7QC_P4%\*>(/&W[(WQ8\->%O!MQ\0=>U!O ;Z;X2M
M/#M[XLNM4>T^)?@Z]NFBT'3K:[O+U;#3[>[U%S! YM8[1[N0K!!(ZN-FTGLV
MK^EQ/9^A_)UK7AOX4?$7Q9IGQ*\"?\&\G[1/Q&\+WGVW9XLT7]I+]KB'3/$O
MV?38M!;[(8_AV8K?^QM1L;S39_LD<GFW%C*)]K$M7])?[#OPO^'?Q<\.^'OV
M@_'?[%_C']E#XN^$(])\ :'X+\<^/?BEK>M:?X5T"Q\)>-M,O1#XEM/!MI>6
MEIXGU*\TG[1=^%[J:XN_#EVMQJ4T<L^G6OXH?LY_MB_\%G?V?OA]IGPSM/V'
M=7\1Z!HOVW^R+GQ#^S1^U7J^KI_:6MZYK]_YDT7B?1;)=U[K31I]FL(MUK!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'[,[^ ?CEH]UX@U+PA^TM-\44^$K:9XRL)[]-4L-1'P_7QDO@!;>]6[DM_\
MA&U\0M)<-'_8A1*EQM.RM96>K7E^/EK\RE*ZU\U^'H?H%_P2G!'_  3Z_9I!
M.2/"GB$$GJ2/'WBT$GKU//6OT';^'_>']:_.[_@DT]RW_!._]EXWHA6];P5K
M+7:P!UMQ=-XX\5-<I )3YHCCE+J%D_>( %?Y@:_0]FX'!)!W;<?,0,\@?H/?
MBIE\4O5_F4MEZ(DHJ-95<D+DX'S'C"L" 8V()VR#(RIY%*KJQ.WD#&&X*MZ[
M2"=V,8;T/%2,?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZB=7\<^)]>E>UUFUL=,@O(K&?5)=/NVCLH/LUW:7%HWFO TTG)?M7ZE^S?\
M%/X>^,/V=/BK\;_A;X(U;Q1I_A_7+W0?$'Q*\!^&O$\6C:#XVTR_M]8ATOQ'
M)J-S'H\FO>'WTD:A-H=Q:O>17-@DT-ZA>'US]G/X3W'P-^#'@_X6WOB"Y\53
M>%E\1>=K][!/;W%^-;\5:YXC42V]SJ^O3+]ECU=;--^JW>^.W5E\A&6VA_*K
M_@I=XK_X)K_ OQ#JOQ8^/O@2[\>_M%2^ O#ND>'?"$?CC]H;PA'XF\#:U\2]
M4GDMAK7@=-5\!:)_9^L1^+_$(EO=+&KW(T@:.DD-I?:4M2K.;U;UNFDM==[.
MR7X(IZ1Z6M9W>VG=;GX@/KG[<7P)63X#_"[_ (*+_L<:U\-DV?\ "/>*;+]K
MKXO:C%HVXCQEJW_$[\.S:/H.G?VCKVL:AIW^@Z./M;1/:7/^FI/=2_U-?\$\
MOA/\./@S^S;X8\#_  X^*'@[XO) =%N_%_C3P7XVT+Q_HNI>-HO ?@K2/$%U
M:^(]"TW2Q>->#2['5H9M4M%U:XM-3M;Z]8"]ABC_  %^&*?\&[_BGX?Z%XB^
M(7@3Q'\*_%E__:G]M^ Q\7_^"A'C=?#GV76M0L=-SXFT/5+;2]9_M?3;>RUD
M?9;=?[..H_V?/NN+29V_:C_@D_XT^#'CS]EZ77?@7\&;CX&^!T\>R:=:^%;K
MXH^-/BY<7=ROP\^'-Y!K3>*?'<,'B"-+C2+S2--.D3!H$DTAM1D8WNI7@%2N
MXO1K57O:SU=K>7I?S?=1WW7736ZT\_\ @'Z<IR2>G)49X=MA*DM_>!QE#_=(
M/&<5)4"%@_+;@Y(48 V&/(<@]3YC#..-O09%3UD6%%%% !1110 T?>;_ (#_
M "KYF_;4_P"3.OVM/^S9/CQ_ZJWQ57TR/O-_P'^5?,W[:G_)G7[6G_9LGQX_
M]5;XJIK=>J_-">S]'^3/AC]D3_E$5\(/^Q53_P!7;?5^87P1X_X-G/!W"L/^
M%<?MD_*XRC?\59^UAPX[J>C#N,BOT\_9$)_X=&?"(=AX5CQ^/QMOJ_,+X)?\
MJS?@_P#[)O\ MD_^I9^UA6F[_P"XC_)D]/\ MV/YC/\ @H;\*_AC#_P;]?LX
M?%*'X;>!8_B7:_LV_L'Z58^/HO!WA]/&MMI]_H'PZGOM.M/%*:<-?ATNZ;4=
M2EFM(=06&>6]NWFC<W-P7_IY^'GP@^$GPHCOX?A3\+_AW\,K;6/LO]J6_P /
M?!/AGP7#JW]GM>M8_P!J1>'-,TZ.^^PR:CJ+V/V@2_97O[UH=C74YD_G&_X*
M*?\ *MY^SJ<D'_AGK]@/!4E6'_%-_"[HRD%>,@X(R"1T)%?U!!57H /0#H/H
M.@SWP!GO4.]OFUN^CT6^RZ%+K_706BBBI&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !112'/4=NW'/MD]/K0 M%0+(6#[3YC*[
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MABS(%8D+@G>I.,(V20'4'YE'0]*='GYQ\^ Q'[SJ2.I7UC/&T]SNJ1DM%%%
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MYBQ"8P.LK,L**** "BBB@ HHHH **** "BBB@ HHI"< G!. 3@<DX[ =R>U
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M9Z?G2TPG.,,1R,@J<D9&1M(!&1D9QP#NZ#-/J"@HHHH **** "BBB@ HHHH
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MHHH **** "BBB@#XA_X*._\ )F7QD_[IY_ZM7P-7Y1>#_P#E7?O?^Q4\=_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %12A3C.,X8#)P<, &.,_=
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M _X1SX6_?R5P1'O^Z?O$=LU[Y_P5E^&_CC]G#XM?"/\ X*=_!;3[=;;X*_\
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MEW(SSS2)=7]O/.6E6^NF)DK]#OB;^S8W[6/_  5"_P""LOP(BU2WT:Z\;?\
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M&876)VB%O+XG^S'^T?\ LS/XEB_95^ _C'3/B4/ ?AF_\4R>+_ /B'PKXR\
MB#6?$]A>7FE+KVD^./$VIIK-G>>.-/FO;.Z@*6]O,)!,B26EO)]K^)O$OA_P
MEHE]XB\6:WI'AWP_IWV8:AJVNZG9:/I5H;N\M[&U-UJ>HSVMI;?:+VZMK6 3
M31^=<S0P1[I941L7\3:5M;I?/3^K?(U5N77M9_=J?RC>$/ '_!>[X'^#]-^
M/@[X16/BCPFWVS^S/&S^*?V(])DU;&J77C2]^VZ!K$NL:M-]@U+5KK2;;^UM
M;G\L6XO;#RK:2*TB_?;_ ()\_LRZS^RE^SGH'PW\3ZM_;/B[59M*\:>+IC86
MFG_9_%5]X%\%Z#K]F(]/U_Q'IC^5J?ARX<7&EWT6G-YNVQM4MT2:?Y<\)_\
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M.AWIM)-<\3W N=(TC4K*8Z68XVMO[0L+R+^H3!P,KEBX)()(!Q@/T&0  ",
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M+V2S\,+;I:ZCH\%Z+F]-Q]LL-,LX%U&XI/62WUVO;;7O;>U[]/F+M?MOY_\
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M^)?V9OVC?[#US^RM;T0:B-&\"^._#^J$Z9XATW2=7M?L>KZ3J%I_IFGP>?\
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MS1B5&BD1)(9%:.:.10ZR(_RF-D8%'C<$K*K AHRPP<U-4;@;D;JR[MJ]-Q(
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M!/R.V1%CX,_$@<*/F3>O)Y^;@]*_?\=.WX=*_G^_X)-XN/V]?^"N<9?$W_&
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M_JC_ ."H7P'\#?'?]AK]IK1/&>G_ &D^'O@C\1?&.AWOVO6(?[-U?P1H\?Q
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M\[DG.S]K+Q$L?L,#^Z!GODUHWMI;]XO2ZBKV^>O]:QWZ^Z[/RZ?Y'7_MM_\
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M_P!5!XPKZL,BJ,L<+D 'DY)('0#(Y('Z]*^0O^"@>J6FF?L*?MF3W<GEQO\
MLJ?M$1J=LKY+?![QHZ\11R,,K&QY  QR<D M;KU7YH#^5?\ X)5_L$>/OVM_
MV?\ 7K[PC^T'\?/V?=-M;]U\0O\ !SXKZU\*+/XC"7XB_$RWT=?$K:9X.\26
M_B\>#)_#5S'HBWSK_P ([)K.IK:Y?49%@_H0_P""=O\ P3DUG]@X7.D:5\?_
M (V>.OAQ'X<\2:)X:^%?CGXJW7B?X=^$;SQ'XFT+Q->:OX:\#VW@?P?H6@:I
M+J6GZW=/J&GQ"5YO%/B*>6*>?7+NX3YI_P"#>2Y\+7G["^@2Z-K:7_B&:^\5
MR^*-)CT>^L)-"BD^.'QS?PXTFJW,:VVM'5],+78%F2=-"FVNECE<(/WHV!G+
MJ[8V^64!P@Y#;PI'^L&<!Q_#QCC-5)N[5NBZ:[?UKU)2ZZ[O3YO^K'X>_P#!
MP^!)_P $M_B[F4J5\=_!J*1E<*%9?B/H+,03DABV%RW)4D$ FOW%!)<@+@#&
MYB,;LCY=I[XZ-GIT%?E#_P %"_\ @G=\:/V\O"6M_"P_M5^&?A9\(=?;0KR^
M\)O\!_%?CO6'U?P[XJO?$>GW[:O_ ,-(>#O#$J>2VDZ?-%-X">Z,FFR7L%_
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ML?!5K9"^\<6_CKPKX20GQ9XJ?PW )Y;0'5H!H\7VC4HBMQ\W?\$W/VF?B?\
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MM;)YY@4KU3]KO/\ P^V_X)%9QD> OVTESD9;;\"_%GS;1]T'.1VZ@$X./?\
MX/?\$D/V3/@?X\\/_$'P#:^*[#7_  [X@TKQ3;12P?#6UM+K6M(UG3-;AU*]
MCT7X;:3>SW,][I-FMS>1WL%W)$A5+B*58I8OS(_;,_;A_9KTO_@L=^P'XPN?
MB9X130/V9X/VR/AY\9;UO&?@)5\(>++WX;^*_!%MI.MW,GBV.R\/WS^) =/-
MAXJNM!U)KD-:1V3W^;2KTNVFW=.^EK-Z+]/Q)5]+VT?379=3^GNF2#<NTM@'
M[PQDLA!#* .1N'&5^;TYKS'X.?&+P#\>OAQX;^*_PN\1:3XL\#>*AK#:+K^B
M:OHNNZ7?+H.O:GX;U,6VJ^'=4UC1[EK;5](U"SD%IJ-P(9[6>WN/)NH)X(O3
MB00",') SW&?0]B*@H_ '_@DR6'[??\ P5T<!G!_X8&P^QE$N/@O\1U.W(Q^
M[Z';GD<XK]_2"1_?&<$?=[<D'OCIQ_,5^ O_  27);]O?_@K<22 /^&"\(#A
M!GX,?$@'"]L]3COS7[_ 8_ST^E5+XF);+T7Y&3JFE6&L64^FZG";FPN!$9K8
MO/ K-#-'-&?M$$D4J[)(T.%E7=MP<J2#^1'[0W_!%7]D_P"+>H0^.OAKH/\
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M<U]A?LR!C^S;^SXQ.6/P-^$^7 !Z^ ] . HX//((Z]!Q7Q7_ ,%D]6TC3/\
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MABX_:9M/$NGP>*-#EO\ 0+F72/AE90V^L6D5\\^E327NG7]HD-_';R/<V-Y
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MI-Y:Z)XBMK;Q!H?B?0+B?1-2EMM2AAUOPUXATB66V2/4M#U:R::PN #\*_\
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M+EO[@'"P_;?.#[3_ &A]G50;3<?Z$Z/Z4E+JU&3\T_T:#E[-KTLOT/\ -?\
M^"NWQ5_;<\4?'>+P1^V=#_8OB7PAYG]B^$/,^$FI?8O[?\'?#75]1_XJ#X5:
M=;V%Q]HL+?PMJG^EW=SY/F_8H/)FCU&)ON__ ((X:A_P55^)GPGUKX=_LJ?'
MO_A4'PGT+Q3J4TE__P *M_9R^('V/6=,\-?##0WM?LOQ'2P\2W'V?PU?^'9O
M/6^FM9?[,\L"2_O;Z9/Z'/\ @N+\!/A7\3_V&/B1\1/&7AA]4\:?"G_A#_\
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M7^OSU&NOF_T"BBBI&%%%% !1110 4444 %,;JO7G(XX/. 2">/EZGG.!P"<
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M*0G )X_$@#\S0!^9O_!8CG_@G-^T0O(!_P"%2<CKQ\=/AB>/ZY%?8?[,F/\
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M3RS^&XQ_;DL=I&9+-QJ%?T-HK;CN6,*!SM!&9."&&>" F%W'YMP(Z 5^7O\
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M?^$YXN_^4%!_:8^" !_XKANG_0N>+O\ Y046?9_<PNNZ^]'NPE0MLSB3;O\
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M'(HL^S^YA==U]Z/?L@GCGW[?3/K2UX(/VFO@@< ^-MNX;U \-^+@=H.PEL:
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MF"UN)G*0P32(W-MIZ]%9-ZI.]OOO;LOO$HJ*?S=^UU;^NY_/U^PM_P $4/\
M@G'\4_V9/A]X]^+G[,_]O?$#5->^+5IJVK_\+E^.VE[[/0/C!X_\,^'8_L'A
MGXK:=HJ_9_#&D:-9;[:SCEE^S_:;YIM0ENKB7ZX'_!!?_@D^S$/^RCBXEP\Z
M_P#"]/VDC^[XBW9'QA"?<2,83#=\9W$_H;\%?VEO@;^T+IEYJ?P>^)G@CQZF
MFSO;WT/AGQGX0\4W5HXO]9T^,W<?A?7M;$ N)= U5[;SI(S-#9SLJ[K>Y2'W
M<$''DO&P9@Q!;($8^5O+"].1W^7<6SR<5+O=O57&MEK?]?U/R _X<'?\$F/^
MC4/_ #.O[2O_ ,^.@_\ ! __ (),CD?LHXQW_P"%Z?M*''X?\+CK]A*0C((R
M1[@X/YT7?=_>QGX\-_P00_X),R)Y;_LI=!N9/^%Z?M*=,;67</C&/4C(/N*_
M,C]H#_@D)^PQX._X*7_\$^_@MX'_ &?/[-^!'Q9\*?M(S_&3P[_PMCXP7G]M
MWW@7X7:]KG@/_B;ZO\2[KQEIO]EZ_#:7/_%*ZKIL-]CR=9%Y9&2$_P!7!=T4
ME@I#.5!C!(0$9#RDD;57!+L.!Q7R'\0/V\?V3?A;\1K;X5^-?CK\+=)\:7$%
M]/)I=]\3OAK876G7&FW.KV>IZ?J%CJWC#3]5L[ZRN=$O;>YM&TYGMIHS%<&.
M19EB:NV]&]'U[]?ZWV$VN]CXY7_@@A_P2:57AC_91PK+LEC_ .%Z?M*'".#D
M[V^,1/(8_=(/S=1@5(O_  0/_P""3!55'[*.1&!&/^+Z?M*C 08 _P"2Q\X]
M>?J:_6W3=4TW6;*VU31-5TW6-.NW=8-1L;ZWU"PN8XII+>Y6SN[226"9X[B%
MX)0DC*D\4D4@#QE1KCOC'!QQVQV/H1Z4KM=[C/Q\_P"'!W_!)C_HU#_S.O[2
MO_SXZ9_PX0_X)-ACM_91X!&X_P#"]?VE.. 2N#\8LG@ALCUQVK]AZC)7)+'&
M,* Y 4G (90>IYVY'/!':B[[O[V!^$_QL_X(4_\ !+KPW\,_$^N>%/V6?LGB
M&V&C1V-Q_P +O_:'GQ'<>(=)AN5\K4OB]/8G=:RS_--"S#_EF5DV$?(?_!*/
M_@CG^P1\?/V!?@)\4_VC/V<O^$H^,OB0_%'_ (3#6_\ A;WQFT3[0='^-/Q%
M\.^'?^);X%^)^C>%8O)\+Z-H5I_Q*].@$GV?S[[S=1EO)Y?ZD2<9$A7'WAD_
MNMA.%#;N^>G;.W%?.W@?]JGX&_$;XD:Q\+/!?CSPWXC\9Z&+#^U-(TCQ1X0U
M>XM!J6@7GB.R!T_2O$5]JMO]HTFQN[D?:-.A\Y()9HO,MHI)T:NT[)WW;\K:
MWZ_C\A;/??2Q\$R?\$$_^"33.AD_93_>!%A!_P"%Y_M*?-&"2%POQBVC+9.3
M\P]<4[_AP=_P28_Z-0_\SK^TK_\ /CK]?QC<I!890':W"@$] .SCICICBI:5
MVMF_O&?CT?\ @@?_ ,$F "3^RC@ $D_\+T_:5Z#D_P#-8ZC;_@@G_P $EE7S
M#^RCB, $O_PO3]I;@D@ ;1\8BQSD<X[^QK]AI&"J6*EL<J ,DL 2 HXRQZ#'
M.:A+[1YNR1_E#%%7=,"Q ,>W/"INW%,_*03VHN^[^]@?R1?M]?\ !)']B7X0
M?M6?\$__  +\'/V?_P#A&_AU\6O^&J_^%S:5_P +5^+6L?\ "0?\('\./!NL
M?#O_ $[Q3\2=3UW2O[*UW4]4N?\ BE;S3?MWG^3KGVRSBMXH_P!7A_P01_X)
M.M&B2?LH[MLBR*G_  O3]I-?)(7 &Y?C$/,\O)&2?GSG%?8/QC_;W_9+^!'B
M&U\*?$CXX_#+0/$$_GYTB[^)?PTTK4+;RK'2]2'VO3]>\8Z/>P^=9:Q8W4'^
MC-YD$RS\0R0R2_5^EZC8:UIVGZUI6H6FIZ5JUG::AH^HZ7=PWNF:AIM_!'=Z
M??VMW;22VUW!=VTL<\-U:RR03V\D<L#O&ZL6V[*Z?J^O_#=!)ZO6_EVM_5M#
M\DA_P01_X)-2;MW[*>_:Q0?\7S_:47:!T3CXQ#=MS][J<]:7_AP=_P $F/\
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M_!):%(89?V4<1--&MO\ \7T_:6.)2-L4?R_&(L<*#\[G;_>YP:MK_P $$/\
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M^]E'X[G_ (()?\$EE&X_LH_*> ?^%Z?M*\GGC'_"XLCH>3QQ7EOQK_X(7?\
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M@G\&O U[^T!^TY^TMJGB+XG2>.OB[>>#;SQK\&GT_P ;ZIXHU?PW\+/&&M^
M_#']B^%=?L]'^(.GWNEIXY:4V<4T5S/?-J<,.J_U,ZU::CJ&D:K8Z5J;:+J%
M[I5]::9JHL8-2&DW]Q;2PV6J&QN7C@OFL)WCN383NL%SY7DRN$D8C\#?&?\
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MAF.1Y%?S\R>9Y4/E?GO^S[_P21^&?[/_ .TU-^T+I'C4:K:17NC:EX=\$?\
M".>(+'^P[S1_!VI^&Y)G\2W7Q(UE]0^TZCJ"ZZL=YHTD47V?^S-CP2F=-8RB
MHM/1V?S;36EOUTU?74AJ7,GTNODDT]3]=8V#9[G))R"=AXR@)Z[>Q''H*FJ
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MX9\5>$TNY- \9M9:E=:)J&CZN)XM4T?4I;P:S&U[JMY%8PVM?M.H 4   <\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>v449009_chrt-org.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v449009_chrt-org.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( AD"6 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_*_\
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MMMI/PH^(K@00V_C2-H?A[XN,I:\E\.ZG8W=WK/\ 2VK*ZJZ,KHZAD=2&5E8
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M+F[IQO*FZ=U'#9BX1E4]E!_5\6HU)894JT9867];U%%%?@I^Y!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !117Y]_\%-/VTH_V&_V5/%GQ-T"UL-?^-'C&_L/A3^SIX(O
M"9!XP^-?C<3V7A=;BT0%[O0/"-O%J7C[Q?'YEJLGA7PMJUHE]:7EW9R'2E2J
M5JM.C1A*I5K5(4J5.$7.=2I4G&G3A",4Y2G.<X1C&*<I2E&*3;2(J5(4J=2K
M5G&G2I0G4J5)R4(4Z=.$IU)SE)J,80A"<Y2DU&,8RDVDFS\</^"O?[;WB?\
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MW$7@;4-+C\16LDMT8]+98[RQC99HU@'SEX<M;#2OA[8ZQ\,_%7PPT;5O"/Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'X1UGQE<7G@&\2Z\2Z9I^E:3X;EM9O'_ (OZ3XWTW]F3P-:>-_ S>!=7TO\
M:-^,MC=Z1'X.7P=';@^ _@\(//T^"RLHI)!-!>Z=!?R))/>PZ5LENKN>TGG9
MT>+J.-Q>7X;"4HT_K688>A4>(Q&$E.>$KQS6'-AZ5'$SJK%4<5EWL<9AZL8U
M\NJ6I8S#PEB,.VJW"=;!X7,,3BZLJGU; 8BO36'H8N,(8JA+*Y\M>K6PT:3P
MM7#9A[;"8BE*5#,(7JX/$3CA\0E\KZGX(\3:/X9T#QCJ.G1V_AOQ3-J%OX?U
M/^T=+F759](:W35HK:VM[V6]\S3'N[2/45DMD-E+=6\5R(I)HU;/U[P[J_AF
M[M['6K>&UNKK3=+U>&*&_P!/ORVFZUI]MJVDW3/IUU=QQ)J&F7EI?VRRNDDE
MI<V]P$\N:-F^D-?\-:YXV_9J^!4W@W2M1\52>$O&'QBT+Q58^']/O]6U#P[?
MZS=>$-=T+^U[2SMI9+6UUW31>3:1=D-;WDFE:M;I()]/GC7JO#^G6NI^)_C!
M>R^!=*\;WWP]_9M^&=PEMJ^FWFL6_AOQ=X)T#X,^&=86ZMM/O$M1/IMQ;^(=
M-U6RU 3(RV=]8W,*!;R$]2S^=.E5JU8T*LL-C,WPV(P]*=*A6IQPN:X#+<O=
M1XBNUAWB%CZ56=2M",*\7?#*<7%3YGD,*E2E3I2KTXXG!Y3B,/B*L*M:C4EB
M<KQV8Y@J:P]!/$+#O U:4849RG1DN7$N,E)Q^*JZGQ1X,\2>#&T%?$=A%8_\
M)/X<T_Q;H3PZCI>IQ:AX>U2:\M['4$FTJ]OHH1/-87<9M;EX;V(PDSVT8>,O
M]H^'_ W@W4+CX3ZO?^$/#]W\)/B;\-_B1XG^)_BG2='>./P/XVM;[QW+J-I8
M:TR7>I>#C\-[>S\#MH/AR.__ +-URQEL3>6^KOXINH&VO$O@,:[X5\-ZI'I"
M:KX\\*?L9?#K7O /AC4]+%^NK/'\2M0L_&6K6.CWMO/8^(;[POX-O=4U(:/=
M6UU'';37&N);R7&BVZ-RU>+J,,5A:?L'3HSGB:>(]I.E*4:D)/"TH.K&<8X2
M=#'4JKQT<32?LL!/#8WW*5>#.FGPG5EA<34==5*L(8:IA_9PJQC*G.*Q56:I
MRA*6+A7P52DL%+#55[7'1Q&"]ZK0FC\ZZ*_2+1/A+X>\0SZU=^"?AA<ZA\0;
M'PE^SQXB\6^'[/P!XD^('A_PKJ^NVWBB3XF>&IO!6@>'_%&K:+>>,+.R\.>(
MK-ET)-.\)R'7/#]MJ_AJ>XTFQD\NMM&\#>//'OQ_^$]OX*TCX376L:IJ'B+X
M1/XNT:YT36?!5GX'O9=3N?!_B&75WN]6TR7Q'\/+6[U#4_M%W+(?%FCVEIIT
M44&OWD$VU'BW"UY8GEP>(4,%1H8C&MU\'*IAJ%7$T,/.M+#4JM;$U*-.%=XR
M%6E1E#$8.C5K4K-T:=?*MPGBJ,<-S8S#N>-K5\/@HJABXT\37I8:O7A1CB*M
M.CAJ=:I.BL).E5K1EA\96IT:MTJTZ'Q=174^-M6TO7/%FO:GH6GVVEZ'/J-P
MFB6-K86NFK#H]NWV?3#<6EDJVR7\UE%#-J4D0"37\ES,H57"CEJ^HI3E4I4J
MDZ<J,YTX3E2FXRG2E.$9.G-Q]US@Y<D^73FC)*Z5W\Q5A&G5J4X5(U8PJ3A&
MK!-0JQA.454@I>\H34>>-]>646[7LBOK#_@DM\9[_P#9P_;]OO@7)J)A^#O[
M=>@^*?$EAH4AV6'AS]J3X2>&K769]:TTM(EM8_\ "U?A#I.MV^O1)";C6/$7
M@#P_,T[7$JPS?)]>*_''7/$OPZT+PA\?_ L+3^/OV7OB9X#_ &C?"4"EP+^7
MX6ZY!K/B71+@1/%+/8>(?!)\3:'?62R*M];W[6TFY)"*_/\ Q3X=I\2<$YSA
MU153&9?0EF^72M>I3Q.7PE6JQIM)R7UC!1QE"<5=37(FFXQ:^^\+N(9\.\:9
M16=5T\'F->.49A&]J<\/CY1HTI5$VH_[/CI8*O"3LX/G::4IW_OZHKEO WC3
MPW\2/!7@_P"(?@W4X=:\(>/?"WA_QIX4UBWS]GU;PWXITFTUS0]3@SSY-_I=
M]:W46>=DJYKJ:_@,_NX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/X?^!;+2+^>[\#^-+GX?_"[7M0\?V6I7MG8:-H!%C)XDN+ZS\/ZI<7/B^_\
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M[URPTGQGJUO:7FEQ:=:1W$J33VM[Y$)7@/AC\4]6^%>H>*=0T?0_#NLMXO\
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M%1>)K*I7G5JU"BBBO5/*"F22)$CRRND<4:-)))(P1(T0%G=W8A515!9F8@*
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MJWBS1_%6NZ?-!J"ZBJ16D&G^$-4-X\UFLJ7$EI#;Q7(E>2+F4\">-GFL(/\
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M$LZS]4Z"E@8QA"A+#T6\KQ*O2P]*I@ZFK?O2IQK2IU)N/NU'%R49*S^P[O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*.O^)==U;X7:QHOB/6=,\2R-X[D\":9XHTC5(=/EBT6>ZLC-_:UDVA3>+(-
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MOC_=6=Q;:O\ #3X?7>V*6U^%VFSVWC#Q!#*\OB:^\/VMK8Q:O_5OX4\)^%O
M?AG0?!?@CPYH7A#PAX6TJRT+PUX6\,Z58Z%X>\/Z+IL"6NGZ3HNC:9!;:?IF
MFV-M''!:V5G;PV\$2+'%&J@"N@HK^1,_XAS?B;,:V:YUC*F,Q=71.3Y:-"DF
MW##X6@G[+#8>G=J%*E%+>4Y5:DIU9_UCD>0Y3PWEU'*\FP=/!X2EJXP7-5KU
M6DIXC%5Y+VN)Q%3E7/6JR<GI&$:5.,*4"BBBO%/8"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFFFFDTTTVFFFFFFTTTTVFFRBBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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M7%Q!:03W5U/#;6UM#)<7-S<2)#!;P0HTDT\\TC+'%#%&K2222,J(BLS,%!-
M'SK^UC^U7\'OV+_@9XP^/_QOUN?2_!_A6*WM;'2=)MX]1\7>.?%FJR&U\,^
M/ >@F>WE\1>-/%6H[;'1]+BFAAC N=5U:\TS0M,U75;'^-;Q%XZ^,'[4_P :
M==_:]_:;A@L_B=XHT[^Q/AC\++6\;5/#'[-GPGD8W&G?#GPS//;P&[\7:CYK
M:C\3_&206T_B7Q#-<6UI!8Z':6MC7>_M+_M+:G_P46_:=UOX^WNIW-]^S'\&
MO$NO>"/V-O!1>8>'-9@T2XN-#\6_M-ZGI]S%"=2\3_$?5;:\A^'MW>VMK+X4
M^'UIIL5K:#5=1OM7N\JOZQ\%O#2G@\/A>,\\HJ>-Q--5LBP=6-U@\/434,SK
M0DK?6\1#F>"BTWAL/-8G2OB*3H_RSXR^)%3%5\5P;DE9PPF'J.CGN,I2L\7B
M(.+GEE&<7?ZKAYJ*QLDU]9Q$'AM</AJRK%%%%?T>?SJ%%%% !1110 4444 %
M%%% !1110 4444 %9WPM^-OQ9_82^.4G[6?P%TN_\6Z3J]EI^B_M0? &RN&B
ML?CG\.=+E1XO$?AZVEN8M/L/C7\.K+[;>>!M=\@W6L64M_X0O99M-U6>QO=&
MBO XFX;RSBO)\5DV:T54P^(CS4JL5'V^#Q4%+V&,PTY)\E:C*5[74*M-U:%5
M2I59*/O<-<1YGPKF^&SC*ZO)7H2Y:M&3E[#&86;C[?!XF$6N>C6C&UTN>E4C
M2KTG&K2BY?V8_ /X\?"K]ISX/> OCQ\$_%MAXW^&/Q)T.+7?"_B"P++YL7G3
M66H:;J-I(%N=*U[0=6M;[0O$>AW\<.I:'KNG:CI&HP07MG/$GK]?QB_L!_M/
MW/\ P3Z_:N\/:;J>MR:7^QS^UQX[A\*?%?0;N1?^$<^#W[0_BQ[73_A[\:=)
M\P;/#N@_$#5HK?P)\4W$]CH<=QJ.@>+]5=Y-(15_LZK^ >+.&,PX0SS&9'F*
M4JF'E&=#$0C)4<9@ZW-/#8NCS:J%6FK3@VY4:T*U";<J2E/^\>%N),!Q9DF#
MSO+FU2Q,90K8>;BZV#Q=%QAB<)6Y=.>C4?NS24:U&="O!*-5Q@4445\X?0A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?@E_P71_:KU?PS\+O"7["GPFU^XTKXO?M=VFJ0?$76
MM)=AJGPR_94T:9;/XJ^*?/BG!TS5?B-<36WPE\)->6LUMJ4>N>,IK26UO]!B
MN(OWMK^%+Q7\5[?]J7]JW]K;]KE)4U/1OB+\7=6^&'P=U4/]HMC\!O@.W_"M
M/!UWH3R@R66F^-=>T/Q/X_OK6$QQ76HZ^+B59)(HI!]]X:<*QXOXNR_+:Z?]
MGX?GS+,VN;WL%@G3G+#\T;<KQE:=#"*5TXPJUI1?,H-?#>(W%$N$N$\PS.@X
M_7ZWL\NRQ2L^7'8U5(0KN,KJ:P=&%?%N-FI2I48R3@YIV-"T32?#.BZ1X<T&
MQATS1-!TRQT;1].M@PM[#3-,M8K*PLX=[._E6UK#%"A=W<J@+NS$L=6BBO\
M0"$(4X0ITXQA3IPC3A"$5&$(0C&$(0C%*,80A"$(QBE&,8QC%)127\%3G.I.
M=2I*4ZE24ISG.3E.<YRE.<YRDW*4YSG.<I2;E*4I2DVY-LHHHJB0HHHH WM#
M\+^(/$L>NRZ#I-WJL?AC0;KQ1K[6B"3^R_#]C=65E>:M<C<&%I;7.HV4<SH'
M,?VA791&KNN#7ZB_L:V.O_#&#X=R:A\-/%/BWP?^TMJFM>'/B??Z?X-UW6].
MTKX-SPZOX!TF&74K*RG@LAJ7C#4-<\4>(;<!KG_A'_"7AN\MS+#JPC/RE>_!
M[PA\-?VF=6^"7QKO_$.D>%M)\;'PG?\ BC0[S3;"]TS2M2O+9O#_ (SN$U72
M-1MKK1YM$O;'6KRT6"QN#87GVB&X1[?[)<_)87BJC6S7/,OG24Z>6X)YA@G@
MJD,9B\?A<'5KX#-TL)2K.I'$83,J'LJ.&:IU:^'G3JPC*52FI?5XGA>M1RO)
M,?&JX5,RQBP&-6,A/!X7 XG&4J&.REO%5:*IRP^+RVM[2MB$ZE.AB(5*4W%4
MZCC\ST5].^)?@CI7P_\ B)^T#X8\>V?BC3=(^#=GJB:>MMJVE)J6J:Q?ZYI>
MD> +>;4;CP^]G>6WB6TU6+Q&PM-*LKIO#UKJ%_!%&+.5*]!U72/A-8?L3^ ?
M$Z^!O$B^)M>^,_B;1-=UFT\;:;!<:IJGAWPG83V-Y*ESX&ODA\/VMOKEW#IW
MANW,5U:7,UW?7/B+4&NC#%V5>),&EEL\+0Q6-IYGC<KP=&MAXT?91_M;+J^:
MX>JZD\3&-11P=&,JD*7-*%2M3A*2UD<E+AS%MYC'$U\+@JF6X+-,96I8B5;V
MLO[*S"AE>(I*G##2=-RQ=:4:<ZG+&=.E4G&+T1\0UZ)X+^$WQ'^(NB^-?$7@
MCPCJOB71OAUI4.M^-+W3%@E&@Z5/'?RQ7ES"\T=S-&8=+U&=ELX;F2.WL;JX
MD1(87<?5P_9B^'3_ +3WP=^"R:MXU/A/XL^"/ 'B8:D^I:$GB'0KSQQX<;Q!
MY9G'AV33=1MM."&U\D:=92W);SOM4.WRW^6/#_C+5?A?K7C2'PY/>)>7VG>)
M?!L5V=0N;>"'3=6M]1\/ZG<W6GVIA@U*^?1[R\@T]KMFM=,NKEM2AM)+Z"RF
MM%#/(YI0<<C<98Z>!P&:4(YAAJ]/#RP6*S*O@9>T]G7C4A5OE^94VE)RH5*=
M&LX8BE-4YN>22RRNI9VI1P4,=CLLKRP&(HU,1'&8;+J&-C[-5*$J<Z5LPRZI
M=Q4:].I6HJ>'J0=2'FE%?8/@G]G[0)_A?\-OC#XGT+XA^+OA[XC\2Z]I?Q+\
M2?#36=(#?".PTC6H-+QXBT.;P;XJOA>C2MWBZ.[O+G2]+U'3=0TW2H9+.[W7
MMQ\?5Z.!S3"9C5QE+"2G4>!KU<+B)\L%"&)HUZF'K4&U6G4A6ISI.4J5>AAI
MNA4H8FG&KAZ]*M/SL;E>+R^EA*N*C"FL=0IXG#PYIN<L/6HTZ]*NKT84YTJD
M*BC&I1KXF"K0K8>I*EB*%6C$HHHKT3SPHHHH Y'Q]X(\/?$KP7XG\!>*[,7W
MA[Q9HU[HNJ09"R""\B*+<VLA5C!?64WE7EA=*/,M+VW@N8B)(E(_HR_X(P?M
ME>(OVCOV=M6^"?QEUQ]6_:=_9$U#2?A1\5M1OIG;4?B+X/FL99_@]\;U$\L]
MU<0_$;PA8M:ZY>W4\MW<>//#/C">Y2W2XM8C_/W7:_LF_%=/V9O^"C/[)_Q>
M>Y_LWPE\;M5U']C?XMO&6":A8_%DIJGP5OKU-RVX70/C1H6@:='J%P"]AIWC
M#5XXWCCNI@WX=XZ<)4LYX9?$.'@EF7#B]K.48WEB,IK5J<,71FTKOZK5J4L;
M2;NHKZU'2,]/VWP0XKJ91Q'_ *O5YMY=Q"^2G&4O=P^;4*-2>%JP3=E];HTJ
MN"JI6<I?59:N"O\ VMT445_&!_884444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y]?\ !4_]HJ]_
M9=_8&_:1^)_A^YD@\?WO@:7X9?":.UN'M]2G^+?Q@O;3X8_#F33!"Z74USI'
MB?Q58>(;B.T>.>/3=&O[KSK:*WEN8?Y.?A?X$T[X8?#KP1\/-*V-8^#?#&C>
M'XYD39]KETVQA@NM0D7C]_J-VL]]<,0"\]Q(Q +&OV]_X."/$2W'@+]A+X50
MRA+WQG^VCIWCN:#?N^V:'\'/@E\7_$-]#):M$L,T-OK6K^&M26=KR*:RO+"R
MFM[2]<G[/^/M?U;]'3*:4,NXBSV4;UZ^,PV4TI.*]W#X:@L=749;_O,1B*'/
M:RM2@G=G\N?2$S6K+'\/9'&5J%'"8G-JL5+XJ^(KO 4'*.W[NAAZ_)>[O5FU
M8****_I,_G(**** "M318]%FU:PB\17NJ:=H;W*#5+W1=,M-9U:WM.3))8:7
M?:MH5G>W/0)#<:O81<EFG&W:V714SCS1E%2E!RC**G!I3AS)KF@Y1FE.-^:+
M<)I22;C))Q=1ERRC)QC-1E&7)--PERM/EFE*#<96Y9)3@W%M*46U)>V_%WXC
MZ?XE\?ZGJ7P^UWQII_@*.'2]'\)Z3J]O!H6H^'_"OA_3[;0?#NC2V&C>)=:T
MZ\NM.T#3=.CO=42_MGUK5/MNHW%M;374C/[!^TE\4/AO^T'!\+-8\&V_Q.U/
MXP^'/AWH7@GQ]<:KX*T*VT[QU)X7L,)XKAET3QUXCU2#4H;9;Q;\3Z3.EW91
M6DCW%@EDR2?&5=K\/OB-XW^%7BBR\:?#WQ'?^%?$^GPW=O::OIQA,\<%_;R6
MEW \5S%<6T\,\$KH\4\$J9VR*HDCC=?!K9#0IK+,3@5/^T,BPV*I9;*KBGAZ
M>*>*PM/#5:.;5\/@:E?%4,0J5.I7ER<_UB/UR,7B+R?NT<]KU'F6&QKA]0SO
M$86KF,:6&6(J898;$U,32JY51KXZG0PM:@ZLX48\_)]7E]4E)8>T5]*_M)?%
MK5_%OPZ^!OA;Q!I4>G>/&^'WAS6?B?JFYSJ7BN/0FU_0_@U=>(%E DCU6Q^&
M]^^M*V9?M]IXTMM1N)VN9VMK'C[;XI_#O4OV7H/@YXDMO&-MXQ\*?$SQ!X]\
M*7.B6NC7'AW6X_$OAFPT-[37[^^U"#4=$_L>]TZ+42=/TC6CJUO_ ,2M3I<E
MVVKZ;\^Z_P"(-<\5ZUJGB3Q+JVH:]K^M7DVH:MK&JW<U]J.HWMPQ>:YN[JX=
MYII78\L['"A54!551E)')*Q6-'D8))(516=A'%&TLKD*"0D42/)(WW4C1G8A
M5)$X3AW!4,NR_!R3H/ 9DLY@\%6J484L?+$8W$2A2E5C5F\%".85L%3H5(Q2
MP4*5."PW+3C0K%<0XROF&/QD6JRQV7/)YK&4:=:=7 *A@Z$958TI4H+&3E@*
M.,J5J<FWC)U*DGB.:I*O^C^B?M)? -?BU^SK\=M=/Q07Q5\-/!G@+P;XM\&:
M9X?\.'1(KCP+H%QH3>)='\27/B(WFJ6VIPB%K;PQ/H>F3++/)-<^*;9+1;:]
M_/\ \77FBZCXHU_4/#HU1=$OM6O;S35UI;1-56VNIWG5+Y;&26T$ZF1E;[/(
M\9 !!R37.T5KE7#V!R>O*OA:N-G)X.. A3Q.*]M1HX.GC\=F-&A2I_5Z7*J.
M(S'%*G.<ZM7V,XTZE2KR1FLLTX@QV;T8T,52P48K%RQ\ZF'PWL:U;&5,#@LO
MK5ZM3ZQ5YG6P^7X5U(1A3I^UA*I3A3YY0?V?\#/CAX*^"]U\*O&7A/QK\3?"
M'B?P_%=V_P 9_!^G>']-U'PC\5;&/QEX@U73[*TFD\7V\%Q]O\(7VF>&-3;Q
M'H-JNA75G%K.AO?W<(S\E^)M5M=>\2>(-<LM)M-!LM9UO5M5M-#L"#8Z-:ZC
M?W%Y;Z39E8H5-IIT4R6=N1#"##"F(HQ\@Q**Z,'D^#P6.Q>8T_;3QF-IJC7K
M5IPE.5"&*Q&,I47*%"A*K&A5Q56&&GB7B:^'POL\'2Q"PM.-)\^+S?%XS!83
M+ZGLH83!U'6HT:4)QA&O/"X?!U:RC.M7C2E7I8:E/$0PRPU#$8KVF,JT'B:D
MJ@4445ZIY84444 %>/\ Q]\#:C\1/A#XX\,Z#<7%EXJ.E+KO@G4;20PWNF>.
MO"MW;>)_!>H6=PN)+:>U\3:1I;B>(B1$WX)!*GV"BN7'8.AF.!QF7XJ//AL=
MA,3@\1'2[HXJA5H5+732DHU7*#L^6<*<OLG5@<97R[&X/,,++DQ.!Q6&QE"6
MME6PM>E7IW2:O%RI*,U?WH3J1^T?U]_L;_M!Z7^U=^RI^S]^T9I(BC3XO_"K
MP?XQU2QB&U=&\47VDP1>,?#CKR%N/#7BV#6O#]T%+(+G391&[IM=OI6OP]_X
M-_=::7]AWQQX$ *VWPA_:_\ VI/ >G1#S D.F:G\0Y?B?8)'&<6T*M;?$:.8
MPV$4%HDDKXB^T&X=_P!PJ_S3Q^%G@<=C<%4UJ8/&8O"3=N6\L+BL1AW)*[LI
M.ASI7=HSBKNUW_H[@L3#&X/!XRGI3QF$PN+@K\UHXK#8?$QBW97<5B%!NRNX
M2=E>R****Y3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@^+5V_B6WU;2?"7A;XL:Q\3_  EIUM::=JEI<^*M5>XN9-*TC6KO[?:67AV
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MCPO.LFJLN'LF<T]],OPT8M^<H0IRM96YK=-2BBBOESZ0**** "BBB@ HHHH
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M\&EM)'Z4_##_ (+O_'OP2(;+]K+]BB7Q;IT$CB^^)?[&WC:T\5^;&Z(MNZ?
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M5YX \6V^@>+ _B.:77K-;"#4'\*:GH8OW7SDV?\ P5G_ ."L$?\ Q,G\1_\
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M;WQO\2?'=A,;O2OA!HYNOA]^S=X+=F22*#P_\)M!O4M?$5W8_-:1^)_B#?\
MBCQ!?VJQ/=RI,H*_H/"?ACQ;QA[.M@,#]3RV;N\VS+GPN"<;V;PZ<'B,:]'9
M82C.#:L\1&SM\%Q5XD\*<(\]''X[ZWF,/^93EO)BL<I6NEB+36'P2U3;Q=:G
M.SNL/*ZO_4#\</\ @LS_ ,$Y?@9J5]X7N_VB="^+GQ#M%9(OAE^SCI6M_M >
M,[K4$G:V;1YU^%]CXA\.>'=429'26W\9>(O#4<$@2&>:*>>VBF_.+Q__ ,%W
MOC_XONW@_9I_89C\->']PEM?&W[7/Q9LO!&HWL4;L'MA\*?A#I'Q-UFPDN(R
MCP7>J>,[-H'WI-IC@!Z_+'PUX2\*^#-,CT7P?X:T#PKH\.WRM+\.:/I^B:?&
M54("MGIMO;6X8(H7=Y>[  )KH*_=LE^CQD>'4)Y_G6/S*I9.>'RZ$,LPM[:K
MVU18O&S5]FE1;MLKM'X?G/T@<YKN4,AR7 Y=3NU'$9E.>9XFU]'["D\'@H-K
M=.59*^[LF?6NL_\ !6G_ (*MZZTT.FVO[!OP^LY-IBN+#X9_';Q[K=NT<OF
M+>:Q\8?"VC2QSQD6LPE\/%T"27,,B/.D5IY)J?[<?_!5W6U<S?MYZ'X5=VW
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M<4HTX8J$)1<*>)IU*4_[,\-_$G"<;86>$Q<*6!X@P=)3Q6$A)^QQM!<L7CL
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MUW;S):WMGXT^'6J2IKNG1VE\YT\ZY91ZEX6O[R.6+2->U$1.X^VZ_+']L_\
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MM[M6/EZO@CX@4Y\L,%EE=7M[2EG.$4;?S-5J-&:7I&3[)GR;17WAHG_!%/\
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M3<:E6I44:M+*5*+]VE3INE7QZBTZM2I0PL[4H585"BE +$*H)8D   DDDX
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MOJU8RM9S6%C=2<%;^KJBBBOY /ZT"BBB@ HHHH **** "BBB@ HHHH ****
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M&-H=#O-666_==1NM&B=HM)N+P33:=&S)9O"K$'1'QD^+@@\7VW_"T/B"T'Q
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M=Z#>W=U\Y5+---</YD\LLTFR./S)I&D?RX8TAA3<Y9MD4,:11KG:D:(B@*H
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M9O%7A_P[K-[/-<:GH&C:Q9:3>&>[AEM#;7U]#<\YX;\=:WX7TW5M%LH-"O\
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MWAGQ'XHU35O@Y\5O"W@+5)M<TW2M/TWQ%I7C:W\>W.D7^G6=C=WMWIE_I/\
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M^$O$'@*/PNFD2ZUJ\\^F?'G3]6M;'Q+I[N=0DO5MX?#SOX_T>"X>?3O["O\
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MGQ*DAC1(=/TGXO\ AW3Y/"/BF[5$1_&^BZ1K&L7LUUX@A6/W_!;C*/#/$O\
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MC*/$G$BRG!554RKAR5?"PG!WAB<SG)0S'$)IM2A2E2C@:+5URX?$33:J)O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(O>]F[ZVL_XU?AKX+_:U_:%>'_AFG]BGX_\ Q#TJYF=+?X@?$K0X?V;OA5-
MA>.2^M/%WQH'AW6-:M8)49+A?#/A'7KQ&CFACM)KZ,63_H+\,?\ @B3^V[\2
M1#>?M&_M3?"C]GO0IXH))_!7[,G@O4/BAXXDMKG+W%A??%7XN6NA>'M"U:TB
M9;>6[T#X9Z_:BY\XV%])'#!?W/\ 4W17Y]G?C!Q[G:G"6<RRO#SNGA\EI1RZ
M*B].5XB#K8Z6FEWBX-^3U/O,F\)>!,E<)PR:.98B%FL1G-668R<EKS*A45+
MPUL[1P<TFNJT/SM_9&_X):_L??L;:L_CCP#X(U3XA?&FYC:*_P#VA/CCJ\?Q
M-^-4\+P_9GM-*\4ZA86>G>"-,EM_W-QHWPZT+P?HMU&%%UI\Y52OZ)445^:U
M:M6O4G6KU:E:M5G*I5JUJDZM6I.3O*=2I5G4J3G)MN4ISE)O5R?3]%ITJ=&G
M"E1ITZ-*G&,*=*E3A2I4X15HPITZ<*=.$(K2,(0A&*T45U****S+"BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>v449009_ifc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v449009_ifc.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$(!/ $U0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7P=6K++<3'#_ .M'[-CZ+=7QM\8\MXNSK*)P\+_"?'9?Q#F=66$J4,MSCB?
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M-'BVTL;"W\47OCF#4/\ A87BG4_!?@RZNDN?"-GHNE:;I=[JMQJ5II0ET_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &V?A'X>T&UL]%V_\+Z/VKPWH5W)_:,_P4^$OPN_L/3[30+#4=;V2IJ0U/\
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M1(D;,;B/:1)"1ME*,?WB\ ]?NG^^'X2?\'EW[//P2^'OA_X8?#W_ ()M>/\
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M[:>);^S\*Z#JOB"^\8^*[R$^!M-T.UUC5=3UR_\ %D=[J]U977^BK0!^6_\
MP5N_X)C?#K_@J+^RCXZ^"^NR:7X?^+-KX3UZ#X%_$G6[KQE)HOP_\8:EK/@[
MQ(UUJ_A_PKXDT.VUS2]:O_ 7A_3-0FU>Q\0MH=H9M4TW1M1FCGTK4_\ 'P_:
MZ_9E\7?L>?M&?%W]G#QQK.B>(_$7PC^(GC[X?7OB#PXFIQ:+KLO@+QUXE\"7
M.L:=%J]E87T5EJ=]X8N[VSCFA9DM)X%DD,PE1/\ =7K_ !DO^"[?_*4O]L'_
M ++_ /M _P#K1/Q?H ^6?^"=O[$OC3_@HQ^V+\'_ -C7X>^,O"_@#QA\8O\
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MBBB@ K_"5_:B_P"2Z^.?^Y9_]0_P_7^[57^$K^U%_P EU\<_]RS_ .H?X?H
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M%G:7]R-\C;;:PU#Q FER96_N;9O/TW4(9-L=M:21;MEPCW"L4^8?A1_P2_\
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M(?"VKV>N:+??8]3M;[3;O[)J5C;3_9M0L;RQG\ORKNUN('DA?_82_P""!_\
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M5\>VWV2^U#P_XILX//O/"UO;3^=H5]YMM--#']EED2\MP#_"]K_3Q_X,L/\
ME%I\>_\ L_WXI?\ K.W[*U?/_P#Q!8?LN?\ 1>_C[_X=+X=__0K5_15_P2,_
MX)@^ O\ @DY^S=XV_9U^'?B[Q?XTT3QI\;_$GQJNM4\::_HWB/5;?5/$7@/X
M:^!I["WO=#\ ?#BTBT^*T^'%C<16LFAW5RES=74SZK/%/#:6(!^IM%%% !7^
M&I^WE\.M=^$_[5_Q5\ >)8_*UO0/^$&^VQ[[-]O]J_#?P?K5M\UA?:E:'-IJ
M4#?NKV;&<2>7*'BC_P!RNOQ&_P""E7_! O\ 89_X*>>,+KXG_&*V\=?#SXK7
M.FZ%9W_C_P""T/P@\)>*_%#^%M%UW0] 3QCXJ\4_!OQ_XCUNUAT_5[#3YEFU
M!C'I_A;PG:62V\&APPR@'^6;^PU_P5$_;J_X)L_\+1_X8K^.7_"F/^%S_P#"
M$_\ "RO^+9_![XB_\))_PKK_ (2[_A#?^2L?#[QU_8_]C_\ "=^*O^0!_97]
MH?VK_P 37[=]ATW[']^_\11'_!=3_H^3_P UG_8]_P#H?J_I_O/^#+#]E'[7
M=?8/CW^T+]A^T3_8OMGQ2^&_VO[)YK?9OM7D_LK>3]H\G9Y_E?NO-W>7\N*K
M_P#$%A^RY_T7OX^_^'2^'?\ ]"M0!_,1_P 11'_!=3_H^3_S6?\ 8]_^A^H_
MXBB/^"ZG_1\G_FL_['O_ -#]7].__$%A^RY_T7OX^_\ ATOAW_\ 0K4?\06'
M[+G_ $7OX^_^'2^'?_T*U '\57[:G_!6S_@H/_P4/\+:!X+_ &Q/V@/^%O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO.L#K<7D740TZ/[)O8M-<6AIM[M-:K^;TZ=_ZW!=$[[]OU/#/ 'P8\(_$_\
M:X^,OB/QAHNC>(['P"=-V:)K^FZ9J^E7W_"4^)?C?8M]ITW5-+U"&Y^S3:?;
M7<.)[/R;F"&<_:&BC1,_]NWP7X,\ 7'[-OC+P=X3\-^%M<M/C]X3MI;WPYH.
ME:)<7MH2NHFWO;G2[6SO+F)+C1[-XHFNEB4J6V[Q$\7U/\&_AWXQ\*?&?]H#
MQ9K^C_8/#_C<^#_^$8U#^T-+NO[3_LKQ7\7M2O\ _1;*^N;VR\BR\4:%-_Q,
M+:T\W[=Y</F2VUY';\)^VO\ "+XA_%S1?@W:?#WP]_PD%QX4^,7A[Q5K\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDG%.*Y4W^HO_  VU\*O^A?\ B#_X*O#G_P U='_#;7PJ_P"A?^(/_@J\.?\
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M_P""KPY_\U=?EU11_P 5*?I3?]#CP^_\5MD__P _P_XEX\-/^@3/?_$AQ?\
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M_P 5MD__ ,_P_P")>/#3_H$SW_Q(<7_\PGZB_P##;7PJ_P"A?^(/_@J\.?\
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MCPT_Z!,]_P#$AQ?_ ,PGZB_\-M?"K_H7_B#_ ."KPY_\U='_  VU\*O^A?\
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M #5T?\-M?"K_ *%_X@_^"KPY_P#-77Y=44?\5*?I3?\ 0X\/O_%;9/\ _/\
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M\.?_ #5T?\-M?"K_ *%_X@_^"KPY_P#-77Y=44?\5*?I3?\ 0X\/O_%;9/\
M_/\ #_B7CPT_Z!,]_P#$AQ?_ ,PGZB_\-M?"K_H7_B#_ ."KPY_\U='_  VU
M\*O^A?\ B#_X*O#G_P U=?EU11_Q4I^E-_T./#[_ ,5MD_\ \_P_XEX\-/\
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MJ_Z%_P"(/_@J\.?_ #5T?\-M?"K_ *%_X@_^"KPY_P#-77Y=44?\5*?I3?\
M0X\/O_%;9/\ _/\ #_B7CPT_Z!,]_P#$AQ?_ ,PGZB_\-M?"K_H7_B#_ ."K
MPY_\U='_  VU\*O^A?\ B#_X*O#G_P U=?EU11_Q4I^E-_T./#[_ ,5MD_\
M\_P_XEX\-/\ H$SW_P 2'%__ #"?J+_PVU\*O^A?^(/_ (*O#G_S5T?\-M?"
MK_H7_B#_ ."KPY_\U=?EU11_Q4I^E-_T./#[_P 5MD__ ,_P_P")>/#3_H$S
MW_Q(<7_\PGZB_P##;7PJ_P"A?^(/_@J\.?\ S5T?\-M?"K_H7_B#_P""KPY_
M\U=?EU11_P 5*?I3?]#CP^_\5MD__P _P_XEX\-/^@3/?_$AQ?\ \PGZB_\
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MVGK+]G3X@?!_78K.*7X;2>*OB$OC'3Q:>%-+\=:=HNJ:MJ5QX?LM!U*;4_\
MA$++59Y+JWT_5W_M9M/D6RGC%Q$PX']EO_@M1IO[5'[4'AG]G_PC^S7XETS0
M/&-[K4&B^.9_B!87VKV&FZ'I6I:W<Z]XE\(1^%+>PTRR.FZ?(US!:>,M2EL[
M@16]O-JL]Y##$4/HI^/^(X/J>(%/P[QBX,I<&RX_?$57.>&:.73X5A3KUWF%
M*K5SZ$JM=X;#5\5'+(4_[3EA(1Q$<*Z=;#+$D_$O@BGFL<CEGM+^UI9LLD6
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M3]/L?$S75[?7EU.R0VUI:6T4D]Q<3.D4,,;R2,J*2/T0\/?\%KM ^+'[0:_
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MOEN!RBHL9">%ITL;B85\17A*&%H8J,955Z6<\9<+\/Y7A<YS;.L%ALMQRIO
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MXW @C-?Z39YX2?1$\*/![P"XX\4^'?&?/,]\8."_[>K/@GB[+,/@L-F& P^
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M=1UB=&T_18ET[6;2\U![6TEOK6:[A0_H_P#M:?M@?!G]C/X;'XC?%_6+F/\
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M).%^-N LIX:S7P_='/LOJY#C\/F.(PF&S2>)_L>>;X#-I82OB50K8=X_ XC
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MNK"6_P##OBK1[/7=$O);&^AM[VRDNM,O[6=[2\@@NK9G,-Q#',CHO5U^$?\
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MFPI?^MGE)_-WTFO^22X>_P"RDE_ZJ,4?T[4445_NP?Q0%%%% !1110 4444
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MKS2K<TJSJ55*I4BY_$C^2G_@XCT74H/CW\ /$4MNZZ1JGPAUC1;&[(.R?4M
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M/A=\3/B5_P ,D_\ "NOAUX[\??V+_P +Z_MC_A"O"/B#Q5_9/]H_\*8_L_\
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M!Y#G^2YMG.*XESS#9<L[P^9_7.%J^>9GC:/#^'S''0RZK1P^+C&DW6Q%%O\
M1\'A<?PWB/'..59 LVC@:7#N#R[ X_*ZN-P6+PN$IY?@ZF(>#J8?V690P>'H
MSQU3#T77C*=)N2Y*<T?*&B_M\^-_%_[-GBO]G7]B#_@F[=_\,_V_@WQ9HNM:
M_P"+XO$OQ%T"/3;VSN)?$?B'Q9<Z9HNA:$NOQ1?:KV2^U_QQK%W)J%O9W#22
MBSCLCE?\&[LMX/C]\?84A1M/D^#^E2W-P0?,BO(?&FEI8PJ?, "3PSZ@[@Q.
M2UO'B2, K+6^!7[<O[<GCG]F/PY^P;\#/V2;\>.(O!UQ\(U^*D5AKVF6.B>%
M+RWDTR]U/6M'U70M/\->%M?32KRY74?&'B#Q:FFG4[H:L^DC4)8XINN_X(8?
M#_XO_!3]J7XI^&_BA\)OBEX%L?%WPKU/2+/5O$?@#Q'IGAR3Q+X6\5:)?C3I
M/$5YI<>G)++I?]NS6$D5\;*_^RR+')-*]EO^S\1\DP/"GT=_I@<,2X6X"X(S
M+-98?/<IP&&\8ZGB7X@^(.58;B#+E/Q$XMJYMQ7C,32S#-Z.'>(RW!X++\/B
MW2CF:QF#K4L!A:AY.08RMF7'?A7F*S+.LXP^&4\%B:U3A2/#^1Y'B:F!Q%LA
MRN.%RVE3E0PLZG)B*M:O.DI/#NE5A*O41\9>+_AKX:^,'_!:#Q-\-O&5FFI>
M$_%/[8^L6OB32Y<B#5]%L_%=QJ>I:-<E?G%IK%K8RZ9=F-DE^S74OE2Q2[)4
M_J_^-/P3^#OPT^ /[3/B#X<_"SX>^ =:UC]G3XC:!JNH^"_!^@>%[C4-%T3P
M+XHETC3;LZ)86*SVFG/=3?9(I%80HR1KB.&%(_YS_#GP4^,D7_!;&X\>R?"7
MXFQ^!3^UIXIUD>-'\!^*D\)G1Y;_ %=HM6'B-M*&CG395=&COOMGV5PZE92&
M&?ZB?VD;"^U3]G;X]Z9IEG=ZCJ6H_!;XI6&GZ?86\UY?7]]>>!M=M[2SL[2W
M22>ZN[J>2."WMX(WFGF=(HD9V53_ #A]+SC+%5N)?HA9+E7%<ZN04?"/PG>;
M99E7$:GE,<;4XD\,_KT<YP>69W/+WB84LIPGMJ><8>5;#TL!"]+"PP\I4_O_
M  MRFG'+_%+%XG+(QQLN*.)EA<1B<!;%.C'+^(?8O"5<1@U75-RQ57DEA9J%
M25=VE4=1*7^>#X(\?_$KP]X<^(/@'P%J6L6FD_%#1;2R\>Z;H5M)->Z_X7\(
M37/BN;3[N2VBEO(]"LWLFUS6TA,4$EII(?49#IL%W')_35_P;W7/P#NOA]\7
M;?2/#]M:?M(:1K-N?&&OZE/!=ZIJWPQU7RG\-1^%O,"3Z9H=EK-E?6WBBPLH
MG\[5AH6HZOJ%REYH-AI'C'_!"+]G[QIX6^,_QTU3XO\ P2\4>'()_A39:+HN
MH_$CX;:MI$,T>L:^MOK^DZ7>>)]%MTD35-,40:Q86DA6]L5$5[%+;@+7B'B3
MX"?M$?\ !,/_ (*,1^//@5\*?BA\0O@X=5_MG3(O!'A+Q-XLLM<^#/C2]9?$
M'PZU?4-+TF^MHM=\.M:W%G8+?R&X74-#\-^)Y$(N(<_V1](CC3@SQRK>._T8
M<@S?*N$^,L)PGPCXC\-\3X7BS(\#DGBAG&6X#Z]CN%,YS##YGA<OQ,*& HY3
ME%/!YCGF,]HIX#%_5Z-+))X(_)^!,HS;@Z'!?B+C<+B<SRFIFF:9!F&75,LQ
ME;&<.87$5O8T<SPE"IAZE>FYUYXK%.K0P=+E<:]+GE+&*L<E_P %W?%7B#Q)
M^W39^%+^2[O='\&_"WP'I/AO2+4E2$UZ?5-?U.2VB47*MJ>I:AJ36SW1M3/+
M#9:;;/#-%96^[W_XZ?MD>,_C+^R]K'[+=E_P2%^)W@OPG%X530_AUJ%JWC35
MC\--<TZTCA\/>+-%LC^SOI=W-J6FW$$,FHM#K6FWWB&S?4-.U/53!JEZ\GT7
M_P %E_V%OB)^T7%\-_VNOV=O"WB#QIKMCX(T_1O''@W2+#4E\:W?A>-IO$?@
M[Q/H7A:2&/5[O5M+_M?4],U_0[2V/B*-9-%-KI4[6.IM;?'_ (J_X*M_\%$?
MBC\'+?\ 9V\._ SQAH'QIO$T'P]J7Q5\!>&OB1:_$R[CL;K3GCDTOPS:63RZ
M'XL\0M;16VLZM;W,UK<PZEJ":3H>D275K)9_"^'%;*_$GP-^BU+@?A3P]XMS
M/P>JK+>+J'%7C+Q%X5XSPCXHR;,'];XNQV1<,YYE<^(,+7G@\3C*]7&4,37Q
M&$Q5;"Y?7Q&#S;/J%/V<_AB<@XQ\2%G&9Y[EF'XJC]8RN>6\)X#B2EQ1EV+H
M+V65T<;F&#Q*P-2"JTZ4(T9TX0JTH5*\*=7"X*<OL7_@A#X"^(FE?#[]ICX1
M_'/X4>*=%\&#Q+\,_&GA?P_\4_ &L:=H^JZMK%EXJTSQ3<Z?8>+='AT^]ELD
M\*>#'N6@266"1[*5U0^4Y_-7_@A=X9\-^+/VU=4TGQ5X?T3Q+I?_  I'QU<_
MV;X@TFPUG3_M,.O^"!#<?8]1M[FW\^(2.(Y?+\R,.X5AN.?Z5O\ @G!X"_:W
M\'? :+4OVQOB5K_C3XC^+KV#6=)\+>(CI=WJOPX\,BUQ9:+K6LV=G%>ZGXEU
M*6:;4=:BO[[4%T=/[/TB)X;NTU%7_E'^#UY^UA_P3%_:R\37VC?!#5=?\;Z1
M8>+?A]:Z5XG\(^*]5\/^+/#NJ7UK)::]H%[X:>PDUBSO&TG3=3T_4-'OGMYH
MO,MI0C--%%\[P%Q'B/&/B#]H'POP[Q!P%1XTX\X?X3PO#-+AKC+&X#A'-\WR
M3 SR+.\]X<SOB>>28V6&JXO+</+-<YAA%%8CEQ'US%95+ YE6[\[P$.%,#X'
M9CC\#G4LIR7'9G4S&68931KYIA<+C*T<;@\%C\'ERQE%5(TL146&PDJMW3O#
MV5/$JMAX^\_\%VM>UC5?VUM$\"0PB+P]X"^#W@+0/!F@:;:^39VD&KSZOJUP
MMC86Z"(3W%U>1:>BVL2@VFFZ=9HF+5%'T/\ &K]LOQG\7/V6];_97L_^"0WQ
M1\&^#QX1;0OA_>V4GB_4?^%=>(K"Q\KPWXRTK3_^&<=-EN=4TO4(X+S5#!JF
ME:AXCM7U/3KW6(%U:[N:]5_X*G?L4?'']K#X:?L\_MH_#7X=ZWJ/Q4NO@CX&
M@^-GPFTO3-3L?%^E?VCI%MXMLKCP_P"#-0NKW6GU#POK?B+Q#H'B#PS!<ZCX
MEM8ET@QV^HG3M8O(?G'Q5_P5;_X*)?$/X-0?L[Z/\#?&&@_&BZAT?PYJGQ9\
M'>&/B+8_$R[CM;NRBCFTSPS96"'0?%^N36\=GJNKV\\MK/\ ;K]-+T+2I[BW
MDM/JN!8Y?Q_X,?1HP7!W#/AOQMGG@KFF,R7C6GQ%XV\0>&]?PLXOX=SS&8?'
M\:ULOX6S[ ?ZV9=B\5E>.S)9AB*>-GF.7YA?*<5BL#Q!G=./FYTZ^2<6^(5;
M-<QS_*,'Q=AJ6+RB6 X0P.?PXDRO'X.E.AE$*^98*M_9E>E3Q-'#NA3E15"O
M0_VJG2K8'!R?N7_!(>?X]? _]F3_ (* :)XN\ _$_P  +X9^'-Q\6/AN?%/A
M3Q#X1@D\76_P_P#B!::]/H]QK\>BH^JN/#/@8[[.:,QI90O=WEH([5V^;/\
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MU[X@\!Z#IL5Y'-?^)=1&G)K$?B'Q*\\$LNB7>JW8TJPL;2348H=<OK^TT_\
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M^J^)_AG-I</C3PIKOA:74HK32O&274MA'KEA8O>1VSSPI</;K(L+31+(5,B
M_$G[$?P4^,N@?\%E(_'.O?"3XFZ)X)'QJ_:JOSXPU?P%XJTWPL+'6/!?QFM]
M(O3X@O-*ATG[)JD]]8PZ=<_:_)OI;RUCMGE>XA5_O<1Q5EV7^-?[1_-\NXFR
MS!XBOX)99+A_,L'G^5T*F)S&AP;4C2_L3&T,YA]<QU&M)JG'*<3C,72K-<D*
M=:,>7Q(9;7K\(^ 6%Q&7XBK3AQ?B%CL/5P6)G&G0GFT7+ZY1GA'[*C."7,\3
M3I4I0O=R@W?[*_X.&?!WA:+X$_ 'Q;!H.E6_B32OBA<^#M/UBWL;:"^MO"U]
MX.US4Y]!CN(HTD&E+?Z-I]U!8[OLUM-$SP1QM+*7\J?Q/K^@?\&YVAS:/=W$
M$VL2ZSX8U*\C:<SQ:!JG[7?B:PU&T65) (K>_L$&AW"S"2!].OI[)8U::)H_
MJK_@O7\/?'WQ&_9T^#FE_#[P/XP\=ZE8_&I+^]T[P;X9UKQ/?6=C_P (-XLM
M_MMU::)97UQ;VGVB:&#[3-&D/G2QQ;]\BJ>V_8U_9=O?C3_P1R\)_LQ_$[1M
M=\!ZSXQ\,?%O3GLO$VC:EHNL>&/$</QZ\?>+O VM:GHFI6UKJ*V]AK=GX<\0
MBUE@A;4=-1/(D6.[BGK\1X/X[X=X;^A_]%O.>)\TPN.PO!_TOL'GN<Y;5QV%
MS'-,%PYEN<9SC,1B/[(EC\3F<<%A88BMCZ4'@*>%JU*,U1=2K7A&O]AFN38_
M,/%3Q(PF78>I1J9KX6U<'A,1&C4H8>MC\1A,'2IT_K2H4\.ZU1TXT)/V\JD8
MS7,HQ@W#YK_X-Y?A?X%'P?\ C5\8Y-)TF[^(UQ\41\/8M8N+2&XUG1/">C>#
M_#>O1VNF7<T+2Z;9Z[J?BB_.II931?VH^C6*WZ2+IMCL_,G_ (+C?"CP#\*_
MVVU?P#H^E:!!\1OA+X0^(OB;2-$M+33]-MO%M[X@\:>%M1N(M/L5CMK2XU:Q
M\):7K>HE889+[4]2O-4N!+<7TMQ-H? A/^"HO_!,+XE^./"7@+]G_P 6^*[?
MQ;+:V>J:%-\,_&WQ3^%OC"ZTBYN;?1/$WAG6? -QITS:AY%Y-%%_9VNZ=J$E
MGJ%O:>)='%W;6-M8_(G[?F@_M3VGQMTOQQ^V$B6/Q?\ C%\/]%^)H\.B2V23
MPCX0N==\3^#O#7AJ;2;!YK#PX]G!X,N+J+0;>ZN[NSM;VWFU^?\ X2>YUR&+
M^Q?#'@/-?^)UN,/&K">+_ O$G 7B7P?FLN#\CR/CS YWGV?X&GD7"<J672X9
MP./QDL%D_ [R_%YM#,<3##X6-3.:5'"T,)F6*S3#/\IXBSK#?\0BRKA&KPMG
M. SOA[-<,LUQF,R6M@\%@:TL;F:E7685J-)5<5G"KTL*\/3<ZCCA)2J3JX>E
MAJA_?3X&_P"1)\'_ /8K>'__ $TVE>%?MM_\F8?M=?\ 9L/Q\_\ 54^+*]X\
M%1O%X-\)12H\<D?AC08Y(Y%*/&Z:5:*Z.C ,KJP*LK %2"" 17BW[8^EZGKG
M[(G[5.B:)IU_K&LZQ^SA\<=+TC2-+L[C4-3U34]0^&/BBTL-.TZPM(YKJ^O[
MZZFBMK.SMHI;BYN)8X88WD=5/^&7!U2G3\4^$*M2I3ITJ?B=PI5J5:DX0I0I
M0\1N&:LZLZLYPIPI0IPG4G4G4A3A3A.I.I"G"52/]DYK&4N&LTC&,I2EP[F4
M8QC%N4I/(,PBHJ*3DY.345%1<G)J*BY-1?\ $3^PK\#_ -L'XY>*?B!HG['_
M (]U_P "^(=*\,6-UXWET#XIZU\+7U;PW>:BUI;65[>Z-?6)UFU6^.YM/NGD
MB0OYRQ'YB/T'T_\ X(F?\%!OC-XJTRY^//Q6\)V&GVI6TN?%/C7XE>)_BGXB
ML-+8JTJZ#IB6]Z+R0-@II]YXA\/VLC(Q>]B(0O[K_P $#/A'\5_AQ\8OCW??
M$/X8_$+P'9:C\-/#UII]YXS\%^)/"]K?W47BD326UE<:YIMC#=7$</[UX8'D
MD2/YV4+S7]1-?ZA_2R^FAXD>%7CAQ7POX8T?"J>"H9'PS/!\9QX/X<XDXG57
M->'O;8R*XHH8_$0QBPE27L,-0Q&*Q=+!THPPU3#2IQ^KR_G+PQ\)<@XEX.RS
M,N(I\2JM/&YBJN4O-<?@,NY<-CN2D_[.G1@Z7M8KGJ3ITZ4JLFZD:BD_:+\N
M_C?^SIX#_93_ ."6'Q]^"'PZ6\FT'PI\ ?B6]SJVIF)]7\1Z[J>CW]_KGB'5
M6@2.$7FJ7\TLJP0HMO8VBVNGVJK;6D*C\2?^"!W[/WPV^+7Q;^./CWXC>"=!
M\<)\+O"/@_3_  W9>*-'L=>T32]9\>ZCXA\W5O[.U*.XLFU:/3?"-[9Z=<2V
MLSV\%YJ+P/#,4<_TC?MYZ+K'B+]C#]I[0O#^DZGKNN:M\%?'MAI6C:-876J:
MKJ=]<Z%=QV]EI^G644]Y>W<\A"0VUM#+-*Y"HC,0*_'7_@WW^%WQ,^&O_#6W
M_"Q?AUX[\ _VU_PH7^Q_^$U\(^(/"O\ :W]G?\+H_M#^S/[=T^P^W_8/M]C]
MM^R^;]E^V6GG[/M$._\ (/"KQ%SE?0H^EWG^+XOJPXZXI\1^%<5BL?4SVE@N
M)LVGQ#+ARAG^-PZHYEE^;5GB:.(Q=+%5<NPRI4L/.KAW/#8:#HT_J>)<APC\
M7O"[ TLKB\FRW(,RITJ$<%*ME^&C@%F$\%1FYX>OA8>SG"E*G&O4YI34:EJE
M1\\N:_X+YIIWPB^!O[,'P,^&'A;2? OPK\0>/OBKXUU#PYX/T>TT#PQ:Z[X?
M31;RR@33M+MK:PM1J.H_$SQ;K0LHEAMYKQ)[M+=WM8WM_P! /^"2_P"S7\&?
M!W[#WPF\26W@;POK?B;XO>';KQ?X^\1ZWH.F:KJFN7.JZCJ-O!HMS<ZA8-+_
M &'HFFQPZ39:2O\ Q+U:.\O0D]UJ5[>779?\%3OV)-7_ &U_V>K;0? KZ?#\
M6_AKKLGC/X>+J5Q!8VFOF73Y]/\ $'@JXU.Y'V?3$\26C6EQ97EP]O9QZ]HN
MB+J5[8Z4]_=1?@-^S_\ MR_\%#_^">G@2\_9NUW]G/4]8T[1M0OU\"V'Q,\!
M>/EN_"NH:[J%W>S6FA:CH%W86/BGPOJ6J/J>IV%I9W$Z7-[<7<^E:V;)C;5]
M-P/E^<_2#^AAPSX5^%G&V28#Q2X4\4\\XD\0^&<_XWH\*YSQA@,UQV88[!\1
M5\RS3,Z&)SJG0EC<MQ]6M6Q&8QEB<DJPQ=2EF."R_P"L>?G-?"<#>+68\2<2
M9/C*_#>9\-X/+\BS#!9//,L)E5?#4:%&K@(8?#8>=/"2FJ.(HQA"G0:IXR,J
M498>M7Y/+_VE?"ND_L<?\%=UL_@4+/POI/A?XT?"+Q9X=T+3'$=CH$'Q#TGP
M?XA\3>#VLK:&TAL/#US_ ,)1KFDV>AVG[BV\&ZC8:?%*JY$?:_\ !9:YO/B!
M_P %+E\"^(M9GMO#^GZ'\&/ ^G3F4;-!T'Q':6.M:I/ MU(UK"R:GXHU?478
MK%"SN&G!VN[>]?L!?L%_M,?M4_M86O[:G[7/AK7?#'A6P\=0_%6>/QKI-SX>
MU[XD^-=+O$O?"FDZ)X2OHH+S3/ 6@7UCI<\LNHV<.CW?A_2]/\,:+;ZE97UW
M=Z3]"_\ !;#_ ()[_%;XJ^,-"_:L^ _AG5/&VHZ;X4L_#/Q1\'>&X9KSQ9&G
MAVZN)O#OC7P]I%LLFHZ^RV%\VC:Y8:2LFHZ=;Z-HNHV>GW=O+K-WI_\ 2F6>
M+OAKPW])3P(X)XD\0>&\WXWX2^CEG_A5Q9XGT\QR_'9/0\1\XAPM4RW 8CB?
M$8BKA:^-]ID>:1GB\7F+I0QV-P>"S+&X?&9WC*%/\_Q'"W$&8>'_ !IG& R/
M,,+D^:<>X+B7+.'98>O1Q4\@PCS*.(KPRZ$(U(4N7&89JE2PZDZ-&K6P]&=+
M"4IR_7/]I/\ 9I^"VI_L4_%'X'+X*\-Z)\//"_P?\4-X4LK32=-CB\(:GX5\
M+7U]H'B?2VE@"6^N:5J%C!J4FJL5NKV87+7UQ,MY=&7^>?\ X-XO^3EOC?\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FS]K3_DB'B/_L(^'/\
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M^25:M6K2****_F _10HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P PA]9Q'_01B/\ PHK_ /R\_G5_X=Q?M8?\^/AG_P +BU_^)H_X=Q?M8?\
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M_P#"BO\ _+S^=7_AW%^UA_SX^&?_  N+7_XFC_AW%^UA_P ^/AG_ ,+BU_\
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M7_XFC_AW%^UA_P ^/AG_ ,+BU_\ B:_HJHH_LW+?^A;EW_AOP'_S"'UG$?\
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M%N7?^&_ ?_,(?6<1_P!!&(_\**__ ,O/YU?^'<7[6'_/CX9_\+BU_P#B:/\
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MYU?^'<7[6'_/CX9_\+BU_P#B:/\ AW%^UA_SX^&?_"XM?_B:_HJHH_LW+?\
MH6Y=_P"&_ ?_ #"'UG$?]!&(_P#"BO\ _+S^=7_AW%^UA_SX^&?_  N+7_XF
MC_AW%^UA_P ^/AG_ ,+BU_\ B:_HJHH_LW+?^A;EW_AOP'_S"'UG$?\ 01B/
M_"BO_P#+S^=7_AW%^UA_SX^&?_"XM?\ XFC_ (=Q?M8?\^/AG_PN+7_XFOZ*
MJ*/[-RW_ *%N7?\ AOP'_P PA]9Q'_01B/\ PHK_ /R\_G5_X=Q?M8?\^/AG
M_P +BU_^)H_X=Q?M8?\ /CX9_P#"XM?_ (FOZ*J*/[-RW_H6Y=_X;\!_\PA]
M9Q'_ $$8C_PHK_\ R\_G5_X=Q?M8?\^/AG_PN+7_ .)H_P"'<7[6'_/CX9_\
M+BU_^)K^BJBC^S<M_P"A;EW_ (;\!_\ ,(?6<1_T$8C_ ,**_P#\O/YU?^'<
M7[6'_/CX9_\ "XM?_B:/^'<7[6'_ #X^&?\ PN+7_P")K^BJBC^S<M_Z%N7?
M^&_ ?_,(?6<1_P!!&(_\**__ ,O/YU?^'<7[6'_/CX9_\+BU_P#B:/\ AW%^
MUA_SX^&?_"XM?_B:_HJHH_LW+?\ H6Y=_P"&_ ?_ #"'UG$?]!&(_P#"BO\
M_+S^=7_AW%^UA_SX^&?_  N+7_XFC_AW%^UA_P ^/AG_ ,+BU_\ B:_HJHH_
MLW+?^A;EW_AOP'_S"'UG$?\ 01B/_"BO_P#+S^=7_AW%^UA_SX^&?_"XM?\
MXFC_ (=Q?M8?\^/AG_PN+7_XFOZ*J*/[-RW_ *%N7?\ AOP'_P PA]9Q'_01
MB/\ PHK_ /R\_G5_X=Q?M8?\^/AG_P +BU_^)H_X=Q?M8?\ /CX9_P#"XM?_
M (FOZ*J*/[-RW_H6Y=_X;\!_\PA]9Q'_ $$8C_PHK_\ R\_G5_X=Q?M8?\^/
MAG_PN+7_ .)H_P"'<7[6'_/CX9_\+BU_^)K^BJBC^S<M_P"A;EW_ (;\!_\
M,(?6<1_T$8C_ ,**_P#\O/YU?^'<7[6'_/CX9_\ "XM?_B:/^'<7[6'_ #X^
M&?\ PN+7_P")K^BJBC^S<M_Z%N7?^&_ ?_,(?6<1_P!!&(_\**__ ,O/YU?^
M'<7[6'_/CX9_\+BU_P#B:/\ AW%^UA_SX^&?_"XM?_B:_HJHH_LW+?\ H6Y=
M_P"&_ ?_ #"'UG$?]!&(_P#"BO\ _+S^=7_AW%^UA_SX^&?_  N+7_XFC_AW
M%^UA_P ^/AG_ ,+BU_\ B:_HJHH_LW+?^A;EW_AOP'_S"'UG$?\ 01B/_"BO
M_P#+S^=7_AW%^UA_SX^&?_"XM?\ XFC_ (=Q?M8?\^/AG_PN+7_XFOZ*J*/[
M-RW_ *%N7?\ AOP'_P PA]9Q'_01B/\ PHK_ /R\_G5_X=Q?M8?\^/AG_P +
MBU_^)H_X=Q?M8?\ /CX9_P#"XM?_ (FOZ*J*/[-RW_H6Y=_X;\!_\PA]9Q'_
M $$8C_PHK_\ R\_G5_X=Q?M8?\^/AG_PN+7_ .)H_P"'<7[6'_/CX9_\+BU_
M^)K^BJBC^S<M_P"A;EW_ (;\!_\ ,(?6<1_T$8C_ ,**_P#\O/YU?^'<7[6'
M_/CX9_\ "XM?_B:/^'<7[6'_ #X^&?\ PN+7_P")K^BJBC^S<M_Z%N7?^&_
M?_,(?6<1_P!!&(_\**__ ,O/YU?^'<7[6'_/CX9_\+BU_P#B:/\ AW%^UA_S
MX^&?_"XM?_B:_HJHH_LW+?\ H6Y=_P"&_ ?_ #"'UG$?]!&(_P#"BO\ _+S^
M=7_AW%^UA_SX^&?_  N+7_XFC_AW%^UA_P ^/AG_ ,+BU_\ B:_HJHH_LW+?
M^A;EW_AOP'_S"'UG$?\ 01B/_"BO_P#+S^=7_AW%^UA_SX^&?_"XM?\ XFC_
M (=Q?M8?\^/AG_PN+7_XFOZ*J*/[-RW_ *%N7?\ AOP'_P PA]9Q'_01B/\
MPHK_ /R\_G5_X=Q?M8?\^/AG_P +BU_^)H_X=Q?M8?\ /CX9_P#"XM?_ (FO
MZ*J*/[-RW_H6Y=_X;\!_\PA]9Q'_ $$8C_PHK_\ R\_G5_X=Q?M8?\^/AG_P
MN+7_ .)H_P"'<7[6'_/CX9_\+BU_^)K^BJBC^S<M_P"A;EW_ (;\!_\ ,(?6
M<1_T$8C_ ,**_P#\O/YU?^'<7[6'_/CX9_\ "XM?_B:/^'<7[6'_ #X^&?\
MPN+7_P")K^BJBC^S<M_Z%N7?^&_ ?_,(?6<1_P!!&(_\**__ ,O/YU?^'<7[
M6'_/CX9_\+BU_P#B:/\ AW%^UA_SX^&?_"XM?_B:_HJHH_LW+?\ H6Y=_P"&
M_ ?_ #"'UG$?]!&(_P#"BO\ _+S^=7_AW%^UA_SX^&?_  N+7_XFC_AW%^UA
M_P ^/AG_ ,+BU_\ B:_HJHH_LW+?^A;EW_AOP'_S"'UG$?\ 01B/_"BO_P#+
MS^=7_AW%^UA_SX^&?_"XM?\ XFC_ (=Q?M8?\^/AG_PN+7_XFOZ*J*/[-RW_
M *%N7?\ AOP'_P PA]9Q'_01B/\ PHK_ /R\_G5_X=Q?M8?\^/AG_P +BU_^
M)H_X=Q?M8?\ /CX9_P#"XM?_ (FOZ*J*/[-RW_H6Y=_X;\!_\PA]9Q'_ $$8
MC_PHK_\ R\_G5_X=Q?M8?\^/AG_PN+7_ .)H_P"'<7[6'_/CX9_\+BU_^)K^
MBJBC^S<M_P"A;EW_ (;\!_\ ,(?6<1_T$8C_ ,**_P#\O/YU?^'<7[6'_/CX
M9_\ "XM?_B:/^'<7[6'_ #X^&?\ PN+7_P")K^BJBC^S<M_Z%N7?^&_ ?_,(
M?6<1_P!!&(_\**__ ,O/YU?^'<7[6'_/CX9_\+BU_P#B:/\ AW%^UA_SX^&?
M_"XM?_B:_HJHH_LW+?\ H6Y=_P"&_ ?_ #"'UG$?]!&(_P#"BO\ _+S^=7_A
MW%^UA_SX^&?_  N+7_XFC_AW%^UA_P ^/AG_ ,+BU_\ B:_HJHH_LW+?^A;E
MW_AOP'_S"'UG$?\ 01B/_"BO_P#+S^=7_AW%^UA_SX^&?_"XM?\ XFC_ (=Q
M?M8?\^/AG_PN+7_XFOZ*J*/[-RW_ *%N7?\ AOP'_P PA]9Q'_01B/\ PHK_
M /R\_G5_X=Q?M8?\^/AG_P +BU_^)H_X=Q?M8?\ /CX9_P#"XM?_ (FOZ*J*
M/[-RW_H6Y=_X;\!_\PA]9Q'_ $$8C_PHK_\ R\_G5_X=Q?M8?\^/AG_PN+7_
M .)H_P"'<7[6'_/CX9_\+BU_^)K^BJBC^S<M_P"A;EW_ (;\!_\ ,(?6<1_T
M$8C_ ,**_P#\O/YU?^'<7[6'_/CX9_\ "XM?_B:]2^!/[ W[1?@+XT_#/QSX
MFTSPRNB>&/&FA:YK$]OXJL[R[6QL+V*>X>*!4\RXE$:DK&IW.1@'-?NQ16M'
M"83#R<L/A,+AY27+*5#"X:A*4;WY92H8:C*4;I/E<G&ZO:^I,ZM6HDJE6K42
M=TIU:DTGM=*=2:3MI=).VE[!111709A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444TLJ]3COWHNKVOKV =
M12!@PR#D4I(')H!Z;Z>H44 @\BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BC/(Z\_I]:BEGAA,8EE2,S.8XO,8()) C2>6A8@-(41W" [BB.P!5&(.
MJ75[+O\ =</TW%DE2/&]L%@Q50&9VVC)"(H9G8#^%06/8$U ]R"@>/.#&LC+
M)B%T5AD&2*?RY8SCJLB*1T(R"*_&_P#X*7?\%D_V>_V"=$U;PII>HZ9\6OVD
M[G389_"?P7T:_G"6DEQ?6]J=3^('B72X;V#P=I=I#]NO18S,=;UDZ?):V=D(
MQ)<Q_P =OQG_ ."S'_!0W]JWQ%J%GXN^-VH_"[P/J$I^Q_#CX&7D_@?1;6V\
MR:1+6^\6VL(\<ZJVR5[>XEN-:CAGAB@"V,#><\WZ'PMX7<5<50^L4:4<MP%7
MF]AC<9"4(U(QBW*4(-N<DI1DN9TX1M9KF34I?,YGQ5E>75%1O4Q-:+BJL:#4
MHPYIQ@E?2+;YX]7M)<UXN,?]'/4?B7\/="G%GXA\=^#="O2HE2TUCQ1H6FW#
M0,S1I,L-W?0NT+2QRQK(JE"\4B!MR,!L:/XN\*^(U+^'?$OA_7U7))T76M.U
M0  *2<V-S<= Z<=?G3^\,_YVOP%O5U>]AO==N[K5[^["3W-UJ-W>:A<37+!=
M\]W>:GJ-[>:C.X +7MQ(LDG^K:-?+#R?T??L/>,-%\(ZG97]Q=O;F&V!861^
MS;H4>T9HRD4ODR.Q _>28=L8;"HA;U,[\)\1D6%]K_:L,?BJ<)>UA1I^Y*HG
M*_+I!M6Y5LG=??KA\_HXBJXQHRIP;7+SM\Z346N9*ZO[VJ3V:U/Z+5.0#@C/
M.""#^((!'T(!I:^5?A_^TSX6\3^,T\ W,CP:CJD=U<:!=O+$1?\ EK&RV):2
M96:_D+R):1)&4D%M*&F&U=WU/']P?,7QD%C@$D$@YP .""/PZGJ?S#$X7$8.
MI[+$TIT9[I3CRN4;V4EJ[IO;7[CWJ<XU(J4=8M;I[>736WE;H/HHHKG+"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7OA'+X?O;RXU^'XC^#/[*@CO-ES/=R:U':65K;J77,%]-?S6;K(T3FY>,%#
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M %%%% !1110 4444 %%%?/?BK]JW]G7P7\>OAA^R[XA^+?A"U_:%^,2^(YO
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M0J2HU83C*$J=2%N:$E))W5U?ITW)A.-2G&K3DI4YJ\)+522ZH****104444
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MM%N9HK:WCEF#R)!"K"-0N2A:/*VW;WK]'_7KH=_11100%?B#_P ''G_*&/\
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M0Z@D<NN75E>@N6#<';=RNHQE9V6CL]='\21[7=_\%C_^"X?[(_Q5^$^G?\%
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M5BUK1F\(:7KEWJFLZE<>'88I?$-E=Z?&$V24I<G,W-QMK9+T6MWW??0^H?\
M@G?_ ,%S?@)^VO\ L?\ QX_:*\7Z#<?"KQ[^R5\/-=^(/[1/PLL]1B\0W47A
MCPUX2U3Q1-XV^&[R_8;W7_#7B1- UK3M)TZ\BAUC1_$%J/#NJ2W:W.BZYKWY
M(_"__@MO_P %R?VX-$^)7QW_ &!?^"?G[/?B7]G7X8^)]5T74+/Q/JUUXN\?
M1W-EH":RVA7PG^/GP?U[QSJL.DZII>K);_#3X;Q3OJ/V?38I;\O/I]Q\"_\
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M:W_!I=\8OA1\'?CI^U]X+^+7Q(\$_#'Q9\0= ^!?A?P-X>\?^)=)\(:MXO\
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M0;/[%KVOV5_>:GI]K!IFC:]#;@YQBE))6<4K-*5^GQ-^Z[]+']FE?PW>%_\
M@YF_X*,_''Q!\5O@5^SA^P]\//BG^T-8>)I5^'EO\/\ PC\6/'VGZ5\/?"=Q
MXLM?B-XA\7>#M)\8C6]3U9)?^$%A\+WMIJ^B>'M.N[K6%UJWUFXO-#T>?^Y&
MOX0/^#4VRM)/V]?V_M1>WA:^M?AY/96UVR*9X+2_^,IGO;>.0C<D-U-IMA+.
M@(61[.W9@3$N B"5IMI/E2:3OWMT/TG_ &J?^"_'QP_8]_9)_9!MOB7^SGX6
MUW_@I-^U5\/+7XB7'[/VDZ=XZ\.^$/A9X>U_Q??:)X&U#Q1X(U+5-7^*,^O>
M.+.V73-%^'<>MVVM1^*;+Q+9WNN6_P#85K9ZWXGX0_X+^_\ !0C]D7XY_"?X
M>?\ !8+]B7PE\#/AE\:KASX>^)/PWTKQ'X<N_#&G7>LZ?:77B"]M-:^)'Q/T
M#Q3I/@8:G;_\)CX;L]7T#QOH>A7>FZK<V>I:B;6P\2?G-_P<3^%_&/@C_@MM
M^S1\2O$GQ/UCX">#/%OAC]G/4O 7[1%IX=7Q1'\'4\%_$?4M.\0>.]+T;^U-
M(36]4^%6O@?$"[T0:MIE_P"5>Z9-'-;C4+"XE?\ \%)_V;O@YJ-U\!O 7[<G
M_!Q+K/[0VG>)_P"WO%_PTF\)?LD0?'W2_!MG=1Z/IDWB/4W^$O[2GB'6-'L/
M%Z7-O;:$;6RU ^)O[%OY+*UG&CM+&&BC!J-TO>3;LI-K?2-KI6[/5G[X_P#!
M;W_@LW\7/^"6GCK]E_1/AE\,OAC\2?#/QLT7QUKWBN^\8CQ-<:IIMAX0UCP9
M:1'PL?#_ (GT#3YI+W3_ !'>S*=2:>&2XALRLT,#2EOS1^+O_!P=_P %=OA'
MI7A3]J[QC_P3:\&^!?V$_'VN6(\$:AXRT7XD1^,-6\*Z\ZZAX8FU3XF6GC&+
M2-"UCQ'H@CD\/:YJGPDL?#6MO,[Z/IVKKY+CY._X.I_",WP_T+_@EEX#N-?O
M_%=QX)_9S\<>$9_%&J^'[[PEJGB2;PW9_!K1I=?U+PKJ<L^I>&;_ %A[)M1O
M/#^H3S7VC7%S)IUW+)/;2.?UU_X+%?\ !3']@OXU_P#!%;XDQ?"_XU?"OQ-J
MW[0G@WX5>'?AA\'?#FNZ#J'CS1-=M_'/@SQ3/I&O_#ZSN;?6_!*_#BQ\,:E/
MJESKNE:18Z3>Z+965F)[_4=#L-1"4H\M/W%+F;3>NU[=-G;7T1P7_!<_]JWX
M;?MN?\$#/!G[3_PH-W#X/^*GQ4^#>J1Z/J<EK)K/A?7=.U_Q)HGBGPCK9LI9
MK;^UO#'B33=4T6\D@D:WNFLUOK0M:75N[=M^RA^WR/\ @G/_ ,&[G['WQXTW
MX6>(/C/XUOM&UWP3X!^'^AP:N+.^\0ZM\4_BIJ4VK^+=7T?2=:N/#OA#0-%T
M?5-1U+5)++R[N_32O#L-S:7VO6=S%^+OBGP)XM\$_P#!I_X2NO%5C?Z=%X[_
M &P++QWX5MM0B,$C^$M2\::OI&FWUO"]O!(MAJMWH6HZK82NUR+RUO8[Z"X-
MK<V\47UMXC_X*7_'7_@G'_P;V?\ !-6\_9P31=(^*/QR?XE^#[7X@:]HEOXD
MA\!^'_#GCKXBZOJU_HNAZI;7/AZ[\4ZA>7VCV^E2^(H-2TRUL8=8D.A:E<&&
MYTT'RZ**U7M9+>UTEU?];#O&O_!>'_@NU\&/A'X-_:^^,G[!/[/_ (?_ &4O
MB&OA:Y\->(KGP9\1]'BO=%\61W6H>%+Z#45^/6M^(]!F\6Z=+:R:9K?B?P@=
M#U2W&GW6D:5$NIPF[_H5\4_\%@/@3X(_X);^#O\ @I_XL\+Z]I?A'QWX.T>\
M\+_"1=3LY?%6M_$_5]7O_"Z?#'2M;FL[6TO/LOB;1M=^T^*/[*AB7PEHFI^+
M?[$V6YTL_P =G_!1WX2_%"Z_X)O?#K]J[]JS_@L/XI_:K^*?Q\M_A7XB^%O[
M)_A;QB+KX9V+>(W@U[Q/J&H>&(/&#65Y/X!T>/5+#6=;LOA=X*BT+QG:Z=X;
MO[F2Z:SM9/=OVT_ _B_QO_P:O?\ !.7Q7X1CN]:\+?"[XWIXD^(<.EVD=]::
M/I-WXE_:8^'=GXEU:_B=FT^WT;QGXFTKPA+"4*/JOBV""Y>&>UCC<!PB^31*
M\^5N/,E;73WMWI:^FNQ]'S?\%_O^"VVH_!V]_;7T'_@G=\'+;]B>PU%9)?&&
MH>#/BU?R-X:.O+I$VIP^,$^+.CW6H65M?12Z!-\0M.^&C^"+#5?.6_L3/#]E
MC_9L?\%]/V9H_P#@EK9?\%)[SPMJUM=WGB5OA'%^SZ/$&FOXKF_:%@VR7?PS
MLO$TMI;V-YI-MH9/Q#;Q6NDQW(^&NW6Y?#4/B%O^$4'@/[('_!7#_@GK\'/^
M"*/P5\6>+OB'\*O%&J_!']F;P-\)/&_[,4WB/PQ_PLWQG\3/!_A?3_!FI^#T
M^&^OF35[Z#Q_KUE<:Z-<FT&^\,-H>IWGB">[ETJPOY8?R'_X+E?M<Z)_P4D_
MX)0?LP_M5_ ;X-_$[X5? OP!^UGXF^&^NZ'XWTSPEIT"ZQ_PKJ[M]%\2:#9^
M!O$?B33F\%VNHMK?@^WUK5X_#5U%XHDN](@T=X;JTO;P%RJ32<.5<_+S)M76
MNCONW;==SW&'_@X)_P""QO@KX6>'_P!MOXK?\$YOA?\ \,(^*-4T.UT_Q1HV
MD_$;PWJXT?4]=DTO3]67QIJ/Q"\3RZ=9>)+ECHNB^,]>^%-KX+UG5;CPU%HK
M-/JMO!KO[%?MH?\ !96R^&O_  2E\ _\%,/V3/#/ACXA:7\1?$W@70]+\+?%
M*#5X(M%EUS6=<\-^,O#_ (AMO"^MZ=<P>)_!GB30=2T&[^QZK<Z5->V$]S93
MZAIT]G=R_P XNH?#C3_%'_!*WX??$#XN_P#!PQJT'[,?B;X6_"?X=:[^R9HO
M[.7A7Q_XE\#7T%MX<TN#X%Q_#C3OVCM'\1WEQ\*+S3(T6ZCT'1HD\.>%(O&N
ME1Q:.^FW$OH_[5?PA^%'P:_X-C-(T+X&?M ZM^TQ\)?$/[6NA>+_  7\4M8^
M!WC3]GZXN[?4O%FK:;KFAP^!_''B#Q+J%W!H?BK1]>M#XDTS4?["U6Y^TPV"
M2R6-U>W8-QBW'1+W^7122:UT?-U7D]3W/QU_P<+?\%7_ !I^S'HO[87[/'_!
M/WP!I7[-?@?3- T[XS?&KXA:)XS\4>%]7\?P7EIHGC,^!](T/XG^$];T[X:Z
M?XJU*#PY!KF?%\UI<VD[ZWKVBWRW^CZ9O#_@XG_X*2?M3_!:Z^)'[ '_  3R
MTG6[/X'^!U\2_M:?$#QS9^(_B#X)\.Z]8C4]5U#1?AEIWASQI\/M2U'31X9T
MF#Q#=QW5[XA\:0V.J7^G)X5M(=(TWQEKWL7@.W@MO^#1V^CMH(;>-OV8/B-<
M-'!&D2-/=_M"^*+JZG98U53-<W4TUS<2$;YIY99I&:21F+/^#>"RM+7_ ((3
M?M8SVUO#!-J7C;]K.]OY8T5'O+N/X$>!M/2XN& !EF6QL+*T5VRP@M8(P=L:
M@ >XDWR+W9\JU>J??77RV_ _0[_@D;_P68\/_M^?LA_&WX_?'KP]X4^!_B;]
MEN:[G^.U]HE[?GX;Q>$8O"U[XOMO'^AIK-]JFOZ+ISZ;HWB."^T#4]0UNYLI
M]#,EKK6J"_2"T_)'2_\ @X&_X*M?M=>(?BK\1?\ @G)_P3R\'^/OV9O@MJ=S
M/XFU#QOHGC'QGX_U#1+73;J_2TO+SPQ\3/ VCQ^+=2T>&37H_ _@;0_'.OZ3
M-)I5JMSXBM&SKOYQ_P#!&#P7XR^(/_!'C_@N9X3\ 6M[?^*;_P"&W@.[LM.T
MU[D:AJ=CHGA'XF:]KVEV45FDES>76I^'],U2PATV-&_M22X7374QW3"L7_@B
MAX,\>?$+]F'XL1> /^"X"_\ !.*/X=?$'Q+XM\9_ 6^\!>$+]-3T27PEX6FF
M^-5AJVM_&SX?7NO6.HVNEGPOJRV>@W5SH=QX1LK6\F\C4]#^U ^2*<W9:222
M?,TDU?:.ODNQ_6Y_P2P_X*_^!?\ @IC^S/\ %#XE:/X0B^'?QQ^!.EA?BS\+
MI]2;5](@O;WP_JNK>&/%?AC4A]GO[SP3XLN-"UNTM8;^*VUG2-0T;5M+O&NH
MH=.UO5_P\_9?_P"#D+_@I1^V7I?CCX8_LS?\$_?AS\8?VEK'[%XAT,>%Y?%U
MM\*O!GP]M+>[M]>U[XA_V[\0],O+W4[O7[G0=,\/6*>,_!-E,);R-=0U/4IK
M/3QU_P#P;X_ []ESPE/^WC\5_P!FO]M[QK^U/>>(_@L^B_%+PKXG_9&\=?L]
MKX2U74[OQ3KOAKQ)<^*]1^(WC[P1KU[KGV'Q5#9>'-.N$UJ"V^VZABRLX;B"
MX\J_X,V;6U>Z_P""BUZ]M U[;P?LE6MO=M#&UU!:WDG[2\UW;0W!4RQ074MC
M92W,*.L<\EG:O*K-;PE EQBO:/EOR\MD[JU]UT=OS5C[K_X)+_\ !=G]I3]K
M?]H[XO\ [$O[7O[/_@OX;_M)^!/!_P 0]2\)CP'H_B_PO!=>./A0QL_%OPU\
M?>"_%GB?Q9J&F>)3*MS?1ZKIFOZ?I>_2-3TPZ3:2W&FS-_,=X8_:9_X*#V'_
M  76N?VDM*_9*TC4/V^I/$/BZ]E_92^QZ_)I4>I:E^S!K7A#6;+[%%XI77Q_
M9OPKNK[QSL/B<RQ7-KNF9K=)+$_J?^R#%%#_ ,':WQU2&..)#X^_:8E*QHL:
MF6?X+ZS//(54 &2::22:5R-TDLCR.6=F)Y"'XB_#_P"$_P#P=U^)O'_Q2\<>
M$/AOX$T'Q[\05USQIX\\2:/X1\)Z*=7_ &"_$.AZ6=6\1:_>:?I&FKJ&LZGI
MVE6;7EY"MQJ%]:6D1:>XB1@I)*4K16M+FMKU6J7D_O[']W/P\U7Q-KW@#P-K
MGC71H_#GC'6?!_AG5?%OAZ)9$BT'Q-J.BV5YKVC1I-/<S+'I>JS75BBRW-Q(
MJP //*P,C?YUG_!PY\6_VH?$G_!5_P"&Z^._@C8>%S\(K_PQX=_9=\N#4H1\
M;_!&E_%"\U[PUXFOWNM:N5GDUCQE>:CX;DETTZ+;>79;4MX)E><_Z-^AZYHW
MB?1='\2>'-5T[7O#WB'2]/US0=<TB\M]1TG6=&U:TAO]+U72]0M));6^T[4;
M&X@O+*\MI9+>ZMIHIX9'C=6/\*'_  <^:EIVC?\ !4W_ ()[ZQK%_9:5I.E?
M#CX:ZEJFJ:E=06.G:;IUC^T5XHNKZ_U"^NI(K:SLK.VBEN+JZN)8X+>".2::
M1(T9@$4OCVZ2^6G]+_@F[_P7_P#B[^T_\<O^"1W[&?Q'_;#^"-E^SQ\=]7_:
M\\6VGB7X6:?;:I:6VBZ9I/@WXJZ;X:O5@UG6=>U!&UK0K:QU5S+J4JLUT6B2
M&,K&M+PE_P %G?\ @K;^SY_P3_\ V7?BQ\#OV /!>D_L1_ /X%_ GX/:O\;?
MB_I'B[Q7=_$*Y\ ^"/#'P@O_ !9##X7^(G@.^\)> ]?\;V,T/AO65\,:QIYO
MVT&"Y\4W1N;S1;WZ@_X.M/BE\,_C%^P#^R]XW^$?Q#\#_%'P7<_M9ZAI=KXP
M^'?BO0O&OA:ZU+1?AG\2--UFPM/$/AN_U+2+J[TC4H+C3=4M[>\DET_4;:YL
M+M8;NWGAC^TOVC=-T]_^#7'P]:FRMOLP_P""8G[+&I>0L,:1?V@GPY^$.KK>
ME$55-R=44:B\Q'F27F;AV:5F8A2:Y(7BG>I)6=]+VVU\]+GUE\!O^"R'P6^(
MG_!*N\_X*=_$SP]>_#[P_P"#M"\1V7Q!^'.GW\&JZD?BCX:UX>$K7P)X+U'4
M!I=MJ\WCWQ#=:"O@Z:^>TCMK7Q-8)K]Q9MIVK7%O^$MC_P ' _\ P63^(?PQ
M\6?MI_"C_@G/\*KK]AGP5?\ B-=9\17NF?$;Q!J]MHFD:@EOJ.I2^.;3XA^'
M)-9M_")5;+Q%XO\ #WPED\):5/#XB;6K>T:PD&A?GMX'\*>/?&__  :L?$Z;
MPM!JNJ:=\.OV]CXK\6VEA:I?&S\!6UMX(L+R>:,N+BVTK3O%7BO1]:O[JRBN
M'M$2>ZNTATL:C>VO:?L<>"]:\2_\$HYOB'K/_!?C4/V;O@AX2\"_$GP;\3OV
M.+#X,^'O&7B#P;9ZMKOB/3M0^&^D^'KCX]>#O$?C>;XI6NNQ:IHCZ?X9L[+6
M)?&3V9NT>QU2YM0%"*YG9/W^6SYG9=ERZW=]&S^FV^_X+0^&/B=_P2 ^+?\
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MVTT>;QQXH\7:OI&IZY%-I2:.JW.EW&J97_!.S_@NQ^V%\1/^"@UA_P $WO\
M@HG^S!X ^#'QEUZ35M%T_5?AW;^*/#=SX4\4Z7\.[KXFZ3I_C'PQXB\8_$FT
MUO3/''A:UCN]!\3^%_$UCIPDU;0KFWTZ_P!%U5]1T[X3^)/_  4-_;S_ ."D
M?_!5[XX?L$?#?]N72O\ @G)\"?A9XY^,?@/0]8T[3K3P]XR\11?!3Q7<^$-9
MN1KMW=^%_'&K_$SQ7]BU3Q+9^$(O'/@?0]"T#2[Z'[-_:VC7E[K'PO\ LA^#
M?!7PN_X.3_@3X \(_M2>+?VQ;'PC\2KW0M=_:0\=Z^OB+4_B'XZF_9^\4R^+
MHK;7Y->\22ZG:>'_ !5?WO@NWFGUW4Y9]1T6ZCMKV^MS:W5P#Y5RM.*34.;3
MF;O:Z;EI'7LDS]L_V]_^#AS]HO\ 8X_X*;_%3]B3P?\ LN>"/CAX0\(2> ?#
MW@?3O#LGC>'XR>.O'/Q3^ 7@SQOX+T2S.GW^KZ1/YGQ1\=:3I%Q9:7X.O=5O
M_"T$]CIEN_B"XM[P>-67_!PW_P %%_V0_P!I3X>?#W_@JU^Q'X'^"?PE^*L]
MCJ%AK'@7P_XU\.^*?"WA.]GMM,O/$VE:IK/Q'^(_A3X@P>$YIK2^\7^%[9]$
M\3Z>]W<)/-ILMWHVBCX1_;-^-WPO_9R_X.O=0^,WQGU*TT3X9>#/BE^SH_BK
M7]0MC=:?X:MM>_8U^%/A>P\4:A&L-Q)%8>&=6UO3]>O;R&&2XL+73I;ZW7S[
M>,CWO_@ZT_:N_9E_: \*_L<_";X$_%KX<?''XD:/XM\>^,K\?"7Q)X>^(\'A
M_P ,^)=(\.Z%H]A>>(/"E]JUI;:GXQU:VBGTSP[;74VH7UMH::E>VEO;OH4V
MH U&-X+DTE!-RUT=MUT7G?NC]4?^"E/_  6V^-__  3U_;H_9O\ A5J_PO\
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M5_#^M0.D5T+>0/'=V&L:?@3:5KVD7<4FGZ]HT\=M-I6I17-FT$7V;;7O,/W
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MY3E)**BWS7TN>G[2G!>TJ3C&C%<\JKDE34$G*3<W9)))MMVM9W:9_/'_ ,'
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M-(TD?Q-XHUKQ!/<8B1(@US+J33'8J*2W XR?UH4\8R,@#('8'IGOT]:_!O\
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M2C*+B>@T5G7MZ;/R2[0HLCLI:5@B@*C.2S,ZA(Q@;Y )73C;;RAF:/\ *_\
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MU+4=*N[);C3G\1Z9K<%I<S-=Q0+>6]A<6?\ <A_PRW^S+_T;I\"?_#1?#_\
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MO#VBZ'K$EQIT*-KEQHFI:LME/?Z9%>1Z;J-[:3_IG^SG_P %E_\ @@?^S/\
MLL7O[%_A0?M$>.OV==1D\7I>?#_XO_"JZ^(FG7&E^.KV75/$GA^9-4NHH)M!
MO=7N;_5TL)K>3R-3U*]NXI5DDC\K^I7_ (9;_9E_Z-T^!/\ X:+X?_\ S/4?
M\,M_LR_]&Z? G_PT7P__ /F>H&YQ>ZF^NLUNOD?P/WVH?\&H-[XV?Q8NE?MM
M66CR7_VU_AS8CQ?%X),9OC>/IR3R7TWCJ"P>(G3MMOXVBNHK'!M[J&]5;T?L
M_?\ _!>G_@@EJG[.W_#)5]\//',_[-H\(0>!4^#Q_9^NH_!T/AJU=)[:VM[.
M+6H[BVU"VU"--:M_$$%S'XA@\1(OB2+55U\#4:_I!_X9;_9E_P"C=/@3_P"&
MB^'_ /\ ,]1_PRW^S+_T;I\"?_#1?#__ .9Z@3G%VNINVUY[?@?P-Z3>_P#!
MJ'IGCA?%TVG_ +;VL:,FIQZA'\-]67Q4_@=88[F&X&DM/875AX\GTQDB:UD%
MSXXFOI+:XF#WQG\F>+]3_P!J#_@LK_P0(_:S_9ETC]D'XC6G[0/AWX#^';OP
M=<^'/!_PP^%-[X"@\/0> HW@\,:7HITN]>WT_2=/MW-NMA!:K"T*HHVE0:_J
M5_X9;_9E_P"C=/@3_P"&B^'_ /\ ,]1_PRW^S+_T;I\"?_#1?#__ .9Z@;G%
MV;YVUM[^WI[I_*WIO_!8K_@@KI7["\G_  3MM=6_:F_X9PE\%ZKX!:PD\!ZN
M_C'_ (1_6/%%YXOO$'BH7ZSB[_MF^G>*Y^RY2WV0%6"EB?LJ_P#!8K_@@K^Q
MO^S3XT_9.^"^K?M36OPA\>W_ (YU'Q!:>)/ >KZ]K\EQ\0_#MAX7\2?9-;DO
M[:6VCDTK3K9;-5A8VD_F3*S%]H_JD_X9;_9E_P"C=/@3_P"&B^'_ /\ ,]7E
M_P 8O W[!/[/G@/4_BC\</AU^RU\*OAUHMSIEGJWC3QS\/?AEX>\.:?=ZS?P
M:7I5O=ZI?Z'%;0S:AJ-U;V5HCN&FN)HXD!9@*!<T=K3U=[<RU??X=S^8C]@?
M_@K!_P &_P!_P3;T3XF^'_V:-2_:LL=,^+>H^&M4\8Q>-_ ^K^+WGNO"EIK5
MEI7V%[F]M/L<7V?7M06ZB D6X+1$[?+PWPC\;_B#_P &JGQM^)>K?$Y_#W[7
M7PLOO$&JW.MZ_P"%/A!X;U7PMX#U+4[V[-Y?SVWAC53XC@\,VUW(TB?V3X,G
M\-Z+9Q2NFF:=8D1LG]T>B_LZ?LH>(M'TGQ!H/P%_9^U?0]=TVQUG1M5L/A3\
M/+FPU/2M3M8KW3M0LKF+0&CN+2]LYX;FVGC9DEAE21"58&M+_AEO]F7_ *-T
M^!/_ (:+X?\ _P SU ^>*;=IW>[YU=^ONG\R?[,G_!;W_@@9^QY\#)?V=OV=
M_#?QG^'GPWOX-3_M^*S^$NOZCXD\5ZMK6GKIFK^)O%?BG5?$-[K>O>(KZT2.
M 7U]=21:=:06>EZ/;:=HUA8:=:^)_P#!/_\ X*F?\&^O_!-+_A;7_#,.I_M8
MZ=_PNK_A _\ A-_^$V\&:SXN\[_A7'_"9_\ "-?V9]HO;3^S_+_X3S7_ +;L
M\S[7OM-VS[,N[^L;5_V=?V3?#]B^J:]\"OV=]$TR.>QM9-1U?X8_#73;%+K4
M[ZVTS3;9[N\T.&W6?4-2O+33[&%I!)=WUU;6D"R7$\4;>3_$_2?^"=GP5\7?
M"GP#\6O"'[)?PZ\:_'3Q&WA#X.>%_%W@7X7Z+K?Q+\4)J?AS17T#P;87FB1S
MZ[JJZMXO\+Z<;.R2687>OZ7#MWWD(8%S1=])N^_O7O;77W=;'\O_ (%_X*;_
M /!O3\.OVY_$G_!0_P -:C^UK%^T=XKU+Q=JVKW]YX0UF[\'/=^-O#D_A;73
M!X6>\6&".32KB06R+=D6UQMF4MC97B/[;'[6G_!M%^WI\<+S]HCXR-^U]H'Q
M1US3M#T[QAK'PR\)7OA:T\<+X;T^VT71KWQ/IVH)K]M+JEGH%AIV@?VEI(TF
M[GTG3-/@N))9+2&9?[6/^&6_V9?^C=/@3_X:+X?_ /S/4?\ #+?[,O\ T;I\
M"?\ PT7P_P#_ )GJ!\\4[VG>UK\ZV[?#L?@7\-/^#EC_ () ?";X<^ /A7X/
M\0_M!P^$OAIX)\*_#_PM#J7PHUG5=1B\.>#="L/#FB17^J7FN/=ZE>QZ9IMJ
MMU?W3O<7DXDN)W:61B?@S_@H+_P4W_X-X/\ @I=#X$N/VDA^U$GBGX;1ZE9^
M$?'GP\\":KX3\66&B:Q-;W6J^'+N2:\UC0]8T6[O+2VO8H=7T*^N]*NEN)-$
MO=,&IZLM_P#US_\ #+?[,O\ T;I\"?\ PT7P_P#_ )GJ/^&6_P!F7_HW3X$_
M^&B^'_\ \SU E*"=TII]U-7_ /23^*O7OVN_^#:SQ+^R#\,?V(]:U#]M"\^"
MGPG^)FN_%WPSG1==B\6S^./$>GZKIFK7^J:Y%.EM)97%MK%X5TG3M+TS3H9R
MMS%;I,T[S?<GBO\ X+C_ /!#3QG^QG:_L':WK/[3<GP!L_@OX,^ D-C;?#K5
MK?Q6/A_X"T/0O#WA^%O$JZD9FU:/3O#NFBZU,VV^ZF6:5HE\TJ/Z</\ AEO]
MF7_HW3X$_P#AHOA__P#,]1_PRW^S+_T;I\"?_#1?#_\ ^9Z@.:+Z3WO\:W?7
MX=S^5_\ 9/\ ^"Q'_! 7]CC]F_Q;^R=\+(?VB-=^!WCO5O&6J^,/"/Q-^%U]
MX[@\1)X_T+3?#?BO1]6.HWL,-[H.K:-I<%E<:5<6\D#PRW2/O2<J/R]\1:A_
MP:C:_P".;KQC!8_MN>&]+O-1GU"3X=^';?Q';^!HA<3SSO86HU&75/&-GIR&
M98H+>U\81-;P0010RHJR>9_?%_PRW^S+_P!&Z? G_P -%\/_ /YGJ^>/VC-1
M_P""9_[(WAC2O&/[2^@?LD?!?P_KVHOI/A^[\<> /AOIEUXAU*%89+JS\/Z2
MOA^;6-=FL8;B"XU(:387@TVUE2[OS;6S"6@:FKNRJ7>]IZO_ ,E/Y]?%O_!9
M/_@WZ\3?L:ZQ^P/I?A_XY?#W]F36/#MAX8E\$_#SX5:UH%Y;:=8>)-.\6&XB
M\07&M:GJ]WK6I:]ID.HZYX@U>YU/6]<NY[V\U:_N[Z\GNFZ']BW_ (+C_P#!
M#3]@CX(V?[/O[/NL_M-V/P[L?$OB#Q9!!XL^'6K>)M7_ +7\3303ZH[ZI/J5
ML[0,]M$((!$%A4$ L6)K^A[X+>!_V#OVB_AEX8^,OP/^%_[-?Q+^%WC2/59/
M"WC;PS\*O =UHNM+H>N:GX:U@6DLOAF"7S-,U_1M5TB]BEACEM[^PNK>1%>)
MA7J7_#+?[,O_ $;I\"?_  T7P_\ _F>H%S0U34][M.?7N_=W/XC_ -K_ /:5
M_P"#8G]M+XUZW^T!\2;+]KGP;\2/%T\%]X[O?A1X4U'PGI/CK5X(XK=M<\0:
M'J/_  D.G0:U>6L$,.J:CX=AT&?5I4?4]3-WK-Q=ZE/=\'?M/?\ !K_\,/C)
M\"_CM\(?#W[5_P )/'O[/DW@^^\$W/@30O%]K9:MK7@WQ#?^(K?Q!XYCUK6=
M<O?&.L:[+J$ND>*9M6OWMM;\-0VOAZ:UCTN!;>O[8_\ AEO]F7_HW3X$_P#A
MHOA__P#,]1_PRW^S+_T;I\"?_#1?#_\ ^9Z@?/&UOWEMK<_3;L?YL_[3/[9_
M[!W[47_!<GQ;^UW\6="\3>/?V%?B#>^#;/QIHFL^$M2MO%6JZ#HW[)_AKX2W
MNSPY8ZI:ZQ8ZC8?$#11=Z-J&FZO::GIYL['Q!IUW:W4%N\?Z._LN?M!_\&N?
M[)WQ@T/XX^"O#?[57CGQUX1UK_A(O Q^+?A#5O&F@>"=;@N8;O2=5T/P_'/I
M&FW.I^';B!+CP]J?B.'7M1TJ]$>IP7?]JVME?6W]MA_9'_91-[_:)_9C_9Z.
MH9!^WGX+_#<WN5C$*G[4?#7GY$($0/F9$8"#Y1BK_P#PRW^S+_T;I\"?_#1?
M#_\ ^9Z@;J1:2M-))*RG:Z7?0_F6_:__ .#I?_@GAXF^!?QD^%OPO^%WQ[^,
MGB/XD?"+QMX-TFU\1^!/"WA/X67-_P",M#U;PO)HWCO4=7\?Q>,(M)6TO7O-
M570/!>MI?6$T>GV]Y!<SW,VG_A/_ ,&]W[??[!W_  3C\5?M _&G]J76?'<7
MQ6\=:%X<^&7PVM?!?P^O/%8T3P!'?GQ1X[NK_4H[BUAA?Q3X@L/!,%K9P3>=
M GA"ZENXVCOK-E_T)-8_8S_8_P#$,EM+K_[*7[-FN2V8<6DFL? SX7ZG):B4
MHT@MGO?"T[0"1HXV<1%0Y1"V2JXVU_99_9B151/V<O@.B(H5$7X0_#Y555 "
MJJCP\ JJ        ,4"4X*+BHRM*U_>73Y?H97[)7[4WPH_;5_9]^'_[3/P/
MN=>O/A?\2_\ A*O^$8N?$VC2>'M;D_X0WQMXD^'^M?;='EFN)+39XA\*ZM';
M;IG^T6BV]T-JSA5^C:PO#/A;PQX*T2R\,^#O#F@^$O#>F_:?[.\/^&=(T_0=
M$T_[9=W&H7GV+2M*M[6PM?M5_=W5[<^1;Q^?=W-Q<R[YII';=H,G:^FW0***
M* "BBB@ HHHH **** &L,J>2.#TX[&OFO]KCX?7?Q<_95_:-^%^GVXNM4\>_
M!?XF^%='MV 99M:UCP?JMEHL<B$,9%?59;,%$&]R0$*MAA]*/G'!QSSTY&#D
M<_TYK+NP4M9L$ ,Y'*JW!P2 KA@Q &<;3G'0C(I4ZSPV(HXE:/#5\/6O>S:I
MSC))/IJDF]+)M[V,ZM-5*=2+M9TJD6N_/%I?\'Y;G\%O_!K_ .!HKW]M#XK^
M,]5MC::E\*OV>/$&CK'>VQ673]0\6?$?PGHNI13><8S97MMI>@WT#I)L<2R7
M2R1-&DD2>"_M1?M):Q\:OVG_ (Z?%RYOI[VP\3>.M8TGPV)69UL_!7AJ\'AW
MPM8V9+L%M%TG2H;J,*[J]U>WLQW1SPQ6_P"L?_!.[X2-^R__ ,%L/^"BW[-\
M<$VC1?$WX+^,?B?\+T+!K";P_P"+_%>F^.]%D21MQN#I%QXKO=,V222^7+H5
M[#,JJ'#?ST7\#0:OJ5I*VQ8=<URQNHE'RQ36VJ7ZS@%_W@:TNH9(-I/S%\2!
MMHV^UXZ9E5QG$N QU.K_ +'BL%EE?"3J64/84\KPJ5-\G-9J?M8R2O%574UL
MG)?P?])S,,1A>$^%,CHSK8:EB,\S;,L9+#RFISKY5##5>237+*4VL=:E3?,I
MJERMQ<8\_P!9^&/CU<Q2QI)>>4TLD"0HX6!/-N9[73H((VPS%5FFCD:+;)(+
M<75RK.8%MIOZ0?\ @FK^Q!XS\37&A?M"_'[0M5T>*RNHM0^'/PZ\0Z5<Z;J,
M-[9O%+;>*_$UC?6C2P&99I)O#^GR?89_LD<&L3F6#48+>W_$?_@CK\!9/CS^
MVEX%O-8T*+7/AU\(H;CXB^/+:]B#V+R26.JV7@"UD?"/)=P>*H8?$4%LDN#-
MH$;S1S)&L=?W;VMI%9PPPVT!CAAO(H!"S+*(XHHTC558DD[XT23<^^16D9 ^
MU54?G7#N6NK!9GB?9R>(G.5&F[VBJ;E3?-=+[<+Q4;J2:E)IWB>Y]&C@?'YQ
M@L?QMQ-B:F)PV'S.>&R+#1<Y1G"FHN>)JJHHTYPC6FJ:C3E)*I"I[2ZC"$]3
M3TCCAV1'<N=S-C#-)M02%L80G<#]Q$0#"JO!9OQ+_P"#B:_FM?\ @E'\?[:-
M8RFJ>)/@QI]P7#%TA3XN>$=0#0E74++YUC"I9UD3RFD4('*NG[91#RG;RQL6
M2X+,N.ID89P"#@''.W SR!DDU^%?_!QU?M;_ /!,#XEVL8$L>J_$7X06-Q&"
M,;5\;V5\IW_?4^;9QXV,"<8^Z6!_2.$'S<8<-4E[K_UBRJ#_ )4Z]2HX;*[2
MY'S>[>[5D]3^QLX@_P"Q\PA:/,\#522T5U[/77RM=]U+U?\ /S_P;@?#+PM\
M7/V@OVQ/!GCOP_H_C'P-XB_9FL/"GBCP=K5I%>V.NVNL>.]#NBMW;SB:":*R
M@M9I[!C"EW:W[O/:SHY#)\E?\%5?^"27Q-_X)Y^.=8\4_#K0?%WQ'_9*UM+_
M %OPU\2(-.O]5/PQ>6^\ZX\'_%/4XK5+;1/L@O(7\+^(]1CTW2_%UO-%I5O-
M:ZG8S2W?Z"?\&LJ+_P -/_M1SX_>S?!7P@LS=!)Y7C-44.@PA*K(Z$[<E#M8
ME0 /[4_&'@CPKX[\.:QX)\8:!I?B7P?XDT*Y\-ZWX9U:R@OM+UC2M3@*:UI5
M_8WJO9WFGZGISK;W,,R%'V9#+*BLOZ[QAQWF?!_B=Q!C:%\3@\3A\LCC,#-_
MNWAI4$XU*&ZCBXQUM)*G*2Y)2::E'XO+<@H9WPY"\OJ^+C4=.C5C'FCRQ]BX
MQJNZDU))+2+=/GDX.]U4_P A^:.&\2XM9DCGM[F';-'(B/%.DT<8+D-YC+'*
MBQ-Y:N8QLC;#2 R-_43_ ,$-/^"S=K\%+O1_V-_VPO'G]G_"D P? KXS^+]8
MBMM%^'6HR?:;:#P!X_\ $EX8;'0O!DMJ_E^&_$NNLVD:$RV^A3#S'BNE^&O^
M"RG_  2GU[_@GQ\4;?X@?#@3:M^RS\5O$UUI_@;5;ZZ\W5/ 'B^[M9=:_P"%
M3ZXL\LUS</#I]IK-]X3U:21O[5T73FL9&?4M-NYI/Q;G$,RBV'^O0[@X9V <
M*8A(!Q&0&(( ;'3 QS7[%F. R#Q)X<C64N;"XVDIX+$.-)XNC7>V%LG44,9A
MIOV=:E*?LU-2@JE2$_:S^8A/%<-YPIPTK8>I*FHSYE#%1A>+;4G%SC4C&*4G
M&S4DU:*2C_L":5K&GZKIFDZMI.HZ=JFBZGI=EJ6EZMITZ7=AJ.DW-O%/:ZE8
M7%O-/#=Z??PR1W-C?6]Q/;36L\$R23(ZR2?B5_P<5$G_ ()<_&<L-I/B+X3D
MKD':3\1M R,C@X/&1P>HK\&_^"'G_!8^[^ WB'P=^Q7^U+XPDC^"?B&^T_1O
M@]\3M?NI;H_#7Q#JLZV=E\.O%-S())HOASX@:*.V\*WYDE7P;JG^AW4UGX6E
MLHM/_=G_ (.)9UN/^"6GQBDMY0XE\0_"AX,*HBD\SX@^'Y;4-/GRGM+@;D26
M *P95_>'=@?S1@>%<RX1\2<DRS,*?N4^(L%4PF)A?V&+HM5'3ITG*%-O$PC*
MG"O3Y5"%95(PG.'LY2_1,5F^'S?(,TK4.=U:=*E&O1:7/&HYX6I+E2E).#E*
MIROF=XQN[6=_Y^O^#8.P\[]O_P",%Z]J\ALOV6O%BP794D6LM]\2OA;Y*;P-
MB//''?HJGETA^4?)(6_ODE8JLC#&1LZ].2!7\)7_  :VLA_;0_:+C))8?L\V
M(V[05B!\?>'-WSXW#<2>"W)Z]%K^[8 .&##(.,]NG(Z8]!79XQ2Y^/,8^E"&
M'C)-[OV4F^5=%>6SMW>IEP=%_P!CNS5Y5)VZ6?)!+O?:]]5:]KG\AW_!PA^U
M1^W-I?QW^$7[$'[,*?$S3_!'Q=^"3?$+4[+X+>&-8U3XJ?$[7%\8^+] \1>"
M-,;PW8ZIXB7PUX5\,Z;H&I:[#X9CT^6Y3Q)&NKWD]L885_*G]GK_ (-U_P#@
MH9\:M$B\7^-8/A[^SAH&IYU"0?%W6-6U7QYJ;7CC?=7/A3PM]OGTS49PT<DL
M7BJ_L]3$Y*W%@K%E7_0(U#P;X1U+Q#IGB^70](N_%.E:5=Z-IOB>338?[;TW
M1;NYANK[2;'4707=IIU[<6UO)?64$T=O>B/9<QRQ,ZGHTCA@@ B.^;85C81A
M90S+PAE<NS)N RKL8\8#+A<#CRKQ0Q_#F3X7)\ARW*<LQ]*"6(S:JI8G,<6W
M*3E[6C[.G2C[2\82E]8D^5-14;IPVJ\,4\QS/$X[%XC$XV%:<G!4[0A"/*E3
MC&<JDE%4VY345!1<I7;NFY?YVG[57_! C]O']FCP_=^-_#T'A?\ :4\.6,:-
MJ&G?!"#Q3>_$.UB&^22?_A7>LZ7;W6HVD44;O*VCWFL7$HQ$ED\DL<,GX?26
M]A+=V]Q#)=V6JV$QFLY8IDTZ]L=1M7,BSQ*H%Y8ZG9SI#*L.8[FSE"/LCD0,
M/]?3Q#XATGP[HNH:QXAU73M(T73+66ZU'6-4OH=+T>PMHH6ENKF\U"\:SM(8
MH((I9'NGEFBM@ID=?E*G_*B_;&U+X?>(OVN_VK_$WPBNK6Z^%NL?'7XA:EX#
MN].1_L%YH-]J]Q+#>6)=V5;2YN9[U[:XM5CM7AB@CM%CMQ&H_:/"CCO..-EF
M^79Y@,)C)X/EQ$L0L#5I14$ZDJMG5Q-2FI0A"-6,H2J<SDG*,>51E\/Q3D.#
MR65#ZM5E-U:D'[*K.+K0Y:M)1F^1TXRY)3O!3CHHRC!3;;/[(/\ @W8_X*+^
M+/VFOAGXU_9B^.?BH^(?C%^S_I^DZAX)\4:Q>6TFO^//@W?1VVE23WI;R[O4
M]3\$^)5M=.U[6VC+&V\1>%+2?;-*\MS^Z/[8GP&?]J7]F'XT?L\V_B>'P9)\
M8/ 6L^!?^$LDT5/$8T--;\J"74(]%?4](34)880XAB;4;;9.4E'G&(02_P .
M?_!MA+*/^"F$EL))%@U#]G'XKP7L:NR"YAAUWX?WT44I4AF1;N**XVYPTL,+
M-DQ1[?\ 0B,$<<#"-=IB!>+#,=KY+ \L=WS<X;(/0C'%?C'B=EE+ACC_ .L9
M-+ZO[6G2S.E3<8JG1Q4:C<:BC[T6XUJ2J)<MK-JVR7VW#-5YID<\)B4W0IMX
M-24G[65.=.#:=[I+]ZXJTFXQ2WV/\U;_ (*C_P#!)FV_X)8Q_!6+_A>Q^-,_
MQAE\8P1$?#*W^'T&C0^#T\,I.\2Q^._%#7CS7&LQJP2U2)8EB\RY$L:B\_(Z
MZD:V2]OF$KK;:;>2^5 \:22 )(55/.E@B,FXYP\H7W'WE_KK_P"#KG4(E\1?
ML0:(8B7?3/CWK$<FYMJ?9;SX26D@"[MNZ5KB)W.,N8\N68DG^0#4V>33-9,N
M7$.GZBT:A5.#%:R-'D 88!\'#!@<<@CBOZ/\.,XQN;<%93F./DL1B<51Q=>E
M4<8TK>P>,4958TXJ-TH)I)2YN5)M7;7Y[G^$H8;.<5A*5%2IJ:IIU9RE)14L
M.G:Z:^T^5W5KMZN.O]1_[-O_  ;/7'[1W[//P@^,]Y^UU/X)/Q@^&WAGQE)X
M2;X"1ZV^@MX@TB+4!ISZG_PMO3I+^&VDN8]K1VT2.B;F4[@R_P!<_P"QE^S]
M=_LA?LM?!O\ 9XU+QA9^,?\ A37@N/PQ-XWDT6S\)V6OV=GJ6HW7]KG28-4U
M"#28K:RO[9+E9;M]T]K.S/YEVK17/V&=%LM._8S_ &5+.&TEMEM/V>OA"D$;
M23;HOM'@'P_=N5=I'DR9II&'S#"L8P!&$1?F_P#X+(?'6_\ V;O^"</[4'Q%
M\/W;6/B:\\!?\(!X=N861;F+7/B?K.D?#JRNH#() 9M.B\3W&IQ$K^ZDLA=H
M5G@BEC_F//<XSWBOB&638['K%85\0UL%@*-2E3IQP:>,Q&%AR2IQ<IQ5**B^
M9MM*]VW*_P"CY;A<!DN6QS2C3KU,3/*Z=2O*K-R3G.G1J2]E&_*FYSY4N6*4
M7O:,6OY?_P#@MO\ \%H?'GQW^(/B7]E+]DOXAW_A[X#^$A/H/Q.^)W@/6+BS
MO/BYXCWR6NM^'M \5:3>R/\ \*ZT>2SFTJ[72Y([;Q9=SWEQ/?7VGQ6$-O\
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M,?NRS,^S>=U?@7_P<C?#33/$7_!-+Q#K[62->?#7XL_"OQA8F-Y@T9U/7I?
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MCQZWPE3XN?##XF:CKNCW?A'XN:0-(TS6;O2O#6DQQ0:W9ZGI]K'XY2[^UK+
MLWPW\3^6\EN;*XG_ )W?^"FG_*([_@WB_P"QN_X)]?\ K,VCU]P_\'"?@K7_
M -GKQC^PK_P5K^&NG7,GBS]C#XY>&O"7Q;.G(7N-=^!WQ UI$DTW5 R(HTO^
MU)M?\!(8]0TZ4O\ &*[0-+*]O<:<!9-1B^]1)^::M][5OF?JE^WG_P %&?!W
M[#OB_P#94^&4WPW\2?&'XK_M>?&.R^$7PR\ >%-=T70]126>[T72[[Q5J5QJ
MZS!-#TK6?%'A?3[R1+?RXEU9KJ:Y@BLY!)^C=?RZ?L_:OI7_  4R_P""_/Q0
M_:.TBZA\4?LW?\$S/@SX>^&WPEU5-\VBZ]\9OBIINLF\\0V]JSPQ?:K=M7^)
MT8GF2]N+0^!O U]/:Z=J$EF;'^HN@B22LNMKOU>J7R5OO/Y_OB=_P7\^&G@;
M]I?]HC]CWP;^R9^TA\<?VCO@U\1-(^'W@?X:?![2;3Q=JGQ=1]*\0:OXQ\90
M/9V[?\(7X0\!6^E:-%K=WJ4>K:G/-XKTN:STI],T_7]1TGUS]@S_ (+,^$/V
MO?VCO&/['7Q;_9H^-7[&W[4GA3PQ<^,[7X6?&6W20^)/#]B+:>^.DZC)I7AS
M4X]4@TF_LO$$%G?^&[6RU70'NM4T75=2M[&X*_$/_!)W1-)N/^"XG_!<?Q'-
MI]M)KNE>)_AYHFFZJ\8-Y9:3X@UO7K_6M/@EZI;:G>>&= N;N,<2RZ39,>81
M6;^U#<S:9_P==_\ !.2+3S':)XB_88\<6VN"&&%6U.&#PO\ MX7D(NG\LN\D
M<^A:.5FW"81:?;6_F?9T\HA?+&[BEJH<U[O?E4MMK:GW9^UC_P %G/"OP5_:
M9U3]C']FC]EKX\_MU?M-^$]'T_Q#\2?!7P0LK:W\+_#+2]1BT^XCC\9^-)+/
M73IFHV]KK&AS7[-H!\.Z9-KNDZ1JGB6RU^Y?2(:'[%?_  6F\-?M*_M67W[$
M'QY_96^./[%?[3\WAO4_%7@_P!\8$@O[/QMI>BZ??:WJD6D:J-+\.:BM[_PC
MFFZCXDTF?_A'[CP[K>C:-KLUCXB:YT^WM=0^![3]L7]I?XW_ +?/[<?PY_X(
MQ?L,?L?Z'XN^%_C:S^'O[6O[9WQV>\TD^//'&F:OXET*,?V9X+O/"NNWS6_B
MOP_XY33-00_$:+Q+:>'&\4:M:6$6I:';7'RWH>G_ +9?@G_@X^_X)J6O_!0+
MXZ? KXJ_&6\^!OQDN-/L/@+X7NO#O@?X=>%?$/P@_:BT3PUX36\U;P_X=\2:
M_>ZSXH35]1@O_$.GK=JFI6\,)2S,0 '*K--)/D<OB]ZZ5]4E9)]F[VMU/V5_
M:,_X+0Q> _VI?'W['7[)O[&/[0/[='QG^#MEIUW\9A\)WT[0/ WPZGU2PM=0
MMM)U+Q?>:=K\<NJP1WD-G?)<Z=ING1:SY^@6FI7VMV.IZ?8^T?\ !.[_ (*N
M_#/]O?Q?\6O@IJGPA^+'[,G[4/P(AM;SXJ?L^?&?2TLO$NDZ3=W<-DNN:)?I
M%8SZKI5G=WNE6FI_VMH7AK4[2?6=(FCTNYTO4[#4[K\G_B;^Q/\ M.V7[='[
M97[5_P#P1&_X*"_L]W/Q-\5>,O#\'[8O[+?BFX\*>*](T7XA6#:Q'-X=U[6;
M+2/'^EV.N:EXBT[QM<+I&OZ5X%\3^$=<D\;:,GC6&4W]A9^B?\$\_P#@HQ\5
M+7]O/XR?LR?\%*/V+/@1^S=^VKIWP,U?XF>)/VF/A%X>T!;GXF_#+P)H_A^]
MG3QKKVF7WC;6M8TF;P7X9TS6=.U33?'^IZ&)/!4?AMO"/AN^T?3=+L03BN71
M7:BF]6I)Z7O%I)K72W2S/>_&W_!=4>*_B[\5/A1^PG^P=^TY^WM;?!#Q%=>$
M/B?\4/A?!9^&?A7IOBBP:_CO=(\/^*+C2?$[Z])'/I]S;6,EU8:(/$#6MY>^
M&4UK1ET_5=2^EO\ @FW_ ,%:?A=_P4/\0?%[X5/\(OBI^S?^T9\!FLF^*7P+
M^+]A%;>(-)L[V]FTQ]0TN\6'3[V[ATG58HM+UZSUSP]X9UC2KV_TP/IDUK?P
M73?C3^Q-^TO_ ,%&OVK/!WQ1U;_@C#^Q)^P;^Q#^QCJ_Q=\76^F>/OC+!X@L
M-=\7^.;/2]"TG4_&L?A7X;/+I%CJ4N@V/A>+4[.+X7^)]#TN\MHO#MKXG\02
MZ)JDK,_X(^Z5\;M#_P""]G_!3'2/VD?BI\/OC3\<]/\ V=/ =M\2OB)\+/#=
MIX2\":GXBC7X >9HNAZ#9Z=I*6K>";0VO@?5;FZT^VU35-:\.:CJVLB35[Z^
MED!N*M+1)Q2?Q7END^9)<JWV3T^\\L_X)E_\HCO^#AW_ +&[_@H+_P"LS:Q7
MU%^P_P#\%)_!G_!.#_@D-_P24UWXI?##Q7XH^%_QY\1^*OA#XC^)VAZOI6G:
M)\(-1OOB[XOO+'5O$]KJ41DU2UN_#P\8>((;6QN;6<VG@?58]^Z>.2'Y=_X)
ME_\ *([_ (.'?^QN_P""@O\ ZS-K%?3WP(_8_3]N#_@UX^&/P0T[36U'Q[#\
M%/'/Q'^$B01B2^_X6G\-?B[\1?%GA73+ L=D4OB\V%[X"NIG23RM+\5Z@\:B
M81R(#E:[OM[17^<%K\M_D?T.?MA_M/\ @?\ 8P_9C^,W[4/Q&MKO4/"?P=\'
MW'B2YT?3[BVM-0\1:M<WEGH?A;PMI]W>$6MK?^*O%6JZ+X=LKFX#Q076IQ2O
M%*$\I[O[)GQXN_VH?V;?@W^T1=?#S7/A5'\9?!.F_$#2O GB6^@U+7-&\-^(
MFFO?"MQJ-Y;6EC;R3:YX:DTGQ"L<-N$MXM5CMEEN1#]IF_C)\<_M=^(O^"N7
M['?_  1<_P""<>BZU=W7Q!^//Q#@M?VOKRR>:;7]+^'?[)TL_A'4?$VIR103
M(TGCKPG9:]\7EDC@M[=/$GA6QLI;S3[;[2I_H1_;<F_X+4^"OBSX?\+?\$U_
MAS^R%=?LT:'\,_"6EV,'Q:DDT_Q'I7BG3IM7L-1T?3K.W\6:%#;^'-.T.V\-
MP:3%%8[(\7$:RN$"1A#A:R=E)N6K=E9:?B[M>1^@O[9G[9'P._8.^ /BO]H_
M]H/6]3TGP%X6GTW3(;'P_IHUKQ7XJ\2:W<&UT/PGX3T9[FQBU'7M6F65XEN[
M_3M,L;&UOM7UG4],T;3K_4+;\2_%7_!P3\9/AUX"TGX]?$W_ () _MK>"?V8
M=173=6N/C-?SZ>7TWP=J[VBZ;XHO_#5YX5TW3]+M=56_LCHKZ_XPT/1=8-Y9
MBQ\02+=0NW'?MS?M<?&']GO_ ()T>#D_X*\?L>_LZ_M4?M5_%#]I6Y\*?L[_
M  "\'Z9;ZO\ "B;5;?PM'!X6\?ZEJ-[/XNO-(UKP_!KGBS2)%\/31^*-;D\2
M:=X;TYM(TS6-:U_2_*?V\)?^"^WQ _83_:E\>_M3>)?V!?V7O@):_L^?$JZ^
M(OPJ^'V@^)O'WQ4\0^'[_P -W=O_ ,((-3\47/Q!\&Z9XAU]I(/#</B70/'E
MK<Z5J6L#5=!MFU.UTZ.U!QBM+I.\K7<K)[+W4DV]]WILNY^_GC;_ (*,?LJ_
M#_\ 8@L/^"A'B+QS=P_LXZSX#\/^.O#^J0Z1.WBOQ#_PE<EO9>'O!VD>%YY+
M>ZG\<:CKERGA]M%FGM[?3=2AOKC5]1T_1=,U+5K3\!OVN_\ @NAXC^*_["'[
M24_Q _X)O?M??!#]G/\ :6_9F^.WPM^#G[3/B?3+35_!NI^)OBK\)/$_AOX6
MW7BO3+;2M.@\,^&O&NKZYI=GIWB.T\1^(-/GENXVTAM:MH[JYMOS1_:N:9O^
M#>/_ ((O6OB5YH?@O=?M16<?Q<E5[N.U731XH^/7V,:B\,;6HLAHS>+9C]KD
M4BZAM7MXI9$9X?[$_P#@I/IGPLU'_@FA^VEI_B[^P+?X8#]D/XS2VLENNEC2
M+*&P^&.MWG@N[\-1F&?3?[1T_6K;0;KP3'96UP3KD&BII5M/<&UA<':,6KIN
M\VMVK*,DNF[]?U/R9_8:_;=\,?\ !/'_ (-W/V6OVIO&'@;7OB-H7@OPZ-%N
M?"GAK4M/TC5KZ7QI^T-XO\+6T\%]JD<MG%'93ZFEW.LD;-)%$T<>'8$0^-_^
M#D/2_#OAH_'?PQ_P3F_;$\8_L4VFN:7HFH?M;/HJ^&?!ER+G5H="U#5O#6G:
MIH,ND:QHT>M3IHNB:AJOC7PW#K6MD:)<G1=5/V0?G5\=?^50?X.?3X>?^M=:
MM7[D?MD>$/#.E?\ ! #XI^$],T:RT_PWX?\ ^"<>B)HNCV<;6UEIR>&_@_H-
M_HB6\<+(56PO-/LYXU9F$KPCSQ*KR!P&HWNU>]24=VM+KMUU/"/BO_P<,>#K
M+0/%7Q0_95_8=_:Q_; _9P^'=M97GQ$_:9\$^$=6\'?"#08O[*L]8\30Z?JV
ML>&-6O\ 4[GP+!?1V_C ZE8>'=/T6YM[R>ZU&/1HH-7NO9?VT/VV_P!B/]I3
M_@BOX[_;,^)/PD\6_M#_ +'_ (\T7X5ZGXK^#$/BC5_ACXWU+4H?VC/ '@J+
MPUJGB+PEXBTS4= UKX>_%BUL;S61HWB-M/U9/#%S;6M]JNAZJC7N1_P34TC2
MM,_X-^?A99Z=IUE8VMW^Q;\9=2NK:UMH88+G4-:T_P").IZO>SQ1HJ2W.IZA
M>75[?32!I+JYN)IIF=Y&)_"3PC_RIS_%+_L>]/\ _7A'PYH!1C=635JBC>[N
MT[Z^3TZ']"7[0O\ P53_ &<O^"<W[,/_  3T\;>(?A;XOTCX&?M%:)\)/!GA
MBWTO6Y-:G^!7PVE^'W@_5K;4O$3WRZQXB\;0^!_"&I0)=0:?)?>(==?2)S'-
M=7UVC2?*/C/_ (.+[?X6-X/^)'QA_P"":O[;WPI_9+\=:QING^'OVEO&OA)-
M)TZZT[6[HG1->_X1.YTR&Q-EJVBXU_3;./QP^K:O8)-_8-CJ[1HTOQ1_P5G\
M/Z+XL_97_P"#=+PKXDTVVUGP[XF^*7[*?A_7M(O4,EGJNBZS\.O@YIVJ:;=Q
M@J9+:^L;F>UG0,"T4KJ",YK]DO\ @X.T33M>_P""/?[9]MJ4/FQV7AGX9ZW:
MLI"R0ZCH7QP^&6K6$T;E69,7-G'',$VF:UDGMV81S." E'W+IMR;3=VK+FLF
MO/UT/)?^"Q_QT_8/TCPW_P $_O&'[3G[//B#]JGPS\4?CMX=O/V>=9\&?$WQ
M;\.[/P9XBU^P\,ZIHGQ#N&\->)?##^)]*N]/O])NH-(U=+^SDBC)>R4RN']^
M_;E_X*V>$OV3?CQX$_9)^$O[._QG_;)_:P\=^&&\<K\&/@E9V^_PCX*>6[M[
M/7O&WB2>VU--$74)K.YNHX8M'OXM+T2VDU[Q+=Z#I][X??7?Y[O^"I4LL_\
MP3A_X-N)YY))IIK;]D*6::5VDEEED^!'P6>2221RSR22.2SNQ+,Q+,2237Z3
M_P#!0']B7QQ\:/\ @I%_PT/_ ,$SO^"@?P<^!O\ P4E^'?P1TG1?BK^S]XOU
M_1O$,VK?#*SGTJ;3M>\5^'+73?'VK>&-.U73/%'@JSO]#\4_#C5O#FL6UQX'
M\2VK:)>7<6K:L!RQM&][>_NW:ZE97LG9=[=;'U[^QA_P66\(_M(_M.W_ .Q/
M\>OV9?C=^Q1^U<?#^H^*_"?PP^,EO;W^G^/M TJPO=8OI?"?B6UL-&FO+V+0
M=+U?Q!"9O#\.@ZEH^C:O/HWB'4[C3KBU7\+_ -C_ /;U^/6K?\%]OVM_BEJ7
M["/[4S^(OC%\*_V?_A)XB^"%_$+CQO\ LP>"Y-.^ -A+\0_B!9RV30:3X!EE
MMYO'[06-M8QR6WC2/4&8W=]=7$_UW\"/V\_VS/@K_P %#_V7?V<?^"O_ .Q1
M^S<WQC^,\>I^ /V:_P!LKX4Z#X+U/QLDT\BVD%E#J\6J^)KNP\/7_B#7KO0M
M?L-$;X:WVER^)[;4Y/"5]IUS<7.I>J_L?_\ *SC_ ,%9?^S7/V>__56?LF4!
M9+F]U:POI*Z^)+1KI>V^J:ML?9_[9/\ P62^''[-W[1=G^QI\$?V?OC=^VG^
MUN=&C\1>(_@Y\#=( C\!Z)=:);:_IUUXS\47MI>Q6$M[IFI:1JDB:9I&KVFD
M:-J$5_K]_I,]QI5AJO0_L2?\%<OAY^U5\<?%G[)?Q9^!WQ?_ &./VOO"6CR>
M)S\!?CEIRQ7OBOPI;V5I>7FO>!?$]O:V-EXBAM(KB2^^S2:?IMQJ>@1-XDT!
M=9TBUUJ?1OYJ_P!A+PE_P5*\<_\ !2G_ (+(:Q^PW\5_V.OAQ\6K+]JOQCIG
MQBMOVF[#QCJ?BJY\+Q_%[XR1>#H/A=+I7PX^(E[;^ +!K*6RU=$OK&WFAMOA
M\+Q;V*UT&:'[ UK]DK_@I!K/_!4[_@G?\:/V_OVT/^"8.F?%;X7^*RW@'P'X
M"\?>//A[\9/BG\,KK6'@\6^%O!GAC6/@SX7A\=:C(NI:[8^'=+FU:QAGO=9U
MJS\Z6*XO(XP'"*TNK\M[W?->U_AY6K:VW\[GW7^T]_P<'?#G]GO]IWXZ_L=>
M&/V3OCQ\>/VAOA5XP\"^$/ _@#X7B/6]1^+\OB?P<WCCQ%JNBVFC:#K^L:/8
M>"M':SBOK=='US5M5O=3LS8Z:FF0:OJ>E>H?$+_@N=\)?A)^S!^S5\7_ (C?
ML[?'G2?VC/VKFUBU^$/[$&BZ1;>(/CMJUUH_C"_\'-?WT$<5B-*\.:G?6EK/
MH5WJ6DVGB;7$U6TMM+\'W=Y;:M!IOQK_ ,$^_">BZC_P<A?\%=O&5Y9P7&M^
M%OA;\/='T2YF@BEDL(/%>D?!B75I;6616DMIYX_#EG;-+ R.]K+<P.QBE=&^
M//VYM _;-\<?\'*&G:-^R=XY_9^\"_'?0_V4=!O?@1J_[35GXBU#P./#$?@[
M6;CQK9^%+72_!/C:[7QG*^H?$>]LY])T@VL>CV7BAY]4MKM+NU("C%M*UK04
MVVWK[J=MG97>K5WN?L!\&?\ @M_HU]^T'\+?V;?VT/V-?VBOV O&WQXD@L?@
MAXB^-5M::E\//'WB"[OH-/L_"A\4VVG:%)HWB*^N]1T;3X;232[VVT_6-5M-
M+\1WN@SWNCOJWTQ_P48_X*H?!K_@G@/ACX,U?P/\0_CQ^T/\<[^33/@M^SM\
M']-75_'?C2>'4;#2FO;PA;E]$TFYU+4(=*TB2'3=9UGQ%K N+#P]H6J#3-<N
M-)_GE_X*@?L=?\%C_C?\#_ WAS_@H3^W/_P2.^%'POTWXP^&-8\!>._$7C#X
MB_!NXTWXI1:+XE@T6TT?Q]J'[/MC_9MQ<Z+-K]W=VZ7MM$UIIKZC=RQPZ5Y\
M/U/=8U#_ (.E?@T_QEO;36-5M/V ;&?X(ZC<#2YM$OM?;PIXPDUN_P# LFHI
M:R/IMS-=_&J\M)_#]O\ ;_M<FL_N(=/&K& #ECH]':,FU%MI\MK6;2>M]=[6
M\S\^_P#@MQ_P4TUO]J3X(?LZ_LU?&[]CK]H+]B[]H'0OVS?@;\;=$\%_&'3X
M]1\.^.OA/:^"?B_X1U+Q+X3\:VNG:+!>W^A^)O%NA:5KFBS:/";*;4$BM]0O
M;VPUVRT?^[:OY8?^#JC2_ <W[/7[#FM:BNE'XGZ?^V]X/TOP@\QB_MM? >K^
M"/%]W\1UT\%3.=*?Q#H?PK.L&-UB%VFAB96<P%/ZGJ"96Y865OBTO?JMKZG\
M2/\ P<%_';Q1\3O^"@__  3T^!OQ _8F^.OCSX3?![X\^,YM,\)RQRCPM^W/
M'KJ?L^:I?^&?A58V\42:Q<^&S'=^"]8^U&\DC?QE+91-#;ZE>13_ +$^+?\
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M383+'#>W7C;]D277?%5Q(R2"59M;UC7-6U"\>.1&^TWTSQ&/*A?YM/B^[O\
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MCT*62;R];\3W"1W;:%:WMK8ZM>:79VNF:SJUU::5>:E=Z?IV@H=9'E7[-?\
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MTVLN@^'?&.J,IDBDL?AM\39]$O[Z[9?M<>BZ_J)N+E[&RA@@_DP_;S^$%W\
M?VQ/V@_AO<VLEC:0>/=8\8>'%DA,:S^'_B'++XYT0V(^:.XL+2/7FTA;K?-+
M+?:7J$-Q+*]OQ_H;^*/!^A^*=+N_#FNZ=!JGA_6['4M.UK3;[S;JVO[2_@\F
M2WN(Y6=6B<,S $J8Y5BFA:.:*.2/^>7_ (+F?L#ZO\1_!6@?M0?"_23J7BOX
M0>'=2B^)&D1R:G=ZYX@^&FC65I)975@6BOC?W_@N:.\U(VTTUI=ZCIU]J6V>
M\NDM[<\7$T:^<91A\/5:G7RSF^IR[T'5J5'3F][IU)\J5U;EUTLOYN^D;X>X
MCBC@RKCLFP<\9B\CS.EF4L'1I\V-KX*I@983,HX2%^67N?5ZTJ?.G.-&M[LI
M*%^A_P"#>3X6Z1I?[._Q5^)\ENQUCQU\63IRRR!U=-+\'Z#%#96:ND@62VCU
M'6M7NO*E1H_-E*\K'"L7]$R1K'N']Z3>.OWB ,]2>H.,\ 8    K^;[_ (-[
M?B[H^L?L_P#Q.^#":K-!XF\!?$J3Q$+.Z6P\ZYT/QY8.]A-:JVR62.QU#29]
M/U3>KR6]]]H19/LILBW]&5NLJPX:[C8K<_-(5C4, HQ$!TW8QS][@\=S>5N$
MLMP;@G%QH0IN#5I>TI7IUI6C=).K&36S::;C%W2^Z\$7EL?"S@NEE<Z-2A3R
MB%+,*E-NU+-*%>O2QM'$J?[Q8A8F,N;F3;]QR?O)NW,!OCX',B9]^6_QK^>S
M_@Y;U3^SO^";UQ9)(8O[:^/?PCTUP,$S!?\ A)=;\G+ LHQH<DN4(;"8SM)5
MOZ$R<R*&8.%17!&/O!\9&.O&>.G/2OYL/^#H6[\C_@G[X B=C_IO[6/PVM@!
M@;OL_P -OC5J"JV,<+!8W &,Y9E8\A67ZO@FG*IQQPO3C;FJ<1995C>Z7+@(
MUJM:]E=.47:G9:M/F<5J_P!%SF:AE6.FTW%865-I)-WJ3A&+5]&KM7\GL?E[
M_P &LQ_XR:_:?[?\68\* _7_ (3>('\SD_C7]Q+!&0(1E@BXY8%2 ""I'W3S
M]Y2&Z DX&/X9_P#@UKNA'^U%^TW:-(/M,OP)T6]CCVCYUM?'-FBL, 'Y&E V
M@8;=ELX%?W-*H\L-U8@<^W  (''R@ ?4>N:^C\8DWQUG>EN; Y2U?_L#>CW5
MUU2OJSRN#W;)*2TTK-OJK>SH[/Y.U[::^GRU^UY^RC\*?VQO@IXM^!?QD\.K
MK?A?Q8;9[&[@%JFL^'M?TZ#4)-&\5>'KV8K-I^OZ%<7-U/:W"2Q@6MS>VT>6
MOKOS/\TC]N;]B3XK?L _'G6?@K\2[>\U+2KQKC5_A)\1%TY[/3/BAX!,BK8:
M]9(EO'8V/B*T1[>+Q)H 8+I6H&>!81 B$?ZKQM[>4OO0,_[IG)).3$6:)E7=
MA6C+$JZA6!/7I7P/_P %!_V#?A)^WM\"==^%7Q"LS8:W;1RZM\.OB-:0R3^(
MOAOXMLHY%MM>TB5I3)/;RR".WUW1;P7>D:O:[I[K3[BZ6*5'X<\=8GA'-UA<
M74E6R3&3;K8;24\%.;CS8O!PE*$)5IR_>58SE!-V:E)I\T<39)3S*A+'8>"_
MM"A!4XK51G3A=*[M*U6*NHRY7?X')0=X_P"6[,T<D4,-T09I+54<1O*4#3?Z
MWRV4_=9QM#[@QB6.,MY:(H_:'2_^"EWBGXQ?\$F_VB?V(OV@O&=MK'CCX>:U
M\%]3_9VUS69)[SQ9XW^'\'CZ.[\2>$M?OLF+4-0^&YTFPO=+O+O?K&L^$=7A
MAO;N_P!5TVYO!^?_ .VE^Q3\:OV%OC,?@[\?](LGUT:=%K?@_P =Z VHR> ?
MB1HD,XBN_%/A'4+K3]+EDL=+OG-GJ^EWMA8ZIH^HO]BDT_4;=4O7^8+F)_W4
MCMO\KYH=RIO0[E*L2@VF5" 5<9,9SY3*#S_6=?#95Q30R[-G*EC:.69C@,XR
MC$T)1=3FI4H6^LR5[2<:EJD(.<>>$J<IQ:=ORW#8G,,O>,H-K#.K+D5*7,YR
MCS*56-2FXQC%NI"2IN,Y)PDJJZ*7]0G_  :PPPR_M5_M2W#*#.GP/\)P+(-R
ML(KOQ;%)<*"I Q));0/TW(4 0J"P/]RSR.H<@X.4&< ]<G/(]!C]:_AS_P"#
M6"-%_:E_:HP,?\60\*-U/6+Q:BH>3_"&8>ASSD@8_N2\M&+@C(RIQD]0#CH?
M>OY2\8(U(\>9LKJ_)AY-W=M</&W1:Z/[T?J7!T>7(X-V;G5J\K71<R2[6MIL
M?E__ ,% /^"IO[,?_!.C1-,@^+>JZCK_ ,2_%.D3:GX#^#WA*);CQGXFLQ?7
M&GKJLD]QOTW1M %W:SQ7&M:B1;YCE^S),\+1/_*I^T%_P<W?MM_$&74++X'^
M /A=^SYX<E61=/U/5= ;XL>/H8II'AB8W-Y>Q^#4U"&!_-6)O#=X@F0!Q-&2
MC_DY_P %%?VGO%G[6O[8_P 9OC1KEQJ*:7#XPU[P)\/M-O%MXKKP]\,/!7B#
M4M+\)Z&T-DBP6<JVEM=ZOJ%M%),3K&OZDDUS=?9X)$^U?^"!'[/7@C]H3_@H
MSX/F^(.E:3XCT'X*_#W7_B];:'K5I#=:=JOC33]:T'P_X;U%K$IY-Q=:%JVL
MQ>)88[@?9@^G*6A? C/ZKD_AOPOP?POB<_SW SS?-L#E]/'XJ&)Y9QJNI3YO
M94E*48249RC"LZD7&*C.I2E*RC+X[$Y_F>=X[ZIAZ\L#@:E6G3H0PTI0DX5*
ME.%)RG%\UWS)7YTUSRC*"<8R/I?X>?\ !.?_ (+3?\%0$L_'G[4GQO\ &WP[
M^$.M21WMI#\:=>UG0/[1L+LQ-;7?AO\ 9U\++HMA86<\,JRV=SXLMO"YU".9
M181:G#(#)^'G[6/P,@_9N_:<^.?P T_6M4U_3O@E\0M4^'EOK^LZ;;:+?>(;
M33+:*1=173+2YN;>TM;B2]/V:V2:8QQ67G[PUQ*TG^L)-8VJ*N22WEB(K;_Z
M,)D$0A2*2.-TBG$<?R0B<,D*D!!& "/\N3_@II=:?JW_  4E_;NOM+:WGTV\
M_:0\:BSO+2?SK:>6TMM.LKV2,QGRF+W-M.KMDM$\;PQE(ODK/PGXQS#B;.<U
MRN6 P66Y33HNK@<NP-+EIT:JKS=)_680=2=_=<H34*<YI\W+=S6G$V14<EP6
M#J+%8K&8K$UU[3ZY:UDJ?/[.47.<Y02;@ZLI-KFC*=DDOT1_X-JX)9_^"F:R
M)G;:?LW_ !=N;C !&R37OAY:19./E&^=!QC)&#[_ .A1)@0.2<#&6.<<!OQX
MQU]17^?E_P &R(5O^"F'BF)@-B?LK_%9B"<8,?C_ .$$<9#?>X$KKR0#NR<D
M#'^@?M$L6T_=8$,#W&<'D'(_ U^=>--6,^-^712H9;2IN/VG)3JRDETNGH[M
M?$M=7;ZC@A)955GJE+&WMI=6I4=ULK;KT1_$_P#\'6%X\WQA_8QTX2 Q6'PX
M^-5_Y6%W++JOB?X<VY?=CS"'&C%=I8HI0[55BQ;^2G5\QZ/KK+\K?V=J9'/7
M-K-CU'<#!&.]?U7_ /!U0=G[3W[)<(\P1GX'^.MV3F'S)/B!IY8@DY$C+CC@
ME1UX '\J.O6\SVFLP1R*D1T?49"K+D,?*F!4L1N'R<G##A2?4U^[^&E-4?#?
MAWD@Y.G@,50E&%KJM56/ES*[2Y4D[MOF\G<^(XBJ17$.,E.2LL0U>W]_#+71
MWU:NVNJZ(_UJ?V0OE_95_9G'11^SY\%"!V&[X<>'#_(*,]?S-?CE_P '-5Y?
MP_\ !->XL[.)Y;;5_CO\)[#5G7<%AL(9-;U6.67'W8_[4TW3HP<K^]>(9.0*
M_8+]CRZAO/V3?V9KJ"6.6&3]GWX,BW=7!,B1?#GPZI(  SM;Y#U^;()S@5\-
M?\%Q?@/XF_:)_P"":?[1?ACP9:M?^+/"&B:1\4]'TQ4F>?4A\-/$.D>+=;TZ
MP2W26674[SPSI>MP:;$8PDUX\4$KPQ2/,G\MY3.&&X[PU;$5*<*5#BRK5Q#E
M-15*+S'&Q49M[-S:C>SBG*.K1^D8R2EPY^[C-R_LG#RII1=YQC1PDY2@K*[4
M(RE9N+:3ZG^:X0GF1;F",\8C50C%@[67FN5V\,5:1@Q;/3 P>*_3#_@G?_P3
MA_:N_;Z7XLW_ .S%\5O!/PX_X5G=^$X_%EIXG^(WC_P'=:C)X@LM2DT*>WA\
M%Z)K2ZC' =!U?SFU$6R6C2Q"V6;[3<M%^8\K27<"7-C*$WM<$2!<EL3R0,=I
M#&-P5G0#"YC$3 !B2/Z4_P#@V8_:4\(_"S]K'XH? 'Q3<2V=Y^TKX#LKGPI>
M?Z+';W7C#X3?VWJD.D375W<PK;3ZEX7\2^()K&&&.>2^O]*MK?RCO=Q_7_'F
M8YGE_"^;8S*(0EB\(\/CJ,W3]M2G2J5L/"I)03O.4*$JM2:M&$81=12E[.)^
M49/0H8K,,'0QLXQPL\1B/;OF2<$\/B8T8-RIS2D\5*C%-QDW=Q<HJ;YK9_X-
MS/\ @JT9X[A?VF_A&6.^-2G[0OQZBS&Y>$)\G@=1EK<*AX+ $Y;=DUS&I_\
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MRZ'ZQQ%RQR?'JI[L)4U3YO=:?/*DXVN]5=+1K6[T/X%9?W3S(6+ -9F(A58
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MZ9?Z_;ZW^R%% <TK6OTMLKV72]KV\KG\V/PR_P""$'[2_P"RY?>-_ W[$/\
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M_P"+(-3UFRDU._NM(OK2]\.Z?%J,L&M7^AW^M:;HM]I,?[2O_!&;Q?\ $_\
MX* 7/_!0;]G']N3XJ?LD_$3QKI?@'0?C7X9\(^#6\3:;\4O#_@&#P=IEMX?E
MU73?B)\/KK2M#US0_ 7A>PUW2M7L_%]E<W.E6VHV\-LZ?9S^Z5% <\KWOTML
MK6[6M:WRWU/Q)_; _P""-%E\9_VH)?VW_P!DG]JKXI?L(_M8ZUHJZ!X_\??#
MK1+3QKX/^)FG6^DV.CV1\8_#^^U[PO;7UW]BTC1;?4@^L3Z%JW]C:5J=]X=F
M\1V,6N4S]C[_ ((U?\*;_:F3]N3]KW]K+XE?MX?M7:-H-UX;\ >-O'OA32_
M/@KX::;?6]_8SR^$? %CKOBY+#4[;3=5U;3M*:TUVP\/:8NN:_J=GX7AUO4H
M=2L/VYHH#FE:U]+6V5[=KVO;RN?FY^S_ /\ !.K1/@-^WU^U]^W;9_%/5?$F
MK_M:Z'X/T74OAQ<^%;33=-\$KX1L?#UE%<6/B2+7+RZUMKU= 222.XT?3A";
MIE5Y!$#)RG_!1?\ X)4_"W_@H!K'PG^*EM\3OB/^S?\ M._ 6[-Q\'OVC/A%
M=I;>+?#EI+J4&IS:+K%B;G3I-=TBWNUNM0T06NM:%JN@ZK?7]Q8:J-/U77])
MUG]3J*!<SNG?5*WR2M;TMH?SN:%_P0B\?_%_XN?"GXD_\%)O^"B/Q?\ V_/"
M_P $=8@\0_#SX-:S\,]"^$/PS?6[.2T,-SXUT73_ !GXZA\56UZMA:-KL-O!
MH6I^($MXM,UW7-5T1]0T[4_M?_@I'_P2S^'_ /P4$_X5;\0=(^*GCK]FG]J+
MX"ZC/J?P0_:5^%XEE\4^#S=3+=S:/K&DP:QX<F\1>'UU&.'5K.VM/$?AS6M*
MU%+@Z3X@L;'6/$-AK'ZF44#YI73OMM9))7WT2MKUTUZG\P?Q1_X-UOB1^TW)
MX)\9_MA_\%.?C=^T+\9?ASXK\*7O@;QCJWPOT;1?!GA3P)HDNM7OB/P;HWPU
MB\?WUA!K'CG5W\':EKGCH:RFIL/!T%G=:=J8OH[G3OZ?***!.3=KO;;1*U^U
MDC\X_P!LC_@GCHG[7W[2_P"P1^TAJ?Q1U7P-??L*?$SQ=\2-(\*6'A:TURT^
M(T_BO5/A;J<FDZEJUQK6FS>'(;)OAC;PI=VMCJ[SKJ\SM!$;-%N.>_X*,_\
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MQG>W>DZ!^R7I/[*B?$-]%@AU&ZT[2O@];_")?&;>'1J,EM%>S6T UQM%&K/
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MCQMH5LBE)WO+K0KBZ%C9+,@;44LR '16K_5?\2>$/#'C+P]JOA[Q3H>C>(M
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M/K9*S;7+?1;03D G<%QQL#$XQSG&/3IVQ3Z**^#2M?S;9]%_FW_P/D%%%%,
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MVDPS76I7?AM-9M1H?B>2PLK6[U'4-+\/:WJ>MZ9I=I=:IJ>EV6GP27*_E?\
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M/AU<)\0OB+\.+*?4?''A/0AJVELVJ^&K*VTS6;BYU%+M;6%8XM,O&\J:4^4
M"Z_*?P"_;)_82_8<_8%_85NY_COX[UWX!?%R[\.?!SX#_%CXC^%]>D\3^,M7
M\07^O7FG7_C_ .S:#IZ^$X UIJ;:CKFOV&C:3IUG:+/>3Q1?O6[?_@N!_P H
MG/VYO^R+7G_J1:!7\MW[;'A?2_&__!"/_@A7X+UP7#:+XO\ V@OAQX7UA;6;
M[/=-I>OZ=\3M*U 6UQM?R+@VEW,(9MC^5)M?:VW! C%-*[=G.VEOY6[[;Z=[
M?F?T/_\ $1K_ ,$CC\6H_A.O[2MRV_59="?XE_\ "MOB''\)8=7BN39>1)XR
MF\.Q[M*EO 8HO%\.FR^!WML:Q_PDPT)DU1OV^LKVSU*SM-1TZ[MK_3[^V@O;
M&^LIXKJSO;.ZB2>UN[2Z@>2"YMKF"1)H)X7>*:)TDC=D8$_A)_P7=_9Z^!?A
MW_@C)^TAX5\._"3X?>'?#OP<\+^ M;^%.C^'_"VDZ'9?#S5K3XH> ]-34/"$
M6EVUI_85S<:;=7FFZC)8&$ZMIU[>V&J?;+2\NH9?T+_X)HW$]W_P3C_X)_W5
MU/-<W5S^Q-^RI<7-S<2/-/<3S? GP')-//-(S22S2R,TDLDC,\CLS,Q8DT$M
M+E4E=:M--I]$[Z)?=^)^0?\ P<I?\%$G_92_947X"?"?XS>-/A)^TW\:9-$U
MCPW<>"[#6]/U6^^$MGK=UHWC]+'Q]8:?);^$[^9C;PI+9:QHWB)[=9AIMVB2
MR+-\7_\ !8W]NCX1?M9_\$G/V,OCC^S?\2/$MWX1T/\ X**? KX9>*O$]W9>
M)_ 5ZOB'PG\!OC!?^++"^&MQ:3J%SID)O]/NI[^0/IMVZ^<)I&MV9/O'_@Z8
M_P"44?B7_LNWP9_]..LU\Y_\'.^BS^)/^"5W[&'AVUEA@NM>_:\_9UT6VGN-
M_D0SZI^SI\?K&&6?RU>3R8Y)U>3RT=]@;:K-@$-(6_=Z:N4KO3MZ?=KIKW/O
MOQ+_ ,'&/_!)/PO\6)/A/>?M(W>HRVNK2Z%J/Q"\/_#CQ_KWPLL-4AN%M'3_
M (3'3= GCU73/M!*+XD\/V.L>%FA1[X:V=/'VL_KOXP^-/PC^'_PHU'X[>-/
MB3X+\-?!K2O"UIXVOOB=JWB'3;;P3'X4U&WMKK2]=B\0-<'3[NPUB*^L1HLE
MI-.VLS7]A;:6MW<WMK%+^6/_  51_97_ &?_  3_ ,$9_P!J;X+>%OA9X/T7
MX<_!G]G'7_$/PWT"PT+3+:/PQXE^&NCQ:QX8\3V$T-I'+'XE&H:1!<:MKRLN
MJZVUUJ8U.ZN1J=]Y_P#-'^W+XU^)'B+_ ((M_P#!!OX&:=HGB'XC^%_C9XX\
M-Z1XL^'=EXL7P</BA)X%U"Q\.?#SX6WGC.X@DB\.V^LQ>*+G3=%U"\NETW0;
MG3=/UR2PNG\/V<^G!*C&5K77O6=[/3E<KK:VB>FWF?T:^!_^#C#_ ()(^/?B
M1:_#?3OVD[W0FU35;71=#\=>-/AA\2?!OPWU;4+J1H@K^+/$'ABQA\-V4#>0
M;O5_&MKX8T:UCO+::;4%A,TD/[>6MU:WUK;7ME<P7EE>00W5I=VLT=Q:W5K<
M1K-;W-M<0L\4\$\3I+#-$[1RQLKHS*P)_D\_::^(G_!0#]I']CCQS^Q9<_\
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M;9[[)GSK_P $M/\ @MU\+/BY_P %*/VXO#'Q?_:$^(?C'PQ^T[\:/@9\,_\
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M*=/NK75]&>S^&B:_K_B'P_J/B6P\&ZGX^^'OB?1K^"TT[3-.\53^)/#W@.8
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M5GN85:7[S!$D(_$O6_\ @O=^REHGPNT7XE6GA+XIZSK'BKQ)KV@Z5\,IM/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^+V?0M'U[4!IW@6+7+Z?4--_J+HH&IM6VTO9VU2=]$^F[MO;H?@__P % _\
M@G#^USX@_; ^#7_!1#_@G'\6OAGX _:!^%W@*3X6^+/A#\:8?$1^#GQ,\&2O
M=6:B7_A'XM1.EW3:%J']C:MIMOIVE"\MO#_A/5-%\0^'=?\ #\-W??/>E?\
M!/3_ (*A_M]?M7_LJ?M ?\%3-<_90^&7PF_8X\>'XF_#SX'_ +,]GXLU;4O&
M?CNSUC0=;M;KQ+JWBS4O%)L=!U#5/"'A2?5E?QQJ\=UH^F3:-:^$=(N]7O\
M68?Z9**!*32MIHK)VU2UT3^;Z-Z[G\Y/[<O_  3P_P""C]C_ ,%+M/\ ^"CW
M_!.3Q]^SO%XG\1? :S^"OCWP;^T%)KD=K:I8S-'--I=OH_AG4HK[1]1LM/\
M#-_%/'K>D:WINO:5=Q.+_1-1DM4W/VG/^"9W[;WP@_;>\6?\%%?^"5OQ5^#?
MA3XC_&?0;#3?VFOV;OV@!XIF^$OQ3O\ 2K>T6+6])U7P_9SWIO\ 4;BPT^>:
MT\WX>ZEI6HPZWK.D^.[>W\6:UX:D_H:HH#G>FVBY=5NNS[VZ;-=S^<?X(_\
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M?CLY].T;7X]:MAX1\4^)O#.N6=\^BZD(KJQU*RU6ZNA(+/R+QW_P3F_X*K?
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M('BFZ?3=4OV <$E>[Z:V3B[VO9IMJU^N]GUT/VK^)/[;O[%WP:\2W/@SXO\
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MP;[1$0I*_/EL' ^08R>@R>.>M6***]$_4^K?>WRLDOTN%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_(C^S]_P:O>&_@;^
MWQX)_:.C_:235_V>_A+\8="^,_PY^%J^"KN'XA7%]X2\16WB[P9X(\3^*9-<
M?0_[%\/ZY9:;#JGB&RTZXOO%>CZ9+;?V)X;NM7>[TO\ KNHH*4I1O9VNK/\
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MVWOV+_VZ_&S_ !2^)'PX^&6I6]K\8/A3\4KO4_%'B6\N-*TN6"^N)-.M]?\
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M$U_HOB.Q\/ZSJ'M?P#^(/_!7?]NW]NSX9?&'Q;\*_B5_P3D_8'^"%I>2Z_\
M"7Q[J6AS_$W]HWQ$ZM,=*\1:#<:6FJ0:9<:BFDQR7<ND:/HNA^&+36(?#_B'
M6_$FMSO8?T2T4!S7WBKVMS:WM:VVU[:7M^)_*U^VCX1_;I_9%_X+:0?\%!/@
M7^P[\0?VS?A+\2OV:- ^"-QIWPR\10:1J&@:FUYIEOKDFKW4.A>*KK1+W1V\
M.:;J=H^MZ#:>&=;T_5A:Q^)["\MM0?3OU=^(7[<'QO\  7_!57]G[]AF]^"N
MAQ? ;X]_!SXA>//#GQSO-0U1-<U'QC\,O#NNZ]XQ\)Z+IT4ITJ:+0$;P0-2E
MN85FCA\4Q-$\C;?+_4BOG;_AEKX/2_M/-^U]J&D:UK7QMMOA;#\'O#NKZYXG
MUW5O#_@CP8^KW6M:Y'X%\)7M[+H'A35O%]U+8Q>+-8TFR@O=7M-&T^W:2$3Z
MNVJ@N9.UTM(N*:OKV;UMH?1-?R^_&#X!_MV?\$P_^"E7Q]_;K_8^_9QU;]M'
M]F/]M2PTNY^/?P2\%^(;'1?BIX)^)6EF\U9O$^B6":1<3:C:07W]OZGX?OK7
M2_$,-^OC7Q+X3\16^D:LWA?Q1??U!44"3M?1--6:>S7_  ^J9_.5\)OBC_P6
M _;Y_;C^"7Q!N/@U\4/^":G["?P%O7USXA^$/B-J.A77Q*_:2U)KFRO+GPAK
M7AJ_T:.^.CZL+&UT.&2#2+#2O"WAZX\5:Y8^--1\7:GH.EZ9\@ZO\)OVPO\
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M:SH=Y>?$SQOJUK;WT$<DR1R3Z;J%E>1A9'#07,39^; _3NBB@EN[;[MO[S\
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MD\7Z2^G0W5GIQN+;50$M[<V-S%'_ %A44 YWO[J7,TV]6[IWZOOT\_0_&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?H%%%% PHHH) Y- !12 @]#2T70!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMBI8J:A?FM&ZYGR[Z7V5U=NR5][V3_IQ!R<!R<@G(3*\<?> V@^Q.>^,4A8
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MX^S'6_%>IZ3I@G^SP33^3]J\SR899=NR-V'!_"#]K3]E?]H/4K_1O@+^TM\
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M?L?_   ^)G[ '[8?@?6=3U']N[X+?"_Q]XN_9V^*O@?QX5\)^)_AE\;=;O\
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M\1OV@/@GX"F^&5IHU_\ $B#QE\5/ WAFX\ 67B,:>WAV[\:6^LZ[93>%[?Q
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M!V8(H%9[6=^W7[MSU"BO _@[^U9^R]^T/=ZE8? ']H_X#?&_4-&MHKS6=/\
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M6_9\^%FA^"O#-];ZG#Y8O=3U>(HT6K:FXF\_489%ED79-YC*N-N0"1@$"O\
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M'5_BC\/O%6HV-[XR^(OAWQ[X(U_5- UFRN?%NLPZKH_B3P[?7-EK&E:IB^N
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M&^,/B7?_ !<\<:1;02Z'X!L]5O/"$NG7&OSR7$4EO'>)8W;0&.*8O]GD&,@
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MZX^W:9#-<>+/B!XKF^,/B Z=9?9EO_ 6I3Q1:7!+8VTW]#/P_P#V=O@G\,O
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M\'VNIZG+!:6NL:EX(GUM]"E$OVR+6;>QFTRVU'4X[/2[WT?]I7PK_P %$?\
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M'XPUWPSJ>N?:IK1H8/AOXUTY[&6XL-0_LOX&_P""NOQ;_9\\'_\ !2;]D/\
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M:'X9\31:;JND "^R=D^6=FY<S3=K7ELNMM=+]+GYA_\ !PQ_P2S_ &4_V7/
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M^,X)(WMXU#^'=1 <B-2X-.T='9^SEUUOSK\;?/J?D[^T=_P2\_9ITK_@X'^
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M\-2)&MNR$:S9?O 9"%/^"KW[-GQW^-'_  4(_P"")_Q/^%GPO\4^./ '[/\
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M:3:/'?WMU<A=+U2]\63:)]KGN%T;3/&>MZ%I\<.FK91VWEO_  1+_9"^!?\
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MQXF\)^&/[4EGGL=!N/%'@+5O$=C8B>Y^R0ZY'9_:9$M8XXO;/ 'PJ_X*#_\
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M9]8DLH[W3))P+I3C[V\6FG).V]DY+1ZZZMV[G+?\%8O^"9W_  3;_9A_9O\
MV4/@'\8O^"A7Q1_9H^ GP<U[Q_XF^'?P1O?!\?QS^(/Q8UKQKXT7Q)\1O$5K
MI7A(>&=3BU.+3+[_ (0_PWXRU;0)?"G@,ZEOO9+Y]7OM-U/^8O\ X*#>(_\
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M?%7]K7P!XT3XL?;[^SD\-!O@OX)_9[T;PC+X8T>VTVUET:2XM?&FLOK8FO\
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MMWMOX>T$7OAOP;HRI::5=>(/%%P$IKEIW:M&34E==WRZ=4N^RW/YG?BI9?\
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MTT^E^,O#>LQIHURTD4-M/JL%OX8\2N#;7-449)2?+9W2NK:I/:]S]./V9/\
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M)VDC3$HX\Q$:6)6V%97'3_/^F21["81C,KV]ZD:C.YG;A$  R6?/RCOZBO\
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M_P &O!UIX'^.?@'29?$BCPY!%8V'BNUM0OVFWU2W@A*-<1(3)(-K1;%D.\8
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MWG>\M?:X[G3A3R^FX;U*EG%12C_#7O=;-)[:WMTN?V*?\&H7@.^TKPM^U/\
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MV6HH*<Y-6TU5F[*[2Z-VNUHONU"BBB@D**** "BBB@ HHHH **** "OY</\
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M^"^W_2:C_P I7B__ .4]'_#JC_@OM_TFH_\ *5XO_P#E/7]55% >TEVC_P"
M1_R/Y5?^'5'_  7V_P"DU'_E*\7_ /RGH_X=4?\ !?;_ *34?^4KQ?\ _*>O
MZJJ* ]I+M'_P"/\ D?RJ_P##JC_@OM_TFH_\I7B__P"4]'_#JC_@OM_TFH_\
MI7B__P"4]?U544![27:/_@$?\C^57_AU1_P7V_Z34?\ E*\7_P#RGH_X=4?\
M%]O^DU'_ )2O%_\ \IZ_JJHH#VDNT?\ P"/^1_*K_P .J/\ @OM_TFH_\I7B
M_P#^4]'_  ZH_P""^W_2:C_RE>+_ /Y3U_5510'M)=H_^ 1_R/Y5?^'5'_!?
M;_I-1_Y2O%__ ,IZ/^'5'_!?;_I-1_Y2O%__ ,IZ_JJHH#VDNT?_  "/^1_*
MK_PZH_X+[?\ 2:C_ ,I7B_\ ^4]'_#JC_@OM_P!)J/\ RE>+_P#Y3U_5510'
MM)=H_P#@$?\ (_E5_P"'5'_!?;_I-1_Y2O%__P IZ/\ AU1_P7V_Z34?^4KQ
M?_\ *>OZJJ* ]I+M'_P"/^1\_?LJ_#[XP?"G]GCX3_#OX_?%'_A=?QD\)^%H
M=*^(/Q5\JX@_X3?7DO+N:36?*NXX;E-UM-;6_P"^B20_9]S*,T5] T4$!111
M0 A.,>YQ2,ZIM!ZNVU1W9MK-@>^U6/T%*1G'L<UFZU#?W&DZE#I<JPZC-87<
M-C*_W(KN6WD2VE)W+M\J9DD+?-@*<*Q(%-14G"/,H7DE*3^&*<HJ[:3:BDVY
M63=D]!-VYG9NRNDMW9-V7FVDO5GP%_P59^(FD_#_ /X)V_MC7U_J%G:W&M?L
M\_%OP?80RW4$5S-?^,? >O\ ANV@M8Y)HV>\9M18PJA)WIN'"U_E8P(;:*,8
M<LJJMU&JM)^^>U:*9'*!@LL6VU=0Q 8/)R2 #_<=^TM_P1&_;^_:GUWQ8?B9
M^V5J.L^#=:UNZU#3?!\E]+!H]A8&XE>RTYH6L%6XB@2;.YP3N0* RLS#X_D_
MX-5/C!)+YQ^..B$ELO')Y;HQ=5267Y((CYC!(^&# E00R8Y_<.",UX<X9P56
MC4SW 2Q&*S' 5ZM2]6*C16&JQFG%8:;Y:$GR5'=ZSTC+=?G>?X3-LXQ%)QRS
M%PHT*T7#W87:IR;<T_;K2;M**LG=)W1^WO\ P;Q>#+3P+_P37^%MJ9;:34M6
MU7Q%JNH7$<BEYYKFYA>-',BQ3$Q1;5PZ KDYX92?W/4 $MM(;:N00"1RP'()
M4GKD G'4]:_DY_9J_P"")/\ P4+_ &7=2\*V7PP_;3N= \$:+XCL=2OO#44I
MN+.XTJ.;?>V,,$_FI"UQ&2H\K8"3EF 5 /ZLO#]E>Z=HFE6&HW)O+^TL+6"\
MO&8LUU=1Q*MQ<,3CYII=TA ^4%B%^4"OS#BNG@ZF;XW&X#,J&.IXK&XBJE1<
MVHPE4;BVYTZ>C6J:6SU2>A]7DBQ5'"4\)B,+4H>P@TIS44JC<Y2;LI2LW>[O
M^)I1[V:3>.!MV\''0YQG\,X[]:9=3"% Q('4$X^;:1M^4G"Y#M&<,RC:"<G&
M#,0QQR!AE/&>@.6!]<CBOSR_X*+_ +/'[3/[2?PLTKP)^S7\81\%=?.J27&K
M>*X /M9TW_0PUG$?,C=&G5;E08UE!R#(T)5/,\3#T:6(Q5&-:O##4G)<U2=_
M9PLOBE92;]$NYZ=9U*=&;I1E5FD^6*U;O=VU:UL[;[G\7O\ P<D_%:/QG_P4
M(G\%:?>I?:9X#^'OA64O!+');1:CJ-J8=1M=ZRLANH)+:<31CE/.C$A!8@=9
M_P &QO@A-;_;S\5^-KVZLC8^&/A9J#06-Q- ETEY)?F"UNH4F(5N+Q5/E2EU
M$+,RA!OKZR\4_P#!KY^T+XW\0:GXL\7_ +1MKXB\2:O=2W%_JNI737-W<[\,
M6EGN8KB1BS[F\H;8XNBL^[*])\-/^#;#]K+X+>(O^$O^$O[4Y\$>)A9S6$>I
M:-??96$-Q)$SM.D=JJW B\O?%$Q(\S@E023^]3SGABGPE+AZAQ)@%-86=%5%
M.M=RJ<TF^581)^].5US*U[)Z7/S>.69R\[IYG4R_$N$JT)SIV@U%0:CJW7=M
M(Q:T>BT2NS^TN,??.58%V*LI!R,#J1T(;((]J_%/_@OG\!/$'QR_X)]?$O\
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M_-*[?-&.MKK37^=7_@Y[N-2\(>!OV._@K(-V@^!--TNWLKIBZ0WFIZ1I-EI
MDC>141P+>S0#.UN>$!) _ES^"_B/P_X-^-?PI\7>*[?SO#6@>.="N]9:159$
MTR2>&"X<J&V/]GES*^YE01@N&9L+7^E-_P %6/\ @F3X5_X*3_!;2O!M]K:^
M%?'?@2[OM>\!^(!$DRG5;B$%+&_GD1I(+$SKD%%F"^8S,@ P?Y)3_P &PO\
MP42EU>*SO=;^"!\/-<36\NLMXLC^WFR>Y?R[E-.ELH5^TO;D2^2TD31RGRPJ
MX./1X,XNR"EPU6RW,L=A<!B)RJ<\*\IQE4E-RE*HE"A534I3<M)73]VVEWCG
MN49DLU5?"8.MBZ+C!\U.,6H\MK4VW4C:R2CJK6ZOI_:3\/OV[/V0-4\&?#EM
M,^//P\@B\06/A[1/#]A+K<<$\VH3^'[:2WT>.%U5S=H=L!0<>8HCW%L"O\Z7
M_@K/KGBOQ/\ \% ?V@M7\:QW46H6NNW=MI\%W<2,)=#MM4O(M,G>=D,D=M/
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M3\6>"_!__!*'Q?=?#?6M(U[0O#_[.1N='G6YCD6:P,49\R> $S1#]Y(O[Z-
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M^_[5,GAKX/\ B>:*/P]\/K*66VTZUTR*WB'V6=5:Z4NUS%'<O'(LL0*Y25I
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M7KX'$3IU)<OM7&*C%3FG.5W4O97;?X:'Z.?\%3_B_!\%?V&?C]XOEO(+1O\
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M'[0_QUL_AI$J[KM?A+J%Q?7UVBSVX-F\\T-IYD5Q;M<K,DHCA)5'\[<B*_\
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M7QE_9^_:2^/GPB^$O@KQ/\2]3M/@QXMNKKX>6^G:-JGQ:T"QTBYN];UNYO\
M5HEU+Q9:RQZA;PQ0W<%C//9Q1/')^PY^RI<:/XZ\?_\ !<W_ (*TW\?[9_B#
MQAXMBU7X?_#+]LWPEIFD?"+PY'KUW'H5AX)^%\/A[4O$.F_;8-.N;V72X?"5
MEX1T"PU#3/#T'A73=<T^ZNKOQ_\ X)T_M.>.?V=(/^"K?_!,/PWX3^+/@/\
MX*%?';XM?M@^.?V:63PY!I^C-XBT?X/>,M1T:2#Q+J.H6K:1K6J/\/W;X<:Z
M--O/#GB#6O$'A&:RU=;*[DO8?'_^"7_[0_\ P1+_ &:_V>= \)?MA?L@>,OB
M7_P4:\.^*_&MI\0OA]\1?V;->^-?Q*\<^-KGQ5K5UX6T_P #:#XSM+GP9H=[
M!X;N- TR/2=?@\(:Y9>)+*_U"[%[=M%KU\#:E>3UWC;E46[6O>[T4;WN[;]5
M8_0C_@A?^W;XC^'?P._X+!6.N?'SQ?\ M9?LW?\ !/<3?%/]GCX@>-=0\02^
M*/%WPK_L3]H77+>Q@G\86MKX@TFV\3:/\'O#=]8>&[J(6>AZ]KNKVVCPFSN(
MFFH?\$\/^"9OCO\ X*T_ -O^"C'[=W[7_P"U;;_%S]H#7/'5[\%=(^#/Q,;X
M;^'_ ()^"?#GB77_  /I[^'M!;1]5TZS6\UC0M0U#2=&T:VTC0_^$>&GWNH1
M:OK>N:IJ8XC_ ((J?#3Q=\>?C%_P7E_9Z_:%^#?B#]F/Q/\ MH^$="U'_A6.
MH^$1H<?PM\%?$6T_:#TY_#^F:9%9:%:&Z^'^@_'/P-!:VL,.GW\4D$+:DFGZ
MJ9@G?_\ !/+_ (*7>,_^"27[/US_ ,$[?V]/V3OVIA\5OV=_$'C?3_@QX@^$
M/PPNOB+X4^-_@GQ1XLUKQEI,?AKQ)_:>FV%TUOJVOZO;Z1JNGR7VA_\ "+6U
MG8W<^F^)=%U'0F EO+EMS7AM:]G'6W3XM[?D:/\ P1<_X::\#_MC?\%H?@S^
MTK\<_&GQN\??!+P9X \$Q>./$.LZK*FMV?A?3?B3H?A;QA9:7=74L>D:GXB\
M':7X9U/4YT,VJW=Z[W.L:MK.J-<ZK=_//[,WQ.^)-]_P:I?M4^.[[XA>.+SQ
MOI_C?Q?%8>,KKQ9KUQXJLHHOC/\ "FWCCM/$,VH/J]M''!<3PHD-XBI%/-&H
M"2.K>P_\$3?B+\4_C)^W)_P7)^)WQC^'&I_"3XD_$#PWX+\2ZS\*]6::;7?
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MNYGO[32[_4K-+>_GTY[RP:.[=GLYH7D5')4?7M!F[W=][N_KU"BBB@04444
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M#B,52Q$,32K0J4:T(TJL55A-0JUH)59=J0",$ CT/(X.1P1[ ^QZ=,TO^?\
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M5:U2*G3I4\7A:DYQ:FXRBH8B5TU3FU9W:BVDU9OIF==T:-M.[?AGV[AM .<
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M<G\(ZQ=WGA^;6%T;25U.33VO5TRP$XM8@;323?7;57^Z]_O1W]%%% @HHHH
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MH.MZ3XLGU+PK<ZBVNPV/B#4N8_98T;]KC]N;_@C=_P %AOV8M(^)GQ)_:O\
MA7\)?B;X0L/V,?B]XVDUZ7Q7\6?"_P 'OB9:?$_Q-X=T#_A*)+[66LKOP5\-
MO >L^&/ ]WK>KSZ#JGCW_A%M.CL&BL(V!M)].5*4;IQ2:3=M)+22[[NVI^BW
MP ^%/_!>3]O?X&>'OVX8/^"D?@W]D?4_BQH:_$K]G[]E[PM^SWX-\4_#FS\"
MZTCZEX%B\:^+-;.HZI;V7B737M-;M9O$FA?&75ET+5K"74YTG:3P[IGT-^Q]
M_P %I/$/B7_@G7^V'\?/VJ? =EHO[37_  3RU7Q=\-?V@O OA>*/3-&\7?$'
M1;BXT'P-=:5$VHZC'H2^-?%<+^%/$,<=P]EIGB'2?$&I:-91:)+I6FQ_BQ^P
MK^S'_P &TOQK_8[\ ?%/]H7QAX0^$7QQ\(^ =*T_]H7P!\0?VGOB'\/_ !A#
M\2O#>DP6?C/5?!WP]U+QC9Z[XJT/Q-JMO-KOANR\ Z;XE$$.KVGAC+>(+*[T
MZ+U?]G+]F?X"_MC_ /!'3_@JKIW_  3S_8U^+OP$\-?%+4_!%E\/Y/%GQG\3
M?%K4/VD=4_99^(<GQ8T2?P5X?\66%JWA6_N[.U@\/:EIVEMJ7]K>)O$4WA"/
M6]0O_!J78!-+5--)2BK\JC97LU>]Y77KWNCZO_9R^&G_  7X_;'_ &?_  [_
M ,% ],_X*$^"O@QXQ^(V@S_%+X$_L:P_ KPG=_"3Q%X!U(IK'@SP]XO\5ZA=
M+=^'K/QUI5O:RZ-J6JZ7\0_$5EX<UK3=0OO&^F:E?:@FE[__  :J:MXBU[]G
M7]M_7?%^DKH'BS6OVWO&.K>*-"2"XM4T7Q%J/@;P9>:WI*VUY-<7=LNFZE-<
MV:P74\]Q"(1'/-)*K.WM7_!,K_@LS_P3]\+?\$Q?@"OQC_:*^&GP?^(/[,7P
M(\#_  8^)?P>\8^([73/BTVM?!?PQIWP^@F\'_#R\,'BOQ__ ,)=I_A_3O$&
MGCP3I>O0V+ZR^D:K/8ZEI.KV]CY1_P &MWC'_A8GP-_;U^( T9O#H\=?MX^/
M_&(\/O:0Z>^A?\)/X0\(ZW_8SV%NJ6]DVF?;OL36D")#;& PQ*J(H *5^6:<
M4DI12LK:7>GGI9WUWWU/Z$?VJO&GB;X;_LO_ +2'Q$\%ZE_8WC'P%\!?C!XT
M\)ZQ]CT_4?[)\3>%OA[XBUS0=2_L_5K6^TN^^PZI8VMU]CU*QO-/NO*\B\M;
MBV>2%_Y;_P#@G]!_P7*_X*P_LO:!^TQJ_P#P4?M?V4/"VDMKGASX-Q>$_P!G
MSX?ZIJ?QY\3^#]8U;3/$WQ ^)<VAP^#-,TGPP?$L-Y\/[.ST/3=5T56\+WUZ
MW@!=3TF[U3QO_3/^W%_R95^V!_V:Y^T!_P"JG\6U_/?_ ,$ _P#@JU^PYX&_
MX)D?#CX-?'']HCX1? KXD?LU?\+$TCQ7X:^)/BS2/ ]YXC\.ZS\0/%OCSPYX
MG\#V.LSVLOC>2^TKQ-#I&I:7X4_MOQ$?%&FWIN=)MQK.BK? HWY6U%-\R6W-
M9-/I9[^G^9]'?\$X_P#@IO\ M?\ Q-^!'[?/P=_:'^%5I\6O^"AO_!/#4]=\
M+:EX.^'=C8:+;?M ZK=0>*;#X?7%C::1;Z?HEI/JGC#PEJFFZ[JWA?2=,T(^
M%KOPYXCT_1;.;4GL3X1X!_97_P""\G[3/P6M?VI/CA_P5(C_ &'?B%J]AK?B
MS0?V9;7]GWPWH_@CX>:?'/*FAZ-\3?$ESK^D7^A1W,=C;7E_!XF\._%#4] T
MZ_ U"\U+4WU#3$_.GX!?&WXZ67PP_P""_O\ P6G_ &9?"_B7P]I?Q+UK1O!'
M[+NOZGH/VC4+WP^OQ0L])^(OQ;M]$UG39;&;_A6?@C4]!\:R&ZM=5T33M>LO
M$6AZJMZ?#&JPR6_V<OV:O^"*/Q#_ &+_  !^VU_P4D_;Z\:?M2?%S7O"MIX]
M^,7@'X@_M7ZK/XITOXD7-A=:IK/PB\/?"?PQK.F?&F^\1:;+<W&F*AUFZU/7
M7%QXHTJ^TKPGJ=N+4*:LVTDM4K*/.T^5-Q2V2N^NM]%L?H?^Q=^U_P#MJ_\
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M0^#_ !CX>U&:#Q-#!HD86]=;)M4XM+E75ZNUM;+96:78^@/A1^U?_P %!/\
M@F]_P4&_9]_84_X*!?&O2?VQO@)^V1]KT3]G#]IZV^&FD?#CQ[H/Q#T^\M=)
M?P5XET3P[.]O>VXUW6O#-KXABU>^\9ZCIEMXY\'ZUIOC1=-MM9\-V?@/[2_[
M3G_!7+]I#_@L9^V'_P $QOV-?VDO#/P=^&WA7P/\)/']MXR\0^!? S7/P2\
M#X'_  =\1^.KOP_XDT[P->^/-9UKQW\1_B=I>G6SZEJVKWVC_P!JF/0;GPYI
M=M+?:95_;L_:#^&?_!3;_@L9_P $G_@'^QMXL\/_ !LTK]C/XQ77[2OQS^+'
MP^FL/&'P^T+1]"\=_"?QE=Z+9>,]-)TRYBLK#X41Z9J&JZ+K.H>'[[Q#X_\
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M/Q6TWP_86OCGQCH.AV6AZ=H^D>(?$,42W^IV&FV'AGP]:6=O<RO'!;Z-I\:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=^-OASX'UOQ=HTEBEWJ%UKFEZ9?7VCWOASQ!X?N-?U+5M*U#1-2EBUB2UO\
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MU+6HHY?M;VFI> /$OAM-.UK4(XX[B/2KW3+:62/095A^ /V$M6T[XU?MV_\
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M7%PD_AVR6:4C[\BVEG:VX8\B*"->BB@F-E&3:3:<4KWMK>^S5]CZ2_X)1?\
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M.QWF@Z,]UJVOC3M"U+5-%LM+U5]2\+VTEDZ'Y%TK]MK2/^"5/_!#W]G[4?V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'Q9HO[ W[/N@?MO>+_^"@VGV/BP?M$^-OAQ;?"S7+^;Q--+X0;PG::?X8TV
M&*U\+_95@M[_ .R^$='#7OVIV9UN7V#S\)_,Y_P5._:*_9R_X+=?M&_L8?\
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MI-GKVCZMH>H+(UAK6FWVDWRQ.8I6L]1M9;.Y6.4 F.0PS.$< E&(8#(KY?\
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MTM=9M-9M=/CM[2XM[9;^SM;R+]VJ* 4I)63:7J?G7X#_ ."6/['G@K]BJ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?'C]M;_@J1^P1?\ P<U3_@M#^QC^R=^V?^S)I/Q7T'3] _:0\+^%/ VN^(O
MGC>>WO%_X3+PQ:+I/]F>'?%5GH$&JZGHD-[\&OAM=^(_L=YH6E>+=/FEF^Q_
MV365Y::C9VFH6%Q#=V-_;07EE=V[K+!=6EU$D]O<02*2LD,T+I+&ZDJZ,K D
M$4$225FDK.^JES)V?3JO-,_.S]GO_@HQX0^.G[<G[6O[!E_\,O%?PW^*G[*^
MG:#XD?4?$.J:9>Z=\2_!/B"32WM/%WARRM8H+[3M.&G^)_!.I!+T3^9!XKLU
M68- QE\N\%?\%?/@EXY_X*C>.O\ @EUI7@[Q /'O@O0]2ND^*1UO19?"&O\
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M/VAK/_@EY\!O$_PQF_:>C\=-\$&^,TW@#XPW?Q%FU:#0-$U7Q#%X\%]IC_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNSL)]2T?7F\27MP;=7M?$]E?PVFHP?T744#4FE9/K=:)V?=73M\C\9?V6?\
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M.M^-/"'Q$T:?Q#>2?$*_^V6MII/B#5_%-YXQ\:-XULUL](L]6M?&7B*#1?\
MA&IIM,N]+_6BB@?/+36UG?1):]]$KOU_4_F*\2?\$!OVGOCW\';[X'?ME?\
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ME;3W\-U<>%],\$V%E/+->KH&IR:IJ,9_IDHH!2:T6V]FDU?O9IZ^9^0>D_\
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MT76[/1]0T?\ <6B@?-*][ZWYKZ;VM?[OD?S4>)O^"&O[9G[0^GZ)\(OVXO\
M@L!\9OVC?V6=$UCPIJFJ_";0_@WHGPR\0?$N+PY+;7T5CXU\:Q>/_%-[(MGJ
M%G;S6UWKL/CV\NKU(?$23:1X@LK2[3]"_P!NS_@DK^SE^VW\$_@S\*UOO$_P
M&\5_LP6VCQ?LM?%OX57<EKXO^"/_  C]CX>T_1]/T=[FZ2ZU/P_!;^$O#!DL
M&U?3M6CN] TG5-*\0Z3K%E#J*_J910'-+36UMK)):[Z)6UZ[Z:'\U^K_ /!!
M[]HO]I'6_ 6A_P#!1S_@J?\ &;]K_P" /PU\1V>O:7\#='^%^E_!NP\976DV
MUO#IM]XY\3:5X[\37-[<S0MJ>DZE</I6I>+X]+O]0ET'X@:'J6KWEU%]0?\
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M#G@VX\SC=QE%WCOI)1=NTK<KZ-E17-)Q6Z5VGIIKU=D]MDV_(LT5$9<,0%W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 -W+NV[EW8SMR-V,XSC.<9XSTS
M7"^,/B;\/O ?V5?&7C;P=X6>]:46<?B;Q3HOA]KH6\<,MPUL-4O+8SBW2YMF
MF\H,(EN8&<J)8]W42N1?L,X_< #@==P;'KTR?2OR+_X+"^!X]=_9HNO%.GSW
MNG^(_!>HZY?V>JZ/K6L^'M3CMH_AMXNN[F$:CHM_I\\EO+=Z'I,[6D[7,#S6
M=I,T!>V2O6X5RVEQ#Q!A,EQ=2>%IXO$QPZK1A";CSJLZ<W&I>/+-TXQO;1S6
MG;R,^S&IE.48O,J%.->>%@Y^SDW%2Y>7F2<=;KF?W,_0U?VF/V?DD>*3XV_!
MVVDB:598Y?BCX*5XVA5C-O636%9#&%;S P'E[6+8P:[/P]\3? /BR4V_A_Q[
MX,U^53)O71?$^A:J\8B6-GW1V%[,1L\V+>3C;YT>?OIG^)#]BC]BO]HO]N[P
M]XN\6^ OVCYO!:^#/%AT#7(O%7B'X@ZI->3ZGI,.JL8VMY)$DC$/VFWDW!M\
MDI<':=P^B_C)^R#_ ,%*OV!-!O?C-I?[0VM>)O GP_LH-8U_6=+^(VJBZN3J
M5S/:LNH^$/%-UJ=KJMC;W9TNWN$E.K&:&."2/394@:./]AS#P=X5PV;XCA^E
MQKA:>>453AA\!BKTE7Q=:,9T\/*%&E&,ZDXSHNG34ISFJJY?M(_-,#XD9_6R
ME9Y5X:J?V?!N=6K2DY2]C&4E*K'GJ;1]G44G)**E%*6C/[&8KM'<B.[AFC0#
M<8VB8(K F(LREL"08*$D;AT)KCO&?Q.\!^ Y]-M?&7CKP=X1FU5)I+*'Q/XF
MT/0);V&%X8I9;2/5KRU>YCC>94D> ,J.ZJS!F45^./\ P2?_ ."E<O[5BVWP
M1^(]CK$?QAT+P1_;S^++Q-&N]+^(-II.J7EOJMX%T30M'BT*ZT:RO?#L/D7M
MJ#J<EQ<R02R26LLUS[=_P5V\$:9K'['?Q0^)%F+VT\<_#OPS;:GX5\4:;?:A
MI6H:3;R>-/!MQJ,%M<V&JV$D:75A;W=M(SVMTQANY4$)W/%)^;1X3Q6#XMH<
M+9M&>#]OB\+@XXB$8.[QF)IX6A7BIR</8U)U(U%?]XJ;2E3]HI07W4>)J..X
M8J<18&"<J6%Q.(5!WC)SPM"KB'0DHKXW*E[*33Y'.5X24;27W+)^TO\  ".W
M>1?CG\&V0*P,@^)_@C8,Y&2W]LE?O87KU('7BNA\,_%CP%XP8_\ "*>./!OB
ME1$)MWAWQ3H6M#RF9E67.F75R/+)210^=I*. <J<?Q@?L5?L&_M#_MR>$=;\
M9^!/VB[KPC8:#KNL:!<:7XE\5_$>07%WHVG^&M0? TV\D@*7 \4V+(SPL 8)
MA(W"K7IW[0'[*'_!1?\ X)X>'Y?BA9?M(:M<^!8+[3=!OM9\'_$/Q%-'I$VH
MP16^E6]UX6\3%'NX-3NM0O8UEL;.^^QW-F;JZ$(FM[E?TK,/!O@^GFN(R!\;
M83_6.A45*GE^,ISC"=;[-**H4(WJ27,U&,FVEI=Z+X_+N/L^QF24<^Q.23PN
M#J>]4Y)WE"%H.4I\TYVBG-1N]$[7LM_[2'991M1@V#G*D-TR,<'W%8VN^)=!
M\*:5>:]XH\0:-X>T33K>6[U#5=>U*PT;2[*TAV^==7FHZA/;VMK;0[E,L\TJ
M1)D;V7-?DQ_P2O\ ^"@]U^VAX5\8^%O%46KV7Q2^&%OX5NO$-S>KI<EAK6F:
MAIT>G3ZA9W.B:-HMDKS>(M.U622VFL4N##/!)Q$JPP_HY\;_  EIOC[X3>//
M"VJ6\$]IXB\*:WI44=TC2JC7-LT>X^7+$X"SB*4A9XR0HPW4#\?S+AW%Y1GB
MR7-W+"UX8FE"4(\VM"M+#NE62E[KBX5G/?:,DTVK'Z!A\YHX[*Y9C@$JU)4*
MM2,G9*4Z<:CG%M6:<94U'16NUK;50)^TC\ &,,I^-WP>BMKD;K>[;XG^"O(N
M(V1WCE@D.LB.5)51BC1NRLH+*2 :]EM;FTOX8+RVNK>]M9TBFL[JVFCFMYXI
MD66&6":%VBFCFC:.2-T9U=&5T)5@3_$'\ ? 'B+Q/_P4FU#X"ZUXH\5WW@#3
M?&OQUT6'0-0\1ZW=>';:+PE#\09-(@LM);Q,_P!FLK*/2K1=-MH3#%9QI$BQ
M1A&C/]LFEQV>GZ-I=G8P^39Z?965O#%"@1(DLK6*)  SAF41"-5W%R0GS9/7
MZ'Q$X-P_!57)*:Q]3%3S/!8?'*$X0A%0Q,:2II.FES+GJ1<5+7EC=I-V?C\(
M\35.)J692EAHT5@,14H-J4I7=.4UJI;+W):I6OHF[,-1\8^%=)U[1O"VI>)/
M#^G^)O$:7TOA[P[?:UIUGKNNQZ9;F[U*31M(N+A-0U1-/M5:YOGL;>=;2W5I
MIS'&"PWHITEP5="&+*H#JV70L'4$=678^Y1RNULCY3C^<C_@J]^TWK?[._[=
MG[$/B^RUC78=!\(6FKZ_XQTK2YDA.H>&]<UZRT#5K94E@N8[AKO1H-7MIH@I
M=X9#&H1Y$DK]T/@?\4]%^,'PR\!_%#P['<MH?CGPIIGBK3+>Z@6WNK<:M#'/
M+#,'CA(FMY)KB"60(J2LK/&#&ZD^3FO"^,R[)\HSVK";P>9T74HU4ER^TC*M
M&5-KFYM8TY2@W'7EDF[I(]3"YU2Q&88G+U95,/)IK=\BY5S*RMI)V:O>S5OM
M6]JC974.""3D'!!Z,5/3C@C!XX/%.9U4$DCCW [XJM;,&)VKL7Y\+Q_?P3Q_
M>.6Q[\\TV4YA=ATRJ]L@LRJ&QT.W<#C/.,5\E]8C5PTZ]%W48U'%OKR*_P".
MA] XI2=]DUVOJ]%V];?(EDN[>)6:6:&((H=O,E1 $9UC5R6(PA=@@8\%B%!R
M0*YS1O$^B:Y=:Y;:5X@T;59]$OI;#4[73M1L+Z?3;R&ZOK26QU".UFDEL[N.
MZL+NUD@N52=+BTN8602P2JOAG[1_[0'@[]G+X6^*?BQXZ@OKGP[X6;0;*_M[
M"QCO;N\_MOQ%I>A6:0PF.50$OM3@N'WC"QP.0P8J#^6/_!%WXZ>)OC79_M%^
M(_%^NZWKNLZYXKTGQ<D&K3K<?V?%XL\>_&75UMHID2&V4Q6UU86LAMK>"/%L
MGEPQH@1?K,!P;C\SX7S#BZHZU' Y(\-SRBW"GBZV*JPH5*3<6G*&$A5I5YJ2
M24JD.7F;DEX&(S_"X?-<%E2<)5L;5JPY6_>C"E3=2+LD[.<HSCJUI%OS?[NM
M>)'#+)*R1I'&[;GD5% 12S$LP  48+$_=!R>*YC7_%WA[PYIEUK/B3Q!HGA[
M2-/C6XO=2US5M/TK3[6-I%@C:YOK^:WMK=)9I$A22610TKI&NYV4'COC1\1?
M#WPC^&OC;XD^*C=CPYX&\)>)?%FM"RMC>7$FG:'IDE_=6\-J#_I%Q=1P&WMU
M=3'YLBM,\40>0?Q_ZI^TK^V=_P %1?CB/A)\'?'_ (H\$^$O$FB6=];Z#)XT
ML_"OA^QT#PRL,7B&[\2)X9TSP]=:E,VKWM[J$%O';:]=3[=%"R)]B@71>_@S
M@6IQM#%8[%8JEE>09>Y/&YCB93C2IPI7J5G^[;7M8TH2E!5%[%1G3E4:;<%Q
M<0\3T<EQ=+ TJ<JV,Q-.<L-0@KN<U&?LH][U:RIP2C>3;F[I69_6C#^U?^SA
M=WCZ./CE\&'NXG=# GQ7\%-.9(U>1D\I=6#!UC21V3)8)'(Q&$8K[GH_B'1O
M$5G#J&@ZMIFKV$ZI]GO-*U"TU.TG5X8[B-H;FSDEAE5X)H9D*.P:*2.4$I(I
M/\E-Y_P1 _;0TJSEU[3OVE/"VO:\GV&X?P];>(?'FBW\%Q=1-;W@'BJ5(_MK
MP)=3O*UP\:7,:N$+.8D;]Q/^"72^)[;]FRUL?&OBC4O%&O\ ASQ(NC:Q?:K=
MWFH7%G=:7\._ D%]86UY=3W4MS;07R7<T=Q%(BSO/)*L09R6]7BW@[A++LI6
M(X>XE6<.%2E0JT(J*E2<DXQJ)PITY=.;W[TYJWLW+6WG\.\0<09A55/-LJ>
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M?C#P1977B#6?$.M:AIUBGA_X9ZB/LYU74;G3C"%U*]B4")9XSJ%R4EVLRO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?):H)Y+DLQ,H5"
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MCZ[^Q/\ !_X2^"?V%?V;OA'X)\*^'&^$T_[.GP^T_P#X1]+*VOM!\2Z5XO\
M VG7_B2\U:"X%Q#K;>-+G6=4U7Q#<WYNGUR[U>_NK][A[N9G_F5_X(X?LX^'
M/VE_V4/^"W__  3PL;N>7X 1_M)?$3P/\#)=1OGU/3/"VJ:A)XML?!GB#3[D
MR:DTLGAS5/AK\+?%LA2]U&WNKRQBO")Y;NZN+T"T'=V:46KZWNF[7VT?730_
MKWM_B5X'N?AI!\88_$-D/AM/X&C^)2>+'\T:</ \N@+XH7Q"V(VG%D-!8:D<
M0F409Q&7^6O@3X0?\%;?V.?BO^QAXE_;ZU+Q'XL^#G[-?AKQ3K/A%_%7QB\/
M6F@ZOKVJ:+-IEA)_PBOASPSK/C#4O$/]HZ[J,OAO1]/T])-<U'6])U>&#2/L
MEK'>W'\N2?\ !1#XBP?\&^DW[$,L.IC]LQ/C]-_P2I'@>6Y#>*QHSZH;E[:3
M3FFC>+2(?A6\GP!C_>O$FMQ1*8_(+1)Z9_P6R_9U\3_LQ? ;_@A%_P $^OA5
MX8\-_$#PUIWQ1O-#UCP-XNUAM#^%OQ=^-OAZ\^"^G6%IX]O+BYTK3K+2_B;X
MN^*GQ1EU#4+V[TQ--T_Q3K[Q7%A;M<30@U35[-ZN32V^&*;;^>B73=]#]>?"
M'_!R+_P3[U_Q!X9M_%_A3]JOX,?#;QMK5GH7@O\ :"^,/P*D\,_ KQ3=7MLU
MW'/I?B_2_%7B'54L(8A&]Y>:CX;L(K.WF74;CR]+BNKZW_7?]HC]JOX ?LJ_
M [7?VCOCE\2M!\'?"#0[#3KX>*A+)K*:\^MA#X?TWPE8:+'?W_BO5O$)EC.B
MZ?H-O?3WT!>]0+I]O=7<'\VW[7T'_!>/]IC]E#XM_LX?&/\ X)V?L&>%O@[X
MM^'UYH5_K%O\<_#VBVWPVM-%M8[SP_XRT&?5?C(V@:#<_#^]T[3]>T:>[MQI
M-BVE0Q74+:=Y\#_$'[8WPV^,'AW]EC_@VZ_8[_:_&C:CX1U?]JV3X>?'R+3?
MB-X9\=^#+KPAX1^-?P]^'7PRTZ3Q/X?O=3\.:WIW_"AO&FNP0W-M<WUIX;MK
M>[T6]D:YCD! Y8NVMM7=*2EHDW=.RUTM\TSZG_X*-_\ !>G]C7]JK]@3]J/X
M(:)X _:E^$>M?&;X.:O:_!#QC\<?@Q#X2^''QEO+/5-)U-K7P%XI\/\ B[QA
MYS3Z9:M>VMSX@L/#]A.)K2S6[_M*\MK&3][/^"0G_*+S]@G_ +-;^$/_ *B=
MA7BO_!=+X3_#'QK_ ,$DOVMM$\6:)H]KHWPW^%UKXY^'ZPZ2PA\*^,? &H:9
M<^"#X>M]+-JVCM+,B^%%DM#%8VVAZUJ%E?P3Z'-?V4_M7_!(3_E%Y^P3_P!F
MM_"'_P!1.PH$[<BLFO?>C=_LKK9'YM?\'+G[:.J_L[?L/:[\&? E[\;/"'Q2
M^.T>D-H7Q(^&FFZI8>%- \)>&_'O@VW\=:!XS^(6DZG8W?A23Q?HFL/H>GZ>
MD4H\20W5[I4LB6\\T<OK_P )_P#@LQ^RQ\'_ /@FC\,_VI_B)X'_ &B_"WPX
M^'7B/X:?LIZOINL_"JVTCQIJ?Q#TWX1>&?$+:[X=T#5_%-A%JOP^O+*5X=/\
M4#48&N[VVN[=-.'V=WK&_P"#FK_E$'\=_P#L>_@3_P"K>\)U\0_\'#'_ "@A
M_9;_ .QM_9)_]4KXNH'%)Q@FMYM-W\EY=ONWZGUIJ7_!<;_@F[^W/H7[;/[)
MFFZ9^TMX@^'WA_\ 9._:B\1?%/XE>&/ /AVQ\+^*O@9X/^&OB*S^*FO_  PU
MV7QCJ&NVNHSZ!=WEEX+U#QOX*\,Z9J7B.[TBUWL;VV2?UGX#?MQ?L"_\$_\
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M,20)JOB"Z\3R7$$4-M>WOB^[E@BCV.*!*,9;)JTHIZWNI-J^VCT]#^AW7_\
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M[4K:>"W76+D^<\,-O+^A?_!(7X0> ?A?_P $R/V"]*\)^&M%T^+5OV;O@_\
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M>/\ @GS^TY\<O^"+'QV^,_A_]JGPM\3OB'\7OBEJ7[%&@)X:T;P>FF^-M/\
M&_P;T+Q3#^T%X;UB[OM3TK2WUK2O \^C0Z1=37$NE2ZM<RL#-;(OW9^W9_P5
M9_8__P"">E]X1\*_&_Q/XI\1?%CQ]'977@GX&_"/PP_CSXN>)-+U"^O=*L]:
MM?#BWVE:?8:3=ZKIUYI6G7>N:UI7]LZG;75CHD>I7-E?1VWY?_\ !:W_ )2B
M?\&]O_9T?QB_]2K]E"O-OV!] TOXH?\ !QY_P5/\??%RSM->^)?P7\#^$]"^
M"YU9OM<G@SP5?:=X(\+OJ/A>T:\EM-+GF\('1;.ZO;6T%T!XPUXO-93^(=7A
MU %9-)N]E%RM?^_9).VBUNW_ )GZ=_L;_P#!:K]C']LWXO2_L\:#'\8?@/\
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MY<C1=!U?QCJGQ).EZA]IM;F&RN;VSTN#P597L5W-.8YUG6.TAM[B.X,_R?\
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M6%X?\3:V69#4J1P->BJM>FZDL12IU%&=5+[:CR3U2:3C&7*M&F?L?^RKX_\
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M.4E*E%4:E/9.I[*I3IU$H2;<E>_+JK7YBTK[.[[6>[VUO;ULM-GJ3^-_B/\
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MP26]FDC2/<QFT^V?@=!;0?!;X0QVR(L$?PN^'\<.U%3]S'X3TA(AM5$  C5
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M?^">G[7.@?$/PMX8\-?L9>(?&FM>*?".KZ9JUWKGC*+Q/<>'I[:#0+RR_P!
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M%H<%R6B,GA[1)8!IR7+.KO:1"=F!=C[-\2/^"37_  5X_:L\'>'/V4OVQ/\
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M:SH^DZE9?HI10'-)M.^L4DO)+^M>_4_E_P#B7_P3%_X+@_M0?"5?V2_VG_\
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M6ELT']@'PD+B&+1_T]\4?\$?O!?A+_@D9X]_X)?_ +._BZV\.S>,O#=A%?\
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MF#2?#>D^'- \.Z7<77]D:#I.EQ7FH:WK)U;7M6_;6B@?/+R6J>B2NULW;?\
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M>3UOJD[-[M7V?_ TT/PO_;P_X(U:/\>/^"9?P=_X)Q?LP>,-!^$7A7X,^-/
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M3> O%&AW;RW7B+Q/I%RDS:CXGTI(_LUI<2B.*^E"A8X?M'ZOD;G8$AXR "A
M(5A@C.<]@#CW!QWJK/:I,")&3:9%V!B4"[0Z[05(+$Y^4>@XQ7KY)FO]B9K@
MLTC3A4JX.<:U*,YN,?:1A4C%MI-OE525X[.^C3LSRLUP"S/+<5@&W&&)YX3=
MDWRN49.RNEJXK]3^>O\ X(Z?"#]H']ES4/B1X&^+_P ,=0TBQ\>>+= U'0-5
MTGQ'\.-=T_3[6PT/Q%8W<NL-I_C>75XR6.FI''9:3J3MN=]J@2,/Z'(F,L;$
MGG=CD = I[?6J*VUK;Y1;=C@EMTKR21_-\IP9FD!!"], <J>IXLVC94@=-YX
MX_NBM>)N()<3YU/-9T84J]:$WB/9RDXU)QA2A&=I:Q?)3C%*[VO>YS</9*N'
M\MHY=&I*K2@W[*^BA%W<DO)RDY>K>Q/D '>>%QZ\=1VYK\P/^"I>D_%3XB?L
MW>//@O\ "?P5J'BK7OB9HNG:;!+'J7@O2M,@D@\<>%KJYAOKWQ3XIT.XMWFT
MRVO&M9+.SO(A,$6>2$D5^G\K%5RI(;'![#YESD'(R1TX)'.,9-9UQ<0BWF$_
MF7"".02>5A0J;2)-Y1TV@C)R2"H#$8P:\_*,YCE&;87%1IQJU\%6H8NC&;7(
MZ]"K2KT9.-GS<E6A2DT]&DTVDVUZ6/P;QV$K8;F<%B:-?#<T?BC]8HU<.I)W
MWBZ]U97YHK;<_GQ_X(^_!;X_?LV>*/&'@OXO_#:^\/6OBN7Q/J.FZC9^(_AY
MKUC:+>:5\.$@74'T3QE?ZFCRR^%-7^6UTV\1%DL_,=/-?R?WUOK:.YMA*S(8
MUE&[>90OF1;[<AA&OF;0Q<#9U8(<[-V="T>R-NACB\G<&V8E:678LK%QEW#8
M8JX.&(VGT)46EFAVLY5H(8V53), BRDATX=FP<.,YW$CA<?,0.SC'/L3QAGL
M\^K*EA<UE&C*JZ*<:<Y0C4C=TX64:<U57[N,I*\(MIV37/DF31R7)J.1593Q
M'L.:"JU%><T^5.[?-)RO3OS:W;;UN[?R2?MJ?\$M_C3\,/V@-,^*O[*'AZRU
M?2_$7B.^\?[-5\;:#)<Z1X]'C75/$=G9RVGC(:,K:"]O)HP\J*ZU6<26D\4M
M^@=Y+G]S/A;\9/VE/%7[*WQ,O?C!\+[[3/C9HF@>*[:RT73+CX9"PU^[NK?4
MIO#DEA+IGQ(U+0HDC@DT^"]_M75M$'FP3DQR*1--^@\MI"\RR-&WE!!& ))0
MK#<6W+A@N2N-I!R!T.":B6")R)!&(BIVQ?:7<SNPP3L\S>Q&7"J YR21@=#[
M>=>(6/SK!Y2LSR>AF&.RN>'I+&I1CC:U'!5:4J:Q%:_-4C*E%4G=KG4;N,-$
M^' <-RP=7&?5\1*E0Q$735/E?)!2C/F48IMW3G-WU2YK.ZNU_']\)_V5?VT_
MAY^V/;_M2:U\&Y+?0M<\4?%/Q%>+:^,_A'=ZOM^(-IXY-B$TG_A81LHV#ZU9
M+<QB_9;94G\N28HID_HC_;;\1_%*\_9HUW0?A1X&U+7O&OQ*\ >-/#-KIUQ=
M^"K6'23KW@#4+*"75KG7/&.D:?&B:MJ>G022:7=ZPR+'=R""6!8I9?N..UCW
M;ML<;DM^\,\C?/R7!1@%!.'!49VG@#CA!INT_OY$<J=PD)=6"-UC49&2VS<3
MN!!"XZDCIXC\1\5Q)FG#>98[)<+1>1TJ<*=2C%480IX6-.IAX5H7J\\HU:%.
M,Y1:YEHE&^G%@.%%E> S7!8?$2B\RK2J2DH6DG4KQE4<6G%WE3YXIZVYI/5:
M/^:3_@DM^SY^TE^RW\5/$&F?%'X72:7X9\?:IX,635M)\4?#[7(K&?2K#QY:
M+->QVOC9M5B@2\UO1\K8:7J,DD37!$1\L@_TU10%PK$*4*GJ6#[PY&>/EV[1
MVYSVJ..&#>OE*54,F8I&8[B&W*ZEG<@H?F& ,L@!(ZK:#[9W7^$*,#C@D(>O
M7N>]>)Q9Q/4XNS;^W\13IPQ-6A3P\_9-NG*%&-.G!Q4KRB^6E'FNY<TM=$DC
MULBRC^P,/4PE.HYQJU'5NXZJ4HV=W=<U[7B[:*ZU/S"_X*9?L(?\-K_"70/"
MNEFUMO%GACQ#J'B'PUJ%WXAN]$T^WU&;PGJVCVRZFT>EZR+BR;49M+FN(XM/
M>=;>VE:*0%GAN/MOX)_"W1?A!X \'>!= M3:V'AG0-"T39+?76H2N^C^']-T
M..8W-P<R,\5A")&"0QMM,B01L[ ^O1R,;F1-K?<!+;0%SA,8/?&X\<=#44,@
M5-H#-O?_ %A8LJD[0@RQ;&6],8R" 3@5QU,[S"ME>&R6I7G/!X656I2I\TW%
M2J)MMQ<^7W6W*-HIJ3;O=V-%DN#PV8/'PI0CB,1[-SDHQ4GLUJDW[VBE=ZI:
M^3-3F:SL+JX\F6X9'C_<P&$2.))HE^0W$L$0VE]S;Y4^56V[FVJW\9?[6G[%
MW[7?QD_:Q^-7QP^'/PDCET+Q%\0-3\0^'I-8\;?#:POC:6$MI;Z-=WFG/XXE
MCB#QZ6)I+<S-,4DC$T,<C211?V<N9&MY4,JB42$] 3L+KC@@$@ @;L=1C)ZU
M5CC($KJ6[ *COM7 ;JH(4@$8Y7CD8Y->QP?QGC>"%FU7 8"CF$\RP,,%5A7@
MIQC1^M/$-QA*<(N4I^[S2NDMDW<X.(>&\)Q#7P%/&RM3P.(>(I**6M65'V3D
MI-2:M#2UEZV/QP_;M^%'QN_:G_9.TG3?A_X)2W\90:=HFJ:KI_B'6_"NE7MI
MK7A[7OAAXXW:;/:^)-4\.21R3Z)J,")=7ES \UH(9/)MIX;J?\;M%\>_\%BO
MASH<?@"U@T:QL9Y+A4M6A_9WOGN!K1D6XMVNVNYF3[4DDT:N'A,)9")X<;Q_
M9";=I5,96)P!POF-$!NX!(CC)8-MQEAQM.,\U#]AA27+HL@V['BC9WX;J2Q*
ML 5(W':, ]P:];(/$F&58*>'K\(Y?BH2KSJTXU\/1J5Z+JU9SCS5J[JJI"E.
MHW#W:;A3C&"B^7F?CYKP-]?Q\<10S/$8>HJ<8ODE-)J,5%.T'!KW8037,[R3
ME?5)?QR?"C_@EO\ MB_M2_$FX\??']]&\(Z?KT>M:UXBUT^+/!%KK,US>,T&
MDVF@:=X*T+QEI<(+V&GIJ0U3355;*,-:W?VQYV;^LSX(_!3P;\!O 6A_#[P-
MI]S8:)X:M+'3]/\ MFIWFJW5W'IFA:5X>M[V^N;N1MUU/8Z3:_:%MHK.U,J-
M+#9P&1EKUD16\:[8$4G 'D,Q<*O4_(QD[X8'8,<8Q4DDL-JI$R,Q !Q$=P"D
M[0!N:/&"#QC &/I7G<7^(O$'%[H9;7BL-EV&C;#X7#I4J%-<J@I2A";C4G&$
M8QI/E@J<5[L$VV=^0<'9;P[.KCJDOK&.KO\ >XJLFYM7<K1YDY13;;D^:7.]
MY621GZKHEKJT$MO?1B?3VC0RVIEEB\R2WE%S$WF0&.<!9HXGPLZ!MFU@4+*W
M@GQ5M/C[HK>%9O@U-X$_X1JVO+N#7-%\3_;)+[["^D.NFOI<WDKF:'5EEDNO
MM6J@&SFQ&DL@6.+Z44J_[Q?E"G!+<8 Y;N1C:<9)XY/:G%TV^:H>09*@1DN#
M@E20H;;P0>1R.>Y-?'T*JH<M*ZFHNWLYWDK^CT4K.W-O;39L^L7)[TH[3?,_
M5I+3?31=#YO^,7[2.A?""^\/V>J>&_%VJMJT N+O^Q+7PS/_ &6JS-%)#J#:
MKXIT8/+&8IMYTH:E$?+)BF?='O\ +_C[\9/C]>Q>%]+_ &6?#>C:QK6L6]])
MJ.J^-8]&M_#VE2/J=I9Z6NH)=^)=-UETDCL=?:7^QM-U-E!LB[(S%5^V_P!W
M)DRE?*N(E@:"5LAF;<3$R.=N]E=D= -S8 8, ,"QQJQR54HHQ$L[D<[F!8$K
MRQ)ZH>%')Q@=5*M0I.,GAE.4%+XY<T)-IJ\H.'O<K::UT26MV5=?+\3X%\'?
MLN^*OBIK?A?XJ?M8VWAO4_B/INAG3Y=*^'^LZMIWAFW MKVWLP(8X+>\EEBB
MUK5VF<:Q+$TTD!421Q*H^^((YT1"6C+E5\Y1N\M9,+O\GY0^PG('F,3M"]#N
M)>75 7>.-3TW;@>#TRS(IY';D= ">M6$<.,C/7'/X>A/K7/7S&6+J0I3E&U*
M+C3HPBHTJ4>JA!.RO9<SWDTF]K#;;3LO=[]7\_RT/Q\_X*Z>&OC5\3O@U??!
MOX3>!YO%4WC3P_9"_OY]5\&:3IL%S:^._#.I6ULUUKWBK1-1BF2WTBXEF>WT
MJZM666UC2X,K7"0_@)\+_P!DC_@I[\)+&;1/ '@W3]%TVZ9=6> ^)_@;JC#4
M;JPTJSNFCFUG6;V40O!80A8W<A0I9=KNV?[<;J4B01*X1I(_E)(R#EP2 >20
M!QCOCIUJL;EK5,.9)L'+LIZ;N@))X(.T%<@8.<]C^C\/>)N+R'AZ7"=/AS X
MW+ZU:6*K5\53IU/;5MN=N5FK1LE%TYV4=)KX5^<Y]P%0SK,IYM/B#%X.M&M3
MG"C1E54:*A"'+!<M2,5K"[:M=RUCU?\ '.?A)_P5\+C_ (E5CN#?]!/]G#[V
M?^OK'7\*_3K_ ()(_!3]I3X=^*OCKXS_ &C=!^P^)_%?B'P3!HU[#J_@&]MA
M;:0GQ"N_$$UU:^"[^:&'[3-XL\NQ'DR.;ACNAMK2$2-^[J7:7)VQ*R."!F20
MX+/PI&-V ",G ].#1;[))9 T<\;Q3!':3>(Y6#'<\67P\;$$JVU>"#M'01Q%
MXF_VQ@89;7X=R?*?W/U:EB,%AXT*E6"]G)PG*";J-*$96ER1LY*SO9>EEG"M
M7!8B.-6>8W,G[.G0=/$5*LXTXTYJHIQYZDU'FY>1V2=DM1\'F981A?+9Y)B7
MSDRL2&*[3D+CC# <YQQMKP+]HWX%1_&[P[HEI!=1Z;XB\%^)(_&/@G4GO9K6
MWLO$=KI]\ME-J4?]FZQ#=V::I+97,UN^GS!H;=U *EX)OHE98_/9 DP94(WG
M/DD;@<+\^TODYSMW8!&<#%+/.(Q@;@=P!( /!!/<_3M7YM1KRP6(>,A-1ESQ
MG!R2E%-<^\7HU*,FFNJTOLU]BHN$8QDN9I;/JI)6ZNW=:W\D?'>A_&SX[:/8
M7&F^/O@W/<>(+*-(UG\%WO@8Z+*\$)AE8G7_ (LV]^5>^MYFC_<1'[&\6Y4G
MWJF+X*\"?'#XE_&7PK\5_BW8^%?#7A3P187LWA+PMI5XO]O'Q-'I^L:'%K&J
M"PG\1V$^G26'BOQ/ +>/Q1"_F1:=-)IB-$TEQ]LHUN/E7>=G#?OG8@]#G,A.
M>#D-CUZYJTJKR59F5@1]]V'H<$L<=,?+C!R>I-=-/,\-*$U@Z=&-2=.=.<XR
MG.3A4CRS4>?EY.9+?WK+0MIQ:LFO6WZ7\CXK\=_"7QS\+/B-JWQK^ FEZ7K7
MB#XA7,B?%'PYXEU)9(M7^S6%M;>'9?"T5W<:';Z>]E,=2O\ 51=^);*.6'"6
M\5U)Y-E6IX@^+WQKU6WA\/\ A/X3ZMI/B+5+,V;:MXLN_AT^@:=J$X$1N8UT
M+XG:GJ;6,3"X8"32[^X(^S9MY?WRU]=ADW%4#,8V.[G<3D,,#DG@GG/(VX^D
MB;0&$;;F/)5Y7?!],L9"G?@#''2K_M%SY/KE&G5K4H1ITYS;]I*G"/+15222
M52--6C!-*2A&,7)I('+[WZ;7O9+IKJWU[=3Y;^!7P.UWX>Z)K'B+QY>:=K7Q
M9\26FKP^*-5T"\G;P[=VSG3K'2X=.M+G3-%^SRQZ+X?T.&=VL85-Y%=2&219
MC(;'P8^'FN:*_P 3+/Q/!9C3?$/C36]6L!9W9DF-C?>-/&>O0+.T>#%<(FHZ
M<)E&Z,2+<1I)(BJ[_348556(1[%&2NQF*#DD@/\ *V2221CID9Q3Y$5@ R(Z
M@\B0Y4#'7!5PS9  R 0"Q#=0R>-JR55N>M5P;DM+*DU*"C;91:32UL];LF[3
M_'Y^FA^>7PLL/C=^S-;ZYX&O?!=OXV\"3>(;ZZ\"/X5U#PU-JNF>%[9+/1])
MM-<G\4>*/ [2:B-'TRS,[0P7ZM<EG:ZRSHF1\:_ WQ]_:A\$^)]"O-'T[P=\
M/9_"^L:>-&U&_P##MMXLUW7/L\U_;23W>D7_ (UTNVT>WUG3]"20P:EI%\U@
M=4'E33-;2+^DF 1M4+LQM)1RI'&,#8!C Z$,"..G!IAC4 # &PDPJ9I%5V.&
MQ(!D$!\8W"7:.0 3MK?^T/WBQ"HTE7NI2JV=I65F^6ZM)I)-W=M79Z(+Z?\
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MJZVLG=I7ZM:=#^L#XV?'?X,_LW_#[5?BK\>OB=X+^$GP[T62&"_\6^.M>L=
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MUK1-2U'3OL>-*N[%;BZ$X**C[11WCS6Z:_\  ;7W'VI_P2#_ ."E'PK^.?\
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M5J]IKWAG7/["UO4O#>L?V9JUC)+:W?\ 9FOZ/JNCWGE2-Y&H:?=VSXDA=1_
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MO\5]3^'VK^)O#6L:'J.O7/AT:#I^D>/=2\(#2SH5M*?[-L->N=OB2&2^.?\
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MHW$,FH?9;S5=-MIOLZOLFO;:,_-*H/\ #]_P7^_X)T? 3_@E'XI_9 _:R_8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-;U:UT+2-3UF\)6UTNPO-0N&VRL!#9P//)N,,4SJ-J'D1NPY(1B,5YYX$N?
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MU#4- O+/PYK/A6*?POX?\07'4?LU_L/?M\?MC_\ !1GX:_\ !2W_ (*4^!?
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M)HWMCXK\(_:+G6V@\/?#6:VU*;6=,_5?]K'_ ((2_M7_ +1O[1WQ?^.7@O\
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M_MKP]XB_L76(]9UB[>S_ +;\*:MKOAW4<6]U!)]HTG5[^U/F;!.75U7\)_\
MB&Z_;6_Z3N_M2?\ A!?%G_Z,ZC_B&Z_;6_Z3N_M2?^$%\6?_ *,Z@3LU;GC;
MF<OAGN_T-#_@WX_X)G_MM_L0_M7?MB?$O]J#X*?\*Q\$_%3PFFF> ]:_X6/\
M)/&G]NWH^)%UKY@_LWX>^/?%FK:7_P 2F1+OS-9L-.A^;R/,^T@P@_X-^/\
M@F?^VW^Q#^U=^V)\2_VH/@I_PK'P3\5/"::9X#UK_A8_PD\:?V[>CXD76OF#
M^S?A[X]\6:MI?_$ID2[\S6;#3H?F\CS/M(,(S_\ B&Z_;6_Z3N_M2?\ A!?%
MG_Z,ZC_B&Z_;6_Z3N_M2?^$%\6?_ *,Z@;:?-[\?>23]V?V=K%_QI_P3._;<
MU;_@Y2L_V_M/^"GVC]DB+Q9X"U.3XL_\+(^$D6VQT7]CGPY\*M3G_P"$#G\>
MQ_$P_9O'MA=Z#Y:^##--Y7]J6\<NC21ZB_RM\;_^";?_  5I_88_X*Z_%K_@
MH%^PC\#? /[5OAKXR>/?BAXVTC_A+_$'A"2+0H/CA>7FJ^,?!'BK1/$?CSX<
M^*_#5[X>U+4-0LO"OBWPCK,VD1^&[;2+?5=5^SZCKOA&3Z:_XANOVUO^D[O[
M4G_A!?%G_P"C.H_XANOVUO\ I.[^U)_X07Q9_P#HSJ YE_/!KE4+.,[-+OUO
MZ,^0-#_X)H_\%K]:_P""L_[,7_!1[]I+X$_#[XGZCJ'Q!^%/C_XS6OP=^*/P
M;\.:-\&O#&BWTWP]O/A]9^'_ !I\1M U#7=<\"?#G2=/\31OX7O_ !QI.O27
M]I9MXYUSQ')KDEO]Y?&+_@FK^V'XT_X.-?AE^W;8_!.'5_V2O#ESX!O-4^*,
M_P 0/A1$EC=^&?@!=^%/M"^!+WQQ!\2)YM,\<K8VMN]KX.F8SQQZE;E]/C-Z
MO&?\0W7[:W_2=W]J3_P@OBS_ /1G4?\ $-U^VM_TG=_:D_\ ""^+/_T9U .2
M?VX+W7#2,UH_\NA_6;J%A8:K87NEZI96FI:9J5I<V&HZ=J%M#>6%_87D+V]W
M97MI<));W5I=6\DD%S;3QR0SPR/%*C(S*?\ +$^$/_!/'0?BM_P6QN_^">G@
M3Q OCGX%>$OVN/'5OK=WHFJ-J6E0?!3X9:YJ7B3QA;WUY+)'I\'B>T\!Z!/\
M/]3U B=5\9A=.M/[59K.VN_Z3?$G_!L;^U9XSL8M+\8?\%MOV@_%>F07<=_!
MIWB3X4?$?7;&&^BAGMXKV*TU3]L6ZMX[N.WNKJ".Y2-9DAN9XE<)-(K>;> /
M^#2;XE_"CQ!)XL^%O_!5_P =?#7Q3-8W.F2^)? '[-VO^#O$$NFWLL$]YI\F
ML^'?VL=.U%[&[FM;::YM&N3;SRV\$DL;O#&5 @XP4OWBNU9>[*R>MGMYG]GM
MO;P6D$%K:P0VUM;0QV]M;6\:0P6\$*+'#!!#&JQQ0Q1JL<<<:JB(JJJA0!7Y
M*_\ !;S]BKXK?M[?\$^?B3\"_@<FF7WQ7MO%'@3X@>#/#VL:GI^AV'BR]\(:
MZDNH>&FUW5;BUTO1KN_T2^U272KW4[BVTYM6M;&SU"\T^RNI]0M/R6_XANOV
MUO\ I.[^U)_X07Q9_P#HSJ/^(;K]M;_I.[^U)_X07Q9_^C.H)2BFFJD;IW^&
M?3Y'FG["W[+W_!:0?\$VOVP_V"OVA/V>=*\+?"_2?V/_ (K?"_\ 96T*?Q/\
M$],\8>+OBUXV\1:EKB:#JVLV'CV\1M.2U\2ZG;6'B7Q%=>%O#%O#'!;W.H:Q
MJ*W5[8?I;_P;G_L4_M-_L(?L2_%'X1?M6_#3_A5?Q#\1_M3^-OB1HWA[_A,O
MA_XX^V>"]7^$GP0\,:=K/]K?#?Q7XPT.W^T:YX/\16/]G76IP:K#_9WVF>QB
ML[NQN+KX=_XANOVUO^D[O[4G_A!?%G_Z,ZC_ (ANOVUO^D[O[4G_ (07Q9_^
MC.H*;BU)<\$I--VC/=?YWU/"?VUO^":O_!4K]ES_ (*]^(?^"FG[ 7PD\'?M
M,Z3XT\0ZAXTL]$\1:MX/$OAG4O&'@:7P/XV\$>+_  SXA\8^ O$$]A+#)JEW
MX8\4>!=5,MAIMWI=KJ.HVE];W=KJ/BOQ3_X)F?\ !<[XT_\ !1;]D?\ X*+?
MM#? OX9?$OQ3X9^+?P(^)7C+X;?![XK?"+PEHOP2\%_!7XJ:%XFLOA?#'X]^
M)%J^IW5QI]CJVMQWGAKQ-\3XFN=6N&OO%=[J,ILX?N#_ (ANOVUO^D[O[4G_
M (07Q9_^C.H_XANOVUO^D[O[4G_A!?%G_P"C.H&I+3WX74>6_).]K6M?_)'4
M_P#!9K_@CC^UM\5_VN_AW_P4M_X)N^(-)@_:6\'?\(5=>)O ^J:_X;\,ZOJ7
MBOX;10V/@KQQX.U7QN(? .HR/X?LM,\*>+/"/CG4M-T#4])TJS#'4[?4M8TY
M_BP?\$X?^"XW_!5G]J[]G_XE_P#!2*QT']F7X-_ C;;1W?A#Q9X,T36Y-#N-
M5M;WQU:?#OPI\+_'7C#Q):^//B)-X?T/3=<\5>)M6\,:%9:/;:;J>@M?1:+9
M^'K[ZJ_XANOVUO\ I.[^U)_X07Q9_P#HSJ/^(;K]M;_I.[^U)_X07Q9_^C.H
M$I))+G@VDTFX2ND^B?\ FC-_X."O^"7O[;_Q_P#VJ?V5_P!M3]ASX?6GQ+\0
M_!?P)X-\#7GAO3O$/A/2O$7A+6_A?\3_ !/\3O 'BB+1?'.KZ%I'B#09-2\7
MW-E=6VFWNH:C;S:<AU'2SI4K7D']"/\ P3R\0?MG^*/V4?A]K?[?_A#P_P"!
MOVH+[4?&L_C7P[X:?PPVFV6C3^,M<G\#H8O!VO>)?#]M<Q^#9=$MY[:VUBZO
M(F@7^V2NM-J K\ /^(;K]M;_ *3N_M2?^$%\6?\ Z,ZC_B&Z_;6_Z3N_M2?^
M$%\6?_HSJ!/E<5%SC[NSY9WMKIZ:]CZ*_P"#DG]@/]K;]OKX,?LT>$_V2_A-
M_P +8\0?#[XG^,O$7B_3_P#A._AIX$_LC1]5\*6FFV%Y]J^)?C+P;97_ -HO
M8I(?L^F7-[=1;?,F@CB*R'S'_@LG_P $X?VSOVK/^"7_ /P3[_9V^ ?P;_X3
MSXQ_! _!W_A:'@__ (6'\*O"_P#PC'_"*_L]:AX&U[_BH/&?CGP[X6UK[!XI
MGBTO_BGM;U;[5O\ MME]HTY6NQP?_$-U^VM_TG=_:D_\(+XL_P#T9U'_ !#=
M?MK?])W?VI/_  @OBS_]&=0--+E]^/NMM>[/KW/T\_;._9/^/_Q8_P""(>I_
ML@_#_P  _P!O_M$W'[+'[//PWA^'G_"4^"M*W^-/ S_"L^*=&_X2W6O$>F^!
ME_LL>&]:/]HOXF72K[[%_P 2Z^N_M%IY_P 0_L4_\$\/VP_A'_P0'_:=_8H^
M(7P@_P"$?_:;^(?AS]I*P\'_  S_ .%@?"[5O[8N_'^EV]MX2B_X3/1/&VI?
M#_3_ .UID9/,U3Q791V&-VIO9H0Q\A_XANOVUO\ I.[^U)_X07Q9_P#HSJ/^
M(;K]M;_I.[^U)_X07Q9_^C.H$K)6YXVYE+X9[K]#ZP_X(*?\$[/CK^S)_P $
MX_VC/V4OVX?A.WP]U+XU_'7XO76I^#5\;^ /&3:Y\)OB/\"?@[\-[V\77/AK
MXJ\8Z+8MJ5QH'BW2A9W.I0ZO;&R%Y-81VEU83W7Y$_ K]A'_ (+Y?\$9OB-\
M<O /[!GPS^%_[4OP&^+FLVYTCQ+KNH>![BP:YLK34K/PIXQNO!^O_$_X:>+?
M!'C[2=)U+[)XA6277?AS=ZA8VL-[<>)].L=*G;[&_P"(;K]M;_I.[^U)_P"$
M%\6?_HSJ/^(;K]M;_I.[^U)_X07Q9_\ HSJ!\RO)N<&I:M.,[76S[_B?<O\
MP1S_ &)_^"C/PO\ !?QB\;_\%1OVDOB1\7/$?QIT>\\-:5^SGXN^+-]\5?#/
MP[T#7)Y;WQ;J&LZM;:QJWA6W\1ZZ\YT'2_#_ ,/;^?PKX3\,075OINJW?]N+
MIOA[\5_#7_!,#_@ME_P1W_:)^-7B+_@EYH_A#]H']G[XP-!%'I^K:S\/IIXM
M!L-:UB3P#IOQ!\$?$+Q=X'UI_'O@"WUO4K.W\6^"-0U70=1T[5;[4=2DL8M2
MO_#^D_8?_$-U^VM_TG=_:D_\(+XL_P#T9U'_ !#=?MK?])W?VI/_  @OBS_]
M&=0%U=OG@U+>/)+ETVT5MCU3_@B7_P $J_VV/@G^T=\</V_?^"B7C&:R^.GQ
M=N?&,UC\']*\8Z)XBLXO%7CS4[.]\7?%'QFWP\U6\^&MOJHTVT?PIX)\->&;
MG5]+T;P[JNI"0:4]CH5A9_F!\+_^"<'_  6W_P""=?\ P4J^._Q+_8P^#7AO
MQS\-OC;XZ\6Z.GQ+O?$?PDU3PKJ7P5\:?%"R\?13ZI8^-?%WAW6_"OC/P[8Z
M=;6VI)=:2"NJ6^HP:+#XETZ]TNZOONO_ (ANOVUO^D[O[4G_ (07Q9_^C.H_
MXANOVUO^D[O[4G_A!?%G_P"C.H#F5Y-S@^9)-<D[66UDK;%_QI_P3._;<U;_
M (.4K/\ ;^T_X*?:/V2(O%G@+4Y/BS_PLCX21;;'1?V.?#GPJU.?_A Y_'L?
MQ,/V;Q[87>@^6O@PS3>5_:EO'+HTD>HOA?\ !4;_ ((V_MQ:!^WI8_\ !4+_
M ()4>(-(_P"%RZCJ5CXD\:?#2Z\1^&O"NO6OC:W\/)X4US7/#$_CN?3_  !X
MG\'_ !!\-136GC[PAXJUO39IK_4-6:SBURP\0R6>@7O^(;K]M;_I.[^U)_X0
M7Q9_^C.H_P"(;K]M;_I.[^U)_P"$%\6?_HSJ YE=/VD=(\MN6=FO,^3]2_X)
M<?\ !:+_ (+#_'SX.>+/^"JH\,?L_?L]?"5KIH?#6AZEX AU>[T:^U?2&\9Z
M7X#\$?#_ ,2^,;W3?&7CN'2+.PN_&/Q"U2SM](TS2K34=,L]3MK33-#U?ZE_
MX.+O^"5O[87[9^L?L7:9^Q+\!H_B+X,^!?PY^(W@K6;6+XE_"KP3%X3L[RZ^
M'MOX/TJ,?%7X@^$]0U:-M*\.7<:7%@=5,*V0_M&XCGGA,UO_ (ANOVUO^D[O
M[4G_ (07Q9_^C.H_XANOVUO^D[O[4G_A!?%G_P"C.H#F5XM3@N6]DH3LK[^?
MXGZ8_P#!?+]DK]H+]M7_ ()]:Y\#_P!F;X?_ /"R_BA>?%GX9^)K;PQ_PE7@
MGP;YFB>'KS4Y=8O?[:^('B3PKX>3[)'<0M]FDU9;NXWXM;>=E8+\/W/_  3&
M_P""C.J_\$5OV2?V<_@E\;_B#^QY^V3^S]IWC*;Q5X%\*?&V^\(^'/B)HWB+
MQSXNU:_^'WB?Q[\&O$NJZ0=4?3[GP_KGA'7(=5UC0[2Y?5O"^M-IEGXEU;5]
M$\N_XANOVUO^D[O[4G_A!?%G_P"C.H_XANOVUO\ I.[^U)_X07Q9_P#HSJ!)
MI)+GCI+FUA)ZVMK=6M\CXH_:&_9Y_P"#CO\ ;>_9X\-_L._M"_L._LU:CHWA
MV#P!H=Q^U'XFUCX.3_%^#2_">L:=J%CKTGQ.3X\^*;"WN-2_LZTC\:W7PR^&
M]KXPUK2/[2TR_LG;6M>M-3_JD_X)9_L.R?\ !.[]B;X2_LOZEXLM/''BSPQ_
MPD7B3Q[XHTN*ZM]"U'QMXUUZ^\1ZY;^'(+Z."]'AW17O8-!T>ZO;6QOM5L]+
MCUF^T[3+S49]/M?PR_XANOVUO^D[O[4G_A!?%G_Z,ZOV$_X)>?\ !/#XR?\
M!/WP_P#&'1OB_P#MO?$S]M2Z^)NL>#M3T/5?B3H7BG1)_ $'ABR\06E]I^DI
MXG^,'Q;DN(?$$FM6US=M9W.B)&^E0":"^9XY+8";3C92C:]^6,9*[?6[O^A^
MJE%%%!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+: 6ML(U1%'V.$$9MX=OF'_!/V&.P\;_ +95O;FY&C:;\<]5;1[(V::=::?
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M?MCZ[\,?"]QJ^HW]Q=7VI:JOA7P?HD&HZG>7$MUJ-[%/>SOYL[ ?2G_!3_\
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MBB@@**** "BBB@ HHHH **** "BBB@ HHHH *88T;<2"=V#RS?*0" 4&[$;
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M!]",XR!3J-0T&)%'''Y4:+'& 0$B C5=Q).T)MVDDDY7!W$G.>:<%  '/RC
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MGQ\GA70D\:W%G%9KIT=I/XJ6P&NRVT>GJMBD$E^T26:K;*@@ 0=K10 4444
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M)IG]8E% ^?K9<UN7FN]K6O;:]M+_ #M<_AE_97_;H^)'["'_  5X_P""R/Q
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M]O:+IFH-<21BSN3'_4I10'.[WLOBE+K]I6:^1_*%^W?\ _BY^PM_P5>\4?\
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MQZM<Z4_AB/P_??O/#]G9V$TD6OQ!48RE>W17>MOZV/[K:***"0HHHH _./\
MX*;?\%(OAG_P31^!&E_%/Q?X5USXG^/O'WBNU^'OP7^#?A6Z2T\1?$CQS>VT
MUXMF+W['JDVD:!IEM"LFM:Y!HVLS6UQ>:1I5CI6H:OK>EV-S^3.L_P#!2W_@
MX!\$^&+[XW^-?^".'@3_ (4AI>D-XJU+PYH_QET>3XOV'AF*W%W<_;/#]A\0
M/$GCFVU.SM8[B:^MIO@FNH:>@+7NBP""4/\ 77_!<3_@GI^T%^VS\-/V>OB9
M^R9K^@V/[2O['GQ=3XQ_#'PQXINM.T[1?&EQOT*_ETRWU364.AV/B73]<\)>
M&-3T+_A))K3PQ?Q0:IIFM7MC'>P7UM\#:?\ \'"?[8'[*AT_P_\ \%/O^"6'
MQP^%2V$=E%X@^,?P>MM1N? ^HLKPVNHW^AZ-XN@?P7<QI)YERD>G_'?58B\T
M-F7@5H[J4-(I.*M&,G=W3=GY65UNNJN[]#]J_P!C/_@HO\.?V_/V,-<_:L_9
MP\/:MJ.OZ'HOC73-6^#VM%+GQ3X=^+OA'PX-:7X<ZFVCF5=1_MAKW0KK0M4T
MU5;6="U_2[U;2PU":ZTJQ](_8#^.'[0_[1/[,G@[XJ?M2_ .]_9G^,VM:QXP
MLO$/PBU"SUZQN="L-%\3:EI7A^_>V\2QQZNBZ[HMK9ZNAG7RW6[#0$PE*^)?
MV,/%_P#P3QU/]@[]J3XZ_P#!+A-.\&>&/%OA7XI^-?'<'A_4/&NF^*_"?QHT
MOX:ZAJ9_X2;P[XNUC4;WPAXOTN*?39XY=&6'1M1MXK#4=#OM6TI-/OC^3'P=
M_P""L_[0_P"S9_P;O_#S]K;Q+XQ\0_&O]JCXJ?&OQW\"/ACXO^)EWJ'C6_?Q
MGK?Q!^(DND:EK"W8NI];C\)> _!/B&[T+1[IA97VI:9I&EW(>TGDMY07+>Z2
MM[ZBD_B5TW9]+:._71>9_8?17\J/B?\ X)X?\%>_V?/V8/$/[7FE?\%7OV@O
MB!^UKX+^'-W\7O'W[/'C[4'US]G76VT;1;GQ)XQ^%&@:/?\ BB[T'1=2L=)_
MM+1])\5:-I6AZ?K&NV%K)9Q>#;:\L]9T'Y;_ .&U_P!K?_B%_P#^&HO^&B_B
M[_PT5_PN3^QO^%T_\)IK'_"Q?[*_X:=_X1?^S_\ A)_M']I?9/\ A'?^)+Y/
MG;/[._T;'E\4!R7M:2=Y*/7=^JVTWZG]J5?)/[=/QC^/'P _97^*7Q;_ &9O
M@E=_M&?&[PE_PA'_  A/P:L;76[VZ\8_V]\1O"/AGQ)Y5KX=2369?^$>\(ZS
MK_BI_L:'9'H;R7&+5)R/YU_B-^Q7_P %7/B1^Q!JO_!03Q?_ ,%8OC]\._V@
M=-^ ,G[2^@?L]_"N?6/A]\ O#NA:3\/]/\?V_P +M:TO0O%T</BC7F\-Z9<:
M=?>)/$FDZQ9R>*+UCJ=OK5LFIZSK/:_%S_@HU^T/\:_^#9+Q#^W#HWQ#UCX<
M?M-V^E?#OPOXA^(7PVGNO!VM6GBGPQ^V7X%^$&O:]IEQIB6<.EW/CSP;;MJ>
MMVNAB+2(1XKU31[.&UM8VL;<!0U5FI>\HM:V3?W73L]4?I;_ ,%#O^"F_BK_
M ()_?\$_/A9^U-XM^"%UXA^.?Q;NOA#\/=#^"DUSJFD6.B?&CXE>!-5\:ZQX
M=\0SI97^O0:=X0@\+^+;=M/AM#J^K:IINGZ!]HTZXU)]2L_G2Q_;?_X+9>"_
MA3X&\4_&3_@FIX$F^('C3]H;X=^ Y/!OPF\1:KX[7PU\$?$?A:_U;QA\3?$H
M\%^._B)/H=_X5UZ.PT.2WUN?2[199;@F"[B\FZ;\??\ @O)\(_BQXY_8._X)
MJ_M3>)OVI/C)JVF_$O5/V)/A]JGP6O\ 41=^ K3XF^(O@%\4/&&J?M#P/+=&
MYF^*5TRWNE3W\T \ZTU.\=[DO(5/VA_P5"C_ &L?^";_ .S%^PYX&\,_MW_M
M*?%KQA\0?^"B'A#2O%_Q<\8>*;K2/''B#X>>)_#%TD_PQU:YTK4)Q?>#[2[T
M5K^&PFF,37-_<,T0*JS!2BK1MRMRE+?FZ7TWV77J]/,_JYHK^;/_ (*4_M,_
MMA?M$_\ !1_X'?\ !(_]BCXRZA^S1#K7PRF^-?[3G[0_AO3EO?'/A;P>_P#:
MMS::!X4EEGTZ]TUK32],TJ87/AW4]/U+7?$?COPSIDNO:#H^B>(C?FB_LG_\
M%:O^"?/[4O[->K_ 7]I_]H3_ (*3?LJ?$GQ/:^$/VG/AY^TMXX\/ZWXW^%^A
MS7VGQ:G\2?"GC7XA^+;.=(;#2[_4M;T+2-&U?3IO[4\.IX<UNU\1V&OV]UI
M1RZ*\DFU=)WVUZ[*]M$]_*Z/Z3**_G,_:1^ ?_!3W]K[]L+X[6OQ=_:R^(__
M  3(_P"">7P@M- M/@KXE^"'Q*\">&O''QZFD>[;6?%NK_$'PSXWM?$OA -_
M8>J:OJ&E^-7TN#0M N?"ND6?@B^NKGQ9XFN/C3]AS]H[X]?LI_\ !9SX6_\
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M:*^./^$R\5_\.^_^%@_\)#JW_"<?\,<?\)E_PE?VV?\ MW_A*_\ A2?]M_\
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MK?FW_P $F_VWY/\ @GI_P;L?'S]I;2M)LM?\<:'^TS\0O"?PPT/5(I9](O\
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M^U]^UE\1_P!HS_@KM^T'^Q+\=_\ @I;\1?\ @EA^SM\$?#'@2#X2#X=^(/\
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M:)7DMV98YI4!"R."#<[[IM<KBVVN9IM/>UM&M-'UOOI^%NG_ /!8_5OVK?\
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MQH[V\1M6O[>XOREW<J;@K/*' YEJFG9QC'1Z^ZV[[?@?S3_LW_$ZT_X*M?\
M!>OPC^V[^SSIGB+4_P!CS]@GX >)OA%IWQ@UK1-8\/>'/B5\3?&NB_%/0[M?
M!\.J:;9ZA//=6GQ?O93INJ1VMS:>'?!=KK]_::7+XDT2VU#%_P""8'_(]_\
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M4-,M;6^UW5O#&K:U-K5A<:C<7%Q'<O<M%*CW4S.!S:R=OB=_3WE+Y['\M_\
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MEO!=R2"^#O=0Q3LQEC1UXS]M[P#^T7\3OV5OC'X,_9)^*$?P;_:/U'0=,O\
MX2?$&=+%K33/$_ASQ-H?B;^Q[]]2TG7;&WTSQEINCW_@K4[VYT?48[#3_$-S
M>_99&@ H!22^%6NTVV[I6=[*RVOOUL?A5^SE_P '&7[%_A7]C+X>^%_&UO\
M$RW_ &U_AK\/O#/P=U']D#3/A3\3-0^(/B_XW>$M&@\%6WA[PWJ2>&KGPW#I
M_B7Q-H[DPZQXCA\2^'(ISI&KZ3-XB&GV&K_E)_P3SU&_UC_@V6_X*VZOJOE_
MVIJG[1OQFU'4O*54B^WWWPT_91N;SRT1F1(_M$LFQ49E5<!6( -?IC8?MH?\
M%B]+\ Q^!M5_X(HW_B3]O?3?!<OPQ@_:_P#^$C^$]OX"U7Q/:6*Z GQ2O-4L
M_#MEH,5O>7TC^(+KPQIWQ-TCP7=W$D\^GZGI/A]SIMG^G_\ P2#_ ."=%S^P
M9_P3^\*_LQ?&5?"7CSQEXLU[Q1\1_C)I*6EOXA\$'Q/XT;3(F\+6T6JVKVNN
M6'AWP_H7AS1;R]GM/L>J:OIU]J-G$ME/:@!3:BGHKN<7924KI-MVMLNU]=?(
M_)SQW^UKI?[*?_!&7_@DK<?&/]D/P3^U-^QM\4_AM\%? 7[5>H^,]-F\41_"
M'PQ<>'?"<VA^*]'\&C0M4LM1UR?3F\:7GA[7+_4M!71O%GA[PWI-A?Q:OXHT
M^\L/R"_X*.^ O^"-?A'0OAE\7?\ @C+\:_B-H_[<7BCXK>!=/^%/PM_9T\4?
M%O4K>Y_MRX274=0N[#QMIK^+? >K03OIL&B:/IGBG3+B77+Y-#7P3<:='JES
MX;_T*%\'^$4\+'P*GA;PXG@DZ._AT^#ET33%\+'P_);-9OH9\/"U&D_V.]FS
M6CZ9]D^Q-;,T!@,1*5Y7\/?V6OV9/A)XBF\8?"G]G/X$?#'Q;<^;]H\4?#WX
M1?#_ ,%^(KC[18P:7/YVM^&_#VFZG+YVF6UMITOF73>98V\%H^ZWBCC4)4TM
M;.]V[)Z.[;M)-/:]M-U]Y_-)_P %QOB7-\!OVE_^#?O]H;]I6YNM"T'X/_%C
MQWKW[07C+2]#N]=TOPSKR?\ #*^J^*IA9>$+'46O&:;0/%FI6&E>';*]NM1L
M=%U#^P;"]%LL)ZW]N+_@HK^P!\:_VD_@%\)_V\?V;_A1\1/^"<?[0OP1'Q,_
M9F_;B\0:/\0Y;\^)]<-C:ZEI,5[I_A?0O'/PKMK?4]*U'P_XPL-+U"PU[2I+
MSP-XA\7KHVC/="R_IO\ 'WPU^'/Q7T ^%/BEX \$_$GPN;VVU(^&_'WA70O&
M.@'4;,2K:7YT?Q%8:CIWVVU6>86UU]F\^ 32B*11(^<76/@A\%_$/@'3/A3K
M_P (?A?KGPNT5;!-&^&VL> /"FI^ =)32MXTM=,\'7NDS^';!=-$DGV!;73H
MA9[W^SB/<V02DK1NG>*:NG;=W379I^JL?P]_ CP1^R)\(O\ @L[^PYX:_P""
M'?QN^*OC_P #^-M6U?5?VPO"6D^(O%OB3X.>&_A3ILL4NJ6MYXA\0Z;I\^O6
MDO@Y_%-P]GXMN_$<>@>+;3P#)H6MCQ9J]M86G]ZE>6?"[X%_!+X':?>Z3\%?
M@[\+/@_I6HM;OJ&F?"[X?>$OA_I]^]G&T5HU[9>$](TFVNFM8G:.W:>.0P1L
MR1%5)!]3H%*7,UOHK7;NWJWJTEZ+R/X^_P!EW]HKX=?\$8_^"LG_  4?^"?[
M9=U?_"?X'_MN?$M?VD_V?/CEJVAZY=^ KI+_ ,0^./%5SX9N=6T^SU2]>"U7
MXE77@Z]U:>.2#1/$O@.6#6);>#Q)IU_-CQ_MX_"?]O#_ (.1_P#@G1XE_9^D
MU3Q/\$OA/\-_VF?AMH'Q7GT+6M'\._$CQJG[/GQ]U[QS+X.FUG3]/DU+0_#<
M&J>%],-R(Q)+>2W%X(QIU]I=Q=?UL_$KX1_"CXSZ /"GQA^&/P\^*_A83FZ'
MAKXE>"_#?CK0!=&":U-R-&\4:;JNG"<VUQ/;&86WF&">:$MY<KJT6@?!OX0^
M%)O"MQX7^%7PW\-S^!;;4K+P3/H'@;PQH\W@ZSUG[9_;%IX5ET[2[9_#UMJO
M]H7_ /:4&D-9Q7WVZ\^U)+]IFWA7.M79\SCRO73X>6]K7O9+2]C^)[XX_ 3]
MB#]E'_@M!^UO_P /;O@A:^(OV9/VRKV/XP?LW?M :U;_ !.F\#>%?%VJZE<:
MCXB\-:EJ/P]NM.N+::?4-4UK0_%-O<1ZG/X9ET/P9K=]:V'A7Q-#X@/JGA"/
M_@CWX\_X*/?LF_LZ_P#!+_\ 8%^%/[3MY%XBTKXD_&3]H#3?'O[0>@^%/V?]
M-\+:]H?B'3_&&C:AJ.JW>C>(=0\(Z=I]_K-Q;:I;CP]KGBJ]\%^ ++5U\0ZK
MJ5G9?V1^.OAU\/OBAH3>%_B9X$\&_$3PRUS'>MX=\=>&-$\7:$UY%#<6T5VV
MD:_8ZAIYN8[>[NH(YS;^:D-S<1*X2:16P_A?\$_@S\$-(G\/_!;X1_#'X0Z#
M=?8_M6B?"_P%X5\ :1<_V? UMI_GZ;X4TG2;.;[#;.]O9^9"WV:!FBAV1L5(
M'/IKS7M;234=K)VWO;I>S?S/YD/VSOVH?^"=GQB_;X^/7[&O_!9?]E7X6_"/
MP_X!\,Z1?_LL?M0ZO+\0;'7OB1X+U!;S4I_-^)W@?3=&UW0+2>WO(+G1=,BU
MF?PAI_BS0O&/AG4KB[\026-E=?)?_!)/P_\ "3X9_P#!;/6?AE_P2D^,/Q>^
M+G_!/:/X#:_X@_:/E\2WNN:C\,=!\<W>E:S%H&G^'-1U'3-#LM?NK+Q=%\.X
MO#/B;4-*7Q7-!J'Q&T33[_6/#>E:CJMU_9'\3_@G\&?C=IEGHGQG^$?PQ^+N
MC:=)=RZ?I'Q/\!>%?'VF6,M_;_9+Z2SL/%>DZM:6LE[:?Z+=O!$C7-O^YF+Q
M_+6K\/OAA\-/A)H \*?"GX>>!OAEX76YEO5\-_#[PEH'@S0%O)PBSW8T?PYI
M^FZ<+F98XUEG%MYL@1 [D*N .=*+23U5K-WC?^9)J]^N]D_N/XRO^"/?_!4/
M]FK]C']K/_@J)\!_VI_&L/PA\+?$7]L_XT?$OX=?$W7M.OY_!=YXETCQSXIT
M#QCX+UC5=*TB\NM)UA](M_#&L:$U]--I-Y%'JUH7TG4Y=-A\1_4'[+GC_3?^
M"JW_  7]L_V]/@/H6N:A^R9^PQ^SOJOP/\-_&C4M#U[P_H?Q,\=Z_IGQ3TOR
M-"AU>&UN)[F;_A>GC:\M[*ZMK6ZM?"GAK1M9UC3-*O/$&D1W'U%_P2<_X)X>
M+/!NN?\ !3/2/VV?V8_!^K^!/C;^VYXP^+'PIT+XO>'/AS\3?#GB[PE?ZIXS
M>P\66&AWDOBJRLO.LM7MUC_M2SL-36&\>)H%!F0?T#^$/!G@_P"'WAW3?"'@
M+PIX:\$>$]'CDBTCPOX0T+2_#7AW2HIII+B6+3=$T:ULM-L8Y;B66>1+6VB5
MYI9)6!=V8@2E%-V6KBE>^FL8IM*V^EM[;G\S/_!%?2[W7/VGO^#B71--C6;4
M=8_;Q^+.EV$3R)"LM[J'Q!_:7M+6-I9&6.)7GFC5I)&5$!+.P4$C\U/^"3/C
M+X2?M:?\$9_VH/\ @D/X8\9?V;^W'XET_P"/WC;PU\(/$_AGQMH4=\OAO6?!
M'BOP[<S>-7T)/!.G_:/%>GV'AZ]TG4O$=OXATZZBU"[O_#LFBVDES<?W&^'_
M  /X*\)W_B'5/"O@_P +>&=3\7:D^M>+-1\/^'])T:_\3ZQ+-=7$FK>(;O3K
M2VN-:U*2XO;V=[_4I+FZ>:[NI6E+W$K/R^C? [X*^'/'NK?%7P]\'_A=H/Q0
MU[[=_;GQ(T;X?^$]+\>ZS_:CQ2:G_:WC"QTB#Q#J/]HO! ]]]LU&;[6\,37'
MF&-" .??3=Q:UV<4EKIJG\C^'G_@GW-_P;R1?LP:-X._X*(? OPK\!?VQ_@9
M8:CX+^/OA7XN0?M#:)XJ\4^(?"\M\B^*=%T;0-8<7NK:_I=M:OK/A.TTG3-?
MTKQ7_:.DV_ATZ=)H=_JO[-?\&_-Q\$?B-9?M5_'7]F_]@'0_V.?@'XD\=:;X
M(^#OQ'B\7_$?5_$W[0O@KPKJ_B^6TU/6?#GC?4]9TO2&\)6UWIHU+4_"NK7^
MC7/B?Q#KGANVN[F7PE>3R?N9\0OV8OV:_BWKD'B?XK?L]? [XF^);9E>V\0_
M$+X3> O&FN6[K8C3%:#5O$>@:E?Q,NF@:>K1W"D6(%H#]G'EU[-86%AI5A9:
M7I=E::;IFFVEM8:=IUA;0V=A86%G"EO:65E:6Z1V]K:6MO''!;6T$<<,$,:1
M1(J*J@%*::?Q:]Y-I:WT7^>R^\MT444$!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0_LH?MO_ +>O[:7B;_@KU\'?A7J_[.O@[XJ_LA?M=/\ !#]FCQ#X]\%^,)/
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M"6FOZ7X0\9ZE;&]@C\'>)] O].MDAU6^N],N=,F>'2?#-UX:UVYT6"\LM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _F>_P""UO\ RE$_X-[?^SH_C%_ZE7[*%4?"/_*U/\4O^T>6G_\ I5\.
M:_=?XU_L>?LY?M$_%']GOXT?&/X=?\)A\2_V5?%.L^-/@+XD_P"$N\=>'_\
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M]8U#_@IG^W_\!OBY\.;GQ;X=^,G[/_PX_;#\%_"OPM\,-1LO%/B&\L-2\/\
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MWB_3O%NKV>MWNFW%IX?U[1=>MKVZU^]M[:Q3Q)!XETF6YEO-&O)6_;C]G?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P":JC_AM/\ 8X_Z.S_9G_\ #[_"W_YJJ_SUZ*/^)8\@_P"BMSW_ ,-N2_\
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MCL_V9_\ P^_PM_\ FJH_X;3_ &./^CL_V9__  ^_PM_^:JO\]>BC_B6/(/\
MHK<]_P##;DO_ ,M#_B97/?\ HE,D_P##EG/_ ,J/]"C_ (;3_8X_Z.S_ &9_
M_#[_  M_^:JC_AM/]CC_ *.S_9G_ /#[_"W_ .:JO\]>BC_B6/(/^BMSW_PV
MY+_\M#_B97/?^B4R3_PY9S_\J/\ 0H_X;3_8X_Z.S_9G_P##[_"W_P":JC_A
MM/\ 8X_Z.S_9G_\ #[_"W_YJJ_SUZ*/^)8\@_P"BMSW_ ,-N2_\ RT/^)E<]
M_P"B4R3_ ,.6<_\ RH_T*/\ AM/]CC_H[/\ 9G_\/O\ "W_YJJ/^&T_V./\
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MM#_B97/?^B4R3_PY9S_\J/\ 0H_X;3_8X_Z.S_9G_P##[_"W_P":JC_AM/\
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MXECR#_HK<]_\-N2__+0_XF5SW_HE,D_\.6<__*C_ $*/^&T_V./^CL_V9_\
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M ,.6<_\ RH_T*/\ AM/]CC_H[/\ 9G_\/O\ "W_YJJ/^&T_V./\ H[/]F?\
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M<]_\-N2__+0_XF5SW_HE,D_\.6<__*C_ $*/^&T_V./^CL_V9_\ P^_PM_\
MFJH_X;3_ &./^CL_V9__  ^_PM_^:JO\]>BC_B6/(/\ HK<]_P##;DO_ ,M#
M_B97/?\ HE,D_P##EG/_ ,J/]"C_ (;3_8X_Z.S_ &9__#[_  M_^:JC_AM/
M]CC_ *.S_9G_ /#[_"W_ .:JO\]>BC_B6/(/^BMSW_PVY+_\M#_B97/?^B4R
M3_PY9S_\J/\ 0H_X;3_8X_Z.S_9G_P##[_"W_P":JC_AM/\ 8X_Z.S_9G_\
M#[_"W_YJJ_SUZ*/^)8\@_P"BMSW_ ,-N2_\ RT/^)E<]_P"B4R3_ ,.6<_\
MRH_T*/\ AM/]CC_H[/\ 9G_\/O\ "W_YJJ/^&T_V./\ H[/]F?\ \/O\+?\
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M &./^CL_V9__  ^_PM_^:JO\]>BC_B6/(/\ HK<]_P##;DO_ ,M#_B97/?\
MHE,D_P##EG/_ ,J/]"C_ (;3_8X_Z.S_ &9__#[_  M_^:JC_AM/]CC_ *.S
M_9G_ /#[_"W_ .:JO\]>BC_B6/(/^BMSW_PVY+_\M#_B97/?^B4R3_PY9S_\
MJ/\ 0H_X;3_8X_Z.S_9G_P##[_"W_P":JC_AM/\ 8X_Z.S_9G_\ #[_"W_YJ
MJ_SUZ*/^)8\@_P"BMSW_ ,-N2_\ RT/^)E<]_P"B4R3_ ,.6<_\ RH_T*/\
MAM/]CC_H[/\ 9G_\/O\ "W_YJJ/^&T_V./\ H[/]F?\ \/O\+?\ YJJ_SUZ*
M/^)8\@_Z*W/?_#;DO_RT/^)E<]_Z)3)/_#EG/_RH_P!"C_AM/]CC_H[/]F?_
M ,/O\+?_ )JJ/^&T_P!CC_H[/]F?_P /O\+?_FJK_/7HH_XECR#_ **W/?\
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M /#[_"W_ .:JO\]>BC_B6/(/^BMSW_PVY+_\M#_B97/?^B4R3_PY9S_\J/\
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MB7K^VC_@M+_RC\^*/_8T?"__ -6!H%?Q+U_<7T</^2"QG_92YE_ZAY6?Q/\
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M_@DU_P %"M4TDZU;?LW:Y%9B(3>3J/C3X7Z/JVPP17  T#5O&]EKIE\N9%,
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M7\1:#IMW=NWEVEIJ&HVUQ<RJ\4$<DD<BK]5//\BIYC')YYUE$,VDU&.63S/
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M]&OPYK]QO^"=O_)1?V6_^QR\)?\ IZ-?SC])?_DD^'_^RCE_ZJ,4?T1]&_\
MY*K/_P#LGH_^K;#']?5%%%?Q:?V0%%%% !1110 4444 %%%% !1110 4444
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M C1":U_X1+P0\&I/97Z$'-CXBUY]!\)SD<K_ &^IR,9'[W?\%IM1_:<\3O\
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MEHES%>V=MXATZ_MG%E-IMS<17-W]G^^4\<?$OPC^PYX^\6?M\6_PPT#Q3:^
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MA^6UN/MEK)HD'C#PU%I,EM=EY?M4#V"V[0W'F2>?&5EWONW'^+2OK?H[<O\
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MB>)-4L(J_),/EGLO :.:Y?A(4Z^,XR>%XDQU&E5]OB,CP>/@\+0QU2A)5JF
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M8/<.C%HU1%B^-7[3/QY_:+_X1K_A=WQ.\2?$?_A#O[9_X1C_ (2"2S?^QO\
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MI&J:['IYO[+2Y[EKQ]/6ZL[*UFEM%NWEN88)VECMYKBYDMUB:ZN#+[1\._\
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MR_\ 51BC^B/HW_\ )59__P!D]'_U;88_KZHHHK^+3^R HHHH **** "BBB@
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
MGB__ .(H_P"&,M(_Z)9X]_\  3Q?_P#$5_;C11_Q$3CW_HLN)O\ P\XS_P"2
M#_B'W O_ $1_#?\ X:,)_P#(G\1W_#&6D?\ 1+/'O_@)XO\ _B*/^&,M(_Z)
M9X]_\!/%_P#\17]N-%'_ !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\
MB?Q'?\,9:1_T2SQ[_P" GB__ .(H_P"&,M(_Z)9X]_\  3Q?_P#$5_;C11_Q
M$3CW_HLN)O\ P\XS_P"2#_B'W O_ $1_#?\ X:,)_P#(G\1W_#&6D?\ 1+/'
MO_@)XO\ _B*/^&,M(_Z)9X]_\!/%_P#\17]N-%'_ !$3CW_HLN)O_#SC/_D@
M_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P" GB__ .(H_P"&,M(_Z)9X
M]_\  3Q?_P#$5_;C11_Q$3CW_HLN)O\ P\XS_P"2#_B'W O_ $1_#?\ X:,)
M_P#(G\1W_#&6D?\ 1+/'O_@)XO\ _B*/^&,M(_Z)9X]_\!/%_P#\17]N-%'_
M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
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M !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P"
MGB__ .(H_P"&,M(_Z)9X]_\  3Q?_P#$5_;C11_Q$3CW_HLN)O\ P\XS_P"2
M#_B'W O_ $1_#?\ X:,)_P#(G\1W_#&6D?\ 1+/'O_@)XO\ _B*/^&,M(_Z)
M9X]_\!/%_P#\17]N-%'_ !$3CW_HLN)O_#SC/_D@_P"(?<"_]$?PW_X:,)_\
MB?Q'?\,9:1_T2SQ[_P" GB__ .(H_P"&,M(_Z)9X]_\  3Q?_P#$5_;C11_Q
M$3CW_HLN)O\ P\XS_P"2#_B'W O_ $1_#?\ X:,)_P#(G\1W_#&6D?\ 1+/'
MO_@)XO\ _B*/^&,M(_Z)9X]_\!/%_P#\17]N-%'_ !$3CW_HLN)O_#SC/_D@
M_P"(?<"_]$?PW_X:,)_\B?Q'?\,9:1_T2SQ[_P" GB__ .(K[6_8_P#A;XD\
M'?'7X#V%OX*\5Z9H6B>/_"Z++?:)K2PVEI'JD<C27%Y=VV%1-S,\LTH"CJP
MK^INBO+S7BCB3/:-+#YUGV;9MAZ-7V]&CF&/KXNE2K.#I^UA"JW&-3V<I0YU
MKRMQV9ZF5\,<.9'6J8C)LBRK*J]:E["K6P&!H86K4H\ZJ>RG.DDY4_:1C/E>
MG,E+=!1117@GN!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXA\0?#[PQH=OY)>WGEGGODBBMY9;B8Q6UI<SI,L!C(1YI8>K9;VCS/[H\S_
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M20)>:YXAUN^TW0-%M[BZLK*75=2LUOK^PLS/>0 'N-%?AK_P3&_X+S_LQ?\
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M)U5MH(P<C\D_^"%__!2S_@EQ^S=_P3B^$WPF_:>^-7PI\&?&'0_%GQ8OM?\
M#_BGX<^*_$6M6MAKGQ&\0ZMH,MQJNE>!-=LIH[K1[JTN+=(]2F:&"1(I$A=3
M&O[Z?LU?\%)/^"6/[37Q>\/?"7]FCXQ_"3QU\8-6M=9U;PYX>\.?#7Q1H6LR
MV_AW2KK6=8O+/5-8\!:)96S6&E6EU=.6U&&5XXW2$22,L;!4HI-KDGI=7N[:
M=?AV^?S/U$K\IOVD?^"S7[#_ .R?^U5X;_8[^-'B?QWH/Q;\37?P[M;:YLO
MU[J?@O3H_B=?6UAX=OM7\2P7:K9V$#727&L3I9SG3[5)9?+F9-A_5FO\^O\
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M0P7A:<Z3?V-R)[R"XAO;G^+/]E_0O'7Q*_X*@?\ !,C_ (*"_%&RN],\9_\
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M3W:=J>H_%GPD_P""C_\ P6\_;L\"ZC^T_P#L+?L8?LG>$_V7'UCQ"GPPT?\
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MO$_Q/FO/$MQIR^$M/^&WAOQ?XF\6?V):^'U_MJVTPOK7ACPZ-5U.R\J\&?\
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MTVS:YE#?9M,TRV_>:AKNN7[(T6F:!H=GJ.MZI.!;Z=874Y$9_F8_X.4OVS?
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M,L#.:Y:6(IRPJI8BG%QC%?K/_P .1_V"?^A1^(W_ (=3Q9_\DT?\.1_V"?\
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MZA<BVFAMV:.Z?[4ZRS%V<'[J6EV[K5JUDGLE=W;[G\SW_!OO^RY_P3W^)_\
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M\DMI86NH:XOA6#6FMYDN]4\01Z5;VUXK7_V3Z>^'/B'0_@#_ ,'4_P"TU/\
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MNF2>9+$\T7V;;!)&DUPLO[>^/?V'/@1\1_VQO@?^W3XFL_%,GQZ_9Z\%^*?
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M@+P?!K.H/JVJQ>'_  Y8Q:=IJ:AJ4D<3WUV+>%//N6CC,KY;8N<#\Q/VE_\
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MPOKVD>*=-FTW7]!\8:7I4!A@\5>'[_2=91;K4(4N4M=0O+:;\[O@I_P;V_\
M!.'X+?%#P1\4U\*_%?XKW_PON;6]^%_A'XV?%76?'_P]^'MY87MKJ.G3>'O"
M4MKIUG/#I]]:QW=MINORZWI NC]IET^6XAM9;<)O%I<U_=OHENFVUK?1ZV>C
M[G[+>!_% \;^"O!_C0:!XA\*#Q?X6\/^*!X7\76=GI_BSPV-?TFTU8:!XGL-
M/U#5K"Q\0Z/]K_L[6K.QU34K.VU*VN8;;4+R%$N)/YA/ 7B#2/@!_P '5?[1
M-U\7]3@\.67[7/[&W@SPW^S[J6NS-9V.MZ[9Z%^SU8-X9TB\O[R#3Q/K&J_
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M#6?#FCPVGA_Q=>>-M/&IZ7!>7"ZA(-<OIWF=IHS+:[+?"A=Y]9_;L_X+/_\
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M//?W>][=?O/*/^#QC_DIO["/_8B?'C_U(/AA7N__  >,?\DP_82_['SX[_\
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M?^"B/_!"2^_:'_9\U/6)O#-Q^T=\*?"OB;PUXHL+?2_&/@'QMI$]S?:KX/\
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ML+!+V2U2XG6W>Y$C0+/,L142.&*[>B@04444 ?PW?\%H/^4D?QE_[%3X5?\
MJM?"%/\ ^",W_*1KX&?]@/XO_P#JJ/%E,_X+0?\ *2/XR_\ 8J?"K_U6OA"G
M_P#!&;_E(U\#/^P'\7__ %5'BROKU_R*?^Y%_P#IIGQS_P"1K+_L/?\ Z<1_
M<=1117R!]B?*?[;O_)L'Q._[DO\ ]6%X3K_/.TW_ )!UA_UY6O\ Z(CK_0Q_
M;=_Y-@^)W_<E_P#JPO"=?YYVF_\ (.L/^O*U_P#1$=?2Y'_!K_\ 7R/_ *2S
MYO//XM#_ *]R_P#2C^NC_@WJ_P"37/C1_P!G!ZG_ .J[\ 5^^M?@5_P;U?\
M)KGQH_[.#U/_ -5WX K]]:\?,?\ ?L3_ -?7_P"DTSULM_W#"_\ 7K_V^J%?
MRX_\'%?_ "-O[)W_ & ?C!_Z<_AO7]1U?RX_\'%?_(V_LG?]@'XP?^G/X;UI
ME7^_4?2K_P"FIF>;?[A7]:7_ *>IG\]OPZ_Y*3\-/^RE?#W_ -3+1*_T0_V?
MO^2"_!+_ +)%\-O_ %#=%K_.\^'7_)2?AI_V4KX>_P#J9:)7^B'^S]_R07X)
M?]DB^&W_ *ANBUZ.>_#AO\53\HGGY%\6)_PT_P Y'\@?_!;;_D^+QC_U[:)_
MZJOX.5^>W[,/_)T'[,__ &<%\&__ %87AZOT)_X+;?\ )\7C'_KVT3_U5?P<
MK\]OV8?^3H/V9_\ LX+X-_\ JPO#U>EAO^1?2_[!7_Z:J'F8G_?JO_85_P"Y
MX'^C%7\*_P#P6#TJ71O^"C?Q]BFV_P#$YM_AWXAMRAW!K:[^&?@NVRW+%'6>
MVFC9#M^YO5=C*Q_NHK^;_P#X+?\ [!GBCQ[.G[8OPSM]6\4^)-"T7P%\.?%/
MPX\/>%]1UK7-5T?^V?$\(\4::V@:9?7]U=V=WKGABRNH=15;6'1[&\F^W"6'
M3[%_G\HK0I8NTVHJK3E23>W.Y0E%-[*[BU=M).UVCZ'-Z,ZN$O"/,Z52-1I:
MOD49QDTM6W%23LDV];)G\[W[-?QB;X _'CX5_%Z6RO=3TKP3XX\':[XCTW3I
M[:"_U#PUH7C+PWXGUFRLFNXI+=[JZMM \BWCD:W5II(RUU"BN6_N-\$?\%#?
MV1/B%H%GXC\,_%2:YTZ[MK.XQ<^ _B/9W%N;ZSM[Z.">*?PDJF9(+F(2FWDG
M@#[E2>0#<?\ /^BFCF!*,"5R'3<I>)P2KQRJ"2DD;JR.AY5U93RIJ)[&RE8O
M)9VLCG.6>WA=CDDG+,A)R22>>I)ZFO>QF7TL9*$IRG"4$XWC9WBW>S36Z>S3
MV;5CP<'CZN#4XPC&<9M2:E=6DDU=-=T]4UT3T/\ 0T_X;5_9F_Z*7_Y9OQ _
M^96C_AM7]F;_ **7_P"6;\0/_F5K_/(_LW3O^?"R_P# 6#_XW1_9NG?\^%E_
MX"P?_&ZX_P"PZ'_/ZK]T/\CM_MRM_P ^*?\ X%+_ "/]#?\ X;5_9F_Z*7_Y
M9OQ _P#F5K!\3_M]?LG^$-!U3Q)KOQ2DMM*T>QN-0O98O WQ%N95@MD#R>7#
M!X2>220Y544  LPW,JAF7_/F_LW3O^?"R_\  6#_ .-TY=/L$8.EE:(RD%66
MVA5E(Z$,$!!'8@YH_L.A_P _JOW0VZ].W7H#SRMTH4K_ .*;_#3\S[M_X*1_
MM&>#_P!J_P#;$\?_ !C^'<NIS^ $T;P[X&\(W>KVDFG7>JZ;X6T^"VN]9339
MHX;O3K+4M;;5KJPM-2C74Q9RPRWL5G-*VGVOB'[+GAR^\5_M0?LVZ+IR1O<S
M_'KX0OMDD6)!&?B%X;M&8NS(.)+N(;0VX@D@?*2/"))8H$WRR1PQK@%Y'6-!
MGA1N8A1DX &>>@K^B'_@B/\ L,^*?$'C:?\ :J^)>D7>B^"=/\-Z5)\)+'4?
M#^HV]WXCUD_$&UU,>*(+S7] 729-/TM_APALKOPSJ%[=3V'BBPN_MVG%Q%-W
MUYT\'@Y*]H4Z/LJ:;O*3Y'"*Z7DW)RE9=V[*QY]&%3&XQ.UY5*WM:C2]V*4X
MSDWVBE%12;U;2U;9_5G7SY^TM^TU\+?V4OA?X@^*WQ6OM4@T/0]-GOH-/T32
M;S5M7UJY2]TO2[72].C@C%E!=WVJZWI-A#-JM[IVGPO>BXNKR"SM[J>'@/VR
MOVT_A5^QA\--6\;>.;BUUKQ,=%O=1\&?#:R\1>'-)\5^.+VWU#2M)CM='L=8
MU&WU"XLXK_6K*35K_2M,UF73-,BOKQ=/NYK>*SN?XD/VO?VM?B=^VE\6A\6O
MB?#IVBS66BZ;H/AWP3X=U+Q!?>$/"ME8VZ)>2Z):^(=1U![.]UV^5M3UB>QC
MT^*[G%JLMO+-:&[N/G,!E\\7)3G>&'3UELYM6]R'775.=FH[:RLE]'C\PAA(
MN$+3Q#6D?LP3O[\^FFC4+J4O):OVO]O[_@H1\3/VU_B-XB73O$/C/PO^S@9M
M''@[X-ZGJ=A_9\[>'UNQ8^+O$EKHEK96USK6JSW][JK:9J-UXC&D/-86L>LW
MG]C:8UE\]?LO_LL_&+]L+XA7_P ,O@?I.D:CK6AV&GZKXHU+7==T[0-'\)Z!
MJ&K:=HRZ[>&^8WNJPV4VI174NG:!8:KJ,EK;W AM'G$%O<>R_L0_L ?%S]N+
MQ;/IGAJ>X\ ?#JPM]?;5_BWK7A3Q-J_AI=5T&'22WAO1KJPM;70M1\03WFN:
M:DVG7/B?3+FUL(=8NS#-+96]K??VQ_LR_LT_#3]E7X3^%/A3\.-+LU@\/:'8
M:3JWBN31= TSQ/XUN[*:_O'UKQ7>:#IFF)JNH37^K:I=)+<QS2PM?W&9IIIK
MFXG]C%8VAE]-8?#Q@ZL4DH+X:>B]^HTESS?5.7.W9S:5D_'PN"KYA4>(Q$IJ
MDVVYO251W^"FFWRP5]&ER):1N]5XM^Q7^P%\%?V,_!UM9>&O#GAO7/B3>P:-
M/XK^*$FC7O\ PD&KZQ8>&XM#O[C3;CQ!K?B:_P##^G7US<^(;Y=)T34-/TR%
M/$%];+8A7E:7YW_X*0?\$N_ 7[6/@S7_ !Q\)/#'@CP5^TS9QZ'<:7XOGM]1
MTJ#QMI?AJ#4(?^$(UZ32]0M]%M9-8L[N"RM?%6J>'];N[#^R]&LYC%I]I:W.
ME?KI17SL<5B(U_K"JR=6]W)MM25_ADKV<'MR?"E:R5DU]%+"X>5'ZNZ4?9)6
M44DG%VMS1E:ZFM^?XK[MW:/\VWXK_#'QK\$?B=XT^#_Q'TZVTCQYX U>71O$
M5C8ZE9ZQ8+<1QPSQ7%AJEA(]O=V=Y9W5I>VS,+>Z6"ZCCO+2SO([FT@^H/V(
M/V[OBW^Q)XW?4?"=]K?B#X8:_?:1/XY^%<>M:?8Z5K2V&KZ1/=:EI?\ ;>@^
M)+/2=>G\/6-_X<CN],@T2YGMK^V^TZQ%%I5DD?\ 7M^WM_P3_P#AU^W5\/=+
M\-:QK/\ PKKQMX=U^#7?#OQ)T7PQH6KZY;+)!!I^KZ1J+W4=GJ]YH^JZ5!!%
M)9V.OZ2/M^G:)=W37MMI::?-_%3^TK^S1\5?V4/B7>_#'XL:2UK?*^K2^'?$
MEKI?B/3_  WXSTC2M?U/P^=;\-W'B71=%FO[2YFTU+\?85U"U@L-4TESJ$S7
M8"_387%T,PI.E5C'VCC:I1DM&E;WZ;:VO>2Y7ST]+M_$_F<5A*^7U55I2E[-
M2_=UH[J]_<FEUM:+NN2HNE[Q/[K?V2/VP?@[^VE\-KKXG_!JX\1?V1IFO7OA
MK6M*\5:))HFMZ-J]HJ3K;W4:37VEW27>GSVFI6T^DZIJ,"V]W%#=26U_'=6=
MO]2U_G0_LY_M$_$W]E[XK^%OBS\,M9O8;SP_K5AJVK^$)];\0:7X1\=6]C!?
M68TCQA9>']2TV75+0V&J:G;6K73726+WDDHM;F%KBSN?[0?^"?W_  46^'?[
M;G@;3UN+?1_ /QITZ+5+;Q=\,W\3:'>7<\WA^/1O[1\3^$M+?4QXKNO!FHG6
MK6;3[S4]$MWLW6]TZ>[O38QZEJ'BX_+9X9NK2O/#WWWE2OM&?62_Z>)*.J3L
M]7[6 S*&)2I56H8A*UMHU;+64.D7K;D;;T;C=:+]':***\L]0**** "BBB@
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M%S^*_#/BG6_'OBJ(S>'++Q#XBUMO"^GZ.RI+I5AI.AVVE:-H]K9Z/HFFZ="
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MXZ>SUC5;7_A+(=86VU"[@6.=_P!4_P#@G-_P1S\3?L&6_P 6?A9XI_;-\?\
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M"NW\#6__  27_8D7X?K8+I$OPIFN-7.GII2J_CF?Q9XCD^(;77]D/);M?_\
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MJB+:W%_/J?A_X<WDUP'.J3S?%'QM<6L%W<3&UO\ T[_@WN\*^(?C_J/[</\
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MJ+QEJOAVV\+7NH/XT\6:KXJEMY-&M-6UN"W73Y-4:SCD74)3<)"LS)$SF-?
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M:H\#:'X1\4C1V^..K_"[XR^%?#4NIZ9H^AC7?B196<WBKX?G3HX)=<\+:)J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!_*Q_P0U^ OPMUG_@I)_P6Z_:.UC1M)UOXM^#?V]OC?\ #/P9J6H6
MEC=ZCX$\,>(OC!\9-7\2WV@22I)>:7=^-9(K32-0OXO)DFTSP]-IMO,;:]U>
M":3XS^'/#W[._P#P='?L=WOP7TRT\-WG[7O[+_Q%N/VB/#'AE[32X_&-Q:^'
M?CQJ"^-M=T^&>WADN+S4?A+X-UW5;B>W8ZUJ7@"ZU)!=^(;F]NF_/G]AGX>_
M\%,H?^"B7_!9[XY_\$X/&_P&N]6\)?MX?&KP9\5_@'^T5!XDB\#?%'3-9^-/
MQNU?PGKVFZIX:N=/NK;Q/X0OK#6+>R5_$/@U!8:]J/F:_=P33:1<?N7_ ,$_
M_P#@FC^T[H/[7WCG_@I7_P %(?BUX ^)_P"UOXI\%S?#;X<^ /A!8:I9?"CX
M$^ YF>"2PT'4+^+2KG6+^31Y+C1;6QETJ>#2X]5\3:MJGB/QMXD\1OKFFAM*
MR<FY)W@HVUO=QBDK6V6][_B?G;_P16_9@^#WQ6_X*??\%V?B_P#%7X:>!?B)
MJG@G]M+XC> ? +>-?#FB^*X?#\7B[X]_M$:WXZN+/3->TV_M;*]U)/#?@NVM
M]5M62\%I#JU@2MM=S+-U/P0^%/@/XX?\'.O[3^B?%+PGX<G\,?L/_LE?"RV_
M9<^%=]INC2^&/ >G6O@[X"1:'KOA/PW!))H>G:/X7E^*OC'5_#NFZ=I,4'A?
M6O&&AWT(T?Q!H5IO_4K_ ()H_L ?&3]C7]H7_@IQ\6?B?XE^&>N^'/VT?VL?
M$?QW^%MEX#UGQ3JFMZ#X1UCQO\5_$MMIWCZV\0^#/"]CI?B-+'QUI$4]GX=U
M+Q5IBW=MJ,<>L2PPVT]YX_\ \% /^"8?[1WB[]KSP%_P4F_X)S?%[X??"#]K
M_P '>$$\!>/?"/Q:L=<N/A/\=O!=O ]C%IWBJ]T2UUJ\LM130?)T VCZ"]EJ
MBZ7X4O[?7O!FL^&;7Q"P)R3E+71P44];)\L?NO9INQ\7_P#!T=X(\)_"7X+?
MLI_MZ^ H++P5^T]\$OVL?A[X?\(?$71$CT?Q/KN@WWA3QUXT_P"$;O\ 5K"V
M6^U1M(UGX=Z/K&A_VG<SVNC:;'XKM+2W*Z_=QR]9_P % ?V2_P#@HS\!?^"F
MT'_!5?\ 89^"7PX_:PM-<^!>D_##QW\$_B!J6EKXQ\$)I$&G6FHW?@.TO]?T
M.2&[O+71M(O=*U7P!K6K>(8M4O/&6F77AO4M%UR=M3TKO_@FA_P4O_X*._M
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M+OB'I-OI?V/4(H+P*YHN4KO2ZFO-Q2T_[>V^1^:/_!6+]G#Q;^QA_P $T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,?!7B#2?%7A77[#S9(/MNB>(="N[_2-5M//AFA^TV-Y/#YL4D>_?&RC\/_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.EV\MS.TES?79MK5)+[4;R6:^U*]DN+^^GGO+F>9_P"6OXU_![P]_P %1/\
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M]F^'+SPKH6DPZCI\5G!>VWC#6KK2YM>\17=Y;5/AO^Q!\)_V$O\ @YE_9P\
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MVM_P5>_X)]_!3XC2?LXZU^P]^WI^P[\<-#\4_ OX>_$[Q7IVJ:;\25\$>$O
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ME?EM)W?-=:J32L[ZW=DW;KK:]C[BHHHH,PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **_*7]L+_ (*53_LT_MR_L+_L0Z%\,8?$VN_M
M>>)]VM>/]6UM[32?!/@RQO[[3+Z/2]#LX#>:SXGO[RV3[+/=W]AI6F6RM--;
MZM+*+>#]6J!M-6;ZJZ]+V"BBB@04444 %%%?F;^W'_P4+;]D/]HO_@GW^SAI
MWPW7QEKW[=7QMU#X;P^*;W7#IND?#SPWX2UWX8V'BO5I-,@M)[W7]<U"U^)-
ME!X>M%N]-L+2XM+J_P!2GNHX(=,OP:3;LO-_<KO\$?IE17XS?M:?MZ_''X)_
M\%7_ /@GE^Q;X-M? LGP>_:@\,?$75_B5<:SH&H7WC&&[\+Z7XNN],'AK6X-
M<L[+2X3-H=E]I2ZT?4FE4SJKQ[U*?LS0#35K]5=>EVOT/RS_ &O_ /@G5K7[
M4'[<?[ G[7MA\4]+\'Z;^Q=K_C'6M5\#7GA2[UF^\?IXHN- GBM]/UV'7-/M
M_#[6?]BNDDESIFJB7[0K*B>60_ZF444 VW9=M%]]_P PHHK\C/\ @MK^V]\9
MO^"?7[#6L_M$_ >V\%W7C^Q^)OP\\(01>/=#OO$/A_\ LKQ1=ZA#J3/IVG:S
MH-PUV$M8_LTWV\)$2Y:&3(V@)-M);MV1^N=?@=^W[_P2=_:L_P""@'[1TNG_
M !!_;FU?PU_P3HUWQ+\,?%WC#]E#1/#]S'KFJW?@'1='M]7T"U\26#Z0?[)\
M5Z_H[^((I]6U?5;+PSKNIGQ-8^&KW6M%TIA^Y7@G5[OQ!X-\(Z_?B%;[7/#&
M@ZO>K;HT< N]2TJTO;@01L\C)")IG$:-([*FU2[$%CT] )M.ZW]$[>E]GYF7
MH>B:/X9T31_#?A[3++1= \/Z7I^B:'H^FV\=IIVDZ/I-I#8:9IEA:0JL-K96
M%E;P6MK;Q*L<,$4<:*%4 :E%% @HHHH **** "BBB@ HHHH **** /YY?B9_
MP2 _:^^$7[4G[0G[4?\ P3%_;XC_ &7;K]JWQ3=^//CC\)/B5\)O#GQ5\#ZI
MX\U'4=4UG4O%.B7GB"S\16]I)=Z[XB\1ZY:VTWA(ZGI%WJVH:?;>(Y_#]\NC
M6'O?_!/C_@D[XD_9F_:!^)O[;G[6'[2WB+]L/]M;XL>'4\(ZE\2M2\,VG@GP
M?X$\).---[X<\$>%+&\NK:/[2-(TVQ34(+;P_I.FZ'90Z-X=\(Z!#<:Q-J_[
M/T4%<\FK76UF[*[2Z-VNUHON"BBB@D**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#\NOB)_P3QUOQS_P5F^ W_!2J'XHZ7IV
MA?!O]FC6/@#=?":3PM=W.K:]>:I?_&:]7Q-;^+5UN&SL+:$?%6VC;3)-!NI7
M.C3L+U?ML:V_ZBT44#;;M?HK+T5_\PHHHH$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXO\ %?B32;+4=&U#1-;\.VFE:7<2:WK5C9Z+H.@]'\'/V)?BC_P5'_X*=_\
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M-?RM;;I8]I_X*/?M3_&S]O[]I7_@F+_P3B_9N^+GB_\ 9N\ _MU?L_\ A_\
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LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>v449009_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v449009_img1.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( 3P!1@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /Z4/V__ /@K+=?L2?&32/A3%\'3X[BU
M/PK!XJDUIO%4>CB 3NT*V:6Y@FD?+A%15+,[,=J$YQ\1O_P<2:JR2+%^RS?W
M'DPP,R6_C.5;@O,X1$)DTI,;@2P8;L@ ]",^0?\ !9&-'_X*1? "V91Y$UG\
M*TGC_P">L<WCS1K.6-SDDQR6]U*A3IEE;@J,?T_^"_ACX!F\$^$O,\+:2^_P
MMX?+$PL=Q_LNU8$Y?^\Q/3J?88]&;P2PV'?LJG/)^]).U[-7O?>]][GF06->
M(K_O*?(E[J:O:Z=MGI9^2/P3\-_\'"7AN_T;Q,OB+X!:SH7BC2[5)?#NF)XJ
M@U"TUN_4;I])N+NUM99+2^B#V[21S1C9#<P2$ /D<F/^#A[58%87'[+]QB+>
M)"OC96.Y7#LJ74U@EDS^1(A6%Y5<,P#$  5\??![2K"3_@M3_8#6< TE?C=X
MDMUL2G^CBWAL=R0;2>8E9W;:WRG(W< &OZH_V@_A%\.=;^!OQ7TN_P#">F36
M+>!/%MT\ 1U N(M!N7CF0J^Y9$:WA92" #'G&2371B*>64<3A'*%7EKTHR<.
M:RO*36VE[<MSGH5<QJX?%04Z7/1J2A"35Y-15]&O6VNO>YXC^PG_ ,%"OAG^
MW+X8UB]\+:;=>$O&GA1+/_A+?!.J727.HZ6;V2XC@GBE2*&&YMIO)B>&6 S(
MXN$4%B<#!^!W[7W[1OQ*_:$\2?"CQ_\ LA>/OAG\/=+O?%EII'Q<O[LG1-;/
MA[5;BQL&@MI88VB34[:-+TR.P1(F ()&1^*'_!  ?8OVE/COIMLTB62> (XQ
M#O.TI9^)GM[8."3O,<2*BDEL8.>>:R?^"9U_J$O_  5B^-%O/?W4UM'XK^/J
MI%)+NC5+;QAJWDC:0,A"BXR<D=\XI2P5%O,'13=.G0I3I<U^:#DYI\KNM&K;
MI_E;HH8FLXX7ZPHJ<IU8347I+EBK-Z[IWMMW9^M_[>/_  5>\#_L7>-K#X<V
M/@Z]^*'CRXL;74-4T;3]3;3;'0HKZ>.WLH]0OY;22VCGN0Y>*+SEDW*H9,NM
M?GTW_!Q5J )'_#,2+@D$'Q[;D@YP 2+/&>AXR/>OGS]I3P]HGC+_ (+H>!?"
MWB73+35_#VM_%KX66NJZ=>)NM[ZTLHXM2AMI@""T1N;6(R*"/,13&Q"L:_K)
MM?AKX!MK:WM;7PMI$5O;0Q0V\*0,5AABC6..-09"0J1@*HSP/<DG"V'PU*FZ
M^&EB)5*,''EFX<K3?,W;=M-+Y;ZF-&>)Q4JRHXE4%2Q-:,DX1J<T;)124MN7
ME;WUNU;0_F\7_@XBU!C'N_9G2'S69I/,\>Q1JELF )HY9+#[.&<E@5:7H <
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MM>UG9O1J^IT*<\/BJGMI2E2E!RBTE-Q6TE"#JT(MKM*I3NU_$BM5_2;^V_\
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MDV$$9(YK^J[PG\&?A/X!O-0U/P#\,OAYX#U;5;<V^I:MX*\$^&_"VI7T>\2
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M$OPQ^'1N3X ^'G@7P3]L7R[K_A$_"/A_PY]HA^4F"7^QM.LM\!=%?RI?-0.
MX4-S7>^0/*6,'RPHVJ8AY>Q <I&FT@JB#"A00"%' '%8+&.A&*PM/V?+)3=W
MSMS75\]XVO=\MK/R6A3P?MY2>*E[3FBXVY5&*@_LVCOIU=VM-WJ?QW?"/XH_
MM5?\$:?C':>#OVB-!\3>,/@;XLE:W5?"6IVUSX2UFQM+];*/Q5X0GU'2)UL_
M$EOI,3WJ^#K2XT*6X,]OI]QJ\/$\7]1WP&_:(^"?[5G@2'Q[\(/%NA>.O#C3
M-:W(MKBSO+[1;^)BXM=7L&D>:PN5*K/&D@*R1X,<C,NVO5?&/PY\"?$'3X=(
M\;^#?"7B[2;>X^UPZ;XG\-:-X@LX;O 47,-MJUG>6\4VT8,D<*RL,#S !BLS
MP?\ !_X6?#NXU"Z^'_PX\!>!YM56)-3;PCX.\.^'/[02/@_:QHNG6!G=HR8]
M\[2X4CC@@Q7KPKPIS=-QKPDVIPE*G?HN;D<.;1O=M+:S5K;1I574E[2I&=%I
M)4Y4Z;BDNBBX.*5UUAKI?8ZUM T]A$HM-/"JY:53I]L?.&V0 9(RA!9&)&[)
M3H-QQ=CL5B18T:-8EROE) B(8R!F/:I"A21G 7&>U75 4       =  , #IP
M.@I:YI2<W%S;DXWY7+5IR=VTW=W[.]ULG8VA3ITW)TZ<(<T>67+""3CKHTH)
M6U_JR,A](C-Q)<QF"&9D$<4L=G"MQ#& H*"Y4K,RDACM9MHWD 8!!2/2$,<4
M=[(FH"&4RQ_:8 X1BTA&U9))0I"2! 1@ +PH!P-BBD[MQDY2O'2+YYJVK?22
M[NW:[2LF[ODI^]^[II2CRR2A!1DKQ=Y045!S;A%N;BYOE5Y.QB-H.GY<Q6UG
M$7D61R+.)MP#%B#D@9(.W=C@8XX%:D< B 6/8B@\*D80! 20G!]"H)_BVCC!
MQ4]%.3<ERRE)KSD[].M[]%UT6BT;)A2ITWS0IP@W_+&,5]KHHI?:;?=N[U28
M4444C0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHIK.BXW,JYZ;B%SCTSC/X>H]10 ZBN
M>U3Q;X5T.:.WUKQ)H.D3S1">*'4]6L+"66$NT8ECCNIXG>/S$9-Z@KO5ESD$
M5P&L?M!?!#0K.]O=0^*W@/R[ HMS!8^)=+U74=[RK"(X-+TNXO-2NI0[C?%:
MVDTD:!Y'58T=U3:6[2]6E^OZ >P45\D:[^V]^SMHEK%=0^+M2UYYK@0"RT;P
MWKAN(T,<CM<RMJMCI5JD,9B6-P;HSF2:,1P.OF/'YSJ'_!1OX&63JL.B?$;4
M%968RVFC>'HDC*G;M9=0\56,C-QN^2-E ."P8%0<R[_K^28:]OZ^=O\ +S/O
MVBOQG^)'_!2OQA/?Z]#\+?#^AZ?H,]O#!H%WXOT*ZF\464LNG6Z7MW=+I7C*
M[T%Y[?5&NY=+0VUU;&U6S&H6L[FXAD^<-4_;^_:LNX!%9^.;#3)A)N-SI_@C
MPA*S+VB_XFFA:E (R&!9A )-P 60#<"US/:,O6VGXV#2U[KTOJ?T3T@.?PZ_
MEG'KG&,Y ZU_+EXF_:M_:@\1ZE+JM_\ &/XA07$D<<31Z%J\WA/3 (8EC79H
M_A3^P]'@?Y-\D\5BEQ*^^6:1W9B? _$7Q&^(.KZK?:SK_C/Q?J^K7K1O>ZGJ
MWB'6]2O[GR(8K6(7%[?7DUQ*(+:&&V@$DK"""**&+9'%&H:A4=TH:Z[M*]OD
MW^'F0YQ6[_#1^6MN_P"!_83G&/?_ #_GW^M+^G^?:OXW]#^,/Q \+:Q;ZYX>
M\=^*M%U.T,T=OJ&EZ_JMG>P)<P26UP(KB&\C=!+;S2PR*6,95W!4C@?LA^RM
M_P %,+3Q)J>B^"_CUK5A9W%\MS9IX[;1+/2+(ZO>:O(^E?V_<:?J46EZ7I,5
MA+'IDNHQ^'-/L[*6&&_UB]BLUOM4JO9U$FW&UM[:^NNGY>ER56@VDGOMWW[:
MZ>9^R%%-5E(!!W XPW4$'D'.,$$$8/?(]:=4&H4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !17FOQ.^,?PM^#.C1Z_\4O'?AOP1ID[/'92:YJ,-
MO=ZG+$T0F@T?2T,FJZS<0+/'+/;Z397L\$!:XFCC@1I!\PWG_!0GX!>9)-X>
MN/$'B[0PZ10>(]%TZ&#2[J;RDDG@BCUNZTG4(YK9G,4L=Q90EBC21>9$R2-#
MJ03Y7./->S5TVF]5=*[6G=+IW5Z4)M749<KO:5FHNV]I.R;79-L^Z/\ /^?S
M%%?FGJ__  4B\(6U]=1:3X"U6\T^/R_LMW?ZQ8V%Q.&C0NTEK;Q:A'$JS%HU
M(NY"RJ'*H28U\O\ $G_!23Q3<1P#PQX$\,Z.ZO/]JFU75;_Q")UPBVPA@MX/
M#XM7C*RM*S3W9F#QQJD7E%Y'S+HI/TC+]4O^"*S\OG)?/2[>G7L?KY1D>OM^
M/I7X)^,OVX?BWXJU.WOHM8B\.);626@LO#-]X@T:RF<2SSFYN88M=D6:Y;SU
MA,V4(@@AC.2-U>-:W^T5\4==%_#J7Q+\>SV.H^;'=:5)XT\2RZ1)#*,-;/8R
MZE) ]LPX,,@D0CJ&!S1^\M>-*3[7:C\[.[_ +*UW)+Y-_EI\]C^C_5M9TC0+
M)]2US4[#2-/B>-)+[4KN"RM$>5MD:/<7#QQ*TC$*@+ L>!DUP-U\;O@Y8S+!
M>?%/X?6DS@,L5SXOT&!RI. V);Y<*2/O' ]3BOYLKGQ8\T:Q&7*@_*=T@PI/
M\.6(!'0$#(  XQ@9K>(GD91N<]!D._J.<9YQP!SG(P.U4H5FK\D8Z7:;;MWV
M20FXIV3D]+Z)+\V_G_3/Z$Y_VQ/V=[=G5OB LFP9+VWAWQ3=Q$8+9CFMM%EB
MEQT/E/)SPH/?R3Q#_P %!?A;80[M \.^*==N!>&'R[A=/TB"2T43!KR*:6[N
MISN=(?+MYK2&7RYB\OE-&8F_$==3GF8C!484@Y;<23U^9ON@Y(Z=!CU%B$7=
MPX4;QQQAG8@9&>!WZ$\GOWQBXT:CWDK]E!VMZMZ/Y>?I+DD[:VZW=OR_0_8#
M6O\ @HUX9AFM5\.?#G5]0MVMU-[)KVN66B3PWNYA)%:PZ9:>(XKFT50FVZFN
M+.=W9E^PJJAF\'\5_MZ_%#5-:OKWPS,/"FCS1VZ6.B)!X>UX6;I:0Q3R_P!H
MZEX6CN[@SW(DN2DBE(C(8(SL50/@8I96@#:CJMA8+@D_;KVUM?N\GBYE0D@@
M9!'')..<$'B'P4T@A3Q%9ZA,2%2WT@2ZY.[G/R1PZ1!?2LQP,(J,2"0 ,9&G
MU>+UE.2M>Z34;]4VT[]TEU7<AU7%M66S=WJM-][ZVU_X+U^B=2_:=^.FKS73
M3_$_QDB7ES)<^7IFI-HGE/*[2^7 =&6R^SP*6V1V]L8K=(PL<<2(%5>*UWXC
M?$KQ<+:+7O%WC+7XK)Y)+2/7/$NM:O';O(5#O;QZC<SI \BHB.T85V"H&)"C
M&%I-OX@U':?#?PS^)OB)&4[;BU\"ZYIUJX"@[OM6N6.E0,.1@B0[@1MW$$+Z
M;HO@'XV7B_Z-\'Y-*C<H/,\5>*_">F..H+?9K34-1OMRJ=SAK;>,.J@NVUH<
M</"]ZD&[;.?,_NN]?ZZ$2K2:5E9+?=>EFE^#ON>5?V5XCU63S722:60@>9,P
M=SZ ML+' & #PJX!P.*U(?AUXGNP-R&-5X82.PZ%1@H& *Y;/..%''I]):3\
M#?C5=(K7>L?#3PU&Y&Z*,:_XANX0V<L'M[728&8$<H)5!R<NN!GH!^RQX@U
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M,E]K2V^EM;:+^M"_81+&%B50@50PPH!R1S@<#&0,]Q\W7%=C;LY52V 0BXV
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M0@)!'8D'T]<UG55Z<U_=;^YJ7_MHXNTD_/\ !W7ZG^+7XAVP^(KP'^"]D8G
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MOT)99WV[=Q.S:2!U+9Z#/3DG!R3QZ=,Z:Y9@OS$8!9LD<@GEL'@C"CK@^N<
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MG""5GHK]+?A]W^1&OXKK_6O]=39N]1L[,[;F\MH&(!\N20+("1D 1@%BH!!
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MZT[4+NTD:-)WEC_6/X4>.[+XC> O#GC&V$P;4K(0:B)8%MGBUG3_ "[368A
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MGI\*ZY;VLA?^R_$$$,?]JZ=.'2-[>YA=XYW@EC5XTN80-T;(Y]5A;*A5^[R
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MIX8$:*WC\H-&LJ+;@'[^<<UPC6C6DT[M!]HM;J!K34++*^3=6\HY<;E>%KJ
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M+43HUTKO)YPN)XI!%) $,22'SF(56_;+]E3QS%X@\*3^$IFD.L>&(ANWP+%
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MI72?EOY;E^ULXQ"4:5U8$[5*#&P'Y3E@0">!R%&!T!XJP(R)00-X"#."<D\
MX.2 0?E P<$9.X<U;22.6%)%4,1@YR261N,X#'.TC';!QGTJ!B@RRL5;<VT+
MZ=LY)&WC#=\9!)QSN^CUZMZ=TK]?EY]N_,I:M/Y*]]O-)?/UMJ/>)"5#2!%Q
MP  2-GSDAB3C&21GI[DU35"\KA1QEBKH<G@[AR1\P/()4>HZ=9FG(!C#1EM[
M,"X!7#'[N>%.  2>O/IUC0%1YA&Z-U8 J"-I;))(7 4!2<X ()7"G/ Y.[2N
MEU6RU[=-?F-+OO\ U9[Z^>NXDR+$H9W4,020>3D $[NI P<#(4$]@:K&('!
M +8.XK\Y'3(Y&PMEOFY'(8#.*O\ [ELA]K+L7&_)/F,!MP>A R3C)SC)R>N>
MSA'*_?9MS84X 48!<@G !8Y'MG;Z5:N]N75<K3Z=%LM7OUL_R$[=7H[JW5_/
MU^5_F5)Y)(F?86?&P]2H.1C:%&"PX!;;SVYP351;IT=BT8WD $'<0J9^7H>3
MC"DGD# YSFK5PK2Y.X-M4! N0H+'+8_#.22001C&>:J1Q@-YQ$F6S@,PSG)
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M'J!W)J6U:SL[/3N[Z?/S*4>B=[:V\EV;_'YG/VMG/=,%V%MYZD-U& !T8@@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^./V]/A/J'QF_9G\;>#]+@UJ]OUN=%U>WTKP[IESJVM:NUC?QQMI]A:VD<]P
M)2ETUTTL=I>%(K9U-N0YEB_A9^,/AK4_#GCJYTS6].NM/U*RA%O/;7,127>&
M.UX2=\=Q;SC;):W5L9;:[A9+BUFGA=)&_P!&TC/^?\_E7\JG_!3/PCX:\%?M
M97&B>%M'M-%TAO!VGZDFFV8D6SM[K5?+U"]%G \CI8VK75Q*UO868@L;&(I:
MV-M;6D44".%HSYK7NFGOT3=].O;I]YI%WC*#U7Q+RVOZGX@>"/@5X]\=ZA M
MQ:77A?PZ)98;[6;NWM7O+9X[:2X6/^QKC4K#5,SR+;6R2_9S$!>"X^>*%L_M
ME^RE_P $:M7\9:WH?B+QYX1U7P+X:LM+U74H_$GQ*T2S\1WWB74H)QIECHES
M\.=0\2>'KW0RSWK^)-+\1S^'(K<Q>'X8[5Y5U>WOJ_I ^%G[,7[/_P &8].;
MX;?";P;X<U#2Y=0GL?$+:8-9\7P2ZG%<6U\W_"9Z^^J^*Y!/9W5Q8;)M9DCB
MTV5]-A2.PQ;CWBM9UY35E>U[[_DEZ=68N-]_P_+JGT^X^./A7^P9^S#\*]<;
MQC:?#+0_%WQ">YT.^/Q \=6=IXG\165]X:N'GT&Y\.+?6YTKP=+IK"T*S>$M
M-T6XOWTS2;K6)M2O],L[N+['HHK)MO=M^H[);+S"BBBD,**** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>v449009_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v449009_img2.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( )(!IP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MPY^M_P#PG6A?\]9/S@_^/T?\)UH7_/23\[?_ ./U^2 _:17'+QY[XM%QGO\
M\Q+UH_X:17^^G_@&O_RRI?7Z79_=_P#;!]5AY_B?JV/B5H F,#O<AO[QC@VC
MY=W_ #U'7M]?SLQ?$7PY))(GG3 1H79F%NOW3@X'G_B,G.![U^0NN?M4:5X=
MC%[XBFL;)<A0TT*P<GRTQ_I.LQ \21 X8GY@<'(SP/\ PW[\$$98Y/$.G*]P
MX@8K<Z, /..T_?\ $_!7 /(8=,@C-/ZYBG_S*\0EM=4\9^N%W7Y?><F+I8?*
MO^1MG61T%U?]L9-&VW\V8X=?:CUTOJ^_[@IX^\.R [+EB<9Y, ^G_+<G'(Z
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MZQ_#RWXQX?\ _#OPY_\ 1 C]9O\ A8?A_P#O3_\ ?,1_E*31_P +#T#UN?\
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MT.K2WADF,*641D51QY$6TR%F4A3C)3<. P#8('L,_4Y8]%T>;4]4LH(C$T8
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M!TM+Z!C@3,P_? >;M9@1\A_??]BC]JI?B]HPT#Q)>V\^IV43N[0B\>0^;?\
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MU))S<QGGUSNYZ5_1&/\ @D/;HN?^$DTI0>,K;:N^><@%1XQ&!WSZC& 33?\
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MW,:RLKVH^'D<9*[(B,3V7Q4=QAA(G"[B?FR?E!]%MO\ @D1\*Q&()/&?VB<
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MC/L;?CIU[TW_ (1[P+_T#(O_  !TC_Y'J^:GVC_X!#_Y QYY_P \_P#P.?\
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MX$ZWPDRP=SABO?M@X (&.OO5N.=6&22>!V[]^E95K;860'KYK'.1TPO/WO\
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M?9'VNS;0"64 9]7SL4#EF8*.37Q3XC),<IO)5"PRF3<[X^[%(6)+[0 !QGC
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MLNME89/^G67I&>2"/RZUZK%K'C22?">((A"D:1A_[6O2J;7/WB+<H,*02IY
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M #U%>;TYJ>O>^GGNR7R6_P X_P :0POV&?R']:N8/M^8_P :8Z3,,0KN;.2
MR@[><GD^I'YTYTL9R2]VAMTIU5V\Q.,OYZ/RNOT7YHJ^5)_=_5?\:!%(.0,?
MBOU]?6IO(OO^>3?]]Q_XTHM[T_\ +-\^@9#_ "/_ .KO7(Z>,ZJE_P" 52>6
M7\U/[_\ [8A,<AZCITY7_'VJO<:5'>[9)H@SJ!$K;V&%4LRJ0DJ _,['/!QQ
MG&,:'V:]_P">;_FO^-3107&QA(&5@Q*J<'( '.-P'? [G^3A1QDW91I;-_!5
M_P RHN=-\RE3OMJWUMVDGT6W_#<+?>'@&(1/EVG.6_VB0>9<X/7H3ZDGFN<N
M-!P[DP\<9._@] "!YV1S_P#J%>LO:RL>>,#'1<\<]=P/X<<<<\Y@FL@T6T8,
MG4Y 8G+#'\1[#N?R[[?4<7*UX44][JG5O?76Z2O_ ,#9[GH4,RQM%WC64E;X
M)SG.%M-%&4W:UK+??H>2PZ6$X6/!X_C//4]#(?\ )X]*UDL9L* @Q@ ?.IP"
M.#G?DXX[\UTATN]W$[0,]03&1G'IO'/?.._7KFU'9798DQ$A> ?W?KP3M.!D
M ]^N,9Q6D<!B87:5%Z=8U/NU2Z#Q.:8K%1C&JXQC%RM926KCRW2<GT2NK*_<
MR;;3Y1M!7 8#NI.2 #CYP>1QP??YNAZ*&Q;:J[#A8UXSST&.=_IZ_G4T%O,
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M*#WG1?HW+]44DN)RP!.!SV3T/HM3>;)_>_1?\*F-L^/E4%NPR/\ V8XZ>O\
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M_P ]0_\ F>IR_LC:MD;HE YR4;4 W?&#_P (^,<X!Z<9K?\ XB3Q7_T,T_\
MN'/_ .:3L_XE>\&.F1YC?_L=5/\ YU'\S_\ P[IU;_H95_\ !W>?_,54L7_!
M.R_1B;CQ-=*A4@&QUF9I=V1@,)_!#)Y> V2!NW;,'&:_I?\ ^&1M2_N3?]_=
M1_\ E!3D_9*U6([HXBQ(P1,^HNN"0<@?V",-D#!],CO4R\1^+'%I9FKM:?NY
M^7_443_Q*]X,]<CS&W_8ZJ_KE1_-+_P[O?\ Z&KQ!_X.(_\ YAJL0?\ !.XG
M?N\4^(#C;C_B<1'USU\#?E_]:OZ5O^&4=;_Y][?_ +YU'_Y14Y?V4];7.+>
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M7XD\63;<L7->M/OZ8O\ KL6OHT>#26O#DYOO];@OSRG_ #/YTV_X)KZ46/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
<4444 %%%% !1110 4444&4'J_3]4%%%%!J?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>v449009_img-testnasal.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v449009_img-testnasal.jpg
M_]C_X  02D9)1@ ! 0$ KP"O  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M 0$! 0$! ?_  !$( 1P!R0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MO?J_R_X8<+[4,G-]><8 _P!)F'USB3.1[T@OM0Q_Q_7@/.<W$Q_G)_\ KS3
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MC#,MPFF^66C[=[-ZWNUJM6F[I7=]4#L]>J5WKT>BUT^6BOLKV/J@IDG;R<X
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MNRZ[]F%O-;[W_P" 52@SU&,] ../?WI-IW9X('8\=N.QZ?KCFK?D'LPQV^E
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MO%";L3R!4A5%>-R#'M.'+<^9]17QCK_Q-$"S^7?LFP3<XR/,RZDKF8_NL#&
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MCNENU#*!$9'&]?+9"< -@#YU'.221VJB?$6HW,LDLLC-,DLB$$G 56!0JNT
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M#PCX&\0W%I<>!O"TL'CCQC:-=)Y^NS:>ZR:+H<\Z2F".R>X6.YGM;H(+G;&
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M,84)*[Q@"-<#<XXX 7)W'! W+@MC)5<L.DL;PO9)<R2E$((%KY0W&3 *'S&
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MUK0C93V-O=V-E'>W,:>1,+*:ZAAD@1DMW3_3O,LY"8R^^"7>,V+.R%_9M?\
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M8CM2TBXY61I;<E8\A3N?:3D"0Y4<'@'E(Y(+W4)D52 =_D/_ *N,[0BG+;L
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MHR<6FNMTTW>UO-/6[-XU(3HRIU*:G"45'EG%2O>-NJTL]F[JZ6C:1^T?AO\
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MW;N[N]]6[ZVNVWJFX0:Y7&+CV<8M?"X;.+6L&XO3X6X_"W%\DWA7PNT<J?\
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MYBU6<PK'<2H)@Q\O]V2L2ELDH4C0[V&<DMC&T=J^;J))M<TM.V]W?=R2[O\
MX-C[>$N:*;A&TNDV[V5[.T=-&EH]M+&GI-IK]U"SW%K8Z>"-^;NZ#R@,0 3#
M:APH<J!EI#C (')K<6)+=52ZGL;F;>P)@N9(E*$\!1+"JY./[Y() (ZXP8+G
M4WPT%T)$9<-O,B;5 &$VLS!L.N5X^49.<L0+\=M<. TP@D?&Y1\XP Q(!.>7
M.1SRHP1G&,U1DXM*S:3W;;\WLOR3Z]PJ0O!W:5];13BDF[6;=W\FUT[EO[;I
MB,LZ,T,MLSF$S98,Y8E\[&:*3);:NUT&2,XS7+:IXDR7A98?,E=E(9RJX/)
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MP'/3;P>/3%6:RBZK@;MV<<DYXZ<<\'C@_K6K4O\ ._Z?/[RX=?Z[G^,J;2%
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MKIRA9(W2)5EW(=T3("^!DB50H?).25+'!X)SU] L+I9%+-$XD&<C@JP!RN2
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M\&_"]U>ZO&MS)'';++;RW<D-[&+DI92NO\K>J>"VMKII4)A=_G\R-4C,;+@
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M[/WN.<G\._<FGK\[]M++;5Z?,-.]U9]=;O?3?Y$FX G.,D'K@=>]=!7-,7R
M(P1Q@G'3V_#H#C_'I:B732VY<>NM]C_.U\5_ #4;66ZW13%%4 L!-DC#>Y'7
MN ?7%?/VK_ 1KAI(]LZY+#+F8=54-@@CKV)!X(P.:_H*\5_!C3;M;HB*+YE
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MU=HVP>,J67/&XX)/\HVE? 3PCJUY)Y5EJ=M:QI\\+Z_=W +[1A\D1N<D@8#
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M3MTDE[K;Z-.]K=&WN>@\+!R<H02OUBVW*W11E[M_-=%M8_5;1/BC=S(-EU:
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M/[W[,%5G63:,J,XP,;2:]Q;X3^$_%&G2Z;K?AG1O$6G2'$^GZI:VFH6TD9C
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MI^./@*S34OAQ\3])^(&EADABTG6=$US3/$D"NZ1;S)X9LM=MKI(U;?(?L-J
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M (K=CACO TZ+'@ !9)1L('S,NU"#P,YR.N!D]*[+6?A3>ECNAZG.3%$3]X@
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M*:AX=9HV.V3N<D'/0=AZ$X[Y]17I9(88+#_OD_XU'-&LJX*KM;@<#(SCU_\
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M_(++:WW;=O\ ,_*+6/AO,2!+;3D!S@9D&/R.3_+C\_/=3^&88L624<N!DOT
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M+-=]I7M\G]I@N,N'<:X<U>6!K)I>QQL?9Q<G:RC5A[2C)7WO.'>UGIT=D;J
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MO;D\.O';!X4?R]Z^I+W3(W4JB,^1A1P 22.N>F>.X]ZY"^T-2C9A(P>N$QG
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M;S2(V!#1H1ACRIYSGOGCOT/?I7(ZAH?&$2/&,D[2!TQC!)Y!Y]?TSZN5##!
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MUR*4=!VHHIVVUV_$5]]-_P  I",C&<>]+10_PM][[>6FMP7XW^Y=_/72P@X
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M[CQ]*FIH)WD=@/\ "C5WVT5_Z^\.9K9_U]Q"T2CH3]"1^?2CR/\ ;_\ '?\
M[*IRH)R1_/\ ETI:?-9*S=^K_)==@N_4@\@?WC[_ -?_ -7ZUKUGUH4FV[7Z
'%PUO\C__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
